
<html lang="en"     class="pb-page"  data-request-id="51aad54d-b5c2-4905-bd09-a70d233a5669"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2016.59.issue-12;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.5b01106"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90–Kinase Interactions" /></meta><meta name="dc.Creator" content="Meining  Wang" /></meta><meta name="dc.Creator" content="Aijun  Shen" /></meta><meta name="dc.Creator" content="Chi  Zhang" /></meta><meta name="dc.Creator" content="Zilan  Song" /></meta><meta name="dc.Creator" content="Jing  Ai" /></meta><meta name="dc.Creator" content="Hongchun  Liu" /></meta><meta name="dc.Creator" content="Liping  Sun" /></meta><meta name="dc.Creator" content="Jian  Ding" /></meta><meta name="dc.Creator" content="Meiyu  Geng" /></meta><meta name="dc.Creator" content="Ao  Zhang" /></meta><meta name="dc.Description" content="Heat shock protein 90 (Hsp90) is a ubiquitous chaperone of all of the oncogenic tyrosine kinases. Many Hsp90 inhibitors, alone or in combination, have shown significant antitumor efficacy against t..." /></meta><meta name="Description" content="Heat shock protein 90 (Hsp90) is a ubiquitous chaperone of all of the oncogenic tyrosine kinases. Many Hsp90 inhibitors, alone or in combination, have shown significant antitumor efficacy against t..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 16, 2016" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b01106" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01106" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b01106" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01106" /></link>
        
    
    

<title>Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90–Kinase Interactions | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b01106" /></meta><meta property="og:title" content="Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90–Kinase Interactions" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0017.jpeg" /></meta><meta property="og:description" content="Heat shock protein 90 (Hsp90) is a ubiquitous chaperone of all of the oncogenic tyrosine kinases. Many Hsp90 inhibitors, alone or in combination, have shown significant antitumor efficacy against the kinase-positive naïve and mutant models. However, clinical trials of these inhibitors are unsuccessful due to insufficient clinical benefits and nonoptimal safety profiles. Recently, much progress has been reported on the Hsp90–cochaperone–client complex, which will undoubtedly assist in the understanding of the interactions between Hsp90 and its clients. Meanwhile, Hsp90 inhibitors have shown promise against patients’ resistance caused by early generation tyrosine kinase inhibitors (TKIs), and at least 13 Hsp90 inhibitors are being reevaluated in the clinic. In this regard, the objectives of the current perspective are to summarize the structure and function of the Hsp90–cochaperone–client complex, to analyze the structural and functional insights into the Hsp90–client interactions to address several existing unresolved problems with Hsp90 inhibitors, and to highlight the preclinical and clinical studies of Hsp90 inhibitors as an effective treatment against resistance to tyrosine kinase inhibitors." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b01106"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01106">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b01106&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b01106&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b01106&amp;href=/doi/10.1021/acs.jmedchem.5b01106" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 12</span><span class="cit-fg-pageRange">, 5563-5586</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/12" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.5b01485" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90–Kinase Interactions</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Meining++Wang">Meining Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Aijun++Shen">Aijun Shen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chi++Zhang">Chi Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zilan++Song">Zilan Song</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jing++Ai">Jing Ai</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hongchun++Liu">Hongchun Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Liping++Sun">Liping Sun</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jian++Ding">Jian Ding</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Meiyu++Geng">Meiyu Geng</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ao++Zhang">Ao Zhang</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">CAS Key Laboratory of Receptor Research, Synthetic Organic & Medicinal Chemistry Laboratory, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zuchongzhi Lu, Building 3, Room 426, Pudong, Shanghai 201203, China</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China</span></div><div class="corresp-info"><strong>*</strong>For Ao Zhang: phone/fax, 86-21-50806035; e-mail, <a href="/cdn-cgi/l/email-protection#ec8d8396848d828bac9f858181c28d8fc28f82"><span class="__cf_email__" data-cfemail="5c3d3326343d323b1c2f353131723d3f723f32">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>For Meiyu Geng: phone/fax, 86-21-50806072; e-mail, <a href="/cdn-cgi/l/email-protection#6c01150b09020b2c1f050101420d0f420f02"><span class="__cf_email__" data-cfemail="0f6276686a61684f7c666262216e6c216c61">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>For Liping Sun: phone/fax, 86-25-83301606; e-mail, <a href="/cdn-cgi/l/email-protection#1a766a696f745a69737777347b79347974"><span class="__cf_email__" data-cfemail="a4c8d4d7d1cae4d7cdc9c98ac5c78ac7ca">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01106&amp;href=/doi/10.1021%2Facs.jmedchem.5b01106" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 12</span><span class="cit-pageRange">, 5563–5586</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 4, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>15 July 2015</li><li><span class="item_label"><b>Published</b> online</span>16 February 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 23 June 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b01106" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01106</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5563%26pageCount%3D24%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMeining%2BWang%252C%2BAijun%2BShen%252C%2BChi%2BZhang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D12%26contentID%3Dacs.jmedchem.5b01106%26title%3DDevelopment%2Bof%2BHeat%2BShock%2BProtein%2B%2528Hsp90%2529%2BInhibitors%2BTo%2BCombat%2BResistance%2Bto%2BTyrosine%2BKinase%2BInhibitors%2Bthrough%2BHsp90%25E2%2580%2593Kinase%2BInteractions%26numPages%3D24%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5586%26publicationDate%3DJune%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b01106"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3373</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">39</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b01106" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90–Kinase Interactions&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Meining&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Aijun&quot;,&quot;last_name&quot;:&quot;Shen&quot;},{&quot;first_name&quot;:&quot;Chi&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Zilan&quot;,&quot;last_name&quot;:&quot;Song&quot;},{&quot;first_name&quot;:&quot;Jing&quot;,&quot;last_name&quot;:&quot;Ai&quot;},{&quot;first_name&quot;:&quot;Hongchun&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Liping&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Jian&quot;,&quot;last_name&quot;:&quot;Ding&quot;},{&quot;first_name&quot;:&quot;Meiyu&quot;,&quot;last_name&quot;:&quot;Geng&quot;},{&quot;first_name&quot;:&quot;Ao&quot;,&quot;last_name&quot;:&quot;Zhang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;16&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;5563-5586&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b01106&quot;},&quot;abstract&quot;:&quot;Heat shock protein 90 (Hsp90) is a ubiquitous chaperone of all of the oncogenic tyrosine kinases. Many Hsp90 inhibitors, alone or in combination, have shown significant antitumor efficacy against the kinase-positive naïve and mutant models. However, clinical trials of these inhibitors are unsuccessful due to insufficient clinical benefits and nonoptimal safety profiles. Recently, much progress has been reported on the Hsp90–cochaperone–client complex, which will undoubtedly assist in the understanding of the interactions between Hsp90 and its clients. Meanwhile, Hsp90 inhibitors have shown promise against patients’ resistance caused by early generation tyrosine kinase inhibitors (TKIs), and at least 13 Hsp90 inhibitors are being reevaluated in the clinic. In this regard, the objectives of the current perspective are to summarize the structure and function of the Hsp90–cochaperone–client complex, to analyze the structural and functional insights into the Hsp90–client interactions to address several existing un&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01106&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01106" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01106&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01106" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01106&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01106" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01106&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01106&amp;href=/doi/10.1021/acs.jmedchem.5b01106" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b01106" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b01106" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b01106%26sid%3Dliteratum%253Aachs%26pmid%3D26844689%26genre%3Darticle%26aulast%3DWang%26date%3D2016%26atitle%3DDevelopment%2Bof%2BHeat%2BShock%2BProtein%2B%2528Hsp90%2529%2BInhibitors%2BTo%2BCombat%2BResistance%2Bto%2BTyrosine%2BKinase%2BInhibitors%2Bthrough%2BHsp90%25E2%2580%2593Kinase%2BInteractions%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D12%26spage%3D5563%26epage%3D5586%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/12" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/jmcmar.2016.59.issue-12/20160623/jmcmar.2016.59.issue-12.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/medium/jm-2015-01106x_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Heat shock protein 90 (Hsp90) is a ubiquitous chaperone of all of the oncogenic tyrosine kinases. Many Hsp90 inhibitors, alone or in combination, have shown significant antitumor efficacy against the kinase-positive naïve and mutant models. However, clinical trials of these inhibitors are unsuccessful due to insufficient clinical benefits and nonoptimal safety profiles. Recently, much progress has been reported on the Hsp90–cochaperone–client complex, which will undoubtedly assist in the understanding of the interactions between Hsp90 and its clients. Meanwhile, Hsp90 inhibitors have shown promise against patients’ resistance caused by early generation tyrosine kinase inhibitors (TKIs), and at least 13 Hsp90 inhibitors are being reevaluated in the clinic. In this regard, the objectives of the current perspective are to summarize the structure and function of the Hsp90–cochaperone–client complex, to analyze the structural and functional insights into the Hsp90–client interactions to address several existing unresolved problems with Hsp90 inhibitors, and to highlight the preclinical and clinical studies of Hsp90 inhibitors as an effective treatment against resistance to tyrosine kinase inhibitors.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">1 Hsp90: An Emerging Drug Target for Cancers</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73160" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73160" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Heat shock protein 90 (Hsp90) is an abundant and evolutionally conserved molecular chaperone that plays vital roles in protein homeostasis through directing the folding and conformational maturation of its bona fide clients in cells under normal conditions as well as in adapting to hostile stress insults.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> Hsp90 is distinguished from other cellular chaperones because it specifically binds to intermediate conformations of partially folded polypeptides at the late stage of protein assembly.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> It interacts with diverse cochaperones to construct fully active multichaperone complexes and serves as a network hub to coordinate cellular functions of a restricted set of oncogenic signal-transducing proteins.<a onclick="showRef(event, 'ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6">(4-6)</a></div><div class="NLM_p">It has been reported that the expression of Hsp90 in cancer cells is generally 2–10-fold higher than that in normal cells.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The small molecule geldanamycin analogue <b>2</b><a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> (17-AAG, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), the first Hsp90 inhibitor entering clinical trials, showed nearly 100-fold higher binding affinity in cancer cells than in normal cells (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>).<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> The high sensitivity of the inhibitor in cancer cells is proposed to be due to the formation of the Hsp90–cochaperone–client supercomplex that is highly unstable and possesses high ATPase activity, whereas in normal cells, Hsp90 either does not form such highly susceptible supercomplexes or it forms different complexes that are independent of cancer cells. All of these results provide a solid rationale for targeting Hsp90 as an attractive molecular-targeted therapy (MTT) in cancer.<a onclick="showRef(event, 'ref8 ref9 ref10 ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10 ref11 ref12 ref13">(8-13)</a> Indeed, the disruption of Hsp90 chaperone activity has been confirmed to induce simultaneous proteasomal degradation of many deregulated oncoproteins that are believed to be critical for all fundamental hallmarks of cancer, including cell development, proliferation, survival, and motility.<a onclick="showRef(event, 'ref2 ref14 ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref2 ref14 ref15 ref16 ref17">(2, 14-17)</a> Therefore, Hsp90 has long been regarded as an emerging drug target for a wide spectrum of cancers, and at least 13 small molecule inhibitors targeting Hsp90 have been or are being investigated in various clinical settings.<a onclick="showRef(event, 'ref16 ref17 ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref19 ref20">(16-20)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/medium/jm-2015-01106x_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Four major classes of clinically well studied N-terminal Hsp90 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="cht1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/medium/jm-2015-01106x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Key Events for Hsp90 Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2 Promise and Remaining Questions of Hsp90-Targeting Inhibitors As an Anticancer Treatment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75313" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75313" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.1 The Structural Types and Interaction Features of Hsp90-Selective Inhibitors</h3><div class="NLM_p">Tremendous efforts have been made during the past several decades to develop selective inhibitors that directly target Hsp90 or cancer-relevant Hsp90–client complexes. Although the crystal structure of the N-terminal domain of Hsp90 was reported in 1997,<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21, 22)</a> the majority of the reported Hsp90 inhibitors, especially those tested in the clinic, originated from modifications of natural products rather than from rational drug design. Structurally, these Hsp90 inhibitors can be roughly classified into three chemotypes,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> including (1) N-terminal Hsp90 inhibitors, (2) C-terminal Hsp90 inhibitors, and (3) non-ATP competitive Hsp90 inhibitors.</div><div class="NLM_p">Derivatives of geldanamycin (GMs), resorcinol (RDs), purine (PUs), and 2-aminobenzamide (ABZs) represent the four major classes of N-terminal Hsp90 inhibitors (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). The GMs include the prototypic natural product geldanamycin (GA, <b>1</b>)<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and its 17-substituted analogues tanespimycin (17-AAG, <b>2</b>),<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> alvespimycin (17-DMAG, <b>3</b>),<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and the hydroquinone analogue retaspimycin (IPI-504, <b>4</b>).<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Compounds <b>1</b>–<b>3</b> showed IC<sub>50</sub> values of 70, 33, and 24 nM, respectively, against SKBR3 breast cancer cells, while compound <b>4</b> was reported to have an IC<sub>50</sub> value of 307 nM against MM1.S human multiple myeloma cells. These compounds interact with Hsp90 through critical H-bonds between the pharmacophoric carbamoyl moiety and the highly conserved residue Asp93 as well as between the central quinone moiety and Asp40 and Lys44 in the ATP-binding domain of Hsp90 (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>A). The resorcinol derivatives (RDs)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> include luminespib (NVP-AUY922, <b>7</b>),<a onclick="showRef(event, 'ref28 ref30'); return false;" href="javascript:void(0);" class="ref ref28 ref30">(28, 30)</a> ganetespib (STA9090, <b>6</b>),<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> and onalespib (AT-13387, <b>8</b>).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The cellular potency of these radicicol analogues <b>6</b>–<b>8</b> was 63 nM (MG63), 16 nM (HCT116), and 48 nM (HCT116), respectively. These compounds bind to the Asp93 residue in the ATP-binding pocket of the N-terminus of Hsp90 through the resorcinol moiety (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>B). The purine analogues (PUs)<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> include <b>9</b> (PU-H71),<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a><b>10</b> (PU3), and <b>11</b> (Debio-0932)<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> showing IC<sub>50</sub> values of 42, 15, and 38 nM, respectively, against Hsp90. They share a “purine-linker-aryl” template, among which the 6-aminopyrimidine group in the adenine part forms one H-bond with the Asp93 residue and two water-mediated H-bonds with Leu48, Asn51, Ile91, Gly97, and Thr184 (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>C).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The 2-aminobenzamide analogues (ABZs)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> include <b>12</b> (SNX-2112) and its prodrug <b>13</b> (SNX-5422), having IC<sub>50</sub> values of 3 and 32 nM, respectively, against HT-29 colonic adenocarcinoma cells. They form key interactions through the typical benzamide functionality with the Asp93 residue of Hsp90 (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>D).<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37, 38)</a></div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/medium/jm-2015-01106x_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Interaction modes of Hsp90 Inhibitors with the N-terminal domain of Hsp90. A critical H-bond is generally formed between Asp93 of Hsp90 and the inhibitors. (A) Geldanamycin and its derivatives. The carbamate moiety forms a H-bond with Asp93. (B) The resorcinol derivatives. The resorcinol moiety forms an H-bond with Asp93. (C) The purine analogues. The 6-aminopyrimidine moiety forms an H-bond with Asp93. (D) The 2-aminobenzamide derivatives. The amide moiety forms an H-bond with Asp93.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The coumarin antibiotic novobiocin was the first natural product identified as a C-terminal Hsp90 inhibitor. It binds at a second ATP-binding site in the C-terminus of the chaperone. In SKBR3 breast cancer cells, novobiocin dose-dependently reduced protein levels of p185erbB2, mutated p53, and Raf-1 with maximal activity occurring at concentrations of 500–800 uM.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Recent efforts have delivered new analogues, showing much improved potency and selectivity against the C-terminal Hsp90, but further validation of these inhibitors in vivo is needed.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div><div class="NLM_p last">In addition to the N- or C-terminal Hsp90 inhibitors that bind to the ATP-binding pocket, the non-ATP competitive Hsp90 inhibitors have attracted more and more interest recently and are expected to arrest the chaperone cycle by different mechanisms. It has been proposed that inhibitors targeting the Hsp90–cochaperone (e.g., celastrol,<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40, 41)</a> (3<i>E</i>,5<i>R</i>,7<i>S</i>,8<i>S</i>,11<i>E</i>,13<i>R</i>,15<i>S</i>,16<i>S</i>)-3,5,7,11,13,15-hexamethyl-8,16-bis(5-oxazolylmethyl)-1,9-dioxacyclohexadeca-3,11-diene-2,10-dione (FW-04-806)<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a>) or the Hsp90–client complex (e.g., gambogic acid,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> San A-amide<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44, 45)</a>) may be more effective in regulating the function of Hsp90. Indeed, some agents have been reported to be capable of inhibiting Hsp90 by disrupting the interactions between Hsp90 and its cochaperones or/and clients. Yet, because of the lack of direct experimental evidence, the exact mechanisms of these inhibitors are elusive.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">2.2 Questions Surrounding Hsp90 Inhibitors As a Monotherapy in the Treatment of Hsp90-Overexpressing Tumors</h3><div class="NLM_p">To date, more than 20 Hsp90 inhibitors have successively entered clinical trials, all of which are ubiquitous N-terminal Hsp90 inhibitors.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Although these inhibitors were expected to exert antitumor effects with more clinical benefits than the traditional chemotherapy, none of them has successfully reached the market (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, in pink). One of the major reasons for the failure of current Hsp90 inhibitors as monotherapy is partially due to chemical structure-related toxicities that limit their clinical applicable dosages. For example, geldanamycin analogues generally suffer from hepatotoxicity likely due to the existence of a quinone moiety, whereas the resorcinol fragment in resorcinol analogues is generally relevant to multiple adverse effects, especially ocular toxicity, diarrhea, and others. Another major concern for Hsp90-targeting therapy lies in the lack of knowledge to stratify the patients who would most likely benefit from the therapy. Meanwhile, the intrinsic supportive “non-oncogene addiction” features of Hsp90 make it difficult to identify therapeutic indicators based on its genetic status, such as mutation or amplification.<a onclick="showRef(event, 'ref23 ref32 ref46'); return false;" href="javascript:void(0);" class="ref ref23 ref32 ref46">(23, 32, 46)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Clinical Status of Representative Hsp90 Inhibitors<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/medium/jm-2015-01106x_0012.gif" alt="" id="GRAPHIC-d604e562-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/medium/jm-2015-01106x_0013.gif" alt="" id="GRAPHIC-d604e563-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/medium/jm-2015-01106x_0014.gif" alt="" id="GRAPHIC-d604e564-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/medium/jm-2015-01106x_0015.gif" alt="" id="GRAPHIC-d604e565-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/medium/jm-2015-01106x_0016.gif" alt="" id="GRAPHIC-d604e566-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Data were from the Thomson Reuters Cortellis at <a href="http://lifesciences.thomsonreuters.com/products/cortellis" class="extLink">http://lifesciences.thomsonreuters.com/products/cortellis</a> (accessed on August 1, 2015). ORR, objective response rate; PR, partial response; CR, complete response; SD, stable disease; PFS, progression-free survival; DCR, disease control rate; NSCLC, nonsmall cell lung cancer; MM, multiple myeloma; MPC, metastatic pancreatic cancer; MBC, metastatic breast cancer; HRPC, hormone-refractory metastatic prostate cancer; TNBC, triple negative breast cancer; GIST, gastrointestinal stromal tumors; CRPC, castration-resistant prostate cancer.</p></div></div><div></div></div><div class="NLM_p last">Compared to the failure of Hsp90 inhibitors as a traditional chemotherapy, fortunately, significant progress has been achieved in several tumor subtypes bearing the “highly sensitive oncogenic tyrosine kinase clients”. Among these, clinical results on Hsp90 inhibitors against human epidermal growth factor receptor-2 (HER2)-positive trastuzumab refractory metastatic breast cancer (MBC) and the fusion protein from echinoderm microtubule-associated protein-like 4 and the anaplastic lymphoma kinase (EML4-ALK)-positive crizotinib-resistant nonsmall cell lung cancers (NSCLCs) are even more promising. Therefore, Hsp90 inhibitors have been reignited as an alternative strategy to combat the endless resistance surrounding tyrosine kinase inhibitors (TKIs) (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, in green). Although the underlying mechanisms are still unknown, significant progress has been achieved recently in the structure and function study of the Hsp90–cochaperone–client complex, which may be useful to rationalize the antiresistance effects of Hsp90 inhibitors and to provide some instructive information to guide the design of new Hsp90 inhibitors as well. In this regard, the rest of this perspective will focus on recent studies on the interactions of Hsp90 with its oncogenic kinase clients followed by the preclinical and clinical uses of Hsp90 inhibitors to fight against the resistance of TKIs.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">3 Recent Advances in the Structure and Function of Complexes between Hsp90 and Its Oncogenic Clients</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03264" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03264" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">3.1 The Thermal and Conformational Stability of the Client Proteins Determines the Hsp90–Client Interaction</h3><div class="NLM_p">In contrast to the smaller chaperones Hsp70 and Hsp60, the mechanism by which Hsp90 recognizes and discriminates its clients as well as the corresponding tumors is not known. A large number of oncogenic proteins have been reported to be the clients of Hsp90, many of which have unrelated amino acid sequences, diverse functions, and metastable folding characteristics. Therefore, many cochaperones have been reported to play important roles to assist Hsp90 functioning by involving in the rather complex Hsp90–client interactions.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><div class="NLM_p">In 2012, Lindquist and co-workers systematically and quantitatively studied the interactions of the cochaperone cell division cycle 37 (CDC37) with many of the Hsp90 clients, including most human kinases, transcription factors (TFs), and E3 ligases.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> They found that most kinases interacted with CDC37 similar to how they interacted with Hsp90. Furthermore, although the interactions between Hsp90 and kinases varied in a range of 100-fold, all of these interactions were reduced after CDC37 knockdown. These results indicated that CDC37 is a highly specialized cochaperone adaptor that assists Hsp90 in recognizing its kinase clients. Considering the role of Hsp90 in the evolutionary process, the Lindquist group proposed that the amino acid sequences of the client kinases may have evolved more quickly than those of nonclients. After analyzing the protein expression data and comparing the thermal stability of 56 known kinase domains with the interaction profiles of Hsp90, they found that the quantitative interaction scores of the Hsp90–clients were highly correlated with the thermal instability of the kinase.</div><div class="NLM_p">As an example, the same group studied the effects of different inhibitors of the fusion oncoprotein BCR-ABL, formed from the breakpoint cluster region protein (BCR) and the Abl protein, on the thermodynamic parameters of the Hsp90–client interactions. The ATP-competitive BCR-ABL inhibitors imatinib and dasatinib, which bind to the inactive and active conformations, respectively, were found to stabilize the BCR-ABL kinase. In the contrast, the T315I gatekeeper mutant prevented the corresponding binding and stabilization of BCR-ABL. As a result, both imatinib and dasatinib decreased the Hsp90–BCR-ABL interactions, whereas the Hsp90–BCR-ABL<sup>T315I</sup> interactions were not affected.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div><div class="NLM_p">More evidence was obtained recently from Bayliss’ study on the variations of another fusion oncoprotein EML4-ALK.<a onclick="showRef(event, 'ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref48 ref49">(48, 49)</a> EML4-ALK is a highly sensitive client of Hsp90, and the fusion of EML4 to ALK in NSCLCs by gene translocation causes the expression of several oncoprotein fusion variants. Bayliss’ group successfully obtained a 2.6 Å crystal structure of the representative ∼70 kDa core of EML1 and named as the tandem atypical propeller in the EML domain (TAPE) that contains two tightly interconnected β-propellers. Subsequent mapping of the characteristic breakpoints of the EML4-ALK variants onto the structure indicated that the EML4 TAPE domain is truncated in many variants (1, 2, 3a, and 5a), likely causing the fusion protein to be structurally unstable.</div><div class="NLM_p last">After testing the sensitivity of EML4-ALK variants to the Hsp90 inhibitor <b>6</b>, variant 1, with the breakpoint falling within the N-terminal β-propeller, and variant 2, with the breakpoint falling within the C-terminal β-propeller, were less stable than the other variants. Subsequent treatment with <b>6</b> led to a significant reduction of both variants 1 and 2, whereas the expression of variants 3a and 5a remained stable. Meanwhile, <b>6</b> showed an IC<sub>50</sub> value of 11 nM against Ba/F3 cells overexpressing EML4-ALK variant 1, which was more potent than that against cells overexpressing the other variants.<a onclick="showRef(event, 'ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref48 ref49">(48, 49)</a></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">3.2 Advances in the Study of Structures of the Hsp90–Client Complex</h3><div id="sec3_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10">3.2.1 Structural Studies of the Hsp90–Cochaperone (CDC37, Aha1, p23) Complexes</h4><div class="NLM_p">Hsp90 function is dependent on the assistance of a number of cochaperones, which are indispensable for ATPase regulation, conformational changes, the selection of and binding with specific substrates, and the subsequent dynamics and activation of Hsp90. For example, CDC37, as mentioned earlier, is an important cochaperone for the recognition of kinase clients; the cochaperone Hop/Sti1 is believed to be involved in the early stages of the Hsp90 functional cycle and to help in recruiting Hsp70-bound client proteins, such as steroid hormone receptors, and for Hsp90 binding.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></div><div id="sec3_2_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i11" class="anchor-spacer"></div><h5 class="article-section__title" id="_i11">1 Structural Study of the Hsp90–CDC37 Complex</h5><div class="NLM_p">In 2004, Prodromou’s group obtained several diffraction-quality crystals of a complex between the C-terminus of human CDC37 (148–347) and the N-terminus of yeast Hsp90 (1–208) and found that CDC37 binds to the lid segment of the N-terminus of Hsp90 (100–121) through helices 2, 3, and 5.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> The interaction center involves a hydrophobic interface formed by Ala103, Ala107, Ala110, Ala112, Met116, and Phe120 of Hsp90, together with Met164, Leu165, and Ala204 of CDC37. The interface is reinforced by several polar interactions formed between Gln119 of Hsp90 and Gln208 of CDC37 and between Ser109 of Hsp90 and Lys202 of CDC37 (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>).</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/medium/jm-2015-01106x_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Interface of the Hsp90 and CDC37 complex. The interface between the lid segment (residues 100–121, yellow cartoon) of N-Hsp90 and the helices (residues Met164, Leu165, and Ala204, blue cartoon) of C-CDC37 is reinforced by several polar interactions highlighted by magenta dot lines (taken from PDB ID code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1US7">1US7</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">After the amino acid residues in the interface were mutated, the ATPase activity of Hsp90 was found no longer sensitive to a CDC37 inhibitor, indicating that the interface observed in the crystal structure is indeed the functional interface of the Hsp90–CDC37 complex. To reveal the mechanism by which CDC37 arrests the ATPase cycle of Hsp90, the same group identified an important H-bond formed between Arg167 of CDC37 and Glu33 of Hsp90, which likely induces alterations of the electronic and chemical environment at the top of the ATP binding pocket. On the basis of this analysis, it can be proposed that CDC37 regulates the ATPase activity of Hsp90 by first inserting the Arg167 into the mouth of the nucleotide binding pocket of Hsp90 and subsequently forming an H-bond with Glu33.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></div><div class="NLM_p last">In 2009, Schwalbe and co-workers studied the complex between the middle domain of human CDC37 and the N-terminal domain of human Hsp90 by heteronuclear magnetic resonance (NMR) spectroscopy. The data suggested a large interface between these two proteins, and Leu205 in CDC37 was crucial for the protein–protein interaction.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></div></div><div id="sec3_2_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i12" class="anchor-spacer"></div><h5 class="article-section__title" id="_i12">2 Structural Study of the Hsp90–p23 Complex</h5><div class="NLM_p">In 2006, Pearl and co-workers disclosed a crystal structure of the full-length yeast Hsp90 in a complex with β-γ-imidoadenosine 5′-phosphate (AMP-PNP, an ATP analogue) and the cochaperone Sba1 (the yeast homologue of p23). As shown in <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>, two p23/Sba1 molecules are symmetrically opposed on each side of the Hsp90 dimer in the “closed” state. Conformational alternations in N- and M-domains of Hsp90 were identified from the Hsp90–p23–ATP complex. The two N-terminal β-strands (residues 1–9) from each monomer swap and bind to the β-sheet in the other monomer. The “lid” segment (residues 94–125) folds over the ATP-binding pocket by swinging nearly 180° from its “open” position. The movement of the lid segment pushes the exposed hydrophobic patch to form a substantial interface with the other monomer. The M-segments move together and interact with the N-domain of the other monomer. All of these changes produce a reinforced ATP-bound conformation and extend the lifetime of the state required for client activation (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>).<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a></div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/medium/jm-2015-01106x_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Crystal structure of the Hsp90–p23–ATP complex. The complex structure is shown as cartoon in green (Hsp90) and purple (p23/Sba1). Two p23/Sba1 molecules bind to the N-terminal domains of the Hsp90 dimer in a symmetrically closed conformation (taken from PDB ID code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2CG9">2CG9</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/medium/jm-2015-01106x_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Conformational changes in the N- and M-domains of Hsp90 (green) upon interacting with an ATP analogue (red) and p23/Sba1. The “lid” segment (residues 94–125), colored in blue, folds over the ATP-binding pocket by nearly 180° from its “open” position, resulting in the exposure of a hydrophobic patch. The M-segments move together and interact with the N-domain of the other monomer (taken from PDB ID codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2IOQ">2IOQ</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2CG9">2CG9</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Because the human chaperone system is far more complex than that of the yeast, cocrystals of full-length human Hsp90 with cochaperones or clients would be more informative. In 2011, Rüdiger and co-workers characterized the Apo and ATP states of the soluble, full-length human Hsp90 protein by NMR spectroscopy.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> By mapping the chemical shift perturbations of the full-length Hsp90, they proposed a mechanism for the Hsp90–p23 interaction. First, ATP binds to both N-terminal domains of Hsp90, followed by the dimerization of the N-domains and the subsequent conformational change of Hsp90 to a closed state. One p23 molecule then binds to both N-terminal domains of the Hsp90 dimer and interacts with the M-domain as well.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></div></div><div id="sec3_2_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i13" class="anchor-spacer"></div><h5 class="article-section__title" id="_i13">3 Structural Study of the Hsp90–Aha1 Complex</h5><div class="NLM_p">In contrast to the cochaperones CDC37 and p23 that inhibit the ATPase cycle of Hsp90, Aha1, the activator of Hsp90 ATPase, is the only cochaperone of Hsp90 that stimulates the ATPase activity. Hch1, the high copy Hsp90 suppressor, is an isoform of Aha1 and shares high sequence homology to the N-terminal part of Aha1. These two cofactors can directly bind through the N-terminal domains to the central segment of Hsp90 that is essential for Hsp90-dependent activation of its clients. To investigate the Aha1-induced regulation mechanism, Pearl and co-workers obtained a crystal of the N-terminal domain (1–153) of Aha1 in complex with the middle segment of Hsp90 (273–530).<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> A structural analysis and mutagenesis study showed that the binding to the N-terminus of Aha1 induced a conformational switch in the catalytic loop (370–390) in the middle segment of Hsp90. As a result, the catalytic Arg380 residue was released to interact with the ATP binding site in the N-terminal domain of Hsp90.</div><div class="NLM_p last">Later, Buchner’s group identified a larger interface and more complex interactions between the full-length Hsp90 and Aha1 proteins using multidimensional NMR techniques than those revealed by crystal structures.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> On the basis of this result, it is likely that one subunit of Aha1 is used for the ATPase activity-related conformational change and the other is responsible for substrate protein processing.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a></div></div></div><div id="sec3_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14">3.2.2 Structural Study of the Hsp90–CDC37–CDK4 Complex</h4><div class="NLM_p">In 2006, Pearl’s group obtained an Hsp90–CDC37–CDK4 (cyclin-dependent kinase 4) complex, defined its stoichiometry, and determined its three-dimensional structure by single-particle electron microscopy (SPEM).<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> They first fit the known crystal structure of Hsp90 into the electron microscopy (EM) reconstruction by adjusting the relative orientations of Hsp90 domains through small rotations in the hinge regions and placing the M-terminal domain of CDC37 into the EM reconstruction. The final docking results revealed that the C-terminal domain of CDC37 binds to the N-terminal domain of Hsp90, while the N-terminal domain of CDC37 interacts with the kinase domain of CDK4. In addition, the larger C-terminal lobe of the CDK4 client is believed to associate with the M-domain of Hsp90, while the smaller N-terminal domain of CDK4 is associated with N-terminal domain of Hsp90, CDC37, or both proteins (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). This robust system is the first structural model of Hsp90 bound to its natural, folded client in a mature state. Although the structural details of the complex are still unavailable due to the low-resolution of the negative stained EM, Pearl’s work provides preliminary evidence on the Hsp90–cochaperone–client supercomplex that may be critical for Hsp90s recognition of both its wild-type and mutant oncogenic kinase clients.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/medium/jm-2015-01106x_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. EM reconstruction of the Hsp90–CDC37–CDK4 complex. The structure was revised from the EM reconstruction and the crystal structures of Hsp90, CDC37, and CDK4 (PDB ID codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2CG9">2CG9</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1US7">1US7</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2W99">2W99</a>). The C-terminal lobe of CDK4 (red cartoon) interacts with the M-domain of the Hsp90 monomer (green cartoon), and the small N-domain interacts with either the N-terminal domain of Hsp90 or the N-terminal domain of CDC37, while the C-terminal domain of CDC37 (blue cartoon) interacts with the other Hsp90 monomer, forming an asymmetrical complex.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In addition to tyrosine kinases, many nonkinase proteins are also clients of Hsp90. Therefore, there might be some similarities in the binding modes of Hsp90 with these diverse classes of clients, which will in turn enlighten our understanding of Hsp90<b>–</b>kinase interactions. For example, Rüdiger and co-workers<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> recently developed a specific isotope labeling strategy and obtained a structural model of Hsp90 with the microtubule-associated protein Tau in the Tau-bound state. Meanwhile, structural study on the interaction between Hsp90 and hormone-bound glucocorticoid receptor (GR) was also reported recently.<a onclick="showRef(event, 'ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref59 ref60">(59, 60)</a></div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">4 Targeting Hsp90 As a Promising Strategy to Combat Tyrosine Kinase Inhibitor Resistance</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08540" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08540" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">4.1 Drug Resistance: An Unmet Challenge of Tyrosine Kinase Inhibitors (TKIs)</h3><div class="NLM_p last">Drugs targeting the mutations in or rearrangements of receptor tyrosine kinases (RTK) (e.g., mutated EGFR, amplified HER2, or fused EML4-ALK) have become the most successful approach in the paradigm of molecular-targeted cancer therapy in the past few decades.<a onclick="showRef(event, 'ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref61 ref62">(61, 62)</a> Nearly 30 small molecule inhibitors targeting one or more different RTKs have been successfully launched in the market to treat the corresponding kinase-addictive patients. Despite the remarkable success, most patients eventually suffer from relapse and tumor regrowth due to the development of acquired resistance.<a onclick="showRef(event, 'ref63 ref64 ref65 ref66 ref67'); return false;" href="javascript:void(0);" class="ref ref63 ref64 ref65 ref66 ref67">(63-67)</a> Therefore, the development of next-generation TKIs that tackle the resistance to the early generation inhibitors has become a major challenge in this field.<a onclick="showRef(event, 'ref63 ref64 ref68 ref69 ref70'); return false;" href="javascript:void(0);" class="ref ref63 ref64 ref68 ref69 ref70">(63, 64, 68-70)</a> Fortunately, more and more studies have shown that the intrinsic feature of the Hsp90 chaperone in complex with multiple oncogenic kinase clients has provided the rationale for targeting Hsp90 as a novel solution to treat both the client kinase-positive and kinase inhibitor-resistant patients.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">4.2 Application of Hsp90 Inhibitors in the Battle against TKI Resistance</h3><div class="NLM_p">Within the last 10 years, a number of preclinical or clinical studies of Hsp90 inhibitors have been conducted in various TKI-resistant tumor cells or patients, and the overall results are promising, particularly for studies investigating the highly sensitive client RTKs, including EML4-ALK, HER2, EGFR, BRAF, c-Met, and others (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, in green).</div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18">4.2.1 Hsp90 Inhibitors Overcome Drug Resistance to EML4–ALK TKIs</h4><div id="sec4_2_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i19" class="anchor-spacer"></div><h5 class="article-section__title" id="_i19">1 ALK Represents One of the Highly Sensitive Clients of Hsp90</h5><div class="NLM_p">EML4-ALK is an oncogenic protein discovered in NSCLC, and its first-generation ALK inhibitor crizotinib was discovered in 2011, showing over 60% of objective response rates (ORR) and impressive rate of progression-free survival (PFS) in EML4-ALK-positive NSCLC patients. However, resistance to this drug was developed rapidly, within one year, leading to patient relapse and tumor regrowth. The recently approved second-generation ALK inhibitors ceritinib and alectinib were found to effectively tackle the major secondary mutations observed in resistant patients, particularly the L1196M gatekeeper mutation. However, because of the highly complex mechanisms of crizotinib resistance, new inhibitors capable of overcoming a wider spectrum of resistant mutants and reducing the activation of multiple bypass signals are needed (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>).<a onclick="showRef(event, 'ref71 ref72'); return false;" href="javascript:void(0);" class="ref ref71 ref72">(71, 72)</a></div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/medium/jm-2015-01106x_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. ALK signaling pathway, mechanisms of resistance to ALK-TKIs, and application of Hsp90 inhibitors to overcome the resistance. The EML4-ALK fusion protein (dark gray) is aberrantly expressed in cancer. ALK-TKIs (dark violet), such as crizotinib, could bind to the ATP-binding pocket of EML4-ALK, inhibit the kinase activity, and block the downstream signaling pathways. The resistance mechanisms of ALK-TKIs are rather complicated, and Hsp90 inhibitors (red) are effective against the acquired resistance through diverse mechanisms.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Earlier in 2010, Wong and co-workers found that the Hsp90 inhibitor <b>2</b> had a dramatic inhibitory effect against EML4-ALK-driven tumor cells. When ALK-dependent H3122 cells were treated with <b>2</b> at concentrations as low as 25 nM for 1 h, a marked degradation of EML4-ALK was observed, indicating that EML4-ALK is a sensitive Hsp90 client.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> The Normant group further demonstrated that EML4-ALK may be one of the most sensitive clients of Hsp90. They incubated EML4-ALK-positive, HER2-positive, and both wild-type and mutant EGFR-dependent cells with the Hsp90 inhibitor <b>4</b> (1 μM) and found that EML4-ALK was completely depleted within 3 h, while most of the HER2 and mutant EGFR were degraded after 24 h, suggesting that EML4-ALK is a more sensitive client than either mutant EGFR or HER2.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a></div></div><div id="sec4_2_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i20" class="anchor-spacer"></div><h5 class="article-section__title" id="_i20">2 Hsp90 Inhibitors Are Even More Potent Than ALK Inhibitors in Both ALK-Dependent Cells and Xenograft Models</h5><div class="NLM_p">In 2011, Normant’s group incubated the Hsp90 inhibitor <b>4</b> with two types of HEK293FT cells for 72 h, one expressing ALK with a kinase dead mutant (293FT<sup>ALK-KD</sup>) and the other expressing the active EML4-ALK fusion protein (293FT<sup>ALK</sup>). They found that <b>4</b> (either 100 nM or 1000 nM) had little effect on the 293FT<sup>ALK-KD</sup> cells, while the growth of the 293FT<sup>ALK</sup> cells was significantly suppressed. Further, the same group studied the antitumor effect of <b>4</b> in the NSCLC xenograft model expressing EML4-ALK-addicted H3122 cells. Encouragingly, <b>4</b> showed tumor regression at the dose of 75 mg/kg twice weekly, which was comparable to that of a daily dose of 50 mg/kg of the ALK inhibitor crizotinib.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a></div><div class="NLM_p last">Proia and co-workers recently investigated the antitumor effects of Hsp90 inhibitor <b>6</b> against ALK-rearranged NSCLC cells as well as ALK-positive NSCLC xenograft models. It was found that <b>6</b> was nearly 20-fold more potent than crizotinib (IC<sub>50</sub>: 13 vs 202 nM) in EML4-ALK-dependent H2228 cells. Similarly, <b>6</b> also showed a significant antiproliferative effect, with an IC<sub>50</sub> of 10 nM against ALK-driven H3122 cells, which was nearly 30-fold more potent than that of crizotinib (IC<sub>50</sub>: 300 nM). More encouragingly, at the weekly dose of 50 mg/kg, <b>6</b> markedly suppressed tumor growth in the ALK-positive NSCLC xenografts and showed extended overall survival in the H3122 xenograft model.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></div></div><div id="sec4_2_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i21" class="anchor-spacer"></div><h5 class="article-section__title" id="_i21">3 Hsp90 Inhibitors Are Highly Effective against Acquired Resistance to ALK Inhibitors Driven by Various Resistant Mechanisms</h5><div class="NLM_p"><i>Hsp90 inhibitors can effectively overcome crizotinib resistance caused by various secondary mutations</i>: By treating nucleophosmin (NPM)-ALK-expressing BaF3 cells with various concentrations of crizotinib, Proia’s group recently successfully obtained 15 different mutations associated with crizotinib resistance in the ALK kinase domain, including six that had been clinically observed in NSCLC patients. Compared to its potency against the parental cells, crizotinib was approximately 1.6–5-fold less potent against these mutants. However, the Hsp90 inhibitor <b>6</b> showed a nearly identical high potency against cells expressing all of these secondary mutations and the corresponding parental cells, indicating that all of these NPM-ALK mutants were sensitive clients of Hsp90.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></div><div class="NLM_p"><i>Hsp90 inhibitors can effectively overcome crizotinib resistance caused by both ALK gene amplification and kinase mutations</i>: Gene amplification is another mechanism of crizotinib resistance in NSCLC patients. To test whether an Hsp90 inhibitor is effective against ALK gene amplification-related resistance, Proia and co-workers treated NB-39-nu neuroblastoma cells that express 30–40 copies of the ALK gene per cell with <b>6</b> and crizotinib, respectively. They found that the Hsp90 inhibitor <b>6</b> showed increased sensitivity in the ALK gene amplified cells, with an IC<sub>50</sub> of 10 nM, whereas the ALK inhibitor crizotinib was at least 20-fold less potent (IC<sub>50</sub> = 240 nM) in the same cell lines.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> Similarly, Shaw and colleagues found that treatment of <b>2</b> at the dose of 10 nM for 72 h significantly suppressed the growth of H3122 CR cells bearing both EML4-ALK gene amplification and the L1196 M gatekeeper mutation.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a></div><div class="NLM_p"><i>Hsp90 inhibitors can effectively overcome ALK inhibitor resistance driven by the activation of alternative signaling pathways</i>: In 2014, Yano and co-workers found that addition of the EGFR ligand EGF and the MET ligand HGF (hepatocyte growth factor) to the EML4-ALK-dependent NSCLC cells induced resistance to the second-generation ALK inhibitor alectinib. However, treating these cells with 0.3 μM of the Hsp90 inhibitor <b>3</b> for 24 h significantly inhibited the viability of the resistant cells.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></div><div class="NLM_p last"><i>Hsp90 inhibitors can effectively overcome crizotinib resistance caused by unknown mechanisms</i>: Recently, Normant’s group incubated H3122 cells with crizotinib and obtained resistant cells (H3122R) with unknown mechanisms other than secondary mutations or gene amplification. Crizotinib was found at least 12-fold less sensitive against the resistant cells than the parental cells. Surprisingly, these resistant cells were sensitive to the Hsp90 inhibitor <b>4</b>, with GI<sub>50</sub> values of 76 nM.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Similarly, Proia’s group also obtained a resistant H3122 CR1 cell line through an unknown mechanism by incubating the H3122 cells with crizotinib. The cell line was insensitive to either the first-generation ALK inhibitor crizotinib or the second-generation ALK inhibitor alectinib; however, it was much more sensitive to the Hsp90 inhibitor <b>6</b>.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></div></div><div id="sec4_2_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i22" class="anchor-spacer"></div><h5 class="article-section__title" id="_i22">4 Clinical Advances of Hsp90 Inhibitors in the Battle against Crizotinib Resistance</h5><div class="NLM_p">On the basis of the promising preclinical results of the Hsp90 inhibitor against the resistance caused by crizotinib treatment, many clinical trials of these inhibitors have been or are being conducted. In a phase II study of <b>2</b> as monotherapy in advanced NSCLC patients, eight ALK<sup>+</sup> patients were identified. Among which, four achieved PR, three showed SD, and one experienced disease progression after 16 weeks. Further compelling evidence was obtained from a 24-year-old male with ALK+ NSCLC and had progressed on crizotinib after 12 month-treatment. The computed tomography (CT) imaging revealed significant tumor shrinkage following one cycle monotherapy with <b>2</b>.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a></div><div class="NLM_p">In 2010, a phase I/II trial with <b>4</b> was reported in 76 NSCLC patients who progressed on EGFR inhibitor treatment. Among the three patients with an ALK gene rearrangement, two had PR and the third had prolonged stable disease (SD, 7.2 months, 24% reduction in tumor size). Grades 1 and 2 fatigue, nausea, and diarrhea were the most common adverse events observed. This result indicated the Hsp90 inhibitor <b>4</b> might be a more efficient treatment for NSCLC patients bearing ALK rearrangements.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a></div><div class="NLM_p">In a phase II trial of <b>6</b> in patients with stage IIIB or IV NSCLC who had received prior TKI treatment or chemotherapy, significant tumor shrinkage was observed in one patient who had ALK<sup>+</sup> cancer progression and was previously treated with crizotinib.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> In 2013, another phase II trial of <b>6</b> with 99 NSCLC patients was disclosed. The objective response rate (ORR) was 4%, and all of the four responders showed PR and were ALK<sup>+</sup> crizotinib-naïve.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> More trials of <b>6</b> in combination with crizotinib in ALK-rearranged NSCLC patients are ongoing (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).</div><div class="NLM_p">In a phase II trial of the Hsp90 inhibitor <b>7</b> in the ALK-positive stratum patients (n = 22), the ORR, disease control rate (DCR), and the rate of progression-free survival (PFS) at 18 weeks were 32, 59, and 36%, respectively.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Meanwhile, in ALK-positive patients who were naïve to crizotinib (n = 8), the ORR, DCR, and the rate of PFS at 18 weeks were 50, 100, and 62.5%, respectively. In a similar phase II trial of <b>7</b> with 121 advanced NSCLC patients, 21 patients were ALK-positive. Six of the patients achieved PR, and the estimated PFS at 18 weeks was 42%.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> More trials of <b>7</b> in combination with ceritinib are ongoing (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).</div><div class="NLM_p last">Because the Hsp90 inhibitor <b>8</b> has showed synergistic tumor growth inhibition in combination with crizotinib in preclinical studies, a phase I trial has been conducted. The maximum tolerated dose (MTD) has been determined to be 260 mg/m<sup>2</sup> iv weekly for three weeks on a four-week cycle. The dose-limiting toxicities (DLTs) include infusion-related symptoms, gastrointestinal effects, and fatigue.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> More clinical trials of <b>8</b> in NSCLC patients with or without crizotinib are ongoing.</div></div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23">4.2.2 Hsp90 Inhibitors Overcome Drug Resistance to EGFR TKIs</h4><div id="sec4_2_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i24" class="anchor-spacer"></div><h5 class="article-section__title" id="_i24">1 Application of Hsp90 Inhibitors to Fight Resistance to EGFR TKIs Driven by the T790 M Gatekeeper Mutation or T790M/L858R Double Mutations</h5><div class="NLM_p">The identification of activating EGFR mutations in the kinase domain, which contain small in-frame deletions in exon 19 and single point mutations, most commonly L858R (EGFR<sup>L858R</sup>), has made EGFR one of the earliest MTT in NSCLC. Small molecule EGFR inhibitors (e.g., gefitinib, erlotinib) were found to deliver double ORR and promising PFS for EGFR mutation-positive patients compared with the traditional chemotherapy.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Acquired resistance against these TKIs generally occurred within one year of treatment, and the T790M gatekeeper mutation (EGFR<sup>T790M</sup>) was found to be the major cause of the acquired resistance. Meanwhile, a number of alternative kinases were unexpectedly activated following suppression of the EGFR-TKIs, including c-Met, AXL, NF-κB (nuclear factor kappa B), and others (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>).<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a></div><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/medium/jm-2015-01106x_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. EGFR signaling pathway, mechanisms of EGFR TKIs resistance, and application of Hsp90 inhibitors to overcome EGFR TKIs resistance. EGFR dimerization mediates phosphorylation of this receptor and initiates downstream signaling pathways, such as the PI3K/AKT and RAS/RAF/MEK/ERK pathways (dark gray), which are essential for cancer cell survival and proliferation. Several mechanisms of EGFR TKI resistance have been identified, and Hsp90 inhibitors (red) are effective against the acquired resistance through diverse mechanisms.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It has been shown that several EGFR mutants, particularly EGFR<sup>L858R</sup> and EGFR <sup>L585R/T790M</sup>, as well as MET kinase are all client proteins of Hsp90. Therefore, Hsp90 inhibition was proposed as a mechanism to overcome the EGFR-TKI resistance induced by EGFR mutations or MET amplification (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>).<a onclick="showRef(event, 'ref84 ref85'); return false;" href="javascript:void(0);" class="ref ref84 ref85">(84, 85)</a> In 2008, Solit and co-workers reported that treatment with 0.1 μM of the Hsp90 inhibitor <b>2</b> degraded the mutant EGFR (L858R and A750P) much more quickly than the wild-type EGFR in NIH-3T3 cells. Meanwhile, degradation of the mutant EGFR (L858R, T790M) as well as Raf-1, p-MAPK, p-AKT, and AKT was also observed in human lung adenocarcinoma H1975 cells upon treatment with 0.1 μM of <b>2</b> for 24 h. At the maximum tolerated dose of 75 mg/kg three times per week, <b>2</b> was found to cause a significant growth delay in H3255 (L858R EGFR), H1650 (ΔE746-A750 EGFR), and H1975 xenografts, all of which showed intermediately high levels of resistance to gefitinib treatment. In addition, promising data from a combination of <b>2</b> with paclitaxel suggested that Hsp90 inhibitors may be most effective in combination with cytotoxic compounds in lung adenocarcinoma patients with EGFR mutations, both with de novo and acquired resistance.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> In addition, <b>2</b> was reported to suppress EGFR-AKT-mTOR-p70S6K-S6 signaling at a low concentration of 0.01 μM in cells, regardless of the presence of T790M.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a></div><div class="NLM_p">In 2011, Ying and co-workers compared the antiproliferative effects of the Hsp90 inhibitor <b>6</b> and the EGFR inhibitor erlotinib against the NCI-H1975 drug-resistant cell line that is driven by the EGFR<sup>L585R/T790M</sup> double mutation. They found that <b>6</b> exhibited full potency at the concentration of 25 nM, whereas erlotinib did not exhibit any effects in concentrations ranging from 0.1 to 50 nM.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a></div><div class="NLM_p">Meanwhile, the Proia group reported that in the EGFR<sup>L585R/T790M</sup> double mutant erlotinib-resistant NCI-H1975 cells, treatment with <b>6</b> at the concentration of 50 nM for 24 h resulted in destabilization of EGFR<sup>L585R/T790M</sup>.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Tumor growth inhibition was significantly improved in mice bearing NCI-H1975 tumors. A similar result was observed when <b>6</b> (50 mg/kg) was used in combination with another EGFR TKI, alatinib (5 mg/kg).<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a></div><div class="NLM_p">Prolonged animal survival was also observed after treatment with the Hsp90 inhibitor <b>13</b> alone or in combination with erlotinib in the resistant NCI-H1975 xenografts.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> In addition, Ono and colleagues reported that a combination of aminopyrimidine <b>14</b> (CH5164840) (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>), another Hsp90 inhibitor (12.5 mg/kg daily for 11 days), with erlotinib (25 mg/kg) markedly enhanced the antitumor efficacy in the T790 M gatekeeper mutant NCI-H1975 xenografts.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a></div><figure id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/medium/jm-2015-01106x_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Representative Hsp90 Inhibitors in preclinical or clinical studies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2014, Jeong’s group investigated the antitumor activity of <b>15</b> (WK88-1) (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>), a new GA-derived Hsp90 inhibitor lacking the benzoquinone moiety, and found that treating the gefitinib-resistant H1975 cells with <b>15</b> resulted in the overall degradation of EGFR, ErbB2, and ErbB3, which then induced growth arrest and apoptosis. Meanwhile, the tumor growth in the corresponding xenografts was also significantly suppressed.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a></div><div class="NLM_p last">In 2012, Toyooka’s group examined the antiproliferative effects of <b>3</b> in various cells expressing 13 different EGFR mutants. They found that all thirteen EGFR mutant cells were significantly more sensitive than cells expressing the wild-type EGFR. The subsequent Western blotting analysis showed that the expression levels of EGFR, p-EGFR, p-AKT, p-MAPK, CDK4, and CD1 were depleted in most of the EGFR mutant cells after treatment with 0.2 μM of <b>3</b>, while the proteins in EGFR wild-type cells were only partially depleted after treatment with 1 μM of <b>3</b>. In the mouse xenograft models, <b>3</b> (25 mg/kg) also showed greater growth inhibition in the EGFR mutant tumors (PC-9 and RPC9).<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a></div></div><div id="sec4_2_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25">2 Application of Hsp90 Inhibitors to Fight the Resistance of EGFR TKIs Driven by Mechanisms Other than EGFR Mutations</h5><div class="NLM_p last">Recently, Toyooka’s group found that the Hsp90 inhibitor <b>7</b> could exert antiproliferative effects in gefitinib-resistant HCC827 cells driven by MET amplification (IC<sub>50</sub> = 7.0 nM), and this effect could be significantly enhanced when <b>7</b> (100 nM) was used in combination with ionizing radiation.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> Meanwhile, the Yano and Ying groups studied the effect of the Hsp90 inhibitor <b>3</b> on HGF-triggered resistance and found that in the presence of HGF, both PC-9 and Ma-1 cells expressing EGFR mutants were insensitive to erlotinib. However, <b>3</b> markedly inhibited the cellular growth, with IC<sub>50</sub> values ranging from 0.01 to 0.03 μM. <b>3</b> also showed growth inhibition against the erlotinib-resistant human HGF-transfected Ma-1/HGF cells and in the severe combined immunodeficient (SCID) mice. A study of the molecular mechanism revealed that the growth inhibition of <b>3</b> was associated with the degradation of EGFR, MET, and their downstream signaling intermediates.<a onclick="showRef(event, 'ref88 ref96'); return false;" href="javascript:void(0);" class="ref ref88 ref96">(88, 96)</a></div></div><div id="sec4_2_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26">3 Clinical Advances of Hsp90 Inhibitors in the Battle against EGFR TKI Resistance</h5><div class="NLM_p">Because Hsp90 inhibitors have provided a solid in vitro and in vivo basis in the battle against EGFR-TKI resistance, several of these inhibitors have been further evaluated in the clinic. In 2010, a phase I/II trial with <b>4</b> was reported in 76 NSCLC patients who progressed on EGFR inhibitor treatment. An ORR of 7% (5 of 76) was observed in the overall study population, 10% (4 of 40) in patients who were EGFR wild-type, and 4% (1 of 28) in those with EGFR mutations. Both EGFR groups were below the target ORR (20%), and grade 3 or higher liver function abnormalities were observed in nine patients (11.8%).<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a></div><div class="NLM_p">Early in 2009, Synta Pharmaceuticals initiated a phase II trial of <b>6</b> plus docetaxel in stage IIIB or IV NSCLC patients. The data presented in June 2011 showed that a clinical response was generally observed in patients with advanced NSCLC tumors harboring wild-type EGFR and KRAS.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Of the 76 evaluated patients, the overall disease control rate (DCR; complete response/partial response or stable disease) at 8 weeks was 54% and the overall ORR was 5.3%.</div><div class="NLM_p last">In 2010, Novartis reported a phase II trial of <b>7</b> in patients with advanced NSCLC. In patients with EGFR mutations (n = 35), the ORR was 20% and the DCR was 57% and the rate of PFS at 18 weeks was 35.2%. In patients with EGFR mutations who had an EGFR-TKI as part of their last treatment regimen (n = 19), the ORR, DCR, and the rate of PFS at 18 weeks were 26, 68, and 46.6%, respectively.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> In 2013, a phase II trial of <b>7</b> plus erlotinib in lung cancer patients with EGFR mutations who had acquired resistance to erlotinib met its primary end point (defined as CR + PR at 8 weeks).<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Recently, a phase I/II study of <b>7</b> and erlotinib for EGFR mutant lung cancer with acquired resistance to erlotinib was reported. In phase I, 18 patients were treated with <b>7</b> once per week and erlotinib once per day in 28-day cycles using a 3 + 3 dose-escalation design. The PR was 16% (4 of 25 patients) that was independent of tumor T790 M status. In phase II, 19 additional patients were treated at the maximum tolerated dose (MTD), however, no CR or PR was observed.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> In another study of <b>7</b> in combination with erlotinib to overcome the resistance from EGFR TKI, 16 patients were enrolled and two achieved a PR, both with T790 M gatekeeper mutation. Subsequently, 25 more patients were enrolled. An ORR of 16% and SD of 25% were achieved. Three of the four patients with PR have EGFR T790 M mutation. The result indicated that combination of <b>7</b> with erlotinib can overcome resistance from EGFR TKI treatment.<a onclick="showRef(event, 'ref100 ref101'); return false;" href="javascript:void(0);" class="ref ref100 ref101">(100, 101)</a></div></div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27">4.2.3 Hsp90 Inhibitors Overcome Drug Resistance to BRAF TKIs</h4><div id="sec4_2_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28">1 Application of Hsp90 Inhibitors to Overcome the Acquired Resistance of BRAF Inhibitors</h5><div class="NLM_p">Melanoma is an aggressive form of skin cancer, and the activated tyrosine kinase BRAF mutant (over 90% BRAF<sup>V600E</sup>) is an oncogenic driver in more than half of the melanoma cases. Selective ATP-competitive BRAF<sup>V600E</sup> inhibitors, such as vemurafenib and dabrafenib, typically induce initial profound tumor regression, but unfortunately, long-lasting responses have been limited due to the emergence of drug resistance.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> The gatekeeper mutation has not been observed in BRAF TKI relapsed patients, which is different from the resistance to EGFR TKIs. Instead, two different mechanisms underlying the acquired resistance of BRAF inhibitors have been identified, including mitogen-activated protein kinase (MAPK)-dependent and MAPK-independent mechanisms. The MAPK-dependent resistance is primarily caused by incomplete inhibition of ERK signaling. Therefore, dual inhibition of MEK and BRAF appears to be a promising approach to overcome the acquired resistance to BRAF inhibitors. MAPK-independent resistance is caused by the loss of BRAF dependence that may be driven by activation of the phosphoinositide-3 kinase (PI3K)/AKT pathway due to the loss of phosphatase and tensin homologue (PTEN) or the upregulation of platelet-derived growth factor receptor-β (PDGFR-β) and insulin-like growth factor receptor 1 (IGF-1R).<a onclick="showRef(event, 'ref71 ref102'); return false;" href="javascript:void(0);" class="ref ref71 ref102">(71, 102)</a></div><div class="NLM_p">In 2012, Smalley’s group tested the inhibitory effect of the Hsp90 inhibitor <b>16</b> (XL-888, <a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>) in vemurafenib-resistant melanoma cells. They found that in the four tested resistant cells (WM164R, M229R, M249R, and 1205LuR), treatment with 300 nM of <b>16</b> for 48 h degraded IGF-1R, PDGFR-β, ARAF, CRAF, pERK, pS6, and cyclin D1 and inhibited pAKT, pERK, and pS6 signaling as well. Furthermore, <b>16</b> significantly inhibited tumor growth in vemurafenib-resistant M229R and 1205LuR xenografts at the dose of 100 mg/kg. In addition, <b>16</b> induced significantly higher levels of apoptosis in resistant cells containing COT amplification (a member of the MEK family) and PDGFR-β overexpression compared to MEK/PI3K inhibitors.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a></div><div class="NLM_p">In 2013, Wallis and co-workers found that the Hsp90 inhibitor <b>8</b> could delay the emergence of BRAF inhibitor resistance. First, they treated vemurafenib-sensitive A537 and SK-MEL-28 cells, respectively, with vemurafenib alone or in combination with <b>8</b>. It was found that the cells treated with the BRAF inhibitor alone generated resistant colonies, while the combination with <b>8</b> did not. In vemurafenib-sensitive SK-MEL-28 xenografts, the combination of <b>8</b> with vemurafenib prevented tumor regrowth over 5 months, whereas under the same conditions, treatment with the BRAF inhibitor vemurafenib alone induced tumor relapse.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a></div><div class="NLM_p last">Meanwhile, Proia’s group recently found that <b>6</b> (IC<sub>50</sub>, 15 nM) was 4–13-fold more potent than either the selective BRAF<sup>V600E</sup> inhibitor vemurafenib (IC<sub>50</sub>, 81 nM) or the MEK inhibitor selumetinib (IC<sub>50</sub>, 255 nM) in A375 melanoma cell lines, and the combination of <b>6</b> with vemurafenib or selumetinib synergistically enhanced tumor growth inhibition. As overexpression of COT is another mechanism of intrinsic resistance to BRAF inhibitors, a study was conducted by treating the vemurafenib-resistant, COT-overexpressing, and selumetinib-insensitive RPMI-7951 melanoma cells with <b>6</b>. The result showed that <b>6</b> (50 nM for 24 h) potently abrogated MAPK and AKT signaling and induced apoptosis. In addition, in the vemurafenib-resistant A375 (A375-VR) xenografts, weekly treatment with <b>6</b> (150 mg/kg) in combination with a MEK inhibitor inhibited 84% of tumor growth, which was much higher than that from treatment with MEK inhibitor alone (34%).<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> All of these results suggest that inhibition of Hsp90 is a practical and effective strategy to overcome diverse mechanisms of resistance to BRAF inhibitors.</div></div><div id="sec4_2_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29">2 Clinical Advance of Hsp90 Inhibitors in the Fight against Resistance to BRAF TKIs</h5><div class="NLM_p">An open label phase I trial was conducted in 2014 to evaluate the safety and efficacy of the Hsp90 inhibitor <b>8</b> in combination with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib in melanoma patients (expected n = 38) with BRAF mutations.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a></div><div class="NLM_p last">Exelixis Inc. started a phase I trial of the Hsp90 inhibitor <b>16</b> in combination with vemurafenib in patients with unresectable BRAF mutated stage III/IV melanoma. The results showed that the combination was well tolerated and an overall ORR of 92% was achieved. Tumor regression was observed in 11 of the 12 responded patients with two CR and nine PR. The estimated PFS at 6 and 12 months was 63% and 39%, respectively.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></div></div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30">4.2.4 Hsp90 Inhibitors Overcome Drug Resistance to BCR-ABL TKIs</h4><div class="NLM_p">Chronic myeloid leukemia (CML) is a bone marrow clonal myeloproliferative disorder characterized by the presence of the fusion oncogene BCR-ABL.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> Imatinib mesylate (gleevec) is the first ATP competitive small molecule BCR-ABL inhibitor and showed dramatically improved long-term survival rates in CML patients. However, acquired drug resistance occurs shortly after the treatment, and patients treated with the drug failed to reach sustained remission. The predominant mechanism of imatinib resistance is the occurrence of point mutations in the ABL kinase domain, particularly the T315I gatekeeper mutation, and a number of other mutations, such as Y253H, E255K, M351T, and G250E. In addition, BCR-ABL overexpression also holds great importance during the resistance of BCR-ABL TKIs.<a onclick="showRef(event, 'ref107 ref108'); return false;" href="javascript:void(0);" class="ref ref107 ref108">(107, 108)</a></div><div class="NLM_p">BCR-ABL is also a typical client of the Hsp90 chaperone, and its mutants were reported to be more dependent on Hsp90. Early in 2002, Sawyer’s group tested the antiproliferative effect of Hsp90 inhibitors <b>1</b> and <b>2</b> against hematopoietic cells expressing wild-type BCR-ABL and two imatinib-resistant BCR-ABL mutants. They found that both <b>1</b> and <b>2</b> were 2–5-fold more potent in these cells (∼1–2 μM) than that in cells expressing the wild-type BCR-ABL (∼5 μM).<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a></div><div class="NLM_p">Similarly, Li’s group transplanted bone marrow cells expressing both wild-type BCR-ABL and the T315I gatekeeper mutant into the same recipient mice and treated them with imatinib (100 mg/kg, twice a day) and the Hsp90 inhibitor <b>4</b> (50 mg/kg, once every 2 days). The result showed that cells expressing the gatekeeper mutation became dominant (81.5%) in the imatinib-treated mice after 15 days, while they were negligible (0.5%) in the <b>4</b>-treated mice after 28 days, indicating that the mutant BCR-ABL protein was more sensitive to the Hsp90 inhibitor.<a onclick="showRef(event, 'ref110 ref111'); return false;" href="javascript:void(0);" class="ref ref110 ref111">(110, 111)</a></div><div class="NLM_p">In 2015, Wu and co-workers reported that the curcumin derivative <b>17</b> (C086, <a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>) could potently inhibit the proliferation of imatinib-resistant CML cells through dual suppression of BCR-ABL kinase activity and Hsp90 chaperone function. This compound was highly potent not only against wild-type and mutant BCR-ABL kinases but also against the proliferation of both imatinib-sensitive and -resistant CML cells.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a></div><div class="NLM_p">To gain a deeper insight into how the Hsp90 inhibitor precisely down-regulates the expression of BCR-ABL, Arlinghaus’s group identified a high molecular weight network complex (HMWNC) of signaling molecules in BCR-ABL-positive cells.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> This HMWNC contains Hsp90 and many of its clients, including BCR-ABL, JAK2, STAT3, and AKT, and Hsp90 was directly bound to these clients. Later, they treated BCL-ABL-positive 32Dp210 cells containing the HMWNC with <b>7</b> (0.5 μM) and found that the expression of BCR-ABL dramatically decreased within 1 h in a time-dependent manner, while the degradation of other kinases (e.g., JAK2, AKT) was much slower, indicating that the stabilization of BCR-ABL is more dependent on Hsp90. Meanwhile, after treatment with 10 nM of <b>7</b> for 16 h, the levels of mutated BCR-ABL in the resistant cells (T315I, E255K, and F359V) were dramatically decreased, while the wild-type BCR-ABL was only modestly reduced, suggesting that the mutated BCR-ABL is more sensitive to the Hsp90 inhibitors.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a></div><div class="NLM_p last">Although a few Hsp90 inhibitors have been tested in the clinic in CML patients harboring BCR-ABL mutations, no objective responses have been reported. Therefore, the fate of the Hsp90 inhibitors in the battle against BCR-ABL TKI-induced drug resistance is still under investigation and requires more well-designed clinical investigations.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a></div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31">4.2.5 Hsp90 Inhibitors Overcome Drug Resistance to HER2 TKIs</h4><div id="sec4_2_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32">1 Application of Hsp90 Inhibitors to Overcome HER2 TKI-Induced Drug Resistance</h5><div class="NLM_p">HER2 amplification has been demonstrated in up to 30% of breast cancers and is an important oncogene for tumor initiation and progression. Trastuzumab, a humanized monoclonal HER2 antibody inhibitor, is currently the main first-line therapy for HER2-overexpressing breast cancer patients; however, its widespread and long-term application is limited by the intrinsic and acquired resistance. Several mechanisms have been proposed to underlie the trastuzumab-induced resistance, including the expression of p95-HER2, an N-terminally truncated form of HER2 that has lost the trastuzumab binding epitope, HER2 gene amplification, activation of parallel or/and downstream signaling pathways, and defects in the apoptosis pathway in tumor cells.<a onclick="showRef(event, 'ref115 ref116'); return false;" href="javascript:void(0);" class="ref ref115 ref116">(115, 116)</a></div><div class="NLM_p">In 2009, Rosen’s group treated p95-HER2-expressing T47D cells with the Hsp90 inhibitor <b>12</b> (1 μM for 3 h or 0.1 μM for 6 h) and found a marked reduction in the expression of HER2, p95-HER2, p-HER2, and p-p95-HER2. This result indicated that both HER2 and p95-HER2 are sensitive client proteins of Hsp90. Subsequent treatment with <b>13</b>, an oral prodrug of <b>12</b>, three times per week resulted in complete tumor growth inhibition over two weeks in the p95-HER2-addicted xenograft mice.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a></div><div class="NLM_p">In addition, Baselga and co-workers assessed the antiproliferative effects of Hsp90 inhibitor <b>4</b> in the HER2-overexpressing, trastuzumab-resistant BT474R, SKBR-3R, and BT474H1047R (BT474 cells bearing H1047R mutation) cells. Dose-dependent growth inhibition against all of the resistant cells and downregulation of the total AKT levels were observed. Meanwhile, <b>4</b> significantly inhibited tumor growth in both trastuzumab-sensitive BT474 and trastuzumab-resistant BT474R xenografts. These results correlate well with the observed decrease in the levels of HER2, p-AKT, and p-MAPKs.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a></div><div class="NLM_p last">Recently, Wainberg’s group treated 16 human gastric and 45 breast cancer cell lines with the Hsp90 inhibitor <b>7</b> at various concentrations. They found that the HER2-amplified cells were much more sensitive to the inhibitor. HER2, p-HER2, and AKT were down-regulated by 18 h with treatment of <b>7</b> at 100 nM in two gastric HER2-amplified cells. HER2 signaling through MAPK and AKT was also inhibited. Furthermore, the combination of <b>7</b> (0.58 μg/mL) with trastuzumab (2.5 μg/mL) was synergistic against HER2-amplified, trastuzumab-resistant breast and gastric cells, and in HER2-amplified, trastuzumab-resistant NCI-N87-TR<sup>C</sup>-bearing gastric cancer xenografts.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a></div></div><div id="sec4_2_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33">2 Clinical Advance of Hsp90 Inhibitors in the Battle against HER2 TKI Resistance in Patients</h5><div class="NLM_p">Early in 2005, a phase II trial of the Hsp90 inhibitor <b>2</b> in combination with trastuzumab was conducted in patients with HER2-positive metastatic breast cancer (MBC). Of the 20 evaluated patients, five showed PR, two showed minor responses, and four showed extended SD. In 2012, Modi and colleagues reported an encouraging phase II study of <b>2</b> with trastuzumab in 31 patients bearing advanced trastuzumab-refractory HER2-positive breast cancer. The ORR is 22%, and the clinical benefit rate (CR + PR + SD) is 59%. The median PFS and median OS (overall survival) are 6 and 17 months, respectively. The most common toxicities, largely grade 1, were diarrhea, fatigue, nausea, and headache. This result indicated that the combination of <b>2</b> with trastuzumab possesses significant anticancer activity in HER2-positive MBC previously progressing on trastuzumab.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a></div><div class="NLM_p">In a phase I trial of <b>3</b> in combination with trastuzumab in patients with HER2-positive MBC, eight (42%) of the 19 evaluated patients showed the expected clinical benefit. A similar phase I trial of <b>3</b> in combination with trastuzumab was reported in 2012.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> Of 28 HER2-positive MBC patients, 6.25% ORR and 18.75% SD were observed. Despite the observed antitumor activity, ocular toxicity emerged as a major concern.</div><div class="NLM_p">A phase II trial of <b>4</b> in combination with trastuzumab in patients with HER2-positive MBC was also reported.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> 5% ORR and 70% SD were observed in heavily pretreated patients previously exposed to trastuzumab. No significant hepatic toxicity was observed that warranted this combination for further evaluation.</div><div class="NLM_p">In 2014, a phase II trial of <b>6</b> in an unselected cohort of patients with MBC was reported. Twenty-two patients were enrolled, and most of them had at least two previous lines of chemotherapy in the metastatic setting. Most common toxicities, largely grade 1/2, were diarrhea, fatigue, nausea, and hypersensitivity reaction. 15% OR was seen from the subset patients with HER2-positive MBC. The study did not meet the prespecified criteria for ORR. However, antitumor activity was observed in trastuzumab-refractory HER2-positive patients.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a></div><div class="NLM_p last">In a phase II trial of <b>7</b> in combination with trastuzumab to treat advanced NSCLC patients with HER2 overexpression or amplification or mutation, seven of 31 patients had PR and 16 had SD.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a></div></div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34">4.2.6 Application of Hsp90 Inhibitors to Overcome JAK TKI-Induced Drug Resistance</h4><div class="NLM_p">Janus kinase (JAK) is a family of intracellular, nonreceptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway. Genetic alternations of JAK2 (e.g., V617F and R683G mutations) have been identified in several diseases, especially in cancer and rheumatoid arthritis. The first JAK1/2 inhibitor, ruxolitinib, received the FDA’s approval in 2011 for the treatment of intermediate to high-risk myelofibrosis (MF) patients. Acquired resistance to ruxolitinib has also been identified, and the underlying mechanisms include stabilization of activated JAK2, increased JAK2 mRNA expression, and heterodimerization of activated JAK2 with JAK1 or TYK2.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a></div><div class="NLM_p">Early in 2007, Albitar’s group reported that the Hsp90 inhibitor <b>2</b> resulted in a reduction of p-JAK2, total JAK2, p-STAT5, total STAT5, and total AKT in HEL cells with a homozygous V617F JAK2 mutation. The cell viability was reduced to a much greater extent than that in cells treated with the JAK2-specific inhibitor or the pan-JAK inhibitor.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a></div><div class="NLM_p">A study on the treatment of the Hsp90 inhibitor <b>7</b> with the JAK2 inhibitor <i>N</i>-<i>tert</i>-butyl-3-(5-methyl-2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yl amino)benzenesulfonamide (TG101209) in the JAK2 TKI-resistant cells (HEL/TGR and UKE-1/TGR) indicated that <b>7</b> was synergistic with the JAK2 inhibitor and the combination treatment effectively suppressed the proliferation of JAK2-resistant cells. This result correlates well with the observed reductions of p-JAK2, p-STAT5, p-AKT, and Bcl-xl in these two resistant cell lines after treatment with <b>7</b> (50 nM, 24 h) alone.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a></div><div class="NLM_p last">Similar to the resistance to other TKIs, secondary mutation is an important mechanism underlying the resistance to JAK2 inhibitors. To this end, the Weigert group generated three synthetic mutations in the JAK2 kinase domain (G935R, Y931C, and E864K) together with clinically relevant JAK2 mutations (V617F or R683G). They found that binding of JAK2 inhibitors in the ATP binding site was interrupted in these mutants, leading to much reduced potency.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> However, the Hsp90 inhibitors <b>2</b> and <b>7</b> both showed high cytotoxicity in Ba/F3EpoR cells with a JAK2 V617F mutation and in Ba/F3CRLF2 cells with a JAK2 R683G mutation. Compared to cells with no secondary mutations, <b>7</b> showed greater potency against cells harboring Y931C or E864K mutations.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> In addition, both the JAK2-inhibitor-persistent (JAK2<sup>Per</sup>) and parental cells were reported equally sensitive to the Hsp90 inhibitor <b>9</b>, and treatment with this inhibitor led to degradation of JAK2 and blockade of the subsequent signaling in the JAK2<sup>Per</sup> cells.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a></div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35">4.2.7 Hsp90 Inhibitors Overcome Acquired Resistance to KIT and PDGFR TKIs</h4><div class="NLM_p">The tyrosine kinases KIT and PDGFR (platelet-derived growth factor receptor) are constitutively activated in over 90% of gastrointestinal stromal tumors (GISTs) due to gain-of-function mutations. Therapeutic inhibition of KIT and/or PDGFR by small molecules such as imatinib has achieved objective responses in most GIST patients. However, nearly 10–20% GIST patients have been reported to exhibit primary resistance to imatinib, and patients who initially responded to imatinib often manifested resistant secondary mutations within ∼2–5 years. Because both KIT and PDGFR are oncogenic clients of the Hsp90 chaperone, Hsp90 inhibition may provide an alternative therapeutic strategy to treat imatinib-resistant GIST patients.<a onclick="showRef(event, 'ref130 ref131'); return false;" href="javascript:void(0);" class="ref ref130 ref131">(130, 131)</a></div><div class="NLM_p">In 2005, Wang and co-workers revealed that the Hsp90 inhibitor <b>2</b> (5 μM, 72 h) induced apoptosis and a significant decrease of the KIT protein level in Kasumi-1 cells harboring a KIT A822L drug-resistant mutation.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> Kiyoi’s group also found that <b>2</b> significantly inhibited the colony formation of D816V-KIT-expressing AML cells that was resistant to KIT inhibitors.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> In addition, <b>2</b> (500 nM) markedly reduced p-KIT and total KIT expression and inactivated KIT signaling intermediates such as AKT and MPK in imatinib-resistant, KIT-dependent GIST430 and GIST48 cells but not in imatinib-resistant, KIT-independent GIST62 cells.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a></div><div class="NLM_p">Recently, Smyth’s group tested the antiproliferative potency of the Hsp90 inhibitor <b>8</b> against imatinib-resistant GIST430 and GIST48 cells. The corresponding IC<sub>50</sub> values were 34 and 55 nM, respectively. The results were well correlated with the observed depletions of KIT, p-KIT, AKT, and p-AKT. At the weekly dose of 70 mg/kg, <b>8</b> exhibited tumor growth inhibition against imatinib-resistant GIST430 xenograft models in vivo.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a></div><div class="NLM_p last">PDGFR<sup>ΔDIM842–844</sup> and PDGFR<sup>D842V</sup> are the two GIST-related PDGFR mutations. Debiec-Rychter and co-workers found that the Hsp90 inhibitor <b>4</b> exhibited 10-fold higher potency against the imatinib resistant PDGFR<sup>D842V</sup> (IC<sub>50</sub>: 62 vs 642 nM).<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> Despite the significant preclinical effects of Hsp90 inhibitors in the treatment of drug resistance caused by KIT or PDGFR inhibitors, no clinical settings have been reported yet.</div></div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">5 Conclusion and Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08680" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08680" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Hsp90 is an ATP-dependent molecular chaperone that comprises 1–2% of the total cellular protein content and regulates the correct folding, activation, stability, and functions of numerous regulatory and signaling proteins. In cancer cells, Hsp90 is constitutively expressed at much higher levels and shows elevated ATPase activity compared to normal cells. Under the stress of cancer, Hsp90 forms highly susceptible complexes with its clients under the assistance of cochaperones. Hsp90 inhibitors have been reported, with over 100-fold higher aggregation in cancer cells than in normal cells. Therefore, Hsp90 has been a viable molecular target for cancer drugs and at least 13 selective Hsp90 inhibitors have been or are being exploited in a large number of clinical trials to combat a wide spectrum of tumor types. All these inhibitors belong to the N-terminal Hsp90 inhibitors, including geldanamycin analogues, resorcinol derivatives, and 2-aminobenzamide analogues. Unfortunately, this rapid growth and widely advancing approach has not successfully brought one Hsp90 inhibitor to the market. The major hurdles for the failure of current Hsp90 inhibitors are likely due to the nonoptimal safety profiles and dose-limited insufficient clinical efficacy.</div><div class="NLM_p">Hsp90 exerts its therapeutical effects through formation of supercomplexes with its clients and cochaperones. Recently, much progress has been achieved in the study of the structure and function of the Hsp90–cochaperone–client complex. The recognition of Hsp90 by its kinase clients is dependent on the cochaperone CDC37, and the interactions of Hsp90 with its kinase clients are determined by the thermal and conformational stability of the client proteins. From the available X-ray structures of Hsp90–cochaperone (CDC37, Aha1, p23) complexes, it is proposed that the binding of the cochaperone to Hsp90 often causes conformational changes in Hsp90, and the binding interface of the complex is the functional interface. Unfortunately, no crystal structures of Hsp90 with its kinase clients have been reported, which largely restricts the study of the relationship between the Hsp90–kinase interactions and the anticancer efficacy of Hsp90 inhibitors. From the limited reports on the electron microscopy and NMR studies on the Hsp90–CDC37–CDK4 complexes, it is believed that Hsp90 binds to a broad region of the client through a large binding interface, which may allow more specific recognition by many kinases, including their mutants. This result may guide the computer-aided rational drug design of new inhibitors to target the highly susceptive Hsp90–cochaperone–client supercomplexes by selectively binding to the interaction interface.</div><div class="NLM_p">Although the final fate of Hsp90 inhibitors as monotherapy require more well-designed multidimensional clinical trials, many new attempts have been conducted on the application of Hsp90 inhibitors to combat drug resistance resulting from treatment with tyrosine kinase inhibitors (TKIs), either alone or in combination. This approach has not only renewed and redirected the interest in targeting Hsp90 for cancer therapy but has also opened a new avenue for design and development of Hsp90 inhibitors to fight acquired resistance, the major challenge surrounding TKIs.</div><div class="NLM_p">The application of Hsp90 inhibitors as a new strategy to combat drug resistance of TKIs is based on the fact that all of the oncogenic tyrosine kinases (TK), including their natural forms, resistant mutants, or other activated forms (fusion, translocations, rearrangements), are the clients of Hsp90. These clients form Hsp90–cochaperone–client supercomplexes that are highly sensitive to Hsp90 inhibitors. Hsp90 inhibition prevents Hsp90 from chaperoning these kinase clients, thus leading to destabilization of the kinases and their eventual degradation by proteasomes. More importantly, secondary mutations in the TKs (kinase<sup>mut</sup>) generally underlie the TKI-induced resistance of tumor cells, and the Hsp90–cochaperone–kinase<sup>mut</sup> complexes are even more sensitive to and dependent on Hsp90. Therefore, numerous preclinical and clinical studies have been conducted and the results showed that Hsp90 inhibitors are more efficacious against mutated EGFR, amplified HER2, or fused EML4-ALK than the corresponding specific TKIs, and also highly effective against the TKI-induced acquired resistance.</div><div class="NLM_p">The most promising results were obtained from studies using Hsp90 inhibitors to treat the acquired resistance after treatment with crizotinib, an inhibitor of EML4-ALK. The mechanism of crizotinib resistance is rather complicated, including secondary mutations, such as the L1196M gatekeeper mutation and many other point mutations, alternative kinase activations, such as c-Met, EGFR, and c-Kit, as well as many unknown reasons. Although two next-generation ALK inhibitors (alectinib and ceritinib) have recently been launched to address the mechanism of crizotinib resistance driven by secondary mutations (particularly L1196M), they are ineffective to address the large portion of drug-resistant patients with gene amplifications, alternative pathway activations, and other mechanisms of resistance. Appreciably, Hsp90 inhibitors, both geldanamycin analogues <b>2–4</b> and resorcinol derivatives <b>6–8</b>, were ubiquitously effective against nearly all cases of crizotinib-induced resistance. In a phase II trial with the Hsp90 inhibitor <b>6</b>, significant tumor shrinkage was observed after treatment of <b>6</b> in NSCLC patients who had ALK-positive cancer progression when treated with crizotinib. This drug is now under more clinical trials in combination with either crizotinib or the new inhibitor ceritinib in resistant patients.</div><div class="NLM_p last">Despite of the above-mentioned progress in clinical applications of Hsp90 inhibitors to fight TKI resistance and in the study of the Hsp90–cochaperone–client complex, we must be aware that several critical questions on Hsp90 inhibitors still need to be addressed that have lingered for decades. First, there is still no clue on which cancer patients would benefit most from a specific Hsp90 inhibitor. Innovative strategies (e.g., biomarker, therapeutic indicators, et al.) to stratify patients are highly needed. For a subportion of patients with a specific overexpressed kinase who are resistant to the corresponding kinase inhibitors, Hsp90 inhibitors have been proposed to exert antiresistant efficacies through the Hsp90–cochaperone–kinase complex, but the exact mechanism is not clear. New Hsp90 inhibitors that are designed based on the interaction complex and selectively targeting the interface of the Hsp90–client complex will be extremely useful. Second, to what extent Hsp90 should be inhibited because complete inhibition of Hsp90 eventually leads to the degradation of many client kinases that may cause toxicity. Meanwhile, is there any information related to the level of kinase sensitivity to Hsp90 (EML4-ALK<sup>Mut</sup> > EML4-ALK > HER2 > EGFR<sup>Mut</sup> > Raf-1 > Akt > BRAF<sup>mut</sup> > EGFR)? Finally, Hsp90 isoform selectivity has recently been reported to correlate with the toxicity of Hsp90 inhibitors.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> Is this also an essential issue for Hsp90 inhibitors to overcome TKI’s resistance? Therefore, there is still a long way to go to develop safe and effective Hsp90 inhibitors as a therapeutic treatment to overcome the TKI-induced acquired resistance.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b01106" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82161" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82161" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liping Sun</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, China Pharmaceutical
University, Nanjing 210009, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#0b677b787e654b78626666256a68256865"><span class="__cf_email__" data-cfemail="65091516100b25160c08084b04064b060b">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Meiyu Geng</span> - <span class="hlFld-Affiliation affiliation">Division
of Anti-tumor Pharmacology, State Key Laboratory of Drug Research,
Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2b46524c4e454c6b58424646054a48054845"><span class="__cf_email__" data-cfemail="f19c8896949f96b182989c9cdf9092df929f">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Meining Wang</span> - <span class="hlFld-Affiliation affiliation">CAS
Key Laboratory of Receptor Research, Synthetic Organic & Medicinal
Chemistry Laboratory, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zuchongzhi Lu, Building 3, Room 426, Pudong, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aijun Shen</span> - <span class="hlFld-Affiliation affiliation">Division
of Anti-tumor Pharmacology, State Key Laboratory of Drug Research,
Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chi Zhang</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, China Pharmaceutical
University, Nanjing 210009, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zilan Song</span> - <span class="hlFld-Affiliation affiliation">CAS
Key Laboratory of Receptor Research, Synthetic Organic & Medicinal
Chemistry Laboratory, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zuchongzhi Lu, Building 3, Room 426, Pudong, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jing Ai</span> - <span class="hlFld-Affiliation affiliation">Division
of Anti-tumor Pharmacology, State Key Laboratory of Drug Research,
Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hongchun Liu</span> - <span class="hlFld-Affiliation affiliation">Division
of Anti-tumor Pharmacology, State Key Laboratory of Drug Research,
Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jian Ding</span> - <span class="hlFld-Affiliation affiliation">Division
of Anti-tumor Pharmacology, State Key Laboratory of Drug Research,
Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ao Zhang</span> - <span class="hlFld-Affiliation affiliation">CAS
Key Laboratory of Receptor Research, Synthetic Organic & Medicinal
Chemistry Laboratory, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, 555 Zuchongzhi Lu, Building 3, Room 426, Pudong, Shanghai 201203, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a0c1cfdac8c1cec7e0d3c9cdcd8ec1c38ec3ce"><span class="__cf_email__" data-cfemail="a3c2ccd9cbc2cdc4e3d0cacece8dc2c08dc0cd">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>These authors contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72712" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72712" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Meining Wang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=BIO-d604e1745-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Meining Wang</b> received her B.S. in Medicine in 2010 from China Pharmaceutical University, China, and then joined Professor Ao Zhang’s research group at Shanghai Institute of Materia Medica as a doctoral student in Medicinal Chemistry. Her dissertation research focused on the synthesis of natural product-based analogues and evaluation of their pharmacological properties. She received her doctorate in 2015 and is currently doing postdoctoral research under supervision of Professor Kenner C. Rice at the National Institute on Drug Abuse in the United States.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Aijun Shen</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=BIO-d604e1750-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Aijun Shen</b> received his doctorate in Pharmacology at Shanghai Institute of Materia Medica, Chinese Academy of Sciences, in 2011. After that, he joined Professor Mei-yu Geng’s research group at the same institute. He is now the Assistant Professor of Pharmacology, and his research topic focuses on the biomarker discovery for tyrosine kinase inhibitors and the exploration of molecular mechanisms of Hsp90 inhibitors.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Chi Zhang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=BIO-d604e1755-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Chi Zhang</b> received his M.S. in Medicine in 2012 from China Pharmaceutical University (CPU), China. He is currently a joint doctoral student in Medicinal Chemistry under the supervision of both Professor Li-Ping Sun at CPU and Professor Ao Zhang at the Shanghai Institute of Materia Medica. His dissertation research focuses on the synthesis of natural product-based analogues and evaluation of their pharmacological properties.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Zilan Song</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=BIO-d604e1760-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Zilan Song</b> received her B.S. degree in 2005 from Shanxi Medical University. She was awarded the M.S. degree in Medicinal Chemistry in 2008 from the Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College. After that, she joined Professor Ao Zhang’s research group at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. She is now the Assistant Professor of Medicinal Chemistry, and her research topic focuses on the design and synthesis of novel small molecules targeting tyrosine kinases.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Jing Ai</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=BIO-d604e1765-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jing Ai</b> received her doctorate from the Ocean University of China in 2009. After that, she joined Professor Meiyu Geng’s research group at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. She is now the Associate Professor of Antitumor Pharmacology. Her research interest is mainly focused on the study of molecular targeting drug discovery and tumor biology, especially the mechanism of inflammatory carcinoma malignant transformation and tumor metastasis, identification, and characterization of tyrosine kinase inhibitors, as well as the development of their biomarkers.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Hongchun Liu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=BIO-d604e1770-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Hongchun Liu</b> received her B.S. degree in Pharmacy in 2004 and doctorate in Pharmaceutical Chemistry in 2010 from the Ocean University of China. After that, she joined Professor Jian Ding’s research group at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. She is now the Senior Engineer of Antitumor Pharmacology, and her research topic focuses on the pharmacological evaluation of small molecules targeting HSP90 or HDACs.</p></figure></div><div class="bio" rid="ath7"><figure id="ath7" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Liping Sun</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=BIO-d604e1775-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Li-Ping Sun</b> received her doctorate in Organic Chemistry at Hongkong University of Science and Technology in 2004. After that, she did postdoctoral research at the National University of Singapore. Since 2006, she has been the Professor in Medicinal Chemistry at the China Pharmaceutical University in Jiangsu, China. She has published a number of research papers and expert reviews in the field of drug design and development. Her research interest focuses on design, synthesis, and pharmacological evaluation of small molecules.</p></figure></div><div class="bio" rid="ath8"><figure id="ath8" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Jian Ding</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=BIO-d604e1780-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jian Ding</b> received his doctorate in Medicine at the National Kyushu University in Japan in 1991. Since 1995, he has been a Professor of Pharmacology at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. He was the Director of Shanghai Institute of Materia Medica between 2004 and 2014 and was elected as an Academician of the Chinese Academy of Engineering in 2009. He has published more than 240 research articles in prestigious international journals. He is a receipt of numerous prestigious national awards, including the National Natural Science Award and a few other major technology awards. Dr. Ding’s scientific research has integrated drug discovery, basic research of cancer biology, and translational research.</p></figure></div><div class="bio" rid="ath9"><figure id="ath9" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Meiyu Geng</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=BIO-d604e1785-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Mei-Yu Geng</b> received her Ph.D. in Pharmacology in 1997 from Tokyo University and set her laboratory of Molecular Pharmacology in the Ocean University of China as a Professor. She was selected as “Hundred Talents Program” of the Chinese Academy of Sciences and became a Principle Investigator of Antitumor Pharmacology of Shanghai Institute of Materia Medica in 2006. She received a number of awards including “National Science Foundation for Distinguished Young Scholars”, “National Award for Technological Invention”, and “Outstanding Academic Leader of Shanghai”. She has published more than 130 research articles and reviews in SCI-cited journals. Her interest centers on the research and development of targeted molecular inhibitors and deciphering their molecular mechanisms of cross talks in signal transduction.</p></figure></div><div class="bio" rid="ath10"><figure id="ath10" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Ao Zhang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=BIO-d604e1790-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Ao Zhang</b> received his doctorate in Organic Chemistry in 2000 and did postdoctoral research in Medicinal Chemistry during 2001–2004 at Georgetown University Medical Center and Harvard Medical School McLean Hospital. In 2004, he was promoted to Research Investigator and Instructor of Harvard Medical School. In 2006, he received the Hundred Talent Project award from the Chinese Academy of Sciences and became the Professor of Medicinal Chemistry at Shanghai Institute of Materia Medica (SIMM). In 2011, he was awarded the Distinguished Young Investigator Award from Chinese Natural Science Foundation. He has coauthored more than 100 original articles and reviews. His research interests include the design and synthesis of novel small molecules as structural and functional probes for the diagnosis and treatment of brain disorders and cancers.</p></figure></div><div class="ack" id="ACK-d604e1739-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i48">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36570" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36570" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by grants from Chinese NSF (81430080, 81125021, 81373277, 81473243, 81321092) and the Major State Basic Research Development Program (2015CB910603). Seeding grants from SIMM (CASIMM0120154002/2002) were also appreciated.</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i49">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48370" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48370" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 162 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Taipale, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarosz, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindquist, S.</span><span> </span><span class="NLM_article-title">HSP90 at the hub of protein homeostasis: emerging mechanistic insights</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">515</span><span class="NLM_x">–</span> <span class="NLM_lpage">528</span><span class="refDoi"> DOI: 10.1038/nrm2918</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnrm2918" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=20531426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntFSmt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=515-528&author=M.+Taipaleauthor=D.+F.+Jaroszauthor=S.+Lindquist&title=HSP90+at+the+hub+of+protein+homeostasis%3A+emerging+mechanistic+insights&doi=10.1038%2Fnrm2918"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">HSP90 at the hub of protein homeostasis: emerging mechanistic insights</span></div><div class="casAuthors">Taipale, Mikko; Jarosz, Daniel F.; Lindquist, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">515-528</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Heat-shock protein 90 (HSP90) is a highly conserved mol. chaperone that facilitates the maturation of a wide range of proteins (known as clients).  Clients are enriched in signal transducers, including kinases and transcription factors.  Therefore, HSP90 regulates diverse cellular functions and exerts marked effects on normal biol., disease, and evolutionary processes.  Recent structural and functional analyses have provided new insights on the transcriptional and biochem. regulation of HSP90 and the structural dynamics it uses to act on a diverse client repertoire.  A comprehensive understanding of how HSP90 functions promises not only to provide new avenues for therapeutic intervention, but to shed light on fundamental biol. questions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuMRSaY8uzGbVg90H21EOLACvtfcHk0lgF-03kSWOG-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntFSmt7c%253D&md5=492dca92cea32384d2ab4145230f53dd</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrm2918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2918%26sid%3Dliteratum%253Aachs%26aulast%3DTaipale%26aufirst%3DM.%26aulast%3DJarosz%26aufirst%3DD.%2BF.%26aulast%3DLindquist%26aufirst%3DS.%26atitle%3DHSP90%2520at%2520the%2520hub%2520of%2520protein%2520homeostasis%253A%2520emerging%2520mechanistic%2520insights%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2010%26volume%3D11%26spage%3D515%26epage%3D528%26doi%3D10.1038%2Fnrm2918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Whitesell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindquist, S.</span><span> </span><span class="NLM_article-title">HSP90 and the chaperoning of cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">761</span><span class="NLM_x">–</span> <span class="NLM_lpage">772</span><span class="refDoi"> DOI: 10.1038/nrc1716</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnrc1716" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=16175177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGjs7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=761-772&author=L.+Whitesellauthor=S.+Lindquist&title=HSP90+and+the+chaperoning+of+cancer&doi=10.1038%2Fnrc1716"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">HSP90 and the chaperoning of cancer</span></div><div class="casAuthors">Whitesell, Luke; Lindquist, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">761-772</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Standing watch over the proteome, mol. chaperones are an ancient and evolutionarily conserved class of proteins that guide the normal folding, intracellular disposition and proteolytic turnover of many of the key regulators of cell growth, differentiation and survival.  This essential guardian function is subverted during oncogenesis to allow malignant transformation and to facilitate rapid somatic evolution.  Pharmacol. 'bribing' the essential guard duty of the chaperone HSP90 (heat-shock protein of 90 kDa) seems to offer a unique anticancer strategy of considerable promise.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4Vmb5bGXgDLVg90H21EOLACvtfcHk0lgF-03kSWOG-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGjs7bF&md5=c418ec249a29c70047081cd241938931</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc1716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1716%26sid%3Dliteratum%253Aachs%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DLindquist%26aufirst%3DS.%26atitle%3DHSP90%2520and%2520the%2520chaperoning%2520of%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D761%26epage%3D772%26doi%3D10.1038%2Fnrc1716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Stankiewicz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer, M. P.</span><span> </span><span class="NLM_article-title">The universe of Hsp90</span> <span class="citation_source-journal">Biomol. Concepts</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">79</span><span class="NLM_x">–</span> <span class="NLM_lpage">97</span><span class="refDoi"> DOI: 10.1515/bmc.2011.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1515%2Fbmc.2011.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=25436526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvFWgsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=79-97&author=M.+Stankiewiczauthor=M.+P.+Mayer&title=The+universe+of+Hsp90&doi=10.1515%2Fbmc.2011.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The universe of Hsp90</span></div><div class="casAuthors">Stankiewicz, Marta; Mayer, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecular Concepts</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">79-97</span>CODEN:
                <span class="NLM_cas:coden">BCIOB8</span>;
        ISSN:<span class="NLM_cas:issn">1868-5021</span>.
    
            (<span class="NLM_cas:orgname">Walter de Gruyter GmbH</span>)
        </div><div class="casAbstract">A review.  Mol. chaperones are key components in the maintenance of cellular homeostasis and survival, not only during stress but also under optimal growth conditions.  Among the ATP-dependent chaperones, heat shock proteins (Hsp90) proteins play a special role.  While Hsp90s can interact with unfolded and misfolded proteins, their main (and in eukaryotic cells essential) function appears to involve interactions with a limited no. of protein clients at late steps of maturation or in "alter-native" conformations for regulating their stability and activity.  Because Hsp90 clients are hubs of diverse signaling networks and participate in nearly every cellular function, Hsp90s interconnect many regulatory circuits and link them to environmental impacts.  The availability and activity of Hsp90 may thus influence complex physiol. and pathophysiol. processes, such as differentiation, development, aging, cancer, neurodegeneration, and infectious diseases.  Furthermore, through homeostatic effects on differentiation and development, Hsp90s act as capacitors of phenotypic evolution.  In this review, we discuss recent insights in the structure and chaperone cycle of Hsp90s, the mechanisms underlying Hsp90 binding to clients, and potential reasons why client proteins specifically require the assistance of Hsp90s.  Moreover, the current views on Hsp90-cochaperone interactions and regulation of Hsp90 proteins via posttranslational modifications are summarized.  The second half of this article is devoted to the role of Hsp90 proteins in health and disease, aging, and evolution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnbY32KkmlGLVg90H21EOLACvtfcHk0lgF-03kSWOG-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvFWgsbc%253D&md5=943ba4e99e8854357c9a4b05de6446d9</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1515%2Fbmc.2011.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252Fbmc.2011.054%26sid%3Dliteratum%253Aachs%26aulast%3DStankiewicz%26aufirst%3DM.%26aulast%3DMayer%26aufirst%3DM.%2BP.%26atitle%3DThe%2520universe%2520of%2520Hsp90%26jtitle%3DBiomol.%2520Concepts%26date%3D2012%26volume%3D3%26spage%3D79%26epage%3D97%26doi%3D10.1515%2Fbmc.2011.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Kamal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sensintaffar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehm, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritz, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, F. J.</span><span> </span><span class="NLM_article-title">A high-affinity conformation of Hsp90 confers tumor selectivity on Hsp90 inhibitors</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">425</span><span class="NLM_x">, </span> <span class="NLM_fpage">407</span><span class="NLM_x">–</span> <span class="NLM_lpage">410</span><span class="refDoi"> DOI: 10.1038/nature01913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnature01913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=14508491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnsV2kt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=425&publication_year=2003&pages=407-410&author=A.+Kamalauthor=L.+Thaoauthor=J.+Sensintaffarauthor=L.+Zhangauthor=M.+F.+Boehmauthor=A.+C.+Fritzauthor=F.+J.+Burrows&title=A+high-affinity+conformation+of+Hsp90+confers+tumor+selectivity+on+Hsp90+inhibitors&doi=10.1038%2Fnature01913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A high-affinity conformation of Hsp90 confers tumor selectivity on Hsp90 inhibitors</span></div><div class="casAuthors">Kamal, Adeela; Thao, Lia; Sensintaffar, John; Zhang, Lin; Boehm, Marcus F.; Fritz, Lawrence C.; Burrows, Francis J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">425</span>
        (<span class="NLM_cas:issue">6956</span>),
    <span class="NLM_cas:pages">407-410</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) is a mol. chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, including HER-2/ErbB2, Akt, Raf-1, Bcr-Abl and mutated p53.  Hsp90 inhibitors bind to Hsp90, and induce the proteasomal degrdn. of Hsp90 client proteins.  Although Hsp90 is highly expressed in most cells, Hsp90 inhibitors selectively kill cancer cells compared to normal cells, and the Hsp90 inhibitor 17-allylaminogeldanamycin (17-AAG) is currently in phase I clin. trials.  However, the mol. basis of the tumor selectivity of Hsp90 inhibitors is unknown.  Here we report that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than does Hsp90 from normal cells.  Tumor Hsp90 is present entirely in multi-chaperone complexes with high ATPase activity, whereas Hsp90 from normal tissues is in a latent, uncomplexed state.  In vitro reconstitution of chaperone complexes with Hsp90 resulted in increased binding affinity to 17-AAG, and increased ATPase activity.  These results suggest that tumor cells contain Hsp90 complexes in an activated, high-affinity conformation that facilitates malignant progression, and that may represent a unique target for cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0ozo1K3wfA7Vg90H21EOLACvtfcHk0ljCCIsVwBRgPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnsV2kt7w%253D&md5=7c83fca7aaf685b589c4aef6e5f39b02</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnature01913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature01913%26sid%3Dliteratum%253Aachs%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DThao%26aufirst%3DL.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DBoehm%26aufirst%3DM.%2BF.%26aulast%3DFritz%26aufirst%3DA.%2BC.%26aulast%3DBurrows%26aufirst%3DF.%2BJ.%26atitle%3DA%2520high-affinity%2520conformation%2520of%2520Hsp90%2520confers%2520tumor%2520selectivity%2520on%2520Hsp90%2520inhibitors%26jtitle%3DNature%26date%3D2003%26volume%3D425%26spage%3D407%26epage%3D410%26doi%3D10.1038%2Fnature01913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Chiosis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neckers, L.</span><span> </span><span class="NLM_article-title">Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">279</span><span class="NLM_x">–</span> <span class="NLM_lpage">284</span><span class="refDoi"> DOI: 10.1021/cb600224w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb600224w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtFSiur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=279-284&author=G.+Chiosisauthor=L.+Neckers&title=Tumor+selectivity+of+Hsp90+inhibitors%3A+the+explanation+remains+elusive&doi=10.1021%2Fcb600224w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor Selectivity of Hsp90 Inhibitors: The Explanation Remains Elusive</span></div><div class="casAuthors">Chiosis, Gabriela; Neckers, Len</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">279-284</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Two recent papers attempt to solve both the tumor selectivity and the in vivo tumor accumulation profiles seen with some Hsp90 inhibitors.  They spotlight the higher affinity of ansamycins' hydroquinone over the quinone form for Hsp90 and further discuss its possible contribution to ansamycins' tumor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMDQyu5SJs37Vg90H21EOLACvtfcHk0ljCCIsVwBRgPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtFSiur8%253D&md5=7956eebef69de36723632b6a16bb1c79</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fcb600224w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb600224w%26sid%3Dliteratum%253Aachs%26aulast%3DChiosis%26aufirst%3DG.%26aulast%3DNeckers%26aufirst%3DL.%26atitle%3DTumor%2520selectivity%2520of%2520Hsp90%2520inhibitors%253A%2520the%2520explanation%2520remains%2520elusive%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2006%26volume%3D1%26spage%3D279%26epage%3D284%26doi%3D10.1021%2Fcb600224w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Trepel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mollapour, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giaccone, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neckers, L.</span><span> </span><span class="NLM_article-title">Targeting the dynamic HSP90 complex in cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">537</span><span class="NLM_x">–</span> <span class="NLM_lpage">549</span><span class="refDoi"> DOI: 10.1038/nrc2887</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnrc2887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=20651736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1GjtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=537-549&author=J.+Trepelauthor=M.+Mollapourauthor=G.+Giacconeauthor=L.+Neckers&title=Targeting+the+dynamic+HSP90+complex+in+cancer&doi=10.1038%2Fnrc2887"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the dynamic HSP90 complex in cancer</span></div><div class="casAuthors">Trepel, Jane; Mollapour, Mehdi; Giaccone, Giuseppe; Neckers, Len</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">537-549</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The mol. chaperone, heat-shock protein 90 (HSP90), has been used by cancer cells to facilitate the function of numerous oncoproteins, and it can be argued that cancer cells are 'addicted' to HSP90.  However, although recent reports of the early clin. efficacy of HSP90 inhibitors are encouraging, the optimal use of HSP90-targeted therapeutics will depend on understanding the complexity of HSP90 regulation and the degree to which HSP90 participates in both neoplastic and normal cellular physiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprGEqkx6m7p7Vg90H21EOLACvtfcHk0ljCCIsVwBRgPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1GjtLs%253D&md5=8acba020073ebb93cf1dee577420dc32</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrc2887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2887%26sid%3Dliteratum%253Aachs%26aulast%3DTrepel%26aufirst%3DJ.%26aulast%3DMollapour%26aufirst%3DM.%26aulast%3DGiaccone%26aufirst%3DG.%26aulast%3DNeckers%26aufirst%3DL.%26atitle%3DTargeting%2520the%2520dynamic%2520HSP90%2520complex%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D537%26epage%3D549%26doi%3D10.1038%2Fnrc2887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Ferrarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heltai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zocchi, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rugarli, C.</span><span> </span><span class="NLM_article-title">Unusual expression and localization of heat-shock proteins in human tumor cells</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">613</span><span class="NLM_x">–</span> <span class="NLM_lpage">619</span><span class="refDoi"> DOI: 10.1002/ijc.2910510418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1002%2Fijc.2910510418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1601523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADyaK38XlvV2hs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1992&pages=613-619&author=M.+Ferrariniauthor=S.+Heltaiauthor=M.+R.+Zocchiauthor=C.+Rugarli&title=Unusual+expression+and+localization+of+heat-shock+proteins+in+human+tumor+cells&doi=10.1002%2Fijc.2910510418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Unusual expression and localization of heat-shock proteins in human tumor cells</span></div><div class="casAuthors">Ferrarini, Marina; Heltai, Silvia; Zocchi, M. Raffaella; Rugarli, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">613-19</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    </div><div class="casAbstract">It has been suggested that members of HSP families represent the surface target of immune responses leading to tumor rejection in mice.  The authors report that tumor cells, compared with normal cells, constitutively expressed 2- to 10-fold higher levels of intracellular HSP90.  Moreover, in the absence of environmental stress, 2 lines (out of 6) expressed the "inducible" HSP72, which was also detectable in fresh tumor cells.  HSP72 expression was not regulated during the cell cycle, in contrast with what has been obsd. with normal cells.  Both HSP90 and HSP72 proteins exhibited a heterogeneous pattern of intracellular distribution in most cells, HSP72 being confined mainly to the nuclear compartment.  Finally, both HSP90 and, to a lesser extent, HSP72 (that are generally believed to be located intracellularly) were detected at the surface of some tumor cell lines.  It is concluded that tumor cells differ from normal cells in their pattern of HSP expression; this might imply a role of HSPs in eliciting an immune response against cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdlQHEKHA7jLVg90H21EOLACvtfcHk0ljmT77oTj5ZWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlvV2hs7s%253D&md5=4ace8651e9b125c68985102a0b3055f3</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fijc.2910510418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.2910510418%26sid%3Dliteratum%253Aachs%26aulast%3DFerrarini%26aufirst%3DM.%26aulast%3DHeltai%26aufirst%3DS.%26aulast%3DZocchi%26aufirst%3DM.%2BR.%26aulast%3DRugarli%26aufirst%3DC.%26atitle%3DUnusual%2520expression%2520and%2520localization%2520of%2520heat-shock%2520proteins%2520in%2520human%2520tumor%2520cells%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D1992%26volume%3D51%26spage%3D613%26epage%3D619%26doi%3D10.1002%2Fijc.2910510418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Darby, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span> </span><span class="NLM_article-title">Many faces of a cancer supporting protein</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">478</span><span class="NLM_x">, </span> <span class="NLM_fpage">334</span><span class="NLM_x">–</span> <span class="NLM_lpage">335</span><span class="refDoi"> DOI: 10.1038/478334b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2F478334b" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=478&publication_year=2011&pages=334-335&author=J.+F.+Darbyauthor=P.+Workman&title=Many+faces+of+a+cancer+supporting+protein&doi=10.1038%2F478334b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2F478334b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F478334b%26sid%3Dliteratum%253Aachs%26aulast%3DDarby%26aufirst%3DJ.%2BF.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DMany%2520faces%2520of%2520a%2520cancer%2520supporting%2520protein%26jtitle%3DNature%26date%3D2011%26volume%3D478%26spage%3D334%26epage%3D335%26doi%3D10.1038%2F478334b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Scaltriti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawood, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Molecular pathways: targeting Hsp90--who benefits and who does not</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4508</span><span class="NLM_x">–</span> <span class="NLM_lpage">4513</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-2138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1078-0432.CCR-11-2138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22718860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ygsL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=4508-4513&author=M.+Scaltritiauthor=S.+Dawoodauthor=J.+Cortes&title=Molecular+pathways%3A+targeting+Hsp90%2D%2Dwho+benefits+and+who+does+not&doi=10.1158%2F1078-0432.CCR-11-2138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: Targeting Hsp90-Who Benefits and Who Does Not</span></div><div class="casAuthors">Scaltriti, Maurizio; Dawood, Shaheenah; Cortes, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4508-4513</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Many kinases and hormone receptors, important for cancer cell proliferation and survival, bind to and are dependent on the Hsp90 cycle for their folding and maturation.  This provides the rationale for the development of small-mol. ATP competitors that, inhibiting Hsp90 function, lead to degrdn. of the "client" proteins.  After continual efforts to improve the pharmacol. properties and the tolerability of these mols., several Hsp90 inhibitors have exhibited activity in both preclin. models and in the clin. setting.  As is the case with many other targeted agents, patient selection seems to be the major limitation to the success of these compds.  ERBB2-pos. patients with breast cancer are exquisitely sensitive to Hsp90 inhibition.  This is because ERBB2 is indispensable for growth and survival of this subtype of cancer, and at the same time ERBB2 is a client protein strictly dependent on Hsp90 for its maturation and stability.  Extensive preclin. work identifying other ERBB-like client proteins will likely lead to the ability to enhance selection of appropriate patients for enrollment in more rational clin. trials.  Hsp90 inhibition has also been reported to synergize with other therapeutic agents.  Several ongoing studies testing different combinations of Hsp90 inhibitors with other targeted agents will confirm whether Hsp90 inhibition can potentiate the efficacy of targeted therapy and/or prevent the emergence of drug resistance.  Clin Cancer Res; 18(17); 4508-13. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcSf5P7B7H8bVg90H21EOLACvtfcHk0ljmT77oTj5ZWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ygsL3L&md5=8274b2b8bedc14970bd02b37acb163e8</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2138%26sid%3Dliteratum%253Aachs%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DDawood%26aufirst%3DS.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DMolecular%2520pathways%253A%2520targeting%2520Hsp90--who%2520benefits%2520and%2520who%2520does%2520not%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D4508%26epage%3D4513%26doi%3D10.1158%2F1078-0432.CCR-11-2138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Moulick, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerchietti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomes DaGama, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldas-Lopes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beebe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perna, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatzi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vu, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zatorska, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taldone, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith-Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alpaugh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pillarsetty, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ku, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erdjument-Bromage, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzman, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melnick, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neckers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span> </span><span class="NLM_article-title">Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">818</span><span class="NLM_x">–</span> <span class="NLM_lpage">826</span><span class="refDoi"> DOI: 10.1038/nchembio.670</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnchembio.670" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=21946277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1anurbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=818-826&author=K.+Moulickauthor=J.+H.+Ahnauthor=H.+Zongauthor=A.+Rodinaauthor=L.+Cerchiettiauthor=E.+M.+Gomes+DaGamaauthor=E.+Caldas-Lopesauthor=K.+Beebeauthor=F.+Pernaauthor=K.+Hatziauthor=L.+P.+Vuauthor=X.+Zhaoauthor=D.+Zatorskaauthor=T.+Taldoneauthor=P.+Smith-Jonesauthor=M.+Alpaughauthor=S.+S.+Grossauthor=N.+Pillarsettyauthor=T.+Kuauthor=J.+S.+Lewisauthor=S.+M.+Larsonauthor=R.+Levineauthor=H.+Erdjument-Bromageauthor=M.+L.+Guzmanauthor=S.+D.+Nimerauthor=A.+Melnickauthor=L.+Neckersauthor=G.+Chiosis&title=Affinity-based+proteomics+reveal+cancer-specific+networks+coordinated+by+Hsp90&doi=10.1038%2Fnchembio.670"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90</span></div><div class="casAuthors">Moulick, Kamalika; Ahn, James H.; Zong, Hongliang; Rodina, Anna; Cerchietti, Leandro; Gomes DaGama, Erica M.; Caldas-Lopes, Eloisi; Beebe, Kristin; Perna, Fabiana; Hatzi, Katerina; Vu, Ly P.; Zhao, Xinyang; Zatorska, Danuta; Taldone, Tony; Smith-Jones, Peter; Alpaugh, Mary; Gross, Steven S.; Pillarsetty, Nagavarakishore; Ku, Thomas; Lewis, Jason S.; Larson, Steven M.; Levine, Ross; Erdjument-Bromage, Hediye; Guzman, Monica L.; Nimer, Stephen D.; Melnick, Ari; Neckers, Len; Chiosis, Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">818-826</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Most cancers were characterized by multiple mol. alterations, but identification of the key proteins involved in these signaling pathways is currently beyond reach.  The inhibitor PU-H71 preferentially targets tumor-enriched Hsp90 complexes and affinity captures Hsp90-dependent oncogenic client proteins.  The authors used PU-H71 affinity capture to design a proteomic approach that, when combined with bioinformatic pathway anal., identifies dysregulated signaling networks and key oncoproteins in chronic myeloid leukemia.  The identified interactome overlaps with the well-characterized altered proteome in this cancer, indicating that this method can provide global insights into the biol. of individual tumors, including primary patient specimens.  In addn., this approach can be used to identify previously uncharacterized oncoproteins and mechanisms, potentially leading to new targeted therapies.  Further the abundance of the PU-H71-enriched Hsp90 species, which is not dictated by Hsp90 expression alone, is predictive of the cell's sensitivity to Hsp90 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXTlQWF_MFU7Vg90H21EOLACvtfcHk0ljmT77oTj5ZWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1anurbN&md5=d62e663a2e054f3715a3a6e2d5e2c10e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.670%26sid%3Dliteratum%253Aachs%26aulast%3DMoulick%26aufirst%3DK.%26aulast%3DAhn%26aufirst%3DJ.%2BH.%26aulast%3DZong%26aufirst%3DH.%26aulast%3DRodina%26aufirst%3DA.%26aulast%3DCerchietti%26aufirst%3DL.%26aulast%3DGomes%2BDaGama%26aufirst%3DE.%2BM.%26aulast%3DCaldas-Lopes%26aufirst%3DE.%26aulast%3DBeebe%26aufirst%3DK.%26aulast%3DPerna%26aufirst%3DF.%26aulast%3DHatzi%26aufirst%3DK.%26aulast%3DVu%26aufirst%3DL.%2BP.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DZatorska%26aufirst%3DD.%26aulast%3DTaldone%26aufirst%3DT.%26aulast%3DSmith-Jones%26aufirst%3DP.%26aulast%3DAlpaugh%26aufirst%3DM.%26aulast%3DGross%26aufirst%3DS.%2BS.%26aulast%3DPillarsetty%26aufirst%3DN.%26aulast%3DKu%26aufirst%3DT.%26aulast%3DLewis%26aufirst%3DJ.%2BS.%26aulast%3DLarson%26aufirst%3DS.%2BM.%26aulast%3DLevine%26aufirst%3DR.%26aulast%3DErdjument-Bromage%26aufirst%3DH.%26aulast%3DGuzman%26aufirst%3DM.%2BL.%26aulast%3DNimer%26aufirst%3DS.%2BD.%26aulast%3DMelnick%26aufirst%3DA.%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DAffinity-based%2520proteomics%2520reveal%2520cancer-specific%2520networks%2520coordinated%2520by%2520Hsp90%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D818%26epage%3D826%26doi%3D10.1038%2Fnchembio.670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Walton-Diaz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourboulia, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trepel, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neckers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mollapour, M.</span><span> </span><span class="NLM_article-title">Contributions of co-chaperones and post-translational modifications towards Hsp90 drug sensitivity</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1059</span><span class="NLM_x">–</span> <span class="NLM_lpage">1071</span><span class="refDoi"> DOI: 10.4155/fmc.13.88</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.4155%2Ffmc.13.88" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=23734688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXos12msbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=1059-1071&author=A.+Walton-Diazauthor=S.+Khanauthor=D.+Bourbouliaauthor=J.+B.+Trepelauthor=L.+Neckersauthor=M.+Mollapour&title=Contributions+of+co-chaperones+and+post-translational+modifications+towards+Hsp90+drug+sensitivity&doi=10.4155%2Ffmc.13.88"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Contributions of co-chaperones and post-translational modifications towards Hsp90 drug sensitivity</span></div><div class="casAuthors">Walton-Diaz, Annerleim; Khan, Sahar; Bourboulia, Dimitra; Trepel, Jane B.; Neckers, Len; Mollapour, Mehdi</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1059-1071</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Hsp90 is a mol. chaperone and important driver of stabilization and activation of several oncogenic proteins that are involved in the malignant transformation of tumor cells.  Therefore, it is not surprising that Hsp90 has been reported to be a promising target for the treatment of several neoplasias, such as non-small-cell lung cancer and HER2-pos. breast cancer.  Hsp90 chaperone function depends on its ability to bind and hydrolyze ATP and Hsp90 inhibitors have been shown to compete with nucleotides for binding to Hsp90.  Multiple factors, such as co-chaperones and post-translational modification, are involved in regulating Hsp90 ATPase activity.  Here, the impact of post-translational modifications and co-chaperones on the efficacy of Hsp90 inhibitors are reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLf3BQtlxU-bVg90H21EOLACvtfcHk0li2ZK7M123bXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXos12msbw%253D&md5=1f887b53846ec728d9ecde40f91b5b42</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.4155%2Ffmc.13.88&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.13.88%26sid%3Dliteratum%253Aachs%26aulast%3DWalton-Diaz%26aufirst%3DA.%26aulast%3DKhan%26aufirst%3DS.%26aulast%3DBourboulia%26aufirst%3DD.%26aulast%3DTrepel%26aufirst%3DJ.%2BB.%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DMollapour%26aufirst%3DM.%26atitle%3DContributions%2520of%2520co-chaperones%2520and%2520post-translational%2520modifications%2520towards%2520Hsp90%2520drug%2520sensitivity%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2013%26volume%3D5%26spage%3D1059%26epage%3D1071%26doi%3D10.4155%2Ffmc.13.88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Bhat, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tummalapalli, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotella, D. P.</span><span> </span><span class="NLM_article-title">Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">8718</span><span class="NLM_x">–</span> <span class="NLM_lpage">8728</span><span class="refDoi"> DOI: 10.1021/jm500823a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500823a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSnsrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8718-8728&author=R.+Bhatauthor=S.+R.+Tummalapalliauthor=D.+P.+Rotella&title=Progress+in+the+discovery+and+development+of+heat+shock+protein+90+%28Hsp90%29+inhibitors&doi=10.1021%2Fjm500823a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in the Discovery and Development of Heat Shock Protein 90 (Hsp90) Inhibitors</span></div><div class="casAuthors">Bhat, Rohit; Tummalapalli, Sreedhar R.; Rotella, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8718-8728</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The discovery and clin. development of heat shock protein 90 (Hsp90) inhibitors continue to progress.  A no. of Hsp90 inhibitors are in clin. trials, and preclin. discoveries of new chemotypes that bind to distinct regions in the protein as well as isoform selective compds. are active areas of research.  This review will highlight progress in the field since 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-SwLv_-B9xLVg90H21EOLACvtfcHk0li2ZK7M123bXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSnsrfK&md5=132784687bbbcf62cfa8fe04a22577ce</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm500823a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500823a%26sid%3Dliteratum%253Aachs%26aulast%3DBhat%26aufirst%3DR.%26aulast%3DTummalapalli%26aufirst%3DS.%2BR.%26aulast%3DRotella%26aufirst%3DD.%2BP.%26atitle%3DProgress%2520in%2520the%2520discovery%2520and%2520development%2520of%2520heat%2520shock%2520protein%252090%2520%2528Hsp90%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8718%26epage%3D8728%26doi%3D10.1021%2Fjm500823a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Workman, P.</span><span> </span><span class="NLM_article-title">Altered states: selectively drugging the Hsp90 cancer chaperone</span> <span class="citation_source-journal">Trends Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">51</span><span class="refDoi"> DOI: 10.1016/j.molmed.2003.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.molmed.2003.12.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=47-51&author=P.+Workman&title=Altered+states%3A+selectively+drugging+the+Hsp90+cancer+chaperone&doi=10.1016%2Fj.molmed.2003.12.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2003.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2003.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DAltered%2520states%253A%2520selectively%2520drugging%2520the%2520Hsp90%2520cancer%2520chaperone%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2004%26volume%3D10%26spage%3D47%26epage%3D51%26doi%3D10.1016%2Fj.molmed.2003.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Chiosis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickey, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, J. L.</span><span> </span><span class="NLM_article-title">A global view of Hsp90 functions</span> <span class="citation_source-journal">Nat. Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">4</span><span class="refDoi"> DOI: 10.1038/nsmb.2481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnsmb.2481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=23288357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsleisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1-4&author=G.+Chiosisauthor=C.+A.+Dickeyauthor=J.+L.+Johnson&title=A+global+view+of+Hsp90+functions&doi=10.1038%2Fnsmb.2481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">A global view of Hsp90 functions</span></div><div class="casAuthors">Chiosis, Gabriela; Dickey, Chad A.; Johnson, Jill L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-4</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Sixth International Conference on Hsp90 in 2012 revealed new functions of this key mol. chaperone.  Attendees of the meeting at Les Diablerets, Switzerland, addressed new discoveries about Hsp90 and its cochaperones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHrJZHeOegBLVg90H21EOLACvtfcHk0li2ZK7M123bXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsleisw%253D%253D&md5=fe27eda8ca2eb9adae4ecb012c171156</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2481%26sid%3Dliteratum%253Aachs%26aulast%3DChiosis%26aufirst%3DG.%26aulast%3DDickey%26aufirst%3DC.%2BA.%26aulast%3DJohnson%26aufirst%3DJ.%2BL.%26atitle%3DA%2520global%2520view%2520of%2520Hsp90%2520functions%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D1%26epage%3D4%26doi%3D10.1038%2Fnsmb.2481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Schwenkert, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hugel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, M. B.</span><span> </span><span class="NLM_article-title">The Hsp90 ensemble: coordinated Hsp90-cochaperone complexes regulate diverse cellular processes</span> <span class="citation_source-journal">Nat. Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1017</span><span class="NLM_x">–</span> <span class="NLM_lpage">1021</span><span class="refDoi"> DOI: 10.1038/nsmb.2927</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnsmb.2927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=25469839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitValurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=1017-1021&author=S.+Schwenkertauthor=T.+Hugelauthor=M.+B.+Cox&title=The+Hsp90+ensemble%3A+coordinated+Hsp90-cochaperone+complexes+regulate+diverse+cellular+processes&doi=10.1038%2Fnsmb.2927"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The Hsp90 ensemble: coordinated Hsp90-cochaperone complexes regulate diverse cellular processes</span></div><div class="casAuthors">Schwenkert, Serena; Hugel, Thorsten; Cox, Marc B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1017-1021</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Seventh International Conference on the Hsp90 Chaperone Machine took place in Oct. 2014, in Seeon, Germany.  The program highlighted recent findings in a variety of areas, including structures of heat-shock protein 90 (Hsp90)-client protein complexes, coordination of Hsp90 with cochaperones, new cellular and physiol. roles for Hsp90 and therapeutic targeting of the Hsp90 ensemble for the treatment of disease and prevention of infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBxBPS4CmbyLVg90H21EOLACvtfcHk0ljCbsqmvB2Vrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitValurzL&md5=fff880ba2746ba98f6d1fe29f0caefae</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2927%26sid%3Dliteratum%253Aachs%26aulast%3DSchwenkert%26aufirst%3DS.%26aulast%3DHugel%26aufirst%3DT.%26aulast%3DCox%26aufirst%3DM.%2BB.%26atitle%3DThe%2520Hsp90%2520ensemble%253A%2520coordinated%2520Hsp90-cochaperone%2520complexes%2520regulate%2520diverse%2520cellular%2520processes%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2014%26volume%3D21%26spage%3D1017%26epage%3D1021%26doi%3D10.1038%2Fnsmb.2927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Garcia-Carbonero, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carnero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paz-Ares, L.</span><span> </span><span class="NLM_article-title">Inhibition of Hsp90 molecular chaperones: moving into the clinic</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">e358</span><span class="NLM_x">–</span> <span class="NLM_lpage">e369</span><span class="refDoi"> DOI: 10.1016/S1470-2045(13)70169-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2FS1470-2045%2813%2970169-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=23896275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2iu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=e358-e369&author=R.+Garcia-Carboneroauthor=A.+Carneroauthor=L.+Paz-Ares&title=Inhibition+of+Hsp90+molecular+chaperones%3A+moving+into+the+clinic&doi=10.1016%2FS1470-2045%2813%2970169-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of HSP90 molecular chaperones: moving into the clinic</span></div><div class="casAuthors">Garcia-Carbonero, Rocio; Carnero, Amancio; Paz-Ares, Luis</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e358-e369</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Heat shock protein 90 (HSP90) is a mol. chaperone that is crucial for the stability and function of many proteins essential for cell survival.  Many oncogenes, including tyrosine kinases, transcription factors, and cell-cycle regulatory proteins, are client proteins of HSP90.  Inhibition of HSP90 causes client protein degrdn. via the ubiquitin-proteasome pathway, and is a mechanism that might simultaneously downregulate several redundant pathways crucial for cell viability and tumor development.  HSP90 inhibitors are currently being developed as anticancer agents, and have shown early promising results in molecularly defined subgroups of solid tumors (eg, ALK-rearranged non-small-cell lung cancer and HER2-amplified breast cancer) and some haematol. malignancies (eg, multiple myeloma).  Here, we review the current status of HSP90 inhibitors in clin. development, including geldanamycin derivs., resorcinol derivs., purine analogs, and other synthetic inhibitors.  We also discuss novel strategies and future perspectives on how to optimize the therapeutic potential of this exciting new class of drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpulM7j4PFcx7Vg90H21EOLACvtfcHk0ljCbsqmvB2Vrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2iu7jI&md5=4821e86073624fb17d7343105d6e82cd</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2813%2970169-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252813%252970169-4%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Carbonero%26aufirst%3DR.%26aulast%3DCarnero%26aufirst%3DA.%26aulast%3DPaz-Ares%26aufirst%3DL.%26atitle%3DInhibition%2520of%2520Hsp90%2520molecular%2520chaperones%253A%2520moving%2520into%2520the%2520clinic%26jtitle%3DLancet%2520Oncol.%26date%3D2013%26volume%3D14%26spage%3De358%26epage%3De369%26doi%3D10.1016%2FS1470-2045%2813%2970169-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Richardson, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsiades, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laubach, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lonial, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chanan-Khan, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers</span> <span class="citation_source-journal">Br. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">152</span><span class="NLM_x">, </span> <span class="NLM_fpage">367</span><span class="NLM_x">–</span> <span class="NLM_lpage">379</span><span class="refDoi"> DOI: 10.1111/j.1365-2141.2010.08360.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1111%2Fj.1365-2141.2010.08360.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=21219297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtVOntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2011&pages=367-379&author=P.+G.+Richardsonauthor=C.+S.+Mitsiadesauthor=J.+P.+Laubachauthor=S.+Lonialauthor=A.+A.+Chanan-Khanauthor=K.+C.+Anderson&title=Inhibition+of+heat+shock+protein+90+%28HSP90%29+as+a+therapeutic+strategy+for+the+treatment+of+myeloma+and+other+cancers&doi=10.1111%2Fj.1365-2141.2010.08360.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers</span></div><div class="casAuthors">Richardson, Paul G.; Mitsiades, Constantine S.; Laubach, Jacob P.; Lonial, Sagar; Chanan-Khan, Asher A.; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">367-379</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Heat shock protein 90 (HSP90) is a mol. chaperone that is induced in response to cellular stress and stabilizes client proteins involved in cell cycle control and proliferative/anti-apoptotic signalling.  HSP90 is overexpressed in a range of cancers, and may contribute to tumor cell survival by stabilizing aberrant signalling proteins and by interfering with apoptosis.  Tanespimycin, an HSP90 inhibitor, reduces tumor cell survival in vitro.  In multiple myeloma (MM), HSP90 inhibition affects multiple client proteins that contribute to tumor cell survival, including the IGF1 receptor and the IL-6 receptor, and elements of the PI3/Akt, STAT3, and MAPK signalling pathways.  HSP90 inhibition also abrogates the protective effect of bone marrow stromal cells and inhibits angiogenesis and osteoclastogenesis.  Tanespimycin acts synergistically with the proteasome inhibitor bortezomib in MM cells and tumor explants, possibly reducing their ability to resist bortezomib-induced stress to the endoplasmic reticulum.  The combination of tanespimycin and bortezomib has demonstrated significant and durable responses with acceptable toxicity in a phase I/II study in patients with relapsed and relapsed/refractory MM.  HSP90 inhibition is a promising strategy in MM esp. in combination with bortezomib; addnl. studies will further evaluate optimal dosings of candidate drugs and schedules, as well as confirm efficacy in comparative phase III trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9tsEVNXnwwrVg90H21EOLACvtfcHk0ljCbsqmvB2Vrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtVOntr4%253D&md5=2ec48571564edbf6ec2bcab69baf01a2</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2010.08360.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2010.08360.x%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26aulast%3DLaubach%26aufirst%3DJ.%2BP.%26aulast%3DLonial%26aufirst%3DS.%26aulast%3DChanan-Khan%26aufirst%3DA.%2BA.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DInhibition%2520of%2520heat%2520shock%2520protein%252090%2520%2528HSP90%2529%2520as%2520a%2520therapeutic%2520strategy%2520for%2520the%2520treatment%2520of%2520myeloma%2520and%2520other%2520cancers%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2011%26volume%3D152%26spage%3D367%26epage%3D379%26doi%3D10.1111%2Fj.1365-2141.2010.08360.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Jhaveri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochiana, S. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunphy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerecitano, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corben, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peter, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janjigian, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomes-DaGama, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koren, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span> </span><span class="NLM_article-title">Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">611</span><span class="NLM_x">–</span> <span class="NLM_lpage">628</span><span class="refDoi"> DOI: 10.1517/13543784.2014.902442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1517%2F13543784.2014.902442" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=611-628&author=K.+Jhaveriauthor=S.+O.+Ochianaauthor=M.+Dunphyauthor=J.+F.+Gerecitanoauthor=A.+D.+Corbenauthor=R.+I.+Peterauthor=Y.+Y.+Janjigianauthor=E.+M.+Gomes-DaGamaauthor=J.+Korenauthor=S.+Modiauthor=G.+Chiosis&title=Heat+shock+protein+90+inhibitors+in+the+treatment+of+cancer%3A+current+status+and+future+directions&doi=10.1517%2F13543784.2014.902442"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1517%2F13543784.2014.902442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2014.902442%26sid%3Dliteratum%253Aachs%26aulast%3DJhaveri%26aufirst%3DK.%26aulast%3DOchiana%26aufirst%3DS.%2BO.%26aulast%3DDunphy%26aufirst%3DM.%26aulast%3DGerecitano%26aufirst%3DJ.%2BF.%26aulast%3DCorben%26aufirst%3DA.%2BD.%26aulast%3DPeter%26aufirst%3DR.%2BI.%26aulast%3DJanjigian%26aufirst%3DY.%2BY.%26aulast%3DGomes-DaGama%26aufirst%3DE.%2BM.%26aulast%3DKoren%26aufirst%3DJ.%26aulast%3DModi%26aufirst%3DS.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DHeat%2520shock%2520protein%252090%2520inhibitors%2520in%2520the%2520treatment%2520of%2520cancer%253A%2520current%2520status%2520and%2520future%2520directions%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2014%26volume%3D23%26spage%3D611%26epage%3D628%26doi%3D10.1517%2F13543784.2014.902442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Jhaveri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taldone, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span> </span><span class="NLM_article-title">Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Mol. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">1823</span><span class="NLM_x">, </span> <span class="NLM_fpage">742</span><span class="NLM_x">–</span> <span class="NLM_lpage">755</span><span class="refDoi"> DOI: 10.1016/j.bbamcr.2011.10.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.bbamcr.2011.10.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22062686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFShsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1823&publication_year=2012&pages=742-755&author=K.+Jhaveriauthor=T.+Taldoneauthor=S.+Modiauthor=G.+Chiosis&title=Advances+in+the+clinical+development+of+heat+shock+protein+90+%28Hsp90%29+inhibitors+in+cancers&doi=10.1016%2Fj.bbamcr.2011.10.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers</span></div><div class="casAuthors">Jhaveri, Komal; Taldone, Tony; Modi, Shanu; Chiosis, Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1823</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">742-755</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Hsp90 is an ATP dependent mol. chaperone protein which integrates multiple oncogenic pathways.  As such, Hsp90 inhibition is a promising anti-cancer strategy.  Several inhibitors that act on Hsp90 by binding to its N-terminal ATP pocket have entered clin. evaluation.  Robust pre-clin. data suggested anti-tumor activity in multiple cancer types.  Clin., encouraging results have been demonstrated in melanoma, acute myeloid leukemia, castrate refractory prostate cancer, non-small cell lung carcinoma and multiple myeloma.  In breast cancer, proof-of-concept was demonstrated by first generation Hsp90 inhibitors in combination with trastuzumab mainly in human epidermal growth factor receptor 2 (HER2) + metastatic breast cancer.  There are a multitude of second generation Hsp90 inhibitors currently under investigation.  To date, however, there is no FDA approved Hsp90 inhibitor nor standardized assay to ascertain Hsp90 inhibition.  This review summarizes the current status of both first and second generation Hsp90 inhibitors based on their chem. classification and stage of clin. development.  It also discusses the pharmacodynamic assays currently implemented in clinic as well as other novel strategies aimed at enhancing the effectiveness of Hsp90 inhibitors.  Ultimately, these efforts will aid in maximizing the full potential of this class of agents.  This article is part of a Special Issue entitled: Heat Shock Protein 90 (HSP90).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDrDTpRQxfYrVg90H21EOLACvtfcHk0lgEBmiuct1ktA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFShsbY%253D&md5=03cef7dc96667a4698324f635aacee7a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2011.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2011.10.008%26sid%3Dliteratum%253Aachs%26aulast%3DJhaveri%26aufirst%3DK.%26aulast%3DTaldone%26aufirst%3DT.%26aulast%3DModi%26aufirst%3DS.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DAdvances%2520in%2520the%2520clinical%2520development%2520of%2520heat%2520shock%2520protein%252090%2520%2528Hsp90%2529%2520inhibitors%2520in%2520cancers%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2012%26volume%3D1823%26spage%3D742%26epage%3D755%26doi%3D10.1016%2Fj.bbamcr.2011.10.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Soláravá, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mojziš, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solár, P.</span><span> </span><span class="NLM_article-title">Hsp90 inhibitor as a sensitizer of cancer cells to different therapies</span> <span class="citation_source-journal">Int. J. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">907</span><span class="NLM_x">–</span> <span class="NLM_lpage">926</span><span class="refDoi"> DOI: 10.3892/ijo.2014.2791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.3892%2Fijo.2014.2791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=25501619" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2015&pages=907-926&author=Z.+Sol%C3%A1rav%C3%A1author=J.+Mojzi%C5%A1author=P.+Sol%C3%A1r&title=Hsp90+inhibitor+as+a+sensitizer+of+cancer+cells+to+different+therapies&doi=10.3892%2Fijo.2014.2791"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.3892%2Fijo.2014.2791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2014.2791%26sid%3Dliteratum%253Aachs%26aulast%3DSol%25C3%25A1rav%25C3%25A1%26aufirst%3DZ.%26aulast%3DMojzi%25C5%25A1%26aufirst%3DJ.%26aulast%3DSol%25C3%25A1r%26aufirst%3DP.%26atitle%3DHsp90%2520inhibitor%2520as%2520a%2520sensitizer%2520of%2520cancer%2520cells%2520to%2520different%2520therapies%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2015%26volume%3D46%26spage%3D907%26epage%3D926%26doi%3D10.3892%2Fijo.2014.2791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Prodromou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roe, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piper, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearl, L. H.</span><span> </span><span class="NLM_article-title">A molecular clamp in the crystal structure of the N-terminal domain of the yeast Hsp90 chaperone</span> <span class="citation_source-journal">Nat. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">477</span><span class="NLM_x">–</span> <span class="NLM_lpage">482</span><span class="refDoi"> DOI: 10.1038/nsb0697-477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnsb0697-477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=9187656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADyaK2sXjs1elur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1997&pages=477-482&author=C.+Prodromouauthor=S.+M.+Roeauthor=P.+W.+Piperauthor=L.+H.+Pearl&title=A+molecular+clamp+in+the+crystal+structure+of+the+N-terminal+domain+of+the+yeast+Hsp90+chaperone&doi=10.1038%2Fnsb0697-477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">A molecular clamp in the crystal structure of the N-terminal domain of the yeast Hsp90 chaperone</span></div><div class="casAuthors">Prodromou, Chrisostomos; Roe, S. Mark; Piper, Peter W.; Pearl, Laurence H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">477-482</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature America</span>)
        </div><div class="casAbstract">Hsp90 is a highly specific chaperone for many signal transduction proteins, including steroid hormone receptors and a broad range of protein kinases.  The crystal structure of the N-terminal domain of Saccharomyces cerevisiae Hsp90 revealed a dimeric structure based on a highly twisted 16-stranded β-sheet, whose topol. suggested a possible 3-dimensional domain-swapped structure for the intact Hsp90 dimer.  The opposing faces of the β-sheets in the dimer defined a potential peptide-binding cleft, suggesting that the N-domain may serve as a mol. 'clamp' in the binding of ligand proteins to Hsp90.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnZBFC02XoTbVg90H21EOLACvtfcHk0lgEBmiuct1ktA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjs1elur0%253D&md5=0ff710b91bfe28e94473cf2d6387f626</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnsb0697-477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb0697-477%26sid%3Dliteratum%253Aachs%26aulast%3DProdromou%26aufirst%3DC.%26aulast%3DRoe%26aufirst%3DS.%2BM.%26aulast%3DPiper%26aufirst%3DP.%2BW.%26aulast%3DPearl%26aufirst%3DL.%2BH.%26atitle%3DA%2520molecular%2520clamp%2520in%2520the%2520crystal%2520structure%2520of%2520the%2520N-terminal%2520domain%2520of%2520the%2520yeast%2520Hsp90%2520chaperone%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D1997%26volume%3D4%26spage%3D477%26epage%3D482%26doi%3D10.1038%2Fnsb0697-477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Stebbins, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russo, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartl, F. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavletich, N. P.</span><span> </span><span class="NLM_article-title">Crystal structure of an Hsp90-geldannamycin complex: targeting of a protein chaperone by an antitumor agent</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">239</span><span class="NLM_x">–</span> <span class="NLM_lpage">250</span><span class="refDoi"> DOI: 10.1016/S0092-8674(00)80203-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2FS0092-8674%2800%2980203-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1997&pages=239-250&author=C.+E.+Stebbinsauthor=A.+A.+Russoauthor=C.+Schneiderauthor=N.+Rosenauthor=F.+U.+Hartlauthor=N.+P.+Pavletich&title=Crystal+structure+of+an+Hsp90-geldannamycin+complex%3A+targeting+of+a+protein+chaperone+by+an+antitumor+agent&doi=10.1016%2FS0092-8674%2800%2980203-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2980203-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252980203-2%26sid%3Dliteratum%253Aachs%26aulast%3DStebbins%26aufirst%3DC.%2BE.%26aulast%3DRusso%26aufirst%3DA.%2BA.%26aulast%3DSchneider%26aufirst%3DC.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DHartl%26aufirst%3DF.%2BU.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26atitle%3DCrystal%2520structure%2520of%2520an%2520Hsp90-geldannamycin%2520complex%253A%2520targeting%2520of%2520a%2520protein%2520chaperone%2520by%2520an%2520antitumor%2520agent%26jtitle%3DCell%26date%3D1997%26volume%3D89%26spage%3D239%26epage%3D250%26doi%3D10.1016%2FS0092-8674%2800%2980203-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Neckers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulte, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mimnaugh, E.</span><span> </span><span class="NLM_article-title">Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">–</span> <span class="NLM_lpage">373</span><span class="refDoi"> DOI: 10.1023/A:1006382320697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1023%2FA%3A1006382320697" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1999&pages=361-373&author=L.+Neckersauthor=T.+W.+Schulteauthor=E.+Mimnaugh&title=Geldanamycin+as+a+potential+anti-cancer+agent%3A+its+molecular+target+and+biochemical+activity&doi=10.1023%2FA%3A1006382320697"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1023%2FA%3A1006382320697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1006382320697%26sid%3Dliteratum%253Aachs%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DSchulte%26aufirst%3DT.%2BW.%26aulast%3DMimnaugh%26aufirst%3DE.%26atitle%3DGeldanamycin%2520as%2520a%2520potential%2520anti-cancer%2520agent%253A%2520its%2520molecular%2520target%2520and%2520biochemical%2520activity%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D1999%26volume%3D17%26spage%3D361%26epage%3D373%26doi%3D10.1023%2FA%3A1006382320697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Franke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eichner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeilinger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschning, A.</span><span> </span><span class="NLM_article-title">Targeting heat-shock-protein 90 (Hsp90) by natural products: geldanamycin, a show case in cancer therapy</span> <span class="citation_source-journal">Nat. Prod. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1299</span><span class="NLM_x">–</span> <span class="NLM_lpage">1323</span><span class="refDoi"> DOI: 10.1039/c3np70012g</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1039%2Fc3np70012g" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=23934201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVehtrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2013&pages=1299-1323&author=J.+Frankeauthor=S.+Eichnerauthor=C.+Zeilingerauthor=A.+Kirschning&title=Targeting+heat-shock-protein+90+%28Hsp90%29+by+natural+products%3A+geldanamycin%2C+a+show+case+in+cancer+therapy&doi=10.1039%2Fc3np70012g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting heat-shock-protein 90 (Hsp90) by natural products: geldanamycin, a show case in cancer therapy</span></div><div class="casAuthors">Franke, Jana; Eichner, Simone; Zeilinger, Carsten; Kirschning, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1299-1323</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">In this review recent progress in the development of heat shock proteins (Hsp90) in oncogenesis is illuminated.  Particular emphasis is put on inhibitors such as geldanamycin and analogs that serve as a natural product show case.  Hsp90 has emerged as an important target in cancer therapy and/or against pathogenic cells which elicit abnormal Hsp patterns.  Competition for ATP by geldanamycin and related compds. abrogate the chaperone function of Hsp90.  In this context, this account pursues three topics in detail: a) Hsp90 and its biochem., b) Hsp90 and its role in oncogenesis and c) strategies to create compd. libraries of structurally complex inhibitors like geldanamycin on which SAR studies and the development of drugs that are currently in different stages of clin. testing rely.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKEXtk_Z4sPrVg90H21EOLACvtfcHk0lhDB9LYwUAzQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVehtrjP&md5=8f326658f18f5bf01fdcad5aaac835be</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1039%2Fc3np70012g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3np70012g%26sid%3Dliteratum%253Aachs%26aulast%3DFranke%26aufirst%3DJ.%26aulast%3DEichner%26aufirst%3DS.%26aulast%3DZeilinger%26aufirst%3DC.%26aulast%3DKirschning%26aufirst%3DA.%26atitle%3DTargeting%2520heat-shock-protein%252090%2520%2528Hsp90%2529%2520by%2520natural%2520products%253A%2520geldanamycin%252C%2520a%2520show%2520case%2520in%2520cancer%2520therapy%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2013%26volume%3D30%26spage%3D1299%26epage%3D1323%26doi%3D10.1039%2Fc3np70012g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Banerji, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scurr, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stapleton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asad, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maloney, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lakhani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I.</span><span> </span><span class="NLM_article-title">Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxy geldanamycin in patients with advanced malignancies</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">4152</span><span class="NLM_x">–</span> <span class="NLM_lpage">4161</span><span class="refDoi"> DOI: 10.1200/JCO.2005.00.612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1200%2FJCO.2005.00.612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=15961763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmt1elsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=4152-4161&author=U.+Banerjiauthor=A.+O%E2%80%99Donnellauthor=M.+Scurrauthor=S.+Paceyauthor=S.+Stapletonauthor=Y.+Asadauthor=L.+Simmonsauthor=A.+Maloneyauthor=F.+Raynaudauthor=M.+Campbellauthor=M.+Waltonauthor=S.+Lakhaniauthor=S.+Kayeauthor=P.+Workmanauthor=I.+Judson&title=Phase+I+pharmacokinetic+and+pharmacodynamic+study+of+17-allylamino%2C+17-demethoxy+geldanamycin+in+patients+with+advanced+malignancies&doi=10.1200%2FJCO.2005.00.612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies</span></div><div class="casAuthors">Banerji, Udai; O'Donnell, Anne; Scurr, Michelle; Pacey, Simon; Stapleton, Sarah; Asad, Yasmin; Simmons, Laura; Maloney, Alison; Raynaud, Florence; Campbell, Maeli; Walton, Michael; Lakhani, Sunil; Kaye, Stanley; Workman, Paul; Judson, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4152-4161</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To study the toxicity and pharmacokinetic-pharmacodynamic profile of 17-allylamino, 17-demethoxygeldanamycin (17-AAG) and to recommend a dose for phase II trials.  Patients and Methods: This was a phase I study examg. a once-weekly dosing schedule of 17-AAG.  Thirty patients with advanced malignancies were treated.  Results: The highest dose level reached was 450 mg/m2/wk.  The dose-limiting toxicities (DLTs) encountered were grade 3 diarrhea in three patients (one at 320 mg/m2/wk and two at 450 mg/m2/wk) and grade 3 to 4 hepatotoxicity (AST/ALT) in one patient at 450 mg/m2/wk.  Two of nine DLTs were at the highest dose level.  Two patients with metastatic melanoma had stable disease and were treated for 15 and 41 mo, resp.  The dose vs. area under the curve-relationship for 17-AAG was linear (r2 = .71) over the dose range 10 to 450 mg/m2/wk, with peak plasma concns. of 8,998 μg/L (std. deviation, 2,881) at the highest dose level.  After the demonstration of pharmacodynamic changes in peripheral blood leukocytes, pre- and 24 h post-treatment, tumor biopsies were performed and demonstrated target inhibition (c-RAF-1 inhibition in four of six patients, CDK4 depletion in eight of nine patients and HSP70 induction in eight of nine patients) at the dose levels 320 and 450 mg/m2/wk.  It was not possible to reproducibly demonstrate these changes in biopsies taken 5 days after treatment.  Conclusion: It has been possible to demonstrate that 17-AAG exhibits a tolerable toxicity profile with therapeutic plasma concns. and target inhibition for 24 h after treatment and some indications of clin. activity at the dose level 450 mg/m2/wk.  We recommend this dose for phase II clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaKgFbodgT_bVg90H21EOLACvtfcHk0lhDB9LYwUAzQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmt1elsrY%253D&md5=6ba10e24a68a1d9bd09d87239eea1ca6</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.00.612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.00.612%26sid%3Dliteratum%253Aachs%26aulast%3DBanerji%26aufirst%3DU.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DA.%26aulast%3DScurr%26aufirst%3DM.%26aulast%3DPacey%26aufirst%3DS.%26aulast%3DStapleton%26aufirst%3DS.%26aulast%3DAsad%26aufirst%3DY.%26aulast%3DSimmons%26aufirst%3DL.%26aulast%3DMaloney%26aufirst%3DA.%26aulast%3DRaynaud%26aufirst%3DF.%26aulast%3DCampbell%26aufirst%3DM.%26aulast%3DWalton%26aufirst%3DM.%26aulast%3DLakhani%26aufirst%3DS.%26aulast%3DKaye%26aufirst%3DS.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DJudson%26aufirst%3DI.%26atitle%3DPhase%2520I%2520pharmacokinetic%2520and%2520pharmacodynamic%2520study%2520of%252017-allylamino%252C%252017-demethoxy%2520geldanamycin%2520in%2520patients%2520with%2520advanced%2520malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D4152%26epage%3D4161%26doi%3D10.1200%2FJCO.2005.00.612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Sydor, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Normant, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pien, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porter, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grenier, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pak, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dembski, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penders, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pink, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodward, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grayzel, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palombella, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, J. K.</span><span> </span><span class="NLM_article-title">Development of 17-allylamino-17- demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">17408</span><span class="NLM_x">–</span> <span class="NLM_lpage">17413</span><span class="refDoi"> DOI: 10.1073/pnas.0608372103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1073%2Fpnas.0608372103" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=17408-17413&author=J.+R.+Sydorauthor=E.+Normantauthor=C.+S.+Pienauthor=J.+R.+Porterauthor=J.+Geauthor=L.+Grenierauthor=R.+H.+Pakauthor=J.+A.+Aliauthor=M.+S.+Dembskiauthor=J.+Hudakauthor=J.+Pattersonauthor=C.+Pendersauthor=M.+Pinkauthor=M.+A.+Readauthor=J.+Sangauthor=C.+Woodwardauthor=Y.+Zhangauthor=D.+S.+Grayzelauthor=J.+Wrightauthor=J.+A.+Barrettauthor=V.+J.+Palombellaauthor=J.+Adamsauthor=J.+K.+Tong&title=Development+of+17-allylamino-17-+demethoxygeldanamycin+hydroquinone+hydrochloride+%28IPI-504%29%2C+an+anti-cancer+agent+directed+against+Hsp90&doi=10.1073%2Fpnas.0608372103"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0608372103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0608372103%26sid%3Dliteratum%253Aachs%26aulast%3DSydor%26aufirst%3DJ.%2BR.%26aulast%3DNormant%26aufirst%3DE.%26aulast%3DPien%26aufirst%3DC.%2BS.%26aulast%3DPorter%26aufirst%3DJ.%2BR.%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DGrenier%26aufirst%3DL.%26aulast%3DPak%26aufirst%3DR.%2BH.%26aulast%3DAli%26aufirst%3DJ.%2BA.%26aulast%3DDembski%26aufirst%3DM.%2BS.%26aulast%3DHudak%26aufirst%3DJ.%26aulast%3DPatterson%26aufirst%3DJ.%26aulast%3DPenders%26aufirst%3DC.%26aulast%3DPink%26aufirst%3DM.%26aulast%3DRead%26aufirst%3DM.%2BA.%26aulast%3DSang%26aufirst%3DJ.%26aulast%3DWoodward%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGrayzel%26aufirst%3DD.%2BS.%26aulast%3DWright%26aufirst%3DJ.%26aulast%3DBarrett%26aufirst%3DJ.%2BA.%26aulast%3DPalombella%26aufirst%3DV.%2BJ.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DJ.%2BK.%26atitle%3DDevelopment%2520of%252017-allylamino-17-%2520demethoxygeldanamycin%2520hydroquinone%2520hydrochloride%2520%2528IPI-504%2529%252C%2520an%2520anti-cancer%2520agent%2520directed%2520against%2520Hsp90%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D17408%26epage%3D17413%26doi%3D10.1073%2Fpnas.0608372103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agatsuma, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, H.</span><span> </span><span class="NLM_article-title">Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">2639</span><span class="NLM_x">–</span> <span class="NLM_lpage">2645</span><span class="refDoi"> DOI: 10.1038/sj.onc.1201790</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fsj.onc.1201790" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1998&pages=2639-2645&author=S.+V.+Sharmaauthor=T.+Agatsumaauthor=H.+Nakano&title=Targeting+of+the+protein+chaperone%2C+HSP90%2C+by+the+transformation+suppressing+agent%2C+radicicol&doi=10.1038%2Fsj.onc.1201790"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1201790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1201790%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DAgatsuma%26aufirst%3DT.%26aulast%3DNakano%26aufirst%3DH.%26atitle%3DTargeting%2520of%2520the%2520protein%2520chaperone%252C%2520HSP90%252C%2520by%2520the%2520transformation%2520suppressing%2520agent%252C%2520radicicol%26jtitle%3DOncogene%26date%3D1998%26volume%3D16%26spage%3D2639%26epage%3D2645%26doi%3D10.1038%2Fsj.onc.1201790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Brough, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barril, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgognoni, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cansfield, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, K.-M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, N. G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drysdale, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martins, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Northfield, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearl, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prodromou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roughley, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharp, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surgenor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walmsley, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, L.</span><span> </span><span class="NLM_article-title">4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">196</span><span class="NLM_x">–</span> <span class="NLM_lpage">218</span><span class="refDoi"> DOI: 10.1021/jm701018h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701018h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlWqsL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=196-218&author=P.+A.+Broughauthor=W.+Aherneauthor=X.+Barrilauthor=J.+Borgognoniauthor=K.+Boxallauthor=J.+E.+Cansfieldauthor=K.-M.+J.+Cheungauthor=I.+Collinsauthor=N.+G.+M.+Daviesauthor=M.+J.+Drysdaleauthor=B.+Dymockauthor=S.+A.+Ecclesauthor=H.+Finchauthor=A.+Finkauthor=A.+Hayesauthor=R.+Howesauthor=R.+E.+Hubbardauthor=K.+Jamesauthor=A.+M.+Jordanauthor=A.+Lockieauthor=V.+Martinsauthor=A.+Masseyauthor=T.+P.+Matthewsauthor=E.+McDonaldauthor=C.+J.+Northfieldauthor=L.+H.+Pearlauthor=C.+Prodromouauthor=S.+Rayauthor=F.+I.+Raynaudauthor=S.+D.+Roughleyauthor=S.+Y.+Sharpauthor=A.+Surgenorauthor=D.+L.+Walmsleyauthor=P.+Webbauthor=M.+Woodauthor=P.+Workmanauthor=L.+Wright&title=4%2C5-Diarylisoxazole+Hsp90+chaperone+inhibitors%3A+potential+therapeutic+agents+for+the+treatment+of+cancer&doi=10.1021%2Fjm701018h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer</span></div><div class="casAuthors">Brough, Paul A.; Aherne, Wynne; Barril, Xavier; Borgognoni, Jennifer; Boxall, Kathy; Cansfield, Julie E.; Cheung, Kwai-Ming J.; Collins, Ian; Davies, Nicholas G. M.; Drysdale, Martin J.; Dymock, Brian; Eccles, Suzanne A.; Finch, Harry; Fink, Alexandra; Hayes, Angela; Howes, Robert; Hubbard, Roderick E.; James, Karen; Jordan, Allan M.; Lockie, Andrea; Martins, Vanessa; Massey, Andrew; Matthews, Thomas P.; McDonald, Edward; Northfield, Christopher J.; Pearl, Laurence H.; Prodromou, Chrisostomos; Ray, Stuart; Raynaud, Florence I.; Roughley, Stephen D.; Sharp, Swee Y.; Surgenor, Allan; Walmsley, D. Lee; Webb, Paul; Wood, Mike; Workman, Paul; Wright, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">196-218</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors of the Hsp90 [heat shock protein 90] mol. chaperone show considerable promise as potential chemotherapeutic agents for cancer.  The structure-based design, synthesis, structure-activity relationships, and pharmacokinetics of potent small-mol. inhibitors of Hsp90 based on the 4,5-diarylisoxazole scaffold were studied.  Analogs from this series have high affinity for Hsp90, as measured in a fluorescence polarization competitive binding assay, and are active in cancer cell lines where they inhibit proliferation and exhibit a characteristic profile of depletion of oncogenic proteins and concomitant elevation of Hsp72.  The [(morpholinomethyl)phenyl]isoxazolecarboxamide I (VER-52296/NVP-AUY922) is potent in the Hsp90 FP binding assay and inhibits proliferation of various human cancer cell lines in vitro, with GI50 averaging 9 nM.  I is retained in tumors in vivo when administered i.p., as evaluated by cassette dosing in tumor-bearing mice.  In a human colon cancer xenograft model, I inhibits tumor growth by ∼50%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTNA9AoWb8gLVg90H21EOLACvtfcHk0lhtYjsUXIYiKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlWqsL%252FK&md5=fdb98dec600987e862b9b05555427948</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm701018h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701018h%26sid%3Dliteratum%253Aachs%26aulast%3DBrough%26aufirst%3DP.%2BA.%26aulast%3DAherne%26aufirst%3DW.%26aulast%3DBarril%26aufirst%3DX.%26aulast%3DBorgognoni%26aufirst%3DJ.%26aulast%3DBoxall%26aufirst%3DK.%26aulast%3DCansfield%26aufirst%3DJ.%2BE.%26aulast%3DCheung%26aufirst%3DK.-M.%2BJ.%26aulast%3DCollins%26aufirst%3DI.%26aulast%3DDavies%26aufirst%3DN.%2BG.%2BM.%26aulast%3DDrysdale%26aufirst%3DM.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DFinch%26aufirst%3DH.%26aulast%3DFink%26aufirst%3DA.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHowes%26aufirst%3DR.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DJordan%26aufirst%3DA.%2BM.%26aulast%3DLockie%26aufirst%3DA.%26aulast%3DMartins%26aufirst%3DV.%26aulast%3DMassey%26aufirst%3DA.%26aulast%3DMatthews%26aufirst%3DT.%2BP.%26aulast%3DMcDonald%26aufirst%3DE.%26aulast%3DNorthfield%26aufirst%3DC.%2BJ.%26aulast%3DPearl%26aufirst%3DL.%2BH.%26aulast%3DProdromou%26aufirst%3DC.%26aulast%3DRay%26aufirst%3DS.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DRoughley%26aufirst%3DS.%2BD.%26aulast%3DSharp%26aufirst%3DS.%2BY.%26aulast%3DSurgenor%26aufirst%3DA.%26aulast%3DWalmsley%26aufirst%3DD.%2BL.%26aulast%3DWebb%26aufirst%3DP.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DWright%26aufirst%3DL.%26atitle%3D4%252C5-Diarylisoxazole%2520Hsp90%2520chaperone%2520inhibitors%253A%2520potential%2520therapeutic%2520agents%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D196%26epage%3D218%26doi%3D10.1021%2Fjm701018h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Ying, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proia, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackman, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatsuta, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acquaviva, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barsoum, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koya, K.</span><span> </span><span class="NLM_article-title">Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">475</span><span class="NLM_x">–</span> <span class="NLM_lpage">484</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0755</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1535-7163.MCT-11-0755" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22144665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFWksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=475-484&author=W.+Yingauthor=Z.+Duauthor=L.+Sunauthor=K.+P.+Foleyauthor=D.+A.+Proiaauthor=R.+K.+Blackmanauthor=D.+Zhouauthor=T.+Inoueauthor=N.+Tatsutaauthor=J.+Sangauthor=S.+Yeauthor=J.+Acquavivaauthor=L.+S.+Ogawaauthor=Y.+Wadaauthor=J.+Barsoumauthor=K.+Koya&title=Ganetespib%2C+a+unique+triazolone-containing+Hsp90+inhibitor%2C+exhibits+potent+antitumor+activity+and+a+superior+safety+profile+for+cancer+therapy&doi=10.1158%2F1535-7163.MCT-11-0755"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy</span></div><div class="casAuthors">Ying, Weiwen; Du, Zhenjian; Sun, Lijun; Foley, Kevin P.; Proia, David A.; Blackman, Ronald K.; Zhou, Dan; Inoue, Takayo; Tatsuta, Noriaki; Sang, Jim; Ye, Shuxia; Acquaviva, Jamie; Ogawa, Luisa Shin; Wada, Yumiko; Barsoum, James; Koya, Keizo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">475-484</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Targeted inhibition of the mol. chaperone Hsp90 results in the simultaneous blockade of multiple oncogenic signaling pathways and has, thus, emerged as an attractive strategy for the development of novel cancer therapeutics.  Ganetespib (formerly known as STA-9090) is a unique resorcinolic triazolone inhibitor of Hsp90 that is currently in clin. trials for a no. of human cancers.  In the present study, we showed that ganetespib exhibits potent in vitro cytotoxicity in a range of solid and hematol. tumor cell lines, including those that express mutated kinases that confer resistance to small-mol. tyrosine kinase inhibitors.  Ganetespib treatment rapidly induced the degrdn. of known Hsp90 client proteins, displayed superior potency to the ansamycin inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG), and exhibited sustained activity even with short exposure times.  In vivo, ganetespib showed potent antitumor efficacy in solid and hematol. xenograft models of oncogene addiction, as evidenced by significant growth inhibition and/or regressions.  Notably, evaluation of the microregional activity of ganetespib in tumor xenografts showed that ganetespib was efficiently distributed throughout tumor tissue, including hypoxic regions >150 μm from the microvasculature, to inhibit proliferation and induce apoptosis.  Importantly, ganetespib showed no evidence of cardiac or liver toxicity.  Taken together, this preclin. activity profile indicates that ganetespib may have broad application for a variety of human malignancies, and with select mechanistic and safety advantages over other first- and second-generation Hsp90 inhibitors.  Mol Cancer Ther; 11(2); 475-84.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFhzG1TPr4lbVg90H21EOLACvtfcHk0ljRHTEohpvuAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFWksrY%253D&md5=269d41b30e5add9b9503cb43a98b0157</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0755%26sid%3Dliteratum%253Aachs%26aulast%3DYing%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DFoley%26aufirst%3DK.%2BP.%26aulast%3DProia%26aufirst%3DD.%2BA.%26aulast%3DBlackman%26aufirst%3DR.%2BK.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DTatsuta%26aufirst%3DN.%26aulast%3DSang%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DS.%26aulast%3DAcquaviva%26aufirst%3DJ.%26aulast%3DOgawa%26aufirst%3DL.%2BS.%26aulast%3DWada%26aufirst%3DY.%26aulast%3DBarsoum%26aufirst%3DJ.%26aulast%3DKoya%26aufirst%3DK.%26atitle%3DGanetespib%252C%2520a%2520unique%2520triazolone-containing%2520Hsp90%2520inhibitor%252C%2520exhibits%2520potent%2520antitumor%2520activity%2520and%2520a%2520superior%2520safety%2520profile%2520for%2520cancer%2520therapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D475%26epage%3D484%26doi%3D10.1158%2F1535-7163.MCT-11-0755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Jensen, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoepfer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radimerski, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guy, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brueggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quadt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cozens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drysdale, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chène, P.</span><span> </span><span class="NLM_article-title">NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models</span> <span class="citation_source-journal">Breast Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">R33</span><span class="refDoi"> DOI: 10.1186/bcr1996</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1186%2Fbcr1996" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=18430202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A280%3ADC%252BD1czktlKhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=R33&author=M.+R.+Jensenauthor=J.+Schoepferauthor=T.+Radimerskiauthor=A.+Masseyauthor=C.+T.+Guyauthor=J.+Brueggenauthor=C.+Quadtauthor=A.+Bucklerauthor=R.+Cozensauthor=M.+J.+Drysdaleauthor=C.+Garcia-Echeverriaauthor=P.+Ch%C3%A8ne&title=NVP-AUY922%3A+a+small+molecule+HSP90+inhibitor+with+potent+antitumor+activity+in+preclinical+breast+cancer+models&doi=10.1186%2Fbcr1996"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models</span></div><div class="casAuthors">Jensen Michael Rugaard; Schoepfer Joseph; Radimerski Thomas; Massey Andrew; Guy Chantale T; Brueggen Josef; Quadt Cornelia; Buckler Alan; Cozens Robert; Drysdale Martin J; Garcia-Echeverria Carlos; Chene Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer research : BCR</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">R33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Heat shock protein 90 (HSP90) is a key component of a multichaperone complex involved in the post-translational folding of a large number of client proteins, many of which play essential roles in tumorigenesis.  HSP90 has emerged in recent years as a promising new target for anticancer therapies.  METHODS:  The concentrations of the HSP90 inhibitor NVP-AUY922 required to reduce cell numbers by 50% (GI50 values) were established in a panel of breast cancer cell lines and patient-derived human breast tumors.  To investigate the properties of the compound in vivo, the pharmacokinetic profile, antitumor effect, and dose regimen were established in a BT-474 breast cancer xenograft model.  The effect on HSP90-p23 complexes, client protein degradation, and heat shock response was investigated in cell culture and breast cancer xenografts by immunohistochemistry, Western blot analysis, and immunoprecipitation.  RESULTS:  We show that the novel small molecule HSP90 inhibitor NVP-AUY922 potently inhibits the proliferation of human breast cancer cell lines with GI50 values in the range of 3 to 126 nM.  NVP-AUY922 induced proliferative inhibition concurrent with HSP70 upregulation and client protein depletion--hallmarks of HSP90 inhibition.  Intravenous acute administration of NVP-AUY922 to athymic mice (30 mg/kg) bearing subcutaneous BT-474 breast tumors resulted in drug levels in excess of 1,000 times the cellular GI50 value for about 2 days.  Significant growth inhibition and good tolerability were observed when the compound was administered once per week.  Therapeutic effects were concordant with changes in pharmacodynamic markers, including HSP90-p23 dissociation, decreases in ERBB2 and P-AKT, and increased HSP70 protein levels.  CONCLUSION:  NVP-AUY922 is a potent small molecule HSP90 inhibitor showing significant activity against breast cancer cells in cellular and in vivo settings.  On the basis of its mechanism of action, preclinical activity profile, tolerability, and pharmaceutical properties, the compound recently has entered clinical phase I breast cancer trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQRY3cZ5prrYd1QT_1O5WBYfW6udTcc2eYhzzvSpIKrkrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1czktlKhuw%253D%253D&md5=2779e042ee1da49407fc813cca82305e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1186%2Fbcr1996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fbcr1996%26sid%3Dliteratum%253Aachs%26aulast%3DJensen%26aufirst%3DM.%2BR.%26aulast%3DSchoepfer%26aufirst%3DJ.%26aulast%3DRadimerski%26aufirst%3DT.%26aulast%3DMassey%26aufirst%3DA.%26aulast%3DGuy%26aufirst%3DC.%2BT.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DQuadt%26aufirst%3DC.%26aulast%3DBuckler%26aufirst%3DA.%26aulast%3DCozens%26aufirst%3DR.%26aulast%3DDrysdale%26aufirst%3DM.%2BJ.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DCh%25C3%25A8ne%26aufirst%3DP.%26atitle%3DNVP-AUY922%253A%2520a%2520small%2520molecule%2520HSP90%2520inhibitor%2520with%2520potent%2520antitumor%2520activity%2520in%2520preclinical%2520breast%2520cancer%2520models%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2008%26volume%3D10%26spage%3DR33%26doi%3D10.1186%2Fbcr1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Woodhead, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angove, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chessari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Congreve, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coyle, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosme, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downham, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feltell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figueroa, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frederickson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMenamin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parra, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rees, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trewartha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vinkovic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolford, A. J.</span><span> </span><span class="NLM_article-title">Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin- 1-yl methyl)-1,3-dihydro isoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">5956</span><span class="NLM_x">–</span> <span class="NLM_lpage">5969</span><span class="refDoi"> DOI: 10.1021/jm100060b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100060b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5956-5969&author=A.+J.+Woodheadauthor=H.+Angoveauthor=M.+G.+Carrauthor=G.+Chessariauthor=M.+Congreveauthor=J.+E.+Coyleauthor=J.+Cosmeauthor=B.+Grahamauthor=P.+J.+Dayauthor=R.+Downhamauthor=L.+Fazalauthor=R.+Feltellauthor=E.+Figueroaauthor=M.+Fredericksonauthor=J.+Lewisauthor=R.+McMenaminauthor=C.+W.+Murrayauthor=M.+A.+O%E2%80%99Brienauthor=L.+Parraauthor=S.+Patelauthor=T.+Phillipsauthor=D.+C.+Reesauthor=S.+Richauthor=D.+M.+Smithauthor=G.+Trewarthaauthor=M.+Vinkovicauthor=B.+Williamsauthor=A.+J.+Woolford&title=Discovery+of+%282%2C4-dihydroxy-5-isopropylphenyl%29-%5B5-%284-methylpiperazin-+1-yl+methyl%29-1%2C3-dihydro+isoindol-2-yl%5Dmethanone+%28AT13387%29%2C+a+novel+inhibitor+of+the+molecular+chaperone+Hsp90+by+fragment+based+drug+design&doi=10.1021%2Fjm100060b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm100060b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100060b%26sid%3Dliteratum%253Aachs%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26aulast%3DAngove%26aufirst%3DH.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DChessari%26aufirst%3DG.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DCoyle%26aufirst%3DJ.%2BE.%26aulast%3DCosme%26aufirst%3DJ.%26aulast%3DGraham%26aufirst%3DB.%26aulast%3DDay%26aufirst%3DP.%2BJ.%26aulast%3DDownham%26aufirst%3DR.%26aulast%3DFazal%26aufirst%3DL.%26aulast%3DFeltell%26aufirst%3DR.%26aulast%3DFigueroa%26aufirst%3DE.%26aulast%3DFrederickson%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DJ.%26aulast%3DMcMenamin%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%2BA.%26aulast%3DParra%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DPhillips%26aufirst%3DT.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DRich%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DD.%2BM.%26aulast%3DTrewartha%26aufirst%3DG.%26aulast%3DVinkovic%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DB.%26aulast%3DWoolford%26aufirst%3DA.%2BJ.%26atitle%3DDiscovery%2520of%2520%25282%252C4-dihydroxy-5-isopropylphenyl%2529-%255B5-%25284-methylpiperazin-%25201-yl%2520methyl%2529-1%252C3-dihydro%2520isoindol-2-yl%255Dmethanone%2520%2528AT13387%2529%252C%2520a%2520novel%2520inhibitor%2520of%2520the%2520molecular%2520chaperone%2520Hsp90%2520by%2520fragment%2520based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5956%26epage%3D5969%26doi%3D10.1021%2Fjm100060b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Taldone, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span> </span><span class="NLM_article-title">Purine-scaffold Hsp90 inhibitors</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1436</span><span class="NLM_x">–</span> <span class="NLM_lpage">1446</span><span class="refDoi"> DOI: 10.2174/156802609789895737</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.2174%2F156802609789895737" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=19860732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFakurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=1436-1446&author=T.+Taldoneauthor=G.+Chiosis&title=Purine-scaffold+Hsp90+inhibitors&doi=10.2174%2F156802609789895737"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Purine-scaffold Hsp90 inhibitors</span></div><div class="casAuthors">Taldone, Tony; Chiosis, Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1436-1446</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Hsp90 is a mol. chaperone with important roles in regulating the function of several proteins with potential pathogenic activity.  Because many of these proteins are involved in cancer and neurodegenerative promoting pathways, Hsp90 has emerged as an attractive therapeutic target in these diseases.  Mols. that bind to the N-terminal nucleotide pocket of Hsp90 inhibit its activity, and consequently, disrupt client protein function.  A no. of these inhibitors from several chem. classes are now known, and some are already in clin. trials.  This review focuses on the purine class of Hsp90 inhibitors, their discovery through rational design, and on efforts aimed towards their optimization and development into clin. viable drugs for the treatment of cancer.  Their potential towards neurodegenerative diseases will also be touched upon.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVLlJs6fJ--rVg90H21EOLACvtfcHk0lgBdAet4JRKWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFakurg%253D&md5=346a3ef4c1503aee2d918074c1ecb46c</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.2174%2F156802609789895737&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802609789895737%26sid%3Dliteratum%253Aachs%26aulast%3DTaldone%26aufirst%3DT.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DPurine-scaffold%2520Hsp90%2520inhibitors%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D1436%26epage%3D1446%26doi%3D10.2174%2F156802609789895737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">He, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zatorska, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguirre, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llauger, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">She, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Immormino, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gewirth, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span> </span><span class="NLM_article-title">Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">381</span><span class="NLM_x">–</span> <span class="NLM_lpage">390</span><span class="refDoi"> DOI: 10.1021/jm0508078</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0508078" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1ynsrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=381-390&author=H.+Heauthor=D.+Zatorskaauthor=J.+Kimauthor=J.+Aguirreauthor=L.+Llaugerauthor=Y.+Sheauthor=N.+Wuauthor=R.+M.+Immorminoauthor=D.+T.+Gewirthauthor=G.+Chiosis&title=Identification+of+potent+water+soluble+purine-scaffold+inhibitors+of+the+heat+shock+protein+90&doi=10.1021%2Fjm0508078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Potent Water Soluble Purine-Scaffold Inhibitors of the Heat Shock Protein 90</span></div><div class="casAuthors">He, Huazhong; Zatorska, Danuta; Kim, Joungnam; Aguirre, Julia; Llauger, Laura; She, Yuhong; Wu, Nian; Immormino, Robert M.; Gewirth, Daniel T.; Chiosis, Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">381-390</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hsp90 is a chaperone protein that allows cancer cells to tolerate the many components of dysregulated pathways.  Its inactivation may result in targeting multiple mol. alterations and, thus, in reverting the transformed phenotype.  The PU-class, a purine-scaffold Hsp90 inhibitor series, has been reported to be potent and selective against Hsp90 both in vitro and in vivo models of cancer.  Here, a series of this class was synthesized and evaluated as inhibitors of the chaperone.  The structure-activity relationship and selectivity for tumor Hsp90 of compds. within the series is presented.  The study identifies water sol. derivs. (>5 mM in PBS pH 7.4) of nanomolar potency (IC50 ∼ 50 nM) in cellular and animal models of cancer.  Binding affinities of these compds. for Hsp90 correlate well with their biol. activities.  When administered in vivo to mice bearing MDA-MB-468 human breast cancer xenografted tumors, these agents result in pharmacol. relevant concns. and, accordingly, in modulation of Hsp90-client proteins in tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRwHp1Wo_iW7Vg90H21EOLACvtfcHk0lgBdAet4JRKWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1ynsrrF&md5=3bd02ca5bc0a147e9cffa58968433917</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm0508078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0508078%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DH.%26aulast%3DZatorska%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DAguirre%26aufirst%3DJ.%26aulast%3DLlauger%26aufirst%3DL.%26aulast%3DShe%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DN.%26aulast%3DImmormino%26aufirst%3DR.%2BM.%26aulast%3DGewirth%26aufirst%3DD.%2BT.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DIdentification%2520of%2520potent%2520water%2520soluble%2520purine-scaffold%2520inhibitors%2520of%2520the%2520heat%2520shock%2520protein%252090%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D381%26epage%3D390%26doi%3D10.1021%2Fjm0508078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Taldone, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochiana, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uddin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gewirth, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span> </span><span class="NLM_article-title">Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">6803</span><span class="NLM_x">–</span> <span class="NLM_lpage">6818</span><span class="refDoi"> DOI: 10.1021/jm400619b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400619b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlWltbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6803-6818&author=T.+Taldoneauthor=P.+D.+Patelauthor=M.+Patelauthor=H.+J.+Patelauthor=C.+E.+Evansauthor=A.+Rodinaauthor=S.+Ochianaauthor=S.+K.+Shahauthor=M.+Uddinauthor=D.+Gewirthauthor=G.+Chiosis&title=Experimental+and+structural+testing+module+to+analyze+paralogue-specificity+and+affinity+in+the+Hsp90+inhibitors+series&doi=10.1021%2Fjm400619b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and Structural Testing Module to Analyze Paralogue-Specificity and Affinity in the Hsp90 Inhibitors Series</span></div><div class="casAuthors">Taldone, Tony; Patel, Pallav D.; Patel, Maulik; Patel, Hardik J.; Evans, Christopher E.; Rodina, Anna; Ochiana, Stefan; Shah, Smit K.; Uddin, Mohammad; Gewirth, Daniel; Chiosis, Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6803-6818</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We here describe the first reported comprehensive anal. of Hsp90 paralogue affinity and selectivity in the clin. Hsp90 inhibitor chemotypes.  This has been possible through the development of a versatile exptl. assay based on a new FP-probe that we both describe here.  The assay can test rapidly and accurately the binding affinity of all major Hsp90 chemotypes and has a testing range that spans low nanomolar to millimolar binding affinities.  We couple this assay with a computational anal. that allows for rationalization of paralogue selectivity and defines not only the major binding modes that relay pan-paralogue binding or, conversely, paralogue selectivity, but also identifies mol. characteristics that impart such features.  The methods developed here provide a blueprint for parsing out the contribution of the four Hsp90 paralogues to the perceived biol. activity with the current Hsp90 chemotypes and set the ground for the development of paralogue selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgOst3-n58BrVg90H21EOLACvtfcHk0lhNwFFzo2djwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlWltbvM&md5=bda49f7f2f61553e344b100d5d6949dd</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm400619b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400619b%26sid%3Dliteratum%253Aachs%26aulast%3DTaldone%26aufirst%3DT.%26aulast%3DPatel%26aufirst%3DP.%2BD.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DH.%2BJ.%26aulast%3DEvans%26aufirst%3DC.%2BE.%26aulast%3DRodina%26aufirst%3DA.%26aulast%3DOchiana%26aufirst%3DS.%26aulast%3DShah%26aufirst%3DS.%2BK.%26aulast%3DUddin%26aufirst%3DM.%26aulast%3DGewirth%26aufirst%3DD.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DExperimental%2520and%2520structural%2520testing%2520module%2520to%2520analyze%2520paralogue-specificity%2520and%2520affinity%2520in%2520the%2520Hsp90%2520inhibitors%2520series%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6803%26epage%3D6818%26doi%3D10.1021%2Fjm400619b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Immormino, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gewirth, D. T.</span><span> </span><span class="NLM_article-title">Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">4953</span><span class="NLM_x">–</span> <span class="NLM_lpage">4960</span><span class="refDoi"> DOI: 10.1021/jm060297x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060297x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD28Xms1SksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4953-4960&author=R.+M.+Immorminoauthor=Y.+Kangauthor=G.+Chiosisauthor=D.+T.+Gewirth&title=Structural+and+quantum+chemical+studies+of+8-aryl-sulfanyl+adenine+class+Hsp90+inhibitors&doi=10.1021%2Fjm060297x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Quantum Chemical Studies of 8-Aryl-sulfanyl Adenine Class Hsp90 Inhibitors</span></div><div class="casAuthors">Immormino, Robert M.; Kang, Yanlong; Chiosis, Gabriela; Gewirth, Daniel T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4953-4960</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hsp90 chaperones play a crit. role in modulating the activity of many cell signaling proteins and are an attractive target for anticancer therapeutics.  The authors report here the structures of the water sol. 8-aryl-sulfanyl adenine class Hsp90 inhibitors, (I, PU-H71) and (II, PU-H64), in complex with the N-terminal domain of human Hsp90α.  The conformation of I when bound to Hsp90 differs from previously reported 8-aryl adenine Hsp90 inhibitors including (III, PU24FCl).  While the binding mode for III places the 2'-halide of the 8-aryl group on top of the adenine ring, for I and II, the authors show that the 2'-halide is rotated approx. 180° away.  This difference explains the opposing trends in Hsp90 inhibitory activity for the 2'-halo derivs. of the 3',4',5'-trimethoxy series where Cl > Br > I compared to the 4',5'-methylenedioxy series where I > Br > Cl.  The authors also present quantum chem. calcns. of II and its analogs that illuminate their basis for Hsp90 inhibition.  The calcd. conformation of II agreed well with the crystallog. obsd. conformations of I and II.  The predictive nature of the calcns. has allowed the exploration of addnl. derivs. based on the 8-aryl adenine scaffold.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9wb5UeDL2DLVg90H21EOLACvtfcHk0lhNwFFzo2djwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xms1SksL8%253D&md5=4f530c5ae8a116d09c098b0b281671a1</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm060297x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060297x%26sid%3Dliteratum%253Aachs%26aulast%3DImmormino%26aufirst%3DR.%2BM.%26aulast%3DKang%26aufirst%3DY.%26aulast%3DChiosis%26aufirst%3DG.%26aulast%3DGewirth%26aufirst%3DD.%2BT.%26atitle%3DStructural%2520and%2520quantum%2520chemical%2520studies%2520of%25208-aryl-sulfanyl%2520adenine%2520class%2520Hsp90%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4953%26epage%3D4960%26doi%3D10.1021%2Fjm060297x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Fadden, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steed, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barabasz, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Partridge, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubois, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freed, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silinski, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barta, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ommen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spangenberg, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaves, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinkley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenks, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pronk, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verleysen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haystead, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S. E.</span><span> </span><span class="NLM_article-title">Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting Hsp90</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">686</span><span class="NLM_x">–</span> <span class="NLM_lpage">694</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2010.04.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.chembiol.2010.04.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=20659681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptleitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=686-694&author=P.+Faddenauthor=K.+H.+Huangauthor=J.+M.+Vealauthor=P.+M.+Steedauthor=A.+F.+Barabaszauthor=B.+Foleyauthor=M.+Huauthor=J.+M.+Partridgeauthor=J.+Riceauthor=A.+Scottauthor=L.+G.+Duboisauthor=T.+A.+Freedauthor=M.+A.+Silinskiauthor=T.+E.+Bartaauthor=P.+F.+Hughesauthor=A.+Ommenauthor=W.+Maauthor=E.+D.+Smithauthor=A.+W.+Spangenbergauthor=J.+Eavesauthor=G.+J.+Hansonauthor=L.+Hinkleyauthor=M.+Jenksauthor=M.+Lewisauthor=J.+Ottoauthor=G.+J.+Pronkauthor=K.+Verleysenauthor=T.+A.+Haysteadauthor=S.+E.+Hall&title=Application+of+chemoproteomics+to+drug+discovery%3A+identification+of+a+clinical+candidate+targeting+Hsp90&doi=10.1016%2Fj.chembiol.2010.04.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Application of Chemoproteomics to Drug Discovery: Identification of a Clinical Candidate Targeting Hsp90</span></div><div class="casAuthors">Fadden, Patrick; Huang, Kenneth H.; Veal, James M.; Steed, Paul M.; Barabasz, Amy F.; Foley, Briana; Hu, Mei; Partridge, Jeffrey M.; Rice, John; Scott, Anisa; Dubois, Laura G.; Freed, Tiffany A.; Rehder Silinski, Melanie A.; Barta, Thomas E.; Hughes, Philip F.; Ommen, Andy; Ma, Wei; Smith, Emilie D.; Woodward Spangenberg, Angela; Eaves, Jeron; Hanson, Gunnar J.; Hinkley, Lindsay; Jenks, Matthew; Lewis, Meredith; Otto, James; Pronk, Gijsbertus J.; Verleysen, Katleen; Haystead, Timothy A.; Hall, Steven E.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">686-694</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: A chemoproteomics-based drug discovery strategy is presented that utilizes a highly parallel screening platform, encompassing more than 1000 targets, with a focused chem. library prior to target selection.  This chemoproteomics-based process enables a data-driven selection of both the biol. target and chem. hit after the screen is complete.  The methodol. has been exemplified for the purine binding proteome (proteins utilizing ATP, NAD, FAD).  Screening of an 8000 member library yielded over 1500 unique protein-ligand interactions, which included novel hits for the oncol. target Hsp90.  The approach, which also provides broad target selectivity information, was used to drive the identification of a potent and orally active Hsp90 inhibitor, SNX-5422, which is currently in phase 1 clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfemxEaaJVH7Vg90H21EOLACvtfcHk0lhNwFFzo2djwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptleitL4%253D&md5=68486178a6847516af3fb5417a9b1911</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.04.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.04.015%26sid%3Dliteratum%253Aachs%26aulast%3DFadden%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DK.%2BH.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DSteed%26aufirst%3DP.%2BM.%26aulast%3DBarabasz%26aufirst%3DA.%2BF.%26aulast%3DFoley%26aufirst%3DB.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DPartridge%26aufirst%3DJ.%2BM.%26aulast%3DRice%26aufirst%3DJ.%26aulast%3DScott%26aufirst%3DA.%26aulast%3DDubois%26aufirst%3DL.%2BG.%26aulast%3DFreed%26aufirst%3DT.%2BA.%26aulast%3DSilinski%26aufirst%3DM.%2BA.%26aulast%3DBarta%26aufirst%3DT.%2BE.%26aulast%3DHughes%26aufirst%3DP.%2BF.%26aulast%3DOmmen%26aufirst%3DA.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DSmith%26aufirst%3DE.%2BD.%26aulast%3DSpangenberg%26aufirst%3DA.%2BW.%26aulast%3DEaves%26aufirst%3DJ.%26aulast%3DHanson%26aufirst%3DG.%2BJ.%26aulast%3DHinkley%26aufirst%3DL.%26aulast%3DJenks%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DM.%26aulast%3DOtto%26aufirst%3DJ.%26aulast%3DPronk%26aufirst%3DG.%2BJ.%26aulast%3DVerleysen%26aufirst%3DK.%26aulast%3DHaystead%26aufirst%3DT.%2BA.%26aulast%3DHall%26aufirst%3DS.%2BE.%26atitle%3DApplication%2520of%2520chemoproteomics%2520to%2520drug%2520discovery%253A%2520identification%2520of%2520a%2520clinical%2520candidate%2520targeting%2520Hsp90%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D686%26epage%3D694%26doi%3D10.1016%2Fj.chembiol.2010.04.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Huang, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fadden, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaves, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strachan, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barabasz, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barta, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silinski, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Partridge, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DuBois, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freed, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steed, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ommen, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodward, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCall, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markworth, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinkley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenks, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pronk, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verleysen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S. E.</span><span> </span><span class="NLM_article-title">Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">4288</span><span class="NLM_x">–</span> <span class="NLM_lpage">4305</span><span class="refDoi"> DOI: 10.1021/jm900230j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900230j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD1MXns1Onsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4288-4305&author=K.+H.+Huangauthor=J.+M.+Vealauthor=R.+P.+Faddenauthor=J.+W.+Riceauthor=J.+Eavesauthor=J.+P.+Strachanauthor=A.+F.+Barabaszauthor=B.+E.+Foleyauthor=T.+E.+Bartaauthor=W.+Maauthor=M.+A.+Silinskiauthor=M.+Huauthor=J.+M.+Partridgeauthor=A.+Scottauthor=L.+G.+DuBoisauthor=T.+Freedauthor=P.+M.+Steedauthor=A.+J.+Ommenauthor=E.+D.+Smithauthor=P.+F.+Hughesauthor=A.+R.+Woodwardauthor=G.+J.+Hansonauthor=W.+S.+McCallauthor=C.+J.+Markworthauthor=L.+Hinkleyauthor=M.+Jenksauthor=L.+Gengauthor=M.+Lewisauthor=J.+Ottoauthor=B.+Pronkauthor=K.+Verleysenauthor=S.+E.+Hall&title=Discovery+of+novel+2-aminobenzamide+inhibitors+of+heat+shock+protein+90+as+potent%2C+selective+and+orally+active+antitumor+agents&doi=10.1021%2Fjm900230j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel 2-Aminobenzamide Inhibitors of Heat Shock Protein 90 as Potent, Selective and Orally Active Antitumor Agents</span></div><div class="casAuthors">Huang, Kenneth H.; Veal, James M.; Fadden, R. Patrick; Rice, John W.; Eaves, Jeron; Strachan, Jon-Paul; Barabasz, Amy F.; Foley, Briana E.; Barta, Thomas E.; Ma, Wei; Silinski, Melanie A.; Hu, Mei; Partridge, Jeffrey M.; Scott, Anisa; DuBois, Laura G.; Freed, Tiffany; Steed, Paul M.; Ommen, Andy J.; Smith, Emilie D.; Hughes, Philip F.; Woodward, Angela R.; Hanson, Gunnar J.; McCall, W. Stephen; Markworth, Christopher J.; Hinkley, Lindsay; Jenks, Matthew; Geng, Lifeng; Lewis, Meredith; Otto, James; Pronk, Bert; Verleysen, Katleen; Hall, Steven E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4288-4305</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel class of heat shock protein 90 (Hsp90) inhibitors was developed from an unbiased screen to identify protein targets for a diverse compd. library.  These indol-4-one and indazol-4-one derived 2-aminobenzamides showed strong binding affinity to Hsp90, and optimized analogs exhibited nanomolar antiproliferative activity across multiple cancer cell lines.  Heat shock protein 70 (Hsp70) induction and specific client protein degrdn. in cells on treatment with the inhibitors supported Hsp90 inhibition as the mechanism of action.  Computational chem. and X-ray crystallog. anal. of selected member compds. clearly defined the protein-inhibitor interaction and assisted the design of analogs. 4-[6,6-Dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-[(trans-4-hydroxycyclohexyl)amino]benzamide (SNX-2112) (I) was identified as highly selective and potent (IC50 Her2 = 11 nM, HT-29 = 3 nM); its prodrug amino-acetic acid 4-[2-carbamoyl-5-(6,6-dimethyl-4-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-indazol-1-yl)-phenylamino]-cyclohexyl ester methanesulfonate (SNX-5422) (II)was orally bioavailable and efficacious in a broad range of xenograft tumor models (e.g. 67% growth delay in a HT-29 model) and is now in multiple phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFjrhELWrFkbVg90H21EOLACvtfcHk0lgY2eEcYmkLjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXns1Onsrk%253D&md5=99e5039e1761e9099d634acd79a15a6a</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm900230j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900230j%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DK.%2BH.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DFadden%26aufirst%3DR.%2BP.%26aulast%3DRice%26aufirst%3DJ.%2BW.%26aulast%3DEaves%26aufirst%3DJ.%26aulast%3DStrachan%26aufirst%3DJ.%2BP.%26aulast%3DBarabasz%26aufirst%3DA.%2BF.%26aulast%3DFoley%26aufirst%3DB.%2BE.%26aulast%3DBarta%26aufirst%3DT.%2BE.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DSilinski%26aufirst%3DM.%2BA.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DPartridge%26aufirst%3DJ.%2BM.%26aulast%3DScott%26aufirst%3DA.%26aulast%3DDuBois%26aufirst%3DL.%2BG.%26aulast%3DFreed%26aufirst%3DT.%26aulast%3DSteed%26aufirst%3DP.%2BM.%26aulast%3DOmmen%26aufirst%3DA.%2BJ.%26aulast%3DSmith%26aufirst%3DE.%2BD.%26aulast%3DHughes%26aufirst%3DP.%2BF.%26aulast%3DWoodward%26aufirst%3DA.%2BR.%26aulast%3DHanson%26aufirst%3DG.%2BJ.%26aulast%3DMcCall%26aufirst%3DW.%2BS.%26aulast%3DMarkworth%26aufirst%3DC.%2BJ.%26aulast%3DHinkley%26aufirst%3DL.%26aulast%3DJenks%26aufirst%3DM.%26aulast%3DGeng%26aufirst%3DL.%26aulast%3DLewis%26aufirst%3DM.%26aulast%3DOtto%26aufirst%3DJ.%26aulast%3DPronk%26aufirst%3DB.%26aulast%3DVerleysen%26aufirst%3DK.%26aulast%3DHall%26aufirst%3DS.%2BE.%26atitle%3DDiscovery%2520of%2520novel%25202-aminobenzamide%2520inhibitors%2520of%2520heat%2520shock%2520protein%252090%2520as%2520potent%252C%2520selective%2520and%2520orally%2520active%2520antitumor%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4288%26epage%3D4305%26doi%3D10.1021%2Fjm900230j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Rajan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trepel, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alarcon, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kummar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutierrez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crandon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zein, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mannargudi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figg, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houk, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shnaidman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brega, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giaccone, G.</span><span> </span><span class="NLM_article-title">A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">6831</span><span class="NLM_x">–</span> <span class="NLM_lpage">6839</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-0821</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1078-0432.CCR-11-0821" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=21908572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVWlsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=6831-6839&author=A.+Rajanauthor=R.+J.+Kellyauthor=J.+B.+Trepelauthor=Y.+S.+Kimauthor=S.+V.+Alarconauthor=S.+Kummarauthor=M.+Gutierrezauthor=S.+Crandonauthor=W.+M.+Zeinauthor=L.+Jainauthor=B.+Mannargudiauthor=W.+D.+Figgauthor=B.+E.+Houkauthor=M.+Shnaidmanauthor=N.+Bregaauthor=G.+Giaccone&title=A+phase+I+study+of+PF-04929113+%28SNX-5422%29%2C+an+orally+bioavailable+heat+shock+protein+90+inhibitor%2C+in+patients+with+refractory+solid+tumor+malignancies+and+lymphomas&doi=10.1158%2F1078-0432.CCR-11-0821"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas</span></div><div class="casAuthors">Rajan, Arun; Kelly, Ronan J.; Trepel, Jane B.; Kim, Yeong Sang; Alarcon, Sylvia V.; Kummar, Shivaani; Gutierrez, Martin; Crandon, Sonja; Zein, Wadih M.; Jain, Lokesh; Mannargudi, Baskar; Figg, William D.; Houk, Brett E.; Shnaidman, Michael; Brega, Nicoletta; Giaccone, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6831-6839</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: To det. the max. tolerated dose (MTD), toxicities, and pharmacokinetic/pharmacodynamic profile of the Hsp90 inhibitor PF-04929113 (SNX-5422) in patients with advanced solid tumors and lymphomas.  METHODS: This was a single-institution, phase I, dose-escalation study of PF-04929113 administered twice weekly.  Endpoints included detn. of dose-limiting toxicities (DLT), MTD, the safety profile of PF-04929113, pharmacodynamic assessment of PF-04929113 on Hsp70 induction, pharmacokinetic anal. of PF-04928473 (SNX-2112) and its prodrug PF-04929113, and assessment of response.  RESULTS: Thirty-three patients with advanced malignancies were treated.  Dose escalation was continued up to 177 mg/m2 administered orally twice a week.  One DLT (nonseptic arthritis) was noted.  No grade 4 drug-related adverse events were seen; grade 3 adverse events included diarrhea (9%), nonseptic arthritis (3%), aspartate aminotransferase elevation (3%), and thrombocytopenia (3%).  No objective responses were seen in 32 evaluable patients.  Fifteen patients (47%) had stable disease; 17 patients (53%) had progressive disease.  Pharmacokinetic data revealed rapid absorption, hepatic, and extrahepatic clearance, extensive tissue binding, and almost linear pharmacokinetics of the active drug PF-04928473.  Pharmacodynamic studies confirmed inhibition of Hsp90 and a linear correlation between pharmacokinetic parameters and Hsp70 induction.  CONCLUSIONS: PF-04929113 administered orally twice a week is well tolerated and inhibits its intended target Hsp90.  No objective responses were seen, but long-lasting stabilizations were obtained.  Although no clin. significant drug-related ocular toxicity was seen in this study, the development of PF-04929113 has been discontinued because of ocular toxicity seen in animal models and in a sep. phase I study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQzbnkoUJnibVg90H21EOLACvtfcHk0lgY2eEcYmkLjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVWlsrzM&md5=2b10fada0eb9d1dc7e06826724edf21f</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-0821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-0821%26sid%3Dliteratum%253Aachs%26aulast%3DRajan%26aufirst%3DA.%26aulast%3DKelly%26aufirst%3DR.%2BJ.%26aulast%3DTrepel%26aufirst%3DJ.%2BB.%26aulast%3DKim%26aufirst%3DY.%2BS.%26aulast%3DAlarcon%26aufirst%3DS.%2BV.%26aulast%3DKummar%26aufirst%3DS.%26aulast%3DGutierrez%26aufirst%3DM.%26aulast%3DCrandon%26aufirst%3DS.%26aulast%3DZein%26aufirst%3DW.%2BM.%26aulast%3DJain%26aufirst%3DL.%26aulast%3DMannargudi%26aufirst%3DB.%26aulast%3DFigg%26aufirst%3DW.%2BD.%26aulast%3DHouk%26aufirst%3DB.%2BE.%26aulast%3DShnaidman%26aufirst%3DM.%26aulast%3DBrega%26aufirst%3DN.%26aulast%3DGiaccone%26aufirst%3DG.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520PF-04929113%2520%2528SNX-5422%2529%252C%2520an%2520orally%2520bioavailable%2520heat%2520shock%2520protein%252090%2520inhibitor%252C%2520in%2520patients%2520with%2520refractory%2520solid%2520tumor%2520malignancies%2520and%2520lymphomas%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D6831%26epage%3D6839%26doi%3D10.1158%2F1078-0432.CCR-11-0821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Marcu, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulte, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neckers, L.</span><span> </span><span class="NLM_article-title">Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">242</span><span class="NLM_x">–</span> <span class="NLM_lpage">248</span><span class="refDoi"> DOI: 10.1093/jnci/92.3.242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1093%2Fjnci%2F92.3.242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10655441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtFShsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2000&pages=242-248&author=M.+G.+Marcuauthor=T.+W.+Schulteauthor=L.+Neckers&title=Novobiocin+and+related+coumarins+and+depletion+of+heat+shock+protein+90-dependent+signaling+proteins&doi=10.1093%2Fjnci%2F92.3.242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins</span></div><div class="casAuthors">Marcu, Monica G.; Schulte, Theodore W.; Neckers, Leonard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">242-248</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) interacts with and stabilizes several oncogenic protein kinases (e.g., p185erbB2, p60v-src, and Raf-1) and is required for the stability and dominant-neg. function of mutated p53 protein.  Two unrelated antibiotics, geldanamycin and radicicol, bind specifically to an atypical nucleotide-binding pocket of Hsp90, a site that shares homol. with the ATP-binding domain of bacterial DNA gyrase B.  This interaction leads to destabilization of proteins that interact with Hsp90.  Since the nucleotide-binding site of gyrase B is targeted by coumarin antibiotics (e.g., novobiocin), we investigated whether these drugs can also interact with Hsp90 and affect its activity.  We used immobilized novobiocin, geldanamycin, or radicicol to isolate either endogenous Hsp90 from cell lysates or Hsp90 deletion fragments translated in vitro.  Effects of the coumarin antibiotics novobiocin, chlorobiocin, and coumermycin A1 on several proteins interacting with Hsp90 were assessed in vitro and in vivo.  Hsp90 binding to immobilized novobiocin was competed by sol. coumarins and ATP but not by geldanamycin or radicicol.  A carboxy-terminal Hsp90 fragment bound immobilized novobiocin but not immobilized geldanamycin, while a geldanamycin-binding amino-terminal fragment did not bind novobiocin.  All three coumarins markedly reduced cellular levels of p185erbB2, p60v-src, Raf-1, and mutated p53.  Furthermore, novobiocin reduced Raf-1 levels in the spleens of mice treated with the drug.  These coumarin antibiotics, particularly novobiocin, represent a first-generation alternative to other Hsp90-targeting drugs that are not as well tolerated.  Novobiocin's unique interaction with Hsp90 identifies an addnl. site on this protein amenable to pharmacol. interference with small mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSMDAYykmhSbVg90H21EOLACvtfcHk0lgjENvnrb43Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtFShsbk%253D&md5=05873d976f0d6a3e721576732e580ff2</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F92.3.242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F92.3.242%26sid%3Dliteratum%253Aachs%26aulast%3DMarcu%26aufirst%3DM.%2BG.%26aulast%3DSchulte%26aufirst%3DT.%2BW.%26aulast%3DNeckers%26aufirst%3DL.%26atitle%3DNovobiocin%2520and%2520related%2520coumarins%2520and%2520depletion%2520of%2520heat%2520shock%2520protein%252090-dependent%2520signaling%2520proteins%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2000%26volume%3D92%26spage%3D242%26epage%3D248%26doi%3D10.1093%2Fjnci%2F92.3.242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Zhang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhan, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, D.</span><span> </span><span class="NLM_article-title">A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">162</span><span class="NLM_x">–</span> <span class="NLM_lpage">170</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-0484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1535-7163.MCT-07-0484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=18202019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVyhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=162-170&author=T.+Zhangauthor=A.+Hamzaauthor=X.+Caoauthor=B.+Wangauthor=S.+Yuauthor=C.+G.+Zhanauthor=D.+Sun&title=A+novel+Hsp90+inhibitor+to+disrupt+Hsp90%2FCdc37+complex+against+pancreatic+cancer+cells&doi=10.1158%2F1535-7163.MCT-07-0484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells</span></div><div class="casAuthors">Zhang, Tao; Hamza, Adel; Cao, Xianhua; Wang, Bing; Yu, Shuwen; Zhan, Chang-Guo; Sun, Duxin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">162-170</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Pancreatic cancer is an aggressive disease with multiple biochem. and genetic alterations.  Thus, a single agent to hit one mol. target may not be sufficient to treat this disease.  The purpose of this study is to identify a novel Hsp90 inhibitor to disrupt protein-protein interactions of Hsp90 and its cochaperones for down-regulating many oncogenes simultaneously against pancreatic cancer cells.  Here, we reported that celastrol disrupted Hsp90-Cdc37 interaction in the superchaperone complex to exhibit antitumor activity in vitro and in vivo.  Mol. docking and mol. dynamic simulations showed that celastrol blocked the crit. interaction of Glu33 (Hsp90) and Arg167 (Cdc37).  Immunopptn. confirmed that celastrol (10 μmol/L) disrupted the Hsp90-Cdc37 interaction in the pancreatic cancer cell line Panc-1.  In contrast to classic Hsp90 inhibitor (geldanamycin), celastrol (0.1-100 μmol/L) did not interfere with ATP binding to Hsp90.  However, celastrol (1-5 μmol/L) induced Hsp90 client protein degrdn. (Cdk4 and Akt) by 70% to 80% and increased Hsp70 expression by 12-fold.  Celastrol induced apoptosis in vitro and significantly inhibited tumor growth in Panc-1 xenografts.  Moreover, celastrol (3 mg/kg) effectively suppressed tumor metastasis by more than 80% in RIP1-Tag2 transgenic mouse model with pancreatic islet cell carcinogenesis.  The data suggest that celastrol is a novel Hsp90 inhibitor to disrupt Hsp90-Cdc37 interaction against pancreatic cancer cells. [Mol Cancer Ther 2008;7(1):162-70].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYaUNr9Bi1cbVg90H21EOLACvtfcHk0lgjENvnrb43Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVyhtQ%253D%253D&md5=2af27701d6ccd4397c7a7486d1335730</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0484%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DHamza%26aufirst%3DA.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DZhan%26aufirst%3DC.%2BG.%26aulast%3DSun%26aufirst%3DD.%26atitle%3DA%2520novel%2520Hsp90%2520inhibitor%2520to%2520disrupt%2520Hsp90%252FCdc37%2520complex%2520against%2520pancreatic%2520cancer%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D162%26epage%3D170%26doi%3D10.1158%2F1535-7163.MCT-07-0484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Sreeramulu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gande, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Göbel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwalbe, H.</span><span> </span><span class="NLM_article-title">Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperone-cochaperone, by triterpene celastrol</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">5853</span><span class="NLM_x">–</span> <span class="NLM_lpage">5855</span><span class="refDoi"> DOI: 10.1002/anie.200900929</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1002%2Fanie.200900929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=19585625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptFGltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=5853-5855&author=S.+Sreeramuluauthor=S.+L.+Gandeauthor=M.+G%C3%B6belauthor=H.+Schwalbe&title=Molecular+mechanism+of+inhibition+of+the+human+protein+complex+Hsp90-Cdc37%2C+a+kinome+chaperone-cochaperone%2C+by+triterpene+celastrol&doi=10.1002%2Fanie.200900929"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Mechanism of Inhibition of the Human Protein Complex Hsp90-Cdc37, a Kinome Chaperone-Cochaperone, by Triterpene Celastrol</span></div><div class="casAuthors">Sreeramulu, Sridhar; Gande, Santosh Lakshmi; Goebel, Michael; Schwalbe, Harald</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">5853-5855, S5853/1-S5853/11</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Inhibition of the ATPase activity of the kinome chaperone Hsp90 (kinome = set of all protein kinases in an organism) has long been known as mol. target for anticancer therapy.  Cdc37, a cochaperone of Hsp90 in mammalian cells, targets protein kinases and is upregulated in various cancers.  Gene-based expression studies have identified the triterpene celastrol, which represents a new class of non ATP-competitive inhibitors of Hsp90.  Herein, we describe in detail how celastrol disrupts the human Hsp90-Cdc37 complex.  We report that celastrol binds to Cdc37 but not to HSP90N as previously described.  This study is important as it will shift efforts in medicinal chem. towards the correct target within the protein-protein complex.  Our results indicates that the N-terminal kinase- binding and middle Hsp90N-binding domain of Cdc37 are the mol. target for the triterpene celastrol.  In light of the considerable potential of Cdc37 as a drug target and the binding of celastrol to it, these results can now be used to further understand the mol. basis for inhibiting this key Cdc37-Hsp90 complex in cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWgmOS-yFB6rVg90H21EOLACvtfcHk0lgjENvnrb43Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptFGltb4%253D&md5=d5264a2213c19a8b33ca56305ac2a29c</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fanie.200900929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200900929%26sid%3Dliteratum%253Aachs%26aulast%3DSreeramulu%26aufirst%3DS.%26aulast%3DGande%26aufirst%3DS.%2BL.%26aulast%3DG%25C3%25B6bel%26aufirst%3DM.%26aulast%3DSchwalbe%26aufirst%3DH.%26atitle%3DMolecular%2520mechanism%2520of%2520inhibition%2520of%2520the%2520human%2520protein%2520complex%2520Hsp90-Cdc37%252C%2520a%2520kinome%2520chaperone-cochaperone%252C%2520by%2520triterpene%2520celastrol%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2009%26volume%3D48%26spage%3D5853%26epage%3D5855%26doi%3D10.1002%2Fanie.200900929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Huang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Q. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, W.</span><span> </span><span class="NLM_article-title">FW-04–806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation</span> <span class="citation_source-journal">Mol. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">150</span><span class="refDoi"> DOI: 10.1186/1476-4598-13-150</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1186%2F1476-4598-13-150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=24927996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivFWns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=150&author=W.+Huangauthor=M.+Yeauthor=L.+R.+Zhangauthor=Q.+D.+Wuauthor=M.+Zhangauthor=J.+H.+Xuauthor=W.+Zheng&title=FW-04%E2%80%93806+inhibits+proliferation+and+induces+apoptosis+in+human+breast+cancer+cells+by+binding+to+N-terminus+of+Hsp90+and+disrupting+Hsp90-Cdc37+complex+formation&doi=10.1186%2F1476-4598-13-150"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation</span></div><div class="casAuthors">Huang, Wei; Ye, Min; Zhang, Lian-Ru; Wu, Qun-Dan; Zhang, Min; Xu, Jian-Hua; Zheng, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">150/1-150/23, 23 pp.</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Heat shock protein 90 (Hsp90) is a promising therapeutic target and inhibition of Hsp90 will presumably result in suppression of multiple signaling pathways.  FW-04-806, a bis-oxazolyl macrolide compd. extd. from China-native Streptomyces FIM-04-806, was reported to be identical in structure to the polyketide Conglobatin.  Methods: We adopted the methods of chemproteomics, computational docking, immunopptn., siRNA gene knock down, Quant. Real-time PCR and xenograft models on the research of FW-04-806 antitumor mechanism, through the HER2-overexpressing breast cancer SKBR3 and HER2-underexpressing breast cancer MCF-7 cell line.  Results: We have verified the direct binding of FW-04-806 to the N-terminal domain of Hsp90 and found that FW-04-806 inhibits Hsp90/cell division cycle protein 37 (Cdc37) chaperone/co-chaperone interactions, but does not affect ATP-binding capability of Hsp90, thereby leading to the degrdn. of multiple Hsp90 client proteins via the proteasome pathway.  In breast cancer cell lines, FW-04-806 inhibits cell proliferation, caused G2/M cell cycle arrest, induced apoptosis, and downregulated Hsp90 client proteins HER2, Akt, Raf-1 and their phosphorylated forms (p-HER2, p-Akt) in a dose and time-dependent manner.  Importantly, FW-04-806 displays a better anti-tumor effect in HER2-overexpressed SKBR3 tumor xenograft model than in HER2-underexpressed MCF-7 model.  The result is consistent with cell proliferation assay and in vitro apoptosis assay applied for SKBR-3 and MCF-7.  Furthermore, FW-04-806 has a favorable toxicity profile.  Conclusions: As a novel Hsp90 inhibitor, FW-04-806 binds to the N-terminal of Hsp90 and inhibits Hsp90/Cdc37 interaction, resulting in the disassocn. of Hsp90/Cdc37/client complexes and the degrdn. of Hsp90 client proteins.  FW-04-806 displays promising antitumor activity against breast cancer cells both in vitro and in vivo, esp. for HER2-overexpressed breast cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI4HO_8pKpELVg90H21EOLACvtfcHk0lhVZ4EV3mWhcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivFWns7o%253D&md5=bfa6127b46be0281667d296f020fde1b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-13-150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-13-150%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DL.%2BR.%26aulast%3DWu%26aufirst%3DQ.%2BD.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DJ.%2BH.%26aulast%3DZheng%26aufirst%3DW.%26atitle%3DFW-04%25E2%2580%2593806%2520inhibits%2520proliferation%2520and%2520induces%2520apoptosis%2520in%2520human%2520breast%2520cancer%2520cells%2520by%2520binding%2520to%2520N-terminus%2520of%2520Hsp90%2520and%2520disrupting%2520Hsp90-Cdc37%2520complex%2520formation%26jtitle%3DMol.%2520Cancer%26date%3D2014%26volume%3D13%26spage%3D150%26doi%3D10.1186%2F1476-4598-13-150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Zhang, H. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasibhatla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guastella, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drewe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, S. X.</span><span> </span><span class="NLM_article-title">Discovery, characterization and SAR of gambogic acid as a potent apoptosis inducer by a HTS assay</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span><span class="refDoi"> DOI: 10.1016/j.bmc.2003.11.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.bmc.2003.11.013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=309-317&author=H.+Z.+Zhangauthor=S.+Kasibhatlaauthor=Y.+Wangauthor=J.+Herichauthor=J.+Guastellaauthor=B.+Tsengauthor=J.+Dreweauthor=S.+X.+Cai&title=Discovery%2C+characterization+and+SAR+of+gambogic+acid+as+a+potent+apoptosis+inducer+by+a+HTS+assay&doi=10.1016%2Fj.bmc.2003.11.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2003.11.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2003.11.013%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%2BZ.%26aulast%3DKasibhatla%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHerich%26aufirst%3DJ.%26aulast%3DGuastella%26aufirst%3DJ.%26aulast%3DTseng%26aufirst%3DB.%26aulast%3DDrewe%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DS.%2BX.%26atitle%3DDiscovery%252C%2520characterization%2520and%2520SAR%2520of%2520gambogic%2520acid%2520as%2520a%2520potent%2520apoptosis%2520inducer%2520by%2520a%2520HTS%2520assay%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2004%26volume%3D12%26spage%3D309%26epage%3D317%26doi%3D10.1016%2Fj.bmc.2003.11.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Vasko, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunningham, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardi, V. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agard, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAlpine, S. R.</span><span> </span><span class="NLM_article-title">Mechanistic studies of Sansalvamide A-amide: an allosteric modulator of Hsp90</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">4</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span><span class="refDoi"> DOI: 10.1021/ml900003t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml900003t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs12isg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=4-8&author=R.+C.+Vaskoauthor=R.+A.+Rodriguezauthor=C.+N.+Cunninghamauthor=V.+C.+Ardiauthor=D.+A.+Agardauthor=S.+R.+McAlpine&title=Mechanistic+studies+of+Sansalvamide+A-amide%3A+an+allosteric+modulator+of+Hsp90&doi=10.1021%2Fml900003t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic Studies of Sansalvamide A-Amide: An Allosteric Modulator of Hsp90</span></div><div class="casAuthors">Vasko, Robert C.; Rodriguez, Rodrigo A.; Cunningham, Christian N.; Ardi, Veronica C.; Agard, David A.; McAlpine, Shelli R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4-8</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein, we show that sansalvamide A-amide (San A-amide), a structurally unique mol., influences a subset of cancer-related pathways involving heat shock protein 90 (Hsp90).  We show that San A-amide specifically binds to the N-middle domain of Hsp90 and allosterically disrupts the binding of proteins thought to interact with the Hsp90 C-terminal domain, while having no effect on an N-terminal domain client protein.  This unique mechanism suggests that San A-amide is a potential tool for studying C-terminal binding proteins of Hsp90 as well as a promising lead in the development of new cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYe__7lCCo8rVg90H21EOLACvtfcHk0lhVZ4EV3mWhcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs12isg%253D%253D&md5=e20bcd814c531b739ecfb91175d34232</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fml900003t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml900003t%26sid%3Dliteratum%253Aachs%26aulast%3DVasko%26aufirst%3DR.%2BC.%26aulast%3DRodriguez%26aufirst%3DR.%2BA.%26aulast%3DCunningham%26aufirst%3DC.%2BN.%26aulast%3DArdi%26aufirst%3DV.%2BC.%26aulast%3DAgard%26aufirst%3DD.%2BA.%26aulast%3DMcAlpine%26aufirst%3DS.%2BR.%26atitle%3DMechanistic%2520studies%2520of%2520Sansalvamide%2520A-amide%253A%2520an%2520allosteric%2520modulator%2520of%2520Hsp90%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D4%26epage%3D8%26doi%3D10.1021%2Fml900003t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Alexander, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardi, V. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasko, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAlpine, S. R.</span><span> </span><span class="NLM_article-title">Evaluation of di-sansalvamideA derivatives: synthesis, structure-activity relationship, and mechanism of action</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7927</span><span class="NLM_x">–</span> <span class="NLM_lpage">7930</span><span class="refDoi"> DOI: 10.1021/jm901566c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901566c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7927-7930&author=L.+D.+Alexanderauthor=R.+P.+Sellersauthor=M.+R.+Davisauthor=V.+C.+Ardiauthor=V.+A.+Johnsonauthor=R.+C.+Vaskoauthor=S.+R.+McAlpine&title=Evaluation+of+di-sansalvamideA+derivatives%3A+synthesis%2C+structure-activity+relationship%2C+and+mechanism+of+action&doi=10.1021%2Fjm901566c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm901566c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901566c%26sid%3Dliteratum%253Aachs%26aulast%3DAlexander%26aufirst%3DL.%2BD.%26aulast%3DSellers%26aufirst%3DR.%2BP.%26aulast%3DDavis%26aufirst%3DM.%2BR.%26aulast%3DArdi%26aufirst%3DV.%2BC.%26aulast%3DJohnson%26aufirst%3DV.%2BA.%26aulast%3DVasko%26aufirst%3DR.%2BC.%26aulast%3DMcAlpine%26aufirst%3DS.%2BR.%26atitle%3DEvaluation%2520of%2520di-sansalvamideA%2520derivatives%253A%2520synthesis%252C%2520structure-activity%2520relationship%252C%2520and%2520mechanism%2520of%2520action%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7927%26epage%3D7930%26doi%3D10.1021%2Fjm901566c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Jhaveri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochiana, S. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunphy, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerecitano, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corben, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peter, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janjigian, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomes-DaGama, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koren, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span> </span><span class="NLM_article-title">Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">611</span><span class="NLM_x">–</span> <span class="NLM_lpage">628</span><span class="refDoi"> DOI: 10.1517/13543784.2014.902442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1517%2F13543784.2014.902442" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=611-628&author=K.+Jhaveriauthor=S.+O.+Ochianaauthor=M.+P.+Dunphyauthor=J.+F.+Gerecitanoauthor=A.+D.+Corbenauthor=R.+I.+Peterauthor=Y.+Y.+Janjigianauthor=E.+M.+Gomes-DaGamaauthor=J.+Korenauthor=S.+Modiauthor=G.+Chiosis&title=Heat+shock+protein+90+inhibitors+in+the+treatment+of+cancer%3A+current+status+and+future+directions&doi=10.1517%2F13543784.2014.902442"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1517%2F13543784.2014.902442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2014.902442%26sid%3Dliteratum%253Aachs%26aulast%3DJhaveri%26aufirst%3DK.%26aulast%3DOchiana%26aufirst%3DS.%2BO.%26aulast%3DDunphy%26aufirst%3DM.%2BP.%26aulast%3DGerecitano%26aufirst%3DJ.%2BF.%26aulast%3DCorben%26aufirst%3DA.%2BD.%26aulast%3DPeter%26aufirst%3DR.%2BI.%26aulast%3DJanjigian%26aufirst%3DY.%2BY.%26aulast%3DGomes-DaGama%26aufirst%3DE.%2BM.%26aulast%3DKoren%26aufirst%3DJ.%26aulast%3DModi%26aufirst%3DS.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DHeat%2520shock%2520protein%252090%2520inhibitors%2520in%2520the%2520treatment%2520of%2520cancer%253A%2520current%2520status%2520and%2520future%2520directions%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2014%26volume%3D23%26spage%3D611%26epage%3D628%26doi%3D10.1517%2F13543784.2014.902442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Taipale, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krykbaeva, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeva, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kayatekin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westover, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karras, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindquist, S.</span><span> </span><span class="NLM_article-title">Quantitative analysis of Hsp90-client interactions reveals principles of substrate recognition</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">150</span><span class="NLM_x">, </span> <span class="NLM_fpage">987</span><span class="NLM_x">–</span> <span class="NLM_lpage">1001</span><span class="refDoi"> DOI: 10.1016/j.cell.2012.06.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.cell.2012.06.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22939624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlSns7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2012&pages=987-1001&author=M.+Taipaleauthor=I.+Krykbaevaauthor=M.+Koevaauthor=C.+Kayatekinauthor=K.+D.+Westoverauthor=G.+I.+Karrasauthor=S.+Lindquist&title=Quantitative+analysis+of+Hsp90-client+interactions+reveals+principles+of+substrate+recognition&doi=10.1016%2Fj.cell.2012.06.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative Analysis of Hsp90-Client Interactions Reveals Principles of Substrate Recognition</span></div><div class="casAuthors">Taipale, Mikko; Krykbaeva, Irina; Koeva, Martina; Kayatekin, Can; Westover, Kenneth D.; Karras, Georgios I.; Lindquist, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">987-1001</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">HSP90 is a mol. chaperone that assocs. with numerous substrate proteins called clients.  It plays many important roles in human biol. and medicine, but determinants of client recognition by HSP90 have remained frustratingly elusive.  We systematically and quant. surveyed most human kinases, transcription factors, and E3 ligases for interaction with HSP90 and its cochaperone CDC37.  Unexpectedly, many more kinases than transcription factors bound HSP90.  CDC37 interacted with kinases, but not with transcription factors or E3 ligases.  HSP90::kinase interactions varied continuously over a 100-fold range and provided a platform to study client protein recognition.  In wild-type clients, HSP90 did not bind particular sequence motifs, but rather assocd. with intrinsically unstable kinases.  Stabilization of the kinase in either its active or inactive conformation with diverse small mols. decreased HSP90 assocn.  Our results establish HSP90 client recognition as a combinatorial process: CDC37 provides recognition of the kinase family, whereas thermodn. parameters det. client binding within the family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHzMXLTn5hx7Vg90H21EOLACvtfcHk0lg3OABsWpcWlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlSns7bF&md5=2ebda06d0ce0b8f65edff9f08f10dd31</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2012.06.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2012.06.047%26sid%3Dliteratum%253Aachs%26aulast%3DTaipale%26aufirst%3DM.%26aulast%3DKrykbaeva%26aufirst%3DI.%26aulast%3DKoeva%26aufirst%3DM.%26aulast%3DKayatekin%26aufirst%3DC.%26aulast%3DWestover%26aufirst%3DK.%2BD.%26aulast%3DKarras%26aufirst%3DG.%2BI.%26aulast%3DLindquist%26aufirst%3DS.%26atitle%3DQuantitative%2520analysis%2520of%2520Hsp90-client%2520interactions%2520reveals%2520principles%2520of%2520substrate%2520recognition%26jtitle%3DCell%26date%3D2012%26volume%3D150%26spage%3D987%26epage%3D1001%26doi%3D10.1016%2Fj.cell.2012.06.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Richards, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Law, E. W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rennalls, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busacca, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Regan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fennell, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayliss, R.</span><span> </span><span class="NLM_article-title">Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">5195</span><span class="NLM_x">–</span> <span class="NLM_lpage">5200</span><span class="refDoi"> DOI: 10.1073/pnas.1322892111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1073%2Fpnas.1322892111" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=5195-5200&author=M.+W.+Richardsauthor=E.+W.+P.+Lawauthor=L.+P.+Rennallsauthor=S.+Busaccaauthor=L.+O%E2%80%99Reganauthor=A.+M.+Fryauthor=D.+A.+Fennellauthor=R.+Bayliss&title=Crystal+structure+of+EML1+reveals+the+basis+for+Hsp90+dependence+of+oncogenic+EML4-ALK+by+disruption+of+an+atypical+%CE%B2-propeller+domain&doi=10.1073%2Fpnas.1322892111"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1322892111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1322892111%26sid%3Dliteratum%253Aachs%26aulast%3DRichards%26aufirst%3DM.%2BW.%26aulast%3DLaw%26aufirst%3DE.%2BW.%2BP.%26aulast%3DRennalls%26aufirst%3DL.%2BP.%26aulast%3DBusacca%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Regan%26aufirst%3DL.%26aulast%3DFry%26aufirst%3DA.%2BM.%26aulast%3DFennell%26aufirst%3DD.%2BA.%26aulast%3DBayliss%26aufirst%3DR.%26atitle%3DCrystal%2520structure%2520of%2520EML1%2520reveals%2520the%2520basis%2520for%2520Hsp90%2520dependence%2520of%2520oncogenic%2520EML4-ALK%2520by%2520disruption%2520of%2520an%2520atypical%2520%25CE%25B2-propeller%2520domain%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D5195%26epage%3D5200%26doi%3D10.1073%2Fpnas.1322892111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Montfort, R.</span><span> </span><span class="NLM_article-title">EML4-ALK fusions: propelling cancer but creating exploitable chaperone dependence</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">642</span><span class="NLM_x">–</span> <span class="NLM_lpage">645</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F2159-8290.CD-14-0409" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=642-645&author=P.+Workmanauthor=R.+van+Montfort&title=EML4-ALK+fusions%3A+propelling+cancer+but+creating+exploitable+chaperone+dependence&doi=10.1158%2F2159-8290.CD-14-0409"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0409%26sid%3Dliteratum%253Aachs%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3Dvan%2BMontfort%26aufirst%3DR.%26atitle%3DEML4-ALK%2520fusions%253A%2520propelling%2520cancer%2520but%2520creating%2520exploitable%2520chaperone%2520dependence%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D642%26epage%3D645%26doi%3D10.1158%2F2159-8290.CD-14-0409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. F.</span><span> </span><span class="NLM_article-title">Hop as an adaptor in the heat shock protein 70 (Hsp70) and Hsp90 chaperone machinery</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">273</span><span class="NLM_x">, </span> <span class="NLM_fpage">35194</span><span class="NLM_x">–</span> <span class="NLM_lpage">35200</span><span class="refDoi"> DOI: 10.1074/jbc.273.52.35194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1074%2Fjbc.273.52.35194" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1998&pages=35194-35200&author=S.+Chenauthor=D.+F.+Smith&title=Hop+as+an+adaptor+in+the+heat+shock+protein+70+%28Hsp70%29+and+Hsp90+chaperone+machinery&doi=10.1074%2Fjbc.273.52.35194"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1074%2Fjbc.273.52.35194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.273.52.35194%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DD.%2BF.%26atitle%3DHop%2520as%2520an%2520adaptor%2520in%2520the%2520heat%2520shock%2520protein%252070%2520%2528Hsp70%2529%2520and%2520Hsp90%2520chaperone%2520machinery%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1998%26volume%3D273%26spage%3D35194%26epage%3D35200%26doi%3D10.1074%2Fjbc.273.52.35194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Roe, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaughan, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panaretou, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piper, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prodromou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearl, L. H.</span><span> </span><span class="NLM_article-title">The mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50 (cdc37)</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">–</span> <span class="NLM_lpage">98</span><span class="refDoi"> DOI: 10.1016/S0092-8674(03)01027-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2FS0092-8674%2803%2901027-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=87-98&author=S.+M.+Roeauthor=M.+M.+Aliauthor=P.+Meyerauthor=C.+K.+Vaughanauthor=B.+Panaretouauthor=P.+W.+Piperauthor=C.+Prodromouauthor=L.+H.+Pearl&title=The+mechanism+of+Hsp90+regulation+by+the+protein+kinase-specific+cochaperone+p50+%28cdc37%29&doi=10.1016%2FS0092-8674%2803%2901027-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2803%2901027-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252803%252901027-4%26sid%3Dliteratum%253Aachs%26aulast%3DRoe%26aufirst%3DS.%2BM.%26aulast%3DAli%26aufirst%3DM.%2BM.%26aulast%3DMeyer%26aufirst%3DP.%26aulast%3DVaughan%26aufirst%3DC.%2BK.%26aulast%3DPanaretou%26aufirst%3DB.%26aulast%3DPiper%26aufirst%3DP.%2BW.%26aulast%3DProdromou%26aufirst%3DC.%26aulast%3DPearl%26aufirst%3DL.%2BH.%26atitle%3DThe%2520mechanism%2520of%2520Hsp90%2520regulation%2520by%2520the%2520protein%2520kinase-specific%2520cochaperone%2520p50%2520%2528cdc37%2529%26jtitle%3DCell%26date%3D2004%26volume%3D116%26spage%3D87%26epage%3D98%26doi%3D10.1016%2FS0092-8674%2803%2901027-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Sreeramulu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonker, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancaster, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwalbe, H.</span><span> </span><span class="NLM_article-title">The human Cdc37.Hsp90 complex studied by heteronuclear NMR spectroscopy</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">284</span><span class="NLM_x">, </span> <span class="NLM_fpage">3885</span><span class="NLM_x">–</span> <span class="NLM_lpage">3896</span><span class="refDoi"> DOI: 10.1074/jbc.M806715200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1074%2Fjbc.M806715200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2009&pages=3885-3896&author=S.+Sreeramuluauthor=H.+R.+Jonkerauthor=T.+Langerauthor=C.+Richterauthor=C.+R.+Lancasterauthor=H.+Schwalbe&title=The+human+Cdc37.Hsp90+complex+studied+by+heteronuclear+NMR+spectroscopy&doi=10.1074%2Fjbc.M806715200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M806715200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M806715200%26sid%3Dliteratum%253Aachs%26aulast%3DSreeramulu%26aufirst%3DS.%26aulast%3DJonker%26aufirst%3DH.%2BR.%26aulast%3DLanger%26aufirst%3DT.%26aulast%3DRichter%26aufirst%3DC.%26aulast%3DLancaster%26aufirst%3DC.%2BR.%26aulast%3DSchwalbe%26aufirst%3DH.%26atitle%3DThe%2520human%2520Cdc37.Hsp90%2520complex%2520studied%2520by%2520heteronuclear%2520NMR%2520spectroscopy%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2009%26volume%3D284%26spage%3D3885%26epage%3D3896%26doi%3D10.1074%2Fjbc.M806715200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Ali, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roe, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaughan, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panaretou, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piper, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prodromou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearl, L. H.</span><span> </span><span class="NLM_article-title">Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">440</span><span class="NLM_x">, </span> <span class="NLM_fpage">1013</span><span class="NLM_x">–</span> <span class="NLM_lpage">1017</span><span class="refDoi"> DOI: 10.1038/nature04716</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnature04716" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=16625188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD28Xjs1agtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=440&publication_year=2006&pages=1013-1017&author=M.+M.+Aliauthor=S.+M.+Roeauthor=C.+K.+Vaughanauthor=P.+Meyerauthor=B.+Panaretouauthor=P.+W.+Piperauthor=C.+Prodromouauthor=L.+H.+Pearl&title=Crystal+structure+of+an+Hsp90-nucleotide-p23%2FSba1+closed+chaperone+complex&doi=10.1038%2Fnature04716"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex</span></div><div class="casAuthors">Ali, Maruf M. U.; Roe, S. Mark; Vaughan, Cara K.; Meyer, Phillipe; Panaretou, Barry; Piper, Peter W.; Prodromou, Chrisostomos; Pearl, Laurence H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">440</span>
        (<span class="NLM_cas:issue">7087</span>),
    <span class="NLM_cas:pages">1013-1017</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hsp90 (heat shock protein of 90 kDa) is a ubiquitous mol. chaperone responsible for the assembly and regulation of many eukaryotic signaling systems and is an emerging target for rational chemotherapy of many cancers.  Although the structures of isolated domains of Hsp90 have been detd., the arrangement and ATP-dependent dynamics of these in the full Hsp90 dimer have been elusive and contentious.  Here we present the crystal structure of full-length yeast Hsp90 in complex with an ATP analog and the co-chaperone p23/Sba1.  The structure reveals the complex architecture of the closed' state of the Hsp90 chaperone, the extensive interactions between domains and between protein chains, the detailed conformational changes in the amino-terminal domain that accompany ATP binding, and the structural basis for stabilization of the closed state by p23/Sba1.  Contrary to expectations, the closed Hsp90 would not enclose its client proteins but provides a bipartite binding surface whose formation and disruption are coupled to the chaperone ATPase cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcaj34ODndPbVg90H21EOLACvtfcHk0ljUiGTdR-vEKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xjs1agtLw%253D&md5=15ea0bcf7cbf297b3f4a7005c7798fb0</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fnature04716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04716%26sid%3Dliteratum%253Aachs%26aulast%3DAli%26aufirst%3DM.%2BM.%26aulast%3DRoe%26aufirst%3DS.%2BM.%26aulast%3DVaughan%26aufirst%3DC.%2BK.%26aulast%3DMeyer%26aufirst%3DP.%26aulast%3DPanaretou%26aufirst%3DB.%26aulast%3DPiper%26aufirst%3DP.%2BW.%26aulast%3DProdromou%26aufirst%3DC.%26aulast%3DPearl%26aufirst%3DL.%2BH.%26atitle%3DCrystal%2520structure%2520of%2520an%2520Hsp90-nucleotide-p23%252FSba1%2520closed%2520chaperone%2520complex%26jtitle%3DNature%26date%3D2006%26volume%3D440%26spage%3D1013%26epage%3D1017%26doi%3D10.1038%2Fnature04716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Karagöz, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duarte, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ippel, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uetrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinnige, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Rosmalen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hausmann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heck, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boelens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rüdiger, S. G.</span><span> </span><span class="NLM_article-title">N-terminal domain of human Hsp90 triggers binding to the cochaperone p23</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">580</span><span class="NLM_x">–</span> <span class="NLM_lpage">585</span><span class="refDoi"> DOI: 10.1073/pnas.1011867108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1073%2Fpnas.1011867108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=21183720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFelsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=580-585&author=G.+E.+Karag%C3%B6zauthor=A.+M.+Duarteauthor=H.+Ippelauthor=C.+Uetrechtauthor=T.+Sinnigeauthor=M.+van+Rosmalenauthor=J.+Hausmannauthor=A.+J.+Heckauthor=R.+Boelensauthor=S.+G.+R%C3%BCdiger&title=N-terminal+domain+of+human+Hsp90+triggers+binding+to+the+cochaperone+p23&doi=10.1073%2Fpnas.1011867108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">N-terminal domain of human Hsp90 triggers binding to the cochaperone p23</span></div><div class="casAuthors">Karagoz, G. Elif; Duarte, Afonso M. S.; Ippel, Hans; Uetrecht, Charlotte; Sinnige, Tessa; van Rosmalen, Martijn; Hausmann, Jens; Heck, Albert J. R.; Boelens, Rolf; Rudiger, Stefan G. D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">580-585, S580/1-S580/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The mol. chaperone Hsp90 is a protein folding machine that is conserved from bacteria to man.  Human, cytosolic Hsp90 is dedicated to folding of chiefly signal transduction components.  The chaperoning mechanism of Hsp90 is controlled by ATP and various cochaperones, but is poorly understood and controversial.  Here, we characterized the Apo and ATP states of the 170-kDa human Hsp90 full-length protein by NMR spectroscopy in soln., and we elucidated the mechanism of the inhibition of its ATPase by its cochaperone p23.  We assigned isoleucine side chains of Hsp90 via specific isotope labeling of their δ-Me groups, which allowed the NMR anal. of the full-length protein.  We found that ATP caused exclusively local changes in Hsp90's N-terminal nucleotide-binding domain.  Native mass spectrometry showed that Hsp90 and p23 form a 2:2 complex via a pos. cooperative mechanism.  Despite this stoichiometry, NMR data indicated that the complex was not fully sym.  The p23-dependent NMR shifts mapped to both the lid and the adenine end of Hsp90's ATP binding pocket, but also to large parts of the middle domain.  Shifts distant from the p23 binding site reflect p23-induced conformational changes in Hsp90.  Together, we conclude that it is Hsp90's nucleotide-binding domain that triggers the formation of the Hsp902p232 complex.  We anticipate that our NMR approach has significant impact on future studies of full-length Hsp90 with cofactors and substrates, but also for the development of Hsp90 inhibiting anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpd2efYORDc8LVg90H21EOLACvtfcHk0ljUiGTdR-vEKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFelsA%253D%253D&md5=a1d95de02cc89096d57043fd409adf20</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1011867108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1011867108%26sid%3Dliteratum%253Aachs%26aulast%3DKarag%25C3%25B6z%26aufirst%3DG.%2BE.%26aulast%3DDuarte%26aufirst%3DA.%2BM.%26aulast%3DIppel%26aufirst%3DH.%26aulast%3DUetrecht%26aufirst%3DC.%26aulast%3DSinnige%26aufirst%3DT.%26aulast%3Dvan%2BRosmalen%26aufirst%3DM.%26aulast%3DHausmann%26aufirst%3DJ.%26aulast%3DHeck%26aufirst%3DA.%2BJ.%26aulast%3DBoelens%26aufirst%3DR.%26aulast%3DR%25C3%25BCdiger%26aufirst%3DS.%2BG.%26atitle%3DN-terminal%2520domain%2520of%2520human%2520Hsp90%2520triggers%2520binding%2520to%2520the%2520cochaperone%2520p23%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D580%26epage%3D585%26doi%3D10.1073%2Fpnas.1011867108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Meyer, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prodromou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roe, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaughan, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vlasic, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panaretou, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piper, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearl, L. H.</span><span> </span><span class="NLM_article-title">Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">511</span><span class="NLM_x">–</span> <span class="NLM_lpage">519</span><span class="refDoi"> DOI: 10.1038/sj.emboj.7600060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fsj.emboj.7600060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=14739935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtV2ru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=511-519&author=P.+L.+Meyerauthor=C.+Prodromouauthor=C.+Liaoauthor=B.+Huauthor=S.+M.+Roeauthor=C.+K.+Vaughanauthor=I.+Vlasicauthor=B.+Panaretouauthor=P.+W.+Piperauthor=L.+H.+Pearl&title=Structural+basis+for+recruitment+of+the+ATPase+activator+Aha1+to+the+Hsp90+chaperone+machinery&doi=10.1038%2Fsj.emboj.7600060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery</span></div><div class="casAuthors">Meyer, Philippe; Prodromou, Chrisostomos; Liao, Chunyan; Hu, Bin; Roe, S. Mark; Vaughan, Cara K.; Vlasic, Ignacija; Panaretou, Barry; Piper, Peter W.; Pearl, Laurence H.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">511-519</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hsp90 is a mol. chaperone essential for the activation and assembly of many key eukaryotic signaling and regulatory proteins.  Hsp90 is assisted and regulated by co-chaperones that participate in an ordered series of dynamic multiprotein complexes, linked to Hsp90s conformationally coupled ATPase cycle.  The co-chaperones Aha1 and Hch1 bind to Hsp90 and stimulate its ATPase activity.  Biochem. anal. shows that this activity is dependent on the N-terminal domain of Aha1, which interacts with the central segment of Hsp90.  The structural basis for this interaction is revealed by the crystal structure of the N-terminal domain (1-153) of Aha1 (equiv. to the whole of Hch1) in complex with the middle segment of Hsp90 (273-530).  Structural anal. and mutagenesis show that binding of N-Aha1 promotes a conformational switch in the middle-segment catalytic loop (370-390) of Hsp90 that releases the catalytic Arg-380 and enables its interaction with ATP in the N-terminal nucleotide-binding domain of the chaperone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpiG2JApXabrVg90H21EOLACvtfcHk0ljCFvnWY4szMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtV2ru7c%253D&md5=8e1699ec0804e3649a613710ba6e9001</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fsj.emboj.7600060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.emboj.7600060%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DP.%2BL.%26aulast%3DProdromou%26aufirst%3DC.%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DRoe%26aufirst%3DS.%2BM.%26aulast%3DVaughan%26aufirst%3DC.%2BK.%26aulast%3DVlasic%26aufirst%3DI.%26aulast%3DPanaretou%26aufirst%3DB.%26aulast%3DPiper%26aufirst%3DP.%2BW.%26aulast%3DPearl%26aufirst%3DL.%2BH.%26atitle%3DStructural%2520basis%2520for%2520recruitment%2520of%2520the%2520ATPase%2520activator%2520Aha1%2520to%2520the%2520Hsp90%2520chaperone%2520machinery%26jtitle%3DEMBO%2520J.%26date%3D2004%26volume%3D23%26spage%3D511%26epage%3D519%26doi%3D10.1038%2Fsj.emboj.7600060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Retzlaff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagn, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitschke, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hessling, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gugel, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchner, J.</span><span> </span><span class="NLM_article-title">Asymmetric activation of the HSP90 dimer by its cochaperone aha1</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">344</span><span class="NLM_x">–</span> <span class="NLM_lpage">354</span><span class="refDoi"> DOI: 10.1016/j.molcel.2010.01.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.molcel.2010.01.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=20159554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlt1Kktbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2010&pages=344-354&author=M.+Retzlaffauthor=F.+Hagnauthor=L.+Mitschkeauthor=M.+Hesslingauthor=F.+Gugelauthor=H.+Kesslerauthor=K.+Richterauthor=J.+Buchner&title=Asymmetric+activation+of+the+HSP90+dimer+by+its+cochaperone+aha1&doi=10.1016%2Fj.molcel.2010.01.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric activation of the Hsp90 dimer by its cochaperone Aha1</span></div><div class="casAuthors">Retzlaff, Marco; Hagn, Franz; Mitschke, Lars; Hessling, Martin; Gugel, Frederik; Kessler, Horst; Richter, Klaus; Buchner, Johannes</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">344-354</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The chaperone Hsp90 is an ATP-dependent, dimeric mol. machine regulated by several cochaperones, including inhibitors and the unique ATPase activator Aha1.  Here, we analyzed the mechanism of the Aha1-mediated acceleration of Hsp90 ATPase activity and identified the interaction surfaces of both proteins using multidimensional NMR techniques.  For max. activation of Hsp90, the two domains of Aha1 bind to sites in the middle and N-terminal domains of Hsp90 in a sequential manner.  This binding induces the kinetically unfavored N terminally dimerized state of Hsp90, which primes for the hydrolysis-competent conformation.  Surprisingly, this activation mechanism is asym.  The presence of one Aha1 mol. per Hsp90 dimer is sufficient to bridge the two subunits and to fully stimulate Hsp90 ATPase activity.  This seems to functionalize the two subunits of the Hsp90 dimer in different ways, in that one subunit can be used for conformational ATPase regulation and the other for substrate protein processing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN6haR106PYbVg90H21EOLACvtfcHk0ljCFvnWY4szMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlt1Kktbo%253D&md5=a57a2df1a7d29f1388d1e426fd3b8772</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2010.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2010.01.006%26sid%3Dliteratum%253Aachs%26aulast%3DRetzlaff%26aufirst%3DM.%26aulast%3DHagn%26aufirst%3DF.%26aulast%3DMitschke%26aufirst%3DL.%26aulast%3DHessling%26aufirst%3DM.%26aulast%3DGugel%26aufirst%3DF.%26aulast%3DKessler%26aufirst%3DH.%26aulast%3DRichter%26aufirst%3DK.%26aulast%3DBuchner%26aufirst%3DJ.%26atitle%3DAsymmetric%2520activation%2520of%2520the%2520HSP90%2520dimer%2520by%2520its%2520cochaperone%2520aha1%26jtitle%3DMol.%2520Cell%26date%3D2010%26volume%3D37%26spage%3D344%26epage%3D354%26doi%3D10.1016%2Fj.molcel.2010.01.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Vaughan, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gohlke, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sobott, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, M. M. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prodromou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saibil, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearl, L. H.</span><span> </span><span class="NLM_article-title">Structure of an Hsp90-Cdc37-Cdk4 complex</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">697</span><span class="NLM_x">–</span> <span class="NLM_lpage">707</span><span class="refDoi"> DOI: 10.1016/j.molcel.2006.07.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.molcel.2006.07.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=16949366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVSkt7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2006&pages=697-707&author=C.+K.+Vaughanauthor=U.+Gohlkeauthor=F.+Sobottauthor=V.+M.+Goodauthor=M.+M.+U.+Aliauthor=C.+Prodromouauthor=C.+V.+Robinsonauthor=H.+R.+Saibilauthor=L.+H.+Pearl&title=Structure+of+an+Hsp90-Cdc37-Cdk4+complex&doi=10.1016%2Fj.molcel.2006.07.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of an Hsp90-Cdc37-Cdk4 complex</span></div><div class="casAuthors">Vaughan, Cara K.; Gohlke, Ulrich; Sobott, Frank; Good, Valerie M.; Ali, Maruf M. U.; Prodromou, Chrisostomos; Robinson, Carol V.; Saibil, Helen R.; Pearl, Laurence H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">697-707</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Activation of many protein kinases depends on their interaction with the Hsp90 mol. chaperone system.  Recruitment of protein kinase clients to the Hsp90 chaperone system is mediated by the cochaperone adaptor protein Cdc37, which acts as a scaffold, simultaneously binding protein kinases and Hsp90.  We have now expressed and purified an Hsp90-Cdc37-Cdk4 complex, defined its stoichiometry, and detd. its 3D structure by single-particle electron microscopy.  Comparison with the crystal structure of Hsp90 allows us to identify the locations of Cdc37 and Cdk4 in the complex and suggests a mechanism by which conformational changes in the kinase are coupled to the Hsp90 ATPase cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9CIsMyAPcErVg90H21EOLACvtfcHk0ljCFvnWY4szMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVSkt7rI&md5=bccf0a0ac99a627ec538e01b7910120f</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2006.07.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2006.07.016%26sid%3Dliteratum%253Aachs%26aulast%3DVaughan%26aufirst%3DC.%2BK.%26aulast%3DGohlke%26aufirst%3DU.%26aulast%3DSobott%26aufirst%3DF.%26aulast%3DGood%26aufirst%3DV.%2BM.%26aulast%3DAli%26aufirst%3DM.%2BM.%2BU.%26aulast%3DProdromou%26aufirst%3DC.%26aulast%3DRobinson%26aufirst%3DC.%2BV.%26aulast%3DSaibil%26aufirst%3DH.%2BR.%26aulast%3DPearl%26aufirst%3DL.%2BH.%26atitle%3DStructure%2520of%2520an%2520Hsp90-Cdc37-Cdk4%2520complex%26jtitle%3DMol.%2520Cell%26date%3D2006%26volume%3D23%26spage%3D697%26epage%3D707%26doi%3D10.1016%2Fj.molcel.2006.07.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Karagöz, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duarte, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akoury, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ippel, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biernat, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morán Luengo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Didenko, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nordhues, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veprintsev, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickey, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandelkow, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zweckstetter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boelens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rüdiger, S. G.</span><span> </span><span class="NLM_article-title">Hsp90-Tau complex reveals molecular basis for specificity in chaperone action</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">963</span><span class="NLM_x">–</span> <span class="NLM_lpage">974</span><span class="refDoi"> DOI: 10.1016/j.cell.2014.01.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.cell.2014.01.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=24581495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A280%3ADC%252BC2cvpsFagtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2014&pages=963-974&author=G.+E.+Karag%C3%B6zauthor=A.+M.+Duarteauthor=E.+Akouryauthor=H.+Ippelauthor=J.+Biernatauthor=T.+Mor%C3%A1n+Luengoauthor=M.+Radliauthor=T.+Didenkoauthor=B.+A.+Nordhuesauthor=D.+B.+Veprintsevauthor=C.+A.+Dickeyauthor=E.+Mandelkowauthor=M.+Zweckstetterauthor=R.+Boelensauthor=T.+Madlauthor=S.+G.+R%C3%BCdiger&title=Hsp90-Tau+complex+reveals+molecular+basis+for+specificity+in+chaperone+action&doi=10.1016%2Fj.cell.2014.01.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90-Tau complex reveals molecular basis for specificity in chaperone action</span></div><div class="casAuthors">Karagoz G Elif; Duarte Afonso M S; Akoury Elias; Ippel Hans; Biernat Jacek; Moran Luengo Tania; Radli Martina; Didenko Tatiana; Nordhues Bryce A; Dickey Chad A; Veprintsev Dmitry B; Mandelkow Eckhard; Zweckstetter Markus; Boelens Rolf; Madl Tobias; Rudiger Stefan G D</div><div class="citationInfo"><span class="NLM_cas:title">Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">963-74</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Protein folding in the cell relies on the orchestrated action of conserved families of molecular chaperones, the Hsp70 and Hsp90 systems.  Hsp70 acts early and Hsp90 late in the folding path, yet the molecular basis of this timing is enigmatic, mainly because the substrate specificity of Hsp90 is poorly understood.  Here, we obtained a structural model of Hsp90 in complex with its natural disease-associated substrate, the intrinsically disordered Tau protein.  Hsp90 binds to a broad region in Tau that includes the aggregation-prone repeats.  Complementarily, a 106-ÅA-long substrate-binding interface in Hsp90 enables many low-affinity contacts.  This allows recognition of scattered hydrophobic residues in late folding intermediates that remain after early burial of the Hsp70 sites.  Our model resolves the paradox of how Hsp90 specifically selects for late folding intermediates but also for some intrinsically disordered proteins-through the eyes of Hsp90 they look the same.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQJ1lLYwX_fzXl8icjszYl0fW6udTcc2eZlxLJkeu013bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvpsFagtg%253D%253D&md5=ac8a4ccf143cd572c3e52517a9d4d2fc</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2014.01.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2014.01.037%26sid%3Dliteratum%253Aachs%26aulast%3DKarag%25C3%25B6z%26aufirst%3DG.%2BE.%26aulast%3DDuarte%26aufirst%3DA.%2BM.%26aulast%3DAkoury%26aufirst%3DE.%26aulast%3DIppel%26aufirst%3DH.%26aulast%3DBiernat%26aufirst%3DJ.%26aulast%3DMor%25C3%25A1n%2BLuengo%26aufirst%3DT.%26aulast%3DRadli%26aufirst%3DM.%26aulast%3DDidenko%26aufirst%3DT.%26aulast%3DNordhues%26aufirst%3DB.%2BA.%26aulast%3DVeprintsev%26aufirst%3DD.%2BB.%26aulast%3DDickey%26aufirst%3DC.%2BA.%26aulast%3DMandelkow%26aufirst%3DE.%26aulast%3DZweckstetter%26aufirst%3DM.%26aulast%3DBoelens%26aufirst%3DR.%26aulast%3DMadl%26aufirst%3DT.%26aulast%3DR%25C3%25BCdiger%26aufirst%3DS.%2BG.%26atitle%3DHsp90-Tau%2520complex%2520reveals%2520molecular%2520basis%2520for%2520specificity%2520in%2520chaperone%2520action%26jtitle%3DCell%26date%3D2014%26volume%3D156%26spage%3D963%26epage%3D974%26doi%3D10.1016%2Fj.cell.2014.01.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Pratt, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toft, D. O.</span><span> </span><span class="NLM_article-title">Steroid receptor interactions with heat shock protein and immunophilin chaperones</span> <span class="citation_source-journal">Endocr. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">306</span><span class="NLM_x">–</span> <span class="NLM_lpage">360</span><span class="refDoi"> DOI: 10.1210/edrv.18.3.0303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1210%2Fedrv.18.3.0303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=9183567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADyaK2sXktV2qsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1997&pages=306-360&author=W.+B.+Prattauthor=D.+O.+Toft&title=Steroid+receptor+interactions+with+heat+shock+protein+and+immunophilin+chaperones&doi=10.1210%2Fedrv.18.3.0303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Steroid receptor interactions with heat shock protein and immunophilin chaperones</span></div><div class="casAuthors">Pratt, William B.; Toft, David O.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine Reviews</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">306-360</span>CODEN:
                <span class="NLM_cas:coden">ERVIDP</span>;
        ISSN:<span class="NLM_cas:issn">0163-769X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review, with 698 refs., on 9S receptors, receptor transformation, molybdate stabilization of receptors, purifications of untransformed receptors leads to hsp90, role of hsp90 in receptor function, other proteins recovered in native receptor heterocomplexes and the receptor heterocomplex assembly mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIRpRIJU8Ze7Vg90H21EOLACvtfcHk0lg_krar7-M4kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktV2qsrs%253D&md5=fe81c7a7b1a1428b0dbfc6d89d628dc2</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1210%2Fedrv.18.3.0303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fedrv.18.3.0303%26sid%3Dliteratum%253Aachs%26aulast%3DPratt%26aufirst%3DW.%2BB.%26aulast%3DToft%26aufirst%3DD.%2BO.%26atitle%3DSteroid%2520receptor%2520interactions%2520with%2520heat%2520shock%2520protein%2520and%2520immunophilin%2520chaperones%26jtitle%3DEndocr.%2520Rev.%26date%3D1997%26volume%3D18%26spage%3D306%26epage%3D360%26doi%3D10.1210%2Fedrv.18.3.0303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Lorenz, O. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freiburger, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutz, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krause, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zierer, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvira, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuéllar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valpuesta, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sattler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchner, J.</span><span> </span><span class="NLM_article-title">Modulation of the Hsp90 chaperone cycle by a stringent client protein</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">941</span><span class="NLM_x">–</span> <span class="NLM_lpage">953</span><span class="refDoi"> DOI: 10.1016/j.molcel.2014.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.molcel.2014.02.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=941-953&author=O.+R.+Lorenzauthor=L.+Freiburgerauthor=D.+A.+Rutzauthor=M.+Krauseauthor=B.+K.+Ziererauthor=S.+Alviraauthor=J.+Cu%C3%A9llarauthor=J.+M.+Valpuestaauthor=T.+Madlauthor=M.+Sattlerauthor=J.+Buchner&title=Modulation+of+the+Hsp90+chaperone+cycle+by+a+stringent+client+protein&doi=10.1016%2Fj.molcel.2014.02.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2014.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2014.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DLorenz%26aufirst%3DO.%2BR.%26aulast%3DFreiburger%26aufirst%3DL.%26aulast%3DRutz%26aufirst%3DD.%2BA.%26aulast%3DKrause%26aufirst%3DM.%26aulast%3DZierer%26aufirst%3DB.%2BK.%26aulast%3DAlvira%26aufirst%3DS.%26aulast%3DCu%25C3%25A9llar%26aufirst%3DJ.%26aulast%3DValpuesta%26aufirst%3DJ.%2BM.%26aulast%3DMadl%26aufirst%3DT.%26aulast%3DSattler%26aufirst%3DM.%26aulast%3DBuchner%26aufirst%3DJ.%26atitle%3DModulation%2520of%2520the%2520Hsp90%2520chaperone%2520cycle%2520by%2520a%2520stringent%2520client%2520protein%26jtitle%3DMol.%2520Cell%26date%3D2014%26volume%3D53%26spage%3D941%26epage%3D953%26doi%3D10.1016%2Fj.molcel.2014.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Targeting cancer with small molecule kinase inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span><span class="refDoi"> DOI: 10.1038/nrc2559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnrc2559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=19104514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1yg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=28-39&author=J.+Zhangauthor=P.+L.+Yangauthor=N.+S.+Gray&title=Targeting+cancer+with+small+molecule+kinase+inhibitors&doi=10.1038%2Fnrc2559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer with small molecule kinase inhibitors</span></div><div class="casAuthors">Zhang, Jianming; Yang, Priscilla L.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-39</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiol. constraints on growth and survival.  To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small mol. inhibitors for a host of other kinases that are implicated in cancer and other diseases.  Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations.  This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriSM3BN_uEz7Vg90H21EOLACvtfcHk0lg_krar7-M4kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1yg&md5=35bc38f414cd21eef5e61ce181b580fb</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fnrc2559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2559%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520cancer%2520with%2520small%2520molecule%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D28%26epage%3D39%26doi%3D10.1038%2Fnrc2559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Lemmon, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span> </span><span class="NLM_article-title">Cell signaling by receptor tyrosine kinases</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">141</span><span class="NLM_x">, </span> <span class="NLM_fpage">1117</span><span class="NLM_x">–</span> <span class="NLM_lpage">1134</span><span class="refDoi"> DOI: 10.1016/j.cell.2010.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.cell.2010.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=20602996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2010&pages=1117-1134&author=M.+A.+Lemmonauthor=J.+Schlessinger&title=Cell+signaling+by+receptor+tyrosine+kinases&doi=10.1016%2Fj.cell.2010.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Cell signaling by receptor tyrosine kinases</span></div><div class="casAuthors">Lemmon, Mark A.; Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1117-1134</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Recent structural studies of receptor tyrosine kinases (RTKs) have revealed unexpected diversity in the mechanisms of their activation by growth factor ligands.  Strategies for inducing dimerization by ligand binding are surprisingly diverse, as are mechanisms that couple this event to activation of the intracellular tyrosine kinase domains.  As the understanding of these details becomes increasingly sophisticated, it provides an important context for therapeutically countering the effects of pathogenic RTK mutations in cancer and other diseases.  Much remains to be learned, however, about the complex signaling networks downstream from RTKs and how alterations in these networks are translated into cellular responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd5NvoN0Q9-7Vg90H21EOLACvtfcHk0lg_krar7-M4kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D&md5=b88b55fe7a3eebc6ff7e883425676e45</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2010.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2010.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCell%2520signaling%2520by%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCell%26date%3D2010%26volume%3D141%26spage%3D1117%26epage%3D1134%26doi%3D10.1016%2Fj.cell.2010.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Garraway, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Circumventing cancer drug resistance in the era of personalized medicine</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">214</span><span class="NLM_x">–</span> <span class="NLM_lpage">226</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F2159-8290.CD-12-0012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=214-226&author=L.+A.+Garrawayauthor=P.+A.+Janne&title=Circumventing+cancer+drug+resistance+in+the+era+of+personalized+medicine&doi=10.1158%2F2159-8290.CD-12-0012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0012%26sid%3Dliteratum%253Aachs%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DCircumventing%2520cancer%2520drug%2520resistance%2520in%2520the%2520era%2520of%2520personalized%2520medicine%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26spage%3D214%26epage%3D226%26doi%3D10.1158%2F2159-8290.CD-12-0012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span> </span><span class="NLM_article-title">Acquired resistance to TKIs in solid tumours: learning from lung cancer</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">473</span><span class="NLM_x">–</span> <span class="NLM_lpage">481</span><span class="refDoi"> DOI: 10.1038/nrclinonc.2014.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnrclinonc.2014.104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=24981256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFWisLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=473-481&author=D.+R.+Camidgeauthor=W.+Paoauthor=L.+V.+Sequist&title=Acquired+resistance+to+TKIs+in+solid+tumours%3A+learning+from+lung+cancer&doi=10.1038%2Fnrclinonc.2014.104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance to TKIs in solid tumours: learning from lung cancer</span></div><div class="casAuthors">Camidge, D. Ross; Pao, William; Sequist, Lecia V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">473-481</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The use of advanced mol. profiling to direct the use of targeted therapy, such as tyrosine kinase inhibitors (TKIs) for patients with advanced-stage non-small-cell lung cancer (NSCLC), has revolutionized the treatment of this disease.  However, acquired resistance, defined as progression after initial benefit, to targeted therapies inevitably occurs.  This Review explores breakthroughs in the understanding and treatment of acquired resistance in NSCLC, focusing on EGFR mutant and ALK rearrangement-pos. disease, which may be relevant across multiple different solid malignancies with oncogene-addicted subtypes.  Mechanisms of acquired resistance may be pharmacol. (i.e., failure of delivery of the drug to its target) or biol., resulting from evolutionary selection on molecularly diverse tumors.  A no. of clin. approaches can maintain control of the disease in the acquired resistance setting, including the use of radiation to treat isolated areas of progression and adding or switching to cytotoxic chemotherapy.  Furthermore, novel approaches that have already proven successful include the development of second-generation and third-generation inhibitors and the combination of some of these inhibitors with antibodies directed against the same target.  With our increased understanding of the spectrum of acquired resistance, major changes in how we conduct clin. research in this setting are now underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp00ixSKYoDuLVg90H21EOLACvtfcHk0ljqMe03D6lxMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFWisLrL&md5=13cc2f49f7ef320ad54f7e84f5102816</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2014.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2014.104%26sid%3Dliteratum%253Aachs%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26atitle%3DAcquired%2520resistance%2520to%2520TKIs%2520in%2520solid%2520tumours%253A%2520learning%2520from%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D11%26spage%3D473%26epage%3D481%26doi%3D10.1038%2Fnrclinonc.2014.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Factors underlying sensitivity of cancers to small-molecule kinase inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">709</span><span class="NLM_x">–</span> <span class="NLM_lpage">723</span><span class="refDoi"> DOI: 10.1038/nrd2871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnrd2871" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=709-723&author=P.+A.+Janneauthor=N.+Grayauthor=J.+Settleman&title=Factors+underlying+sensitivity+of+cancers+to+small-molecule+kinase+inhibitors&doi=10.1038%2Fnrd2871"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fnrd2871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2871%26sid%3Dliteratum%253Aachs%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DFactors%2520underlying%2520sensitivity%2520of%2520cancers%2520to%2520small-molecule%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D709%26epage%3D723%26doi%3D10.1038%2Fnrd2871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Acquired resistance to tyrosine kinase inhibitors during cancer therapy</span> <span class="citation_source-journal">Curr. Opin. Genet. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="NLM_x">–</span> <span class="NLM_lpage">79</span><span class="refDoi"> DOI: 10.1016/j.gde.2008.01.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.gde.2008.01.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=18325754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVartbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=73-79&author=J.+A.+Engelmanauthor=J.+Settleman&title=Acquired+resistance+to+tyrosine+kinase+inhibitors+during+cancer+therapy&doi=10.1016%2Fj.gde.2008.01.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance to tyrosine kinase inhibitors during cancer therapy</span></div><div class="casAuthors">Engelman, Jeffrey A.; Settleman, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Genetics & Development</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-79</span>CODEN:
                <span class="NLM_cas:coden">COGDET</span>;
        ISSN:<span class="NLM_cas:issn">0959-437X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Selective tyrosine kinase inhibitors have emerged as important therapeutic agents in the treatment of a variety of human malignancies.  Although several of these inhibitors have marked clin. activity, it is widely recognized that the overall value of these agents is substantially limited by the acquisition of drug resistance, which eventually arises in most, if not all treated patients.  Mechanisms of drug resistance are beginning to be elucidated through the mol. anal. of clin. specimens as well as through cell culture modeling.  By identifying resistance mechanisms, it should be possible to develop second-generation' inhibitors as well as rational drug combinations that can overcome or even prevent acquired resistance to kinase inhibitors, thereby enhancing clin. benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJCEQIe-JFI7Vg90H21EOLACvtfcHk0ljqMe03D6lxMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVartbc%253D&md5=db27057c8cb1a4deceb779bae6d19398</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.gde.2008.01.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gde.2008.01.004%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DAcquired%2520resistance%2520to%2520tyrosine%2520kinase%2520inhibitors%2520during%2520cancer%2520therapy%26jtitle%3DCurr.%2520Opin.%2520Genet.%2520Dev.%26date%3D2008%26volume%3D18%26spage%3D73%26epage%3D79%26doi%3D10.1016%2Fj.gde.2008.01.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Kuczynski, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sargent, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grothey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerbel, R. S.</span><span> </span><span class="NLM_article-title">Drug rechallenge and treatment beyond progression--implications for drug resistance</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">571</span><span class="NLM_x">–</span> <span class="NLM_lpage">587</span><span class="refDoi"> DOI: 10.1038/nrclinonc.2013.158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnrclinonc.2013.158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=23999218" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVWqtrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=571-587&author=E.+A.+Kuczynskiauthor=D.+J.+Sargentauthor=A.+Grotheyauthor=R.+S.+Kerbel&title=Drug+rechallenge+and+treatment+beyond+progression%2D%2Dimplications+for+drug+resistance&doi=10.1038%2Fnrclinonc.2013.158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Drug rechallenge and treatment beyond progression-implications for drug resistance</span></div><div class="casAuthors">Kuczynski, Elizabeth A.; Sargent, Daniel J.; Grothey, Axel; Kerbel, Robert S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">571-587</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The established dogma in oncol. for managing recurrent or refractory disease dictates that therapy is changed at disease progression, because the cancer is assumed to have become drug-resistant.  Drug resistance, whether pre-existing or acquired, is largely thought to be a stable and heritable process; thus, reuse of therapeutic agents that have failed is generally contraindicated.  Over the past few decades, clin. evidence has suggested a role for unstable, non-heritable mechanisms of acquired drug resistance pertaining to chemotherapy and targeted agents.  There are many examples of circumstances where patients respond to reintroduction of the same therapy (drug rechallenge) after a drug holiday following disease relapse or progression during therapy.  Addnl., albeit limited, evidence suggests that, in certain circumstances, continuing a therapy beyond disease progression can also have antitumor activity.  In this Review, we describe the anticancer agents used in these treatment strategies and discuss the potential mechanisms explaining the apparent tumor re-sensitization with reintroduced or continued therapy.  The extensive no. of malignancies and drugs that challenge the custom of permanently switching to different drugs at each line of therapy warrants a more in-depth examn. of the definitions of disease progression and drug resistance and the resulting implications for patient care.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGVmbq8ucsa7Vg90H21EOLACvtfcHk0ljqMe03D6lxMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVWqtrzJ&md5=513ca799d7cabdd8208b0c4ae9507753</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2013.158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2013.158%26sid%3Dliteratum%253Aachs%26aulast%3DKuczynski%26aufirst%3DE.%2BA.%26aulast%3DSargent%26aufirst%3DD.%2BJ.%26aulast%3DGrothey%26aufirst%3DA.%26aulast%3DKerbel%26aufirst%3DR.%2BS.%26atitle%3DDrug%2520rechallenge%2520and%2520treatment%2520beyond%2520progression--implications%2520for%2520drug%2520resistance%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D10%26spage%3D571%26epage%3D587%26doi%3D10.1038%2Fnrclinonc.2013.158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Lackner, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Mechanisms of acquired resistance to targeted cancer therapies</span> <span class="citation_source-journal">Future Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">999</span><span class="NLM_x">–</span> <span class="NLM_lpage">1014</span><span class="refDoi"> DOI: 10.2217/fon.12.86</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.2217%2Ffon.12.86" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22894672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1WlsLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=999-1014&author=M.+R.+Lacknerauthor=T.+R.+Wilsonauthor=J.+Settleman&title=Mechanisms+of+acquired+resistance+to+targeted+cancer+therapies&doi=10.2217%2Ffon.12.86"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of acquired resistance to targeted cancer therapies</span></div><div class="casAuthors">Lackner, Mark R.; Wilson, Timothy R.; Settleman, Jeff</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">999-1014</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Drugs that target genomically defined vulnerabilities in human tumors have now been clin. validated as effective cancer therapies.  However, the relatively rapid acquisition of resistance to such treatments that is obsd. in virtually all cases significantly limits their utility and remains a substantial challenge to the clin. management of advanced cancers.  As mol. mechanisms of resistance have begun to be elucidated, new strategies to overcome or prevent the development of resistance have begun to emerge.  In some cases, specific mutational mechanisms contribute directly to acquired drug resistance, and in other cases it appears that nonmutational and possibly epigenetic mechanisms play a significant role.  This article discusses the various genetic and nongenetic mechanisms of acquired drug resistance that have been reported in the context of rationally targeted' drug therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooztN62IERZrVg90H21EOLACvtfcHk0ljtyXf_WcWpHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1WlsLzK&md5=8a0a8ccb076874d753bfed5ace2ba169</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.2217%2Ffon.12.86&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.12.86%26sid%3Dliteratum%253Aachs%26aulast%3DLackner%26aufirst%3DM.%2BR.%26aulast%3DWilson%26aufirst%3DT.%2BR.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DMechanisms%2520of%2520acquired%2520resistance%2520to%2520targeted%2520cancer%2520therapies%26jtitle%3DFuture%2520Oncol.%26date%3D2012%26volume%3D8%26spage%3D999%26epage%3D1014%26doi%3D10.2217%2Ffon.12.86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Gillies, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verduzco, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gatenby, R. A.</span><span> </span><span class="NLM_article-title">Evolutionary dynamics of carcinogenesis and why targeted therapy does not work</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">487</span><span class="NLM_x">–</span> <span class="NLM_lpage">493</span><span class="refDoi"> DOI: 10.1038/nrc3298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnrc3298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22695393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1egsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=487-493&author=R.+J.+Gilliesauthor=D.+Verduzcoauthor=R.+A.+Gatenby&title=Evolutionary+dynamics+of+carcinogenesis+and+why+targeted+therapy+does+not+work&doi=10.1038%2Fnrc3298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Evolutionary dynamics of carcinogenesis and why targeted therapy does not work</span></div><div class="casAuthors">Gillies, Robert J.; Verduzco, Daniel; Gatenby, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">487-493</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  All malignant cancers, whether inherited or sporadic, are fundamentally governed by Darwinian dynamics.  The process of carcinogenesis requires genetic instability and highly selective local microenvironments, the combination of which promotes somatic evolution.  These microenvironmental forces, specifically hypoxia, acidosis and reactive oxygen species, are not only highly selective, but are also able to induce genetic instability.  As a result, malignant cancers are dynamically evolving clades of cells living in distinct microhabitats that almost certainly ensure the emergence of therapy-resistant populations.  Cytotoxic cancer therapies also impose intense evolutionary selection pressures on the surviving cells and thus increase the evolutionary rate.  Importantly, the principles of Darwinian dynamics also embody fundamental principles that can illuminate strategies for the successful management of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorCHoXr5jY_rVg90H21EOLACvtfcHk0ljtyXf_WcWpHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1egsL4%253D&md5=ae041c5a9585d882c6512e386afb26c2</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fnrc3298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3298%26sid%3Dliteratum%253Aachs%26aulast%3DGillies%26aufirst%3DR.%2BJ.%26aulast%3DVerduzco%26aufirst%3DD.%26aulast%3DGatenby%26aufirst%3DR.%2BA.%26atitle%3DEvolutionary%2520dynamics%2520of%2520carcinogenesis%2520and%2520why%2520targeted%2520therapy%2520does%2520not%2520work%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D487%26epage%3D493%26doi%3D10.1038%2Fnrc3298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Holohan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Schaeybroeck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longley, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, P. G.</span><span> </span><span class="NLM_article-title">Cancer drug resistance: an evolving paradigm</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">714</span><span class="NLM_x">–</span> <span class="NLM_lpage">726</span><span class="refDoi"> DOI: 10.1038/nrc3599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnrc3599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=24060863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyqurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=714-726&author=C.+Holohanauthor=S.+Van+Schaeybroeckauthor=D.+B.+Longleyauthor=P.+G.+Johnston&title=Cancer+drug+resistance%3A+an+evolving+paradigm&doi=10.1038%2Fnrc3599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer drug resistance: an evolving paradigm</span></div><div class="casAuthors">Holohan, Caitriona; Van Schaeybroeck, Sandra; Longley, Daniel B.; Johnston, Patrick G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">714-726</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Resistance to chemotherapy and molecularly targeted therapies is a major problem facing current cancer research.  The mechanisms of resistance to 'classical' cytotoxic chemotherapeutics and to therapies that are designed to be selective for specific mol. targets share many features, such as alterations in the drug target, activation of prosurvival pathways and ineffective induction of cell death.  With the increasing arsenal of anticancer agents, improving preclin. models and the advent of powerful high-throughput screening techniques, there are now unprecedented opportunities to understand and overcome drug resistance through the clin. assessment of rational therapeutic drug combinations and the use of predictive biomarkers to enable patient stratification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrykBEUSgvv7Vg90H21EOLACvtfcHk0ljtyXf_WcWpHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyqurnE&md5=b497a823bbd968904ce1591b918d0679</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1038%2Fnrc3599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3599%26sid%3Dliteratum%253Aachs%26aulast%3DHolohan%26aufirst%3DC.%26aulast%3DVan%2BSchaeybroeck%26aufirst%3DS.%26aulast%3DLongley%26aufirst%3DD.%2BB.%26aulast%3DJohnston%26aufirst%3DP.%2BG.%26atitle%3DCancer%2520drug%2520resistance%253A%2520an%2520evolving%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D714%26epage%3D726%26doi%3D10.1038%2Fnrc3599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Tartarone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazzari, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerose, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conteduca, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Improta, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zupa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bulotta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aieta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregorc, V.</span><span> </span><span class="NLM_article-title">Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib</span> <span class="citation_source-journal">Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">328</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1016/j.lungcan.2013.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.lungcan.2013.05.020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2013&pages=328-336&author=A.+Tartaroneauthor=C.+Lazzariauthor=R.+Leroseauthor=V.+Conteducaauthor=G.+Improtaauthor=A.+Zupaauthor=A.+Bulottaauthor=M.+Aietaauthor=V.+Gregorc&title=Mechanisms+of+resistance+to+EGFR+tyrosine+kinase+inhibitors+gefitinib%2Ferlotinib+and+to+ALK+inhibitor+crizotinib&doi=10.1016%2Fj.lungcan.2013.05.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2013.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2013.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DTartarone%26aufirst%3DA.%26aulast%3DLazzari%26aufirst%3DC.%26aulast%3DLerose%26aufirst%3DR.%26aulast%3DConteduca%26aufirst%3DV.%26aulast%3DImprota%26aufirst%3DG.%26aulast%3DZupa%26aufirst%3DA.%26aulast%3DBulotta%26aufirst%3DA.%26aulast%3DAieta%26aufirst%3DM.%26aulast%3DGregorc%26aufirst%3DV.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%2520gefitinib%252Ferlotinib%2520and%2520to%2520ALK%2520inhibitor%2520crizotinib%26jtitle%3DLung%2520Cancer%26date%3D2013%26volume%3D81%26spage%3D328%26epage%3D336%26doi%3D10.1016%2Fj.lungcan.2013.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Song, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, A.</span><span> </span><span class="NLM_article-title">Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance</span> <span class="citation_source-journal">Acta Pharm. Sin. B</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">34</span><span class="NLM_x">–</span> <span class="NLM_lpage">37</span><span class="refDoi"> DOI: 10.1016/j.apsb.2014.12.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.apsb.2014.12.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=26579422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A280%3ADC%252BC28rgtlOnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=34-37&author=Z.+Songauthor=M.+Wangauthor=A.+Zhang&title=Alectinib%3A+a+novel+second+generation+anaplastic+lymphoma+kinase+%28ALK%29+inhibitor+for+overcoming+clinically-acquired+resistance&doi=10.1016%2Fj.apsb.2014.12.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance</span></div><div class="casAuthors">Song Zilan; Wang Meining; Zhang Ao</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-7</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">The development of inhibitors for the tyrosine anaplastic lymphoma kinase (ALK) has advanced rapidly, driven by biology and medicinal chemistry.  The first generation ALK inhibitor crizotinib was granted US FDA approval with only four years of preclinical and clinical testing.  Although this drug offers significant clinical benefit to the ALK-positive patients, resistance has been developed through a variety of mechanisms.  In addition to ceritinib, alectinib is another second-generation ALK inhibitor launched in 2014 in Japan.  This drug has a unique chemical structure bearing a 5H-benzo[b]carbazol-11(6H)-one structural scaffold with an IC50 value of 1.9 nmol/L, and is highly potent against ALK bearing the gatekeeper mutation L1196M with an IC50 of 1.56 nmol/L.  In the clinic, alectinib is highly efficacious in treatment of ALK-positive non-small cell lung cancer (NSCLC), and retains potency to combat crizotinib-resistant ALK mutations L1196M, F1174L, R1275Q and C1156Y.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-qtzzXrDFl0loaUqgkFHkfW6udTcc2eZH8uv0pP6Rnbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rgtlOnsQ%253D%253D&md5=897904214b032d104d09280ebe1b95ca</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2014.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2014.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DAlectinib%253A%2520a%2520novel%2520second%2520generation%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitor%2520for%2520overcoming%2520clinically-acquired%2520resistance%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2015%26volume%3D5%26spage%3D34%26epage%3D37%26doi%3D10.1016%2Fj.apsb.2014.12.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carretero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adelmant, G. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodig, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marto, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span> </span><span class="NLM_article-title">Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">9827</span><span class="NLM_x">–</span> <span class="NLM_lpage">9836</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-1671</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F0008-5472.CAN-10-1671" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=9827-9836&author=Z.+Chenauthor=T.+Sasakiauthor=X.+Tanauthor=J.+Carreteroauthor=T.+Shimamuraauthor=D.+Liauthor=C.+Xuauthor=Y.+Wangauthor=G.+O.+Adelmantauthor=M.+Capellettiauthor=H.+J.+Leeauthor=S.+J.+Rodigauthor=C.+Borgmanauthor=S.+I.+Parkauthor=H.+R.+Kimauthor=R.+Paderaauthor=J.+A.+Martoauthor=N.+S.+Grayauthor=A.+L.+Kungauthor=G.+I.+Shapiroauthor=P.+A.+J%C3%A4nneauthor=K.+K.+Wong&title=Inhibition+of+ALK%2C+PI3K%2FMEK%2C+and+HSP90+in+murine+lung+adenocarcinoma+induced+by+EML4-ALK+fusion+oncogene&doi=10.1158%2F0008-5472.CAN-10-1671"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-1671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-1671%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DX.%26aulast%3DCarretero%26aufirst%3DJ.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DAdelmant%26aufirst%3DG.%2BO.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DBorgman%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DS.%2BI.%26aulast%3DKim%26aufirst%3DH.%2BR.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DMarto%26aufirst%3DJ.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DInhibition%2520of%2520ALK%252C%2520PI3K%252FMEK%252C%2520and%2520HSP90%2520in%2520murine%2520lung%2520adenocarcinoma%2520induced%2520by%2520EML4-ALK%2520fusion%2520oncogene%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D9827%26epage%3D9836%26doi%3D10.1158%2F0008-5472.CAN-10-1671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Normant, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paez, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slocum, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tunkey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDougall, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wylie, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robison, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caliri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palombella, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritz, C. C.</span><span> </span><span class="NLM_article-title">The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2581</span><span class="NLM_x">–</span> <span class="NLM_lpage">2586</span><span class="refDoi"> DOI: 10.1038/onc.2010.625</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fonc.2010.625" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2011&pages=2581-2586&author=E.+Normantauthor=G.+Paezauthor=K.+A.+Westauthor=A.+R.+Limauthor=K.+L.+Slocumauthor=C.+Tunkeyauthor=J.+McDougallauthor=A.+A.+Wylieauthor=K.+Robisonauthor=K.+Caliriauthor=V.+J.+Palombellaauthor=C.+C.+Fritz&title=The+Hsp90+inhibitor+IPI-504+rapidly+lowers+EML4-ALK+levels+and+induces+tumor+regression+in+ALK-driven+NSCLC+models&doi=10.1038%2Fonc.2010.625"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1038%2Fonc.2010.625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2010.625%26sid%3Dliteratum%253Aachs%26aulast%3DNormant%26aufirst%3DE.%26aulast%3DPaez%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DK.%2BA.%26aulast%3DLim%26aufirst%3DA.%2BR.%26aulast%3DSlocum%26aufirst%3DK.%2BL.%26aulast%3DTunkey%26aufirst%3DC.%26aulast%3DMcDougall%26aufirst%3DJ.%26aulast%3DWylie%26aufirst%3DA.%2BA.%26aulast%3DRobison%26aufirst%3DK.%26aulast%3DCaliri%26aufirst%3DK.%26aulast%3DPalombella%26aufirst%3DV.%2BJ.%26aulast%3DFritz%26aufirst%3DC.%2BC.%26atitle%3DThe%2520Hsp90%2520inhibitor%2520IPI-504%2520rapidly%2520lowers%2520EML4-ALK%2520levels%2520and%2520induces%2520tumor%2520regression%2520in%2520ALK-driven%2520NSCLC%2520models%26jtitle%3DOncogene%26date%3D2011%26volume%3D30%26spage%3D2581%26epage%3D2586%26doi%3D10.1038%2Fonc.2010.625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Sang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acquaviva, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedland, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequeira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovly, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimenez, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doebele, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bates, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Hariry, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proia, D. A.</span><span> </span><span class="NLM_article-title">Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non–small cell lung cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">430</span><span class="NLM_x">–</span> <span class="NLM_lpage">443</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0440</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F2159-8290.CD-12-0440" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=430-443&author=J.+Sangauthor=J.+Acquavivaauthor=J.+C.+Friedlandauthor=D.+L.+Smithauthor=M.+Sequeiraauthor=C.+Zhangauthor=Q.+Jiangauthor=L.+Xueauthor=C.+M.+Lovlyauthor=J.-P.+Jimenezauthor=A.+T.+Shawauthor=R.+C.+Doebeleauthor=S.+Heauthor=R.+C.+Batesauthor=D.+R.+Camidgeauthor=S.+W.+Morrisauthor=I.+El-Hariryauthor=D.+A.+Proia&title=Targeted+inhibition+of+the+molecular+chaperone+Hsp90+overcomes+ALK+inhibitor+resistance+in+non%E2%80%93small+cell+lung+cancer&doi=10.1158%2F2159-8290.CD-12-0440"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0440%26sid%3Dliteratum%253Aachs%26aulast%3DSang%26aufirst%3DJ.%26aulast%3DAcquaviva%26aufirst%3DJ.%26aulast%3DFriedland%26aufirst%3DJ.%2BC.%26aulast%3DSmith%26aufirst%3DD.%2BL.%26aulast%3DSequeira%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DJimenez%26aufirst%3DJ.-P.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DBates%26aufirst%3DR.%2BC.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DEl-Hariry%26aufirst%3DI.%26aulast%3DProia%26aufirst%3DD.%2BA.%26atitle%3DTargeted%2520inhibition%2520of%2520the%2520molecular%2520chaperone%2520Hsp90%2520overcomes%2520ALK%2520inhibitor%2520resistance%2520in%2520non%25E2%2580%2593small%2520cell%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D430%26epage%3D443%26doi%3D10.1158%2F2159-8290.CD-12-0440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">7535</span><span class="NLM_x">–</span> <span class="NLM_lpage">7540</span><span class="refDoi"> DOI: 10.1073/pnas.1019559108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1073%2Fpnas.1019559108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=21502504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFSrsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=7535-7540&author=R.+Katayamaauthor=T.+M.+Khanauthor=C.+Benesauthor=E.+Lifshitsauthor=H.+Ebiauthor=V.+M.+Riveraauthor=W.+C.+Shakespeareauthor=A.+J.+Iafrateauthor=J.+A.+Engelmanauthor=A.+T.+Shaw&title=Therapeutic+strategies+to+overcome+crizotinib+resistance+in+non-small+cell+lung+cancers+harboring+the+fusion+oncogene+EML4-ALK&doi=10.1073%2Fpnas.1019559108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK</span></div><div class="casAuthors">Katayama, Ryohei; Khan, Tahsin M.; Benes, Cyril; Lifshits, Eugene; Ebi, Hiromichi; Rivera, Victor M.; Shakespeare, William C.; Iafrate, A. John; Engelman, Jeffrey A.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7535-7540, S7535/1-S7535/17</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The echinoderm microtubule-assocd. protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion oncogene represents a mol. target in a small subset of non-small cell lung cancers (NSCLCs).  This fusion leads to constitutive ALK activation with potent transforming activity.  In a pivotal phase 1 clin. trial, the ALK tyrosine kinase inhibitor (TKI) crizotinib (PF-02341066) demonstrated impressive antitumor activity in the majority of patients with NSCLC harboring ALK fusions.  However, despite these remarkable initial responses, cancers eventually develop resistance to crizotinib, usually within 1 y, thereby limiting the potential clin. benefit.  To det. how cancers acquire resistance to ALK inhibitors, we established a model of acquired resistance to crizotinib by exposing a highly sensitive EML4-ALK-pos. NSCLC cell line to increasing doses of crizotinib until resistance emerged.  We found that cells resistant to intermediate doses of crizotinib developed amplification of the EML4-ALK gene.  Cells resistant to higher doses (1 μM) also developed a gatekeeper mutation, L1196M, within the kinase domain, rendering EML4-ALK insensitive to crizotinib.  This gatekeeper mutation was readily detected using a unique and highly sensitive allele-specific PCR assay.  Although crizotinib was ineffectual against EML4-ALK harboring the gatekeeper mutation, we obsd. that two structurally different ALK inhibitors, NVPTAE684 and AP26113, were highly active against the resistant cancer cells in vitro and in vivo.  Furthermore, these resistant cells remained highly sensitive to the Hsp90 inhibitor 17-AAG.  Thus, we have developed a model of acquired resistance to ALK inhibitors and have shown that second-generation ALK TKIs or Hsp90 inhibitors are effective in treating crizotinib-resistant tumors harboring secondary gatekeeper mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPbiLG5xpg0LVg90H21EOLACvtfcHk0liwChHAxPiVfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFSrsbY%253D&md5=82f47736429e6f71f9fd5852e4df64cb</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1019559108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1019559108%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DEbi%26aufirst%3DH.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTherapeutic%2520strategies%2520to%2520overcome%2520crizotinib%2520resistance%2520in%2520non-small%2520cell%2520lung%2520cancers%2520harboring%2520the%2520fusion%2520oncogene%2520EML4-ALK%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D7535%26epage%3D7540%26doi%3D10.1073%2Fpnas.1019559108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Tanimoto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nanjo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, S.</span><span> </span><span class="NLM_article-title">Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">4920</span><span class="NLM_x">–</span> <span class="NLM_lpage">4928</span><span class="refDoi"> DOI: 10.18632/oncotarget.2055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.18632%2Foncotarget.2055" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=4920-4928&author=A.+Tanimotoauthor=T.+Yamadaauthor=S.+Nanjoauthor=S.+Takeuchiauthor=H.+Ebiauthor=K.+Kitaauthor=K.+Matsumotoauthor=S.+Yano&title=Receptor+ligand-triggered+resistance+to+alectinib+and+its+circumvention+by+Hsp90+inhibition+in+EML4-ALK+lung+cancer+cells&doi=10.18632%2Foncotarget.2055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2055%26sid%3Dliteratum%253Aachs%26aulast%3DTanimoto%26aufirst%3DA.%26aulast%3DYamada%26aufirst%3DT.%26aulast%3DNanjo%26aufirst%3DS.%26aulast%3DTakeuchi%26aufirst%3DS.%26aulast%3DEbi%26aufirst%3DH.%26aulast%3DKita%26aufirst%3DK.%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DYano%26aufirst%3DS.%26atitle%3DReceptor%2520ligand-triggered%2520resistance%2520to%2520alectinib%2520and%2520its%2520circumvention%2520by%2520Hsp90%2520inhibition%2520in%2520EML4-ALK%2520lung%2520cancer%2520cells%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D4920%26epage%3D4928%26doi%3D10.18632%2Foncotarget.2055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Wong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koczywas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paschold, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lufkin, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackman, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teofilovici, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Socinski, M. A.</span><span> </span><span class="NLM_article-title">An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non–small cell lung cancer (NSCLC)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">S7500</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=S7500&author=K.+Wongauthor=M.+Koczywasauthor=J.+W.+Goldmanauthor=E.+H.+Pascholdauthor=L.+Hornauthor=J.+M.+Lufkinauthor=R.+K.+Blackmanauthor=F.+Teofiloviciauthor=G.+Shapiroauthor=M.+A.+Socinski&title=An+open-label+phase+II+study+of+the+Hsp90+inhibitor+ganetespib+%28STA-9090%29+as+monotherapy+in+patients+with+advanced+non%E2%80%93small+cell+lung+cancer+%28NSCLC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DK.%26aulast%3DKoczywas%26aufirst%3DM.%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DPaschold%26aufirst%3DE.%2BH.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DLufkin%26aufirst%3DJ.%2BM.%26aulast%3DBlackman%26aufirst%3DR.%2BK.%26aulast%3DTeofilovici%26aufirst%3DF.%26aulast%3DShapiro%26aufirst%3DG.%26aulast%3DSocinski%26aufirst%3DM.%2BA.%26atitle%3DAn%2520open-label%2520phase%2520II%2520study%2520of%2520the%2520Hsp90%2520inhibitor%2520ganetespib%2520%2528STA-9090%2529%2520as%2520monotherapy%2520in%2520patients%2520with%2520advanced%2520non%25E2%2580%2593small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3DS7500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gettinger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senzer, N. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martins, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lilenbaum, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hafeez, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grayzel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borger, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paez, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natale, R.</span><span> </span><span class="NLM_article-title">Activity of IPI-504, a novel Hsp90 inhibitor, in patients with molecularly defined non-small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">4953</span><span class="NLM_x">–</span> <span class="NLM_lpage">4960</span><span class="refDoi"> DOI: 10.1200/JCO.2010.30.8338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1200%2FJCO.2010.30.8338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=20940188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFCntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=4953-4960&author=L.+V.+Sequistauthor=S.+Gettingerauthor=N.+N.+Senzerauthor=R.+G.+Martinsauthor=P.+A.+J%C3%A4nneauthor=R.+Lilenbaumauthor=J.+E.+Grayauthor=A.+J.+Iafrateauthor=R.+Katayamaauthor=N.+Hafeezauthor=J.+Sweeneyauthor=J.+R.+Walkerauthor=C.+Fritzauthor=R.+W.+Rossauthor=D.+Grayzelauthor=J.+A.+Engelmanauthor=D.+R.+Borgerauthor=G.+Paezauthor=R.+Natale&title=Activity+of+IPI-504%2C+a+novel+Hsp90+inhibitor%2C+in+patients+with+molecularly+defined+non-small-cell+lung+cancer&doi=10.1200%2FJCO.2010.30.8338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer</span></div><div class="casAuthors">Sequist, Lecia V.; Gettinger, Scott; Senzer, Neil N.; Martins, Renato G.; Janne, Pasi A.; Lilenbaum, Rogerio; Gray, Jhanelle E.; Iafrate, A. John; Katayama, Ryohei; Hafeez, Nafeeza; Sweeney, Jennifer; Walker, John R.; Fritz, Christian; Ross, Robert W.; Grayzel, David; Engelman, Jeffrey A.; Borger, Darrell R.; Paez, Guillermo; Natale, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">4953-4960</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: IPI-504 is a novel, water-sol., potent inhibitor of heat-shock protein 90 (Hsp90).  Its potential anticancer activity has been validated in preclin. in vitro and in vivo models.  We studied the activity of IPI-504 after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced, molecularly defined non-small-cell lung cancer (NSCLC).  Patients and Methods: Patients with advanced NSCLC, prior treatment with EGFR TKIs, and tumor tissue available for mol. genotyping were enrolled in this prospective, nonrandomized, multicenter, phase II study of IPI-504 monotherapy.  The primary outcome was objective response rate (ORR).  Secondary aims included safety, progression-free survival (PFS), and anal. of activity by mol. subtypes.  Results: Seventy-six patients were enrolled between Dec. 2007 and May 2009 from 10 United States cancer centers.  An ORR of 7% (five of 76) was obsd. in the overall study population, 10% (four of 40) in patients who were EGFR wild-type, and 4% (one of 28) in those with EGFR mutations.  Although both EGFR groups were below the target ORR of 20%, among the three patients with an ALK gene rearrangement, two had partial responses and the third had prolonged stable disease (7.2 mo, 24% redn. in tumor size).  The most common adverse events included grades 1 and 2 fatigue, nausea, and diarrhea.  Grade 3 or higher liver function abnormalities were obsd. in nine patients (11.8%).  Conclusion: IPI-504 has clin. activity in patients with NSCLC, particularly among patients with ALK rearrangements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyleDQqYi1qLVg90H21EOLACvtfcHk0liBj9UaBl0zEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFCntA%253D%253D&md5=accaddc9ab9e334d40d513a70fbcd9ed</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.30.8338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.30.8338%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DGettinger%26aufirst%3DS.%26aulast%3DSenzer%26aufirst%3DN.%2BN.%26aulast%3DMartins%26aufirst%3DR.%2BG.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DLilenbaum%26aufirst%3DR.%26aulast%3DGray%26aufirst%3DJ.%2BE.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DHafeez%26aufirst%3DN.%26aulast%3DSweeney%26aufirst%3DJ.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DFritz%26aufirst%3DC.%26aulast%3DRoss%26aufirst%3DR.%2BW.%26aulast%3DGrayzel%26aufirst%3DD.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DBorger%26aufirst%3DD.%2BR.%26aulast%3DPaez%26aufirst%3DG.%26aulast%3DNatale%26aufirst%3DR.%26atitle%3DActivity%2520of%2520IPI-504%252C%2520a%2520novel%2520Hsp90%2520inhibitor%252C%2520in%2520patients%2520with%2520molecularly%2520defined%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D4953%26epage%3D4960%26doi%3D10.1200%2FJCO.2010.30.8338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span>Data were obtained from the Thomson Reuters Cortellis at <a href="http://lifesciences.thomsonreuters.com/products/cortellis" class="extLink">http://lifesciences.thomsonreuters.com/products/cortellis</a> (accessed on August 1,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Data+were+obtained+from+the+Thomson+Reuters+Cortellis+at+http%3A%2F%2Flifesciences.thomsonreuters.com%2Fproducts%2Fcortellis+%28accessed+on+August+1%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Socinski, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Hariry, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koczywas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vukovic, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paschold, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonomi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brahmer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belani, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huberman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramalingam, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teofilovici, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span> </span><span class="NLM_article-title">A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3068</span><span class="NLM_x">–</span> <span class="NLM_lpage">3077</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-3381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1078-0432.CCR-12-3381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=23553849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXos12isLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=3068-3077&author=M.+A.+Socinskiauthor=J.+Goldmanauthor=I.+El-Hariryauthor=M.+Koczywasauthor=V.+Vukovicauthor=L.+Hornauthor=E.+Pascholdauthor=R.+Salgiaauthor=H.+Westauthor=L.+V.+Sequistauthor=P.+Bonomiauthor=J.+Brahmerauthor=L.+C.+Chenauthor=A.+Sandlerauthor=C.+P.+Belaniauthor=T.+Webbauthor=H.+Harperauthor=M.+Hubermanauthor=S.+Ramalingamauthor=K.+K.+Wongauthor=F.+Teofiloviciauthor=W.+Guoauthor=G.+I.+Shapiro&title=A+multicenter+phase+II+study+of+ganetespib+monotherapy+in+patients+with+genotypically+defined+advanced+non-small+cell+lung+cancer&doi=10.1158%2F1078-0432.CCR-12-3381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Socinski, Mark A.; Goldman, Jonathan; El-Hariry, Iman; Koczywas, Marianna; Vukovic, Vojo; Horn, Leora; Paschold, Eugene; Salgia, Ravi; West, Howard; Sequist, Lecia V.; Bonomi, Philip; Brahmer, Julie; Chen, Lin-Chi; Sandler, Alan; Belani, Chandra P.; Webb, Timothy; Harper, Harry; Huberman, Mark; Ramalingam, Suresh; Wong, Kwok-Kin; Teofilovici, Florentina; Guo, Wei; Shapiro, Geoffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3068-3077</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Ganetespib is a novel inhibitor of the heat shock protein 90 (Hsp90), a chaperone protein crit. to tumor growth and proliferation.  In this phase II study, we evaluated the activity and tolerability of ganetespib in previously treated patients with non-small cell lung cancer (NSCLC).  Exptl. Design: Patients were enrolled into cohort A (mutant EGFR), B (mutant KRAS), or C (no EGFR or KRAS mutations).  Patients were treated with 200 mg/m2 ganetespib by i.v. infusion once weekly for 3 wk followed by 1 wk of rest, until disease progression.  The primary endpoint was progression-free survival (PFS) at 16 wk.  Secondary endpoints included objective response (ORR), duration of treatment, tolerability, median PFS, overall survival (OS), and correlative studies.  Results: Ninety-nine patients with a median of 2 prior systemic therapies were enrolled; 98 were assigned to cohort A (n = 15), B (n = 17), or C (n = 66), with PFS rates at 16 wk of 13.3%, 5.9%, and 19.7%, resp.  Four patients (4%) achieved partial response (PR); all had disease that harbored anaplastic lymphoma kinase (ALK) gene rearrangement, retrospectively detected by FISH (n = 1) or PCR-based assays (n = 3), in crizotinib-naive patients enrolled to cohort C. Eight patients (8.1%) experienced treatment-related serious adverse events (AE); 2 of these (cardiac arrest and renal failure) resulted in death.  The most common AEs were diarrhea, fatigue, nausea, and anorexia.  Conclusions: Ganetespib monotherapy showed a manageable side effect profile as well as clin. activity in heavily pretreated patients with advanced NSCLCs, particularly in patients with tumors harboring ALK gene rearrangement.  Clin Cancer Res; 19(11); 3068-77. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFukeZlyNCmbVg90H21EOLACvtfcHk0liaZdrmlYUAmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXos12isLw%253D&md5=7fe5177633a6f003a7412431e6fb492d</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-3381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-3381%26sid%3Dliteratum%253Aachs%26aulast%3DSocinski%26aufirst%3DM.%2BA.%26aulast%3DGoldman%26aufirst%3DJ.%26aulast%3DEl-Hariry%26aufirst%3DI.%26aulast%3DKoczywas%26aufirst%3DM.%26aulast%3DVukovic%26aufirst%3DV.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DPaschold%26aufirst%3DE.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DWest%26aufirst%3DH.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DBonomi%26aufirst%3DP.%26aulast%3DBrahmer%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DL.%2BC.%26aulast%3DSandler%26aufirst%3DA.%26aulast%3DBelani%26aufirst%3DC.%2BP.%26aulast%3DWebb%26aufirst%3DT.%26aulast%3DHarper%26aufirst%3DH.%26aulast%3DHuberman%26aufirst%3DM.%26aulast%3DRamalingam%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DTeofilovici%26aufirst%3DF.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DA%2520multicenter%2520phase%2520II%2520study%2520of%2520ganetespib%2520monotherapy%2520in%2520patients%2520with%2520genotypically%2520defined%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D3068%26epage%3D3077%26doi%3D10.1158%2F1078-0432.CCR-12-3381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Garon, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlesi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groen, H. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smit, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akimov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avsar, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E. B.</span><span> </span><span class="NLM_article-title">Phase II study of the Hsp90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">7543</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=7543&issue=Suppl&author=E.+B.+Garonauthor=T.+Moranauthor=F.+Barlesiauthor=L.+Gandhiauthor=L.+V.+Sequistauthor=S.-W.+Kimauthor=H.+J.+M.+Groenauthor=B.+Besseauthor=E.+F.+Smitauthor=D.-W.+Kimauthor=M.+Akimovauthor=E.+Avsarauthor=S.+Baileyauthor=E.+B.+Felip&title=Phase+II+study+of+the+Hsp90+inhibitor+AUY922+in+patients+with+previously+treated%2C+advanced+non-small+cell+lung+cancer+%28NSCLC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGaron%26aufirst%3DE.%2BB.%26aulast%3DMoran%26aufirst%3DT.%26aulast%3DBarlesi%26aufirst%3DF.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DGroen%26aufirst%3DH.%2BJ.%2BM.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DSmit%26aufirst%3DE.%2BF.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DAkimov%26aufirst%3DM.%26aulast%3DAvsar%26aufirst%3DE.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DFelip%26aufirst%3DE.%2BB.%26atitle%3DPhase%2520II%2520study%2520of%2520the%2520Hsp90%2520inhibitor%2520AUY922%2520in%2520patients%2520with%2520previously%2520treated%252C%2520advanced%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26issue%3DSuppl%26spage%3D7543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Mahadevan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rensvold, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurtin, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleary, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lock, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G.</span><span> </span><span class="NLM_article-title">First-in-human phase I study: results of a second-generation non-ansamycin heat shock protein (Hsp90) inhibitor AT13387 in refractory solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">S3028</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=S3028&author=D.+Mahadevanauthor=D.+M.+Rensvoldauthor=S.+E.+Kurtinauthor=J.+M.+Clearyauthor=L.+Gandhiauthor=J.+F.+Lyonsauthor=V.+Lockauthor=S.+Lewisauthor=G.+Shapiro&title=First-in-human+phase+I+study%3A+results+of+a+second-generation+non-ansamycin+heat+shock+protein+%28Hsp90%29+inhibitor+AT13387+in+refractory+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMahadevan%26aufirst%3DD.%26aulast%3DRensvold%26aufirst%3DD.%2BM.%26aulast%3DKurtin%26aufirst%3DS.%2BE.%26aulast%3DCleary%26aufirst%3DJ.%2BM.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DLyons%26aufirst%3DJ.%2BF.%26aulast%3DLock%26aufirst%3DV.%26aulast%3DLewis%26aufirst%3DS.%26aulast%3DShapiro%26aufirst%3DG.%26atitle%3DFirst-in-human%2520phase%2520I%2520study%253A%2520results%2520of%2520a%2520second-generation%2520non-ansamycin%2520heat%2520shock%2520protein%2520%2528Hsp90%2529%2520inhibitor%2520AT13387%2520in%2520refractory%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3DS3028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Nguyen, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, D. B.</span><span> </span><span class="NLM_article-title">Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway</span> <span class="citation_source-journal">Clin. Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">281</span><span class="NLM_x">–</span> <span class="NLM_lpage">289</span><span class="refDoi"> DOI: 10.3816/CLC.2009.n.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.3816%2FCLC.2009.n.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=19632948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVSms7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=281-289&author=K.+S.+Nguyenauthor=S.+Kobayashiauthor=D.+B.+Costa&title=Acquired+resistance+to+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+in+non-small-cell+lung+cancers+dependent+on+the+epidermal+growth+factor+receptor+pathway&doi=10.3816%2FCLC.2009.n.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway</span></div><div class="casAuthors">Nguyen, Kim-Son H.; Kobayashi, Susumu; Costa, Daniel B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Lung Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">281-289</span>CODEN:
                <span class="NLM_cas:coden">CLCLCA</span>;
        ISSN:<span class="NLM_cas:issn">1525-7304</span>.
    
            (<span class="NLM_cas:orgname">CIG Media Group, LP</span>)
        </div><div class="casAbstract">A review.  Most advanced non-small-cell lung cancers (NSCLCs) with activating epidermal growth factor receptor (EGFR) mutations (exon 19 deletions or L858R) initially respond to the EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib.  However, over time (median of 6-12 mo), most tumors develop acquired resistance to EGFR TKIs.  Intense research in these NSCLCs has identified two major mechanisms of resistance to gefitinib/erlotinib: secondary resistance mutations and "oncogene kinase switch" systems.  The secondary T790M mutation occurs in 50% of EGFR-mutated patients with TKI resistance, and in vitro, this mutation negates the hypersensitivity of activating EGFR mutations.  Sensitive detection methods have identified a proportion of TKI-naive tumors that carry T790M, and these resistant clones may be selected after exposure to gefitinib or erlotinib.  Other secondary resistance mutations (D761Y, L747S, T854A) seem to be rare.  The amplification of the MET oncogene is present in 20% of TKI-resistant tumors; however, in half of the cases with this "oncogene kinase switch" mechanism the T790M is coexistent.  It is possible that other kinases (such as insulin-like growth factor-1 receptor [IGF-1R]) might also be selected to bypass EGFR pathways in resistant tumors.  The growing preclin. data in EGFR-mutated NSCLCs with acquired resistance to gefitinib or erlotinib has spawned the initiation or conception of clin. trials testing novel EGFR inhibitors that in vitro inhibit T790M (neratinib, XL647, BIBW 2992, and PF-00299804), MET, or IGF-1R inhibitors in combination with EGFR TKIs, and heat shock protein 90 inhibitors.  Ongoing preclin. and clin. research in EGFR-mutated NSCLC has the potential to significantly improve the outcomes of patients with these somatic mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzBC9bsn7YdrVg90H21EOLACvtfcHk0ljQFzbU-OIilw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVSms7bO&md5=3522508ea4f2761e4dcedea18d914fe7</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.3816%2FCLC.2009.n.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3816%252FCLC.2009.n.039%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DK.%2BS.%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26atitle%3DAcquired%2520resistance%2520to%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520in%2520non-small-cell%2520lung%2520cancers%2520dependent%2520on%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520pathway%26jtitle%3DClin.%2520Lung%2520Cancer%26date%3D2009%26volume%3D10%26spage%3D281%26epage%3D289%26doi%3D10.3816%2FCLC.2009.n.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Pines, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Köstler, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yarden, Y.</span><span> </span><span class="NLM_article-title">Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy</span> <span class="citation_source-journal">FEBS Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">584</span><span class="NLM_x">, </span> <span class="NLM_fpage">2699</span><span class="NLM_x">–</span> <span class="NLM_lpage">2706</span><span class="refDoi"> DOI: 10.1016/j.febslet.2010.04.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.febslet.2010.04.019" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=584&publication_year=2010&pages=2699-2706&author=G.+Pinesauthor=W.+J.+K%C3%B6stlerauthor=Y.+Yarden&title=Oncogenic+mutant+forms+of+EGFR%3A+lessons+in+signal+transduction+and+targets+for+cancer+therapy&doi=10.1016%2Fj.febslet.2010.04.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.febslet.2010.04.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.febslet.2010.04.019%26sid%3Dliteratum%253Aachs%26aulast%3DPines%26aufirst%3DG.%26aulast%3DK%25C3%25B6stler%26aufirst%3DW.%2BJ.%26aulast%3DYarden%26aufirst%3DY.%26atitle%3DOncogenic%2520mutant%2520forms%2520of%2520EGFR%253A%2520lessons%2520in%2520signal%2520transduction%2520and%2520targets%2520for%2520cancer%2520therapy%26jtitle%3DFEBS%2520Lett.%26date%3D2010%26volume%3D584%26spage%3D2699%26epage%3D2706%26doi%3D10.1016%2Fj.febslet.2010.04.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Sawai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandarlapaty, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arteaga, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D. B.</span><span> </span><span class="NLM_article-title">Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">589</span><span class="NLM_x">–</span> <span class="NLM_lpage">596</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-1570</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F0008-5472.CAN-07-1570" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=589-596&author=A.+Sawaiauthor=S.+Chandarlapatyauthor=H.+Greulichauthor=M.+Gonenauthor=Q.+Yeauthor=C.+L.+Arteagaauthor=W.+Sellersauthor=N.+Rosenauthor=D.+B.+Solit&title=Inhibition+of+Hsp90+down-regulates+mutant+epidermal+growth+factor+receptor+%28EGFR%29+expression+and+sensitizes+EGFR+mutant+tumors+to+paclitaxel&doi=10.1158%2F0008-5472.CAN-07-1570"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-1570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-1570%26sid%3Dliteratum%253Aachs%26aulast%3DSawai%26aufirst%3DA.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DGonen%26aufirst%3DM.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26aulast%3DSellers%26aufirst%3DW.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26atitle%3DInhibition%2520of%2520Hsp90%2520down-regulates%2520mutant%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520expression%2520and%2520sensitizes%2520EGFR%2520mutant%2520tumors%2520to%2520paclitaxel%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D589%26epage%3D596%26doi%3D10.1158%2F0008-5472.CAN-07-1570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liniker, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgman, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perera, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaghlul, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G.</span><span> </span><span class="NLM_article-title">Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">5827</span><span class="NLM_x">–</span> <span class="NLM_lpage">5838</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-5428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F0008-5472.CAN-07-5428" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=5827-5838&author=T.+Shimamuraauthor=D.+Liauthor=H.+Jiauthor=H.+J.+Haringsmaauthor=E.+Linikerauthor=C.+L.+Borgmanauthor=A.+M.+Lowellauthor=Y.+Minamiauthor=K.+McNamaraauthor=S.+A.+Pereraauthor=S.+Zaghlulauthor=R.+K.+Thomasauthor=H.+Greulichauthor=S.+Kobayashiauthor=L.+R.+Chirieacauthor=R.+F.+Paderaauthor=S.+Kuboauthor=M.+Takahashiauthor=D.+G.+Tenenauthor=M.+Meyersonauthor=K.-K.+Wongauthor=G.+Shapiro&title=Hsp90+inhibition+suppresses+mutant+EGFR-T790M+signaling+and+overcomes+kinase+inhibitor+resistance&doi=10.1158%2F0008-5472.CAN-07-5428"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-5428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-5428%26sid%3Dliteratum%253Aachs%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DLiniker%26aufirst%3DE.%26aulast%3DBorgman%26aufirst%3DC.%2BL.%26aulast%3DLowell%26aufirst%3DA.%2BM.%26aulast%3DMinami%26aufirst%3DY.%26aulast%3DMcNamara%26aufirst%3DK.%26aulast%3DPerera%26aufirst%3DS.%2BA.%26aulast%3DZaghlul%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DPadera%26aufirst%3DR.%2BF.%26aulast%3DKubo%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DShapiro%26aufirst%3DG.%26atitle%3DHsp90%2520inhibition%2520suppresses%2520mutant%2520EGFR-T790M%2520signaling%2520and%2520overcomes%2520kinase%2520inhibitor%2520resistance%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D5827%26epage%3D5838%26doi%3D10.1158%2F0008-5472.CAN-07-5428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Ying, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proia, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackman, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatsuta, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acquaviva, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barsoum, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koya, K.</span><span> </span><span class="NLM_article-title">Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">475</span><span class="NLM_x">–</span> <span class="NLM_lpage">484</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0755</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1535-7163.MCT-11-0755" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22144665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFWksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=475-484&author=W.+Yingauthor=Z.+Duauthor=L.+Sunauthor=K.+P.+Foleyauthor=D.+A.+Proiaauthor=R.+K.+Blackmanauthor=D.+Zhouauthor=T.+Inoueauthor=N.+Tatsutaauthor=J.+Sangauthor=S.+Yeauthor=J.+Acquavivaauthor=L.+S.+Ogawaauthor=Y.+Wadaauthor=J.+Barsoumauthor=K.+Koya&title=Ganetespib%2C+a+unique+triazolone-containing+Hsp90+inhibitor%2C+exhibits+potent+antitumor+activity+and+a+superior+safety+profile+for+cancer+therapy&doi=10.1158%2F1535-7163.MCT-11-0755"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy</span></div><div class="casAuthors">Ying, Weiwen; Du, Zhenjian; Sun, Lijun; Foley, Kevin P.; Proia, David A.; Blackman, Ronald K.; Zhou, Dan; Inoue, Takayo; Tatsuta, Noriaki; Sang, Jim; Ye, Shuxia; Acquaviva, Jamie; Ogawa, Luisa Shin; Wada, Yumiko; Barsoum, James; Koya, Keizo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">475-484</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Targeted inhibition of the mol. chaperone Hsp90 results in the simultaneous blockade of multiple oncogenic signaling pathways and has, thus, emerged as an attractive strategy for the development of novel cancer therapeutics.  Ganetespib (formerly known as STA-9090) is a unique resorcinolic triazolone inhibitor of Hsp90 that is currently in clin. trials for a no. of human cancers.  In the present study, we showed that ganetespib exhibits potent in vitro cytotoxicity in a range of solid and hematol. tumor cell lines, including those that express mutated kinases that confer resistance to small-mol. tyrosine kinase inhibitors.  Ganetespib treatment rapidly induced the degrdn. of known Hsp90 client proteins, displayed superior potency to the ansamycin inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG), and exhibited sustained activity even with short exposure times.  In vivo, ganetespib showed potent antitumor efficacy in solid and hematol. xenograft models of oncogene addiction, as evidenced by significant growth inhibition and/or regressions.  Notably, evaluation of the microregional activity of ganetespib in tumor xenografts showed that ganetespib was efficiently distributed throughout tumor tissue, including hypoxic regions >150 μm from the microvasculature, to inhibit proliferation and induce apoptosis.  Importantly, ganetespib showed no evidence of cardiac or liver toxicity.  Taken together, this preclin. activity profile indicates that ganetespib may have broad application for a variety of human malignancies, and with select mechanistic and safety advantages over other first- and second-generation Hsp90 inhibitors.  Mol Cancer Ther; 11(2); 475-84.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFhzG1TPr4lbVg90H21EOLACvtfcHk0ljQFzbU-OIilw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFWksrY%253D&md5=269d41b30e5add9b9503cb43a98b0157</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0755%26sid%3Dliteratum%253Aachs%26aulast%3DYing%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DFoley%26aufirst%3DK.%2BP.%26aulast%3DProia%26aufirst%3DD.%2BA.%26aulast%3DBlackman%26aufirst%3DR.%2BK.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DTatsuta%26aufirst%3DN.%26aulast%3DSang%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DS.%26aulast%3DAcquaviva%26aufirst%3DJ.%26aulast%3DOgawa%26aufirst%3DL.%2BS.%26aulast%3DWada%26aufirst%3DY.%26aulast%3DBarsoum%26aufirst%3DJ.%26aulast%3DKoya%26aufirst%3DK.%26atitle%3DGanetespib%252C%2520a%2520unique%2520triazolone-containing%2520Hsp90%2520inhibitor%252C%2520exhibits%2520potent%2520antitumor%2520activity%2520and%2520a%2520superior%2520safety%2520profile%2520for%2520cancer%2520therapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D475%26epage%3D484%26doi%3D10.1158%2F1535-7163.MCT-11-0755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Proia, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequeira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackman, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wada, Y.</span><span> </span><span class="NLM_article-title">Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2201</span><span class="NLM_x">–</span> <span class="NLM_lpage">2209</span><span class="refDoi"> DOI: 10.1007/s10637-011-9790-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1007%2Fs10637-011-9790-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=2201-2209&author=D.+A.+Proiaauthor=J.+Sangauthor=S.+Heauthor=D.+L.+Smithauthor=M.+Sequeiraauthor=C.+Zhangauthor=Y.+Liuauthor=S.+Yeauthor=D.+Zhouauthor=R.+K.+Blackmanauthor=K.+P.+Foleyauthor=K.+Koyaauthor=Y.+Wada&title=Synergistic+activity+of+the+Hsp90+inhibitor+ganetespib+with+taxanes+in+non-small+cell+lung+cancer+models&doi=10.1007%2Fs10637-011-9790-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1007%2Fs10637-011-9790-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-011-9790-6%26sid%3Dliteratum%253Aachs%26aulast%3DProia%26aufirst%3DD.%2BA.%26aulast%3DSang%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DD.%2BL.%26aulast%3DSequeira%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DBlackman%26aufirst%3DR.%2BK.%26aulast%3DFoley%26aufirst%3DK.%2BP.%26aulast%3DKoya%26aufirst%3DK.%26aulast%3DWada%26aufirst%3DY.%26atitle%3DSynergistic%2520activity%2520of%2520the%2520Hsp90%2520inhibitor%2520ganetespib%2520with%2520taxanes%2520in%2520non-small%2520cell%2520lung%2520cancer%2520models%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2012%26volume%3D30%26spage%3D2201%26epage%3D2209%26doi%3D10.1007%2Fs10637-011-9790-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Smith, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acquaviva, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequeira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimenez, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bates, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proia, D. A.</span><span> </span><span class="NLM_article-title">The Hsp90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer</span> <span class="citation_source-journal">Target Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">245</span><span class="refDoi"> DOI: 10.1007/s11523-014-0329-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1007%2Fs11523-014-0329-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=25077897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A280%3ADC%252BC2cbntlOktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=235-245&author=D.+L.+Smithauthor=J.+Acquavivaauthor=M.+Sequeiraauthor=J.+P.+Jimenezauthor=C.+Zhangauthor=J.+Sangauthor=R.+C.+Batesauthor=D.+A.+Proia&title=The+Hsp90+inhibitor+ganetespib+potentiates+the+antitumor+activity+of+EGFR+tyrosine+kinase+inhibition+in+mutant+and+wild-type+non-small+cell+lung+cancer&doi=10.1007%2Fs11523-014-0329-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer</span></div><div class="casAuthors">Smith Donald L; Acquaviva Jaime; Sequeira Manuel; Jimenez John-Paul; Zhang Chaohua; Sang Jim; Bates Richard C; Proia David A</div><div class="citationInfo"><span class="NLM_cas:title">Targeted oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">235-45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Small molecule inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase activity, such as erlotinib and gefitinib, revolutionized therapy for non-small cell lung cancer (NSCLC) patients whose tumors harbor activating EGFR mutations.  However, mechanisms to overcome the invariable development of acquired resistance to such agents, as well as realizing their full clinical potential within the context of wild-type EGFR (WT-EGFR) disease, remain to be established.  Here, the antitumor efficacy of targeted EGFR tyrosine kinase inhibitors (TKIs) and the HSP90 inhibitor ganetespib, alone and in combination, were evaluated in NSCLC.  Ganetespib potentiated the efficacy of erlotinib in TKI-sensitive, mutant EGFR-driven NCI-HCC827 xenograft tumors, with combination treatment causing significant tumor regressions.  In erlotinib-resistant NCI-H1975 xenografts, concurrent administration of ganetespib overcame erlotinib resistance to significantly improve tumor growth inhibition.  Ganetespib co-treatment also significantly enhanced antitumor responses to afatinib in the same model.  In WT-EGFR cell lines, ganetespib potently reduced cell viability.  In NCI-H1666 cells, ganetespib-induced loss of client protein expression, perturbation of oncogenic signaling pathways, and induction of apoptosis translated to robust single-agent activity in vivo.  Dual ganetespib/erlotinib therapy induced regressions in NCI-H322 xenograft tumors, indicating that the sensitizing properties of ganetespib for erlotinib were conserved within the WT-EGFR setting.  Mechanistically, combined ganetespib/erlotinib exposure stabilized EGFR protein levels in an inactive state and completely abrogated extracellular-signal-regulated kinase (ERK) and AKT signaling activity.  Thus, selective HSP90 blockade by ganetespib represents a potentially important complementary strategy to targeted TKI inhibition alone for inducing substantial antitumor responses and overcoming resistance, in both the mutant and WT-EGFR settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR7Z4-ACfup-svLc4ARHEmzfW6udTcc2eYyqv02u1J4ibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbntlOktg%253D%253D&md5=f198433a45b62102e3a9fb3e0a063f94</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1007%2Fs11523-014-0329-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-014-0329-6%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BL.%26aulast%3DAcquaviva%26aufirst%3DJ.%26aulast%3DSequeira%26aufirst%3DM.%26aulast%3DJimenez%26aufirst%3DJ.%2BP.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DSang%26aufirst%3DJ.%26aulast%3DBates%26aufirst%3DR.%2BC.%26aulast%3DProia%26aufirst%3DD.%2BA.%26atitle%3DThe%2520Hsp90%2520inhibitor%2520ganetespib%2520potentiates%2520the%2520antitumor%2520activity%2520of%2520EGFR%2520tyrosine%2520kinase%2520inhibition%2520in%2520mutant%2520and%2520wild-type%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DTarget%2520Oncol.%26date%3D2015%26volume%3D10%26spage%3D235%26epage%3D245%26doi%3D10.1007%2Fs11523-014-0329-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Rice, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barabasz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fadden, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steed, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S.</span><span> </span><span class="NLM_article-title">Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib</span> <span class="citation_source-journal">Oncol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">229</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span><span class="refDoi"> DOI: 10.3727/096504009X12596189659240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.3727%2F096504009X12596189659240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=20225761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivFaisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=229-242&author=J.+W.+Riceauthor=J.+M.+Vealauthor=A.+Barabaszauthor=B.+Foleyauthor=P.+Faddenauthor=A.+Scottauthor=K.+Huangauthor=P.+Steedauthor=S.+Hall&title=Targeting+of+multiple+signaling+pathways+by+the+Hsp90+inhibitor+SNX-2112+in+EGFR+resistance+models+as+a+single+agent+or+in+combination+with+erlotinib&doi=10.3727%2F096504009X12596189659240"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib</span></div><div class="casAuthors">Rice, John W.; Veal, James M.; Barabasz, Amy; Foley, Briana; Fadden, Patrick; Scott, Anisa; Huang, Ken; Steed, Paul; Hall, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5/6</span>),
    <span class="NLM_cas:pages">229-242</span>CODEN:
                <span class="NLM_cas:coden">ONREE8</span>;
        ISSN:<span class="NLM_cas:issn">0965-0407</span>.
    
            (<span class="NLM_cas:orgname">Cognizant Communications Corp.</span>)
        </div><div class="casAbstract">Inhibition of Hsp90 has emerged as a therapeutic strategy to target NSCLC subtypes, which are refractory to epidermal growth factor receptor (EGFR) inhibitor-based treatment.  We report on a novel small mol. inhibitor of Hsp90, SNX-2112, and an orally bioavailable prodrug analog, SNX-5422.  In cellular models of wild-type or mutant EGFR (L858R and T790M mutations), SNX-2112 alone and in combination with erlotinib inhibited EGF activation of pAKT(473) and pSTAT3(705).  PERK1/2 and pS6 were also potently inhibited by similar treatments.  SNX-2112 reduced EGF cross-talk and activation of the c-Met receptor by causing c-Met degrdn.  In NCI-H1975 xenograft models, SNX-5422 showed activity as a single agent and in combination with erlotinib resulted in prolonged animal survival at reduced compd. concns. relative to either compd. alone.  These results support the advanced evaluation of SNX-5422 as a treatment for non-small cell lung cancer (NSCLC), esp. in cases where the cancer is driven by c-Met amplification or mutated EGFR forms that are resistant to EGFR inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFgrvd_hLObbVg90H21EOLACvtfcHk0lgHjqycUhrwew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivFaisr8%253D&md5=30c4a56819cd7f368dd61b7f61ca9c63</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.3727%2F096504009X12596189659240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3727%252F096504009X12596189659240%26sid%3Dliteratum%253Aachs%26aulast%3DRice%26aufirst%3DJ.%2BW.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DBarabasz%26aufirst%3DA.%26aulast%3DFoley%26aufirst%3DB.%26aulast%3DFadden%26aufirst%3DP.%26aulast%3DScott%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DK.%26aulast%3DSteed%26aufirst%3DP.%26aulast%3DHall%26aufirst%3DS.%26atitle%3DTargeting%2520of%2520multiple%2520signaling%2520pathways%2520by%2520the%2520Hsp90%2520inhibitor%2520SNX-2112%2520in%2520EGFR%2520resistance%2520models%2520as%2520a%2520single%2520agent%2520or%2520in%2520combination%2520with%2520erlotinib%26jtitle%3DOncol.%2520Res.%26date%3D2009%26volume%3D18%26spage%3D229%26epage%3D242%26doi%3D10.3727%2F096504009X12596189659240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Ono, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mio, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondoh, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, Y.</span><span> </span><span class="NLM_article-title">Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">1346</span><span class="NLM_x">–</span> <span class="NLM_lpage">1352</span><span class="refDoi"> DOI: 10.1111/cas.12237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1111%2Fcas.12237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=23863134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFOgs7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2013&pages=1346-1352&author=N.+Onoauthor=T.+Yamazakiauthor=T.+Tsukaguchiauthor=T.+Fujiiauthor=K.+Sakataauthor=A.+Sudaauthor=T.+Tsukudaauthor=T.+Mioauthor=N.+Ishiiauthor=O.+Kondohauthor=Y.+Aoki&title=Enhanced+antitumor+activity+of+erlotinib+in+combination+with+the+Hsp90+inhibitor+CH5164840+against+non-small-cell+lung+cancer&doi=10.1111%2Fcas.12237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer</span></div><div class="casAuthors">Ono, Naomi; Yamazaki, Toshikazu; Tsukaguchi, Toshiyuki; Fujii, Toshihiko; Sakata, Kiyoaki; Suda, Atsushi; Tsukuda, Takuo; Mio, Toshiyuki; Ishii, Nobuya; Kondoh, Osamu; Aoki, Yuko</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1346-1352</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Inhibition of heat shock protein 90 (Hsp90) can lead to degrdn. of multiple client proteins, which are involved in tumor progression.  Epidermal growth factor receptor (EGFR) is one of the most potent oncogenic client proteins of Hsp90.  Targeted inhibition of EGFR has shown clin. efficacy in the treatment of patients with non-small-cell lung cancer (NSCLC).  However, primary and acquired resistance to the existing EGFR inhibitors is a major clin. problem.  In the present study, we investigated the effect of the novel Hsp90 inhibitor CH5164840 on the antitumor activity of erlotinib.  The NSCLC cell lines and xenograft models were treated with CH5164840 and erlotinib to examine their mechanisms of action and cell growth inhibition.  We found that CH5164840 showed remarkable antitumor activity against NSCLC cell lines and xenograft models.  The addn. of CH5164840 enhanced the antitumor activity of erlotinib against NCI-H292 EGFR-overexpressing xenograft models.  Phosphorylation of Stat3 increased with erlotinib treatment in NCI-H292 cells, which was abrogated by Hsp90 inhibition.  Furthermore, in a NCI-H1975 T790M mutation erlotinib-resistant model, CH5164840 enhanced the antitumor activity of erlotinib despite the low efficacy of erlotinib treatment alone.  In addn., ERK signaling was effectively suppressed by combination treatment with erlotinib and CH5164840 in a NCI-H1975 erlotinib-resistant model.  Taken together, these data indicate that CH5164840 has potent antitumor activity and is highly effective in combination with erlotinib against NSCLC tumors with EGFR overexpression and mutations.  Our results support the therapeutic potential of CH5164840 as a Hsp90 inhibitor for combination therapy with EGFR-targeting agents against EGFR-addicted NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3CT9qZgpeRrVg90H21EOLACvtfcHk0ljfff92Mou20Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFOgs7rL&md5=c967fa4d51e33b73e5eee8a668ede13f</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1111%2Fcas.12237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.12237%26sid%3Dliteratum%253Aachs%26aulast%3DOno%26aufirst%3DN.%26aulast%3DYamazaki%26aufirst%3DT.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DFujii%26aufirst%3DT.%26aulast%3DSakata%26aufirst%3DK.%26aulast%3DSuda%26aufirst%3DA.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DMio%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DKondoh%26aufirst%3DO.%26aulast%3DAoki%26aufirst%3DY.%26atitle%3DEnhanced%2520antitumor%2520activity%2520of%2520erlotinib%2520in%2520combination%2520with%2520the%2520Hsp90%2520inhibitor%2520CH5164840%2520against%2520non-small-cell%2520lung%2520cancer%26jtitle%3DCancer%2520Sci.%26date%3D2013%26volume%3D104%26spage%3D1346%26epage%3D1352%26doi%3D10.1111%2Fcas.12237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Hong, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeong, C. H.</span><span> </span><span class="NLM_article-title">Hsp90 inhibition by WK88–1 potently suppresses the growth of gefitinib-resistant H1975 cells harboring the T790M mutation in EGFR</span> <span class="citation_source-journal">Oncol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">2619</span><span class="NLM_x">–</span> <span class="NLM_lpage">2624</span><span class="refDoi"> DOI: 10.3892/or.2014.3161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.3892%2For.2014.3161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=24789511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFKksbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2014&pages=2619-2624&author=Y.+S.+Hongauthor=W.+J.+Jangauthor=K.+S.+Chunauthor=C.+H.+Jeong&title=Hsp90+inhibition+by+WK88%E2%80%931+potently+suppresses+the+growth+of+gefitinib-resistant+H1975+cells+harboring+the+T790M+mutation+in+EGFR&doi=10.3892%2For.2014.3161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 inhibition by WK88-1 potently suppresses the growth of gefitinib-resistant H1975 cells harboring the T790M mutation in EGFR</span></div><div class="casAuthors">Hong, Young-Soo; Jang, Won-Jun; Chun, Kyung-Soo; Jeong, Chul-Ho</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2619-2624</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) is a mol. chaperone for numerous client proteins, many of which are crucial for the pathogenesis of non-small cell lung cancers (NSCLCs).  To date, therapeutic approaches using epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib or erlotinib for the treatment of NSCLCs have been limited due to the emergence of acquired drug resistance mainly mediated by a secondary T790M mutation in EGFR.  Considering this, Hsp90 inhibition seems promising as it leads to overall degrdn. of the oncogenic EGFR family proteins.  In this regard, the present study provides the preclin. basis for a new Hsp90 inhibitor, WK88-1, for the treatment of NSCLCs harboring the T790M mutation in EGFR.  Our data revealed that inhibition of Hsp90 by WK88-1 induced overall degrdn. of multiple oncogenic signaling mols. including EGFR, ErbB2 and ErbB3, leading to subsequent growth arrest and apoptosis in the gefitinib-resistant H1975 cell line.  In addn., treatment with WK88-1 markedly inhibited proliferation, migration and invasion in H1975 cells.  Moreover, an in vivo xenograft assay indicated that WK88-1 markedly suppressed tumor growth in the H1975 xenografts, highlighting the potential efficacy of WK88-1 for overcoming gefitinib resistance in NSCLCs harboring the T790M mutation in EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBz7z9J02-drVg90H21EOLACvtfcHk0ljfff92Mou20Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFKksbbN&md5=c00bebb182c68a267bccf268fd1e81bf</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.3892%2For.2014.3161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2014.3161%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DY.%2BS.%26aulast%3DJang%26aufirst%3DW.%2BJ.%26aulast%3DChun%26aufirst%3DK.%2BS.%26aulast%3DJeong%26aufirst%3DC.%2BH.%26atitle%3DHsp90%2520inhibition%2520by%2520WK88%25E2%2580%25931%2520potently%2520suppresses%2520the%2520growth%2520of%2520gefitinib-resistant%2520H1975%2520cells%2520harboring%2520the%2520T790M%2520mutation%2520in%2520EGFR%26jtitle%3DOncol.%2520Rep.%26date%3D2014%26volume%3D31%26spage%3D2619%26epage%3D2624%26doi%3D10.3892%2For.2014.3161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group">Kobayashi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyooka, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dote, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawasaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyoshi, S.</span><span> </span><span class="NLM_article-title">The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor</span> <span class="citation_source-journal">Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">166</span><span class="refDoi"> DOI: 10.1016/j.lungcan.2011.04.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.lungcan.2011.04.022" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2012&pages=161-166&author=N.+Kobayashiauthor=S.+Toyookaauthor=J.+Sohauthor=H.+Yamamotoauthor=H.+Doteauthor=K.+Kawasakiauthor=H.+Otaniauthor=T.+Kuboauthor=M.+Jidaauthor=T.+Uenoauthor=M.+Andoauthor=A.+Oginoauthor=K.+Kiuraauthor=S.+Miyoshi&title=The+anti-proliferative+effect+of+heat+shock+protein+90+inhibitor%2C+17-DMAG%2C+on+non-small-cell+lung+cancers+being+resistant+to+EGFR+tyrosine+kinase+inhibitor&doi=10.1016%2Fj.lungcan.2011.04.022"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2011.04.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2011.04.022%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DN.%26aulast%3DToyooka%26aufirst%3DS.%26aulast%3DSoh%26aufirst%3DJ.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DDote%26aufirst%3DH.%26aulast%3DKawasaki%26aufirst%3DK.%26aulast%3DOtani%26aufirst%3DH.%26aulast%3DKubo%26aufirst%3DT.%26aulast%3DJida%26aufirst%3DM.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DM.%26aulast%3DOgino%26aufirst%3DA.%26aulast%3DKiura%26aufirst%3DK.%26aulast%3DMiyoshi%26aufirst%3DS.%26atitle%3DThe%2520anti-proliferative%2520effect%2520of%2520heat%2520shock%2520protein%252090%2520inhibitor%252C%252017-DMAG%252C%2520on%2520non-small-cell%2520lung%2520cancers%2520being%2520resistant%2520to%2520EGFR%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DLung%2520Cancer%26date%3D2012%26volume%3D75%26spage%3D161%26epage%3D166%26doi%3D10.1016%2Fj.lungcan.2011.04.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">Hashida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shien, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtsuka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furukawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyoshi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanazawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyooka, S.</span><span> </span><span class="NLM_article-title">Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors</span> <span class="citation_source-journal">Oncol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1499</span><span class="NLM_x">–</span> <span class="NLM_lpage">1504</span><span class="refDoi"> DOI: 10.3892/or.2015.3735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.3892%2For.2015.3735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=25607753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A280%3ADC%252BC2MvotVyruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=1499-1504&author=S.+Hashidaauthor=H.+Yamamotoauthor=K.+Shienauthor=T.+Ohtsukaauthor=K.+Suzawaauthor=Y.+Makiauthor=M.+Furukawaauthor=J.+Sohauthor=H.+Asanoauthor=K.+Tsukudaauthor=S.+Miyoshiauthor=S.+Kanazawaauthor=S.+Toyooka&title=Hsp90+inhibitor+NVP-AUY922+enhances+the+radiation+sensitivity+of+lung+cancer+cell+lines+with+acquired+resistance+to+EGFR-tyrosine+kinase+inhibitors&doi=10.3892%2For.2015.3735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors</span></div><div class="casAuthors">Hashida Shinsuke; Yamamoto Hiromasa; Shien Kazuhiko; Ohtsuka Tomoaki; Suzawa Ken; Maki Yuho; Furukawa Masashi; Soh Junichi; Asano Hiroaki; Tsukuda Kazunori; Miyoshi Shinichiro; Toyooka Shinichi; Kanazawa Susumu</div><div class="citationInfo"><span class="NLM_cas:title">Oncology reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1499-504</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) is a critical issue that needs to be overcome in the treatment of patients with non-small cell lung cancer (NSCLC) harboring EGFR activating mutations.  EGFR and AKT are client proteins of the 90-kDa heat shock protein (Hsp90).  Therefore, it was hypothesized that the use of Hsp90 inhibitors might allow the resistance to EGFR-TKIs to be overcome.  Furthermore, Hsp90 inhibitors are known to function as radiosensitizers in various types of cancer.  In the present study, we evaluated the radiosensitizing effect of the novel Hsp90 inhibitor, NVP-AUY922 (AUY), on NSCLC cell lines harboring EGFR activating mutations and showing acquired resistance to EGFR-TKIs via any of several mechanisms.  We used HCC827 and PC-9, which are NSCLC cell lines harboring EGFR exon 19 deletions, and gefitinib-resistant sublines derived from the same cell lines with T790M mutation, MET amplification or stem-cell like properties.  AUY was more effective against the gefitinib-resistant sublines with T790M mutation and MET amplification than against the parental cell lines, although the subline with stem cell-like properties showed more than a 10-fold higher resistance to AUY than the parental cell line.  AUY exerted a significant radiosensitizing effect on the parental cell line and the MET-amplified subline through inducing G2/M arrest and inhibition of non-homologous end joining (NHEJ).  In contrast, the radiosensitizing effect of AUY was limited on the subline with stem cell-like properties, in which it did not induce G2/M arrest or inhibition of NHEJ.  In conclusion, combined inhibition of Hsp90 plus radiation was effective, and therefore a promising treatment alternative for overcoming major EGFR-TKI resistance, such as that induced by T790M mutation or MET amplification.  However, other approaches are required to overcome minor resistance to EGFR-TKIs, such as that observed in cells with stem cell-like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQr_6qrIy_OsApJitSxOdIlfW6udTcc2eaA-gRSzAwLh7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvotVyruw%253D%253D&md5=6bc40e1827240f1c4a0384bf7e297aaf</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.3892%2For.2015.3735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2015.3735%26sid%3Dliteratum%253Aachs%26aulast%3DHashida%26aufirst%3DS.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DShien%26aufirst%3DK.%26aulast%3DOhtsuka%26aufirst%3DT.%26aulast%3DSuzawa%26aufirst%3DK.%26aulast%3DMaki%26aufirst%3DY.%26aulast%3DFurukawa%26aufirst%3DM.%26aulast%3DSoh%26aufirst%3DJ.%26aulast%3DAsano%26aufirst%3DH.%26aulast%3DTsukuda%26aufirst%3DK.%26aulast%3DMiyoshi%26aufirst%3DS.%26aulast%3DKanazawa%26aufirst%3DS.%26aulast%3DToyooka%26aufirst%3DS.%26atitle%3DHsp90%2520inhibitor%2520NVP-AUY922%2520enhances%2520the%2520radiation%2520sensitivity%2520of%2520lung%2520cancer%2520cell%2520lines%2520with%2520acquired%2520resistance%2520to%2520EGFR-tyrosine%2520kinase%2520inhibitors%26jtitle%3DOncol.%2520Rep.%26date%3D2015%26volume%3D33%26spage%3D1499%26epage%3D1504%26doi%3D10.3892%2For.2015.3735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group">Koizumi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, S.</span><span> </span><span class="NLM_article-title">Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1078</span><span class="NLM_x">–</span> <span class="NLM_lpage">1085</span><span class="refDoi"> DOI: 10.1097/JTO.0b013e3182519a2c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1097%2FJTO.0b013e3182519a2c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22592212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1aisb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1078-1085&author=H.+Koizumiauthor=T.+Yamadaauthor=S.+Takeuchiauthor=T.+Nakagawaauthor=K.+Kitaauthor=T.+Nakamuraauthor=K.+Matsumotoauthor=K.+Sudaauthor=T.+Mitsudomiauthor=S.+Yano&title=Hsp90+inhibition+overcomes+HGF-triggering+resistance+to+EGFR-TKIs+in+EGFR-mutant+lung+cancer+by+decreasing+client+protein+expression+and+angiogenesis&doi=10.1097%2FJTO.0b013e3182519a2c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis</span></div><div class="casAuthors">Koizumi, Hitomi; Yamada, Tadaaki; Takeuchi, Shinji; Nakagawa, Takayuki; Kita, Kenji; Nakamura, Takahiro; Matsumoto, Kunio; Suda, Kenichi; Mitsudomi, Tetsuya; Yano, Seiji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1078-1085</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-0864</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Introduction: The three major clin. relevant mechanisms of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR mutant lung cancer are a second mutation in the EGFR gene (T790M), Met amplification, and increased expression of hepatocyte growth factor (HGF).  Heat shock protein90 (Hsp90) is a 90 kDa mol. chaperone for proteins that include EGFR, Met, and echinoderm microtubule-assocd. proetin-like-4-the anaplastic lymphoma kinase.  Here, we detd. whether inhibition of Hsp90 could overcome HGF-triggered EGFR-TKI resistance in EGFR mutant lung cancer cells.  Methods: The effects of the Hsp90 inhibitor 17-demethoxygeldanamycin (17-DMAG) on the growth of lung cancer cells resistant to the EGFR-TKI were examd. in the presence and absence of HGF, and in cells transfected with the HGF gene in vitro and in vivo.  Results: EGFR-TKI erlotinib did not inhibit the growth of HGF-gene transfected Ma-1 (Ma-1/HGF) cells and H1975 cells, contg. the EGFR L858R and T790M mutations, resp.  Erlotinib also did not inhibit the growth of PC-9 and Ma-1 cells, with deletions in EGFR exon19, in the presence of HGF.  However, 17-DMAG induced apoptosis and markedly inhibited the growth of these cell lines, even in the presence of HGF.  This inhibition by 17-DMAG was assocd. with decreased expression of EGFR and Met in tumor cells.  An in vivo model of HGF-triggered erlotinib-resistance, which used Ma-1/HGF cells, showed that 17-DMAG markedly suppressed tumor growth by decreasing angiogenesis and increasing apoptosis.  Conclusions: Hsp90 inhibitors may overcome HGF-triggered resistance to EGFR-TKIs and may result in more successful treatment of patients with EGFR-mutant lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ_uwltpW9ErVg90H21EOLACvtfcHk0lg-KAj2PT2Gfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1aisb%252FE&md5=49990a4e0826d5ae6629c8dfac7e4ea3</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1097%2FJTO.0b013e3182519a2c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0b013e3182519a2c%26sid%3Dliteratum%253Aachs%26aulast%3DKoizumi%26aufirst%3DH.%26aulast%3DYamada%26aufirst%3DT.%26aulast%3DTakeuchi%26aufirst%3DS.%26aulast%3DNakagawa%26aufirst%3DT.%26aulast%3DKita%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DSuda%26aufirst%3DK.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DYano%26aufirst%3DS.%26atitle%3DHsp90%2520inhibition%2520overcomes%2520HGF-triggering%2520resistance%2520to%2520EGFR-TKIs%2520in%2520EGFR-mutant%2520lung%2520cancer%2520by%2520decreasing%2520client%2520protein%2520expression%2520and%2520angiogenesis%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2012%26volume%3D7%26spage%3D1078%26epage%3D1085%26doi%3D10.1097%2FJTO.0b013e3182519a2c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group">Ramalingam, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaric, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceric, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poddubskaya, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciuleanu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khuri, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spicer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skrylnik, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manegold, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andric, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badovinac, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pieters, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modiano, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vukovic, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yalcin, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teofilovici, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">EI-Hariry, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahcall, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goss, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fennell, D.</span><span> </span><span class="NLM_article-title">GALAXY-1: randomized phase II study of docetaxel with or without ganetespib in advanced lung adenocarcinoma: results in biomarker sub-groups and all adenocarcinoma patients</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">S139</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=S139&author=S.+S.+Ramalingamauthor=G+Shapiroauthor=V.+Hirshauthor=B.+Zaricauthor=T.+Cericauthor=E.+Poddubskayaauthor=J.+Goldmanauthor=T.+Ciuleanuauthor=F.+R.+Khuriauthor=J.+Spicerauthor=O.+Skrylnikauthor=E.+Felipauthor=C.+Manegoldauthor=Z.+Andricauthor=R.+Rosellauthor=S.+Badovinacauthor=T.+Pietersauthor=M.+R.+Modianoauthor=V.+M.+Vukovicauthor=I.+Yalcinauthor=F.+Teofiloviciauthor=I.+EI-Hariryauthor=W.+Guoauthor=S.+R.+Bahcallauthor=G.+Gossauthor=D.+Fennell&title=GALAXY-1%3A+randomized+phase+II+study+of+docetaxel+with+or+without+ganetespib+in+advanced+lung+adenocarcinoma%3A+results+in+biomarker+sub-groups+and+all+adenocarcinoma+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DShapiro%26aufirst%3DG%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DZaric%26aufirst%3DB.%26aulast%3DCeric%26aufirst%3DT.%26aulast%3DPoddubskaya%26aufirst%3DE.%26aulast%3DGoldman%26aufirst%3DJ.%26aulast%3DCiuleanu%26aufirst%3DT.%26aulast%3DKhuri%26aufirst%3DF.%2BR.%26aulast%3DSpicer%26aufirst%3DJ.%26aulast%3DSkrylnik%26aufirst%3DO.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DManegold%26aufirst%3DC.%26aulast%3DAndric%26aufirst%3DZ.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DBadovinac%26aufirst%3DS.%26aulast%3DPieters%26aufirst%3DT.%26aulast%3DModiano%26aufirst%3DM.%2BR.%26aulast%3DVukovic%26aufirst%3DV.%2BM.%26aulast%3DYalcin%26aufirst%3DI.%26aulast%3DTeofilovici%26aufirst%3DF.%26aulast%3DEI-Hariry%26aufirst%3DI.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DBahcall%26aufirst%3DS.%2BR.%26aulast%3DGoss%26aufirst%3DG.%26aulast%3DFennell%26aufirst%3DD.%26atitle%3DGALAXY-1%253A%2520randomized%2520phase%2520II%2520study%2520of%2520docetaxel%2520with%2520or%2520without%2520ganetespib%2520in%2520advanced%2520lung%2520adenocarcinoma%253A%2520results%2520in%2520biomarker%2520sub-groups%2520and%2520all%2520adenocarcinoma%2520patients%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2013%26volume%3D8%26spage%3DS139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group">Garon, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlesi, F.</span><span> </span><span class="NLM_article-title">Phase II study of the Hsp90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">S7543</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=S7543&author=E.+B.+Garonauthor=T.+Moranauthor=F.+Barlesi&title=Phase+II+study+of+the+Hsp90+inhibitor+AUY922+in+patients+with+previously+treated%2C+advanced+non-small+cell+lung+cancer+%28NSCLC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGaron%26aufirst%3DE.%2BB.%26aulast%3DMoran%26aufirst%3DT.%26aulast%3DBarlesi%26aufirst%3DF.%26atitle%3DPhase%2520II%2520study%2520of%2520the%2520Hsp90%2520inhibitor%2520AUY922%2520in%2520patients%2520with%2520previously%2520treated%252C%2520advanced%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3DS7543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group">Johnson, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weitner, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rademaker, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span> </span><span class="NLM_article-title">Phase I/II study of Hsp90 inhibitor AUY922 and erlotinib for EGFR-mutant lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1666</span><span class="NLM_x">–</span> <span class="NLM_lpage">1673</span><span class="refDoi"> DOI: 10.1200/JCO.2014.59.7328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1200%2FJCO.2014.59.7328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=25870087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFarsLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=1666-1673&author=M.+L.+Johnsonauthor=H.+A.+Yuauthor=E.+M.+Hartauthor=B.+B.+Weitnerauthor=A.+W.+Rademakerauthor=J.+D.+Patelauthor=M.+G.+Krisauthor=G.+J.+Riely&title=Phase+I%2FII+study+of+Hsp90+inhibitor+AUY922+and+erlotinib+for+EGFR-mutant+lung+cancer+with+acquired+resistance+to+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors&doi=10.1200%2FJCO.2014.59.7328"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I/II study of HSP90 inhibitor AUY922 and erlotinib for EGFR-mutant lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors</span></div><div class="casAuthors">Johnson, Melissa L.; Yu, Helena A.; Hart, Eric M.; Weitner, Bing Bing; Rademaker, Alfred W.; Patel, Jyoti D.; Kris, Mark G.; Riely, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1666-1673</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose AUY922 is an HSP90 inhibitor that causes degrdn. of HSP chaperones and their client proteins, including epidermal growth factor receptor.  We conducted a phase I/II trial to evaluate AUY922 and erlotinib for patients with EGFR-mutant lung cancer and disease progression during erlotinib treatment.  Patients and Methods All patients had developed acquired resistance after treatment with erlotinib and underwent repeat tumor biopsies before study entry to assess for EGFR T790M.  In phase I, 18 patients were treated with AUY922 i.v. once per wk and erlotinib once per day in 28-day cycles using a 3 + 3 dose-escalation design.  In phase II, 19 addnl. patients were treated at the max.-tolerated dose.  The primary end point of the phase II trial was complete plus partial response rate.  Results In phase I (n = 18), three patients were treated in each cohort, except the highest-dose cohort (AUY922 70 mg and erlotinib 150 mg), which expanded to six patients because of a dose-limiting toxicity (ie, junctional cardiac rhythm).  Common drug-related adverse events were diarrhea, skin rash, hyperglycemia, and night blindness.  All patients treated at max.-tolerated dose (n = 25) were evaluable for response.  The partial response rate was 16% (four of 25 patients; 95% CI, 5% to 36%) and was independent of tumor T790M status.  Conclusion Partial responses were obsd., but the duration of treatment with AUY922 and erlotinib was limited by toxicities, esp. night blindness.  This phase II study of AUY922 and erlotinib did not meet its primary end point.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWsVjdo4lIfrVg90H21EOLACvtfcHk0lg9QcW9lX8UPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFarsLnM&md5=807c3e61ee5babe4c8994fd69e8888a4</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.59.7328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.59.7328%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DM.%2BL.%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DHart%26aufirst%3DE.%2BM.%26aulast%3DWeitner%26aufirst%3DB.%2BB.%26aulast%3DRademaker%26aufirst%3DA.%2BW.%26aulast%3DPatel%26aufirst%3DJ.%2BD.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26atitle%3DPhase%2520I%252FII%2520study%2520of%2520Hsp90%2520inhibitor%2520AUY922%2520and%2520erlotinib%2520for%2520EGFR-mutant%2520lung%2520cancer%2520with%2520acquired%2520resistance%2520to%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D1666%26epage%3D1673%26doi%3D10.1200%2FJCO.2014.59.7328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Johnson, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rademaker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weitner, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simm, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fountas, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worden, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span> </span><span class="NLM_article-title">A phase II study of Hsp90 inhibitor AUY922 and erlotinib (E) for patients (pts) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">S8036</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=S8036&author=M.+L.+Johnsonauthor=E.+M.+Hartauthor=A.+Rademakerauthor=B.+B.+Weitnerauthor=A.+Urmanauthor=H.+D.+Simmauthor=L.+M.+Fountasauthor=R.+Wordenauthor=J.+D.+Patelauthor=V.+A.+Millerauthor=G.+J.+Riely&title=A+phase+II+study+of+Hsp90+inhibitor+AUY922+and+erlotinib+%28E%29+for+patients+%28pts%29+with+EGFR-mutant+lung+cancer+and+acquired+resistance+%28AR%29+to+EGFR+tyrosine+kinase+inhibitors+%28EGFR+TKIs%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DM.%2BL.%26aulast%3DHart%26aufirst%3DE.%2BM.%26aulast%3DRademaker%26aufirst%3DA.%26aulast%3DWeitner%26aufirst%3DB.%2BB.%26aulast%3DUrman%26aufirst%3DA.%26aulast%3DSimm%26aufirst%3DH.%2BD.%26aulast%3DFountas%26aufirst%3DL.%2BM.%26aulast%3DWorden%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DJ.%2BD.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520Hsp90%2520inhibitor%2520AUY922%2520and%2520erlotinib%2520%2528E%2529%2520for%2520patients%2520%2528pts%2529%2520with%2520EGFR-mutant%2520lung%2520cancer%2520and%2520acquired%2520resistance%2520%2528AR%2529%2520to%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%2520%2528EGFR%2520TKIs%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3DS8036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Yu, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rademaker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weitner, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G.</span><span> </span><span class="NLM_article-title">A phase II study of Hsp90 inhibitor AUY922 and erlotinib (E) in patients with EGFR-mutant lung cancer and acquired resistance to EGFR tyrosine kinase inhibitors</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">S596</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=S596&author=H.+A.+Yuauthor=M.+L.+Johnsonauthor=A.+Urmanauthor=A.+Rademakerauthor=E.+Hartauthor=B.+B.+Weitnerauthor=J.+D.+Patelauthor=M.+Krisauthor=G.+Riely&title=A+phase+II+study+of+Hsp90+inhibitor+AUY922+and+erlotinib+%28E%29+in+patients+with+EGFR-mutant+lung+cancer+and+acquired+resistance+to+EGFR+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DJohnson%26aufirst%3DM.%2BL.%26aulast%3DUrman%26aufirst%3DA.%26aulast%3DRademaker%26aufirst%3DA.%26aulast%3DHart%26aufirst%3DE.%26aulast%3DWeitner%26aufirst%3DB.%2BB.%26aulast%3DPatel%26aufirst%3DJ.%2BD.%26aulast%3DKris%26aufirst%3DM.%26aulast%3DRiely%26aufirst%3DG.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520Hsp90%2520inhibitor%2520AUY922%2520and%2520erlotinib%2520%2528E%2529%2520in%2520patients%2520with%2520EGFR-mutant%2520lung%2520cancer%2520and%2520acquired%2520resistance%2520to%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2013%26volume%3D8%26spage%3DS596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Catalanotti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D. B.</span><span> </span><span class="NLM_article-title">Will Hsp90 inhibitors prove effective in BRAF-mutant melanomas?</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2420</span><span class="NLM_x">–</span> <span class="NLM_lpage">2422</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-0626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1078-0432.CCR-12-0626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22442059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsFejtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2420-2422&author=F.+Catalanottiauthor=D.+B.+Solit&title=Will+Hsp90+inhibitors+prove+effective+in+BRAF-mutant+melanomas%3F&doi=10.1158%2F1078-0432.CCR-12-0626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Will Hsp90 Inhibitors Prove Effective in BRAF-Mutant Melanomas?</span></div><div class="casAuthors">Catalanotti, Federica; Solit, David B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2420-2422</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The RAF inhibitor vemurafenib has unprecedented activity in BRAF-mutant melanomas, but resistance invariably develops.  As Hsp90 is required for the stability of several of the oncoproteins that mediate RAF inhibitor resistance, inhibitors of this cellular chaperone may be effective in patients with intrinsic or acquired resistance to RAF inhibitors.  Clin Cancer Res; 18(9); 2420-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwnY0Rm7HJq7Vg90H21EOLACvtfcHk0lg9QcW9lX8UPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsFejtb4%253D&md5=3f771f2ea4b2e14a35243bbd7dd54f79</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0626%26sid%3Dliteratum%253Aachs%26aulast%3DCatalanotti%26aufirst%3DF.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26atitle%3DWill%2520Hsp90%2520inhibitors%2520prove%2520effective%2520in%2520BRAF-mutant%2520melanomas%253F%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D2420%26epage%3D2422%26doi%3D10.1158%2F1078-0432.CCR-12-0626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">Paraiso, K. H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haarberg, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rebecca, V. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sondak, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">John, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarnaik, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koomen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smalley, K. S. M.</span><span> </span><span class="NLM_article-title">The Hsp90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2502</span><span class="NLM_x">–</span> <span class="NLM_lpage">2514</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-2612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1078-0432.CCR-11-2612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22351686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsFeju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2502-2514&author=K.+H.+T.+Paraisoauthor=H.+E.+Haarbergauthor=E.+Woodauthor=V.+W.+Rebeccaauthor=Y.+A.+Chenauthor=Y.+Xiangauthor=A.+Ribasauthor=R.+S.+Loauthor=J.+S.+Weberauthor=V.+K.+Sondakauthor=J.+K.+Johnauthor=A.+A.+Sarnaikauthor=J.+M.+Koomenauthor=K.+S.+M.+Smalley&title=The+Hsp90+inhibitor+XL888+overcomes+BRAF+inhibitor+resistance+mediated+through+diverse+mechanisms&doi=10.1158%2F1078-0432.CCR-11-2612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms</span></div><div class="casAuthors">Paraiso, Kim H. T.; Haarberg, H. Eirik; Wood, Elizabeth; Rebecca, Vito W.; Chen, Y. Ann; Xiang, Yun; Ribas, Antoni; Lo, Roger S.; Weber, Jeffrey S.; Sondak, Vernon K.; John, Jobin K.; Sarnaik, Amod A.; Koomen, John M.; Smalley, Keiran S. M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2502-2514</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: The clin. use of BRAF inhibitors is being hampered by the acquisition of drug resistance.  This study shows the potential therapeutic use of the HSP90 inhibitor (XL888) in six different models of vemurafenib resistance.  Exptl. Design: The ability of XL888 to inhibit growth and to induce apoptosis and tumor regression of vemurafenib-resistant melanoma cell lines was shown in vitro and in vivo.  A novel mass spectrometry-based pharmacodynamic assay was developed to measure intratumoral HSP70 levels following HSP90 inhibition in melanoma cell lines, xenografts, and melanoma biopsies.  Mechanistic studies were carried out to det. the mechanism of XL888-induced apoptosis.  RESULTS: XL888 potently inhibited cell growth, induced apoptosis, and prevented the growth of vemurafenib-resistant melanoma cell lines in 3-dimensional cell culture, long-term colony formation assays, and human melanoma mouse xenografts.  The reversal of the resistance phenotype was assocd. with the degrdn. of PDGFRβ, COT, IGFR1, CRAF, ARAF, S6, cyclin D1, and AKT, which in turn led to the nuclear accumulation of FOXO3a, an increase in BIM (Bcl-2 interacting mediator of cell death) expression, and the downregulation of Mcl-1.  In most resistance models, XL888 treatment increased BIM expression, decreased Mcl-1 expression, and induced apoptosis more effectively than dual mitogen-activated protein-extracellular signal-regulated kinase/phosphoinositide 3-kinase (MEK/PI3K) inhibition.  CONCLUSIONS: HSP90 inhibition may be a highly effective strategy at managing the diverse array of resistance mechanisms being reported to BRAF inhibitors and appears to be more effective at restoring BIM expression and downregulating Mcl-1 expression than combined MEK/PI3K inhibitor therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPrQ97z5o17LVg90H21EOLACvtfcHk0ljjqkiL08yLsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsFeju74%253D&md5=4aa227917f72ea77f3d44e2268dc213e</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2612%26sid%3Dliteratum%253Aachs%26aulast%3DParaiso%26aufirst%3DK.%2BH.%2BT.%26aulast%3DHaarberg%26aufirst%3DH.%2BE.%26aulast%3DWood%26aufirst%3DE.%26aulast%3DRebecca%26aufirst%3DV.%2BW.%26aulast%3DChen%26aufirst%3DY.%2BA.%26aulast%3DXiang%26aufirst%3DY.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26aulast%3DWeber%26aufirst%3DJ.%2BS.%26aulast%3DSondak%26aufirst%3DV.%2BK.%26aulast%3DJohn%26aufirst%3DJ.%2BK.%26aulast%3DSarnaik%26aufirst%3DA.%2BA.%26aulast%3DKoomen%26aufirst%3DJ.%2BM.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%2BM.%26atitle%3DThe%2520Hsp90%2520inhibitor%2520XL888%2520overcomes%2520BRAF%2520inhibitor%2520resistance%2520mediated%2520through%2520diverse%2520mechanisms%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D2502%26epage%3D2514%26doi%3D10.1158%2F1078-0432.CCR-11-2612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group">Smyth, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paraiso, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hearn, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Lopez, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munck, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haarberg, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sondak, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, N. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azab, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smalley, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallis, N. G.</span><span> </span><span class="NLM_article-title">Inhibition of Hsp90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2793</span><span class="NLM_x">–</span> <span class="NLM_lpage">2804</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0452</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1535-7163.MCT-14-0452" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=25349308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCju7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2793-2804&author=T.+Smythauthor=K.+H.+Paraisoauthor=K.+Hearnauthor=A.+M.+Rodriguez-Lopezauthor=J.+M.+Munckauthor=H.+E.+Haarbergauthor=V.+K.+Sondakauthor=N.+T.+Thompsonauthor=M.+Azabauthor=J.+F.+Lyonsauthor=K.+S.+Smalleyauthor=N.+G.+Wallis&title=Inhibition+of+Hsp90+by+AT13387+delays+the+emergence+of+resistance+to+BRAF+inhibitors+and+overcomes+resistance+to+dual+BRAF+and+MEK+inhibition+in+melanoma+models&doi=10.1158%2F1535-7163.MCT-14-0452"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models</span></div><div class="casAuthors">Smyth, Tomoko; Paraiso, Kim H. T.; Hearn, Keisha; Rodriguez-Lopez, Ana M.; Munck, Joanne M.; Haarberg, H. Eirik; Sondak, Vernon K.; Thompson, Neil T.; Azab, Mohammad; Lyons, John F.; Smalley, Keiran S. M.; Wallis, Nicola G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2793-2804</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Emergence of clin. resistance to BRAF inhibitors, alone or in combination with MEK inhibitors, limits clin. responses in melanoma.  Inhibiting HSP90 offers an approach to simultaneously interfere with multiple resistance mechanisms.  Using the HSP90 inhibitor AT13387, which is currently in clin. trials, we investigated the potential of HSP90 inhibition to overcome or delay the emergence of resistance to these kinase inhibitors in melanoma models.  In vitro, treating vemurafenib-sensitive cells (A375 or SK-MEL-28) with a combination of AT13387 and vemurafenib prevented colony growth under conditions in which vemurafenib treatment alone generated resistant colonies.  In vivo, when AT13387 was combined with vemurafenib in a SK-MEL-28, vemurafenib-sensitive model, no regrowth of tumors was obsd. over 5 mo, although 2 of 7 tumors in the vemurafenib monotherapy group relapsed in this time.  Together, these data suggest that the combination of these agents can delay the emergence of resistance.  Cell lines with acquired vemurafenib resistance, derived from these models (A375R and SK-MEL-28R) were also sensitive to HSP90 inhibitor treatment; key clients were depleted, apoptosis was induced, and growth in 3D culture was inhibited.  Similar effects were obsd. in cell lines with acquired resistance to both BRAF and MEK inhibitors (SK-MEL-28RR, WM164RR, and 1205LuRR).  These data suggest that treatment with an HSP90 inhibitor, such as AT13387, is a potential approach for combating resistance to BRAF and MEK inhibition in melanoma.  Moreover, frontline combination of these agents with an HSP90 inhibitor could delay the emergence of resistance, providing a strong rationale for clin. investigation of such combinations in BRAF-mutated melanoma.  Mol Cancer Ther; 13(12); 2793-804. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRaNHdCGIPV7Vg90H21EOLACvtfcHk0ljjqkiL08yLsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCju7rF&md5=e3fc50e38f259b38a8259f8f5db959f3</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0452%26sid%3Dliteratum%253Aachs%26aulast%3DSmyth%26aufirst%3DT.%26aulast%3DParaiso%26aufirst%3DK.%2BH.%26aulast%3DHearn%26aufirst%3DK.%26aulast%3DRodriguez-Lopez%26aufirst%3DA.%2BM.%26aulast%3DMunck%26aufirst%3DJ.%2BM.%26aulast%3DHaarberg%26aufirst%3DH.%2BE.%26aulast%3DSondak%26aufirst%3DV.%2BK.%26aulast%3DThompson%26aufirst%3DN.%2BT.%26aulast%3DAzab%26aufirst%3DM.%26aulast%3DLyons%26aufirst%3DJ.%2BF.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%26aulast%3DWallis%26aufirst%3DN.%2BG.%26atitle%3DInhibition%2520of%2520Hsp90%2520by%2520AT13387%2520delays%2520the%2520emergence%2520of%2520resistance%2520to%2520BRAF%2520inhibitors%2520and%2520overcomes%2520resistance%2520to%2520dual%2520BRAF%2520and%2520MEK%2520inhibition%2520in%2520melanoma%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D2793%26epage%3D2804%26doi%3D10.1158%2F1535-7163.MCT-14-0452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group">Acquaviva, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimenez, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequeira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bates, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proia, D. A.</span><span> </span><span class="NLM_article-title">Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">353</span><span class="NLM_x">–</span> <span class="NLM_lpage">363</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1535-7163.MCT-13-0481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=24398428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWmsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=353-363&author=J.+Acquavivaauthor=D.+L.+Smithauthor=J.-P.+Jimenezauthor=C.+Zhangauthor=M.+Sequeiraauthor=S.+Heauthor=J.+Sangauthor=R.+C.+Batesauthor=D.+A.+Proia&title=Overcoming+acquired+BRAF+inhibitor+resistance+in+melanoma+via+targeted+inhibition+of+Hsp90+with+ganetespib&doi=10.1158%2F1535-7163.MCT-13-0481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib</span></div><div class="casAuthors">Acquaviva, Jaime; Smith, Donald L.; Jimenez, John-Paul; Zhang, Chaohua; Sequeira, Manuel; He, Suqin; Sang, Jim; Bates, Richard C.; Proia, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">353-363</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activating BRAF kinase mutations serve as oncogenic drivers in over half of all melanomas, a feature that has been exploited in the development of new molecularly targeted approaches to treat this disease.  Selective BRAFV600E inhibitors, such as vemurafenib, typically induce initial, profound tumor regressions within this group of patients; however, durable responses have been hampered by the emergence of drug resistance.  Here, we examd. the activity of ganetespib, a small-mol. inhibitor of Hsp90, in melanoma lines harboring the BRAFV600E mutation.  Ganetespib exposure resulted in the loss of mutant BRAF expression and depletion of mitogen-activated protein kinase and AKT signaling, resulting in greater in vitro potency and antitumor efficacy compared with targeted BRAF and MAP-ERK kinase (MEK) inhibitors.  Dual targeting of Hsp90 and BRAFV600E provided combinatorial benefit in vemurafenib-sensitive melanoma cells in vitro and in vivo.  Importantly, ganetespib overcame mechanisms of intrinsic and acquired resistance to vemurafenib, the latter of which was characterized by reactivation of extracellular signal-regulated kinase (ERK) signaling.  Continued suppression of BRAFV600E by vemurafenib potentiated sensitivity to MEK inhibitors after acquired resistance had been established.  Ganetespib treatment reduced, but not abolished, elevations in steady-state ERK activity.  Profiling studies revealed that the addn. of a MEK inhibitor could completely abrogate ERK reactivation in the resistant phenotype, with ganetespib displaying superior combinatorial activity over vemurafenib.  Moreover, ganetespib plus the MEK inhibitor TAK-733 induced tumor regressions in vemurafenib-resistant xenografts.  Overall these data highlight the potential of ganetespib as a single-agent or combination treatment in BRAFV600E-driven melanoma, particularly as a strategy to overcome acquired resistance to selective BRAF inhibitors.  Mol Cancer Ther; 13(2); 353-63. 2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4u2EBwPctjLVg90H21EOLACvtfcHk0ljjqkiL08yLsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWmsb0%253D&md5=de32b9abbb6d2a0ee21c0185a9966271</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0481%26sid%3Dliteratum%253Aachs%26aulast%3DAcquaviva%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DD.%2BL.%26aulast%3DJimenez%26aufirst%3DJ.-P.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DSequeira%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DSang%26aufirst%3DJ.%26aulast%3DBates%26aufirst%3DR.%2BC.%26aulast%3DProia%26aufirst%3DD.%2BA.%26atitle%3DOvercoming%2520acquired%2520BRAF%2520inhibitor%2520resistance%2520in%2520melanoma%2520via%2520targeted%2520inhibition%2520of%2520Hsp90%2520with%2520ganetespib%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D353%26epage%3D363%26doi%3D10.1158%2F1535-7163.MCT-13-0481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span>XL888; <span class="NLM_publisher-name">Exelixis</span>: <span class="NLM_publisher-loc">South San Francisco, CA</span>; <a href="http://www.exelixis.net/pipeline/xl888" class="extLink">http://www.exelixis.net/pipeline/xl888</a> (accessed on September 27,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.)</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=XL888%3B+Exelixis%3A+South+San+Francisco%2C+CA%3B+http%3A%2F%2Fwww.exelixis.net%2Fpipeline%2Fxl888+%28accessed+on+September+27%2C+2015.%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DXL888%26pub%3DExelixis%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group">Ren, R.</span><span> </span><span class="NLM_article-title">Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">172</span><span class="NLM_x">–</span> <span class="NLM_lpage">183</span><span class="refDoi"> DOI: 10.1038/nrc1567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnrc1567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=15719031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhslSnt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=172-183&author=R.+Ren&title=Mechanisms+of+BCR-ABL+in+the+pathogenesis+of+chronic+myelogenous+leukaemia&doi=10.1038%2Fnrc1567"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukemia</span></div><div class="casAuthors">Ren, Ruibao</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">172-183</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Imatinib, a potent inhibitor of the oncogenic tyrosine kinase BCR-ABL, has shown remarkable clin. activity in patients with chronic myelogenous leukemia (CML).  However, this drug does not completely eradicate BCR-ABL-expressing cells from the body, and resistance to imatinib emerges.  Although BCR-ABL remains an attractive therapeutic target, it is important to identify other components involved in CML pathogenesis to overcome this resistance.  What have clin. trials of imatinib and studies using mouse models for BCR-ABL leukemogenesis taught us about the functions of BCR-ABL beyond its kinase activity, and how these functions contribute to CML pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZfXdfv0o4nrVg90H21EOLACvtfcHk0lglOAprvvsLlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhslSnt7g%253D&md5=ab087682ff29710660e761c4dc758711</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1038%2Fnrc1567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1567%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DR.%26atitle%3DMechanisms%2520of%2520BCR-ABL%2520in%2520the%2520pathogenesis%2520of%2520chronic%2520myelogenous%2520leukaemia%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D172%26epage%3D183%26doi%3D10.1038%2Fnrc1567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group">Lamontanara, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gencer, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuzyk, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hantschel, O.</span><span> </span><span class="NLM_article-title">Mechanisms of resistance to BCR-ABL and other kinase inhibitors</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Proteins Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">1834</span><span class="NLM_x">, </span> <span class="NLM_fpage">1449</span><span class="NLM_x">–</span> <span class="NLM_lpage">1459</span><span class="refDoi"> DOI: 10.1016/j.bbapap.2012.12.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.bbapap.2012.12.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=23277196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1yjtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1834&publication_year=2013&pages=1449-1459&author=A.+J.+Lamontanaraauthor=E.+B.+Gencerauthor=O.+Kuzykauthor=O.+Hantschel&title=Mechanisms+of+resistance+to+BCR-ABL+and+other+kinase+inhibitors&doi=10.1016%2Fj.bbapap.2012.12.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of resistance to BCR-ABL and other kinase inhibitors</span></div><div class="casAuthors">Lamontanara, Allan Joaquim; Gencer, Emel Basak; Kuzyk, Orest; Hantschel, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1834</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1449-1459</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  In this article, we are reviewing the mol. mechanisms that lead to kinase inhibitor resistance.  As the oncogenic BCR-ABL kinase is the target of the first approved small-mol. kinase inhibitor imatinib, we will first focus on the structural and mechanistic basis for imatinib resistance.  We will then show ways how next generations of BCR-ABL inhibitors and alternative targeting strategies have helped to offer effective treatment options for imatinib-resistant patients.  Based on these insights, we discuss commonalities and further mechanisms that lead to resistance to other kinase inhibitors in solid tumors.  This article is part of a Special Issue entitled: Inhibitors of Protein Kinases (2012).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkaBpN0j3KxrVg90H21EOLACvtfcHk0lglOAprvvsLlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1yjtrg%253D&md5=7706253e67a867b87ddadcec0bd5f972</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2012.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2012.12.009%26sid%3Dliteratum%253Aachs%26aulast%3DLamontanara%26aufirst%3DA.%2BJ.%26aulast%3DGencer%26aufirst%3DE.%2BB.%26aulast%3DKuzyk%26aufirst%3DO.%26aulast%3DHantschel%26aufirst%3DO.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520BCR-ABL%2520and%2520other%2520kinase%2520inhibitors%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2013%26volume%3D1834%26spage%3D1449%26epage%3D1459%26doi%3D10.1016%2Fj.bbapap.2012.12.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Gorre, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellwood-Yen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">BCR-ABL point mutants isolated from patients with imatinib mesylate–resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone Hsp90</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">3041</span><span class="NLM_x">–</span> <span class="NLM_lpage">3044</span><span class="refDoi"> DOI: 10.1182/blood-2002-05-1361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1182%2Fblood-2002-05-1361" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2002&pages=3041-3044&author=M.+E.+Gorreauthor=K.+Ellwood-Yenauthor=G.+Chiosisauthor=N.+Rosenauthor=C.+L.+Sawyers&title=BCR-ABL+point+mutants+isolated+from+patients+with+imatinib+mesylate%E2%80%93resistant+chronic+myeloid+leukemia+remain+sensitive+to+inhibitors+of+the+BCR-ABL+chaperone+Hsp90&doi=10.1182%2Fblood-2002-05-1361"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1182%2Fblood-2002-05-1361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2002-05-1361%26sid%3Dliteratum%253Aachs%26aulast%3DGorre%26aufirst%3DM.%2BE.%26aulast%3DEllwood-Yen%26aufirst%3DK.%26aulast%3DChiosis%26aufirst%3DG.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DBCR-ABL%2520point%2520mutants%2520isolated%2520from%2520patients%2520with%2520imatinib%2520mesylate%25E2%2580%2593resistant%2520chronic%2520myeloid%2520leukemia%2520remain%2520sensitive%2520to%2520inhibitors%2520of%2520the%2520BCR-ABL%2520chaperone%2520Hsp90%26jtitle%3DBlood%26date%3D2002%26volume%3D100%26spage%3D3041%26epage%3D3044%26doi%3D10.1182%2Fblood-2002-05-1361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Peng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span> </span><span class="NLM_article-title">Heat shock protein 90: a potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors</span> <span class="citation_source-journal">Cell Cycle</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2227</span><span class="NLM_x">–</span> <span class="NLM_lpage">2231</span><span class="refDoi"> DOI: 10.4161/cc.6.18.4722</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.4161%2Fcc.6.18.4722" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=2227-2231&author=C.+Pengauthor=D.+Liauthor=S.+Li&title=Heat+shock+protein+90%3A+a+potential+therapeutic+target+in+leukemic+progenitor+and+stem+cells+harboring+mutant+BCR-ABL+resistant+to+kinase+inhibitors&doi=10.4161%2Fcc.6.18.4722"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.4161%2Fcc.6.18.4722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.6.18.4722%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DS.%26atitle%3DHeat%2520shock%2520protein%252090%253A%2520a%2520potential%2520therapeutic%2520target%2520in%2520leukemic%2520progenitor%2520and%2520stem%2520cells%2520harboring%2520mutant%2520BCR-ABL%2520resistant%2520to%2520kinase%2520inhibitors%26jtitle%3DCell%2520Cycle%26date%3D2007%26volume%3D6%26spage%3D2227%26epage%3D2231%26doi%3D10.4161%2Fcc.6.18.4722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group">Peng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grayzel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pak, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span> </span><span class="NLM_article-title">Inhibition of Hsp90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">678</span><span class="NLM_x">–</span> <span class="NLM_lpage">685</span><span class="refDoi"> DOI: 10.1182/blood-2006-10-054098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1182%2Fblood-2006-10-054098" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=678-685&author=C.+Pengauthor=J.+Brainauthor=Y.+Huauthor=A.+Goodrichauthor=L.+Kongauthor=D.+Grayzelauthor=R.+Pakauthor=M.+Readauthor=S.+Li&title=Inhibition+of+Hsp90+prolongs+survival+of+mice+with+BCR-ABL-T315I-induced+leukemia+and+suppresses+leukemic+stem+cells&doi=10.1182%2Fblood-2006-10-054098"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1182%2Fblood-2006-10-054098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2006-10-054098%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DBrain%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DGoodrich%26aufirst%3DA.%26aulast%3DKong%26aufirst%3DL.%26aulast%3DGrayzel%26aufirst%3DD.%26aulast%3DPak%26aufirst%3DR.%26aulast%3DRead%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DS.%26atitle%3DInhibition%2520of%2520Hsp90%2520prolongs%2520survival%2520of%2520mice%2520with%2520BCR-ABL-T315I-induced%2520leukemia%2520and%2520suppresses%2520leukemic%2520stem%2520cells%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D678%26epage%3D685%26doi%3D10.1182%2Fblood-2006-10-054098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">Wu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span> </span><span class="NLM_article-title">Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">833</span><span class="NLM_x">–</span> <span class="NLM_lpage">843</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-3317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1078-0432.CCR-13-3317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=25501124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2MXislGgsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=833-843&author=L.+Wuauthor=J.+Yuauthor=R.+Chenauthor=Y.+Liuauthor=L.+Louauthor=Y.+Wuauthor=L.+Huangauthor=Y.+Fanauthor=P.+Gaoauthor=M.+Huangauthor=Y.+Wuauthor=Y.+Chenauthor=J.+Xu&title=Dual+inhibition+of+Bcr-Abl+and+Hsp90+by+C086+potently+inhibits+the+proliferation+of+imatinib-resistant+CML+cells&doi=10.1158%2F1078-0432.CCR-13-3317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibition of Bcr-Abl and Hsp90 by C086 Potently Inhibits the Proliferation of Imatinib-Resistant CML Cells</span></div><div class="casAuthors">Wu, Lixian; Yu, Jing; Chen, Ruijia; Liu, Yang; Lou, Liguang; Wu, Ying; Huang, Lisen; Fan, Yingjuan; Gao, Pinzhang; Huang, Meijuan; Wu, Yong; Chen, Yuanzhong; Xu, Jianhua</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">833-843</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Although tyrosine kinase inhibitors (TKI) such as imatinib provide an effective treatment against Bcr-Abl kinase activity in the mature cells of patients with chronic myelogenous leukemia (CML), TKIs probably cannot eradicate the leukemia stem cell (LSC) population.  Therefore, alternative therapies are required to target both mature CML cells with wild-type (WT) or mutant Bcr-Abl and LSCs.  To investigate the effect of C086, a deriv. of curcumin, on imatinib-resistant cells, we explored its underlying mechanisms of Bcr-Abl kinase and heat shock protein 90 (Hsp90) function inhibition.  Exptl. Design: Biochem. assays were used to test ABL kinase activity; fluorescence measurements using recombinant NHsp90, Hsp90 ATPase assay, immunopptn., and immunoblotting were applied to examine Hsp90 function.  Colony-forming unit, long-term culture-initiating cells (LTC-IC), and flow cytometry were used to test CML progenitor and stem cells.  Results: Biochem. assays with purified recombinant Abl kinase confirmed that C086 can directly inhibit the kinase activity of Abl, including WT and the Q252H, Y253F, and T315I mutations.  Furthermore, we identified C086 as a novel Hsp90 inhibitor with the capacity to disrupt the Hsp90 chaperone function in CML cells.  Consequently, it inhibited the growth of both imatinib-sensitive and -resistant CML cells.  Interestingly, C086 has the capacity to inhibit LTC-ICs and to induce apoptosis in both CD34+CD38+ and CD34+CD38- cells in vitro.  Moreover, C086 could decrease the no. of CD45+, CD45+CD34+CD38+, and CD45+CD34+CD38- cells in CML NOD-SCID mice.  Conclusions: Dual suppression of Abl kinase activity and Hsp90 chaperone function by C086 provides a new therapeutic strategy for treating Bcr-Abl-induced leukemia resistant to TKIs.  Clin Cancer Res; 21(4); 833-43. 2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQyfdHK77YL7Vg90H21EOLACvtfcHk0lgAvYJAnxWeqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXislGgsL8%253D&md5=f3a1844c124c123bde13f5b4791ef731</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-3317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-3317%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLou%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DDual%2520inhibition%2520of%2520Bcr-Abl%2520and%2520Hsp90%2520by%2520C086%2520potently%2520inhibits%2520the%2520proliferation%2520of%2520imatinib-resistant%2520CML%2520cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D833%26epage%3D843%26doi%3D10.1158%2F1078-0432.CCR-13-3317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group">Samanta, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakraborty, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlette, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arlinghaus, R. B.</span><span> </span><span class="NLM_article-title">Destabilization of Bcr-Abl/Jak2 network by a Jak2/Abl kinase inhibitor ON044580 overcomes drug resistance in blast crisis chronic myelogenous leukemia (CML)</span> <span class="citation_source-journal">Genes Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">346</span><span class="NLM_x">–</span> <span class="NLM_lpage">359</span><span class="refDoi"> DOI: 10.1177/1947601910372232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1177%2F1947601910372232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=20798787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVOms7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=346-359&author=A.+K.+Samantaauthor=S.+N.+Chakrabortyauthor=Y.+Wangauthor=E.+Schletteauthor=E.+P.+Reddyauthor=R.+B.+Arlinghaus&title=Destabilization+of+Bcr-Abl%2FJak2+network+by+a+Jak2%2FAbl+kinase+inhibitor+ON044580+overcomes+drug+resistance+in+blast+crisis+chronic+myelogenous+leukemia+%28CML%29&doi=10.1177%2F1947601910372232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Destabilization of Bcr-Abl/Jak2 network by a Jak2/Abl kinase inhibitor ON044580 overcomes drug resistance in blast crisis chronic myelogenous leukemia (CML)</span></div><div class="casAuthors">Samanta, Ajoy K.; Chakraborty, Sandip N.; Wang, Yan; Schlette, Ellen; Reddy, E. Premkumar; Arlinghaus, Ralph B.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">346-359</span>CODEN:
                <span class="NLM_cas:coden">GCEAAY</span>;
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Bcr-Abl is the predominant therapeutic target in chronic myeloid leukemia (CML), and tyrosine kinase inhibitors (TKIs) that inhibit Bcr-Abl have been successful in treating CML.  With progression of CML disease esp. in blast crisis stage, cells from CML patients become resistant to imatinib mesylate (IM) and other TKIs, resulting in relapse.  Because Bcr-Abl is known to drive multiple signaling pathways, the study of the regulation of stability of Bcr-Abl in IM-resistant CML cells is a crit. issue as a possible therapeutic strategy.  Here, we report that a new dual-kinase chem. inhibitor, ON044580, induced apoptosis of Bcr-Abl+ IM-sensitive, IM-resistant cells, including the gatekeeper Bcr-Abl mutant, T315I, and also cells from blast crisis patients.  In addn., IM-resistant K562-R cells, cells from blast crisis CML patients, and all IM-resistant cell lines tested had reduced ability to form colonies in soft agar in the presence of 0.5 μM ON044580.  In in vitro kinase assays, ON044580 inhibited the recombinant Jak2 and Abl kinase activities when the resp. Jak2 and Abl peptides were used as substrates.  Incubation of the Bcr-Abl+ cells with ON044580 rapidly reduced the levels of the Bcr-Abl protein and also reduced the expression of HSP90 and its client protein levels.  Lysates of Bcr-Abl+ cell lines were found to contain a large signaling network complex composed of Bcr-Abl, Jak2, HSP90, and its client proteins as detected by a gel filtration column chromatog., which was rapidly disrupted by ON044580.  Therefore, targeting Jak2 and Bcr-Abl kinases is an effective way to destabilize Bcr-Abl and its network complex, which leads to the onset of apoptosis in IM-sensitive and IM-resistant Bcr-Abl+ cells.  This inhibitory strategy has potential to manage all types of drug-resistant CML cells, esp. at the terminal blast crisis stage of CML, where TKIs are not clin. useful.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2URs_gr_udLVg90H21EOLACvtfcHk0lgAvYJAnxWeqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVOms7%252FJ&md5=059567e997e0ccf1c3711b7d5ca935f1</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1177%2F1947601910372232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1947601910372232%26sid%3Dliteratum%253Aachs%26aulast%3DSamanta%26aufirst%3DA.%2BK.%26aulast%3DChakraborty%26aufirst%3DS.%2BN.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSchlette%26aufirst%3DE.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26aulast%3DArlinghaus%26aufirst%3DR.%2BB.%26atitle%3DDestabilization%2520of%2520Bcr-Abl%252FJak2%2520network%2520by%2520a%2520Jak2%252FAbl%2520kinase%2520inhibitor%2520ON044580%2520overcomes%2520drug%2520resistance%2520in%2520blast%2520crisis%2520chronic%2520myelogenous%2520leukemia%2520%2528CML%2529%26jtitle%3DGenes%2520Cancer%26date%3D2010%26volume%3D1%26spage%3D346%26epage%3D359%26doi%3D10.1177%2F1947601910372232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group">Tao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakraborty, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arlinghaus, R. B.</span><span> </span><span class="NLM_article-title">Hsp90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and Hsp90 signaling network complex in leukemia cells</span> <span class="citation_source-journal">Genes Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">29</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=25821558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjt1Cmu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=19-29&author=W.+Taoauthor=S.+N.+Chakrabortyauthor=X.+Lengauthor=H.+Maauthor=R.+B.+Arlinghaus&title=Hsp90+inhibitor+AUY922+induces+cell+death+by+disruption+of+the+Bcr-Abl%2C+Jak2+and+Hsp90+signaling+network+complex+in+leukemia+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">HSP90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and HSP90 signaling network complex in leukemia cells</span></div><div class="casAuthors">Tao, Wenjing; Chakraborty, Sandip N.; Leng, Xiaohong; Ma, Helen; Arlinghaus, Ralph B.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">19-29, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">GCEAAY</span>;
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    
            (<span class="NLM_cas:orgname">Impact Journals LLC</span>)
        </div><div class="casAbstract">The Bcr-Abl protein is an important client protein of heat shock protein 90 (HSP90).  We evaluated the inhibitory effects of the HSP90 ATPase inhibitor AUY922 on 32D mouse hematopoietic cells expressing wild-type Bcr-Abl (b3a2, 32Dp210) and mutant Bcr-Abl imatinib (IM)-resistant cell lines.  Western blotting results of fractions from gel filtration column chromatog. of 32Dp210 cells showed that HSP90 together with Bcr-Abl, Jak2 Stat3 and several other proteins co-eluted in peak column fractions of a high mol. wt. network complex (HMWNC).  Co-IP results showed that HSP90 directly bound to Bcr-Abl, Jak2, Stat 3 and Akt.  The assocns. between HSP90 and Bcr-Abl or Bcr-Abl kinase domain mutants (T315I and E255K) were interrupted by AUY922 treatment.  Tyrosine phosphorylation of Bcr-Abl showed a dose-dependent decrease in 32Dp210T315I following AUY922 treatment for 16h.  AUY922 also markedly inhibited cell proliferation of both IM-sensitive 32Dp210 (IC50 = 6 nM) and IM-resistant 32Dp210T315I cells (IC50 ≈ 6 nM) and human KBM-5R/KBM-7R cell lines (IC50 = 50 nM).  AUY922 caused significant G1 arrest in 32Dp210 cells but not in T315I or E255K cells.  AUY922 efficiently induced apoptosis in 32Dp210 (IC50 = 10 nM) and T315I or E255K lines with IC50s around 20 to 50 nM.  Our results showed that Bcr-Abl and Jak2 form HMWNC with HSP90 in CML cells.  Inhibition of HSP90 by AUY922 disrupted the structure of HMWNC, leading to Bcr-Abl degrdn., inhibiting cell proliferation and inducing apoptosis.  Thus, inhibition of HSP90 is a powerful way to inhibit not only IM-sensitive CML cells but also IM-resistant CML cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS9Vh85mWkNbVg90H21EOLACvtfcHk0lgAvYJAnxWeqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjt1Cmu74%253D&md5=3298d8cd05ce6f3c979b05292669e004</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DW.%26aulast%3DChakraborty%26aufirst%3DS.%2BN.%26aulast%3DLeng%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DArlinghaus%26aufirst%3DR.%2BB.%26atitle%3DHsp90%2520inhibitor%2520AUY922%2520induces%2520cell%2520death%2520by%2520disruption%2520of%2520the%2520Bcr-Abl%252C%2520Jak2%2520and%2520Hsp90%2520signaling%2520network%2520complex%2520in%2520leukemia%2520cells%26jtitle%3DGenes%2520Cancer%26date%3D2015%26volume%3D6%26spage%3D19%26epage%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group">Gajria, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandarlapaty, S.</span><span> </span><span class="NLM_article-title">HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies</span> <span class="citation_source-journal">Expert Rev. Anticancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">263</span><span class="NLM_x">–</span> <span class="NLM_lpage">275</span><span class="refDoi"> DOI: 10.1586/era.10.226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1586%2Fera.10.226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=21342044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVWmsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=263-275&author=D.+Gajriaauthor=S.+Chandarlapaty&title=HER2-amplified+breast+cancer%3A+mechanisms+of+trastuzumab+resistance+and+novel+targeted+therapies&doi=10.1586%2Fera.10.226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies</span></div><div class="casAuthors">Gajria, Devika; Chandarlapaty, Sarat</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-275</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  HER2 amplification is seen in up to 20% of breast cancers and is assocd. with an aggressive phenotype.  Trastuzumab, a monoclonal antibody to HER2, accrues significant clin. benefit in the metastatic and adjuvant settings.  However, some patients suffer disease recurrence despite adjuvant trastuzumab therapy, and many patients with metastatic disease do not respond to therapy or develop refractory disease within 1 yr of treatment.  Given the increased recognition of de novo and acquired resistance to therapy, considerable research has been dedicated to understanding the mol. mechanisms of trastuzumab resistance.  Here, we highlight putative models of resistance, including activation of the downstream PI3K-signaling pathway, accumulation of a constitutively active form of HER2, and crosstalk of HER2 with other growth factor receptors.  The identification of these specific mechanisms of trastuzumab resistance has provided a rationale for the development of several novel HER2-targeted agents as the mechanisms have largely suggested a continued tumor dependence on HER2 signaling.  We explore the emerging data for the treatment of trastuzumab-refractory disease with novel agents including lapatinib, neratinib, pertuzumab, trastuzumab-DM1, HSP90 and PI3K pathway inhibitors, and the future potential for these inhibitors which, if combined with reliable biomarkers of resistance, may ultimately usher in a new era of personalized medicine for this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQzYCqTtLhBLVg90H21EOLACvtfcHk0lj4B3z8kFZkMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVWmsbk%253D&md5=28f18c9e392a7bb764f029634a915b85</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1586%2Fera.10.226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fera.10.226%26sid%3Dliteratum%253Aachs%26aulast%3DGajria%26aufirst%3DD.%26aulast%3DChandarlapaty%26aufirst%3DS.%26atitle%3DHER2-amplified%2520breast%2520cancer%253A%2520mechanisms%2520of%2520trastuzumab%2520resistance%2520and%2520novel%2520targeted%2520therapies%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2011%26volume%3D11%26spage%3D263%26epage%3D275%26doi%3D10.1586%2Fera.10.226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group">Brufsky, A. M.</span><span> </span><span class="NLM_article-title">Current approaches and emerging directions in HER2-resistant breast cancer</span> <span class="citation_source-journal">Breast Cancer: Basic Clin. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">109</span><span class="NLM_x">–</span> <span class="NLM_lpage">118</span><span class="refDoi"> DOI: 10.4137/BCBCR.S9453</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.4137%2FBCBCR.S9453" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=25125981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFSksLnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=109-118&author=A.+M.+Brufsky&title=Current+approaches+and+emerging+directions+in+HER2-resistant+breast+cancer&doi=10.4137%2FBCBCR.S9453"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Current approaches and emerging directions in HER2-resistant breast cancer</span></div><div class="casAuthors">Brufsky, Adam M.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer: Basic and Clinical Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">109-118</span>CODEN:
                <span class="NLM_cas:coden">BCRACC</span>;
        ISSN:<span class="NLM_cas:issn">1178-2234</span>.
    
            (<span class="NLM_cas:orgname">Libertas Academica Ltd.</span>)
        </div><div class="casAbstract">A review.  Human epidermal growth factor receptor-2 (HER2) is overexpressed in up to 30% of breast cancers; HER2 overexpression is indicative of poor prognosis.  Trastuzumab, an anti-HER2 monoclonal antibody, has led to improved outcomes in patients with HER2-pos. breast cancer, including improved overall survival in adjuvant and first-line settings.  However, a large proportion of patients with breast cancer have intrinsic resistance to HER2-targeted therapies, and nearly all become resistant to therapy after initial response.  Elucidation of underlying mechanisms contributing to HER2 resistance has led to development of novel therapeutic strategies, including those targeting HER2 and downstream pathways, heat shock protein 90, telomerase, and vascular endothelial growth factor inhibitors.  Numerous clin. trials are ongoing or completed, including phase 3 data for the mammalian target of rapamycin inhibitor everolimus in patients with HER2-resistant breast cancer.  This review considers the mol. mechanisms assocd. with HER2 resistance and evaluates the evidence for use of evolving strategies in patients with HER2-resistant breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq43ZVh1UUDW7Vg90H21EOLACvtfcHk0lj4B3z8kFZkMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFSksLnI&md5=9202af8f5e73b21fdc80d8cac381776d</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.4137%2FBCBCR.S9453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4137%252FBCBCR.S9453%26sid%3Dliteratum%253Aachs%26aulast%3DBrufsky%26aufirst%3DA.%2BM.%26atitle%3DCurrent%2520approaches%2520and%2520emerging%2520directions%2520in%2520HER2-resistant%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%253A%2520Basic%2520Clin.%2520Res.%26date%3D2014%26volume%3D8%26spage%3D109%26epage%3D118%26doi%3D10.4137%2FBCBCR.S9453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group">Chandarlapaty, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scaltriti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angelini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudis, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arribas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span> </span><span class="NLM_article-title">Inhibitors of Hsp90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">334</span><span class="refDoi"> DOI: 10.1038/onc.2009.337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fonc.2009.337" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=325-334&author=S.+Chandarlapatyauthor=M.+Scaltritiauthor=P.+Angeliniauthor=Q.+Yeauthor=M.+Guzmanauthor=C.+A.+Hudisauthor=L.+Nortonauthor=D.+B.+Solitauthor=J.+Arribasauthor=J.+Baselgaauthor=N.+Rosen&title=Inhibitors+of+Hsp90+block+p95-HER2+signaling+in+Trastuzumab-resistant+tumors+and+suppress+their+growth&doi=10.1038%2Fonc.2009.337"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1038%2Fonc.2009.337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2009.337%26sid%3Dliteratum%253Aachs%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DAngelini%26aufirst%3DP.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DGuzman%26aufirst%3DM.%26aulast%3DHudis%26aufirst%3DC.%2BA.%26aulast%3DNorton%26aufirst%3DL.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DArribas%26aufirst%3DJ.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DInhibitors%2520of%2520Hsp90%2520block%2520p95-HER2%2520signaling%2520in%2520Trastuzumab-resistant%2520tumors%2520and%2520suppress%2520their%2520growth%26jtitle%3DOncogene%26date%3D2010%26volume%3D29%26spage%3D325%26epage%3D334%26doi%3D10.1038%2Fonc.2009.337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group">Scaltriti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serra, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Normant, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigue, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slocum, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prudkin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimenez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aura, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">817</span><span class="NLM_x">–</span> <span class="NLM_lpage">824</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-10-0966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1535-7163.MCT-10-0966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=21383049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlslKgt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=817-824&author=M.+Scaltritiauthor=V.+Serraauthor=E.+Normantauthor=M.+Guzmanauthor=O.+Rodrigueauthor=A.+R.+Limauthor=K.+L.+Slocumauthor=K.+A.+Westauthor=V.+Rodriguezauthor=L.+Prudkinauthor=J.+Jimenezauthor=C.+Auraauthor=J.+Baselga&title=Antitumor+activity+of+the+Hsp90+inhibitor+IPI-504+in+HER2-positive+trastuzumab-resistant+breast+cancer&doi=10.1158%2F1535-7163.MCT-10-0966"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer</span></div><div class="casAuthors">Scaltriti, Maurizio; Serra, Violeta; Normant, Emmanuel; Guzman, Marta; Rodriguez, Olga; Lim, Alice R.; Slocum, Kelly L.; West, Kip A.; Rodriguez, Varenka; Prudkin, Ludmila; Jimenez, Jose; Aura, Claudia; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">817-824</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Hsp90 facilitates the maturation and stability of numerous oncoproteins, including HER2.  The aim of this study was to assess the antitumor activity of the Hsp90 inhibitor IPI-504 in trastuzumab-resistant, HER2-overexpressing breast cancer cells.  Therapy with trastuzumab, IPI-504, and the combination of trastuzumab and IPI-504 was evaluated in trastuzumab-sensitive and trastuzumab-resistant cells.  Inhibition of protein targets, cell proliferation, and tumor growth was assessed in vitro and in xenograft models.  IPI-504 inhibited proliferation of both trastuzumab-sensitive and trastuzumab-resistant cells.  Administration of IPI-504 markedly reduced total levels of HER2 and Akt, as well as phosphorylated Akt and mitogen-activated protein kinase (MAPK), to an equal extent in trastuzumab-sensitive and trastuzumab-resistant cells.  IPI-504, used as single agent or in combination with trastuzumab, also inhibited in vivo the growth of both trastuzumab-sensitive and -resistant tumor xenografts.  As a mechanism for the obsd. antitumor activity, IPI-504 resulted in a marked decrease in the levels of HER2, Akt, p-Akt, and p-MAPK in trastuzumab-resistant xenografts as early as 12 h after a single dose of IPI-504.  IPI-504-mediated Hsp90 inhibition may represent a novel therapeutic approach in trastuzumab refractory HER2-pos. breast cancer.  Mol Cancer Ther; 10(5); 817-24.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhf3Bk6GOlM7Vg90H21EOLACvtfcHk0lgEasIJdc3jiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlslKgt74%253D&md5=ca88b288fc1deb6076e63f7210544338</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0966%26sid%3Dliteratum%253Aachs%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DSerra%26aufirst%3DV.%26aulast%3DNormant%26aufirst%3DE.%26aulast%3DGuzman%26aufirst%3DM.%26aulast%3DRodrigue%26aufirst%3DO.%26aulast%3DLim%26aufirst%3DA.%2BR.%26aulast%3DSlocum%26aufirst%3DK.%2BL.%26aulast%3DWest%26aufirst%3DK.%2BA.%26aulast%3DRodriguez%26aufirst%3DV.%26aulast%3DPrudkin%26aufirst%3DL.%26aulast%3DJimenez%26aufirst%3DJ.%26aulast%3DAura%26aufirst%3DC.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DAntitumor%2520activity%2520of%2520the%2520Hsp90%2520inhibitor%2520IPI-504%2520in%2520HER2-positive%2520trastuzumab-resistant%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D817%26epage%3D824%26doi%3D10.1158%2F1535-7163.MCT-10-0966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group">Wainberg, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anghel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalous, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conklin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayala, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quadt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akimov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, R. S.</span><span> </span><span class="NLM_article-title">Inhibition of Hsp90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">509</span><span class="NLM_x">–</span> <span class="NLM_lpage">519</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1535-7163.MCT-12-0507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=23395886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXls12qsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=509-519&author=Z.+A.+Wainbergauthor=A.+Anghelauthor=A.+M.+Rogersauthor=A.+J.+Desaiauthor=O.+Kalousauthor=D.+Conklinauthor=R.+Ayalaauthor=N.+A.+O%E2%80%99Brienauthor=C.+Quadtauthor=M.+Akimovauthor=D.+J.+Slamonauthor=R.+S.+Finn&title=Inhibition+of+Hsp90+with+AUY922+induces+synergy+in+HER2-amplified+trastuzumab-resistant+breast+and+gastric+cancer&doi=10.1158%2F1535-7163.MCT-12-0507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer</span></div><div class="casAuthors">Wainberg, Zev A.; Anghel, Adrian; Rogers, Amy M.; Desai, Amrita J.; Kalous, Ondrej; Conklin, Dylan; Ayala, Raul; O'Brien, Neil A.; Quadt, Cornelia; Akimov, Mikhail; Slamon, Dennis J.; Finn, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">509-519</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">HSP90 enables the activation of many client proteins of which the most clin. validated is HER2.  NVP-AUY922, a potent HSP90 inhibitor, is currently in phase II clin. trials.  To explore its potential clin. use in HER2-amplified breast and gastric cancers, we evaluated the effect of AUY922 alone and in combination with trastuzumab in both trastuzumab-sensitive and -resistant models.  A panel of 16 human gastric and 45 breast cancer cell lines, including 16 HER2-amplified (3 and 13, resp.) cells, was treated with AUY922 over various concns.  In both breast and gastric cancer, we used cell lines and xenograft models with conditioned trastuzumab-resistance to investigate the efficacy of AUY922 alongside trastuzumab.  Effects of this combination on downstream markers were analyzed via Western blot anal.  AUY922 exhibited potent antiproliferative activity in the low nanomolar range (<40 nmol/L) for 59 of 61 cell lines.  In both histologies, HER2-amplified cells expressed greater sensitivity to AUY than HER2-neg. cells.  In conditioned trastuzumab-resistant models, AUY922 showed a synergistic effect with trastuzumab.  In vitro, the combination induced greater decreases in HER2, a G2 cell-cycle arrest, and increased apoptosis.  In a trastuzumab-resistant gastric cancer xenograft model, the combination of AUY922 and trastuzumab showed greater antitumor efficacy than either drug alone.  These data suggest that AUY922 in combination with trastuzumab has unique efficacy in trastuzumab-resistant models.  The combination of HSP90 inhibition and direct HER2 blockade represents a novel approach to the treatment of HER2-amplified cancers and clin. trials based on the above data are ongoing.  Mol Cancer Ther; 12(4); 509-19. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDibuToKti3LVg90H21EOLACvtfcHk0lgEasIJdc3jiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXls12qsLc%253D&md5=12644a86e6220c0cd2ba16c813e4728f</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0507%26sid%3Dliteratum%253Aachs%26aulast%3DWainberg%26aufirst%3DZ.%2BA.%26aulast%3DAnghel%26aufirst%3DA.%26aulast%3DRogers%26aufirst%3DA.%2BM.%26aulast%3DDesai%26aufirst%3DA.%2BJ.%26aulast%3DKalous%26aufirst%3DO.%26aulast%3DConklin%26aufirst%3DD.%26aulast%3DAyala%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DN.%2BA.%26aulast%3DQuadt%26aufirst%3DC.%26aulast%3DAkimov%26aufirst%3DM.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26atitle%3DInhibition%2520of%2520Hsp90%2520with%2520AUY922%2520induces%2520synergy%2520in%2520HER2-amplified%2520trastuzumab-resistant%2520breast%2520and%2520gastric%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D509%26epage%3D519%26doi%3D10.1158%2F1535-7163.MCT-12-0507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group">Modi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stopeck, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linden, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandarlapaty, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moynahan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugarman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannah, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudis, C.</span><span> </span><span class="NLM_article-title">Hsp90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">5132</span><span class="NLM_x">–</span> <span class="NLM_lpage">5139</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-0072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1078-0432.CCR-11-0072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=21558407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFSksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=5132-5139&author=S.+Modiauthor=A.+Stopeckauthor=H.+Lindenauthor=D.+Solitauthor=S.+Chandarlapatyauthor=N.+Rosenauthor=G.+D%E2%80%99Andreaauthor=M.+Dicklerauthor=M.+E.+Moynahanauthor=S.+Sugarmanauthor=W.+Maauthor=S.+Patilauthor=L.+Nortonauthor=A.+L.+Hannahauthor=C.+Hudis&title=Hsp90+inhibition+is+effective+in+breast+cancer%3A+a+phase+II+trial+of+tanespimycin+%2817-AAG%29+plus+trastuzumab+in+patients+with+HER2-positive+metastatic+breast+cancer+progressing+on+trastuzumab&doi=10.1158%2F1078-0432.CCR-11-0072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab</span></div><div class="casAuthors">Modi, Shanu; Stopeck, Alison; Linden, Hannah; Solit, David; Chandarlapaty, Sarat; Rosen, Neal; D'Andrea, Gabriella; Dickler, Maura; Moynahan, Mary E.; Sugarman, Steven; Ma, Weining; Patil, Sujata; Norton, Larry; Hannah, Alison L.; Hudis, Clifford</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5132-5139</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: HSP90 is a chaperone protein required for the stability of a variety of client proteins. 17-Demethoxygeldanamycin (17-AAG) is a natural product that binds to HSP90 and inhibits its activity, thereby inducing the degrdn. of these clients.  In preclin. studies, HER2 is one of the most sensitive known client proteins of 17-AAG.  On the basis of these data and activity in a phase I study, we conducted a phase II study of 17-AAG (tanespimycin) with trastuzumab in advanced trastuzumab-refractory HER2-pos. breast cancer.  Exptl. Design: We enrolled patients with metastatic HER2+ breast cancer whose disease had previously progressed on trastuzumab.  All patients received weekly treatment with tanespimycin at 450 mg/m2 i.v. and trastuzumab at a conventional dose.  Therapy was continued until disease progression.  The primary endpoint was response rate by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.  RESULTS: Thirty-one patients were enrolled with a median age of 53 years and a median Karnofsky performance status (KPS) of 90%.  The most common toxicities, largely grade 1, were diarrhea, fatigue, nausea, and headache.  The overall response rate was 22%, the clin. benefit rate [complete response + partial response + stable disease] was 59%, the median progression-free survival was 6 mo (95% CI: 4-9), and the median overall survival was 17 mo (95% CI: 16-28).  CONCLUSIONS: This is the first phase II study to definitively show RECIST-defined responses for 17-AAG in solid tumors.  Tanespimycin plus trastuzumab has significant anticancer activity in patients with HER2-pos., metastatic breast cancer previously progressing on trastuzumab.  Further research exploring this therapeutic interaction and the activity of HSP90 inhibitors is clearly warranted.  Clin Cancer Res; 17(15); 5132-9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFgVCzhN1fHLVg90H21EOLACvtfcHk0lgEasIJdc3jiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFSksbw%253D&md5=07d9e8e06caad7cd7abe03f9e9f7375a</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-0072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-0072%26sid%3Dliteratum%253Aachs%26aulast%3DModi%26aufirst%3DS.%26aulast%3DStopeck%26aufirst%3DA.%26aulast%3DLinden%26aufirst%3DH.%26aulast%3DSolit%26aufirst%3DD.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DG.%26aulast%3DDickler%26aufirst%3DM.%26aulast%3DMoynahan%26aufirst%3DM.%2BE.%26aulast%3DSugarman%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DPatil%26aufirst%3DS.%26aulast%3DNorton%26aufirst%3DL.%26aulast%3DHannah%26aufirst%3DA.%2BL.%26aulast%3DHudis%26aufirst%3DC.%26atitle%3DHsp90%2520inhibition%2520is%2520effective%2520in%2520breast%2520cancer%253A%2520a%2520phase%2520II%2520trial%2520of%2520tanespimycin%2520%252817-AAG%2529%2520plus%2520trastuzumab%2520in%2520patients%2520with%2520HER2-positive%2520metastatic%2520breast%2520cancer%2520progressing%2520on%2520trastuzumab%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D5132%26epage%3D5139%26doi%3D10.1158%2F1078-0432.CCR-11-0072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group">Jhaveri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chap, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannah, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, S.</span><span> </span><span class="NLM_article-title">A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5090</span><span class="NLM_x">–</span> <span class="NLM_lpage">5098</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-3200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1078-0432.CCR-11-3200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22781552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2lt7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=5090-5098&author=K.+Jhaveriauthor=K.+Millerauthor=L.+Rosenauthor=B.+Schneiderauthor=L.+Chapauthor=A.+Hannahauthor=Z.+Zhongauthor=W.+Maauthor=C.+Hudisauthor=S.+Modi&title=A+phase+I+dose-escalation+trial+of+trastuzumab+and+alvespimycin+hydrochloride+%28KOS-1022%3B+17+DMAG%29+in+the+treatment+of+advanced+solid+tumors&doi=10.1158%2F1078-0432.CCR-11-3200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors</span></div><div class="casAuthors">Jhaveri, Komal; Miller, Kathy; Rosen, Lee; Schneider, Bryan; Chap, Linnea; Hannah, Alison; Zhong, Ziyang; Ma, Weining; Hudis, Clifford; Modi, Shanu</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5090-5098</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: We conducted a phase I dose-escalation study to define the max. tolerated dose (MTD), pharmacokinetics (PK), and pharmacodynamics of alvespimycin (17-DMAG), a heat shock protein 90 (Hsp90) inhibitor, given in combination with trastuzumab.  Exptl. Design: Patients were treated with trastuzumab followed by i.v. alvespimycin on a weekly schedule.  Hsp90 client proteins were measured at baseline and serially in peripheral blood lymphocytes (PBL) during cycle 1.  Patients with advanced solid tumors progressing on std. therapy were eligible.  Results: Twenty-eight patients (25, breast; 3, ovarian) were enrolled onto three dose cohorts: 60 (n = 9), 80 (n = 13), and 100 mg/m2 (n = 6).  Dose-limiting toxicities (DLT) were: grade III left ventricular systolic dysfunction presenting as congestive heart failure in 1 patient (100 mg/m2), and reversible grade III keratitis in two patients (80 mg/m2).  Drug-related grade III toxicity included one episode each of fatigue, diarrhea, myalgia, and back pain.  Common mild to moderate toxicities included diarrhea, fatigue, myalgia, arthralgia, nausea, blurry vision, headache, back pain, and dry eyes.  There was one partial response and seven cases of stable disease (range, 4-10 mo), all in HER2+ MBC.  In addn., an ovarian cancer patient had complete resoln. of ascites and pleural effusion that lasted 24.8 mo.  There was no change in PK upon weekly dosing.  Hsp70 effect continued to increase across four weeks and was most pronounced at 80 and 100 mg/m2.  Conclusion: The combination of alvespimycin and trastuzumab is safe and tolerable at MTD.  Antitumor activity was seen in patients with refractory HER2+ MBC and ovarian cancer.  The recommended dose of alvespimycin for further study in this combination is 80 mg/m2 weekly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq36__p9-L8obVg90H21EOLACvtfcHk0ljIgApM1_5cxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2lt7vJ&md5=422b8841c2a0993fae0933d1b8ad8a52</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-3200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-3200%26sid%3Dliteratum%253Aachs%26aulast%3DJhaveri%26aufirst%3DK.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DRosen%26aufirst%3DL.%26aulast%3DSchneider%26aufirst%3DB.%26aulast%3DChap%26aufirst%3DL.%26aulast%3DHannah%26aufirst%3DA.%26aulast%3DZhong%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DHudis%26aufirst%3DC.%26aulast%3DModi%26aufirst%3DS.%26atitle%3DA%2520phase%2520I%2520dose-escalation%2520trial%2520of%2520trastuzumab%2520and%2520alvespimycin%2520hydrochloride%2520%2528KOS-1022%253B%252017%2520DMAG%2529%2520in%2520the%2520treatment%2520of%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D5090%26epage%3D5098%26doi%3D10.1158%2F1078-0432.CCR-11-3200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group">Modi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saura, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, N. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahtani, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goddard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodenas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shaughnessy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">Efficacy and safety of retaspimycin hydrochloride (IPI-504) in combination with trastuzumab in patients (pts) with pretreated, locally advanced or metastatic HER2-positive breast cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">S590</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=S590&author=S.+Modiauthor=C.+Sauraauthor=C.+A.+Hendersonauthor=N.+U.+Linauthor=R.+L.+Mahtaniauthor=J.+Goddardauthor=E.+Rodenasauthor=J.+O%E2%80%99Shaughnessyauthor=J.+Baselga&title=Efficacy+and+safety+of+retaspimycin+hydrochloride+%28IPI-504%29+in+combination+with+trastuzumab+in+patients+%28pts%29+with+pretreated%2C+locally+advanced+or+metastatic+HER2-positive+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DModi%26aufirst%3DS.%26aulast%3DSaura%26aufirst%3DC.%26aulast%3DHenderson%26aufirst%3DC.%2BA.%26aulast%3DLin%26aufirst%3DN.%2BU.%26aulast%3DMahtani%26aufirst%3DR.%2BL.%26aulast%3DGoddard%26aufirst%3DJ.%26aulast%3DRodenas%26aufirst%3DE.%26aulast%3DO%25E2%2580%2599Shaughnessy%26aufirst%3DJ.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520retaspimycin%2520hydrochloride%2520%2528IPI-504%2529%2520in%2520combination%2520with%2520trastuzumab%2520in%2520patients%2520%2528pts%2529%2520with%2520pretreated%252C%2520locally%2520advanced%2520or%2520metastatic%2520HER2-positive%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3DS590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group">Jhaveri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandarlapaty, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lake, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilewski, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldfarb, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drullinsky, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugarman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wasserheit-Leiblich, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fasano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moynahan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddington, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haque, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vukovic, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Hariry, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, S.</span><span> </span><span class="NLM_article-title">A phase II open-label study of ganetespib, a novel Hsp90 inhibitor for patients with metastatic breast cancer</span> <span class="citation_source-journal">Clin. Breast Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">154</span><span class="NLM_x">–</span> <span class="NLM_lpage">160</span><span class="refDoi"> DOI: 10.1016/j.clbc.2013.12.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.clbc.2013.12.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=24512858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFegsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=154-160&author=K.+Jhaveriauthor=S.+Chandarlapatyauthor=D.+Lakeauthor=T.+Gilewskiauthor=M.+Robsonauthor=S.+Goldfarbauthor=P.+Drullinskyauthor=S.+Sugarmanauthor=C.+Wasserheit-Leiblichauthor=J.+Fasanoauthor=M.+E.+Moynahanauthor=G.+D%E2%80%99Andreaauthor=K.+Limauthor=L.+Reddingtonauthor=S.+Haqueauthor=S.+Patilauthor=L.+Baumanauthor=V.+Vukovicauthor=I.+El-Hariryauthor=C.+Hudisauthor=S.+Modi&title=A+phase+II+open-label+study+of+ganetespib%2C+a+novel+Hsp90+inhibitor+for+patients+with+metastatic+breast+cancer&doi=10.1016%2Fj.clbc.2013.12.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer</span></div><div class="casAuthors">Jhaveri, Komal; Chandarlapaty, Sarat; Lake, Diana; Gilewski, Teresa; Robson, Mark; Goldfarb, Shari; Drullinsky, Pamela; Sugarman, Steven; Wasserheit-Leiblich, Carolyn; Fasano, Julie; Moynahan, Mary Ellen; D'Andrea, Gabriella; Lim, Kristina; Reddington, Laura; Haque, Sofia; Patil, Sujata; Bauman, Lynne; Vukovic, Vojo; El-Hariry, Iman; Hudis, Clifford; Modi, Shanu</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Breast Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">154-160</span>CODEN:
                <span class="NLM_cas:coden">CBCLB7</span>;
        ISSN:<span class="NLM_cas:issn">1526-8209</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Background:Ganetespib is a small mol., nongeldanamycin HSP90 inhibitor with potent inhibitory effects on HSP90-dependent oncoproteins of relevance to breast cancer pathogenesis.  We therefore tested ganetespib in an unselected cohort of patients with MBC.  Patients and Methods: Patients were treated with single agent ganetespib at 200 mg/m2 once weekly for 3 wk, on a 28-day cycle.  Therapy was continued until disease progression.  The primary end point was ORR using Reponse Evaluation Criteria in Solid Tumors version 1.1.  Results: Twenty-two patients were enrolled with a median age of 51(range, 38-70) years and a median Eastern Cooperative Oncol. Group performance status of 0 (range, 0-1).  Most patients had at least 2 previous lines of chemotherapy in the metastatic setting.  Most common toxicities, largely grade 1/2, were diarrhea, fatigue, nausea, and hypersensitivity reaction.  The ORR in this unselected population was 9%, with all responses coming from the subset of patients with HER2-pos. MBC (2/13; 15%).  One patient with TNBC had objective tumor regression in the lung metastases.  The clin. benefit rate (complete response + partial response + stable disease > 6 mo) was 9%, median progression-free survival was 7 wk (95% confidence interval [CI], 7-19), and median overall survival was 46 wk (95% CI, 27-not applicable).  Conclusion: The study did not meet the prespecified criteria for ORR in the first stage of the Simon 2-stage model in this heavily pretreated unselected population of MBC.  However, activity was obsd. in trastuzumab-refractory HER2-pos. and TNBC.  Ganetespib was well tolerated and responses in more targeted populations harboring specific HSP90-dependent oncoproteins justifies its further study, particularly as part of rational combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKRWFzPxBRzbVg90H21EOLACvtfcHk0ljIgApM1_5cxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFegsLc%253D&md5=15edad6cf71a9559eb42997563c57f53</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.clbc.2013.12.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clbc.2013.12.012%26sid%3Dliteratum%253Aachs%26aulast%3DJhaveri%26aufirst%3DK.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DLake%26aufirst%3DD.%26aulast%3DGilewski%26aufirst%3DT.%26aulast%3DRobson%26aufirst%3DM.%26aulast%3DGoldfarb%26aufirst%3DS.%26aulast%3DDrullinsky%26aufirst%3DP.%26aulast%3DSugarman%26aufirst%3DS.%26aulast%3DWasserheit-Leiblich%26aufirst%3DC.%26aulast%3DFasano%26aufirst%3DJ.%26aulast%3DMoynahan%26aufirst%3DM.%2BE.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DG.%26aulast%3DLim%26aufirst%3DK.%26aulast%3DReddington%26aufirst%3DL.%26aulast%3DHaque%26aufirst%3DS.%26aulast%3DPatil%26aufirst%3DS.%26aulast%3DBauman%26aufirst%3DL.%26aulast%3DVukovic%26aufirst%3DV.%26aulast%3DEl-Hariry%26aufirst%3DI.%26aulast%3DHudis%26aufirst%3DC.%26aulast%3DModi%26aufirst%3DS.%26atitle%3DA%2520phase%2520II%2520open-label%2520study%2520of%2520ganetespib%252C%2520a%2520novel%2520Hsp90%2520inhibitor%2520for%2520patients%2520with%2520metastatic%2520breast%2520cancer%26jtitle%3DClin.%2520Breast%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D154%26epage%3D160%26doi%3D10.1016%2Fj.clbc.2013.12.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group">Nogova, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardizi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheffler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papachristou, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wompner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heukamp, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schildhaus, H.-U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuhr, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberhardt, W. E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesweg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Büttner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, J.</span><span> </span><span class="NLM_article-title">A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small-cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">S914</span><span class="NLM_x">–</span> <span class="NLM_lpage">S915</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=S914-S915&author=L.+Nogovaauthor=M.+Bosauthor=M.+Gardiziauthor=M.+Schefflerauthor=I.+Papachristouauthor=C.+Wompnerauthor=L.+C.+Heukampauthor=H.-U.+Schildhausauthor=U.+Fuhrauthor=M.+L.+Sosauthor=W.+E.+E.+Eberhardtauthor=M.+Wieswegauthor=K.+W.+Schmidauthor=M.+Schulerauthor=R.+B%C3%BCttnerauthor=J.+Wolf&title=A+phase+II+study+to+evaluate+safety+and+efficacy+of+combined+trastuzumab+and+AUY922+in+advanced+non-small-cell+lung+cancer+%28NSCLC%29+with+HER2+overexpression+or+amplification+or+mutation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNogova%26aufirst%3DL.%26aulast%3DBos%26aufirst%3DM.%26aulast%3DGardizi%26aufirst%3DM.%26aulast%3DScheffler%26aufirst%3DM.%26aulast%3DPapachristou%26aufirst%3DI.%26aulast%3DWompner%26aufirst%3DC.%26aulast%3DHeukamp%26aufirst%3DL.%2BC.%26aulast%3DSchildhaus%26aufirst%3DH.-U.%26aulast%3DFuhr%26aufirst%3DU.%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DEberhardt%26aufirst%3DW.%2BE.%2BE.%26aulast%3DWiesweg%26aufirst%3DM.%26aulast%3DSchmid%26aufirst%3DK.%2BW.%26aulast%3DSchuler%26aufirst%3DM.%26aulast%3DB%25C3%25BCttner%26aufirst%3DR.%26aulast%3DWolf%26aufirst%3DJ.%26atitle%3DA%2520phase%2520II%2520study%2520to%2520evaluate%2520safety%2520and%2520efficacy%2520of%2520combined%2520trastuzumab%2520and%2520AUY922%2520in%2520advanced%2520non-small-cell%2520lung%2520cancer%2520%2528NSCLC%2529%2520with%2520HER2%2520overexpression%2520or%2520amplification%2520or%2520mutation%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2013%26volume%3D8%26spage%3DS914%26epage%3DS915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group">Vainchenker, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Constantinescu, S. N.</span><span> </span><span class="NLM_article-title">JAK/STAT signaling in hematological malignancies</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">2601</span><span class="NLM_x">–</span> <span class="NLM_lpage">2613</span><span class="refDoi"> DOI: 10.1038/onc.2012.347</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fonc.2012.347" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22869151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCrtr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=2601-2613&author=W.+Vainchenkerauthor=S.+N.+Constantinescu&title=JAK%2FSTAT+signaling+in+hematological+malignancies&doi=10.1038%2Fonc.2012.347"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">JAK/STAT signaling in hematological malignancies</span></div><div class="casAuthors">Vainchenker, W.; Constantinescu, S. N.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2601-2613</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is crit. in blood formation and immune response.  Many of those receptors transmit anti-apoptotic, proliferative and differentiation signals, and their expression and functions are crit. for the formation of blood lineages.  Several cancers, including blood malignancies, have been assocd. with constitutive activation of members of the STAT family, which normally require JAK-mediated tyrosine phosphorylation for transcriptional activation.  More recently, human myeloproliferative neoplasms were discovered to be assocd. with a unique acquired somatic mutation in JAK2 (JAK2 V617F), rare exon 12 JAK2 mutations, or thrombopoietin receptor mutations that constitutively activate wild-type JAK2.  Prompted by these observations, many studies have explored the possibility that JAKs, cytokine receptors, or other components of the JAK/STAT pathway are mutated or upregulated in several hematol. malignancies.  This has been obsd. in certain pediatric acute lymphoblastic leukemias and adult T-cell lymphoblastic leukemias, and overexpression of JAK2 seems to be important in Hodgkin lymphoma.  Here we discuss the nature and resp. contribution of mutations dysregulating the JAK/STAT pathway in hematol. malignancies and present examples in which such mutations drive the disease, contribute to the phenotype, or provide a survival and proliferative advantage.  JAK inhibitors are making their way into the therapeutic arsenal (for example, in myelofibrosis), and we discuss the possibility that other hematol. diseases might benefit from treatment with these inhibitors in combination with other agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVwfhpAymyJbVg90H21EOLACvtfcHk0likx2Gt3uQg0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCrtr%252FN&md5=f491a126765e10fbfbb73f6e04fd64e6</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1038%2Fonc.2012.347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2012.347%26sid%3Dliteratum%253Aachs%26aulast%3DVainchenker%26aufirst%3DW.%26aulast%3DConstantinescu%26aufirst%3DS.%2BN.%26atitle%3DJAK%252FSTAT%2520signaling%2520in%2520hematological%2520malignancies%26jtitle%3DOncogene%26date%3D2013%26volume%3D32%26spage%3D2601%26epage%3D2613%26doi%3D10.1038%2Fonc.2012.347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group">Bareng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jilani, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorre, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannah, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albitar, M.</span><span> </span><span class="NLM_article-title">A potential role for Hsp90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry</span> <span class="citation_source-journal">Leuk. Lymphoma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">2189</span><span class="NLM_x">–</span> <span class="NLM_lpage">2195</span><span class="refDoi"> DOI: 10.1080/10428190701607576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1080%2F10428190701607576" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=17926180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1Krt7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2007&pages=2189-2195&author=J.+Barengauthor=I.+Jilaniauthor=M.+Gorreauthor=H.+Kantarjianauthor=F.+Gilesauthor=A.+Hannahauthor=M.+Albitar&title=A+potential+role+for+Hsp90+inhibitors+in+the+treatment+of+JAK2+mutant-positive+diseases+as+demonstrated+using+quantitative+flow+cytometry&doi=10.1080%2F10428190701607576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry</span></div><div class="casAuthors">Bareng, Joanne; Jilani, Iman; Gorre, Mercedes; Kantarjian, Hagop; Giles, Francis; Hannah, Alison; Albitar, Maher</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2189-2195</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1042-8194</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">The V617F mutation of the JAK2 tyrosine kinase is found in a majority of patients with myeloproliferative disorders.  Flow cytometry assays for quantitation of phosphorylated and total protein for JAK2, STAT5, and heat shock proteins (HSPs) were developed to facilitate the study of the JAK/STAT pathway.  A cell line homozygous for V617F (HEL) was treated with inhibitors of JAK2 tyrosine kinase activity and the HSP90 inhibitor 17-AAG. 17-AAG reduced HSP90 levels, but increased HSP70 levels.  Phospho-STAT5, total STAT5, and total AKT levels were also reduced by17-AAG treatment.  Further, phospho-JAK2, total JAK2, and cell viability were reduced to a greater extent by 17-AAG than by the pan-JAK kinase family inhibitor JKII or the JAK2-specific inhibitor AG490, and these inhibitors failed to synergize with 17-AAG.  Flow-cytometry-based assays for JAK/STAT signaling pathway and HSPs are likely to have broad clin. utility for monitoring patients with abnormalities in the JAK2 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaPOwsJaUsULVg90H21EOLACvtfcHk0likx2Gt3uQg0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1Krt7nN&md5=a85b1452d36135baebfb78ae2e287ace</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1080%2F10428190701607576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10428190701607576%26sid%3Dliteratum%253Aachs%26aulast%3DBareng%26aufirst%3DJ.%26aulast%3DJilani%26aufirst%3DI.%26aulast%3DGorre%26aufirst%3DM.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DGiles%26aufirst%3DF.%26aulast%3DHannah%26aufirst%3DA.%26aulast%3DAlbitar%26aufirst%3DM.%26atitle%3DA%2520potential%2520role%2520for%2520Hsp90%2520inhibitors%2520in%2520the%2520treatment%2520of%2520JAK2%2520mutant-positive%2520diseases%2520as%2520demonstrated%2520using%2520quantitative%2520flow%2520cytometry%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2007%26volume%3D48%26spage%3D2189%26epage%3D2195%26doi%3D10.1080%2F10428190701607576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group">Fiskus, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verstovsek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manshouri, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balusu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkannagari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, N. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ha, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hembruff, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abhyankar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGuirk, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhalla, K. N.</span><span> </span><span class="NLM_article-title">Hsp90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">7347</span><span class="NLM_x">–</span> <span class="NLM_lpage">7358</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-1541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1078-0432.CCR-11-1541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=21976548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCmtrjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=7347-7358&author=W.+Fiskusauthor=S.+Verstovsekauthor=T.+Manshouriauthor=R.+Raoauthor=R.+Balusuauthor=S.+Venkannagariauthor=N.+N.+Raoauthor=K.+Haauthor=J.+E.+Smithauthor=S.+L.+Hembruffauthor=S.+Abhyankarauthor=J.+McGuirkauthor=K.+N.+Bhalla&title=Hsp90+inhibitor+is+synergistic+with+JAK2+inhibitor+and+overcomes+resistance+to+JAK2-TKI+in+human+myeloproliferative+neoplasm+cells&doi=10.1158%2F1078-0432.CCR-11-1541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells</span></div><div class="casAuthors">Fiskus, Warren; Verstovsek, Srdan; Manshouri, Taghi; Rao, Rekha; Balusu, Ramesh; Venkannagari, Sreedhar; Rao, Nalabothula Narasimha; Ha, Kyungsoo; Smith, Jacqueline E.; Hembruff, Stacey L.; Abhyankar, Sunil; McGuirk, Joseph; Bhalla, Kapil N.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7347-7358</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: We detd. the activity of hsp90 inhibitor, and/or Janus-activated kinase 2 (JAK2) tyrosine kinase inhibitor (TKI), against JAK2-V617F-expressing cultured mouse (Ba/F3-JAK2-V617F) and human (HEL92.1.7 and UKE-1) or primary human CD34+ myeloproliferative neoplasm (MPN) cells.  Exptl. Design: Following exposure to the hsp90 inhibitor AUY922 and/or JAK2-TKI TG101209, the levels of JAK2-V617F, its downstream signaling proteins, as well as apoptosis were detd.  RESULTS: Treatment with AUY922 induced proteasomal degrdn. and depletion of JAK2-V617F as well as attenuated the signaling proteins downstream of JAK2-V617F, i.e., phospho (p)-STAT5, p-AKT, and p-ERK1/2.  AUY922 treatment also induced apoptosis of HEL92.1.7, UKE-1, and Ba/F3-hJAK2-V617F cells.  Combined treatment with AUY922 and TG101209 caused greater depletion of the signaling proteins than either agent alone and synergistically induced apoptosis of HEL92.1.7 and UKE-1 cells.  Cotreatment with AUY922 and TG101209 also induced significantly more apoptosis of human CD34+ MPN than normal hematopoietic progenitor cells.  As compared with the sensitive controls, JAK2-TKI-resistant HEL/TGR and UKE-1/TGR cells exhibited significantly higher IC50 values for JAK2-TKI (P < 0.001), which was assocd. with higher expression of p-JAK2, p-STAT5, p-AKT, and Bcl-xL, but reduced levels of BIM.  Unlike the sensitive controls, HEL/TGR and UKE/TGR cells were collaterally sensitive to the hsp90 inhibitors AUY922 and 17-AAG, accompanied by marked redn. in p-JAK2, p-STAT5, p-AKT, and Bcl-xL, with concomitant induction of BIM.  CONCLUSIONS: Findings presented here show that cotreatment with hsp90 inhibitor and JAK2-TKI exerts synergistic activity against cultured and primary MPN cells.  In addn., treatment with hsp90 inhibitor may overcome resistance to JAK2-TKI in human MPN cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7mMbjQ3mqu7Vg90H21EOLACvtfcHk0likx2Gt3uQg0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCmtrjI&md5=c4df75f96ef342b3d54e441cb5bccc9e</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1541%26sid%3Dliteratum%253Aachs%26aulast%3DFiskus%26aufirst%3DW.%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DManshouri%26aufirst%3DT.%26aulast%3DRao%26aufirst%3DR.%26aulast%3DBalusu%26aufirst%3DR.%26aulast%3DVenkannagari%26aufirst%3DS.%26aulast%3DRao%26aufirst%3DN.%2BN.%26aulast%3DHa%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DJ.%2BE.%26aulast%3DHembruff%26aufirst%3DS.%2BL.%26aulast%3DAbhyankar%26aufirst%3DS.%26aulast%3DMcGuirk%26aufirst%3DJ.%26aulast%3DBhalla%26aufirst%3DK.%2BN.%26atitle%3DHsp90%2520inhibitor%2520is%2520synergistic%2520with%2520JAK2%2520inhibitor%2520and%2520overcomes%2520resistance%2520to%2520JAK2-TKI%2520in%2520human%2520myeloproliferative%2520neoplasm%2520cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D7347%26epage%3D7358%26doi%3D10.1158%2F1078-0432.CCR-11-1541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group">Weigert, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bird, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopp, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapuy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Bodegom, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marubayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christie, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeown, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paranal, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaul, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vangrevelinghe, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romanet, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiedt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evrot, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Pover, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Régnier, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erdmann, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sallan, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baffert, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radimerski, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstock, D. M.</span><span> </span><span class="NLM_article-title">Genetic resistance to JAK2 enzymatic inhibitors is overcome by Hsp90 inhibition</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">209</span><span class="NLM_x">, </span> <span class="NLM_fpage">259</span><span class="NLM_x">–</span> <span class="NLM_lpage">273</span><span class="refDoi"> DOI: 10.1084/jem.20111694</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1084%2Fjem.20111694" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=209&publication_year=2012&pages=259-273&author=O.+Weigertauthor=A.+A.+Laneauthor=L.+Birdauthor=N.+Koppauthor=B.+Chapuyauthor=D.+van+Bodegomauthor=A.+V.+Tomsauthor=S.+Marubayashiauthor=A.+L.+Christieauthor=M.+McKeownauthor=R.+M.+Paranalauthor=J.+E.+Bradnerauthor=A.+Yodaauthor=C.+Gaulauthor=E.+Vangrevelingheauthor=V.+Romanetauthor=M.+Murakamiauthor=R.+Tiedtauthor=N.+Ebelauthor=E.+Evrotauthor=A.+De+Poverauthor=C.+H.+R%C3%A9gnierauthor=D.+Erdmannauthor=F.+Hofmannauthor=M.+J.+Eckauthor=S.+E.+Sallanauthor=R.+L.+Levineauthor=A.+L.+Kungauthor=F.+Baffertauthor=T.+Radimerskiauthor=D.+M.+Weinstock&title=Genetic+resistance+to+JAK2+enzymatic+inhibitors+is+overcome+by+Hsp90+inhibition&doi=10.1084%2Fjem.20111694"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1084%2Fjem.20111694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20111694%26sid%3Dliteratum%253Aachs%26aulast%3DWeigert%26aufirst%3DO.%26aulast%3DLane%26aufirst%3DA.%2BA.%26aulast%3DBird%26aufirst%3DL.%26aulast%3DKopp%26aufirst%3DN.%26aulast%3DChapuy%26aufirst%3DB.%26aulast%3Dvan%2BBodegom%26aufirst%3DD.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DMarubayashi%26aufirst%3DS.%26aulast%3DChristie%26aufirst%3DA.%2BL.%26aulast%3DMcKeown%26aufirst%3DM.%26aulast%3DParanal%26aufirst%3DR.%2BM.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DYoda%26aufirst%3DA.%26aulast%3DGaul%26aufirst%3DC.%26aulast%3DVangrevelinghe%26aufirst%3DE.%26aulast%3DRomanet%26aufirst%3DV.%26aulast%3DMurakami%26aufirst%3DM.%26aulast%3DTiedt%26aufirst%3DR.%26aulast%3DEbel%26aufirst%3DN.%26aulast%3DEvrot%26aufirst%3DE.%26aulast%3DDe%2BPover%26aufirst%3DA.%26aulast%3DR%25C3%25A9gnier%26aufirst%3DC.%2BH.%26aulast%3DErdmann%26aufirst%3DD.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSallan%26aufirst%3DS.%2BE.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DBaffert%26aufirst%3DF.%26aulast%3DRadimerski%26aufirst%3DT.%26aulast%3DWeinstock%26aufirst%3DD.%2BM.%26atitle%3DGenetic%2520resistance%2520to%2520JAK2%2520enzymatic%2520inhibitors%2520is%2520overcome%2520by%2520Hsp90%2520inhibition%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2012%26volume%3D209%26spage%3D259%26epage%3D273%26doi%3D10.1084%2Fjem.20111694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group">Fridman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarlis, N. J.</span><span> </span><span class="NLM_article-title">The interplay between inhibition of JAK2 and Hsp90</span> <span class="citation_source-journal">JAKSTAT</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">–</span> <span class="NLM_lpage">79</span><span class="refDoi"> DOI: 10.4161/jkst.20293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.4161%2Fjkst.20293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=24058754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252FgsV2rug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2012&pages=77-79&author=J.+S.+Fridmanauthor=N.+J.+Sarlis&title=The+interplay+between+inhibition+of+JAK2+and+Hsp90&doi=10.4161%2Fjkst.20293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">The interplay between inhibition of JAK2 and HSP90</span></div><div class="casAuthors">Fridman Jordan S; Sarlis Nicholas J</div><div class="citationInfo"><span class="NLM_cas:title">JAK-STAT</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">77-9</span>
        ISSN:<span class="NLM_cas:issn">2162-3988</span>.
    </div><div class="casAbstract">A recent article by Weigert et al. published in The Journal of Experimental Medicine described the in vitro generation of synthetic mutations in Janus kinase 2 (JAK 2) that decreased the potency of JAK2 (or JAK1/JAK2) inhibitors in artificial systems.  The authors found that heat shock protein 90 (HSP90) inhibitors circumvented the potency shift and suggested that HSP90 inhibition may abrogate JAK inhibitor resistance in these experimental systems.  However, the clinical relevance of these laboratory-generated JAK2 mutations, which have not been identified to-date in patients treated with JAK inhibitors, and the therapeutic potential of HSP90 inhibitors in diseases involving aberrant JAK-STAT signaling remain to be determined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcScWPrS0MCP8Y2y4bB4mnvYfW6udTcc2eb3HHrFXcuMw7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FgsV2rug%253D%253D&md5=e8226718916d6711fe850e96eed94126</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.4161%2Fjkst.20293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fjkst.20293%26sid%3Dliteratum%253Aachs%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DSarlis%26aufirst%3DN.%2BJ.%26atitle%3DThe%2520interplay%2520between%2520inhibition%2520of%2520JAK2%2520and%2520Hsp90%26jtitle%3DJAKSTAT%26date%3D2012%26volume%3D1%26spage%3D77%26epage%3D79%26doi%3D10.4161%2Fjkst.20293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, B. P.</span><span> </span><span class="NLM_article-title">KIT mutations in GIST</span> <span class="citation_source-journal">Curr. Opin. Genet. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">7</span><span class="refDoi"> DOI: 10.1016/j.gde.2006.12.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.gde.2006.12.010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=3-7&author=J.+A.+Fletcherauthor=B.+P.+Rubin&title=KIT+mutations+in+GIST&doi=10.1016%2Fj.gde.2006.12.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.gde.2006.12.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gde.2006.12.010%26sid%3Dliteratum%253Aachs%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DRubin%26aufirst%3DB.%2BP.%26atitle%3DKIT%2520mutations%2520in%2520GIST%26jtitle%3DCurr.%2520Opin.%2520Genet.%2520Dev.%26date%3D2007%26volume%3D17%26spage%3D3%26epage%3D7%26doi%3D10.1016%2Fj.gde.2006.12.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group">Rossi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasparotto, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miceli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toffolatti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallina, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scaramel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marzotto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boscato, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messerini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearzi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzoleni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capella, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrigoni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonzogni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sidoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amore, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gronchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maestro, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dei Tos, A. P.</span><span> </span><span class="NLM_article-title">KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study</span> <span class="citation_source-journal">Am. J. Surg. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">922</span><span class="NLM_x">–</span> <span class="NLM_lpage">930</span><span class="refDoi"> DOI: 10.1097/PAS.0000000000000418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1097%2FPAS.0000000000000418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=25970686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A280%3ADC%252BC2MfjsFyguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2015&pages=922-930&author=S.+Rossiauthor=D.+Gasparottoauthor=R.+Miceliauthor=L.+Toffolattiauthor=G.+Gallinaauthor=E.+Scaramelauthor=A.+Marzottoauthor=E.+Boscatoauthor=L.+Messeriniauthor=I.+Bearziauthor=G.+Mazzoleniauthor=C.+Capellaauthor=G.+Arrigoniauthor=A.+Sonzogniauthor=A.+Sidoniauthor=L.+Marianiauthor=P.+Amoreauthor=A.+Gronchiauthor=P.+G.+Casaliauthor=R.+Maestroauthor=A.+P.+Dei+Tos&title=KIT%2C+PDGFRA%2C+and+BRAF+mutational+spectrum+impacts+on+the+natural+history+of+imatinib-naive+localized+GIST%3A+a+population-based+study&doi=10.1097%2FPAS.0000000000000418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study</span></div><div class="casAuthors">Rossi Sabrina; Gasparotto Daniela; Miceli Rosalba; Toffolatti Luisa; Gallina Giovanna; Scaramel Enrico; Marzotto Alessandra; Boscato Elena; Messerini Luca; Bearzi Italo; Mazzoleni Guido; Capella Carlo; Arrigoni Gianluigi; Sonzogni Aurelio; Sidoni Angelo; Mariani Luigi; Amore Paola; Gronchi Alessandro; Casali Paolo G; Maestro Roberta; Dei Tos Angelo P</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of surgical pathology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">922-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The mutation status of KIT or PDGFRA notoriously affects the response of advanced gastrointestinal stromal tumors (GISTs) to tyrosine kinase inhibitors.  Conversely, it is currently still unclear whether mutation status impinges on the prognosis of localized, untreated GISTs.  Hence, at present, this variable is not included in decision making for adjuvant therapy.  A series of 451 primary localized GISTs were analyzed for KIT, PDGFRA, and BRAF mutations.  Univariable and multivariable analyses and a backward selection procedure were used to assess the impact of mutation status on overall survival and to identify prognostically homogenous groups.  Mutation was a significant prognostic indicator of overall survival in naive, localized GISTs (P<0.001): KIT-mutated patients had a worse outcome than PDGFRA-mutated or triple-negative (KIT, PDGFRA, BRAF wild-type) cases.  Multivariable Cox regression models allowed us to identify 3 molecular risk groups: group I exhibited the best outcome and included PDGFRA exon 12, BRAF, and KIT exon 13-mutated cases; group II, of intermediate clinical phenotype (HR=3.06), included triple-negative, KIT exon 17, PDGFRA exon 18 D842V, and PDGFRA exon 14-mutated cases; group III displayed the worst outcome (hazard ratio=4.52), and comprised KIT exon 9 and exon 11 and PDGFRA exon 18 mutations apart from D842V.  This study highlights the prognostic impact of mutation status on the natural course of GIST and suggests that the molecular prognostic grouping may complement the conventional clinicopathologic risk stratification criteria in decision making for adjuvant therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRn1i1qso7YZ0loaUqgkFHkfW6udTcc2eb3HHrFXcuMw7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfjsFyguw%253D%253D&md5=85caca04b3567e99602f94a812abbae4</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1097%2FPAS.0000000000000418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FPAS.0000000000000418%26sid%3Dliteratum%253Aachs%26aulast%3DRossi%26aufirst%3DS.%26aulast%3DGasparotto%26aufirst%3DD.%26aulast%3DMiceli%26aufirst%3DR.%26aulast%3DToffolatti%26aufirst%3DL.%26aulast%3DGallina%26aufirst%3DG.%26aulast%3DScaramel%26aufirst%3DE.%26aulast%3DMarzotto%26aufirst%3DA.%26aulast%3DBoscato%26aufirst%3DE.%26aulast%3DMesserini%26aufirst%3DL.%26aulast%3DBearzi%26aufirst%3DI.%26aulast%3DMazzoleni%26aufirst%3DG.%26aulast%3DCapella%26aufirst%3DC.%26aulast%3DArrigoni%26aufirst%3DG.%26aulast%3DSonzogni%26aufirst%3DA.%26aulast%3DSidoni%26aufirst%3DA.%26aulast%3DMariani%26aufirst%3DL.%26aulast%3DAmore%26aufirst%3DP.%26aulast%3DGronchi%26aufirst%3DA.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26aulast%3DMaestro%26aufirst%3DR.%26aulast%3DDei%2BTos%26aufirst%3DA.%2BP.%26atitle%3DKIT%252C%2520PDGFRA%252C%2520and%2520BRAF%2520mutational%2520spectrum%2520impacts%2520on%2520the%2520natural%2520history%2520of%2520imatinib-naive%2520localized%2520GIST%253A%2520a%2520population-based%2520study%26jtitle%3DAm.%2520J.%2520Surg.%2520Pathol.%26date%3D2015%26volume%3D39%26spage%3D922%26epage%3D930%26doi%3D10.1097%2FPAS.0000000000000418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span> </span><span class="NLM_article-title">The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level</span> <span class="citation_source-journal">Leuk. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">575</span><span class="NLM_x">–</span> <span class="NLM_lpage">582</span><span class="refDoi"> DOI: 10.1016/j.leukres.2005.08.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.leukres.2005.08.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=16213582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD28Xit1Clsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2006&pages=575-582&author=W.+Yuauthor=Q.+Raoauthor=M.+Wangauthor=Z.+Tianauthor=D.+Linauthor=X.+Liuauthor=J.+Wang&title=The+Hsp90+inhibitor+17-allylamide-17-demethoxygeldanamycin+induces+apoptosis+and+differentiation+of+Kasumi-1+harboring+the+Asn822Lys+KIT+mutation+and+down-regulates+KIT+protein+level&doi=10.1016%2Fj.leukres.2005.08.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level</span></div><div class="casAuthors">Yu, Wenjuan; Rao, Qing; Wang, Min; Tian, Zheng; Lin, Dong; Liu, Xiangrong; Wang, Jianxiang</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">575-582</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) serves as a chaperone for a no. of cell signaling proteins, including many tyrosine and serine/threonine kinases, which are involved in proliferation and/or survival.  The benzoquinone ansamycin geldanamycin has been shown to bind to Hsp90 and to specifically inhibit this chaperone's function, resulting in client protein destabilization. 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is a chem. deriv. of geldanamycin.  KIT is the receptor for stem cell factor (SCF) and required for normal hematopoiesis.  Mutations in c-Kit result in ligand-independent tyrosine kinase activity and uncontrolled cell proliferation.  Kasumi-1 is t(8;21) acute myeloid leukemia (AML) cell line harboring mutated KIT with Asn822Lys substitution.  Our present studies demonstrate that 17-AAG inhibits Kasumi-1 cells proliferation and exerts apoptosis- and differentiation-inducing effects in a dose- and time-dependent manner.  The growth-inhibitory IC50 value for 17-AAG treatment is 0.62 μmol/L.  Characteristic apoptotic features were confirmed by morphol., internucleosomal DNA fragmentation, and annexin V staining. 17-AAG also causes the G0/G1 block of Kasumi-1 cells.  Significantly, 17-AAG-induced apoptosis of Kasumi-1 cells is assocd. with a decline in KIT protein level.  Our findings strongly suggest that 17-AAG might be an effective therapeutic agent targeting AML cells harboring mutated KIT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXmaHCIsAsBLVg90H21EOLACvtfcHk0lgPJ9kn_MpIDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xit1Clsbk%253D&md5=aed39d768b6b0885712cb68856e28905</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2005.08.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2005.08.028%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26aulast%3DRao%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DTian%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DThe%2520Hsp90%2520inhibitor%252017-allylamide-17-demethoxygeldanamycin%2520induces%2520apoptosis%2520and%2520differentiation%2520of%2520Kasumi-1%2520harboring%2520the%2520Asn822Lys%2520KIT%2520mutation%2520and%2520down-regulates%2520KIT%2520protein%2520level%26jtitle%3DLeuk.%2520Res.%26date%3D2006%26volume%3D30%26spage%3D575%26epage%3D582%26doi%3D10.1016%2Fj.leukres.2005.08.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group">Tsujimura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyoi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiotsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishida, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoe, T.</span><span> </span><span class="NLM_article-title">Selective KIT inhibitor KI-328 and Hsp90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia</span> <span class="citation_source-journal">Int. J. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">624</span><span class="NLM_x">–</span> <span class="NLM_lpage">633</span><span class="refDoi"> DOI: 10.1007/s12185-010-0692-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1007%2Fs12185-010-0692-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=20890793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlyktr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2010&pages=624-633&author=A.+Tsujimuraauthor=H.+Kiyoiauthor=Y.+Shiotsuauthor=Y.+Ishikawaauthor=Y.+Moriauthor=H.+Ishidaauthor=T.+Tokiauthor=E.+Itoauthor=T.+Naoe&title=Selective+KIT+inhibitor+KI-328+and+Hsp90+inhibitor+show+different+potency+against+the+type+of+KIT+mutations+recurrently+identified+in+acute+myeloid+leukemia&doi=10.1007%2Fs12185-010-0692-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia</span></div><div class="casAuthors">Tsujimura, Akane; Kiyoi, Hitoshi; Shiotsu, Yukimasa; Ishikawa, Yu-Ichi; Mori, Yumiko; Ishida, Hiroshi; Toki, Tsutomu; Ito, Etsuro; Naoe, Tomoki</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Hematology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">624-633</span>CODEN:
                <span class="NLM_cas:coden">IJHEEY</span>;
        ISSN:<span class="NLM_cas:issn">0925-5710</span>.
    
            (<span class="NLM_cas:orgname">Springer Japan</span>)
        </div><div class="casAbstract">Activating mutations of KIT play an important role in the pathophysiol. of several human malignancies, including acute myeloid leukemia.  Activated KIT kinase is therefore a promising mol. target for the treatment of many malignancies harboring KIT activation.  Here we examd. the potency of a novel KIT inhibitor KI-328 against different types of mutant KIT kinases recurrently identified in AML.  KI-328 shows selective potency against KIT kinase for the in vitro kinase assay, and inhibits the growth of wild-type (Wt)- and mutant-KIT-expressing cells, while it has little potency against D816V-KIT.  Comparable anal. of several potent KIT inhibitors regarding growth inhibitory effects on a variety of mutant-KIT-expressing cells revealed that multi-kinase inhibitors have the same potency against D816V-KIT as other mutant KITs; however, the predominant potency against D816V-KIT was obsd. in heat shock protein 90 (HSP90) inhibitors.  Furthermore, HSP90 inhibitors suppress the growth of D816V-KIT-expressing cells at the concn. at which the growth of other mutant-KIT-expressing cells is not affected.  These results collectively indicated that potent KIT inhibitors have different potency against the type of mutant KIT kinases.  Therefore, KIT inhibitors are required to validate potency against several types of mutant KIT kinases for the clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2QECYq8hX9rVg90H21EOLACvtfcHk0lgPJ9kn_MpIDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlyktr3O&md5=ae10484c99fd2fd8b4ebb5e7602ceffa</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1007%2Fs12185-010-0692-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12185-010-0692-8%26sid%3Dliteratum%253Aachs%26aulast%3DTsujimura%26aufirst%3DA.%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DShiotsu%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DMori%26aufirst%3DY.%26aulast%3DIshida%26aufirst%3DH.%26aulast%3DToki%26aufirst%3DT.%26aulast%3DIto%26aufirst%3DE.%26aulast%3DNaoe%26aufirst%3DT.%26atitle%3DSelective%2520KIT%2520inhibitor%2520KI-328%2520and%2520Hsp90%2520inhibitor%2520show%2520different%2520potency%2520against%2520the%2520type%2520of%2520KIT%2520mutations%2520recurrently%2520identified%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DInt.%2520J.%2520Hematol.%26date%3D2010%26volume%3D92%26spage%3D624%26epage%3D633%26doi%3D10.1007%2Fs12185-010-0692-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">Hsp90 inhibition in imatinib-resistant gastrointestinal stromal tumor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">9153</span><span class="NLM_x">–</span> <span class="NLM_lpage">9161</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-0165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F0008-5472.CAN-06-0165" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=9153-9161&author=S.+Bauerauthor=L.+K.+Yuauthor=G.+D.+Demetriauthor=J.+A.+Fletcher&title=Hsp90+inhibition+in+imatinib-resistant+gastrointestinal+stromal+tumor&doi=10.1158%2F0008-5472.CAN-06-0165"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-0165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-0165%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DL.%2BK.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DHsp90%2520inhibition%2520in%2520imatinib-resistant%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D9153%26epage%3D9161%26doi%3D10.1158%2F0008-5472.CAN-06-0165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group">Smyth, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Looy, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Lopez, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wozniak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayeda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schöffski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, N. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallis, N. G.</span><span> </span><span class="NLM_article-title">The Hsp90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1799</span><span class="NLM_x">–</span> <span class="NLM_lpage">1808</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-1046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1535-7163.MCT-11-1046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22714264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOisLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1799-1808&author=T.+Smythauthor=T.+V.+Van+Looyauthor=J.+E.+Curryauthor=A.+M.+Rodriguez-Lopezauthor=A.+Wozniakauthor=M.+Zhuauthor=R.+Donskyauthor=J.+G.+Morganauthor=M.+Mayedaauthor=J.+A.+Fletcherauthor=P.+Sch%C3%B6ffskiauthor=J.+Lyonsauthor=N.+T.+Thompsonauthor=N.+G.+Wallis&title=The+Hsp90+inhibitor%2C+AT13387%2C+is+effective+against+imatinib-sensitive+and+-resistant+gastrointestinal+stromal+tumor+models&doi=10.1158%2F1535-7163.MCT-11-1046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models</span></div><div class="casAuthors">Smyth, Tomoko; Van Looy, Thomas; Curry, Jayne E.; Rodriguez-Lopez, Ana M.; Wozniak, Agnieszka; Zhu, Meijun; Donsky, Rachel; Morgan, Jennifer G.; Mayeda, Mark; Fletcher, Jonathan A.; Schoeffski, Patrick; Lyons, John; Thompson, Neil T.; Wallis, Nicola G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1799-1808</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The majority of gastrointestinal stromal tumors (GIST) are characterized by activating mutations of KIT, an HSP90 client protein.  Further secondary resistance mutations within KIT limit clin. responses to tyrosine kinase inhibitors, such as imatinib.  The dependence of KIT and its mutated forms on HSP90 suggests that HSP90 inhibition might be a valuable treatment option for GIST, which would be equally effective on imatinib-sensitive and -resistant clones.  We investigated the activity of AT13387, a potent HSP90 inhibitor currently being evaluated in clin. trials, in both in vitro and in vivo GIST models.  AT13387 inhibited the proliferation of imatinib-sensitive (GIST882, GIST-T1) and -resistant (GIST430, GIST48) cell lines, including those resistant to the geldanamycin analog HSP90 inhibitor, 17-AAG.  Treatment with AT13387 resulted in depletion of HSP90 client proteins, KIT and AKT, along with their phospho-forms in imatinib-sensitive and -resistant cell lines, irresp. of KIT mutation.  KIT signaling was ablated, whereas HSP70, a marker of HSP90 inhibition, was induced.  In vivo, antitumor activity of AT13387 was showed in both the imatinib-sensitive, GIST-PSW, xenograft model and a newly characterized imatinib-resistant, GIST430, xenograft model.  Induction of HSP70, depletion of phospho-KIT and inhibition of KIT signaling were seen in tumors from both models after treatment with AT13387.  A combination of imatinib and AT13387 treatment in the imatinib-resistant GIST430 model significantly enhanced tumor growth inhibition over either of the monotherapies.  Importantly, the combination of AT13387 and imatinib was well tolerated.  These results suggest AT13387 is an excellent candidate for clin. testing in GIST in combination with imatinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot4atmFxxE_bVg90H21EOLACvtfcHk0ljeSX7pXiJkXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOisLrJ&md5=2649c9efc1250257611243731d0fa561</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-1046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-1046%26sid%3Dliteratum%253Aachs%26aulast%3DSmyth%26aufirst%3DT.%26aulast%3DVan%2BLooy%26aufirst%3DT.%2BV.%26aulast%3DCurry%26aufirst%3DJ.%2BE.%26aulast%3DRodriguez-Lopez%26aufirst%3DA.%2BM.%26aulast%3DWozniak%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DDonsky%26aufirst%3DR.%26aulast%3DMorgan%26aufirst%3DJ.%2BG.%26aulast%3DMayeda%26aufirst%3DM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DSch%25C3%25B6ffski%26aufirst%3DP.%26aulast%3DLyons%26aufirst%3DJ.%26aulast%3DThompson%26aufirst%3DN.%2BT.%26aulast%3DWallis%26aufirst%3DN.%2BG.%26atitle%3DThe%2520Hsp90%2520inhibitor%252C%2520AT13387%252C%2520is%2520effective%2520against%2520imatinib-sensitive%2520and%2520-resistant%2520gastrointestinal%2520stromal%2520tumor%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1799%26epage%3D1808%26doi%3D10.1158%2F1535-7163.MCT-11-1046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group">Dewaele, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wasag, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cools, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sciot, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prenen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandenberghe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wozniak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schöffski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marynen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debiec-Rychter, M.</span><span> </span><span class="NLM_article-title">Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, an Hsp90 inhibitor, against gastrointestinal stromal tumor associated PDGFRAD842V mutation</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">5749</span><span class="NLM_x">–</span> <span class="NLM_lpage">5758</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-0533</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1078-0432.CCR-08-0533" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=18794084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFaitrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=5749-5758&author=B.+Dewaeleauthor=B.+Wasagauthor=J.+Coolsauthor=R.+Sciotauthor=H.+Prenenauthor=P.+Vandenbergheauthor=A.+Wozniakauthor=P.+Sch%C3%B6ffskiauthor=P.+Marynenauthor=M.+Debiec-Rychter&title=Activity+of+dasatinib%2C+a+dual+SRC%2FABL+kinase+inhibitor%2C+and+IPI-504%2C+an+Hsp90+inhibitor%2C+against+gastrointestinal+stromal+tumor+associated+PDGFRAD842V+mutation&doi=10.1158%2F1078-0432.CCR-08-0533"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor-Associated PDGFRAD842V Mutation</span></div><div class="casAuthors">Dewaele, Barbara; Wasag, Bartosz; Cools, Jan; Sciot, Raf; Prenen, Hans; Vandenberghe, Peter; Wozniak, Agnieszka; Schoeffski, Patrick; Marynen, Peter; Debiec-Rychter, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5749-5758</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Activating mutations in platelet-derived growth factor receptor-α (PDGFRA) have been reported in ∼5% to 10% of patients with gastrointestinal stromal tumors (GIST).  Imatinib efficiently inhibits the juxtamembrane PDGFRA mutations, whereas many tyrosine kinase domain activation loop PDGFRA mutations confer primary resistance to imatinib.  In this study, we compared the efficacy of second-line tyrosine kinase inhibitors such as dasatinib, sorafenib, and nilotinib against two GIST-related PDGFRA mutants, PDGFRAD842V and PDGFRAΔDIM842-844.  In addn., we sought to investigate the inhibitory effect of the heat shock protein 90 inhibitor, IPI-504, on these mutants.  Exptl. Design: Primary imatinib-resistant tumor cells and cell lines expressing imatinib-resistant PDGFRAD842V or imatinib-sensitive PDGFRAΔDIM842-844 mutants were treated with different concns. of dasatinib, sorafenib, nilotinib, and IPI-504.  The effect of treatment on proliferation, survival, and signaling was detd.  Results: All inhibitors tested exhibited a high efficacy toward the PDGFRAΔDIM842-844 mutant.  In contrast, ex vivo and in vitro assays revealed that only dasatinib potently inhibited the PDGFRAD842V isoform with an IC50 value of 62 nmol/L.  Sorafenib and nilotinib were significantly less efficacious against this mutation, inhibiting the PDGFRA kinase activity at >1,000 and >5,000 nmol/L, and suppressing the proliferation of the cells expressing the PDGFRAD842V mutant with an IC50 value of 239 and 1,310 nmol/L, resp.  IPI-504 treatment potently inhibited PDGFRA kinase activity by inducing the degrdn. of PDGFRAD842V and PDGFRAΔDIM842-844 at 256 and 182 nmol/L, resp. Conclusions: Treatment with dasatinib or the heat shock protein 90 inhibitor IPI-504 may provide a therapeutic alternative for GIST patients whose tumors carry the imatinib-resistant PDGFRAD842V mutant isoform.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4gIQAF7OaK7Vg90H21EOLACvtfcHk0ljeSX7pXiJkXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFaitrrF&md5=d69e8d1c2317678641ac944f59e6121b</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-0533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-0533%26sid%3Dliteratum%253Aachs%26aulast%3DDewaele%26aufirst%3DB.%26aulast%3DWasag%26aufirst%3DB.%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DSciot%26aufirst%3DR.%26aulast%3DPrenen%26aufirst%3DH.%26aulast%3DVandenberghe%26aufirst%3DP.%26aulast%3DWozniak%26aufirst%3DA.%26aulast%3DSch%25C3%25B6ffski%26aufirst%3DP.%26aulast%3DMarynen%26aufirst%3DP.%26aulast%3DDebiec-Rychter%26aufirst%3DM.%26atitle%3DActivity%2520of%2520dasatinib%252C%2520a%2520dual%2520SRC%252FABL%2520kinase%2520inhibitor%252C%2520and%2520IPI-504%252C%2520an%2520Hsp90%2520inhibitor%252C%2520against%2520gastrointestinal%2520stromal%2520tumor%2520associated%2520PDGFRAD842V%2520mutation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D5749%26epage%3D5758%26doi%3D10.1158%2F1078-0432.CCR-08-0533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group">Richardson, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chanan-Khan, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lonial, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnan, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alsina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albitar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study</span> <span class="citation_source-journal">Br. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">153</span><span class="NLM_x">, </span> <span class="NLM_fpage">729</span><span class="NLM_x">–</span> <span class="NLM_lpage">740</span><span class="refDoi"> DOI: 10.1111/j.1365-2141.2011.08664.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1111%2Fj.1365-2141.2011.08664.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=21534941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXoslajtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=2011&pages=729-740&author=P.+G.+Richardsonauthor=A.+A.+Chanan-Khanauthor=S.+Lonialauthor=A.+Y.+Krishnanauthor=M.+P.+Carrollauthor=M.+Alsinaauthor=M.+Albitarauthor=D.+Bermanauthor=M.+Messinaauthor=K.+C.+Anderson&title=Tanespimycin+and+bortezomib+combination+treatment+in+patients+with+relapsed+or+relapsed+and+refractory+multiple+myeloma%3A+results+of+a+phase+1%2F2+study&doi=10.1111%2Fj.1365-2141.2011.08664.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study</span></div><div class="casAuthors">Richardson, Paul G.; Chanan-Khan, Asher A.; Lonial, Sagar; Krishnan, Amrita Y.; Carroll, Michael P.; Alsina, Melissa; Albitar, Maher; Berman, David; Messina, Marianne; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">153</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">729-740</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">This open-label, dose escalation, multicentre phase 1/2 trial was undertaken to det. the safety and tolerability of the heat shock protein 90 (HSP90) inhibitor tanespimycin (100-340 mg/m2) + bortezomib (0.7-1.3 mg/m2) given on days 1, 4, 8 and 11 in each 21-d cycle.  Phase 2 expansion occurred at the highest tested dose of tanespimycin at 340 mg/m2 and bortezomib at 1.3 mg/m2.  Seventy-two patients (median age, 60 years) with relapsed or relapsed and refractory multiple myeloma (MM) were enrolled; 63 patients (89%) completed the study.  Tanespimycin in combination with bortezomib was well tolerated; few patients experienced significant neutropenia, constipation and anorexia (<10%), and no patients developed severe peripheral neuropathy.  Among 67 efficacy-evaluable patients, there were 2 (3%) complete responses and 8 (12%) partial responses, for an objective response rate (ORR) of 27%, including 8 (12%) minimal responses.  Response rates were highest among bortezomib-naive patients and proved durable in all patient subgroups, including those with bortezomib-refractory disease.  Pharmacodynamic analyses indicated that tanespimycin plus bortezomib effectively inhibited the proteasome, as evidenced by decreased 20S proteasome activity, and inhibited HSP90, as reflected by increased HSP70 expression.  The results of this study support addnl. studies of this combination approach in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw1MlwVkziIrVg90H21EOLACvtfcHk0ljeSX7pXiJkXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXoslajtrY%253D&md5=c1d4ac3b4758b8830cf2b192979e3961</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2011.08664.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2011.08664.x%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DChanan-Khan%26aufirst%3DA.%2BA.%26aulast%3DLonial%26aufirst%3DS.%26aulast%3DKrishnan%26aufirst%3DA.%2BY.%26aulast%3DCarroll%26aufirst%3DM.%2BP.%26aulast%3DAlsina%26aufirst%3DM.%26aulast%3DAlbitar%26aufirst%3DM.%26aulast%3DBerman%26aufirst%3DD.%26aulast%3DMessina%26aufirst%3DM.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DTanespimycin%2520and%2520bortezomib%2520combination%2520treatment%2520in%2520patients%2520with%2520relapsed%2520or%2520relapsed%2520and%2520refractory%2520multiple%2520myeloma%253A%2520results%2520of%2520a%2520phase%25201%252F2%2520study%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2011%26volume%3D153%26spage%3D729%26epage%3D740%26doi%3D10.1111%2Fj.1365-2141.2011.08664.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group">Schenk, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrickson, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Northfelt, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toft, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ames, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menefee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satele, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlichman, C.</span><span> </span><span class="NLM_article-title">Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1251</span><span class="NLM_x">–</span> <span class="NLM_lpage">1256</span><span class="refDoi"> DOI: 10.1007/s10637-013-9946-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1007%2Fs10637-013-9946-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=1251-1256&author=E.+Schenkauthor=A.+E.+Hendricksonauthor=D.+Northfeltauthor=D.+O.+Toftauthor=M.+M.+Amesauthor=M.+Menefeeauthor=D.+Sateleauthor=R.+Qinauthor=C.+Erlichman&title=Phase+I+study+of+tanespimycin+in+combination+with+bortezomib+in+patients+with+advanced+solid+malignancies&doi=10.1007%2Fs10637-013-9946-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1007%2Fs10637-013-9946-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-013-9946-7%26sid%3Dliteratum%253Aachs%26aulast%3DSchenk%26aufirst%3DE.%26aulast%3DHendrickson%26aufirst%3DA.%2BE.%26aulast%3DNorthfelt%26aufirst%3DD.%26aulast%3DToft%26aufirst%3DD.%2BO.%26aulast%3DAmes%26aufirst%3DM.%2BM.%26aulast%3DMenefee%26aufirst%3DM.%26aulast%3DSatele%26aufirst%3DD.%26aulast%3DQin%26aufirst%3DR.%26aulast%3DErlichman%26aufirst%3DC.%26atitle%3DPhase%2520I%2520study%2520of%2520tanespimycin%2520in%2520combination%2520with%2520bortezomib%2520in%2520patients%2520with%2520advanced%2520solid%2520malignancies%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2013%26volume%3D31%26spage%3D1251%26epage%3D1256%26doi%3D10.1007%2Fs10637-013-9946-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group">Pedersen, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang-Gillam, A</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlichman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McWilliams, R. R.</span><span> </span><span class="NLM_article-title">Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a mayo clinic phase II consortium study</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">963</span><span class="NLM_x">–</span> <span class="NLM_lpage">968</span><span class="refDoi"> DOI: 10.1007/s10637-015-0246-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1007%2Fs10637-015-0246-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=25952464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotFaktr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=963-968&author=K.+S.+Pedersenauthor=G.+P.+Kimauthor=N.+R.+Fosterauthor=A+Wang-Gillamauthor=C.+Erlichmanauthor=R.+R.+McWilliams&title=Phase+II+trial+of+gemcitabine+and+tanespimycin+%2817AAG%29+in+metastatic+pancreatic+cancer%3A+a+mayo+clinic+phase+II+consortium+study&doi=10.1007%2Fs10637-015-0246-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study</span></div><div class="casAuthors">Pedersen, Katrina S.; Kim, George P.; Foster, Nathan R.; Wang-Gillam, Andrea; Erlichman, Charles; McWilliams, Robert R.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">963-968</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Heat Shock Protein 90 (HSP90) is a mol. chaperone that stabilizes many oncogenic proteins.  HSP90 inhibitors may sensitize tumors to cytotoxic agents by causing client protein degrdn.  Gemcitabine, which has modest activity in pancreas cancer, activates Chk1, a client protein of HSP90.  This phase II trial was designed to det. whether 17AAG could enhance the clin. activity of gemcitabine through degrdn. of Chk1 in patients with stage IV pancreatic cancer.  A multicenter, prospective study combining gemcitabine and 17AAG enrolled patients with stage IV pancreatic adenocarcinoma, adequate liver and kidney function, ECOG performance status 0-2, and no prior chemotherapy for metastatic disease.  The primary goal was to achieve a 60 % overall survival at 6 mo.  Sixty-six patients were planned for accrual, with an interim anal. after 25 patients enrolled.  After a futility anal. to achieve the endpoint, accrual was halted with 21 patients enrolled.  No complete or partial responses were seen.  Forty percent of patients were alive at 6 mo.  Median overall survival was 5.4 mo.  Tolerability was moderate, with 65 % of patients having ≥ grade 3 adverse events (AE), and 15 % having grade 4 events.  The lack of clin. activity suggests that targeting Chk1 by inhibiting HSP90 is not important in pancreatic cancer sensitivity to gemcitabine alone.  Further studies of HSP90 targeted agents with gemcitabine alone are not warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3s_FEEPV0JLVg90H21EOLACvtfcHk0ljVeknE9UDYMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotFaktr4%253D&md5=9f29c2150dcdab2f143dc804ec504da5</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1007%2Fs10637-015-0246-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-015-0246-2%26sid%3Dliteratum%253Aachs%26aulast%3DPedersen%26aufirst%3DK.%2BS.%26aulast%3DKim%26aufirst%3DG.%2BP.%26aulast%3DFoster%26aufirst%3DN.%2BR.%26aulast%3DWang-Gillam%26aufirst%3DA%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3DMcWilliams%26aufirst%3DR.%2BR.%26atitle%3DPhase%2520II%2520trial%2520of%2520gemcitabine%2520and%2520tanespimycin%2520%252817AAG%2529%2520in%2520metastatic%2520pancreatic%2520cancer%253A%2520a%2520mayo%2520clinic%2520phase%2520II%2520consortium%2520study%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2015%26volume%3D33%26spage%3D963%26epage%3D968%26doi%3D10.1007%2Fs10637-015-0246-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group">Wahner Hendrickson, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oberg, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaser, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camoriano, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peethambaram, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colon-Otero, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlichman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karnitz, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haluska, P.</span><span> </span><span class="NLM_article-title">A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma</span> <span class="citation_source-journal">Gynecol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">210</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span><span class="refDoi"> DOI: 10.1016/j.ygyno.2011.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.ygyno.2011.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22047770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1WhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2012&pages=210-215&author=A.+E.+Wahner+Hendricksonauthor=A.+L.+Obergauthor=G.+Glaserauthor=J.+K.+Camorianoauthor=P.+P.+Peethambaramauthor=G.+Colon-Oteroauthor=C.+Erlichmanauthor=S.+P.+Ivyauthor=S.+H.+Kaufmannauthor=L.+M.+Karnitzauthor=P.+Haluska&title=A+phase+II+study+of+gemcitabine+in+combination+with+tanespimycin+in+advanced+epithelial+ovarian+and+primary+peritoneal+carcinoma&doi=10.1016%2Fj.ygyno.2011.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma</span></div><div class="casAuthors">Wahner Hendrickson, Andrea E.; Oberg, Ann L.; Glaser, Gretchen; Camoriano, John K.; Peethambaram, Prema P.; Colon-Otero, Gerardo; Erlichman, Charles; Ivy, S. Percy; Kaufmann, Scott H.; Karnitz, Larry M.; Haluska, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">210-215</span>CODEN:
                <span class="NLM_cas:coden">GYNOA3</span>;
        ISSN:<span class="NLM_cas:issn">0090-8258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Objective: To evaluate the efficacy and biol. effects of the gemcitabine/tanespimycin combination in patients with advanced ovarian and peritoneal cancer.  To assess the effect of tanespimycin on tumor cells, levels of the chaperone proteins HSP90 and HSP70 were examd. in peripheral blood mononuclear cells (PBMC) and paired tumor biopsy lysates.  Methods: Two-cohort phase II clin. trial.  Patients were grouped according to prior gemcitabine therapy.  All participants received tanespimycin 154 mg/m2 on days 1 and 9 of cycle 1 and days 2 and 9 of subsequent cycles.  Patients also received gemcitabine 750 mg/m2 on day 8 of the first treatment cycle and days 1 and 8 of subsequent cycles.  Results: The tanespimycin/gemcitabine combination induced a partial response in 1 gemcitabine naive patient and no partial responses in gemcitabine resistant patients.  Stable disease was seen in 6 patients (2 gemcitabine naive and 4 gemcitabine resistant).  The most common toxicities were hematol. (anemia and neutropenia) as well as nausea and vomiting.  Immunoblotting demonstrated limited upregulation of HSP70 but little or no change in levels of most client proteins in PBMC and paired tumor samples.  Conclusions: Although well tolerated, the tanespimycin/gemcitabine combination exhibited limited anticancer activity in patients with advanced epithelial ovarian and primary peritoneal carcinoma, perhaps because of failure to significantly downregulate the client proteins at clin. achievable exposures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-T12pU461n7Vg90H21EOLACvtfcHk0ljVeknE9UDYMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1WhsLs%253D&md5=869250ea826ae9c99a0ea0200747e57c</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1016%2Fj.ygyno.2011.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ygyno.2011.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DWahner%2BHendrickson%26aufirst%3DA.%2BE.%26aulast%3DOberg%26aufirst%3DA.%2BL.%26aulast%3DGlaser%26aufirst%3DG.%26aulast%3DCamoriano%26aufirst%3DJ.%2BK.%26aulast%3DPeethambaram%26aufirst%3DP.%2BP.%26aulast%3DColon-Otero%26aufirst%3DG.%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3DIvy%26aufirst%3DS.%2BP.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26aulast%3DKarnitz%26aufirst%3DL.%2BM.%26aulast%3DHaluska%26aufirst%3DP.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520gemcitabine%2520in%2520combination%2520with%2520tanespimycin%2520in%2520advanced%2520epithelial%2520ovarian%2520and%2520primary%2520peritoneal%2520carcinoma%26jtitle%3DGynecol.%2520Oncol.%26date%3D2012%26volume%3D124%26spage%3D210%26epage%3D215%26doi%3D10.1016%2Fj.ygyno.2011.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group">Heath, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hillman, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaishampayan, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkar, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaskins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitot, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pili, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carducci, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlichman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, G.</span><span> </span><span class="NLM_article-title">A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">7940</span><span class="NLM_x">–</span> <span class="NLM_lpage">7946</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-0221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1078-0432.CCR-08-0221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=19047126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVegt7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=7940-7946&author=E.+I.+Heathauthor=D.+W.+Hillmanauthor=U.+Vaishampayanauthor=S.+Shengauthor=F.+Sarkarauthor=F.+Harperauthor=M.+Gaskinsauthor=H.+C.+Pitotauthor=W.+Tanauthor=S.+P.+Ivyauthor=R.+Piliauthor=M.+A.+Carducciauthor=C.+Erlichmanauthor=G.+Liu&title=A+phase+II+trial+of+17-allylamino-17-demethoxygeldanamycin+in+patients+with+hormone-refractory+metastatic+prostate+cancer&doi=10.1158%2F1078-0432.CCR-08-0221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer</span></div><div class="casAuthors">Heath, Elisabeth I.; Hillman, David W.; Vaishampayan, Ulka; Sheng, Shijie; Sarkar, Fazlul; Harper, Felicity; Gaskins, Melvin; Pitot, Henry C.; Tan, Winston; Ivy, S. Percy; Pili, Roberto; Carducci, Michael A.; Erlichman, Charles; Liu, Glenn</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7940-7946</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is a benzoquinone ansamycin antibiotic with antiproliferative activity in several mouse xenograft models, including prostate cancer models.  A two-stage phase II study was conducted to assess the activity and toxicity profile of 17-AAG administered to patients with metastatic, hormone-refractory prostate cancer.  Exptl. Design: Patients with at least one prior systemic therapy and a rising prostate-specific antigen (PSA) were eligible.  Patients received 17-AAG at a dose of 300 mg/m2 i.v. weekly for 3 of 4 wk.  The primary objective was to assess the PSA response.  Secondary objectives were to det. overall survival, to assess toxicity, and to measure interleukin-6, interleukin-8, and maspin levels and quality of life.  RESULTS: Fifteen eligible patients were enrolled.  The median age was 68 years and the median PSA was 261 ng/mL.  Patients received 17-AAG for a median no. of two cycles.  Severe adverse events included grade 3 fatigue (four patients), grade 3 lymphopenia (two patients), and grade 3 back pain (two patients).  The median PSA progression-free survival was 1.8 mo (95% confidence interval, 1.3-3.4 mo).  The 6-mo overall survival was 71% (95% confidence interval, 52-100%).  CONCLUSIONS: 17-AAG did not show any activity with regard to PSA response.  Due to insufficient PSA response, enrollment was stopped at the end of first stage per study design.  The most significant severe toxicity was grade 3 fatigue.  Further evaluation of 17-AAG at a dose of 300 mg/m2 i.v. weekly as a single agent in patients with metastatic, hormone-refractory prostate cancer who received at least one prior systemic therapy is not warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptpyi-7O-7xLVg90H21EOLACvtfcHk0lgZyatx_iOC0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVegt7%252FI&md5=2292fa62e7694ded8386cf693faae8c0</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-0221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-0221%26sid%3Dliteratum%253Aachs%26aulast%3DHeath%26aufirst%3DE.%2BI.%26aulast%3DHillman%26aufirst%3DD.%2BW.%26aulast%3DVaishampayan%26aufirst%3DU.%26aulast%3DSheng%26aufirst%3DS.%26aulast%3DSarkar%26aufirst%3DF.%26aulast%3DHarper%26aufirst%3DF.%26aulast%3DGaskins%26aufirst%3DM.%26aulast%3DPitot%26aufirst%3DH.%2BC.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DIvy%26aufirst%3DS.%2BP.%26aulast%3DPili%26aufirst%3DR.%26aulast%3DCarducci%26aufirst%3DM.%2BA.%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DG.%26atitle%3DA%2520phase%2520II%2520trial%2520of%252017-allylamino-17-demethoxygeldanamycin%2520in%2520patients%2520with%2520hormone-refractory%2520metastatic%2520prostate%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D7940%26epage%3D7946%26doi%3D10.1158%2F1078-0432.CCR-08-0221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group">Gartner, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorusso, P. M.</span><span> </span><span class="NLM_article-title">A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">933</span><span class="NLM_x">–</span> <span class="NLM_lpage">937</span><span class="refDoi"> DOI: 10.1007/s10549-011-1866-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1007%2Fs10549-011-1866-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22083229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFKmsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2012&pages=933-937&author=E.+M.+Gartnerauthor=P.+Silvermanauthor=M.+Simonauthor=L.+Flahertyauthor=J.+Abramsauthor=P.+Ivyauthor=P.+M.+Lorusso&title=A+phase+II+study+of+17-allylamino-17-demethoxygeldanamycin+in+metastatic+or+locally+advanced%2C+unresectable+breast+cancer&doi=10.1007%2Fs10549-011-1866-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer</span></div><div class="casAuthors">Gartner, Elaina M.; Silverman, Paula; Simon, Michael; Flaherty, Lawrence; Abrams, Judith; Ivy, Percy; LoRusso, Patricia M.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">933-937</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) is an attractive target for breast cancer treatment, as it is required for the proper folding and stabilization of several proteins known to be involved in breast cancer growth and development.  These proteins include the epidermal growth factor receptor, human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), progesterone receptor (PR), and src. 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is an i.v. Hsp90 inhibitor in development for breast cancer treatment.  We conducted a phase II study of 17-AAG 220 mg/m2 on days 1, 4, 8, and 11 every 21 days in patients with metastatic and locally advanced breast cancer.  Since we expected the mol. effects of Hsp90 inhibition to extend beyond just ER, PR, and HER2 down regulation and to impact a variety of other cellular proteins, patients were not selected based on ER, PR, or HER2 status.  Eleven patients, including 6 patients with triple neg. breast cancer, were enrolled and treated.  There were no responses and 3 patients had stable disease as their best response.  Five patients developed grade 3/4 toxicities, which were primarily hepatic and pulmonary.  Based on these results, we do not recommend further study of 17-AAG at this dosing schedule or in unselected breast cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPbrnPczyKWrVg90H21EOLACvtfcHk0lgZyatx_iOC0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFKmsbg%253D&md5=d2e926f25ffed4022232774aaa410203</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1007%2Fs10549-011-1866-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-011-1866-7%26sid%3Dliteratum%253Aachs%26aulast%3DGartner%26aufirst%3DE.%2BM.%26aulast%3DSilverman%26aufirst%3DP.%26aulast%3DSimon%26aufirst%3DM.%26aulast%3DFlaherty%26aufirst%3DL.%26aulast%3DAbrams%26aufirst%3DJ.%26aulast%3DIvy%26aufirst%3DP.%26aulast%3DLorusso%26aufirst%3DP.%2BM.%26atitle%3DA%2520phase%2520II%2520study%2520of%252017-allylamino-17-demethoxygeldanamycin%2520in%2520metastatic%2520or%2520locally%2520advanced%252C%2520unresectable%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2012%26volume%3D131%26spage%3D933%26epage%3D937%26doi%3D10.1007%2Fs10549-011-1866-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group">Pacey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asad, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisen, T.</span><span> </span><span class="NLM_article-title">A phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">349</span><span class="refDoi"> DOI: 10.1007/s10637-010-9493-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1007%2Fs10637-010-9493-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=341-349&author=S.+Paceyauthor=M.+Goreauthor=D.+Chaoauthor=U.+Banerjiauthor=J.+Larkinauthor=S.+Sarkerauthor=K.+Owenauthor=Y.+Asadauthor=F.+Raynaudauthor=M.+Waltonauthor=I.+Judsonauthor=P.+Workmanauthor=T.+Eisen&title=A+phase+II+trial+of+17-allylamino%2C+17-demethoxygeldanamycin+%2817-AAG%2C+tanespimycin%29+in+patients+with+metastatic+melanoma&doi=10.1007%2Fs10637-010-9493-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1007%2Fs10637-010-9493-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-010-9493-4%26sid%3Dliteratum%253Aachs%26aulast%3DPacey%26aufirst%3DS.%26aulast%3DGore%26aufirst%3DM.%26aulast%3DChao%26aufirst%3DD.%26aulast%3DBanerji%26aufirst%3DU.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DSarker%26aufirst%3DS.%26aulast%3DOwen%26aufirst%3DK.%26aulast%3DAsad%26aufirst%3DY.%26aulast%3DRaynaud%26aufirst%3DF.%26aulast%3DWalton%26aufirst%3DM.%26aulast%3DJudson%26aufirst%3DI.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DEisen%26aufirst%3DT.%26atitle%3DA%2520phase%2520II%2520trial%2520of%252017-allylamino%252C%252017-demethoxygeldanamycin%2520%252817-AAG%252C%2520tanespimycin%2529%2520in%2520patients%2520with%2520metastatic%2520melanoma%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2012%26volume%3D30%26spage%3D341%26epage%3D349%26doi%3D10.1007%2Fs10637-010-9493-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group">Hubbard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlichman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toft, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stensgard, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felten, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ten Eyck, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batzel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haluska, P.</span><span> </span><span class="NLM_article-title">Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">473</span><span class="NLM_x">–</span> <span class="NLM_lpage">480</span><span class="refDoi"> DOI: 10.1007/s10637-009-9381-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1007%2Fs10637-009-9381-y" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=473-480&author=J.+Hubbardauthor=C.+Erlichmanauthor=D.+O.+Toftauthor=R.+Qinauthor=B.+A.+Stensgardauthor=S.+Feltenauthor=C.+Ten+Eyckauthor=G.+Batzelauthor=S.+P.+Ivyauthor=P.+Haluska&title=Phase+I+study+of+17-allylamino-17+demethoxygeldanamycin%2C+gemcitabine+and%2For+cisplatin+in+patients+with+refractory+solid+tumors&doi=10.1007%2Fs10637-009-9381-y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1007%2Fs10637-009-9381-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-009-9381-y%26sid%3Dliteratum%253Aachs%26aulast%3DHubbard%26aufirst%3DJ.%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3DToft%26aufirst%3DD.%2BO.%26aulast%3DQin%26aufirst%3DR.%26aulast%3DStensgard%26aufirst%3DB.%2BA.%26aulast%3DFelten%26aufirst%3DS.%26aulast%3DTen%2BEyck%26aufirst%3DC.%26aulast%3DBatzel%26aufirst%3DG.%26aulast%3DIvy%26aufirst%3DS.%2BP.%26aulast%3DHaluska%26aufirst%3DP.%26atitle%3DPhase%2520I%2520study%2520of%252017-allylamino-17%2520demethoxygeldanamycin%252C%2520gemcitabine%2520and%252For%2520cisplatin%2520in%2520patients%2520with%2520refractory%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2011%26volume%3D29%26spage%3D473%26epage%3D480%26doi%3D10.1007%2Fs10637-009-9381-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Litzow, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesa, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steensma, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flatten, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loegering, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reid, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ames, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlichman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karnitz, L. M.</span><span> </span><span class="NLM_article-title">Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia</span> <span class="citation_source-journal">Haematologica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">1619</span><span class="NLM_x">–</span> <span class="NLM_lpage">1626</span><span class="refDoi"> DOI: 10.3324/haematol.2011.049551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.3324%2Fhaematol.2011.049551" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2011&pages=1619-1626&author=S.+H.+Kaufmannauthor=J.+E.+Karpauthor=M.+R.+Litzowauthor=R.+A.+Mesaauthor=W.+Hoganauthor=D.+P.+Steensmaauthor=K.+S.+Flattenauthor=D.+A.+Loegeringauthor=P.+A.+Schneiderauthor=K.+L.+Petersonauthor=M.+J.+Maurerauthor=B.+D.+Smithauthor=J.+Greerauthor=Y.+Chenauthor=J.+M.+Reidauthor=S.+P.+Ivyauthor=M.+M.+Amesauthor=A.+A.+Adjeiauthor=C.+Erlichmanauthor=L.+M.+Karnitz&title=Phase+I+and+pharmacological+study+of+cytarabine+and+tanespimycin+in+relapsed+and+refractory+acute+leukemia&doi=10.3324%2Fhaematol.2011.049551"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2011.049551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2011.049551%26sid%3Dliteratum%253Aachs%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26aulast%3DKarp%26aufirst%3DJ.%2BE.%26aulast%3DLitzow%26aufirst%3DM.%2BR.%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DHogan%26aufirst%3DW.%26aulast%3DSteensma%26aufirst%3DD.%2BP.%26aulast%3DFlatten%26aufirst%3DK.%2BS.%26aulast%3DLoegering%26aufirst%3DD.%2BA.%26aulast%3DSchneider%26aufirst%3DP.%2BA.%26aulast%3DPeterson%26aufirst%3DK.%2BL.%26aulast%3DMaurer%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DGreer%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DReid%26aufirst%3DJ.%2BM.%26aulast%3DIvy%26aufirst%3DS.%2BP.%26aulast%3DAmes%26aufirst%3DM.%2BM.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3DKarnitz%26aufirst%3DL.%2BM.%26atitle%3DPhase%2520I%2520and%2520pharmacological%2520study%2520of%2520cytarabine%2520and%2520tanespimycin%2520in%2520relapsed%2520and%2520refractory%2520acute%2520leukemia%26jtitle%3DHaematologica%26date%3D2011%26volume%3D96%26spage%3D1619%26epage%3D1626%26doi%3D10.3324%2Fhaematol.2011.049551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group">Iyer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rathkopf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slovin, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeLaCruz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heller, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egorin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scher, H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D. B.</span><span> </span><span class="NLM_article-title">A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">1089</span><span class="NLM_x">–</span> <span class="NLM_lpage">1097</span><span class="refDoi"> DOI: 10.1007/s00280-011-1789-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1007%2Fs00280-011-1789-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22124669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVCrsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=1089-1097&author=G.+Iyerauthor=M.+J.+Morrisauthor=D.+Rathkopfauthor=S.+F.+Slovinauthor=M.+Steersauthor=S.+M.+Larsonauthor=L.+H.+Schwartzauthor=T.+Curleyauthor=A.+DeLaCruzauthor=Q.+Yeauthor=G.+Hellerauthor=M.+J.+Egorinauthor=S.+P.+Ivyauthor=N.+Rosenauthor=H.+I.+Scherauthor=D.+B.+Solit&title=A+phase+I+trial+of+docetaxel+and+pulse-dose+17-allylamino-17-demethoxygeldanamycin+in+adult+patients+with+solid+tumors&doi=10.1007%2Fs00280-011-1789-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors</span></div><div class="casAuthors">Iyer, Gopa; Morris, Michael J.; Rathkopf, Dana; Slovin, Susan F.; Steers, Macaulay; Larson, Steven M.; Schwartz, Lawrence H.; Curley, Tracy; DeLaCruz, Anthony; Ye, Qing; Heller, Glenn; Egorin, Merrill J.; Ivy, S. Percy; Rosen, Neal; Scher, Howard I.; Solit, David B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1089-1097</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose. To define max. tolerated dose (MTD), clin. toxicities, and pharmacokinetics of 17-allylamino-17-demethoxygeldanamycin (17-AAG) when administered in combination with docetaxel once every 21 days in patients with advanced solid tumor malignancies.  Exptl. design Docetaxel was administered over 1 h at doses of 55, 70, and 75 mg/m2. 17-AAG was administered over 1-2 h, following the completion of the docetaxel infusion, at escalating doses ranging from 80 to 650 mg/m2 in 12 patient cohorts.  Serum was collected for pharmacokinetic and pharmacodynamic studies during cycle 1.  Docetaxel, 17-AAG, and 17-AG levels were detd. by high-performance liq. chromatog.  Biol. effects of 17-AAG were monitored in peripheral blood mononuclear cells by immunoblot.  Results. Forty-nine patients received docetaxel and 17-AAG.  The most common all-cause grade 3 and 4 toxicities were leukopenia, lymphopenia, and neutropenia.  An MTD was not defined; however, three dose-limiting toxicities were obsd., including 2 incidences of neutropenic fever and 1 of junctional bradycardia.  Dose escalation was halted at docetaxel 75 mg/m2-17-AAG 650 mg/m2 due to delayed toxicities attributed to patient intolerance of the DMSO-based 17-AAG formulation.  Of 46 evaluable patients, 1 patient with lung cancer experienced a partial response.  Minor responses were obsd. in patients with lung, prostate, melanoma, and bladder cancers.  A correlation between reduced docetaxel clearance and 17-AAG dose level was obsd.  Conclusions. The combination of docetaxel and 17-AAG was well tolerated in adult patients with solid tumors, although patient intolerance to the DMSO formulation precluded further dose escalation.  The recommended phase II dose is docetaxel 70 mg/m2 and 17-AAG 500 mg/m2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvmRRqmnGc67Vg90H21EOLACvtfcHk0livefgua-n17g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVCrsrc%253D&md5=2d520d32e69f8712ae6b251b606aef42</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1007%2Fs00280-011-1789-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-011-1789-3%26sid%3Dliteratum%253Aachs%26aulast%3DIyer%26aufirst%3DG.%26aulast%3DMorris%26aufirst%3DM.%2BJ.%26aulast%3DRathkopf%26aufirst%3DD.%26aulast%3DSlovin%26aufirst%3DS.%2BF.%26aulast%3DSteers%26aufirst%3DM.%26aulast%3DLarson%26aufirst%3DS.%2BM.%26aulast%3DSchwartz%26aufirst%3DL.%2BH.%26aulast%3DCurley%26aufirst%3DT.%26aulast%3DDeLaCruz%26aufirst%3DA.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DHeller%26aufirst%3DG.%26aulast%3DEgorin%26aufirst%3DM.%2BJ.%26aulast%3DIvy%26aufirst%3DS.%2BP.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DScher%26aufirst%3DH.%2BI.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26atitle%3DA%2520phase%2520I%2520trial%2520of%2520docetaxel%2520and%2520pulse-dose%252017-allylamino-17-demethoxygeldanamycin%2520in%2520adult%2520patients%2520with%2520solid%2520tumors%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2012%26volume%3D69%26spage%3D1089%26epage%3D1097%26doi%3D10.1007%2Fs00280-011-1789-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group">Pacey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eatock, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hardcastle, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zetterlund, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arkenau, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno-Farre, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roels, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peachey, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I.</span><span> </span><span class="NLM_article-title">A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1561</span><span class="NLM_x">–</span> <span class="NLM_lpage">1570</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-10-1927</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1078-0432.CCR-10-1927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=21278242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFChtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=1561-1570&author=S.+Paceyauthor=R.+H.+Wilsonauthor=M.+Waltonauthor=M.+M.+Eatockauthor=A.+Hardcastleauthor=A.+Zetterlundauthor=H.+T.+Arkenauauthor=J.+Moreno-Farreauthor=U.+Banerjiauthor=B.+Roelsauthor=H.+Peacheyauthor=W.+Aherneauthor=J.+S.+de+Bonoauthor=F.+Raynaudauthor=P.+Workmanauthor=I.+Judson&title=A+phase+I+study+of+the+heat+shock+protein+90+inhibitor+alvespimycin+%2817-DMAG%29+given+intravenously+to+patients+with+advanced+solid+tumors&doi=10.1158%2F1078-0432.CCR-10-1927"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Pacey, Simon; Wilson, Richard H.; Walton, Mike; Eatock, Martin M.; Hardcastle, Anthea; Zetterlund, Anna; Arkenau, Hendrik-Tobias; Moreno-Farre, Javier; Banerji, Udai; Roels, Belle; Peachey, Heidi; Aherne, Wynne; de Bono, Johan S.; Raynaud, Florence; Workman, Paul; Judson, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1561-1570</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A phase I study to define toxicity and recommend a phase II dose of the HSP90 inhibitor alvespimycin (17-DMAG; 17-dimethylaminoethylamino-17-demethoxygeldanamycin).  Secondary endpoints included evaluation of pharmacokinetic profile, tumor response, and definition of a biol. ED (BED).  Patients with advanced solid cancers were treated with weekly, i.v. 17-DMAG.  An accelerated titrn. dose escalation design was used.  The max. tolerated dose (MTD) was the highest dose at which ≤1/6 patients experienced dose limiting toxicity (DLT).  Dose de-escalation from the MTD was planned with mandatory, sequential tumor biopsies to det. a BED.  Pharmacokinetic and pharmacodynamic assays were validated prior to patient accrual.  25 Patients received 17-DMAG (range 2.5-106 mg/m2).  At 106 mg/m2 of 17-DMAG 2/4 patients experienced DLT, including one treatment-related death.  No DLT occurred at 80 mg/m2.  Common adverse events were gastrointestinal, liver function changes, and ocular.  Area under the curve and mean peak concn. increased proportionally with 17-DMAG doses 80 mg/m2 or less.  In peripheral blood mononuclear cells significant (P < 0.05) HSP72 induction was detected (≥20 mg/m2) and sustained for 96 h (≥40 mg/m2).  Plasma HSP72 levels were greatest in the two patients who experienced DLT.  At 80 mg/m2 client protein (CDK4, LCK) depletion was detected and tumor samples from 3 of 5 patients confirmed HSP90 inhibition.  Clin. activity included complete response (castration refractory prostate cancer, CRPC 124 wk), partial response (melanoma, 159 wk), and stable disease (chondrosarcoma, CRPC, and renal cancer for 28, 59, and 76 wk, resp.).  The recommended phase II dose of 17-DMAG is 80 mg/m2 weekly i.v.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMLxm3kvKAe7Vg90H21EOLACvtfcHk0livefgua-n17g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFChtrw%253D&md5=964d12c9ee4eb41f11de41d41b98a40c</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-1927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-1927%26sid%3Dliteratum%253Aachs%26aulast%3DPacey%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DR.%2BH.%26aulast%3DWalton%26aufirst%3DM.%26aulast%3DEatock%26aufirst%3DM.%2BM.%26aulast%3DHardcastle%26aufirst%3DA.%26aulast%3DZetterlund%26aufirst%3DA.%26aulast%3DArkenau%26aufirst%3DH.%2BT.%26aulast%3DMoreno-Farre%26aufirst%3DJ.%26aulast%3DBanerji%26aufirst%3DU.%26aulast%3DRoels%26aufirst%3DB.%26aulast%3DPeachey%26aufirst%3DH.%26aulast%3DAherne%26aufirst%3DW.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DRaynaud%26aufirst%3DF.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DJudson%26aufirst%3DI.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520the%2520heat%2520shock%2520protein%252090%2520inhibitor%2520alvespimycin%2520%252817-DMAG%2529%2520given%2520intravenously%2520to%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D1561%26epage%3D1570%26doi%3D10.1158%2F1078-0432.CCR-10-1927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group">Kummar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutierrez, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figg, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zajac-Kaye, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yancey, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horneffer, Y. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juwara, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melillo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neckers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steeg, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conley, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giaccone, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doroshow, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murgo, A. J.</span><span> </span><span class="NLM_article-title">Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">340</span><span class="NLM_x">–</span> <span class="NLM_lpage">347</span><span class="refDoi"> DOI: 10.1016/j.ejca.2009.10.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.ejca.2009.10.026" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2010&pages=340-347&author=S.+Kummarauthor=M.+E.+Gutierrezauthor=E.+R.+Gardnerauthor=X.+Chenauthor=W.+D.+Figgauthor=M.+Zajac-Kayeauthor=M.+Chenauthor=S.+M.+Steinbergauthor=C.+A.+Muirauthor=M.+A.+Yanceyauthor=Y.+R.+Hornefferauthor=L.+Juwaraauthor=G.+Melilloauthor=S.+P.+Ivyauthor=M.+Merinoauthor=L.+Neckersauthor=P.+S.+Steegauthor=B.+A.+Conleyauthor=G.+Giacconeauthor=J.+H.+Doroshowauthor=A.+J.+Murgo&title=Phase+I+trial+of+17-dimethylaminoethylamino-17-demethoxygeldanamycin+%2817-DMAG%29%2C+a+heat+shock+protein+inhibitor%2C+administered+twice+weekly+in+patients+with+advanced+malignancies&doi=10.1016%2Fj.ejca.2009.10.026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2009.10.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2009.10.026%26sid%3Dliteratum%253Aachs%26aulast%3DKummar%26aufirst%3DS.%26aulast%3DGutierrez%26aufirst%3DM.%2BE.%26aulast%3DGardner%26aufirst%3DE.%2BR.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DFigg%26aufirst%3DW.%2BD.%26aulast%3DZajac-Kaye%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DSteinberg%26aufirst%3DS.%2BM.%26aulast%3DMuir%26aufirst%3DC.%2BA.%26aulast%3DYancey%26aufirst%3DM.%2BA.%26aulast%3DHorneffer%26aufirst%3DY.%2BR.%26aulast%3DJuwara%26aufirst%3DL.%26aulast%3DMelillo%26aufirst%3DG.%26aulast%3DIvy%26aufirst%3DS.%2BP.%26aulast%3DMerino%26aufirst%3DM.%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DSteeg%26aufirst%3DP.%2BS.%26aulast%3DConley%26aufirst%3DB.%2BA.%26aulast%3DGiaccone%26aufirst%3DG.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DMurgo%26aufirst%3DA.%2BJ.%26atitle%3DPhase%2520I%2520trial%2520of%252017-dimethylaminoethylamino-17-demethoxygeldanamycin%2520%252817-DMAG%2529%252C%2520a%2520heat%2520shock%2520protein%2520inhibitor%252C%2520administered%2520twice%2520weekly%2520in%2520patients%2520with%2520advanced%2520malignancies%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2010%26volume%3D46%26spage%3D340%26epage%3D347%26doi%3D10.1016%2Fj.ejca.2009.10.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group">Oh, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galsky, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stadler, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srinivas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bubley, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goddard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunbar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, R. W.</span><span> </span><span class="NLM_article-title">Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer</span> <span class="citation_source-journal">Urology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">626</span><span class="NLM_x">–</span> <span class="NLM_lpage">630</span><span class="refDoi"> DOI: 10.1016/j.urology.2011.04.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.urology.2011.04.041" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2011&pages=626-630&author=W.+K.+Ohauthor=M.+D.+Galskyauthor=W.+M.+Stadlerauthor=S.+Srinivasauthor=F.+Chuauthor=G.+Bubleyauthor=J.+Goddardauthor=J.+Dunbarauthor=R.+W.+Ross&title=Multicenter+phase+II+trial+of+the+heat+shock+protein+90+inhibitor%2C+retaspimycin+hydrochloride+%28IPI-504%29%2C+in+patients+with+castration-resistant+prostate+cancer&doi=10.1016%2Fj.urology.2011.04.041"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.urology.2011.04.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.urology.2011.04.041%26sid%3Dliteratum%253Aachs%26aulast%3DOh%26aufirst%3DW.%2BK.%26aulast%3DGalsky%26aufirst%3DM.%2BD.%26aulast%3DStadler%26aufirst%3DW.%2BM.%26aulast%3DSrinivas%26aufirst%3DS.%26aulast%3DChu%26aufirst%3DF.%26aulast%3DBubley%26aufirst%3DG.%26aulast%3DGoddard%26aufirst%3DJ.%26aulast%3DDunbar%26aufirst%3DJ.%26aulast%3DRoss%26aufirst%3DR.%2BW.%26atitle%3DMulticenter%2520phase%2520II%2520trial%2520of%2520the%2520heat%2520shock%2520protein%252090%2520inhibitor%252C%2520retaspimycin%2520hydrochloride%2520%2528IPI-504%2529%252C%2520in%2520patients%2520with%2520castration-resistant%2520prostate%2520cancer%26jtitle%3DUrology%26date%3D2011%26volume%3D78%26spage%3D626%26epage%3D630%26doi%3D10.1016%2Fj.urology.2011.04.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group">Wagner, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chugh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunbar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Normant, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grayzel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span> </span><span class="NLM_article-title">A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6020</span><span class="NLM_x">–</span> <span class="NLM_lpage">6029</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1078-0432.CCR-13-0953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=24045182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslartrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=6020-6029&author=A.+J.+Wagnerauthor=R.+Chughauthor=L.+S.+Rosenauthor=J.+A.+Morganauthor=S.+Georgeauthor=M.+Gordonauthor=J.+Dunbarauthor=E.+Normantauthor=D.+Grayzelauthor=G.+D.+Demetri&title=A+phase+I+study+of+the+HSP90+inhibitor+retaspimycin+hydrochloride+%28IPI-504%29+in+patients+with+gastrointestinal+stromal+tumors+or+soft-tissue+sarcomas&doi=10.1158%2F1078-0432.CCR-13-0953"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas</span></div><div class="casAuthors">Wagner, Andrew J.; Chugh, Rashmi; Rosen, Lee S.; Morgan, Jeffrey A.; George, Suzanne; Gordon, Michael; Dunbar, Joi; Normant, Emmanuel; Grayzel, David; Demetri, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6020-6029</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Heat shock protein 90 (HSP90) is required for the proper folding, function, and stability of various client proteins, two of which (KIT and PDGFRα) are crit. in the pathogenesis and progression of gastrointestinal stromal tumors (GIST).  This phase I study investigated the safety and max. tolerated dose (MTD) of retaspimycin hydrochloride (IPI-504), a novel potent and selective HSP90 inhibitor, in patients with metastatic and/or unresectable GIST or other soft-tissue sarcomas (STS).  Exptl. Design: IPI-504 was administered i.v. at doses ranging from 90 to 500 mg/m2 twice weekly for 2 wk on/1 wk off.  Safety, pharmacokinetic, and pharmacodynamic profiles were detd.  Response was assessed by Response Evaluation Criteria for Solid Tumors (RECIST) 1.0 and optionally via 18-fluorodeoxyglucose positron emission tomog. (18-FDG-PET) imaging.  Results: Fifty-four patients received IPI-504; 37 with GIST and 17 with other STS.  The MTD was 400 mg/m2 twice weekly for 2 wk on/1 wk off.  Common related adverse events were fatigue (59%), headache (44%), and nausea (43%).  Exposure to IPI-504, 17-AAG, and 17-AG increased with IPI-504 dose.  Stable disease (SD) was obsd. in 70% (26 of 37) of patients with GIST and 59% (10 of 17) of patients with STS.  There was one confirmed partial response (PR) in a patient with GIST and one PR in a patient with liposarcoma.  Metabolic partial responses occurred in 11 of 29 (38%) patients with GIST.  Conclusions: In this study of advanced GIST or other STS, IPI-504 was generally well-tolerated with some evidence of antitumor activity, serving as a clin. proof-of-concept that HSP90 inhibition remains a promising strategy.  Clin Cancer Res; 19(21); 6020-9. 2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVRMGwZ4YMWbVg90H21EOLACvtfcHk0liJa6D0W2hlFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslartrzM&md5=7b84094fc8bc4420ab5d3574c68eaae0</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0953%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DA.%2BJ.%26aulast%3DChugh%26aufirst%3DR.%26aulast%3DRosen%26aufirst%3DL.%2BS.%26aulast%3DMorgan%26aufirst%3DJ.%2BA.%26aulast%3DGeorge%26aufirst%3DS.%26aulast%3DGordon%26aufirst%3DM.%26aulast%3DDunbar%26aufirst%3DJ.%26aulast%3DNormant%26aufirst%3DE.%26aulast%3DGrayzel%26aufirst%3DD.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520the%2520HSP90%2520inhibitor%2520retaspimycin%2520hydrochloride%2520%2528IPI-504%2529%2520in%2520patients%2520with%2520gastrointestinal%2520stromal%2520tumors%2520or%2520soft-tissue%2520sarcomas%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D6020%26epage%3D6029%26doi%3D10.1158%2F1078-0432.CCR-13-0953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group">Siegel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagannath, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vesole, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borello, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazumder, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsiades, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goddard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunbar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Normant, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grayzel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P.</span><span> </span><span class="NLM_article-title">A phase I study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma</span> <span class="citation_source-journal">Leuk. Lymphoma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">2308</span><span class="NLM_x">–</span> <span class="NLM_lpage">2315</span><span class="refDoi"> DOI: 10.3109/10428194.2011.600481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.3109%2F10428194.2011.600481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=21851215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFeqsLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2011&pages=2308-2315&author=D.+Siegelauthor=S.+Jagannathauthor=D.+H.+Vesoleauthor=I.+Borelloauthor=A.+Mazumderauthor=C.+Mitsiadesauthor=J.+Goddardauthor=J.+Dunbarauthor=E.+Normantauthor=J.+Adamsauthor=D.+Grayzelauthor=K.+C.+Andersonauthor=P.+Richardson&title=A+phase+I+study+of+IPI-504+%28retaspimycin+hydrochloride%29+in+patients+with+relapsed+or+relapsed+and+refractory+multiple+myeloma&doi=10.3109%2F10428194.2011.600481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma</span></div><div class="casAuthors">Siegel, David; Jagannath, Sundar; Vesole, David H.; Borello, Ivan; Mazumder, Amitabha; Mitsiades, Constantine; Goddard, Jill; Dunbar, Joi; Normant, Emmanuel; Adams, Julian; Grayzel, David; Anderson, Kenneth C.; Richardson, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2308-2315</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1029-2403</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A phase 1 study of IPI-504 (retaspimycin hydrochloride) administered i.v. twice weekly for 2 wk at 22.5, 45, 90, 150, 225, 300 or 400 mg/m2 followed by 10 days off-treatment was conducted to det. the safety and max. tolerated dose (MTD) of IPI-504 in patients with relapsed or relapsed/refractory multiple myeloma (MM).  Anti-tumor activity and pharmacokinetics were also evaluated.  Eighteen patients (mean age 60.5 years; median 9 prior therapies) were enrolled.  No dose-limiting toxicities (DLTs) were reported for IPI-504 doses up to 400 mg/m2.  The most common treatment-related adverse event was grade 1 infusion site pain (four patients).  All other treatment-related events were assessed as grade 1 or 2 in severity.  The area under the curve (AUC) increased with increasing dose, and the mean half-life was approx. 2-4 h for IPI-504 and its metabolites.  Four patients had stable disease, demonstrating modest single-agent activity in relapsed or relapsed/refractory MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9MaC9a0KML7Vg90H21EOLACvtfcHk0liJa6D0W2hlFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFeqsLfI&md5=7be83ec5b9b1fdfe361a3bc7633b894f</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.3109%2F10428194.2011.600481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10428194.2011.600481%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DJagannath%26aufirst%3DS.%26aulast%3DVesole%26aufirst%3DD.%2BH.%26aulast%3DBorello%26aufirst%3DI.%26aulast%3DMazumder%26aufirst%3DA.%26aulast%3DMitsiades%26aufirst%3DC.%26aulast%3DGoddard%26aufirst%3DJ.%26aulast%3DDunbar%26aufirst%3DJ.%26aulast%3DNormant%26aufirst%3DE.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DGrayzel%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DRichardson%26aufirst%3DP.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520IPI-504%2520%2528retaspimycin%2520hydrochloride%2529%2520in%2520patients%2520with%2520relapsed%2520or%2520relapsed%2520and%2520refractory%2520multiple%2520myeloma%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2011%26volume%3D52%26spage%3D2308%26epage%3D2315%26doi%3D10.3109%2F10428194.2011.600481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group">Ramalingam, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goss, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid-Bindert, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaric, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andric, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bondarenko, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komov, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceric, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khuri, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samarzija, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciuleanu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wehler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spicer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheldon, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teofilovici, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vukovic, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fennell, D.</span><span> </span><span class="NLM_article-title">A randomized phase II study of ganetespib, an Hsp90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1741</span><span class="NLM_x">–</span> <span class="NLM_lpage">1748</span><span class="refDoi"> DOI: 10.1093/annonc/mdv220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1093%2Fannonc%2Fmdv220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=25997818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A280%3ADC%252BC2Mfmt1Wqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=1741-1748&author=S.+Ramalingamauthor=G.+Gossauthor=R.+Rosellauthor=G.+Schmid-Bindertauthor=B.+Zaricauthor=Z.+Andricauthor=I.+Bondarenkoauthor=D.+Komovauthor=T.+Cericauthor=F.+Khuriauthor=M.+Samarzijaauthor=E.+Felipauthor=T.+Ciuleanuauthor=V.+Hirshauthor=T.+Wehlerauthor=J.+Spicerauthor=R.+Salgiaauthor=G.+Shapiroauthor=E.+Sheldonauthor=F.+Teofiloviciauthor=V.+Vukovicauthor=D.+Fennell&title=A+randomized+phase+II+study+of+ganetespib%2C+an+Hsp90+inhibitor%2C+in+combination+with+docetaxel+in+second-line+therapy+of+advanced+non-small+cell+lung+cancer+%28GALAXY-1%29&doi=10.1093%2Fannonc%2Fmdv220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)</span></div><div class="casAuthors">Ramalingam S; Khuri F; Goss G; Rosell R; Schmid-Bindert G; Zaric B; Andric Z; Bondarenko I; Komov D; Ceric T; Samarzija M; Felip E; Ciuleanu T; Hirsh V; Wehler T; Spicer J; Salgia R; Shapiro G; Sheldon E; Teofilovici F; Vukovic V; Fennell D</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1741-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  This trial was designed to evaluate the activity and safety of ganetespib in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) and to identify patient populations most likely to benefit from the combination.  PATIENTS AND METHODS:  Patients with one prior systemic therapy for advanced disease were eligible.  Docetaxel (75 mg/m(2) on day 1) was administered alone or with ganetespib (150 mg/m(2) on days 1 and 15) every 3 weeks.  The primary end points were progression-free survival (PFS) in two subgroups of the adenocarcinoma population: patients with elevated lactate dehydrogenase (eLDH) and mutated KRAS (mKRAS).  RESULTS:  Of 385 patients enrolled, 381 were treated.  Early in the trial, increased hemoptysis and lack of efficacy were observed in nonadenocarcinoma patients (n = 71); therefore, only patients with adenocarcinoma histology were subsequently enrolled.  Neutropenia was the most common grade ≥3 adverse event: 41% in the combination arm versus 42% in docetaxel alone.  There was no improvement in PFS for the combination arm in the eLDH (N = 114, adjusted hazard ratio (HR) = 0.77, P = 0.1134) or mKRAS (N = 89, adjusted HR = 1.11, P = 0.3384) subgroups.  In the intent-to-treat adenocarcinoma population, there was a trend in favor of the combination, with PFS (N = 253, adjusted HR = 0.82, P = 0.0784) and overall survival (OS) (adjusted HR = 0.84, P = 0.1139).  Exploratory analyses showed significant benefit of the ganetespib combination in the prespecified subgroup of adenocarcinoma patients diagnosed with advanced disease >6 months before study entry (N = 177): PFS (adjusted HR = 0.74, P = 0.0417); OS (adjusted HR = 0.69, P = 0.0191).  CONCLUSION:  Advanced lung adenocarcinoma patients treated with ganetespib in combination with docetaxel had an acceptable safety profile.  While the study's primary end points were not met, significant prolongation of PFS and OS was observed in patients >6 months from diagnosis of advanced disease, a subgroup chosen as the target population for the phase III study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSN5VxVyhJaE0PI-fCgwosgfW6udTcc2easJbSKLESdNbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mfmt1Wqsw%253D%253D&md5=cff9b71d0bb8b17bd09d5d234d3ce6ff</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdv220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdv220%26sid%3Dliteratum%253Aachs%26aulast%3DRamalingam%26aufirst%3DS.%26aulast%3DGoss%26aufirst%3DG.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DSchmid-Bindert%26aufirst%3DG.%26aulast%3DZaric%26aufirst%3DB.%26aulast%3DAndric%26aufirst%3DZ.%26aulast%3DBondarenko%26aufirst%3DI.%26aulast%3DKomov%26aufirst%3DD.%26aulast%3DCeric%26aufirst%3DT.%26aulast%3DKhuri%26aufirst%3DF.%26aulast%3DSamarzija%26aufirst%3DM.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCiuleanu%26aufirst%3DT.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DWehler%26aufirst%3DT.%26aulast%3DSpicer%26aufirst%3DJ.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DShapiro%26aufirst%3DG.%26aulast%3DSheldon%26aufirst%3DE.%26aulast%3DTeofilovici%26aufirst%3DF.%26aulast%3DVukovic%26aufirst%3DV.%26aulast%3DFennell%26aufirst%3DD.%26atitle%3DA%2520randomized%2520phase%2520II%2520study%2520of%2520ganetespib%252C%2520an%2520Hsp90%2520inhibitor%252C%2520in%2520combination%2520with%2520docetaxel%2520in%2520second-line%2520therapy%2520of%2520advanced%2520non-small%2520cell%2520lung%2520cancer%2520%2528GALAXY-1%2529%26jtitle%3DAnn.%2520Oncol.%26date%3D2015%26volume%3D26%26spage%3D1741%26epage%3D1748%26doi%3D10.1093%2Fannonc%2Fmdv220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group">Jhaveri, K.; Chandarlapaty, S.; Lake, D.; Gilewski, T.; Drullinsky, P.; Sugarman, S.; Wasserheit-Leiblich, C.; Moynahan, M. E.; D’Andrea, G.; Haque, S.; Patil, S.; Bauman, L.; Vukovic, V.; EI-Hariry, I.; Hudis, C.; Modi, S.</span><span> </span><span class="NLM_article-title">A phase II trial of ganetespib: efficacy and safety in patients (pts) with metastatic breast cancer (MBC)</span>. <span class="NLM_conf-name">Proceedings of the 34th Annual San Antonio Breast Cancer Symposium</span>, <span class="NLM_conf-loc">San Antonio, TX</span>, <span class="NLM_conf-date">December 6–10, 2011</span>,  <span class="NLM_fpage">Abstract P1-17-08</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Jhaveri%2C+K.%3B+Chandarlapaty%2C+S.%3B+Lake%2C+D.%3B+Gilewski%2C+T.%3B+Drullinsky%2C+P.%3B+Sugarman%2C+S.%3B+Wasserheit-Leiblich%2C+C.%3B+Moynahan%2C+M.+E.%3B+D%E2%80%99Andrea%2C+G.%3B+Haque%2C+S.%3B+Patil%2C+S.%3B+Bauman%2C+L.%3B+Vukovic%2C+V.%3B+EI-Hariry%2C+I.%3B+Hudis%2C+C.%3B+Modi%2C+S.+A+phase+II+trial+of+ganetespib%3A+efficacy+and+safety+in+patients+%28pts%29+with+metastatic+breast+cancer+%28MBC%29.+Proceedings+of+the+34th+Annual+San+Antonio+Breast+Cancer+Symposium%2C+San+Antonio%2C+TX%2C+December+6%E2%80%9310%2C+2011%2C+Abstract+P1-17-08."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DJhaveri%26aufirst%3DK.%26atitle%3DA%2520phase%2520II%2520trial%2520of%2520ganetespib%253A%2520efficacy%2520and%2520safety%2520in%2520patients%2520%2528pts%2529%2520with%2520metastatic%2520breast%2520cancer%2520%2528MBC%2529%26spage%3DAbstract%2520P1-17-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group">Goyal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wadlow, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaszkowsky, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolpin, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCleary, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaram, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karol, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, A. X.</span><span> </span><span class="NLM_article-title">A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">128</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span><span class="refDoi"> DOI: 10.1007/s10637-014-0164-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1007%2Fs10637-014-0164-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=128-137&author=L.+Goyalauthor=R.+C.+Wadlowauthor=L.+S.+Blaszkowskyauthor=B.+M.+Wolpinauthor=T.+A.+Abramsauthor=N.+J.+McClearyauthor=S.+Sheehanauthor=E.+Sundaramauthor=M.+D.+Karolauthor=J.+Chenauthor=A.+X.+Zhu&title=A+phase+I+and+pharmacokinetic+study+of+ganetespib+%28STA-9090%29+in+advanced+hepatocellular+carcinoma&doi=10.1007%2Fs10637-014-0164-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1007%2Fs10637-014-0164-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-014-0164-8%26sid%3Dliteratum%253Aachs%26aulast%3DGoyal%26aufirst%3DL.%26aulast%3DWadlow%26aufirst%3DR.%2BC.%26aulast%3DBlaszkowsky%26aufirst%3DL.%2BS.%26aulast%3DWolpin%26aufirst%3DB.%2BM.%26aulast%3DAbrams%26aufirst%3DT.%2BA.%26aulast%3DMcCleary%26aufirst%3DN.%2BJ.%26aulast%3DSheehan%26aufirst%3DS.%26aulast%3DSundaram%26aufirst%3DE.%26aulast%3DKarol%26aufirst%3DM.%2BD.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DA.%2BX.%26atitle%3DA%2520phase%2520I%2520and%2520pharmacokinetic%2520study%2520of%2520ganetespib%2520%2528STA-9090%2529%2520in%2520advanced%2520hepatocellular%2520carcinoma%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2015%26volume%3D33%26spage%3D128%26epage%3D137%26doi%3D10.1007%2Fs10637-014-0164-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group">Sessa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhalla, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Britten, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacks, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadimitrakopoulou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pluard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuel, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akimov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quadt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez-Ibarra, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chica, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, U.</span><span> </span><span class="NLM_article-title">First-in-human phase I dose-escalation study of the Hsp90 inhibitor AUY922 in patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3671</span><span class="NLM_x">–</span> <span class="NLM_lpage">3680</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-3404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1078-0432.CCR-12-3404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=23757357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtValt7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=3671-3680&author=C.+Sessaauthor=G.+I.+Shapiroauthor=K.+N.+Bhallaauthor=C.+Brittenauthor=K.+S.+Jacksauthor=M.+Mitaauthor=V.+Papadimitrakopoulouauthor=T.+Pluardauthor=T.+A.+Samuelauthor=M.+Akimovauthor=C.+Quadtauthor=C.+Fernandez-Ibarraauthor=H.+Luauthor=S.+Baileyauthor=S.+Chicaauthor=U.+Banerji&title=First-in-human+phase+I+dose-escalation+study+of+the+Hsp90+inhibitor+AUY922+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1078-0432.CCR-12-3404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Sessa, Cristiana; Shapiro, Geoffrey I.; Bhalla, Kapil N.; Britten, Carolyn; Jacks, Karen S.; Mita, Monica; Papadimitrakopoulou, Vali; Pluard, Tim; Samuel, Thomas A.; Akimov, Mikhail; Quadt, Cornelia; Fernandez-Ibarra, Cristina; Lu, Hong; Bailey, Stuart; Chica, Sandra; Banerji, Udai</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3671-3680</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: A phase I study was conducted with the primary objective of detg. the max. tolerated dose (MTD) of AUY922 in patients with advanced solid tumors.  Secondary objectives included characterization of the safety, pharmacokinetic, and pharmacodynamic profiles.  Patients and Methods: Patients with advanced solid tumors received 1-h i.v. infusions of AUY922 once a week in a 28-day cycle.  An adaptive Bayesian logistic regression model that employed obsd. dose-limiting toxicities (DLT) in the first treatment cycle was used to guide dose-escalation decisions, with the established MTD to be used in phase II studies.  Results: One hundred and one patients were enrolled and explored at doses in the range of 2 to 70 mg/m2.  DLTs occurred in 8 patients (22-70 mg/m2) and included diarrhea, asthenia/fatigue, anorexia, atrial flutter, and visual symptoms.  At 70 mg/m2, the AUY922 concn. achieved was consistent with active concns. in a range of xenograft models.  There was evidence of target inhibition in peripheral blood mononuclear cells (HSP70 induction) and tumor (client protein depletion and redn. of metabolic activity by 18F-FDG PET).  The recommended phase II dose (RP2D) of 70 mg/m2 was proposed on the basis of toxicity and pharmacokinetic and pharmacodynamic profiles.  Conclusions: At the RP2D of 70 mg/m2, AUY922 exhibited acceptable tolerability, and phase II single-agent and combination studies have been initiated in patients with HER2-pos. breast, gastric, and non-small cell lung cancers.  Clin Cancer Res; 19(13); 3671-80. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqWielpmNf9rVg90H21EOLACvtfcHk0lgi4mcbCOZDbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtValt7fI&md5=3a428b5489b6390c84fc046945e6d575</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-3404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-3404%26sid%3Dliteratum%253Aachs%26aulast%3DSessa%26aufirst%3DC.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DBhalla%26aufirst%3DK.%2BN.%26aulast%3DBritten%26aufirst%3DC.%26aulast%3DJacks%26aufirst%3DK.%2BS.%26aulast%3DMita%26aufirst%3DM.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%26aulast%3DPluard%26aufirst%3DT.%26aulast%3DSamuel%26aufirst%3DT.%2BA.%26aulast%3DAkimov%26aufirst%3DM.%26aulast%3DQuadt%26aufirst%3DC.%26aulast%3DFernandez-Ibarra%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DChica%26aufirst%3DS.%26aulast%3DBanerji%26aufirst%3DU.%26atitle%3DFirst-in-human%2520phase%2520I%2520dose-escalation%2520study%2520of%2520the%2520Hsp90%2520inhibitor%2520AUY922%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D3671%26epage%3D3680%26doi%3D10.1158%2F1078-0432.CCR-12-3404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group">Doi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onozawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuse, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshino, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akimov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boku, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtsu, A.</span><span> </span><span class="NLM_article-title">Phase I dose-escalation study of the Hsp90 inhibitor AUY922 in Japanese patients with advanced solid tumors</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">629</span><span class="NLM_x">–</span> <span class="NLM_lpage">636</span><span class="refDoi"> DOI: 10.1007/s00280-014-2521-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1007%2Fs00280-014-2521-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=25059319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1egu7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=629-636&author=T.+Doiauthor=Y.+Onozawaauthor=N.+Fuseauthor=T.+Yoshinoauthor=K.+Yamazakiauthor=J.+Watanabeauthor=M.+Akimovauthor=M.+Robsonauthor=N.+Bokuauthor=A.+Ohtsu&title=Phase+I+dose-escalation+study+of+the+Hsp90+inhibitor+AUY922+in+Japanese+patients+with+advanced+solid+tumors&doi=10.1007%2Fs00280-014-2521-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors</span></div><div class="casAuthors">Doi, Toshihiko; Onozawa, Yusuke; Fuse, Nozomu; Yoshino, Takayuki; Yamazaki, Kentaro; Watanabe, Junichiro; Akimov, Mikhail; Robson, Matthew; Boku, Narikazu; Ohtsu, Atsushi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">629-636</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: AUY922 is a potent non-geldanamycin inhibitor of heat-shock protein 90.  This study was carried out in Japanese patients to det. the max. tolerated dose (MTD), and to characterize safety, tolerability and pharmacokinetics of single-agent AUY922.  Methods: Japanese patients with advanced solid tumors whose disease had progressed on at least one line of std. therapy, or for whom no std. therapy existed, were treated with AUY922 (i.v., once-weekly, 28-day cycle, starting dose 8 mg/m2).  Results: Thirty-one patients were treated.  Two DLTs were reported in one patient of the 54 mg/m2 cohort; fatigue and decreased appetite (both Grade 3, resolving to Grade 1 within 8 days).  No MTD was detd., and the dose recommended for Phase II studies was detd. to be 70 mg/m2 once-weekly.  Most common drug-related toxicities were diarrhea, night blindness and nausea.  Grade 1 and 2 visual toxicities at high AUY922 doses ≥22 mg/m2 were obsd.  Ten patients (32 %) achieved a best overall response of stable disease, and one patient (3 %) achieved a confirmed partial response.  Conclusion: Overall, AUY922 exhibited acceptable toxicities and demonstrated potential clin. activity in Japanese patients, with similar safety and pharmacokinetic profiles to those reported in a preceding global Phase I study in Western patients (CAUY922A2101).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHpBWf7yeQ6rVg90H21EOLACvtfcHk0lgi4mcbCOZDbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1egu7bI&md5=b45329cadb86c932a68ced6951b796db</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1007%2Fs00280-014-2521-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-014-2521-x%26sid%3Dliteratum%253Aachs%26aulast%3DDoi%26aufirst%3DT.%26aulast%3DOnozawa%26aufirst%3DY.%26aulast%3DFuse%26aufirst%3DN.%26aulast%3DYoshino%26aufirst%3DT.%26aulast%3DYamazaki%26aufirst%3DK.%26aulast%3DWatanabe%26aufirst%3DJ.%26aulast%3DAkimov%26aufirst%3DM.%26aulast%3DRobson%26aufirst%3DM.%26aulast%3DBoku%26aufirst%3DN.%26aulast%3DOhtsu%26aufirst%3DA.%26atitle%3DPhase%2520I%2520dose-escalation%2520study%2520of%2520the%2520Hsp90%2520inhibitor%2520AUY922%2520in%2520Japanese%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2014%26volume%3D74%26spage%3D629%26epage%3D636%26doi%3D10.1007%2Fs00280-014-2521-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group">Seggewiss-Bernhardt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bargou, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alegre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bladé, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottmann, O. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez-Ibarra, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pain, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akimov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, S. P.</span><span> </span><span class="NLM_article-title">Phase 1/1B trial of the Hsp90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">2185</span><span class="NLM_x">–</span> <span class="NLM_lpage">2192</span><span class="refDoi"> DOI: 10.1002/cncr.29339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1002%2Fcncr.29339" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2015&pages=2185-2192&author=R.+Seggewiss-Bernhardtauthor=R.+C.+Bargouauthor=Y.+T.+Gohauthor=A.+K.+Stewartauthor=A.+Spencerauthor=A.+Alegreauthor=J.+Blad%C3%A9author=O.+G.+Ottmannauthor=C.+Fernandez-Ibarraauthor=H.+Luauthor=S.+Painauthor=M.+Akimovauthor=S.+P.+Iyer&title=Phase+1%2F1B+trial+of+the+Hsp90+inhibitor+NVP-AUY922+as+monotherapy+or+in+combination+with+bortezomib+in+patients+with+relapsed+or+refractory+multiple+myeloma&doi=10.1002%2Fcncr.29339"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1002%2Fcncr.29339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.29339%26sid%3Dliteratum%253Aachs%26aulast%3DSeggewiss-Bernhardt%26aufirst%3DR.%26aulast%3DBargou%26aufirst%3DR.%2BC.%26aulast%3DGoh%26aufirst%3DY.%2BT.%26aulast%3DStewart%26aufirst%3DA.%2BK.%26aulast%3DSpencer%26aufirst%3DA.%26aulast%3DAlegre%26aufirst%3DA.%26aulast%3DBlad%25C3%25A9%26aufirst%3DJ.%26aulast%3DOttmann%26aufirst%3DO.%2BG.%26aulast%3DFernandez-Ibarra%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DPain%26aufirst%3DS.%26aulast%3DAkimov%26aufirst%3DM.%26aulast%3DIyer%26aufirst%3DS.%2BP.%26atitle%3DPhase%25201%252F1B%2520trial%2520of%2520the%2520Hsp90%2520inhibitor%2520NVP-AUY922%2520as%2520monotherapy%2520or%2520in%2520combination%2520with%2520bortezomib%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520multiple%2520myeloma%26jtitle%3DCancer%26date%3D2015%26volume%3D121%26spage%3D2185%26epage%3D2192%26doi%3D10.1002%2Fcncr.29339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group">Do, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speranza, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polley, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bishop, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trepel, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinders, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antony, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neckers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doroshow, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kummar, S.</span><span> </span><span class="NLM_article-title">Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">921</span><span class="NLM_x">–</span> <span class="NLM_lpage">930</span><span class="refDoi"> DOI: 10.1007/s10637-015-0255-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1007%2Fs10637-015-0255-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=921-930&author=K.+Doauthor=G.+Speranzaauthor=L.+C.+Changauthor=E.+C.+Polleyauthor=R.+Bishopauthor=W.+Zhuauthor=J.+B.+Trepelauthor=S.+Leeauthor=M.+J.+Leeauthor=R.+J.+Kindersauthor=L.+Phillipsauthor=J.+Collinsauthor=J.+Lyonsauthor=W.+Jeongauthor=R.+Antonyauthor=A.+P.+Chenauthor=L.+Neckersauthor=J.+H.+Doroshowauthor=S.+Kummar&title=Phase+I+study+of+the+heat+shock+protein+90+%28Hsp90%29+inhibitor+onalespib+%28AT13387%29+administered+on+a+daily+for+2+consecutive+days+per+week+dosing+schedule+in+patients+with+advanced+solid+tumors&doi=10.1007%2Fs10637-015-0255-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1007%2Fs10637-015-0255-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-015-0255-1%26sid%3Dliteratum%253Aachs%26aulast%3DDo%26aufirst%3DK.%26aulast%3DSperanza%26aufirst%3DG.%26aulast%3DChang%26aufirst%3DL.%2BC.%26aulast%3DPolley%26aufirst%3DE.%2BC.%26aulast%3DBishop%26aufirst%3DR.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DTrepel%26aufirst%3DJ.%2BB.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DM.%2BJ.%26aulast%3DKinders%26aufirst%3DR.%2BJ.%26aulast%3DPhillips%26aufirst%3DL.%26aulast%3DCollins%26aufirst%3DJ.%26aulast%3DLyons%26aufirst%3DJ.%26aulast%3DJeong%26aufirst%3DW.%26aulast%3DAntony%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DA.%2BP.%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DKummar%26aufirst%3DS.%26atitle%3DPhase%2520I%2520study%2520of%2520the%2520heat%2520shock%2520protein%252090%2520%2528Hsp90%2529%2520inhibitor%2520onalespib%2520%2528AT13387%2529%2520administered%2520on%2520a%2520daily%2520for%25202%2520consecutive%2520days%2520per%2520week%2520dosing%2520schedule%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2015%26volume%3D33%26spage%3D921%26epage%3D930%26doi%3D10.1007%2Fs10637-015-0255-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwak, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dezube, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yule, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayrton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahadevan, D.</span><span> </span><span class="NLM_article-title">First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">–</span> <span class="NLM_lpage">97</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-0979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1078-0432.CCR-14-0979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=25336693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2MXis12ltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=87-97&author=G.+I.+Shapiroauthor=E.+Kwakauthor=B.+J.+Dezubeauthor=M.+Yuleauthor=J.+Ayrtonauthor=J.+Lyonsauthor=D.+Mahadevan&title=First-in-human+phase+I+dose+escalation+study+of+a+second-generation+non-ansamycin+HSP90+inhibitor%2C+AT13387%2C+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1078-0432.CCR-14-0979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Shapiro, Geoffrey I.; Kwak, Eunice; Dezube, Bruce J.; Yule, Murray; Ayrton, John; Lyons, John; Mahadevan, Daruka</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-97</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: AT13387 is a potent second-generation, fragment-derived HSP90 inhibitor.  This phase I study investigated the max. tolerated dose (MTD)/recommended phase II dose (RP2D) and safety, pharmacokinetic, and pharmacodynamic profiles of two AT13387 regimens in a refractory solid tumor population.  Exptl. Design: Std. 3+3 dose escalation was used.  MTD and RP2D detns. were based on the occurrence of dose-limiting toxicities (DLT) and overall toxicity, resp.  Pharmacokinetic parameters were measured after single and multiple doses.  AT13387-mediated induction of HSP70 was evaluated in plasma, peripheral blood mononuclear cells, and paired tumor biopsies.  Results: Sixty-two patients were treated with doses ranging from 10 to 120 mg/m2 twice weekly and 150 to 310 mg/m2 once weekly (both for 3 wk every 28 days).  One DLT of visual disturbance occurred at 120 mg/m2, which was considered the MTD and RP2D for the twice-weekly regimen.  No formal DLTs occurred in the once-weekly regimen, but multiple moderately severe toxicities, including diarrhea, nausea, vomiting, fatigue, and systemic infusion reactions, led to selection of 260 mg/m2 as the RP2D.  Exposures of AT13387 increased proportionally with dose.  Target engagement as measured by HSP70 induction occurred in plasma and tumor biopsy samples.  One patient with gastrointestinal stromal tumor (GIST) who had progressive disease on imatinib had a partial response and remained on treatment for 10 mo.  Twenty-one patients (34%) had stable disease, which lasted >120 days in 7 patients.  Conclusion: AT13387 administered once or twice weekly has an acceptable safety profile and demonstrated evidence of target engagement and preliminary antitumor activity.  Clin Cancer Res; 21(1); 87-97. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrB7A3RmZpiAbVg90H21EOLACvtfcHk0lh9m2ISOrUclw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXis12ltA%253D%253D&md5=7683701e7cde5f4b599c2e6bdb8cd6ac</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-0979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-0979%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DKwak%26aufirst%3DE.%26aulast%3DDezube%26aufirst%3DB.%2BJ.%26aulast%3DYule%26aufirst%3DM.%26aulast%3DAyrton%26aufirst%3DJ.%26aulast%3DLyons%26aufirst%3DJ.%26aulast%3DMahadevan%26aufirst%3DD.%26atitle%3DFirst-in-human%2520phase%2520I%2520dose%2520escalation%2520study%2520of%2520a%2520second-generation%2520non-ansamycin%2520HSP90%2520inhibitor%252C%2520AT13387%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D87%26epage%3D97%26doi%3D10.1158%2F1078-0432.CCR-14-0979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group">Infante, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendell, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinson, J. M.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Von Hoff, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlemans, E. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramanathan, R. K.</span><span> </span><span class="NLM_article-title">Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumors</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2897</span><span class="NLM_x">–</span> <span class="NLM_lpage">2904</span><span class="refDoi"> DOI: 10.1016/j.ejca.2014.07.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.ejca.2014.07.017" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2014&pages=2897-2904&author=J.+R.+Infanteauthor=G.+J.+Weissauthor=S.+Jonesauthor=R.+Tibesauthor=T.+M.+Bauerauthor=J.+C.+Bendellauthor=J.+M.+Hinsonauthor=D.+D.+Von+Hoffauthor=H.+A.+Burrisauthor=E.+O.+Orlemansauthor=R.+K.+Ramanathan&title=Phase+I+dose-escalation+studies+of+SNX-5422%2C+an+orally+bioavailable+heat+shock+protein+90+inhibitor%2C+in+patients+with+refractory+solid+tumors&doi=10.1016%2Fj.ejca.2014.07.017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2014.07.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2014.07.017%26sid%3Dliteratum%253Aachs%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DWeiss%26aufirst%3DG.%2BJ.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DTibes%26aufirst%3DR.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DBendell%26aufirst%3DJ.%2BC.%26aulast%3DHinson%26aufirst%3DJ.%2BM.%26aulast%3DVon%2BHoff%26aufirst%3DD.%2BD.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DOrlemans%26aufirst%3DE.%2BO.%26aulast%3DRamanathan%26aufirst%3DR.%2BK.%26atitle%3DPhase%2520I%2520dose-escalation%2520studies%2520of%2520SNX-5422%252C%2520an%2520orally%2520bioavailable%2520heat%2520shock%2520protein%252090%2520inhibitor%252C%2520in%2520patients%2520with%2520refractory%2520solid%2520tumors%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2014%26volume%3D50%26spage%3D2897%26epage%3D2904%26doi%3D10.1016%2Fj.ejca.2014.07.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group">Reddy, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voorhees, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houk, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brega, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinson, J. M.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jillela, A.</span><span> </span><span class="NLM_article-title">Phase I trial of the Hsp90 inhibitor PF-04929113 (SNX5422) in adult patients with recurrent, refractory hematologic malignancies</span> <span class="citation_source-journal">Clin. Lymphoma. Myeloma. Leuk</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">391</span><span class="refDoi"> DOI: 10.1016/j.clml.2013.03.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.clml.2013.03.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=23763921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpt1Clt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=385-391&author=N.+Reddyauthor=P.+M.+Voorheesauthor=B.+E.+Houkauthor=N.+Bregaauthor=J.+M.+Hinsonauthor=A.+Jillela&title=Phase+I+trial+of+the+Hsp90+inhibitor+PF-04929113+%28SNX5422%29+in+adult+patients+with+recurrent%2C+refractory+hematologic+malignancies&doi=10.1016%2Fj.clml.2013.03.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Trial of the HSP90 Inhibitor PF-04929113 (SNX5422) in Adult Patients With Recurrent, Refractory Hematologic Malignancies</span></div><div class="casAuthors">Reddy, Nishitha; Voorhees, Peter M.; Houk, Brett E.; Brega, Nicoletta; Hinson, James M.; Jillela, Anand</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Lymphoma, Myeloma & Leukemia</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">385-391</span>CODEN:
                <span class="NLM_cas:coden">CLMLCQ</span>;
        ISSN:<span class="NLM_cas:issn">2152-2669</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Heat shock protein (HSP)90 regulates the function of proteins responsible for cell growth and survival, is overexpressed in many cancers and is an attractive therapeutic target.  We undertook a phase 1 trial of PF-04929113 (SNX-5422), a novel oral HSP90 inhibitor, to est. the max. tolerated dose and describe the pharmacokinetic and toxicity profiles.Patients with relapsed, refractory, hematol. malignancies and adequate organ function were eligible.  PF-04929113 was administered orally every other day for 21 days of a 28-day cycle.  Twenty-five patients were treated, with dose escalation ranging from 5.32 mg/m2 to 74 mg/m2 using a 3 plus 3 trial design.All 25 patients enrolled were evaluable for toxicity.  Most common toxicities included prolonged QTc interval, diarrhea, pruritus, thrombocytopenia, fatigue, and nausea.  Grade 3/4 treatment-related adverse events were experienced by 7/25 patients (28%); thrombocytopenia was the most common (n = 3 grade 3; n = 2 grade 4).  Partial response was experienced by a patient with transformed lymphoma, and prolonged stabilization of disease was obsd. in a patient with multiple myeloma.Alternate-day oral dosing of PF-04929113 at 74 mg/m2 for 21/28 days was generally well tolerated with reversible toxicity.  The responses obsd. in myeloma and lymphoma patients are encouraging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2rDxl5z95e7Vg90H21EOLACvtfcHk0lh9m2ISOrUclw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpt1Clt7o%253D&md5=3564e52bdef2dda0ce6b8c6c869c2b8b</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1016%2Fj.clml.2013.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clml.2013.03.010%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DN.%26aulast%3DVoorhees%26aufirst%3DP.%2BM.%26aulast%3DHouk%26aufirst%3DB.%2BE.%26aulast%3DBrega%26aufirst%3DN.%26aulast%3DHinson%26aufirst%3DJ.%2BM.%26aulast%3DJillela%26aufirst%3DA.%26atitle%3DPhase%2520I%2520trial%2520of%2520the%2520Hsp90%2520inhibitor%2520PF-04929113%2520%2528SNX5422%2529%2520in%2520adult%2520patients%2520with%2520recurrent%252C%2520refractory%2520hematologic%2520malignancies%26jtitle%3DClin.%2520Lymphoma.%2520Myeloma.%2520Leuk%26date%3D2013%26volume%3D13%26spage%3D385%26epage%3D391%26doi%3D10.1016%2Fj.clml.2013.03.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group">Duerfeldt, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maynard, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eletto, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ostrovsky, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinogle, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Argon, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicchitta, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span> </span><span class="NLM_article-title">Development of a Grp94 inhibitor</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">134</span><span class="NLM_x">, </span> <span class="NLM_fpage">9796</span><span class="NLM_x">–</span> <span class="NLM_lpage">9804</span><span class="refDoi"> DOI: 10.1021/ja303477g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja303477g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38XnslGqsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=9796-9804&author=A.+S.+Duerfeldtauthor=L.+B.+Petersonauthor=J.+C.+Maynardauthor=C.+L.+Ngauthor=D.+Elettoauthor=O.+Ostrovskyauthor=H.+E.+Shinogleauthor=D.+S.+Mooreauthor=Y.+Argonauthor=C.+V.+Nicchittaauthor=B.+S.+J.+Blagg&title=Development+of+a+Grp94+inhibitor&doi=10.1021%2Fja303477g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Grp94 inhibitor</span></div><div class="casAuthors">Duerfeldt, Adam S.; Peterson, Laura B.; Maynard, Jason C.; Ng, Chun Leung; Eletto, Davide; Ostrovsky, Olga; Shinogle, Heather E.; Moore, David S.; Argon, Yair; Nicchitta, Christopher V.; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9796-9804</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) represents a promising therapeutic target for the treatment of cancer and other diseases.  Unfortunately, results from clin. trials have been disappointing as off-target effects and toxicities have been obsd.  These detriments may be a consequence of pan-Hsp90 inhibition, as all clin. evaluated Hsp90 inhibitors simultaneously disrupt all four human Hsp90 isoforms.  Using a structure-based approach, we designed an inhibitor of Grp94, the ER-resident Hsp90.  The effect manifested by compd. (I) on several Grp94 and Hsp90α/β (cytosolic isoforms) clients were investigated.  Compd. I prevented intracellular trafficking of the Toll receptor, inhibited the secretion of IGF-II, affected the conformation of Grp94, and suppressed Drosophila larval growth, all Grp94-dependent processes.  In contrast, compd. I had no effect on cell viability or cytosolic Hsp90α/β client proteins at similar concns.  The design, synthesis, and evaluation of I are described herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoayCAvZU_mzrVg90H21EOLACvtfcHk0lgpMwB-OmhD6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnslGqsLw%253D&md5=00c0b3f15f2cfd04658225c8a6fb708d</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1021%2Fja303477g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja303477g%26sid%3Dliteratum%253Aachs%26aulast%3DDuerfeldt%26aufirst%3DA.%2BS.%26aulast%3DPeterson%26aufirst%3DL.%2BB.%26aulast%3DMaynard%26aufirst%3DJ.%2BC.%26aulast%3DNg%26aufirst%3DC.%2BL.%26aulast%3DEletto%26aufirst%3DD.%26aulast%3DOstrovsky%26aufirst%3DO.%26aulast%3DShinogle%26aufirst%3DH.%2BE.%26aulast%3DMoore%26aufirst%3DD.%2BS.%26aulast%3DArgon%26aufirst%3DY.%26aulast%3DNicchitta%26aufirst%3DC.%2BV.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DDevelopment%2520of%2520a%2520Grp94%2520inhibitor%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2012%26volume%3D134%26spage%3D9796%26epage%3D9804%26doi%3D10.1021%2Fja303477g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 39 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Emily J. Hanan, Jun Liang, Xiaojing Wang, Robert A. Blake, Nicole Blaquiere, <span class="NLM_string-name hlFld-ContribAuthor">Steven T. Staben</span>. </span><span class="cited-content_cbyCitation_article-title">Monomeric Targeted Protein Degraders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 11330-11361. <a href="https://doi.org/10.1021/acs.jmedchem.0c00093" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00093</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00093%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMonomeric%252BTargeted%252BProtein%252BDegraders%26aulast%3DHanan%26aufirst%3DEmily%2BJ.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17012020%26date%3D15062020%26date%3D30042020%26volume%3D63%26issue%3D20%26spage%3D11330%26epage%3D11361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Li Li, Lei Wang, Qi-Dong You, <span class="NLM_string-name hlFld-ContribAuthor">Xiao-Li Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (5)
                                     , 1798-1822. <a href="https://doi.org/10.1021/acs.jmedchem.9b00940" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00940</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00940%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHeat%252BShock%252BProtein%252B90%252BInhibitors%25253A%252BAn%252BUpdate%252Bon%252BAchievements%25252C%252BChallenges%25252C%252Band%252BFuture%252BDirections%26aulast%3DLi%26aufirst%3DLi%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D13062019%26date%3D12112019%26date%3D30102019%26volume%3D63%26issue%3D5%26spage%3D1798%26epage%3D1822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lei Wang, Jingsheng Jiang, Lixiao Zhang, Qiuyue Zhang, Jianrui Zhou, Li Li, Xiaoli Xu, <span class="NLM_string-name hlFld-ContribAuthor">Qidong You</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Optimization of Small Molecules Targeting the Protein–Protein Interaction of Heat Shock Protein 90 (Hsp90) and Cell Division Cycle 37 as Orally Active Inhibitors for the Treatment of Colorectal Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (3)
                                     , 1281-1297. <a href="https://doi.org/10.1021/acs.jmedchem.9b01659" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01659</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01659%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BOptimization%252Bof%252BSmall%252BMolecules%252BTargeting%252Bthe%252BProtein%2525E2%252580%252593Protein%252BInteraction%252Bof%252BHeat%252BShock%252BProtein%252B90%252B%252528Hsp90%252529%252Band%252BCell%252BDivision%252BCycle%252B37%252Bas%252BOrally%252BActive%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BColorectal%252BCancer%26aulast%3DWang%26aufirst%3DLei%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D13102019%26date%3D24012020%26date%3D14012020%26volume%3D63%26issue%3D3%26spage%3D1281%26epage%3D1297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Fen Jiang, An-ping Guo, Jia-chen Xu, Qi-Dong You, <span class="NLM_string-name hlFld-ContribAuthor">Xiao-Li Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Potent Grp94 Selective Inhibitor with Anti-Inflammatory Efficacy in a Mouse Model of Ulcerative Colitis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (21)
                                     , 9513-9533. <a href="https://doi.org/10.1021/acs.jmedchem.8b00800" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00800</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00800%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BPotent%252BGrp94%252BSelective%252BInhibitor%252Bwith%252BAnti-Inflammatory%252BEfficacy%252Bin%252Ba%252BMouse%252BModel%252Bof%252BUlcerative%252BColitis%26aulast%3DJiang%26aufirst%3DFen%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D19052018%26date%3D26102018%26date%3D15102018%26volume%3D61%26issue%3D21%26spage%3D9513%26epage%3D9533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li-Dong  Shao</span>, <span class="hlFld-ContribAuthor ">Jia  Su</span>, <span class="hlFld-ContribAuthor ">Baixin  Ye</span>, <span class="hlFld-ContribAuthor ">Jiang-Xin  Liu</span>, <span class="hlFld-ContribAuthor ">Zhi-Li  Zuo</span>, <span class="hlFld-ContribAuthor ">Yan  Li</span>, <span class="hlFld-ContribAuthor ">Yue-Ying  Wang</span>, <span class="hlFld-ContribAuthor ">Chengfeng  Xia</span>, and <span class="hlFld-ContribAuthor ">Qin-Shi  Zhao</span>  . </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Activities of Vibsanin B Derivatives: A New Class of HSP90 C-Terminal Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (21)
                                     , 9053-9066. <a href="https://doi.org/10.1021/acs.jmedchem.7b01395" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01395</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01395%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BActivities%252Bof%252BVibsanin%252BB%252BDerivatives%25253A%252BA%252BNew%252BClass%252Bof%252BHSP90%252BC-Terminal%252BInhibitors%26aulast%3DShao%26aufirst%3DLi-Dong%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D20092017%26date%3D24102017%26date%3D09112017%26date%3D11102017%26volume%3D60%26issue%3D21%26spage%3D9053%26epage%3D9066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hyeonjeong  Choe</span>, <span class="hlFld-ContribAuthor ">Hyukjoon  Cho</span>, <span class="hlFld-ContribAuthor ">Hyun-Jeong  Ko</span>, and <span class="hlFld-ContribAuthor ">Jongkook  Lee</span>  . </span><span class="cited-content_cbyCitation_article-title">Total Synthesis of (+)-Pochonin D and (+)-Monocillin II via Chemo- and Regioselective Intramolecular Nitrile Oxide Cycloaddition. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2017,</strong> <em>19 </em>
                                    (21)
                                     , 6004-6007. <a href="https://doi.org/10.1021/acs.orglett.7b03054" title="DOI URL">https://doi.org/10.1021/acs.orglett.7b03054</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.7b03054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.7b03054%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DTotal%252BSynthesis%252Bof%252B%252528%25252B%252529-Pochonin%252BD%252Band%252B%252528%25252B%252529-Monocillin%252BII%252Bvia%252BChemo-%252Band%252BRegioselective%252BIntramolecular%252BNitrile%252BOxide%252BCycloaddition%26aulast%3DChoe%26aufirst%3DHyeonjeong%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D29092017%26date%3D19102017%26date%3D03112017%26volume%3D19%26issue%3D21%26spage%3D6004%26epage%3D6007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fen  Jiang</span>, <span class="hlFld-ContribAuthor ">Hui-Jie  Wang</span>, <span class="hlFld-ContribAuthor ">Yu-Hui  Jin</span>, <span class="hlFld-ContribAuthor ">Qiong  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhi-Hui  Wang</span>, <span class="hlFld-ContribAuthor ">Jian-Min  Jia</span>, <span class="hlFld-ContribAuthor ">Fang  Liu</span>, <span class="hlFld-ContribAuthor ">Lei  Wang</span>, <span class="hlFld-ContribAuthor ">Qi-Chao  Bao</span>, <span class="hlFld-ContribAuthor ">Dong-Dong  Li</span>, <span class="hlFld-ContribAuthor ">Qi-Dong  You</span>, and <span class="hlFld-ContribAuthor ">Xiao-Li  Xu</span>  . </span><span class="cited-content_cbyCitation_article-title">Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (23)
                                     , 10498-10519. <a href="https://doi.org/10.1021/acs.jmedchem.6b00912" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00912</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00912%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252BTetrahydropyrido%25255B4%25252C3-d%25255Dpyrimidines%252Bas%252BPotent%252BInhibitors%252Bof%252BChaperone%252BHeat%252BShock%252BProtein%252B90%26aulast%3DJiang%26aufirst%3DFen%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D17062016%26date%3D22112016%26date%3D08122016%26date%3D09112016%26volume%3D59%26issue%3D23%26spage%3D10498%26epage%3D10519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuhang  Peng</span>, <span class="hlFld-ContribAuthor ">Zhenglan  Huang</span>, <span class="hlFld-ContribAuthor ">Fangzhu  Zhou</span>, <span class="hlFld-ContribAuthor ">Teng  Wang</span>, <span class="hlFld-ContribAuthor ">Ke  Mou</span>, <span class="hlFld-ContribAuthor ">Wenli  Feng</span>. </span><span class="cited-content_cbyCitation_article-title">Effect of HSP90AB1 and CC domain interaction on Bcr-Abl protein cytoplasm localization and function in chronic myeloid leukemia cells. </span><span class="cited-content_cbyCitation_journal-name">Cell Communication and Signaling</span><span> <strong>2021,</strong> <em>19 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12964-021-00752-9" title="DOI URL">https://doi.org/10.1186/s12964-021-00752-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12964-021-00752-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12964-021-00752-9%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Communication%2520and%2520Signaling%26atitle%3DEffect%252Bof%252BHSP90AB1%252Band%252BCC%252Bdomain%252Binteraction%252Bon%252BBcr-Abl%252Bprotein%252Bcytoplasm%252Blocalization%252Band%252Bfunction%252Bin%252Bchronic%252Bmyeloid%252Bleukemia%252Bcells%26aulast%3DPeng%26aufirst%3DYuhang%26date%3D2021%26date%3D2021%26volume%3D19%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wanqian  Li</span>, <span class="hlFld-ContribAuthor ">Manjari  Shrivastava</span>, <span class="hlFld-ContribAuthor ">Hui  Lu</span>, <span class="hlFld-ContribAuthor ">Yuanying  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Calcium-calcineurin signaling pathway in Candida albicans: A potential drug target. </span><span class="cited-content_cbyCitation_journal-name">Microbiological Research</span><span> <strong>2021,</strong> <em>249 </em>, 126786. <a href="https://doi.org/10.1016/j.micres.2021.126786" title="DOI URL">https://doi.org/10.1016/j.micres.2021.126786</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.micres.2021.126786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.micres.2021.126786%26sid%3Dliteratum%253Aachs%26jtitle%3DMicrobiological%2520Research%26atitle%3DCalcium-calcineurin%252Bsignaling%252Bpathway%252Bin%252BCandida%252Balbicans%25253A%252BA%252Bpotential%252Bdrug%252Btarget%26aulast%3DLi%26aufirst%3DWanqian%26date%3D2021%26volume%3D249%26spage%3D126786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cong-Truong  Nguyen</span>, <span class="hlFld-ContribAuthor ">Minh  Thanh La</span>, <span class="hlFld-ContribAuthor ">Jihyae  Ann</span>, <span class="hlFld-ContribAuthor ">Gibeom  Nam</span>, <span class="hlFld-ContribAuthor ">Hyun-Ju  Park</span>, <span class="hlFld-ContribAuthor ">Jung  Min Park</span>, <span class="hlFld-ContribAuthor ">Yoon-Jae  Kim</span>, <span class="hlFld-ContribAuthor ">Ji  Young Kim</span>, <span class="hlFld-ContribAuthor ">Jae  Hong Seo</span>, <span class="hlFld-ContribAuthor ">Jeewoo  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a simplified deguelin analog as an HSP90 C-terminal inhibitor for HER2-positive breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>45 </em>, 128134. <a href="https://doi.org/10.1016/j.bmcl.2021.128134" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128134</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128134%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252Bsimplified%252Bdeguelin%252Banalog%252Bas%252Ban%252BHSP90%252BC-terminal%252Binhibitor%252Bfor%252BHER2-positive%252Bbreast%252Bcancer%26aulast%3DNguyen%26aufirst%3DCong-Truong%26date%3D2021%26volume%3D45%26spage%3D128134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yi-Min  Liu</span>, <span class="hlFld-ContribAuthor ">Huang-Ju  Tu</span>, <span class="hlFld-ContribAuthor ">Chueh-Heng  Wu</span>, <span class="hlFld-ContribAuthor ">Mei-Jung  Lai</span>, <span class="hlFld-ContribAuthor ">Shu-Chieh  Yu</span>, <span class="hlFld-ContribAuthor ">Min-Wu  Chao</span>, <span class="hlFld-ContribAuthor ">Yi-Wen  Wu</span>, <span class="hlFld-ContribAuthor ">Che-Ming  Teng</span>, <span class="hlFld-ContribAuthor ">Shiow-Lin  Pan</span>, <span class="hlFld-ContribAuthor ">Jing-Ping  Liou</span>. </span><span class="cited-content_cbyCitation_article-title">Ring-opening of five-membered heterocycles conjugated 4-isopropylresorcinol scaffold-based benzamides as HSP90 inhibitors suppressing tumor growth in vitro and in vivo. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>219 </em>, 113428. <a href="https://doi.org/10.1016/j.ejmech.2021.113428" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113428</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113428%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRing-opening%252Bof%252Bfive-membered%252Bheterocycles%252Bconjugated%252B4-isopropylresorcinol%252Bscaffold-based%252Bbenzamides%252Bas%252BHSP90%252Binhibitors%252Bsuppressing%252Btumor%252Bgrowth%252Bin%2525C2%2525A0vitro%252Band%252Bin%2525C2%2525A0vivo%26aulast%3DLiu%26aufirst%3DYi-Min%26date%3D2021%26volume%3D219%26spage%3D113428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Albert A.  Antolin</span>, <span class="hlFld-ContribAuthor ">Paul A.  Clarke</span>, <span class="hlFld-ContribAuthor ">Ian  Collins</span>, <span class="hlFld-ContribAuthor ">Paul  Workman</span>, <span class="hlFld-ContribAuthor ">Bissan  Al-Lazikani</span>. </span><span class="cited-content_cbyCitation_article-title">Evolution of kinase polypharmacology across HSP90 drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2021,</strong> <em>5 </em><a href="https://doi.org/10.1016/j.chembiol.2021.05.004" title="DOI URL">https://doi.org/10.1016/j.chembiol.2021.05.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2021.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2021.05.004%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DEvolution%252Bof%252Bkinase%252Bpolypharmacology%252Bacross%252BHSP90%252Bdrug%252Bdiscovery%26aulast%3DAntolin%26aufirst%3DAlbert%2BA.%26date%3D2021%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Wang</span>, <span class="hlFld-ContribAuthor ">Qiuyue  Zhang</span>, <span class="hlFld-ContribAuthor ">Qidong  You</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the HSP90–CDC37–kinase chaperone cycle: A promising therapeutic strategy for cancer. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2021,</strong> <em>95 </em><a href="https://doi.org/10.1002/med.21807" title="DOI URL">https://doi.org/10.1002/med.21807</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21807%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DTargeting%252Bthe%252BHSP90%2525E2%252580%252593CDC37%2525E2%252580%252593kinase%252Bchaperone%252Bcycle%25253A%252BA%252Bpromising%252Btherapeutic%252Bstrategy%252Bfor%252Bcancer%26aulast%3DWang%26aufirst%3DLei%26date%3D2021%26date%3D2021%26volume%3D95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li  Li</span>, <span class="hlFld-ContribAuthor ">Nan-Nan  Chen</span>, <span class="hlFld-ContribAuthor ">Qi-Dong  You</span>, <span class="hlFld-ContribAuthor ">Xiao-Li  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">An updated patent review of anticancer Hsp90 inhibitors (2013-present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2021,</strong> <em>31 </em>
                                    (1)
                                     , 67-80. <a href="https://doi.org/10.1080/13543776.2021.1829595" title="DOI URL">https://doi.org/10.1080/13543776.2021.1829595</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2021.1829595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2021.1829595%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DAn%252Bupdated%252Bpatent%252Breview%252Bof%252Banticancer%252BHsp90%252Binhibitors%252B%2525282013-present%252529%26aulast%3DLi%26aufirst%3DLi%26date%3D2021%26date%3D2020%26volume%3D31%26issue%3D1%26spage%3D67%26epage%3D80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christopher E.  Eyermann</span>, <span class="hlFld-ContribAuthor ">John D.  Haley</span>, <span class="hlFld-ContribAuthor ">Evguenia M.  Alexandrova</span>. </span><span class="cited-content_cbyCitation_article-title">The HSP-RTK-Akt axis mediates acquired resistance to Ganetespib in HER2-positive breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Cell Death & Disease</span><span> <strong>2021,</strong> <em>12 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41419-021-03414-3" title="DOI URL">https://doi.org/10.1038/s41419-021-03414-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41419-021-03414-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41419-021-03414-3%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Death%2520%2526%2520Disease%26atitle%3DThe%252BHSP-RTK-Akt%252Baxis%252Bmediates%252Bacquired%252Bresistance%252Bto%252BGanetespib%252Bin%252BHER2-positive%252Bbreast%252Bcancer%26aulast%3DEyermann%26aufirst%3DChristopher%2BE.%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sang Chul  Shin</span>, <span class="hlFld-ContribAuthor ">Ashraf K.  El-Damasy</span>, <span class="hlFld-ContribAuthor ">Ju Hyeon  Lee</span>, <span class="hlFld-ContribAuthor ">Seon Hee  Seo</span>, <span class="hlFld-ContribAuthor ">Ji Hyun  Kim</span>, <span class="hlFld-ContribAuthor ">Young Ho  Seo</span>, <span class="hlFld-ContribAuthor ">Yuri  Lee</span>, <span class="hlFld-ContribAuthor ">Ji Hoon  Yu</span>, <span class="hlFld-ContribAuthor ">Eun Kyoung  Bang</span>, <span class="hlFld-ContribAuthor ">Eunice EunKyeong  Kim</span>, <span class="hlFld-ContribAuthor ">Gyochang  Keum</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Basis for Design of New Purine-Based Inhibitors Targeting the Hydrophobic Binding Pocket of Hsp90. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (24)
                                     , 9377. <a href="https://doi.org/10.3390/ijms21249377" title="DOI URL">https://doi.org/10.3390/ijms21249377</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21249377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21249377%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DStructural%252BBasis%252Bfor%252BDesign%252Bof%252BNew%252BPurine-Based%252BInhibitors%252BTargeting%252Bthe%252BHydrophobic%252BBinding%252BPocket%252Bof%252BHsp90%26aulast%3DShin%26aufirst%3DSang%2BChul%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D24%26spage%3D9377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cong-Truong  Nguyen</span>, <span class="hlFld-ContribAuthor ">Jihyae  Ann</span>, <span class="hlFld-ContribAuthor ">Raghaba  Sahu</span>, <span class="hlFld-ContribAuthor ">Woong Sub  Byun</span>, <span class="hlFld-ContribAuthor ">Sangkook  Lee</span>, <span class="hlFld-ContribAuthor ">Gibeom  Nam</span>, <span class="hlFld-ContribAuthor ">Hyun-Ju  Park</span>, <span class="hlFld-ContribAuthor ">Soeun  Park</span>, <span class="hlFld-ContribAuthor ">Yoon-Jae  Kim</span>, <span class="hlFld-ContribAuthor ">Ji Young  Kim</span>, <span class="hlFld-ContribAuthor ">Jae Hong  Seo</span>, <span class="hlFld-ContribAuthor ">Jeewoo  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel anti-breast cancer agents derived from deguelin as inhibitors of heat shock protein 90 (HSP90). </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (17)
                                     , 127374. <a href="https://doi.org/10.1016/j.bmcl.2020.127374" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127374</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127374%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bnovel%252Banti-breast%252Bcancer%252Bagents%252Bderived%252Bfrom%252Bdeguelin%252Bas%252Binhibitors%252Bof%252Bheat%252Bshock%252Bprotein%252B90%252B%252528HSP90%252529%26aulast%3DNguyen%26aufirst%3DCong-Truong%26date%3D2020%26volume%3D30%26issue%3D17%26spage%3D127374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ameneh  Jafari</span>, <span class="hlFld-ContribAuthor ">Mostafa  Rezaei-Tavirani</span>, <span class="hlFld-ContribAuthor ">Behrouz  Farhadihosseinabadi</span>, <span class="hlFld-ContribAuthor ">Shahrouz  Taranejoo</span>, <span class="hlFld-ContribAuthor ">Hakimeh  Zali</span>. </span><span class="cited-content_cbyCitation_article-title">HSP90 and Co-chaperones: Impact on Tumor Progression and Prospects for Molecular-Targeted Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Cancer Investigation</span><span> <strong>2020,</strong> <em>38 </em>
                                    (5)
                                     , 310-328. <a href="https://doi.org/10.1080/07357907.2020.1752227" title="DOI URL">https://doi.org/10.1080/07357907.2020.1752227</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07357907.2020.1752227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07357907.2020.1752227%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Investigation%26atitle%3DHSP90%252Band%252BCo-chaperones%25253A%252BImpact%252Bon%252BTumor%252BProgression%252Band%252BProspects%252Bfor%252BMolecular-Targeted%252BCancer%252BTherapy%26aulast%3DJafari%26aufirst%3DAmeneh%26date%3D2020%26date%3D2020%26volume%3D38%26issue%3D5%26spage%3D310%26epage%3D328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kuanglei  Wang</span>, <span class="hlFld-ContribAuthor ">Hongxi  Zhu</span>, <span class="hlFld-ContribAuthor ">Hongqian  Zhao</span>, <span class="hlFld-ContribAuthor ">Kun  Zhang</span>, <span class="hlFld-ContribAuthor ">Yongshou  Tian</span>. </span><span class="cited-content_cbyCitation_article-title">Application of carbamyl in structural optimization. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>98 </em>, 103757. <a href="https://doi.org/10.1016/j.bioorg.2020.103757" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103757</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103757%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DApplication%252Bof%252Bcarbamyl%252Bin%252Bstructural%252Boptimization%26aulast%3DWang%26aufirst%3DKuanglei%26date%3D2020%26volume%3D98%26spage%3D103757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiufeng  Yu</span>, <span class="hlFld-ContribAuthor ">Min  Mao</span>, <span class="hlFld-ContribAuthor ">Xia  Liu</span>, <span class="hlFld-ContribAuthor ">Tingting  Shen</span>, <span class="hlFld-ContribAuthor ">Tingting  Li</span>, <span class="hlFld-ContribAuthor ">Hao  Yu</span>, <span class="hlFld-ContribAuthor ">Junting  Zhang</span>, <span class="hlFld-ContribAuthor ">Xinxin  Chen</span>, <span class="hlFld-ContribAuthor ">Xijuan  Zhao</span>, <span class="hlFld-ContribAuthor ">Daling  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">A cytosolic heat shock protein 90 and co-chaperone p23 complex activates RIPK3/MLKL during necroptosis of endothelial cells in acute respiratory distress syndrome. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Medicine</span><span> <strong>2020,</strong> <em>98 </em>
                                    (4)
                                     , 569-583. <a href="https://doi.org/10.1007/s00109-020-01886-y" title="DOI URL">https://doi.org/10.1007/s00109-020-01886-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00109-020-01886-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00109-020-01886-y%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Medicine%26atitle%3DA%252Bcytosolic%252Bheat%252Bshock%252Bprotein%252B90%252Band%252Bco-chaperone%252Bp23%252Bcomplex%252Bactivates%252BRIPK3%25252FMLKL%252Bduring%252Bnecroptosis%252Bof%252Bendothelial%252Bcells%252Bin%252Bacute%252Brespiratory%252Bdistress%252Bsyndrome%26aulast%3DYu%26aufirst%3DXiufeng%26date%3D2020%26date%3D2020%26volume%3D98%26issue%3D4%26spage%3D569%26epage%3D583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shulei  Zhu</span>, <span class="hlFld-ContribAuthor ">Yalei  Li</span>, <span class="hlFld-ContribAuthor ">Yushu  Huang</span>, <span class="hlFld-ContribAuthor ">Minmin  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaofan  Gu</span>, <span class="hlFld-ContribAuthor ">Yang  He</span>, <span class="hlFld-ContribAuthor ">Hongchun  Liu</span>, <span class="hlFld-ContribAuthor ">Mingliang  Ma</span>, <span class="hlFld-ContribAuthor ">Wei  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Optimized HSP90 mediated fluorescent probes for cancer-specific bioimaging. </span><span class="cited-content_cbyCitation_journal-name">Journal of Materials Chemistry B</span><span> <strong>2020,</strong> <em>8 </em>
                                    (9)
                                     , 1878-1896. <a href="https://doi.org/10.1039/C9TB02505G" title="DOI URL">https://doi.org/10.1039/C9TB02505G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9TB02505G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9TB02505G%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Materials%2520Chemistry%2520B%26atitle%3DOptimized%252BHSP90%252Bmediated%252Bfluorescent%252Bprobes%252Bfor%252Bcancer-specific%252Bbioimaging%26aulast%3DZhu%26aufirst%3DShulei%26date%3D2020%26date%3D2020%26volume%3D8%26issue%3D9%26spage%3D1878%26epage%3D1896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kaidi  Wang</span>, <span class="hlFld-ContribAuthor ">Xuan  Wang</span>, <span class="hlFld-ContribAuthor ">Yiying  Hou</span>, <span class="hlFld-ContribAuthor ">Huihui  Zhou</span>, <span class="hlFld-ContribAuthor ">Kangsen  Mai</span>, <span class="hlFld-ContribAuthor ">Gen  He</span>. </span><span class="cited-content_cbyCitation_article-title">Apoptosis of cancer cells is triggered by selective crosslinking and inhibition of receptor tyrosine kinases. </span><span class="cited-content_cbyCitation_journal-name">Communications Biology</span><span> <strong>2019,</strong> <em>2 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s42003-019-0484-5" title="DOI URL">https://doi.org/10.1038/s42003-019-0484-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s42003-019-0484-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs42003-019-0484-5%26sid%3Dliteratum%253Aachs%26jtitle%3DCommunications%2520Biology%26atitle%3DApoptosis%252Bof%252Bcancer%252Bcells%252Bis%252Btriggered%252Bby%252Bselective%252Bcrosslinking%252Band%252Binhibition%252Bof%252Breceptor%252Btyrosine%252Bkinases%26aulast%3DWang%26aufirst%3DKaidi%26date%3D2019%26date%3D2019%26volume%3D2%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Teodora  Alexa-Stratulat</span>, <span class="hlFld-ContribAuthor ">Milica  Pešić</span>, <span class="hlFld-ContribAuthor ">Ana Čipak  Gašparović</span>, <span class="hlFld-ContribAuthor ">Ioannis P.  Trougakos</span>, <span class="hlFld-ContribAuthor ">Chiara  Riganti</span>. </span><span class="cited-content_cbyCitation_article-title">What sustains the multidrug resistance phenotype beyond ABC efflux transporters? Looking beyond the tip of the iceberg. </span><span class="cited-content_cbyCitation_journal-name">Drug Resistance Updates</span><span> <strong>2019,</strong> <em>46 </em>, 100643. <a href="https://doi.org/10.1016/j.drup.2019.100643" title="DOI URL">https://doi.org/10.1016/j.drup.2019.100643</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drup.2019.100643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drup.2019.100643%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Resistance%2520Updates%26atitle%3DWhat%252Bsustains%252Bthe%252Bmultidrug%252Bresistance%252Bphenotype%252Bbeyond%252BABC%252Befflux%252Btransporters%25253F%252BLooking%252Bbeyond%252Bthe%252Btip%252Bof%252Bthe%252Biceberg%26aulast%3DAlexa-Stratulat%26aufirst%3DTeodora%26date%3D2019%26volume%3D46%26spage%3D100643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Melkon  Iradyan</span>, <span class="hlFld-ContribAuthor ">Nina  Iradyan</span>, <span class="hlFld-ContribAuthor ">Philippe  Hulin</span>, <span class="hlFld-ContribAuthor ">Artur  Hambardzumyan</span>, <span class="hlFld-ContribAuthor ">Aram  Gyulkhandanyan</span>, <span class="hlFld-ContribAuthor ">Rodolphe  Alves de Sousa</span>, <span class="hlFld-ContribAuthor ">Assia  Hessani</span>, <span class="hlFld-ContribAuthor ">Christos  Roussakis</span>, <span class="hlFld-ContribAuthor ">Guillaume  Bollot</span>, <span class="hlFld-ContribAuthor ">Cyril  Bauvais</span>, <span class="hlFld-ContribAuthor ">Vehary  Sakanyan</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Degradation of EGFR through the Allosteric Site Leads to Cancer Cell Detachment-Promoted Death. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2019,</strong> <em>11 </em>
                                    (8)
                                     , 1094. <a href="https://doi.org/10.3390/cancers11081094" title="DOI URL">https://doi.org/10.3390/cancers11081094</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers11081094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers11081094%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DTargeting%252BDegradation%252Bof%252BEGFR%252Bthrough%252Bthe%252BAllosteric%252BSite%252BLeads%252Bto%252BCancer%252BCell%252BDetachment-Promoted%252BDeath%26aulast%3DIradyan%26aufirst%3DMelkon%26date%3D2019%26date%3D2019%26volume%3D11%26issue%3D8%26spage%3D1094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ho Shin  Kim</span>, <span class="hlFld-ContribAuthor ">Van-Hai  Hoang</span>, <span class="hlFld-ContribAuthor ">Mannkyu  Hong</span>, <span class="hlFld-ContribAuthor ">Kyung  Chul Kim</span>, <span class="hlFld-ContribAuthor ">Jihyae  Ann</span>, <span class="hlFld-ContribAuthor ">Cong-Truong  Nguyen</span>, <span class="hlFld-ContribAuthor ">Ji Hae  Seo</span>, <span class="hlFld-ContribAuthor ">Hoon  Choi</span>, <span class="hlFld-ContribAuthor ">Jun  Yong Kim</span>, <span class="hlFld-ContribAuthor ">Kyu-Won  Kim</span>, <span class="hlFld-ContribAuthor ">Woong  Sub Byun</span>, <span class="hlFld-ContribAuthor ">Sangkook  Lee</span>, <span class="hlFld-ContribAuthor ">Seungbeom  Lee</span>, <span class="hlFld-ContribAuthor ">Young-Ger  Suh</span>, <span class="hlFld-ContribAuthor ">Jie  Chen</span>, <span class="hlFld-ContribAuthor ">Hyun-Ju  Park</span>, <span class="hlFld-ContribAuthor ">Tae-Min  Cho</span>, <span class="hlFld-ContribAuthor ">Ji Young  Kim</span>, <span class="hlFld-ContribAuthor ">Jae Hong  Seo</span>, <span class="hlFld-ContribAuthor ">Jeewoo  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Investigation of B,C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors for use as anti-breast cancer agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (7)
                                     , 1370-1381. <a href="https://doi.org/10.1016/j.bmc.2019.02.040" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.02.040</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.02.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.02.040%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DInvestigation%252Bof%252BB%25252CC-ring%252Btruncated%252Bdeguelin%252Bderivatives%252Bas%252Bheat%252Bshock%252Bprotein%252B90%252B%252528HSP90%252529%252Binhibitors%252Bfor%252Buse%252Bas%252Banti-breast%252Bcancer%252Bagents%26aulast%3DKim%26aufirst%3DHo%2BShin%26date%3D2019%26volume%3D27%26issue%3D7%26spage%3D1370%26epage%3D1381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hong  Yao</span>, <span class="hlFld-ContribAuthor ">Feijie  Xu</span>, <span class="hlFld-ContribAuthor ">Guangyu  Wang</span>, <span class="hlFld-ContribAuthor ">Shaowen  Xie</span>, <span class="hlFld-ContribAuthor ">Wenlong  Li</span>, <span class="hlFld-ContribAuthor ">Hequan  Yao</span>, <span class="hlFld-ContribAuthor ">Cong  Ma</span>, <span class="hlFld-ContribAuthor ">Zheying  Zhu</span>, <span class="hlFld-ContribAuthor ">Jinyi  Xu</span>, <span class="hlFld-ContribAuthor ">Shengtao  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of truncated deguelin derivatives as Hsp90 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>167 </em>, 485-498. <a href="https://doi.org/10.1016/j.ejmech.2019.02.014" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.02.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.02.014%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Btruncated%252Bdeguelin%252Bderivatives%252Bas%252BHsp90%252Binhibitors%26aulast%3DYao%26aufirst%3DHong%26date%3D2019%26volume%3D167%26spage%3D485%26epage%3D498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jae-Hyoung  Song</span>, <span class="hlFld-ContribAuthor ">Aeri  Shim</span>, <span class="hlFld-ContribAuthor ">Yeon-Jeong  Kim</span>, <span class="hlFld-ContribAuthor ">Jae-Hee  Ahn</span>, <span class="hlFld-ContribAuthor ">Bo-Eun  Kwon</span>, <span class="hlFld-ContribAuthor ">Thuy Trang  Pham</span>, <span class="hlFld-ContribAuthor ">Jongkook  Lee</span>, <span class="hlFld-ContribAuthor ">Sun-Young  Chang</span>, <span class="hlFld-ContribAuthor ">Hyun-Jeong  Ko</span>. </span><span class="cited-content_cbyCitation_article-title">Antiviral and Anti-Inflammatory Activities of Pochonin D, a Heat Shock Protein 90 Inhibitor, against Rhinovirus Infection. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules & Therapeutics</span><span> <strong>2018,</strong> <em>26 </em>
                                    (6)
                                     , 576-583. <a href="https://doi.org/10.4062/biomolther.2017.233" title="DOI URL">https://doi.org/10.4062/biomolther.2017.233</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4062/biomolther.2017.233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4062%2Fbiomolther.2017.233%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%2520%2526%2520Therapeutics%26atitle%3DAntiviral%252Band%252BAnti-Inflammatory%252BActivities%252Bof%252BPochonin%252BD%25252C%252Ba%252BHeat%252BShock%252BProtein%252B90%252BInhibitor%25252C%252Bagainst%252BRhinovirus%252BInfection%26aulast%3DSong%26aufirst%3DJae-Hyoung%26date%3D2018%26volume%3D26%26issue%3D6%26spage%3D576%26epage%3D583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sanil  Bhatia</span>, <span class="hlFld-ContribAuthor ">Daniela  Diedrich</span>, <span class="hlFld-ContribAuthor ">Benedikt  Frieg</span>, <span class="hlFld-ContribAuthor ">Heinz  Ahlert</span>, <span class="hlFld-ContribAuthor ">Stefan  Stein</span>, <span class="hlFld-ContribAuthor ">Bertan  Bopp</span>, <span class="hlFld-ContribAuthor ">Franziska  Lang</span>, <span class="hlFld-ContribAuthor ">Tao  Zang</span>, <span class="hlFld-ContribAuthor ">Tobias  Kröger</span>, <span class="hlFld-ContribAuthor ">Thomas  Ernst</span>, <span class="hlFld-ContribAuthor ">Gesine  Kögler</span>, <span class="hlFld-ContribAuthor ">Andreas  Krieg</span>, <span class="hlFld-ContribAuthor ">Steffen  Lüdeke</span>, <span class="hlFld-ContribAuthor ">Hana  Kunkel</span>, <span class="hlFld-ContribAuthor ">Ana J.  Rodrigues Moita</span>, <span class="hlFld-ContribAuthor ">Matthias U.  Kassack</span>, <span class="hlFld-ContribAuthor ">Viktoria  Marquardt</span>, <span class="hlFld-ContribAuthor ">Friederike V.  Opitz</span>, <span class="hlFld-ContribAuthor ">Marina  Oldenburg</span>, <span class="hlFld-ContribAuthor ">Marc  Remke</span>, <span class="hlFld-ContribAuthor ">Florian  Babor</span>, <span class="hlFld-ContribAuthor ">Manuel  Grez</span>, <span class="hlFld-ContribAuthor ">Andreas  Hochhaus</span>, <span class="hlFld-ContribAuthor ">Arndt  Borkhardt</span>, <span class="hlFld-ContribAuthor ">Georg  Groth</span>, <span class="hlFld-ContribAuthor ">Luitgard  Nagel-Steger</span>, <span class="hlFld-ContribAuthor ">Joachim  Jose</span>, <span class="hlFld-ContribAuthor ">Thomas  Kurz</span>, <span class="hlFld-ContribAuthor ">Holger  Gohlke</span>, <span class="hlFld-ContribAuthor ">Finn K.  Hansen</span>, <span class="hlFld-ContribAuthor ">Julia  Hauer</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response. </span><span class="cited-content_cbyCitation_journal-name">Blood</span><span> <strong>2018,</strong> <em>132 </em>
                                    (3)
                                     , 307-320. <a href="https://doi.org/10.1182/blood-2017-10-810986" title="DOI URL">https://doi.org/10.1182/blood-2017-10-810986</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1182/blood-2017-10-810986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1182%2Fblood-2017-10-810986%26sid%3Dliteratum%253Aachs%26jtitle%3DBlood%26atitle%3DTargeting%252BHSP90%252Bdimerization%252Bvia%252Bthe%252BC%252Bterminus%252Bis%252Beffective%252Bin%252Bimatinib-resistant%252BCML%252Band%252Blacks%252Bthe%252Bheat%252Bshock%252Bresponse%26aulast%3DBhatia%26aufirst%3DSanil%26date%3D2018%26volume%3D132%26issue%3D3%26spage%3D307%26epage%3D320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Le  Jin</span>, <span class="hlFld-ContribAuthor ">Rizhen  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaochao  Huang</span>, <span class="hlFld-ContribAuthor ">Bin  Zhang</span>, <span class="hlFld-ContribAuthor ">Min  Ji</span>, <span class="hlFld-ContribAuthor ">Hengshan  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 18β-glycyrrhetinic acid conjugated aminobenzothiazole derivatives as Hsp90-Cdc37 interaction disruptors that inhibit cell migration and reverse drug resistance. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (8)
                                     , 1759-1775. <a href="https://doi.org/10.1016/j.bmc.2018.02.021" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.02.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.02.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.02.021%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B18%2525CE%2525B2-glycyrrhetinic%252Bacid%252Bconjugated%252Baminobenzothiazole%252Bderivatives%252Bas%252BHsp90-Cdc37%252Binteraction%252Bdisruptors%252Bthat%252Binhibit%252Bcell%252Bmigration%252Band%252Breverse%252Bdrug%252Bresistance%26aulast%3DJin%26aufirst%3DLe%26date%3D2018%26volume%3D26%26issue%3D8%26spage%3D1759%26epage%3D1775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kaijun  Geng</span>, <span class="hlFld-ContribAuthor ">Hongchun  Liu</span>, <span class="hlFld-ContribAuthor ">Zilan  Song</span>, <span class="hlFld-ContribAuthor ">Chi  Zhang</span>, <span class="hlFld-ContribAuthor ">Minmin  Zhang</span>, <span class="hlFld-ContribAuthor ">Hong  Yang</span>, <span class="hlFld-ContribAuthor ">Jingchen  Cao</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Aijun  Shen</span>, <span class="hlFld-ContribAuthor ">Ao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and pharmacological evaluation of ALK and Hsp90 dual inhibitors bearing resorcinol and 2,4-diaminopyrimidine motifs. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>152 </em>, 76-86. <a href="https://doi.org/10.1016/j.ejmech.2018.04.019" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.04.019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.04.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.04.019%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bpharmacological%252Bevaluation%252Bof%252BALK%252Band%252BHsp90%252Bdual%252Binhibitors%252Bbearing%252Bresorcinol%252Band%252B2%25252C4-diaminopyrimidine%252Bmotifs%26aulast%3DGeng%26aufirst%3DKaijun%26date%3D2018%26volume%3D152%26spage%3D76%26epage%3D86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fleur M.  Ferguson</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase inhibitors: the road ahead. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2018,</strong> <em>17 </em>
                                    (5)
                                     , 353-377. <a href="https://doi.org/10.1038/nrd.2018.21" title="DOI URL">https://doi.org/10.1038/nrd.2018.21</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nrd.2018.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnrd.2018.21%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DKinase%252Binhibitors%25253A%252Bthe%252Broad%252Bahead%26aulast%3DFerguson%26aufirst%3DFleur%2BM.%26date%3D2018%26date%3D2018%26volume%3D17%26issue%3D5%26spage%3D353%26epage%3D377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katherine M.  Byrd</span>, <span class="hlFld-ContribAuthor ">Caitlin N.  Kent</span>, <span class="hlFld-ContribAuthor ">Brian S. J.  Blagg</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Biological Evaluation of Stilbene Analogues as Hsp90 C-Terminal Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2017,</strong> <em>12 </em>
                                    (24)
                                     , 2022-2029. <a href="https://doi.org/10.1002/cmdc.201700630" title="DOI URL">https://doi.org/10.1002/cmdc.201700630</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201700630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201700630%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BStilbene%252BAnalogues%252Bas%252BHsp90%252BC-Terminal%252BInhibitors%26aulast%3DByrd%26aufirst%3DKatherine%2BM.%26date%3D2017%26date%3D2017%26volume%3D12%26issue%3D24%26spage%3D2022%26epage%3D2029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chau D.  Vo</span>, <span class="hlFld-ContribAuthor ">Hanna L.  Shebert</span>, <span class="hlFld-ContribAuthor ">Shannon  Zikovich</span>, <span class="hlFld-ContribAuthor ">Rebecca A.  Dryer</span>, <span class="hlFld-ContribAuthor ">Tony P.  Huang</span>, <span class="hlFld-ContribAuthor ">Lindsey J.  Moran</span>, <span class="hlFld-ContribAuthor ">Juno  Cho</span>, <span class="hlFld-ContribAuthor ">Douglas R.  Wassarman</span>, <span class="hlFld-ContribAuthor ">Bryn E.  Falahee</span>, <span class="hlFld-ContribAuthor ">Peter D.  Young</span>, <span class="hlFld-ContribAuthor ">Garrick H.  Gu</span>, <span class="hlFld-ContribAuthor ">James F.  Heinl</span>, <span class="hlFld-ContribAuthor ">John W.  Hammond</span>, <span class="hlFld-ContribAuthor ">Taylor N.  Jackvony</span>, <span class="hlFld-ContribAuthor ">Thomas E.  Frederick</span>, <span class="hlFld-ContribAuthor ">Jimmy A.  Blair</span>. </span><span class="cited-content_cbyCitation_article-title">Repurposing Hsp90 inhibitors as antibiotics targeting histidine kinases. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (23)
                                     , 5235-5244. <a href="https://doi.org/10.1016/j.bmcl.2017.10.036" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.10.036</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.10.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.10.036%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DRepurposing%252BHsp90%252Binhibitors%252Bas%252Bantibiotics%252Btargeting%252Bhistidine%252Bkinases%26aulast%3DVo%26aufirst%3DChau%2BD.%26date%3D2017%26volume%3D27%26issue%3D23%26spage%3D5235%26epage%3D5244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fen  Jiang</span>, <span class="hlFld-ContribAuthor ">An-ping  Guo</span>, <span class="hlFld-ContribAuthor ">Jia-cheng  Xu</span>, <span class="hlFld-ContribAuthor ">Hui-Jie  Wang</span>, <span class="hlFld-ContribAuthor ">Xiao-fei  Mo</span>, <span class="hlFld-ContribAuthor ">Qi-Dong  You</span>, <span class="hlFld-ContribAuthor ">Xiao-Li  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Identification and optimization of novel 6-acylamino-2-aminoquinolines as potent Hsp90 C-terminal inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>141 </em>, 1-14. <a href="https://doi.org/10.1016/j.ejmech.2017.07.080" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.07.080</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.07.080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.07.080%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Band%252Boptimization%252Bof%252Bnovel%252B6-acylamino-2-aminoquinolines%252Bas%252Bpotent%252BHsp90%2525C2%2525A0C-terminal%252Binhibitors%26aulast%3DJiang%26aufirst%3DFen%26date%3D2017%26volume%3D141%26spage%3D1%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ryan C.  Chai</span>, <span class="hlFld-ContribAuthor ">Jessica L.  Vieusseux</span>, <span class="hlFld-ContribAuthor ">Benjamin J.  Lang</span>, <span class="hlFld-ContribAuthor ">Chau H.  Nguyen</span>, <span class="hlFld-ContribAuthor ">Michelle M.  Kouspou</span>, <span class="hlFld-ContribAuthor ">Kara L.  Britt</span>, <span class="hlFld-ContribAuthor ">John T.  Price</span>. </span><span class="cited-content_cbyCitation_article-title">Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecular Oncology</span><span> <strong>2017,</strong> <em>11 </em>
                                    (5)
                                     , 567-583. <a href="https://doi.org/10.1002/1878-0261.12054" title="DOI URL">https://doi.org/10.1002/1878-0261.12054</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/1878-0261.12054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F1878-0261.12054%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Oncology%26atitle%3DHistone%252Bdeacetylase%252Bactivity%252Bmediates%252Bacquired%252Bresistance%252Btowards%252Bstructurally%252Bdiverse%252BHSP90%252Binhibitors%26aulast%3DChai%26aufirst%3DRyan%2BC.%26date%3D2017%26date%3D2017%26volume%3D11%26issue%3D5%26spage%3D567%26epage%3D583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sasidhar  Eda</span>, <span class="hlFld-ContribAuthor ">Ramakrishna  Vadde</span>, <span class="hlFld-ContribAuthor ">Rajeswari  Jinka</span>. </span><span class="cited-content_cbyCitation_article-title">Role of Hypoxia-Inducible Factor (HIF) in the Initiation of Cancer and Its Therapeutic Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 131-159. <a href="https://doi.org/10.1007/978-981-10-6728-0_10" title="DOI URL">https://doi.org/10.1007/978-981-10-6728-0_10</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-981-10-6728-0_10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-981-10-6728-0_10%26sid%3Dliteratum%253Aachs%26atitle%3DRole%252Bof%252BHypoxia-Inducible%252BFactor%252B%252528HIF%252529%252Bin%252Bthe%252BInitiation%252Bof%252BCancer%252Band%252BIts%252BTherapeutic%252BInhibitors%26aulast%3DEda%26aufirst%3DSasidhar%26date%3D2017%26date%3D2018%26spage%3D131%26epage%3D159%26pub%3DSpringer%2520Singapore%26atitle%3DRole%252Bof%252BTranscription%252BFactors%252Bin%252BGastrointestinal%252BMalignancies%26aulast%3DNagaraju%26aufirst%3DGanji%2BPurnachandra%26date%3D2017%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ju-Hyeon  Lee</span>, <span class="hlFld-ContribAuthor ">Sang Chul  Shin</span>, <span class="hlFld-ContribAuthor ">Seon Hee  Seo</span>, <span class="hlFld-ContribAuthor ">Young Ho  Seo</span>, <span class="hlFld-ContribAuthor ">Nakcheol  Jeong</span>, <span class="hlFld-ContribAuthor ">Chan-Wha  Kim</span>, <span class="hlFld-ContribAuthor ">Eunice EunKyeong  Kim</span>, <span class="hlFld-ContribAuthor ">Gyochang  Keum</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and in vitro antiproliferative activity of C5-benzyl substituted 2-amino-pyrrolo[2,3- d ]pyrimidines as potent Hsp90 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (2)
                                     , 237-241. <a href="https://doi.org/10.1016/j.bmcl.2016.11.062" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.11.062</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.11.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.11.062%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bin%252Bvitro%252Bantiproliferative%252Bactivity%252Bof%252BC5-benzyl%252Bsubstituted%252B2-amino-pyrrolo%25255B2%25252C3-%252Bd%252B%25255Dpyrimidines%252Bas%252Bpotent%252BHsp90%252Binhibitors%26aulast%3DLee%26aufirst%3DJu-Hyeon%26date%3D2017%26volume%3D27%26issue%3D2%26spage%3D237%26epage%3D241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chi  Zhang</span>, <span class="hlFld-ContribAuthor ">Xin  Wang</span>, <span class="hlFld-ContribAuthor ">Hongchun  Liu</span>, <span class="hlFld-ContribAuthor ">Minmin  Zhang</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Liping  Sun</span>, <span class="hlFld-ContribAuthor ">Aijun  Shen</span>, <span class="hlFld-ContribAuthor ">Ao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and pharmacological evaluation of 4,5-diarylisoxazols bearing amino acid residues within the 3-amido motif as potent heat shock protein 90 (Hsp90) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>125 </em>, 315-326. <a href="https://doi.org/10.1016/j.ejmech.2016.09.043" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.09.043</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.09.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.09.043%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bpharmacological%252Bevaluation%252Bof%252B4%25252C5-diarylisoxazols%252Bbearing%252Bamino%252Bacid%252Bresidues%252Bwithin%252Bthe%252B3-amido%252Bmotif%252Bas%252Bpotent%252Bheat%252Bshock%252Bprotein%252B90%252B%252528Hsp90%252529%252Binhibitors%26aulast%3DZhang%26aufirst%3DChi%26date%3D2017%26volume%3D125%26spage%3D315%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ho Shin  Kim</span>, <span class="hlFld-ContribAuthor ">Mannkyu  Hong</span>, <span class="hlFld-ContribAuthor ">Jihyae  Ann</span>, <span class="hlFld-ContribAuthor ">Suyoung  Yoon</span>, <span class="hlFld-ContribAuthor ">Cong-Truong  Nguyen</span>, <span class="hlFld-ContribAuthor ">Su-Chan  Lee</span>, <span class="hlFld-ContribAuthor ">Ho-Young  Lee</span>, <span class="hlFld-ContribAuthor ">Young-Ger  Suh</span>, <span class="hlFld-ContribAuthor ">Ji Hae  Seo</span>, <span class="hlFld-ContribAuthor ">Hoon  Choi</span>, <span class="hlFld-ContribAuthor ">Jun Yong  Kim</span>, <span class="hlFld-ContribAuthor ">Kyu-Won  Kim</span>, <span class="hlFld-ContribAuthor ">Joohwan  Kim</span>, <span class="hlFld-ContribAuthor ">Young-Myeong  Kim</span>, <span class="hlFld-ContribAuthor ">So-Jung  Park</span>, <span class="hlFld-ContribAuthor ">Hyun-Ju  Park</span>, <span class="hlFld-ContribAuthor ">Jeewoo  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2016,</strong> <em>24 </em>
                                    (22)
                                     , 6082-6093. <a href="https://doi.org/10.1016/j.bmc.2016.09.067" title="DOI URL">https://doi.org/10.1016/j.bmc.2016.09.067</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2016.09.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2016.09.067%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252BC-ring%252Btruncated%252Bdeguelin%252Bderivatives%252Bas%252Bheat%252Bshock%252Bprotein%252B90%252B%252528HSP90%252529%252Binhibitors%26aulast%3DKim%26aufirst%3DHo%2BShin%26date%3D2016%26volume%3D24%26issue%3D22%26spage%3D6082%26epage%3D6093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/medium/jm-2015-01106x_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/medium/jm-2015-01106x_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Four major classes of clinically well studied N-terminal Hsp90 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/medium/jm-2015-01106x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Key Events for Hsp90 Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/medium/jm-2015-01106x_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Interaction modes of Hsp90 Inhibitors with the N-terminal domain of Hsp90. A critical H-bond is generally formed between Asp93 of Hsp90 and the inhibitors. (A) Geldanamycin and its derivatives. The carbamate moiety forms a H-bond with Asp93. (B) The resorcinol derivatives. The resorcinol moiety forms an H-bond with Asp93. (C) The purine analogues. The 6-aminopyrimidine moiety forms an H-bond with Asp93. (D) The 2-aminobenzamide derivatives. The amide moiety forms an H-bond with Asp93.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/medium/jm-2015-01106x_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Interface of the Hsp90 and CDC37 complex. The interface between the lid segment (residues 100–121, yellow cartoon) of N-Hsp90 and the helices (residues Met164, Leu165, and Ala204, blue cartoon) of C-CDC37 is reinforced by several polar interactions highlighted by magenta dot lines (taken from PDB ID code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1US7">1US7</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/medium/jm-2015-01106x_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Crystal structure of the Hsp90–p23–ATP complex. The complex structure is shown as cartoon in green (Hsp90) and purple (p23/Sba1). Two p23/Sba1 molecules bind to the N-terminal domains of the Hsp90 dimer in a symmetrically closed conformation (taken from PDB ID code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2CG9">2CG9</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/medium/jm-2015-01106x_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Conformational changes in the N- and M-domains of Hsp90 (green) upon interacting with an ATP analogue (red) and p23/Sba1. The “lid” segment (residues 94–125), colored in blue, folds over the ATP-binding pocket by nearly 180° from its “open” position, resulting in the exposure of a hydrophobic patch. The M-segments move together and interact with the N-domain of the other monomer (taken from PDB ID codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2IOQ">2IOQ</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2CG9">2CG9</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/medium/jm-2015-01106x_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. EM reconstruction of the Hsp90–CDC37–CDK4 complex. The structure was revised from the EM reconstruction and the crystal structures of Hsp90, CDC37, and CDK4 (PDB ID codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2CG9">2CG9</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1US7">1US7</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2W99">2W99</a>). The C-terminal lobe of CDK4 (red cartoon) interacts with the M-domain of the Hsp90 monomer (green cartoon), and the small N-domain interacts with either the N-terminal domain of Hsp90 or the N-terminal domain of CDC37, while the C-terminal domain of CDC37 (blue cartoon) interacts with the other Hsp90 monomer, forming an asymmetrical complex.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/medium/jm-2015-01106x_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. ALK signaling pathway, mechanisms of resistance to ALK-TKIs, and application of Hsp90 inhibitors to overcome the resistance. The EML4-ALK fusion protein (dark gray) is aberrantly expressed in cancer. ALK-TKIs (dark violet), such as crizotinib, could bind to the ATP-binding pocket of EML4-ALK, inhibit the kinase activity, and block the downstream signaling pathways. The resistance mechanisms of ALK-TKIs are rather complicated, and Hsp90 inhibitors (red) are effective against the acquired resistance through diverse mechanisms.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/medium/jm-2015-01106x_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. EGFR signaling pathway, mechanisms of EGFR TKIs resistance, and application of Hsp90 inhibitors to overcome EGFR TKIs resistance. EGFR dimerization mediates phosphorylation of this receptor and initiates downstream signaling pathways, such as the PI3K/AKT and RAS/RAF/MEK/ERK pathways (dark gray), which are essential for cancer cell survival and proliferation. Several mechanisms of EGFR TKI resistance have been identified, and Hsp90 inhibitors (red) are effective against the acquired resistance through diverse mechanisms.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/medium/jm-2015-01106x_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Representative Hsp90 Inhibitors in preclinical or clinical studies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.5b01106/20160804/images/large/jm-2015-01106x_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01106&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i49">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77180" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77180" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 162 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Taipale, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarosz, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindquist, S.</span><span> </span><span class="NLM_article-title">HSP90 at the hub of protein homeostasis: emerging mechanistic insights</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">515</span><span class="NLM_x">–</span> <span class="NLM_lpage">528</span><span class="refDoi"> DOI: 10.1038/nrm2918</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnrm2918" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=20531426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntFSmt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=515-528&author=M.+Taipaleauthor=D.+F.+Jaroszauthor=S.+Lindquist&title=HSP90+at+the+hub+of+protein+homeostasis%3A+emerging+mechanistic+insights&doi=10.1038%2Fnrm2918"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">HSP90 at the hub of protein homeostasis: emerging mechanistic insights</span></div><div class="casAuthors">Taipale, Mikko; Jarosz, Daniel F.; Lindquist, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">515-528</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Heat-shock protein 90 (HSP90) is a highly conserved mol. chaperone that facilitates the maturation of a wide range of proteins (known as clients).  Clients are enriched in signal transducers, including kinases and transcription factors.  Therefore, HSP90 regulates diverse cellular functions and exerts marked effects on normal biol., disease, and evolutionary processes.  Recent structural and functional analyses have provided new insights on the transcriptional and biochem. regulation of HSP90 and the structural dynamics it uses to act on a diverse client repertoire.  A comprehensive understanding of how HSP90 functions promises not only to provide new avenues for therapeutic intervention, but to shed light on fundamental biol. questions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuMRSaY8uzGbVg90H21EOLACvtfcHk0ljaHYCQBHmoZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntFSmt7c%253D&md5=492dca92cea32384d2ab4145230f53dd</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrm2918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2918%26sid%3Dliteratum%253Aachs%26aulast%3DTaipale%26aufirst%3DM.%26aulast%3DJarosz%26aufirst%3DD.%2BF.%26aulast%3DLindquist%26aufirst%3DS.%26atitle%3DHSP90%2520at%2520the%2520hub%2520of%2520protein%2520homeostasis%253A%2520emerging%2520mechanistic%2520insights%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2010%26volume%3D11%26spage%3D515%26epage%3D528%26doi%3D10.1038%2Fnrm2918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Whitesell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindquist, S.</span><span> </span><span class="NLM_article-title">HSP90 and the chaperoning of cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">761</span><span class="NLM_x">–</span> <span class="NLM_lpage">772</span><span class="refDoi"> DOI: 10.1038/nrc1716</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnrc1716" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=16175177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGjs7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=761-772&author=L.+Whitesellauthor=S.+Lindquist&title=HSP90+and+the+chaperoning+of+cancer&doi=10.1038%2Fnrc1716"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">HSP90 and the chaperoning of cancer</span></div><div class="casAuthors">Whitesell, Luke; Lindquist, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">761-772</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Standing watch over the proteome, mol. chaperones are an ancient and evolutionarily conserved class of proteins that guide the normal folding, intracellular disposition and proteolytic turnover of many of the key regulators of cell growth, differentiation and survival.  This essential guardian function is subverted during oncogenesis to allow malignant transformation and to facilitate rapid somatic evolution.  Pharmacol. 'bribing' the essential guard duty of the chaperone HSP90 (heat-shock protein of 90 kDa) seems to offer a unique anticancer strategy of considerable promise.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4Vmb5bGXgDLVg90H21EOLACvtfcHk0lg4H_BkQLdUOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGjs7bF&md5=c418ec249a29c70047081cd241938931</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc1716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1716%26sid%3Dliteratum%253Aachs%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DLindquist%26aufirst%3DS.%26atitle%3DHSP90%2520and%2520the%2520chaperoning%2520of%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D761%26epage%3D772%26doi%3D10.1038%2Fnrc1716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Stankiewicz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer, M. P.</span><span> </span><span class="NLM_article-title">The universe of Hsp90</span> <span class="citation_source-journal">Biomol. Concepts</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">79</span><span class="NLM_x">–</span> <span class="NLM_lpage">97</span><span class="refDoi"> DOI: 10.1515/bmc.2011.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1515%2Fbmc.2011.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=25436526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvFWgsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=79-97&author=M.+Stankiewiczauthor=M.+P.+Mayer&title=The+universe+of+Hsp90&doi=10.1515%2Fbmc.2011.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The universe of Hsp90</span></div><div class="casAuthors">Stankiewicz, Marta; Mayer, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecular Concepts</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">79-97</span>CODEN:
                <span class="NLM_cas:coden">BCIOB8</span>;
        ISSN:<span class="NLM_cas:issn">1868-5021</span>.
    
            (<span class="NLM_cas:orgname">Walter de Gruyter GmbH</span>)
        </div><div class="casAbstract">A review.  Mol. chaperones are key components in the maintenance of cellular homeostasis and survival, not only during stress but also under optimal growth conditions.  Among the ATP-dependent chaperones, heat shock proteins (Hsp90) proteins play a special role.  While Hsp90s can interact with unfolded and misfolded proteins, their main (and in eukaryotic cells essential) function appears to involve interactions with a limited no. of protein clients at late steps of maturation or in "alter-native" conformations for regulating their stability and activity.  Because Hsp90 clients are hubs of diverse signaling networks and participate in nearly every cellular function, Hsp90s interconnect many regulatory circuits and link them to environmental impacts.  The availability and activity of Hsp90 may thus influence complex physiol. and pathophysiol. processes, such as differentiation, development, aging, cancer, neurodegeneration, and infectious diseases.  Furthermore, through homeostatic effects on differentiation and development, Hsp90s act as capacitors of phenotypic evolution.  In this review, we discuss recent insights in the structure and chaperone cycle of Hsp90s, the mechanisms underlying Hsp90 binding to clients, and potential reasons why client proteins specifically require the assistance of Hsp90s.  Moreover, the current views on Hsp90-cochaperone interactions and regulation of Hsp90 proteins via posttranslational modifications are summarized.  The second half of this article is devoted to the role of Hsp90 proteins in health and disease, aging, and evolution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnbY32KkmlGLVg90H21EOLACvtfcHk0lg4H_BkQLdUOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvFWgsbc%253D&md5=943ba4e99e8854357c9a4b05de6446d9</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1515%2Fbmc.2011.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252Fbmc.2011.054%26sid%3Dliteratum%253Aachs%26aulast%3DStankiewicz%26aufirst%3DM.%26aulast%3DMayer%26aufirst%3DM.%2BP.%26atitle%3DThe%2520universe%2520of%2520Hsp90%26jtitle%3DBiomol.%2520Concepts%26date%3D2012%26volume%3D3%26spage%3D79%26epage%3D97%26doi%3D10.1515%2Fbmc.2011.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Kamal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sensintaffar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehm, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritz, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, F. J.</span><span> </span><span class="NLM_article-title">A high-affinity conformation of Hsp90 confers tumor selectivity on Hsp90 inhibitors</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">425</span><span class="NLM_x">, </span> <span class="NLM_fpage">407</span><span class="NLM_x">–</span> <span class="NLM_lpage">410</span><span class="refDoi"> DOI: 10.1038/nature01913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnature01913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=14508491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnsV2kt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=425&publication_year=2003&pages=407-410&author=A.+Kamalauthor=L.+Thaoauthor=J.+Sensintaffarauthor=L.+Zhangauthor=M.+F.+Boehmauthor=A.+C.+Fritzauthor=F.+J.+Burrows&title=A+high-affinity+conformation+of+Hsp90+confers+tumor+selectivity+on+Hsp90+inhibitors&doi=10.1038%2Fnature01913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A high-affinity conformation of Hsp90 confers tumor selectivity on Hsp90 inhibitors</span></div><div class="casAuthors">Kamal, Adeela; Thao, Lia; Sensintaffar, John; Zhang, Lin; Boehm, Marcus F.; Fritz, Lawrence C.; Burrows, Francis J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">425</span>
        (<span class="NLM_cas:issue">6956</span>),
    <span class="NLM_cas:pages">407-410</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) is a mol. chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, including HER-2/ErbB2, Akt, Raf-1, Bcr-Abl and mutated p53.  Hsp90 inhibitors bind to Hsp90, and induce the proteasomal degrdn. of Hsp90 client proteins.  Although Hsp90 is highly expressed in most cells, Hsp90 inhibitors selectively kill cancer cells compared to normal cells, and the Hsp90 inhibitor 17-allylaminogeldanamycin (17-AAG) is currently in phase I clin. trials.  However, the mol. basis of the tumor selectivity of Hsp90 inhibitors is unknown.  Here we report that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than does Hsp90 from normal cells.  Tumor Hsp90 is present entirely in multi-chaperone complexes with high ATPase activity, whereas Hsp90 from normal tissues is in a latent, uncomplexed state.  In vitro reconstitution of chaperone complexes with Hsp90 resulted in increased binding affinity to 17-AAG, and increased ATPase activity.  These results suggest that tumor cells contain Hsp90 complexes in an activated, high-affinity conformation that facilitates malignant progression, and that may represent a unique target for cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0ozo1K3wfA7Vg90H21EOLACvtfcHk0lgJwazdH-4SKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnsV2kt7w%253D&md5=7c83fca7aaf685b589c4aef6e5f39b02</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnature01913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature01913%26sid%3Dliteratum%253Aachs%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DThao%26aufirst%3DL.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DBoehm%26aufirst%3DM.%2BF.%26aulast%3DFritz%26aufirst%3DA.%2BC.%26aulast%3DBurrows%26aufirst%3DF.%2BJ.%26atitle%3DA%2520high-affinity%2520conformation%2520of%2520Hsp90%2520confers%2520tumor%2520selectivity%2520on%2520Hsp90%2520inhibitors%26jtitle%3DNature%26date%3D2003%26volume%3D425%26spage%3D407%26epage%3D410%26doi%3D10.1038%2Fnature01913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Chiosis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neckers, L.</span><span> </span><span class="NLM_article-title">Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">279</span><span class="NLM_x">–</span> <span class="NLM_lpage">284</span><span class="refDoi"> DOI: 10.1021/cb600224w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb600224w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtFSiur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=279-284&author=G.+Chiosisauthor=L.+Neckers&title=Tumor+selectivity+of+Hsp90+inhibitors%3A+the+explanation+remains+elusive&doi=10.1021%2Fcb600224w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor Selectivity of Hsp90 Inhibitors: The Explanation Remains Elusive</span></div><div class="casAuthors">Chiosis, Gabriela; Neckers, Len</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">279-284</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Two recent papers attempt to solve both the tumor selectivity and the in vivo tumor accumulation profiles seen with some Hsp90 inhibitors.  They spotlight the higher affinity of ansamycins' hydroquinone over the quinone form for Hsp90 and further discuss its possible contribution to ansamycins' tumor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMDQyu5SJs37Vg90H21EOLACvtfcHk0lgJwazdH-4SKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtFSiur8%253D&md5=7956eebef69de36723632b6a16bb1c79</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fcb600224w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb600224w%26sid%3Dliteratum%253Aachs%26aulast%3DChiosis%26aufirst%3DG.%26aulast%3DNeckers%26aufirst%3DL.%26atitle%3DTumor%2520selectivity%2520of%2520Hsp90%2520inhibitors%253A%2520the%2520explanation%2520remains%2520elusive%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2006%26volume%3D1%26spage%3D279%26epage%3D284%26doi%3D10.1021%2Fcb600224w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Trepel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mollapour, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giaccone, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neckers, L.</span><span> </span><span class="NLM_article-title">Targeting the dynamic HSP90 complex in cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">537</span><span class="NLM_x">–</span> <span class="NLM_lpage">549</span><span class="refDoi"> DOI: 10.1038/nrc2887</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnrc2887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=20651736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1GjtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=537-549&author=J.+Trepelauthor=M.+Mollapourauthor=G.+Giacconeauthor=L.+Neckers&title=Targeting+the+dynamic+HSP90+complex+in+cancer&doi=10.1038%2Fnrc2887"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the dynamic HSP90 complex in cancer</span></div><div class="casAuthors">Trepel, Jane; Mollapour, Mehdi; Giaccone, Giuseppe; Neckers, Len</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">537-549</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The mol. chaperone, heat-shock protein 90 (HSP90), has been used by cancer cells to facilitate the function of numerous oncoproteins, and it can be argued that cancer cells are 'addicted' to HSP90.  However, although recent reports of the early clin. efficacy of HSP90 inhibitors are encouraging, the optimal use of HSP90-targeted therapeutics will depend on understanding the complexity of HSP90 regulation and the degree to which HSP90 participates in both neoplastic and normal cellular physiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprGEqkx6m7p7Vg90H21EOLACvtfcHk0lhE-3EP3A1HJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1GjtLs%253D&md5=8acba020073ebb93cf1dee577420dc32</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrc2887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2887%26sid%3Dliteratum%253Aachs%26aulast%3DTrepel%26aufirst%3DJ.%26aulast%3DMollapour%26aufirst%3DM.%26aulast%3DGiaccone%26aufirst%3DG.%26aulast%3DNeckers%26aufirst%3DL.%26atitle%3DTargeting%2520the%2520dynamic%2520HSP90%2520complex%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D537%26epage%3D549%26doi%3D10.1038%2Fnrc2887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Ferrarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heltai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zocchi, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rugarli, C.</span><span> </span><span class="NLM_article-title">Unusual expression and localization of heat-shock proteins in human tumor cells</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">613</span><span class="NLM_x">–</span> <span class="NLM_lpage">619</span><span class="refDoi"> DOI: 10.1002/ijc.2910510418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1002%2Fijc.2910510418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1601523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADyaK38XlvV2hs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1992&pages=613-619&author=M.+Ferrariniauthor=S.+Heltaiauthor=M.+R.+Zocchiauthor=C.+Rugarli&title=Unusual+expression+and+localization+of+heat-shock+proteins+in+human+tumor+cells&doi=10.1002%2Fijc.2910510418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Unusual expression and localization of heat-shock proteins in human tumor cells</span></div><div class="casAuthors">Ferrarini, Marina; Heltai, Silvia; Zocchi, M. Raffaella; Rugarli, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">613-19</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    </div><div class="casAbstract">It has been suggested that members of HSP families represent the surface target of immune responses leading to tumor rejection in mice.  The authors report that tumor cells, compared with normal cells, constitutively expressed 2- to 10-fold higher levels of intracellular HSP90.  Moreover, in the absence of environmental stress, 2 lines (out of 6) expressed the "inducible" HSP72, which was also detectable in fresh tumor cells.  HSP72 expression was not regulated during the cell cycle, in contrast with what has been obsd. with normal cells.  Both HSP90 and HSP72 proteins exhibited a heterogeneous pattern of intracellular distribution in most cells, HSP72 being confined mainly to the nuclear compartment.  Finally, both HSP90 and, to a lesser extent, HSP72 (that are generally believed to be located intracellularly) were detected at the surface of some tumor cell lines.  It is concluded that tumor cells differ from normal cells in their pattern of HSP expression; this might imply a role of HSPs in eliciting an immune response against cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdlQHEKHA7jLVg90H21EOLACvtfcHk0lhE-3EP3A1HJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlvV2hs7s%253D&md5=4ace8651e9b125c68985102a0b3055f3</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fijc.2910510418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.2910510418%26sid%3Dliteratum%253Aachs%26aulast%3DFerrarini%26aufirst%3DM.%26aulast%3DHeltai%26aufirst%3DS.%26aulast%3DZocchi%26aufirst%3DM.%2BR.%26aulast%3DRugarli%26aufirst%3DC.%26atitle%3DUnusual%2520expression%2520and%2520localization%2520of%2520heat-shock%2520proteins%2520in%2520human%2520tumor%2520cells%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D1992%26volume%3D51%26spage%3D613%26epage%3D619%26doi%3D10.1002%2Fijc.2910510418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Darby, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span> </span><span class="NLM_article-title">Many faces of a cancer supporting protein</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">478</span><span class="NLM_x">, </span> <span class="NLM_fpage">334</span><span class="NLM_x">–</span> <span class="NLM_lpage">335</span><span class="refDoi"> DOI: 10.1038/478334b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2F478334b" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=478&publication_year=2011&pages=334-335&author=J.+F.+Darbyauthor=P.+Workman&title=Many+faces+of+a+cancer+supporting+protein&doi=10.1038%2F478334b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2F478334b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F478334b%26sid%3Dliteratum%253Aachs%26aulast%3DDarby%26aufirst%3DJ.%2BF.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DMany%2520faces%2520of%2520a%2520cancer%2520supporting%2520protein%26jtitle%3DNature%26date%3D2011%26volume%3D478%26spage%3D334%26epage%3D335%26doi%3D10.1038%2F478334b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Scaltriti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawood, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Molecular pathways: targeting Hsp90--who benefits and who does not</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4508</span><span class="NLM_x">–</span> <span class="NLM_lpage">4513</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-2138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1078-0432.CCR-11-2138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22718860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ygsL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=4508-4513&author=M.+Scaltritiauthor=S.+Dawoodauthor=J.+Cortes&title=Molecular+pathways%3A+targeting+Hsp90%2D%2Dwho+benefits+and+who+does+not&doi=10.1158%2F1078-0432.CCR-11-2138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: Targeting Hsp90-Who Benefits and Who Does Not</span></div><div class="casAuthors">Scaltriti, Maurizio; Dawood, Shaheenah; Cortes, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4508-4513</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Many kinases and hormone receptors, important for cancer cell proliferation and survival, bind to and are dependent on the Hsp90 cycle for their folding and maturation.  This provides the rationale for the development of small-mol. ATP competitors that, inhibiting Hsp90 function, lead to degrdn. of the "client" proteins.  After continual efforts to improve the pharmacol. properties and the tolerability of these mols., several Hsp90 inhibitors have exhibited activity in both preclin. models and in the clin. setting.  As is the case with many other targeted agents, patient selection seems to be the major limitation to the success of these compds.  ERBB2-pos. patients with breast cancer are exquisitely sensitive to Hsp90 inhibition.  This is because ERBB2 is indispensable for growth and survival of this subtype of cancer, and at the same time ERBB2 is a client protein strictly dependent on Hsp90 for its maturation and stability.  Extensive preclin. work identifying other ERBB-like client proteins will likely lead to the ability to enhance selection of appropriate patients for enrollment in more rational clin. trials.  Hsp90 inhibition has also been reported to synergize with other therapeutic agents.  Several ongoing studies testing different combinations of Hsp90 inhibitors with other targeted agents will confirm whether Hsp90 inhibition can potentiate the efficacy of targeted therapy and/or prevent the emergence of drug resistance.  Clin Cancer Res; 18(17); 4508-13. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcSf5P7B7H8bVg90H21EOLACvtfcHk0li6athC_eVYXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ygsL3L&md5=8274b2b8bedc14970bd02b37acb163e8</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2138%26sid%3Dliteratum%253Aachs%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DDawood%26aufirst%3DS.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DMolecular%2520pathways%253A%2520targeting%2520Hsp90--who%2520benefits%2520and%2520who%2520does%2520not%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D4508%26epage%3D4513%26doi%3D10.1158%2F1078-0432.CCR-11-2138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Moulick, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerchietti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomes DaGama, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldas-Lopes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beebe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perna, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatzi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vu, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zatorska, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taldone, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith-Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alpaugh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pillarsetty, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ku, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erdjument-Bromage, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzman, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melnick, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neckers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span> </span><span class="NLM_article-title">Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">818</span><span class="NLM_x">–</span> <span class="NLM_lpage">826</span><span class="refDoi"> DOI: 10.1038/nchembio.670</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnchembio.670" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=21946277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1anurbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=818-826&author=K.+Moulickauthor=J.+H.+Ahnauthor=H.+Zongauthor=A.+Rodinaauthor=L.+Cerchiettiauthor=E.+M.+Gomes+DaGamaauthor=E.+Caldas-Lopesauthor=K.+Beebeauthor=F.+Pernaauthor=K.+Hatziauthor=L.+P.+Vuauthor=X.+Zhaoauthor=D.+Zatorskaauthor=T.+Taldoneauthor=P.+Smith-Jonesauthor=M.+Alpaughauthor=S.+S.+Grossauthor=N.+Pillarsettyauthor=T.+Kuauthor=J.+S.+Lewisauthor=S.+M.+Larsonauthor=R.+Levineauthor=H.+Erdjument-Bromageauthor=M.+L.+Guzmanauthor=S.+D.+Nimerauthor=A.+Melnickauthor=L.+Neckersauthor=G.+Chiosis&title=Affinity-based+proteomics+reveal+cancer-specific+networks+coordinated+by+Hsp90&doi=10.1038%2Fnchembio.670"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90</span></div><div class="casAuthors">Moulick, Kamalika; Ahn, James H.; Zong, Hongliang; Rodina, Anna; Cerchietti, Leandro; Gomes DaGama, Erica M.; Caldas-Lopes, Eloisi; Beebe, Kristin; Perna, Fabiana; Hatzi, Katerina; Vu, Ly P.; Zhao, Xinyang; Zatorska, Danuta; Taldone, Tony; Smith-Jones, Peter; Alpaugh, Mary; Gross, Steven S.; Pillarsetty, Nagavarakishore; Ku, Thomas; Lewis, Jason S.; Larson, Steven M.; Levine, Ross; Erdjument-Bromage, Hediye; Guzman, Monica L.; Nimer, Stephen D.; Melnick, Ari; Neckers, Len; Chiosis, Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">818-826</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Most cancers were characterized by multiple mol. alterations, but identification of the key proteins involved in these signaling pathways is currently beyond reach.  The inhibitor PU-H71 preferentially targets tumor-enriched Hsp90 complexes and affinity captures Hsp90-dependent oncogenic client proteins.  The authors used PU-H71 affinity capture to design a proteomic approach that, when combined with bioinformatic pathway anal., identifies dysregulated signaling networks and key oncoproteins in chronic myeloid leukemia.  The identified interactome overlaps with the well-characterized altered proteome in this cancer, indicating that this method can provide global insights into the biol. of individual tumors, including primary patient specimens.  In addn., this approach can be used to identify previously uncharacterized oncoproteins and mechanisms, potentially leading to new targeted therapies.  Further the abundance of the PU-H71-enriched Hsp90 species, which is not dictated by Hsp90 expression alone, is predictive of the cell's sensitivity to Hsp90 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXTlQWF_MFU7Vg90H21EOLACvtfcHk0li6athC_eVYXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1anurbN&md5=d62e663a2e054f3715a3a6e2d5e2c10e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.670%26sid%3Dliteratum%253Aachs%26aulast%3DMoulick%26aufirst%3DK.%26aulast%3DAhn%26aufirst%3DJ.%2BH.%26aulast%3DZong%26aufirst%3DH.%26aulast%3DRodina%26aufirst%3DA.%26aulast%3DCerchietti%26aufirst%3DL.%26aulast%3DGomes%2BDaGama%26aufirst%3DE.%2BM.%26aulast%3DCaldas-Lopes%26aufirst%3DE.%26aulast%3DBeebe%26aufirst%3DK.%26aulast%3DPerna%26aufirst%3DF.%26aulast%3DHatzi%26aufirst%3DK.%26aulast%3DVu%26aufirst%3DL.%2BP.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DZatorska%26aufirst%3DD.%26aulast%3DTaldone%26aufirst%3DT.%26aulast%3DSmith-Jones%26aufirst%3DP.%26aulast%3DAlpaugh%26aufirst%3DM.%26aulast%3DGross%26aufirst%3DS.%2BS.%26aulast%3DPillarsetty%26aufirst%3DN.%26aulast%3DKu%26aufirst%3DT.%26aulast%3DLewis%26aufirst%3DJ.%2BS.%26aulast%3DLarson%26aufirst%3DS.%2BM.%26aulast%3DLevine%26aufirst%3DR.%26aulast%3DErdjument-Bromage%26aufirst%3DH.%26aulast%3DGuzman%26aufirst%3DM.%2BL.%26aulast%3DNimer%26aufirst%3DS.%2BD.%26aulast%3DMelnick%26aufirst%3DA.%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DAffinity-based%2520proteomics%2520reveal%2520cancer-specific%2520networks%2520coordinated%2520by%2520Hsp90%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D818%26epage%3D826%26doi%3D10.1038%2Fnchembio.670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Walton-Diaz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourboulia, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trepel, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neckers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mollapour, M.</span><span> </span><span class="NLM_article-title">Contributions of co-chaperones and post-translational modifications towards Hsp90 drug sensitivity</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1059</span><span class="NLM_x">–</span> <span class="NLM_lpage">1071</span><span class="refDoi"> DOI: 10.4155/fmc.13.88</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.4155%2Ffmc.13.88" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=23734688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXos12msbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=1059-1071&author=A.+Walton-Diazauthor=S.+Khanauthor=D.+Bourbouliaauthor=J.+B.+Trepelauthor=L.+Neckersauthor=M.+Mollapour&title=Contributions+of+co-chaperones+and+post-translational+modifications+towards+Hsp90+drug+sensitivity&doi=10.4155%2Ffmc.13.88"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Contributions of co-chaperones and post-translational modifications towards Hsp90 drug sensitivity</span></div><div class="casAuthors">Walton-Diaz, Annerleim; Khan, Sahar; Bourboulia, Dimitra; Trepel, Jane B.; Neckers, Len; Mollapour, Mehdi</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1059-1071</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Hsp90 is a mol. chaperone and important driver of stabilization and activation of several oncogenic proteins that are involved in the malignant transformation of tumor cells.  Therefore, it is not surprising that Hsp90 has been reported to be a promising target for the treatment of several neoplasias, such as non-small-cell lung cancer and HER2-pos. breast cancer.  Hsp90 chaperone function depends on its ability to bind and hydrolyze ATP and Hsp90 inhibitors have been shown to compete with nucleotides for binding to Hsp90.  Multiple factors, such as co-chaperones and post-translational modification, are involved in regulating Hsp90 ATPase activity.  Here, the impact of post-translational modifications and co-chaperones on the efficacy of Hsp90 inhibitors are reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLf3BQtlxU-bVg90H21EOLACvtfcHk0lhrwYfnunJ1Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXos12msbw%253D&md5=1f887b53846ec728d9ecde40f91b5b42</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.4155%2Ffmc.13.88&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.13.88%26sid%3Dliteratum%253Aachs%26aulast%3DWalton-Diaz%26aufirst%3DA.%26aulast%3DKhan%26aufirst%3DS.%26aulast%3DBourboulia%26aufirst%3DD.%26aulast%3DTrepel%26aufirst%3DJ.%2BB.%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DMollapour%26aufirst%3DM.%26atitle%3DContributions%2520of%2520co-chaperones%2520and%2520post-translational%2520modifications%2520towards%2520Hsp90%2520drug%2520sensitivity%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2013%26volume%3D5%26spage%3D1059%26epage%3D1071%26doi%3D10.4155%2Ffmc.13.88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Bhat, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tummalapalli, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotella, D. P.</span><span> </span><span class="NLM_article-title">Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">8718</span><span class="NLM_x">–</span> <span class="NLM_lpage">8728</span><span class="refDoi"> DOI: 10.1021/jm500823a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500823a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSnsrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8718-8728&author=R.+Bhatauthor=S.+R.+Tummalapalliauthor=D.+P.+Rotella&title=Progress+in+the+discovery+and+development+of+heat+shock+protein+90+%28Hsp90%29+inhibitors&doi=10.1021%2Fjm500823a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in the Discovery and Development of Heat Shock Protein 90 (Hsp90) Inhibitors</span></div><div class="casAuthors">Bhat, Rohit; Tummalapalli, Sreedhar R.; Rotella, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8718-8728</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The discovery and clin. development of heat shock protein 90 (Hsp90) inhibitors continue to progress.  A no. of Hsp90 inhibitors are in clin. trials, and preclin. discoveries of new chemotypes that bind to distinct regions in the protein as well as isoform selective compds. are active areas of research.  This review will highlight progress in the field since 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-SwLv_-B9xLVg90H21EOLACvtfcHk0lhrwYfnunJ1Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSnsrfK&md5=132784687bbbcf62cfa8fe04a22577ce</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm500823a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500823a%26sid%3Dliteratum%253Aachs%26aulast%3DBhat%26aufirst%3DR.%26aulast%3DTummalapalli%26aufirst%3DS.%2BR.%26aulast%3DRotella%26aufirst%3DD.%2BP.%26atitle%3DProgress%2520in%2520the%2520discovery%2520and%2520development%2520of%2520heat%2520shock%2520protein%252090%2520%2528Hsp90%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8718%26epage%3D8728%26doi%3D10.1021%2Fjm500823a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Workman, P.</span><span> </span><span class="NLM_article-title">Altered states: selectively drugging the Hsp90 cancer chaperone</span> <span class="citation_source-journal">Trends Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">51</span><span class="refDoi"> DOI: 10.1016/j.molmed.2003.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.molmed.2003.12.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=47-51&author=P.+Workman&title=Altered+states%3A+selectively+drugging+the+Hsp90+cancer+chaperone&doi=10.1016%2Fj.molmed.2003.12.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2003.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2003.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DAltered%2520states%253A%2520selectively%2520drugging%2520the%2520Hsp90%2520cancer%2520chaperone%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2004%26volume%3D10%26spage%3D47%26epage%3D51%26doi%3D10.1016%2Fj.molmed.2003.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Chiosis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickey, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, J. L.</span><span> </span><span class="NLM_article-title">A global view of Hsp90 functions</span> <span class="citation_source-journal">Nat. Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">4</span><span class="refDoi"> DOI: 10.1038/nsmb.2481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnsmb.2481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=23288357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsleisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1-4&author=G.+Chiosisauthor=C.+A.+Dickeyauthor=J.+L.+Johnson&title=A+global+view+of+Hsp90+functions&doi=10.1038%2Fnsmb.2481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">A global view of Hsp90 functions</span></div><div class="casAuthors">Chiosis, Gabriela; Dickey, Chad A.; Johnson, Jill L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-4</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Sixth International Conference on Hsp90 in 2012 revealed new functions of this key mol. chaperone.  Attendees of the meeting at Les Diablerets, Switzerland, addressed new discoveries about Hsp90 and its cochaperones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHrJZHeOegBLVg90H21EOLACvtfcHk0lhTAy6AybnOeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsleisw%253D%253D&md5=fe27eda8ca2eb9adae4ecb012c171156</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2481%26sid%3Dliteratum%253Aachs%26aulast%3DChiosis%26aufirst%3DG.%26aulast%3DDickey%26aufirst%3DC.%2BA.%26aulast%3DJohnson%26aufirst%3DJ.%2BL.%26atitle%3DA%2520global%2520view%2520of%2520Hsp90%2520functions%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D1%26epage%3D4%26doi%3D10.1038%2Fnsmb.2481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Schwenkert, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hugel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, M. B.</span><span> </span><span class="NLM_article-title">The Hsp90 ensemble: coordinated Hsp90-cochaperone complexes regulate diverse cellular processes</span> <span class="citation_source-journal">Nat. Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1017</span><span class="NLM_x">–</span> <span class="NLM_lpage">1021</span><span class="refDoi"> DOI: 10.1038/nsmb.2927</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnsmb.2927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=25469839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitValurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=1017-1021&author=S.+Schwenkertauthor=T.+Hugelauthor=M.+B.+Cox&title=The+Hsp90+ensemble%3A+coordinated+Hsp90-cochaperone+complexes+regulate+diverse+cellular+processes&doi=10.1038%2Fnsmb.2927"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The Hsp90 ensemble: coordinated Hsp90-cochaperone complexes regulate diverse cellular processes</span></div><div class="casAuthors">Schwenkert, Serena; Hugel, Thorsten; Cox, Marc B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1017-1021</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Seventh International Conference on the Hsp90 Chaperone Machine took place in Oct. 2014, in Seeon, Germany.  The program highlighted recent findings in a variety of areas, including structures of heat-shock protein 90 (Hsp90)-client protein complexes, coordination of Hsp90 with cochaperones, new cellular and physiol. roles for Hsp90 and therapeutic targeting of the Hsp90 ensemble for the treatment of disease and prevention of infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBxBPS4CmbyLVg90H21EOLACvtfcHk0lhTAy6AybnOeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitValurzL&md5=fff880ba2746ba98f6d1fe29f0caefae</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2927%26sid%3Dliteratum%253Aachs%26aulast%3DSchwenkert%26aufirst%3DS.%26aulast%3DHugel%26aufirst%3DT.%26aulast%3DCox%26aufirst%3DM.%2BB.%26atitle%3DThe%2520Hsp90%2520ensemble%253A%2520coordinated%2520Hsp90-cochaperone%2520complexes%2520regulate%2520diverse%2520cellular%2520processes%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2014%26volume%3D21%26spage%3D1017%26epage%3D1021%26doi%3D10.1038%2Fnsmb.2927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Garcia-Carbonero, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carnero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paz-Ares, L.</span><span> </span><span class="NLM_article-title">Inhibition of Hsp90 molecular chaperones: moving into the clinic</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">e358</span><span class="NLM_x">–</span> <span class="NLM_lpage">e369</span><span class="refDoi"> DOI: 10.1016/S1470-2045(13)70169-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2FS1470-2045%2813%2970169-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=23896275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2iu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=e358-e369&author=R.+Garcia-Carboneroauthor=A.+Carneroauthor=L.+Paz-Ares&title=Inhibition+of+Hsp90+molecular+chaperones%3A+moving+into+the+clinic&doi=10.1016%2FS1470-2045%2813%2970169-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of HSP90 molecular chaperones: moving into the clinic</span></div><div class="casAuthors">Garcia-Carbonero, Rocio; Carnero, Amancio; Paz-Ares, Luis</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e358-e369</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Heat shock protein 90 (HSP90) is a mol. chaperone that is crucial for the stability and function of many proteins essential for cell survival.  Many oncogenes, including tyrosine kinases, transcription factors, and cell-cycle regulatory proteins, are client proteins of HSP90.  Inhibition of HSP90 causes client protein degrdn. via the ubiquitin-proteasome pathway, and is a mechanism that might simultaneously downregulate several redundant pathways crucial for cell viability and tumor development.  HSP90 inhibitors are currently being developed as anticancer agents, and have shown early promising results in molecularly defined subgroups of solid tumors (eg, ALK-rearranged non-small-cell lung cancer and HER2-amplified breast cancer) and some haematol. malignancies (eg, multiple myeloma).  Here, we review the current status of HSP90 inhibitors in clin. development, including geldanamycin derivs., resorcinol derivs., purine analogs, and other synthetic inhibitors.  We also discuss novel strategies and future perspectives on how to optimize the therapeutic potential of this exciting new class of drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpulM7j4PFcx7Vg90H21EOLACvtfcHk0lhTAy6AybnOeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2iu7jI&md5=4821e86073624fb17d7343105d6e82cd</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2813%2970169-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252813%252970169-4%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Carbonero%26aufirst%3DR.%26aulast%3DCarnero%26aufirst%3DA.%26aulast%3DPaz-Ares%26aufirst%3DL.%26atitle%3DInhibition%2520of%2520Hsp90%2520molecular%2520chaperones%253A%2520moving%2520into%2520the%2520clinic%26jtitle%3DLancet%2520Oncol.%26date%3D2013%26volume%3D14%26spage%3De358%26epage%3De369%26doi%3D10.1016%2FS1470-2045%2813%2970169-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Richardson, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsiades, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laubach, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lonial, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chanan-Khan, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers</span> <span class="citation_source-journal">Br. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">152</span><span class="NLM_x">, </span> <span class="NLM_fpage">367</span><span class="NLM_x">–</span> <span class="NLM_lpage">379</span><span class="refDoi"> DOI: 10.1111/j.1365-2141.2010.08360.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1111%2Fj.1365-2141.2010.08360.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=21219297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtVOntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2011&pages=367-379&author=P.+G.+Richardsonauthor=C.+S.+Mitsiadesauthor=J.+P.+Laubachauthor=S.+Lonialauthor=A.+A.+Chanan-Khanauthor=K.+C.+Anderson&title=Inhibition+of+heat+shock+protein+90+%28HSP90%29+as+a+therapeutic+strategy+for+the+treatment+of+myeloma+and+other+cancers&doi=10.1111%2Fj.1365-2141.2010.08360.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers</span></div><div class="casAuthors">Richardson, Paul G.; Mitsiades, Constantine S.; Laubach, Jacob P.; Lonial, Sagar; Chanan-Khan, Asher A.; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">367-379</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Heat shock protein 90 (HSP90) is a mol. chaperone that is induced in response to cellular stress and stabilizes client proteins involved in cell cycle control and proliferative/anti-apoptotic signalling.  HSP90 is overexpressed in a range of cancers, and may contribute to tumor cell survival by stabilizing aberrant signalling proteins and by interfering with apoptosis.  Tanespimycin, an HSP90 inhibitor, reduces tumor cell survival in vitro.  In multiple myeloma (MM), HSP90 inhibition affects multiple client proteins that contribute to tumor cell survival, including the IGF1 receptor and the IL-6 receptor, and elements of the PI3/Akt, STAT3, and MAPK signalling pathways.  HSP90 inhibition also abrogates the protective effect of bone marrow stromal cells and inhibits angiogenesis and osteoclastogenesis.  Tanespimycin acts synergistically with the proteasome inhibitor bortezomib in MM cells and tumor explants, possibly reducing their ability to resist bortezomib-induced stress to the endoplasmic reticulum.  The combination of tanespimycin and bortezomib has demonstrated significant and durable responses with acceptable toxicity in a phase I/II study in patients with relapsed and relapsed/refractory MM.  HSP90 inhibition is a promising strategy in MM esp. in combination with bortezomib; addnl. studies will further evaluate optimal dosings of candidate drugs and schedules, as well as confirm efficacy in comparative phase III trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9tsEVNXnwwrVg90H21EOLACvtfcHk0li5yTLDH7kaSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtVOntr4%253D&md5=2ec48571564edbf6ec2bcab69baf01a2</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2010.08360.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2010.08360.x%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26aulast%3DLaubach%26aufirst%3DJ.%2BP.%26aulast%3DLonial%26aufirst%3DS.%26aulast%3DChanan-Khan%26aufirst%3DA.%2BA.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DInhibition%2520of%2520heat%2520shock%2520protein%252090%2520%2528HSP90%2529%2520as%2520a%2520therapeutic%2520strategy%2520for%2520the%2520treatment%2520of%2520myeloma%2520and%2520other%2520cancers%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2011%26volume%3D152%26spage%3D367%26epage%3D379%26doi%3D10.1111%2Fj.1365-2141.2010.08360.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Jhaveri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochiana, S. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunphy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerecitano, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corben, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peter, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janjigian, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomes-DaGama, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koren, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span> </span><span class="NLM_article-title">Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">611</span><span class="NLM_x">–</span> <span class="NLM_lpage">628</span><span class="refDoi"> DOI: 10.1517/13543784.2014.902442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1517%2F13543784.2014.902442" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=611-628&author=K.+Jhaveriauthor=S.+O.+Ochianaauthor=M.+Dunphyauthor=J.+F.+Gerecitanoauthor=A.+D.+Corbenauthor=R.+I.+Peterauthor=Y.+Y.+Janjigianauthor=E.+M.+Gomes-DaGamaauthor=J.+Korenauthor=S.+Modiauthor=G.+Chiosis&title=Heat+shock+protein+90+inhibitors+in+the+treatment+of+cancer%3A+current+status+and+future+directions&doi=10.1517%2F13543784.2014.902442"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1517%2F13543784.2014.902442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2014.902442%26sid%3Dliteratum%253Aachs%26aulast%3DJhaveri%26aufirst%3DK.%26aulast%3DOchiana%26aufirst%3DS.%2BO.%26aulast%3DDunphy%26aufirst%3DM.%26aulast%3DGerecitano%26aufirst%3DJ.%2BF.%26aulast%3DCorben%26aufirst%3DA.%2BD.%26aulast%3DPeter%26aufirst%3DR.%2BI.%26aulast%3DJanjigian%26aufirst%3DY.%2BY.%26aulast%3DGomes-DaGama%26aufirst%3DE.%2BM.%26aulast%3DKoren%26aufirst%3DJ.%26aulast%3DModi%26aufirst%3DS.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DHeat%2520shock%2520protein%252090%2520inhibitors%2520in%2520the%2520treatment%2520of%2520cancer%253A%2520current%2520status%2520and%2520future%2520directions%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2014%26volume%3D23%26spage%3D611%26epage%3D628%26doi%3D10.1517%2F13543784.2014.902442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Jhaveri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taldone, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span> </span><span class="NLM_article-title">Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Mol. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">1823</span><span class="NLM_x">, </span> <span class="NLM_fpage">742</span><span class="NLM_x">–</span> <span class="NLM_lpage">755</span><span class="refDoi"> DOI: 10.1016/j.bbamcr.2011.10.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.bbamcr.2011.10.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22062686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFShsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1823&publication_year=2012&pages=742-755&author=K.+Jhaveriauthor=T.+Taldoneauthor=S.+Modiauthor=G.+Chiosis&title=Advances+in+the+clinical+development+of+heat+shock+protein+90+%28Hsp90%29+inhibitors+in+cancers&doi=10.1016%2Fj.bbamcr.2011.10.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers</span></div><div class="casAuthors">Jhaveri, Komal; Taldone, Tony; Modi, Shanu; Chiosis, Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1823</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">742-755</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Hsp90 is an ATP dependent mol. chaperone protein which integrates multiple oncogenic pathways.  As such, Hsp90 inhibition is a promising anti-cancer strategy.  Several inhibitors that act on Hsp90 by binding to its N-terminal ATP pocket have entered clin. evaluation.  Robust pre-clin. data suggested anti-tumor activity in multiple cancer types.  Clin., encouraging results have been demonstrated in melanoma, acute myeloid leukemia, castrate refractory prostate cancer, non-small cell lung carcinoma and multiple myeloma.  In breast cancer, proof-of-concept was demonstrated by first generation Hsp90 inhibitors in combination with trastuzumab mainly in human epidermal growth factor receptor 2 (HER2) + metastatic breast cancer.  There are a multitude of second generation Hsp90 inhibitors currently under investigation.  To date, however, there is no FDA approved Hsp90 inhibitor nor standardized assay to ascertain Hsp90 inhibition.  This review summarizes the current status of both first and second generation Hsp90 inhibitors based on their chem. classification and stage of clin. development.  It also discusses the pharmacodynamic assays currently implemented in clinic as well as other novel strategies aimed at enhancing the effectiveness of Hsp90 inhibitors.  Ultimately, these efforts will aid in maximizing the full potential of this class of agents.  This article is part of a Special Issue entitled: Heat Shock Protein 90 (HSP90).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDrDTpRQxfYrVg90H21EOLACvtfcHk0ljnXXrRBe0MPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFShsbY%253D&md5=03cef7dc96667a4698324f635aacee7a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2011.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2011.10.008%26sid%3Dliteratum%253Aachs%26aulast%3DJhaveri%26aufirst%3DK.%26aulast%3DTaldone%26aufirst%3DT.%26aulast%3DModi%26aufirst%3DS.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DAdvances%2520in%2520the%2520clinical%2520development%2520of%2520heat%2520shock%2520protein%252090%2520%2528Hsp90%2529%2520inhibitors%2520in%2520cancers%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2012%26volume%3D1823%26spage%3D742%26epage%3D755%26doi%3D10.1016%2Fj.bbamcr.2011.10.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Soláravá, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mojziš, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solár, P.</span><span> </span><span class="NLM_article-title">Hsp90 inhibitor as a sensitizer of cancer cells to different therapies</span> <span class="citation_source-journal">Int. J. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">907</span><span class="NLM_x">–</span> <span class="NLM_lpage">926</span><span class="refDoi"> DOI: 10.3892/ijo.2014.2791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.3892%2Fijo.2014.2791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=25501619" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2015&pages=907-926&author=Z.+Sol%C3%A1rav%C3%A1author=J.+Mojzi%C5%A1author=P.+Sol%C3%A1r&title=Hsp90+inhibitor+as+a+sensitizer+of+cancer+cells+to+different+therapies&doi=10.3892%2Fijo.2014.2791"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.3892%2Fijo.2014.2791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2014.2791%26sid%3Dliteratum%253Aachs%26aulast%3DSol%25C3%25A1rav%25C3%25A1%26aufirst%3DZ.%26aulast%3DMojzi%25C5%25A1%26aufirst%3DJ.%26aulast%3DSol%25C3%25A1r%26aufirst%3DP.%26atitle%3DHsp90%2520inhibitor%2520as%2520a%2520sensitizer%2520of%2520cancer%2520cells%2520to%2520different%2520therapies%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2015%26volume%3D46%26spage%3D907%26epage%3D926%26doi%3D10.3892%2Fijo.2014.2791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Prodromou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roe, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piper, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearl, L. H.</span><span> </span><span class="NLM_article-title">A molecular clamp in the crystal structure of the N-terminal domain of the yeast Hsp90 chaperone</span> <span class="citation_source-journal">Nat. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">477</span><span class="NLM_x">–</span> <span class="NLM_lpage">482</span><span class="refDoi"> DOI: 10.1038/nsb0697-477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnsb0697-477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=9187656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADyaK2sXjs1elur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1997&pages=477-482&author=C.+Prodromouauthor=S.+M.+Roeauthor=P.+W.+Piperauthor=L.+H.+Pearl&title=A+molecular+clamp+in+the+crystal+structure+of+the+N-terminal+domain+of+the+yeast+Hsp90+chaperone&doi=10.1038%2Fnsb0697-477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">A molecular clamp in the crystal structure of the N-terminal domain of the yeast Hsp90 chaperone</span></div><div class="casAuthors">Prodromou, Chrisostomos; Roe, S. Mark; Piper, Peter W.; Pearl, Laurence H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">477-482</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature America</span>)
        </div><div class="casAbstract">Hsp90 is a highly specific chaperone for many signal transduction proteins, including steroid hormone receptors and a broad range of protein kinases.  The crystal structure of the N-terminal domain of Saccharomyces cerevisiae Hsp90 revealed a dimeric structure based on a highly twisted 16-stranded β-sheet, whose topol. suggested a possible 3-dimensional domain-swapped structure for the intact Hsp90 dimer.  The opposing faces of the β-sheets in the dimer defined a potential peptide-binding cleft, suggesting that the N-domain may serve as a mol. 'clamp' in the binding of ligand proteins to Hsp90.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnZBFC02XoTbVg90H21EOLACvtfcHk0ljnXXrRBe0MPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjs1elur0%253D&md5=0ff710b91bfe28e94473cf2d6387f626</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnsb0697-477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb0697-477%26sid%3Dliteratum%253Aachs%26aulast%3DProdromou%26aufirst%3DC.%26aulast%3DRoe%26aufirst%3DS.%2BM.%26aulast%3DPiper%26aufirst%3DP.%2BW.%26aulast%3DPearl%26aufirst%3DL.%2BH.%26atitle%3DA%2520molecular%2520clamp%2520in%2520the%2520crystal%2520structure%2520of%2520the%2520N-terminal%2520domain%2520of%2520the%2520yeast%2520Hsp90%2520chaperone%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D1997%26volume%3D4%26spage%3D477%26epage%3D482%26doi%3D10.1038%2Fnsb0697-477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Stebbins, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russo, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartl, F. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavletich, N. P.</span><span> </span><span class="NLM_article-title">Crystal structure of an Hsp90-geldannamycin complex: targeting of a protein chaperone by an antitumor agent</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">239</span><span class="NLM_x">–</span> <span class="NLM_lpage">250</span><span class="refDoi"> DOI: 10.1016/S0092-8674(00)80203-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2FS0092-8674%2800%2980203-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1997&pages=239-250&author=C.+E.+Stebbinsauthor=A.+A.+Russoauthor=C.+Schneiderauthor=N.+Rosenauthor=F.+U.+Hartlauthor=N.+P.+Pavletich&title=Crystal+structure+of+an+Hsp90-geldannamycin+complex%3A+targeting+of+a+protein+chaperone+by+an+antitumor+agent&doi=10.1016%2FS0092-8674%2800%2980203-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2980203-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252980203-2%26sid%3Dliteratum%253Aachs%26aulast%3DStebbins%26aufirst%3DC.%2BE.%26aulast%3DRusso%26aufirst%3DA.%2BA.%26aulast%3DSchneider%26aufirst%3DC.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DHartl%26aufirst%3DF.%2BU.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26atitle%3DCrystal%2520structure%2520of%2520an%2520Hsp90-geldannamycin%2520complex%253A%2520targeting%2520of%2520a%2520protein%2520chaperone%2520by%2520an%2520antitumor%2520agent%26jtitle%3DCell%26date%3D1997%26volume%3D89%26spage%3D239%26epage%3D250%26doi%3D10.1016%2FS0092-8674%2800%2980203-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Neckers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulte, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mimnaugh, E.</span><span> </span><span class="NLM_article-title">Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">–</span> <span class="NLM_lpage">373</span><span class="refDoi"> DOI: 10.1023/A:1006382320697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1023%2FA%3A1006382320697" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1999&pages=361-373&author=L.+Neckersauthor=T.+W.+Schulteauthor=E.+Mimnaugh&title=Geldanamycin+as+a+potential+anti-cancer+agent%3A+its+molecular+target+and+biochemical+activity&doi=10.1023%2FA%3A1006382320697"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1023%2FA%3A1006382320697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1006382320697%26sid%3Dliteratum%253Aachs%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DSchulte%26aufirst%3DT.%2BW.%26aulast%3DMimnaugh%26aufirst%3DE.%26atitle%3DGeldanamycin%2520as%2520a%2520potential%2520anti-cancer%2520agent%253A%2520its%2520molecular%2520target%2520and%2520biochemical%2520activity%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D1999%26volume%3D17%26spage%3D361%26epage%3D373%26doi%3D10.1023%2FA%3A1006382320697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Franke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eichner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeilinger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschning, A.</span><span> </span><span class="NLM_article-title">Targeting heat-shock-protein 90 (Hsp90) by natural products: geldanamycin, a show case in cancer therapy</span> <span class="citation_source-journal">Nat. Prod. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1299</span><span class="NLM_x">–</span> <span class="NLM_lpage">1323</span><span class="refDoi"> DOI: 10.1039/c3np70012g</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1039%2Fc3np70012g" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=23934201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVehtrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2013&pages=1299-1323&author=J.+Frankeauthor=S.+Eichnerauthor=C.+Zeilingerauthor=A.+Kirschning&title=Targeting+heat-shock-protein+90+%28Hsp90%29+by+natural+products%3A+geldanamycin%2C+a+show+case+in+cancer+therapy&doi=10.1039%2Fc3np70012g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting heat-shock-protein 90 (Hsp90) by natural products: geldanamycin, a show case in cancer therapy</span></div><div class="casAuthors">Franke, Jana; Eichner, Simone; Zeilinger, Carsten; Kirschning, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1299-1323</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">In this review recent progress in the development of heat shock proteins (Hsp90) in oncogenesis is illuminated.  Particular emphasis is put on inhibitors such as geldanamycin and analogs that serve as a natural product show case.  Hsp90 has emerged as an important target in cancer therapy and/or against pathogenic cells which elicit abnormal Hsp patterns.  Competition for ATP by geldanamycin and related compds. abrogate the chaperone function of Hsp90.  In this context, this account pursues three topics in detail: a) Hsp90 and its biochem., b) Hsp90 and its role in oncogenesis and c) strategies to create compd. libraries of structurally complex inhibitors like geldanamycin on which SAR studies and the development of drugs that are currently in different stages of clin. testing rely.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKEXtk_Z4sPrVg90H21EOLACvtfcHk0ljXapn1w3gDvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVehtrjP&md5=8f326658f18f5bf01fdcad5aaac835be</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1039%2Fc3np70012g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3np70012g%26sid%3Dliteratum%253Aachs%26aulast%3DFranke%26aufirst%3DJ.%26aulast%3DEichner%26aufirst%3DS.%26aulast%3DZeilinger%26aufirst%3DC.%26aulast%3DKirschning%26aufirst%3DA.%26atitle%3DTargeting%2520heat-shock-protein%252090%2520%2528Hsp90%2529%2520by%2520natural%2520products%253A%2520geldanamycin%252C%2520a%2520show%2520case%2520in%2520cancer%2520therapy%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2013%26volume%3D30%26spage%3D1299%26epage%3D1323%26doi%3D10.1039%2Fc3np70012g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Banerji, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scurr, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stapleton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asad, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maloney, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lakhani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I.</span><span> </span><span class="NLM_article-title">Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxy geldanamycin in patients with advanced malignancies</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">4152</span><span class="NLM_x">–</span> <span class="NLM_lpage">4161</span><span class="refDoi"> DOI: 10.1200/JCO.2005.00.612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1200%2FJCO.2005.00.612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=15961763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmt1elsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=4152-4161&author=U.+Banerjiauthor=A.+O%E2%80%99Donnellauthor=M.+Scurrauthor=S.+Paceyauthor=S.+Stapletonauthor=Y.+Asadauthor=L.+Simmonsauthor=A.+Maloneyauthor=F.+Raynaudauthor=M.+Campbellauthor=M.+Waltonauthor=S.+Lakhaniauthor=S.+Kayeauthor=P.+Workmanauthor=I.+Judson&title=Phase+I+pharmacokinetic+and+pharmacodynamic+study+of+17-allylamino%2C+17-demethoxy+geldanamycin+in+patients+with+advanced+malignancies&doi=10.1200%2FJCO.2005.00.612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies</span></div><div class="casAuthors">Banerji, Udai; O'Donnell, Anne; Scurr, Michelle; Pacey, Simon; Stapleton, Sarah; Asad, Yasmin; Simmons, Laura; Maloney, Alison; Raynaud, Florence; Campbell, Maeli; Walton, Michael; Lakhani, Sunil; Kaye, Stanley; Workman, Paul; Judson, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4152-4161</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To study the toxicity and pharmacokinetic-pharmacodynamic profile of 17-allylamino, 17-demethoxygeldanamycin (17-AAG) and to recommend a dose for phase II trials.  Patients and Methods: This was a phase I study examg. a once-weekly dosing schedule of 17-AAG.  Thirty patients with advanced malignancies were treated.  Results: The highest dose level reached was 450 mg/m2/wk.  The dose-limiting toxicities (DLTs) encountered were grade 3 diarrhea in three patients (one at 320 mg/m2/wk and two at 450 mg/m2/wk) and grade 3 to 4 hepatotoxicity (AST/ALT) in one patient at 450 mg/m2/wk.  Two of nine DLTs were at the highest dose level.  Two patients with metastatic melanoma had stable disease and were treated for 15 and 41 mo, resp.  The dose vs. area under the curve-relationship for 17-AAG was linear (r2 = .71) over the dose range 10 to 450 mg/m2/wk, with peak plasma concns. of 8,998 μg/L (std. deviation, 2,881) at the highest dose level.  After the demonstration of pharmacodynamic changes in peripheral blood leukocytes, pre- and 24 h post-treatment, tumor biopsies were performed and demonstrated target inhibition (c-RAF-1 inhibition in four of six patients, CDK4 depletion in eight of nine patients and HSP70 induction in eight of nine patients) at the dose levels 320 and 450 mg/m2/wk.  It was not possible to reproducibly demonstrate these changes in biopsies taken 5 days after treatment.  Conclusion: It has been possible to demonstrate that 17-AAG exhibits a tolerable toxicity profile with therapeutic plasma concns. and target inhibition for 24 h after treatment and some indications of clin. activity at the dose level 450 mg/m2/wk.  We recommend this dose for phase II clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaKgFbodgT_bVg90H21EOLACvtfcHk0li0eGDh_pDJVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmt1elsrY%253D&md5=6ba10e24a68a1d9bd09d87239eea1ca6</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.00.612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.00.612%26sid%3Dliteratum%253Aachs%26aulast%3DBanerji%26aufirst%3DU.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DA.%26aulast%3DScurr%26aufirst%3DM.%26aulast%3DPacey%26aufirst%3DS.%26aulast%3DStapleton%26aufirst%3DS.%26aulast%3DAsad%26aufirst%3DY.%26aulast%3DSimmons%26aufirst%3DL.%26aulast%3DMaloney%26aufirst%3DA.%26aulast%3DRaynaud%26aufirst%3DF.%26aulast%3DCampbell%26aufirst%3DM.%26aulast%3DWalton%26aufirst%3DM.%26aulast%3DLakhani%26aufirst%3DS.%26aulast%3DKaye%26aufirst%3DS.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DJudson%26aufirst%3DI.%26atitle%3DPhase%2520I%2520pharmacokinetic%2520and%2520pharmacodynamic%2520study%2520of%252017-allylamino%252C%252017-demethoxy%2520geldanamycin%2520in%2520patients%2520with%2520advanced%2520malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D4152%26epage%3D4161%26doi%3D10.1200%2FJCO.2005.00.612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Sydor, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Normant, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pien, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porter, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grenier, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pak, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dembski, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penders, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pink, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodward, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grayzel, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palombella, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, J. K.</span><span> </span><span class="NLM_article-title">Development of 17-allylamino-17- demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">17408</span><span class="NLM_x">–</span> <span class="NLM_lpage">17413</span><span class="refDoi"> DOI: 10.1073/pnas.0608372103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1073%2Fpnas.0608372103" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=17408-17413&author=J.+R.+Sydorauthor=E.+Normantauthor=C.+S.+Pienauthor=J.+R.+Porterauthor=J.+Geauthor=L.+Grenierauthor=R.+H.+Pakauthor=J.+A.+Aliauthor=M.+S.+Dembskiauthor=J.+Hudakauthor=J.+Pattersonauthor=C.+Pendersauthor=M.+Pinkauthor=M.+A.+Readauthor=J.+Sangauthor=C.+Woodwardauthor=Y.+Zhangauthor=D.+S.+Grayzelauthor=J.+Wrightauthor=J.+A.+Barrettauthor=V.+J.+Palombellaauthor=J.+Adamsauthor=J.+K.+Tong&title=Development+of+17-allylamino-17-+demethoxygeldanamycin+hydroquinone+hydrochloride+%28IPI-504%29%2C+an+anti-cancer+agent+directed+against+Hsp90&doi=10.1073%2Fpnas.0608372103"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0608372103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0608372103%26sid%3Dliteratum%253Aachs%26aulast%3DSydor%26aufirst%3DJ.%2BR.%26aulast%3DNormant%26aufirst%3DE.%26aulast%3DPien%26aufirst%3DC.%2BS.%26aulast%3DPorter%26aufirst%3DJ.%2BR.%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DGrenier%26aufirst%3DL.%26aulast%3DPak%26aufirst%3DR.%2BH.%26aulast%3DAli%26aufirst%3DJ.%2BA.%26aulast%3DDembski%26aufirst%3DM.%2BS.%26aulast%3DHudak%26aufirst%3DJ.%26aulast%3DPatterson%26aufirst%3DJ.%26aulast%3DPenders%26aufirst%3DC.%26aulast%3DPink%26aufirst%3DM.%26aulast%3DRead%26aufirst%3DM.%2BA.%26aulast%3DSang%26aufirst%3DJ.%26aulast%3DWoodward%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGrayzel%26aufirst%3DD.%2BS.%26aulast%3DWright%26aufirst%3DJ.%26aulast%3DBarrett%26aufirst%3DJ.%2BA.%26aulast%3DPalombella%26aufirst%3DV.%2BJ.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DJ.%2BK.%26atitle%3DDevelopment%2520of%252017-allylamino-17-%2520demethoxygeldanamycin%2520hydroquinone%2520hydrochloride%2520%2528IPI-504%2529%252C%2520an%2520anti-cancer%2520agent%2520directed%2520against%2520Hsp90%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D17408%26epage%3D17413%26doi%3D10.1073%2Fpnas.0608372103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agatsuma, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, H.</span><span> </span><span class="NLM_article-title">Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">2639</span><span class="NLM_x">–</span> <span class="NLM_lpage">2645</span><span class="refDoi"> DOI: 10.1038/sj.onc.1201790</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fsj.onc.1201790" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1998&pages=2639-2645&author=S.+V.+Sharmaauthor=T.+Agatsumaauthor=H.+Nakano&title=Targeting+of+the+protein+chaperone%2C+HSP90%2C+by+the+transformation+suppressing+agent%2C+radicicol&doi=10.1038%2Fsj.onc.1201790"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1201790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1201790%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DAgatsuma%26aufirst%3DT.%26aulast%3DNakano%26aufirst%3DH.%26atitle%3DTargeting%2520of%2520the%2520protein%2520chaperone%252C%2520HSP90%252C%2520by%2520the%2520transformation%2520suppressing%2520agent%252C%2520radicicol%26jtitle%3DOncogene%26date%3D1998%26volume%3D16%26spage%3D2639%26epage%3D2645%26doi%3D10.1038%2Fsj.onc.1201790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Brough, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barril, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgognoni, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cansfield, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, K.-M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, N. G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drysdale, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martins, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Northfield, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearl, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prodromou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roughley, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharp, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surgenor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walmsley, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, L.</span><span> </span><span class="NLM_article-title">4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">196</span><span class="NLM_x">–</span> <span class="NLM_lpage">218</span><span class="refDoi"> DOI: 10.1021/jm701018h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701018h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlWqsL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=196-218&author=P.+A.+Broughauthor=W.+Aherneauthor=X.+Barrilauthor=J.+Borgognoniauthor=K.+Boxallauthor=J.+E.+Cansfieldauthor=K.-M.+J.+Cheungauthor=I.+Collinsauthor=N.+G.+M.+Daviesauthor=M.+J.+Drysdaleauthor=B.+Dymockauthor=S.+A.+Ecclesauthor=H.+Finchauthor=A.+Finkauthor=A.+Hayesauthor=R.+Howesauthor=R.+E.+Hubbardauthor=K.+Jamesauthor=A.+M.+Jordanauthor=A.+Lockieauthor=V.+Martinsauthor=A.+Masseyauthor=T.+P.+Matthewsauthor=E.+McDonaldauthor=C.+J.+Northfieldauthor=L.+H.+Pearlauthor=C.+Prodromouauthor=S.+Rayauthor=F.+I.+Raynaudauthor=S.+D.+Roughleyauthor=S.+Y.+Sharpauthor=A.+Surgenorauthor=D.+L.+Walmsleyauthor=P.+Webbauthor=M.+Woodauthor=P.+Workmanauthor=L.+Wright&title=4%2C5-Diarylisoxazole+Hsp90+chaperone+inhibitors%3A+potential+therapeutic+agents+for+the+treatment+of+cancer&doi=10.1021%2Fjm701018h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer</span></div><div class="casAuthors">Brough, Paul A.; Aherne, Wynne; Barril, Xavier; Borgognoni, Jennifer; Boxall, Kathy; Cansfield, Julie E.; Cheung, Kwai-Ming J.; Collins, Ian; Davies, Nicholas G. M.; Drysdale, Martin J.; Dymock, Brian; Eccles, Suzanne A.; Finch, Harry; Fink, Alexandra; Hayes, Angela; Howes, Robert; Hubbard, Roderick E.; James, Karen; Jordan, Allan M.; Lockie, Andrea; Martins, Vanessa; Massey, Andrew; Matthews, Thomas P.; McDonald, Edward; Northfield, Christopher J.; Pearl, Laurence H.; Prodromou, Chrisostomos; Ray, Stuart; Raynaud, Florence I.; Roughley, Stephen D.; Sharp, Swee Y.; Surgenor, Allan; Walmsley, D. Lee; Webb, Paul; Wood, Mike; Workman, Paul; Wright, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">196-218</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors of the Hsp90 [heat shock protein 90] mol. chaperone show considerable promise as potential chemotherapeutic agents for cancer.  The structure-based design, synthesis, structure-activity relationships, and pharmacokinetics of potent small-mol. inhibitors of Hsp90 based on the 4,5-diarylisoxazole scaffold were studied.  Analogs from this series have high affinity for Hsp90, as measured in a fluorescence polarization competitive binding assay, and are active in cancer cell lines where they inhibit proliferation and exhibit a characteristic profile of depletion of oncogenic proteins and concomitant elevation of Hsp72.  The [(morpholinomethyl)phenyl]isoxazolecarboxamide I (VER-52296/NVP-AUY922) is potent in the Hsp90 FP binding assay and inhibits proliferation of various human cancer cell lines in vitro, with GI50 averaging 9 nM.  I is retained in tumors in vivo when administered i.p., as evaluated by cassette dosing in tumor-bearing mice.  In a human colon cancer xenograft model, I inhibits tumor growth by ∼50%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTNA9AoWb8gLVg90H21EOLACvtfcHk0lg3jMh7OrMi3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlWqsL%252FK&md5=fdb98dec600987e862b9b05555427948</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm701018h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701018h%26sid%3Dliteratum%253Aachs%26aulast%3DBrough%26aufirst%3DP.%2BA.%26aulast%3DAherne%26aufirst%3DW.%26aulast%3DBarril%26aufirst%3DX.%26aulast%3DBorgognoni%26aufirst%3DJ.%26aulast%3DBoxall%26aufirst%3DK.%26aulast%3DCansfield%26aufirst%3DJ.%2BE.%26aulast%3DCheung%26aufirst%3DK.-M.%2BJ.%26aulast%3DCollins%26aufirst%3DI.%26aulast%3DDavies%26aufirst%3DN.%2BG.%2BM.%26aulast%3DDrysdale%26aufirst%3DM.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DFinch%26aufirst%3DH.%26aulast%3DFink%26aufirst%3DA.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHowes%26aufirst%3DR.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DJordan%26aufirst%3DA.%2BM.%26aulast%3DLockie%26aufirst%3DA.%26aulast%3DMartins%26aufirst%3DV.%26aulast%3DMassey%26aufirst%3DA.%26aulast%3DMatthews%26aufirst%3DT.%2BP.%26aulast%3DMcDonald%26aufirst%3DE.%26aulast%3DNorthfield%26aufirst%3DC.%2BJ.%26aulast%3DPearl%26aufirst%3DL.%2BH.%26aulast%3DProdromou%26aufirst%3DC.%26aulast%3DRay%26aufirst%3DS.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DRoughley%26aufirst%3DS.%2BD.%26aulast%3DSharp%26aufirst%3DS.%2BY.%26aulast%3DSurgenor%26aufirst%3DA.%26aulast%3DWalmsley%26aufirst%3DD.%2BL.%26aulast%3DWebb%26aufirst%3DP.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DWright%26aufirst%3DL.%26atitle%3D4%252C5-Diarylisoxazole%2520Hsp90%2520chaperone%2520inhibitors%253A%2520potential%2520therapeutic%2520agents%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D196%26epage%3D218%26doi%3D10.1021%2Fjm701018h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Ying, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proia, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackman, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatsuta, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acquaviva, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barsoum, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koya, K.</span><span> </span><span class="NLM_article-title">Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">475</span><span class="NLM_x">–</span> <span class="NLM_lpage">484</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0755</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1535-7163.MCT-11-0755" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22144665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFWksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=475-484&author=W.+Yingauthor=Z.+Duauthor=L.+Sunauthor=K.+P.+Foleyauthor=D.+A.+Proiaauthor=R.+K.+Blackmanauthor=D.+Zhouauthor=T.+Inoueauthor=N.+Tatsutaauthor=J.+Sangauthor=S.+Yeauthor=J.+Acquavivaauthor=L.+S.+Ogawaauthor=Y.+Wadaauthor=J.+Barsoumauthor=K.+Koya&title=Ganetespib%2C+a+unique+triazolone-containing+Hsp90+inhibitor%2C+exhibits+potent+antitumor+activity+and+a+superior+safety+profile+for+cancer+therapy&doi=10.1158%2F1535-7163.MCT-11-0755"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy</span></div><div class="casAuthors">Ying, Weiwen; Du, Zhenjian; Sun, Lijun; Foley, Kevin P.; Proia, David A.; Blackman, Ronald K.; Zhou, Dan; Inoue, Takayo; Tatsuta, Noriaki; Sang, Jim; Ye, Shuxia; Acquaviva, Jamie; Ogawa, Luisa Shin; Wada, Yumiko; Barsoum, James; Koya, Keizo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">475-484</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Targeted inhibition of the mol. chaperone Hsp90 results in the simultaneous blockade of multiple oncogenic signaling pathways and has, thus, emerged as an attractive strategy for the development of novel cancer therapeutics.  Ganetespib (formerly known as STA-9090) is a unique resorcinolic triazolone inhibitor of Hsp90 that is currently in clin. trials for a no. of human cancers.  In the present study, we showed that ganetespib exhibits potent in vitro cytotoxicity in a range of solid and hematol. tumor cell lines, including those that express mutated kinases that confer resistance to small-mol. tyrosine kinase inhibitors.  Ganetespib treatment rapidly induced the degrdn. of known Hsp90 client proteins, displayed superior potency to the ansamycin inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG), and exhibited sustained activity even with short exposure times.  In vivo, ganetespib showed potent antitumor efficacy in solid and hematol. xenograft models of oncogene addiction, as evidenced by significant growth inhibition and/or regressions.  Notably, evaluation of the microregional activity of ganetespib in tumor xenografts showed that ganetespib was efficiently distributed throughout tumor tissue, including hypoxic regions >150 μm from the microvasculature, to inhibit proliferation and induce apoptosis.  Importantly, ganetespib showed no evidence of cardiac or liver toxicity.  Taken together, this preclin. activity profile indicates that ganetespib may have broad application for a variety of human malignancies, and with select mechanistic and safety advantages over other first- and second-generation Hsp90 inhibitors.  Mol Cancer Ther; 11(2); 475-84.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFhzG1TPr4lbVg90H21EOLACvtfcHk0lg3jMh7OrMi3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFWksrY%253D&md5=269d41b30e5add9b9503cb43a98b0157</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0755%26sid%3Dliteratum%253Aachs%26aulast%3DYing%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DFoley%26aufirst%3DK.%2BP.%26aulast%3DProia%26aufirst%3DD.%2BA.%26aulast%3DBlackman%26aufirst%3DR.%2BK.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DTatsuta%26aufirst%3DN.%26aulast%3DSang%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DS.%26aulast%3DAcquaviva%26aufirst%3DJ.%26aulast%3DOgawa%26aufirst%3DL.%2BS.%26aulast%3DWada%26aufirst%3DY.%26aulast%3DBarsoum%26aufirst%3DJ.%26aulast%3DKoya%26aufirst%3DK.%26atitle%3DGanetespib%252C%2520a%2520unique%2520triazolone-containing%2520Hsp90%2520inhibitor%252C%2520exhibits%2520potent%2520antitumor%2520activity%2520and%2520a%2520superior%2520safety%2520profile%2520for%2520cancer%2520therapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D475%26epage%3D484%26doi%3D10.1158%2F1535-7163.MCT-11-0755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Jensen, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoepfer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radimerski, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guy, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brueggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quadt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cozens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drysdale, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chène, P.</span><span> </span><span class="NLM_article-title">NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models</span> <span class="citation_source-journal">Breast Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">R33</span><span class="refDoi"> DOI: 10.1186/bcr1996</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1186%2Fbcr1996" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=18430202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A280%3ADC%252BD1czktlKhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=R33&author=M.+R.+Jensenauthor=J.+Schoepferauthor=T.+Radimerskiauthor=A.+Masseyauthor=C.+T.+Guyauthor=J.+Brueggenauthor=C.+Quadtauthor=A.+Bucklerauthor=R.+Cozensauthor=M.+J.+Drysdaleauthor=C.+Garcia-Echeverriaauthor=P.+Ch%C3%A8ne&title=NVP-AUY922%3A+a+small+molecule+HSP90+inhibitor+with+potent+antitumor+activity+in+preclinical+breast+cancer+models&doi=10.1186%2Fbcr1996"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models</span></div><div class="casAuthors">Jensen Michael Rugaard; Schoepfer Joseph; Radimerski Thomas; Massey Andrew; Guy Chantale T; Brueggen Josef; Quadt Cornelia; Buckler Alan; Cozens Robert; Drysdale Martin J; Garcia-Echeverria Carlos; Chene Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer research : BCR</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">R33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Heat shock protein 90 (HSP90) is a key component of a multichaperone complex involved in the post-translational folding of a large number of client proteins, many of which play essential roles in tumorigenesis.  HSP90 has emerged in recent years as a promising new target for anticancer therapies.  METHODS:  The concentrations of the HSP90 inhibitor NVP-AUY922 required to reduce cell numbers by 50% (GI50 values) were established in a panel of breast cancer cell lines and patient-derived human breast tumors.  To investigate the properties of the compound in vivo, the pharmacokinetic profile, antitumor effect, and dose regimen were established in a BT-474 breast cancer xenograft model.  The effect on HSP90-p23 complexes, client protein degradation, and heat shock response was investigated in cell culture and breast cancer xenografts by immunohistochemistry, Western blot analysis, and immunoprecipitation.  RESULTS:  We show that the novel small molecule HSP90 inhibitor NVP-AUY922 potently inhibits the proliferation of human breast cancer cell lines with GI50 values in the range of 3 to 126 nM.  NVP-AUY922 induced proliferative inhibition concurrent with HSP70 upregulation and client protein depletion--hallmarks of HSP90 inhibition.  Intravenous acute administration of NVP-AUY922 to athymic mice (30 mg/kg) bearing subcutaneous BT-474 breast tumors resulted in drug levels in excess of 1,000 times the cellular GI50 value for about 2 days.  Significant growth inhibition and good tolerability were observed when the compound was administered once per week.  Therapeutic effects were concordant with changes in pharmacodynamic markers, including HSP90-p23 dissociation, decreases in ERBB2 and P-AKT, and increased HSP70 protein levels.  CONCLUSION:  NVP-AUY922 is a potent small molecule HSP90 inhibitor showing significant activity against breast cancer cells in cellular and in vivo settings.  On the basis of its mechanism of action, preclinical activity profile, tolerability, and pharmaceutical properties, the compound recently has entered clinical phase I breast cancer trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQRY3cZ5prrYd1QT_1O5WBYfW6udTcc2eYqlI6Njf5Qd7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1czktlKhuw%253D%253D&md5=2779e042ee1da49407fc813cca82305e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1186%2Fbcr1996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fbcr1996%26sid%3Dliteratum%253Aachs%26aulast%3DJensen%26aufirst%3DM.%2BR.%26aulast%3DSchoepfer%26aufirst%3DJ.%26aulast%3DRadimerski%26aufirst%3DT.%26aulast%3DMassey%26aufirst%3DA.%26aulast%3DGuy%26aufirst%3DC.%2BT.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DQuadt%26aufirst%3DC.%26aulast%3DBuckler%26aufirst%3DA.%26aulast%3DCozens%26aufirst%3DR.%26aulast%3DDrysdale%26aufirst%3DM.%2BJ.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DCh%25C3%25A8ne%26aufirst%3DP.%26atitle%3DNVP-AUY922%253A%2520a%2520small%2520molecule%2520HSP90%2520inhibitor%2520with%2520potent%2520antitumor%2520activity%2520in%2520preclinical%2520breast%2520cancer%2520models%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2008%26volume%3D10%26spage%3DR33%26doi%3D10.1186%2Fbcr1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Woodhead, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angove, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chessari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Congreve, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coyle, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosme, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downham, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feltell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figueroa, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frederickson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMenamin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parra, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rees, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trewartha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vinkovic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolford, A. J.</span><span> </span><span class="NLM_article-title">Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin- 1-yl methyl)-1,3-dihydro isoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">5956</span><span class="NLM_x">–</span> <span class="NLM_lpage">5969</span><span class="refDoi"> DOI: 10.1021/jm100060b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100060b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5956-5969&author=A.+J.+Woodheadauthor=H.+Angoveauthor=M.+G.+Carrauthor=G.+Chessariauthor=M.+Congreveauthor=J.+E.+Coyleauthor=J.+Cosmeauthor=B.+Grahamauthor=P.+J.+Dayauthor=R.+Downhamauthor=L.+Fazalauthor=R.+Feltellauthor=E.+Figueroaauthor=M.+Fredericksonauthor=J.+Lewisauthor=R.+McMenaminauthor=C.+W.+Murrayauthor=M.+A.+O%E2%80%99Brienauthor=L.+Parraauthor=S.+Patelauthor=T.+Phillipsauthor=D.+C.+Reesauthor=S.+Richauthor=D.+M.+Smithauthor=G.+Trewarthaauthor=M.+Vinkovicauthor=B.+Williamsauthor=A.+J.+Woolford&title=Discovery+of+%282%2C4-dihydroxy-5-isopropylphenyl%29-%5B5-%284-methylpiperazin-+1-yl+methyl%29-1%2C3-dihydro+isoindol-2-yl%5Dmethanone+%28AT13387%29%2C+a+novel+inhibitor+of+the+molecular+chaperone+Hsp90+by+fragment+based+drug+design&doi=10.1021%2Fjm100060b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm100060b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100060b%26sid%3Dliteratum%253Aachs%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26aulast%3DAngove%26aufirst%3DH.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DChessari%26aufirst%3DG.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DCoyle%26aufirst%3DJ.%2BE.%26aulast%3DCosme%26aufirst%3DJ.%26aulast%3DGraham%26aufirst%3DB.%26aulast%3DDay%26aufirst%3DP.%2BJ.%26aulast%3DDownham%26aufirst%3DR.%26aulast%3DFazal%26aufirst%3DL.%26aulast%3DFeltell%26aufirst%3DR.%26aulast%3DFigueroa%26aufirst%3DE.%26aulast%3DFrederickson%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DJ.%26aulast%3DMcMenamin%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%2BA.%26aulast%3DParra%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DPhillips%26aufirst%3DT.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DRich%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DD.%2BM.%26aulast%3DTrewartha%26aufirst%3DG.%26aulast%3DVinkovic%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DB.%26aulast%3DWoolford%26aufirst%3DA.%2BJ.%26atitle%3DDiscovery%2520of%2520%25282%252C4-dihydroxy-5-isopropylphenyl%2529-%255B5-%25284-methylpiperazin-%25201-yl%2520methyl%2529-1%252C3-dihydro%2520isoindol-2-yl%255Dmethanone%2520%2528AT13387%2529%252C%2520a%2520novel%2520inhibitor%2520of%2520the%2520molecular%2520chaperone%2520Hsp90%2520by%2520fragment%2520based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5956%26epage%3D5969%26doi%3D10.1021%2Fjm100060b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Taldone, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span> </span><span class="NLM_article-title">Purine-scaffold Hsp90 inhibitors</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1436</span><span class="NLM_x">–</span> <span class="NLM_lpage">1446</span><span class="refDoi"> DOI: 10.2174/156802609789895737</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.2174%2F156802609789895737" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=19860732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFakurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=1436-1446&author=T.+Taldoneauthor=G.+Chiosis&title=Purine-scaffold+Hsp90+inhibitors&doi=10.2174%2F156802609789895737"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Purine-scaffold Hsp90 inhibitors</span></div><div class="casAuthors">Taldone, Tony; Chiosis, Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1436-1446</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Hsp90 is a mol. chaperone with important roles in regulating the function of several proteins with potential pathogenic activity.  Because many of these proteins are involved in cancer and neurodegenerative promoting pathways, Hsp90 has emerged as an attractive therapeutic target in these diseases.  Mols. that bind to the N-terminal nucleotide pocket of Hsp90 inhibit its activity, and consequently, disrupt client protein function.  A no. of these inhibitors from several chem. classes are now known, and some are already in clin. trials.  This review focuses on the purine class of Hsp90 inhibitors, their discovery through rational design, and on efforts aimed towards their optimization and development into clin. viable drugs for the treatment of cancer.  Their potential towards neurodegenerative diseases will also be touched upon.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVLlJs6fJ--rVg90H21EOLACvtfcHk0lhxRZQ8CRB07g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFakurg%253D&md5=346a3ef4c1503aee2d918074c1ecb46c</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.2174%2F156802609789895737&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802609789895737%26sid%3Dliteratum%253Aachs%26aulast%3DTaldone%26aufirst%3DT.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DPurine-scaffold%2520Hsp90%2520inhibitors%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D1436%26epage%3D1446%26doi%3D10.2174%2F156802609789895737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">He, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zatorska, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguirre, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llauger, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">She, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Immormino, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gewirth, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span> </span><span class="NLM_article-title">Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">381</span><span class="NLM_x">–</span> <span class="NLM_lpage">390</span><span class="refDoi"> DOI: 10.1021/jm0508078</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0508078" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1ynsrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=381-390&author=H.+Heauthor=D.+Zatorskaauthor=J.+Kimauthor=J.+Aguirreauthor=L.+Llaugerauthor=Y.+Sheauthor=N.+Wuauthor=R.+M.+Immorminoauthor=D.+T.+Gewirthauthor=G.+Chiosis&title=Identification+of+potent+water+soluble+purine-scaffold+inhibitors+of+the+heat+shock+protein+90&doi=10.1021%2Fjm0508078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Potent Water Soluble Purine-Scaffold Inhibitors of the Heat Shock Protein 90</span></div><div class="casAuthors">He, Huazhong; Zatorska, Danuta; Kim, Joungnam; Aguirre, Julia; Llauger, Laura; She, Yuhong; Wu, Nian; Immormino, Robert M.; Gewirth, Daniel T.; Chiosis, Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">381-390</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hsp90 is a chaperone protein that allows cancer cells to tolerate the many components of dysregulated pathways.  Its inactivation may result in targeting multiple mol. alterations and, thus, in reverting the transformed phenotype.  The PU-class, a purine-scaffold Hsp90 inhibitor series, has been reported to be potent and selective against Hsp90 both in vitro and in vivo models of cancer.  Here, a series of this class was synthesized and evaluated as inhibitors of the chaperone.  The structure-activity relationship and selectivity for tumor Hsp90 of compds. within the series is presented.  The study identifies water sol. derivs. (>5 mM in PBS pH 7.4) of nanomolar potency (IC50 ∼ 50 nM) in cellular and animal models of cancer.  Binding affinities of these compds. for Hsp90 correlate well with their biol. activities.  When administered in vivo to mice bearing MDA-MB-468 human breast cancer xenografted tumors, these agents result in pharmacol. relevant concns. and, accordingly, in modulation of Hsp90-client proteins in tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRwHp1Wo_iW7Vg90H21EOLACvtfcHk0lhxRZQ8CRB07g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1ynsrrF&md5=3bd02ca5bc0a147e9cffa58968433917</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm0508078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0508078%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DH.%26aulast%3DZatorska%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DAguirre%26aufirst%3DJ.%26aulast%3DLlauger%26aufirst%3DL.%26aulast%3DShe%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DN.%26aulast%3DImmormino%26aufirst%3DR.%2BM.%26aulast%3DGewirth%26aufirst%3DD.%2BT.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DIdentification%2520of%2520potent%2520water%2520soluble%2520purine-scaffold%2520inhibitors%2520of%2520the%2520heat%2520shock%2520protein%252090%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D381%26epage%3D390%26doi%3D10.1021%2Fjm0508078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Taldone, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochiana, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uddin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gewirth, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span> </span><span class="NLM_article-title">Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">6803</span><span class="NLM_x">–</span> <span class="NLM_lpage">6818</span><span class="refDoi"> DOI: 10.1021/jm400619b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400619b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlWltbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6803-6818&author=T.+Taldoneauthor=P.+D.+Patelauthor=M.+Patelauthor=H.+J.+Patelauthor=C.+E.+Evansauthor=A.+Rodinaauthor=S.+Ochianaauthor=S.+K.+Shahauthor=M.+Uddinauthor=D.+Gewirthauthor=G.+Chiosis&title=Experimental+and+structural+testing+module+to+analyze+paralogue-specificity+and+affinity+in+the+Hsp90+inhibitors+series&doi=10.1021%2Fjm400619b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and Structural Testing Module to Analyze Paralogue-Specificity and Affinity in the Hsp90 Inhibitors Series</span></div><div class="casAuthors">Taldone, Tony; Patel, Pallav D.; Patel, Maulik; Patel, Hardik J.; Evans, Christopher E.; Rodina, Anna; Ochiana, Stefan; Shah, Smit K.; Uddin, Mohammad; Gewirth, Daniel; Chiosis, Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6803-6818</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We here describe the first reported comprehensive anal. of Hsp90 paralogue affinity and selectivity in the clin. Hsp90 inhibitor chemotypes.  This has been possible through the development of a versatile exptl. assay based on a new FP-probe that we both describe here.  The assay can test rapidly and accurately the binding affinity of all major Hsp90 chemotypes and has a testing range that spans low nanomolar to millimolar binding affinities.  We couple this assay with a computational anal. that allows for rationalization of paralogue selectivity and defines not only the major binding modes that relay pan-paralogue binding or, conversely, paralogue selectivity, but also identifies mol. characteristics that impart such features.  The methods developed here provide a blueprint for parsing out the contribution of the four Hsp90 paralogues to the perceived biol. activity with the current Hsp90 chemotypes and set the ground for the development of paralogue selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgOst3-n58BrVg90H21EOLACvtfcHk0ljCz5nca_tuvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlWltbvM&md5=bda49f7f2f61553e344b100d5d6949dd</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm400619b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400619b%26sid%3Dliteratum%253Aachs%26aulast%3DTaldone%26aufirst%3DT.%26aulast%3DPatel%26aufirst%3DP.%2BD.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DH.%2BJ.%26aulast%3DEvans%26aufirst%3DC.%2BE.%26aulast%3DRodina%26aufirst%3DA.%26aulast%3DOchiana%26aufirst%3DS.%26aulast%3DShah%26aufirst%3DS.%2BK.%26aulast%3DUddin%26aufirst%3DM.%26aulast%3DGewirth%26aufirst%3DD.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DExperimental%2520and%2520structural%2520testing%2520module%2520to%2520analyze%2520paralogue-specificity%2520and%2520affinity%2520in%2520the%2520Hsp90%2520inhibitors%2520series%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6803%26epage%3D6818%26doi%3D10.1021%2Fjm400619b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Immormino, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gewirth, D. T.</span><span> </span><span class="NLM_article-title">Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">4953</span><span class="NLM_x">–</span> <span class="NLM_lpage">4960</span><span class="refDoi"> DOI: 10.1021/jm060297x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060297x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD28Xms1SksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4953-4960&author=R.+M.+Immorminoauthor=Y.+Kangauthor=G.+Chiosisauthor=D.+T.+Gewirth&title=Structural+and+quantum+chemical+studies+of+8-aryl-sulfanyl+adenine+class+Hsp90+inhibitors&doi=10.1021%2Fjm060297x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Quantum Chemical Studies of 8-Aryl-sulfanyl Adenine Class Hsp90 Inhibitors</span></div><div class="casAuthors">Immormino, Robert M.; Kang, Yanlong; Chiosis, Gabriela; Gewirth, Daniel T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4953-4960</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hsp90 chaperones play a crit. role in modulating the activity of many cell signaling proteins and are an attractive target for anticancer therapeutics.  The authors report here the structures of the water sol. 8-aryl-sulfanyl adenine class Hsp90 inhibitors, (I, PU-H71) and (II, PU-H64), in complex with the N-terminal domain of human Hsp90α.  The conformation of I when bound to Hsp90 differs from previously reported 8-aryl adenine Hsp90 inhibitors including (III, PU24FCl).  While the binding mode for III places the 2'-halide of the 8-aryl group on top of the adenine ring, for I and II, the authors show that the 2'-halide is rotated approx. 180° away.  This difference explains the opposing trends in Hsp90 inhibitory activity for the 2'-halo derivs. of the 3',4',5'-trimethoxy series where Cl > Br > I compared to the 4',5'-methylenedioxy series where I > Br > Cl.  The authors also present quantum chem. calcns. of II and its analogs that illuminate their basis for Hsp90 inhibition.  The calcd. conformation of II agreed well with the crystallog. obsd. conformations of I and II.  The predictive nature of the calcns. has allowed the exploration of addnl. derivs. based on the 8-aryl adenine scaffold.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9wb5UeDL2DLVg90H21EOLACvtfcHk0ljCz5nca_tuvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xms1SksL8%253D&md5=4f530c5ae8a116d09c098b0b281671a1</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm060297x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060297x%26sid%3Dliteratum%253Aachs%26aulast%3DImmormino%26aufirst%3DR.%2BM.%26aulast%3DKang%26aufirst%3DY.%26aulast%3DChiosis%26aufirst%3DG.%26aulast%3DGewirth%26aufirst%3DD.%2BT.%26atitle%3DStructural%2520and%2520quantum%2520chemical%2520studies%2520of%25208-aryl-sulfanyl%2520adenine%2520class%2520Hsp90%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4953%26epage%3D4960%26doi%3D10.1021%2Fjm060297x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Fadden, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steed, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barabasz, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Partridge, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubois, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freed, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silinski, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barta, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ommen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spangenberg, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaves, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinkley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenks, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pronk, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verleysen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haystead, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S. E.</span><span> </span><span class="NLM_article-title">Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting Hsp90</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">686</span><span class="NLM_x">–</span> <span class="NLM_lpage">694</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2010.04.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.chembiol.2010.04.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=20659681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptleitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=686-694&author=P.+Faddenauthor=K.+H.+Huangauthor=J.+M.+Vealauthor=P.+M.+Steedauthor=A.+F.+Barabaszauthor=B.+Foleyauthor=M.+Huauthor=J.+M.+Partridgeauthor=J.+Riceauthor=A.+Scottauthor=L.+G.+Duboisauthor=T.+A.+Freedauthor=M.+A.+Silinskiauthor=T.+E.+Bartaauthor=P.+F.+Hughesauthor=A.+Ommenauthor=W.+Maauthor=E.+D.+Smithauthor=A.+W.+Spangenbergauthor=J.+Eavesauthor=G.+J.+Hansonauthor=L.+Hinkleyauthor=M.+Jenksauthor=M.+Lewisauthor=J.+Ottoauthor=G.+J.+Pronkauthor=K.+Verleysenauthor=T.+A.+Haysteadauthor=S.+E.+Hall&title=Application+of+chemoproteomics+to+drug+discovery%3A+identification+of+a+clinical+candidate+targeting+Hsp90&doi=10.1016%2Fj.chembiol.2010.04.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Application of Chemoproteomics to Drug Discovery: Identification of a Clinical Candidate Targeting Hsp90</span></div><div class="casAuthors">Fadden, Patrick; Huang, Kenneth H.; Veal, James M.; Steed, Paul M.; Barabasz, Amy F.; Foley, Briana; Hu, Mei; Partridge, Jeffrey M.; Rice, John; Scott, Anisa; Dubois, Laura G.; Freed, Tiffany A.; Rehder Silinski, Melanie A.; Barta, Thomas E.; Hughes, Philip F.; Ommen, Andy; Ma, Wei; Smith, Emilie D.; Woodward Spangenberg, Angela; Eaves, Jeron; Hanson, Gunnar J.; Hinkley, Lindsay; Jenks, Matthew; Lewis, Meredith; Otto, James; Pronk, Gijsbertus J.; Verleysen, Katleen; Haystead, Timothy A.; Hall, Steven E.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">686-694</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: A chemoproteomics-based drug discovery strategy is presented that utilizes a highly parallel screening platform, encompassing more than 1000 targets, with a focused chem. library prior to target selection.  This chemoproteomics-based process enables a data-driven selection of both the biol. target and chem. hit after the screen is complete.  The methodol. has been exemplified for the purine binding proteome (proteins utilizing ATP, NAD, FAD).  Screening of an 8000 member library yielded over 1500 unique protein-ligand interactions, which included novel hits for the oncol. target Hsp90.  The approach, which also provides broad target selectivity information, was used to drive the identification of a potent and orally active Hsp90 inhibitor, SNX-5422, which is currently in phase 1 clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfemxEaaJVH7Vg90H21EOLACvtfcHk0lhXpHOXNngQIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptleitL4%253D&md5=68486178a6847516af3fb5417a9b1911</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.04.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.04.015%26sid%3Dliteratum%253Aachs%26aulast%3DFadden%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DK.%2BH.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DSteed%26aufirst%3DP.%2BM.%26aulast%3DBarabasz%26aufirst%3DA.%2BF.%26aulast%3DFoley%26aufirst%3DB.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DPartridge%26aufirst%3DJ.%2BM.%26aulast%3DRice%26aufirst%3DJ.%26aulast%3DScott%26aufirst%3DA.%26aulast%3DDubois%26aufirst%3DL.%2BG.%26aulast%3DFreed%26aufirst%3DT.%2BA.%26aulast%3DSilinski%26aufirst%3DM.%2BA.%26aulast%3DBarta%26aufirst%3DT.%2BE.%26aulast%3DHughes%26aufirst%3DP.%2BF.%26aulast%3DOmmen%26aufirst%3DA.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DSmith%26aufirst%3DE.%2BD.%26aulast%3DSpangenberg%26aufirst%3DA.%2BW.%26aulast%3DEaves%26aufirst%3DJ.%26aulast%3DHanson%26aufirst%3DG.%2BJ.%26aulast%3DHinkley%26aufirst%3DL.%26aulast%3DJenks%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DM.%26aulast%3DOtto%26aufirst%3DJ.%26aulast%3DPronk%26aufirst%3DG.%2BJ.%26aulast%3DVerleysen%26aufirst%3DK.%26aulast%3DHaystead%26aufirst%3DT.%2BA.%26aulast%3DHall%26aufirst%3DS.%2BE.%26atitle%3DApplication%2520of%2520chemoproteomics%2520to%2520drug%2520discovery%253A%2520identification%2520of%2520a%2520clinical%2520candidate%2520targeting%2520Hsp90%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D686%26epage%3D694%26doi%3D10.1016%2Fj.chembiol.2010.04.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Huang, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fadden, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaves, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strachan, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barabasz, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barta, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silinski, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Partridge, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DuBois, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freed, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steed, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ommen, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodward, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCall, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markworth, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinkley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenks, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pronk, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verleysen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S. E.</span><span> </span><span class="NLM_article-title">Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">4288</span><span class="NLM_x">–</span> <span class="NLM_lpage">4305</span><span class="refDoi"> DOI: 10.1021/jm900230j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900230j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD1MXns1Onsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4288-4305&author=K.+H.+Huangauthor=J.+M.+Vealauthor=R.+P.+Faddenauthor=J.+W.+Riceauthor=J.+Eavesauthor=J.+P.+Strachanauthor=A.+F.+Barabaszauthor=B.+E.+Foleyauthor=T.+E.+Bartaauthor=W.+Maauthor=M.+A.+Silinskiauthor=M.+Huauthor=J.+M.+Partridgeauthor=A.+Scottauthor=L.+G.+DuBoisauthor=T.+Freedauthor=P.+M.+Steedauthor=A.+J.+Ommenauthor=E.+D.+Smithauthor=P.+F.+Hughesauthor=A.+R.+Woodwardauthor=G.+J.+Hansonauthor=W.+S.+McCallauthor=C.+J.+Markworthauthor=L.+Hinkleyauthor=M.+Jenksauthor=L.+Gengauthor=M.+Lewisauthor=J.+Ottoauthor=B.+Pronkauthor=K.+Verleysenauthor=S.+E.+Hall&title=Discovery+of+novel+2-aminobenzamide+inhibitors+of+heat+shock+protein+90+as+potent%2C+selective+and+orally+active+antitumor+agents&doi=10.1021%2Fjm900230j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel 2-Aminobenzamide Inhibitors of Heat Shock Protein 90 as Potent, Selective and Orally Active Antitumor Agents</span></div><div class="casAuthors">Huang, Kenneth H.; Veal, James M.; Fadden, R. Patrick; Rice, John W.; Eaves, Jeron; Strachan, Jon-Paul; Barabasz, Amy F.; Foley, Briana E.; Barta, Thomas E.; Ma, Wei; Silinski, Melanie A.; Hu, Mei; Partridge, Jeffrey M.; Scott, Anisa; DuBois, Laura G.; Freed, Tiffany; Steed, Paul M.; Ommen, Andy J.; Smith, Emilie D.; Hughes, Philip F.; Woodward, Angela R.; Hanson, Gunnar J.; McCall, W. Stephen; Markworth, Christopher J.; Hinkley, Lindsay; Jenks, Matthew; Geng, Lifeng; Lewis, Meredith; Otto, James; Pronk, Bert; Verleysen, Katleen; Hall, Steven E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4288-4305</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel class of heat shock protein 90 (Hsp90) inhibitors was developed from an unbiased screen to identify protein targets for a diverse compd. library.  These indol-4-one and indazol-4-one derived 2-aminobenzamides showed strong binding affinity to Hsp90, and optimized analogs exhibited nanomolar antiproliferative activity across multiple cancer cell lines.  Heat shock protein 70 (Hsp70) induction and specific client protein degrdn. in cells on treatment with the inhibitors supported Hsp90 inhibition as the mechanism of action.  Computational chem. and X-ray crystallog. anal. of selected member compds. clearly defined the protein-inhibitor interaction and assisted the design of analogs. 4-[6,6-Dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-[(trans-4-hydroxycyclohexyl)amino]benzamide (SNX-2112) (I) was identified as highly selective and potent (IC50 Her2 = 11 nM, HT-29 = 3 nM); its prodrug amino-acetic acid 4-[2-carbamoyl-5-(6,6-dimethyl-4-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-indazol-1-yl)-phenylamino]-cyclohexyl ester methanesulfonate (SNX-5422) (II)was orally bioavailable and efficacious in a broad range of xenograft tumor models (e.g. 67% growth delay in a HT-29 model) and is now in multiple phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFjrhELWrFkbVg90H21EOLACvtfcHk0lhipvi5sfyRoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXns1Onsrk%253D&md5=99e5039e1761e9099d634acd79a15a6a</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm900230j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900230j%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DK.%2BH.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DFadden%26aufirst%3DR.%2BP.%26aulast%3DRice%26aufirst%3DJ.%2BW.%26aulast%3DEaves%26aufirst%3DJ.%26aulast%3DStrachan%26aufirst%3DJ.%2BP.%26aulast%3DBarabasz%26aufirst%3DA.%2BF.%26aulast%3DFoley%26aufirst%3DB.%2BE.%26aulast%3DBarta%26aufirst%3DT.%2BE.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DSilinski%26aufirst%3DM.%2BA.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DPartridge%26aufirst%3DJ.%2BM.%26aulast%3DScott%26aufirst%3DA.%26aulast%3DDuBois%26aufirst%3DL.%2BG.%26aulast%3DFreed%26aufirst%3DT.%26aulast%3DSteed%26aufirst%3DP.%2BM.%26aulast%3DOmmen%26aufirst%3DA.%2BJ.%26aulast%3DSmith%26aufirst%3DE.%2BD.%26aulast%3DHughes%26aufirst%3DP.%2BF.%26aulast%3DWoodward%26aufirst%3DA.%2BR.%26aulast%3DHanson%26aufirst%3DG.%2BJ.%26aulast%3DMcCall%26aufirst%3DW.%2BS.%26aulast%3DMarkworth%26aufirst%3DC.%2BJ.%26aulast%3DHinkley%26aufirst%3DL.%26aulast%3DJenks%26aufirst%3DM.%26aulast%3DGeng%26aufirst%3DL.%26aulast%3DLewis%26aufirst%3DM.%26aulast%3DOtto%26aufirst%3DJ.%26aulast%3DPronk%26aufirst%3DB.%26aulast%3DVerleysen%26aufirst%3DK.%26aulast%3DHall%26aufirst%3DS.%2BE.%26atitle%3DDiscovery%2520of%2520novel%25202-aminobenzamide%2520inhibitors%2520of%2520heat%2520shock%2520protein%252090%2520as%2520potent%252C%2520selective%2520and%2520orally%2520active%2520antitumor%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4288%26epage%3D4305%26doi%3D10.1021%2Fjm900230j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Rajan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trepel, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alarcon, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kummar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutierrez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crandon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zein, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mannargudi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figg, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houk, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shnaidman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brega, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giaccone, G.</span><span> </span><span class="NLM_article-title">A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">6831</span><span class="NLM_x">–</span> <span class="NLM_lpage">6839</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-0821</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1078-0432.CCR-11-0821" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=21908572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVWlsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=6831-6839&author=A.+Rajanauthor=R.+J.+Kellyauthor=J.+B.+Trepelauthor=Y.+S.+Kimauthor=S.+V.+Alarconauthor=S.+Kummarauthor=M.+Gutierrezauthor=S.+Crandonauthor=W.+M.+Zeinauthor=L.+Jainauthor=B.+Mannargudiauthor=W.+D.+Figgauthor=B.+E.+Houkauthor=M.+Shnaidmanauthor=N.+Bregaauthor=G.+Giaccone&title=A+phase+I+study+of+PF-04929113+%28SNX-5422%29%2C+an+orally+bioavailable+heat+shock+protein+90+inhibitor%2C+in+patients+with+refractory+solid+tumor+malignancies+and+lymphomas&doi=10.1158%2F1078-0432.CCR-11-0821"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas</span></div><div class="casAuthors">Rajan, Arun; Kelly, Ronan J.; Trepel, Jane B.; Kim, Yeong Sang; Alarcon, Sylvia V.; Kummar, Shivaani; Gutierrez, Martin; Crandon, Sonja; Zein, Wadih M.; Jain, Lokesh; Mannargudi, Baskar; Figg, William D.; Houk, Brett E.; Shnaidman, Michael; Brega, Nicoletta; Giaccone, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6831-6839</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: To det. the max. tolerated dose (MTD), toxicities, and pharmacokinetic/pharmacodynamic profile of the Hsp90 inhibitor PF-04929113 (SNX-5422) in patients with advanced solid tumors and lymphomas.  METHODS: This was a single-institution, phase I, dose-escalation study of PF-04929113 administered twice weekly.  Endpoints included detn. of dose-limiting toxicities (DLT), MTD, the safety profile of PF-04929113, pharmacodynamic assessment of PF-04929113 on Hsp70 induction, pharmacokinetic anal. of PF-04928473 (SNX-2112) and its prodrug PF-04929113, and assessment of response.  RESULTS: Thirty-three patients with advanced malignancies were treated.  Dose escalation was continued up to 177 mg/m2 administered orally twice a week.  One DLT (nonseptic arthritis) was noted.  No grade 4 drug-related adverse events were seen; grade 3 adverse events included diarrhea (9%), nonseptic arthritis (3%), aspartate aminotransferase elevation (3%), and thrombocytopenia (3%).  No objective responses were seen in 32 evaluable patients.  Fifteen patients (47%) had stable disease; 17 patients (53%) had progressive disease.  Pharmacokinetic data revealed rapid absorption, hepatic, and extrahepatic clearance, extensive tissue binding, and almost linear pharmacokinetics of the active drug PF-04928473.  Pharmacodynamic studies confirmed inhibition of Hsp90 and a linear correlation between pharmacokinetic parameters and Hsp70 induction.  CONCLUSIONS: PF-04929113 administered orally twice a week is well tolerated and inhibits its intended target Hsp90.  No objective responses were seen, but long-lasting stabilizations were obtained.  Although no clin. significant drug-related ocular toxicity was seen in this study, the development of PF-04929113 has been discontinued because of ocular toxicity seen in animal models and in a sep. phase I study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQzbnkoUJnibVg90H21EOLACvtfcHk0lhipvi5sfyRoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVWlsrzM&md5=2b10fada0eb9d1dc7e06826724edf21f</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-0821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-0821%26sid%3Dliteratum%253Aachs%26aulast%3DRajan%26aufirst%3DA.%26aulast%3DKelly%26aufirst%3DR.%2BJ.%26aulast%3DTrepel%26aufirst%3DJ.%2BB.%26aulast%3DKim%26aufirst%3DY.%2BS.%26aulast%3DAlarcon%26aufirst%3DS.%2BV.%26aulast%3DKummar%26aufirst%3DS.%26aulast%3DGutierrez%26aufirst%3DM.%26aulast%3DCrandon%26aufirst%3DS.%26aulast%3DZein%26aufirst%3DW.%2BM.%26aulast%3DJain%26aufirst%3DL.%26aulast%3DMannargudi%26aufirst%3DB.%26aulast%3DFigg%26aufirst%3DW.%2BD.%26aulast%3DHouk%26aufirst%3DB.%2BE.%26aulast%3DShnaidman%26aufirst%3DM.%26aulast%3DBrega%26aufirst%3DN.%26aulast%3DGiaccone%26aufirst%3DG.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520PF-04929113%2520%2528SNX-5422%2529%252C%2520an%2520orally%2520bioavailable%2520heat%2520shock%2520protein%252090%2520inhibitor%252C%2520in%2520patients%2520with%2520refractory%2520solid%2520tumor%2520malignancies%2520and%2520lymphomas%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D6831%26epage%3D6839%26doi%3D10.1158%2F1078-0432.CCR-11-0821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Marcu, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulte, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neckers, L.</span><span> </span><span class="NLM_article-title">Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">242</span><span class="NLM_x">–</span> <span class="NLM_lpage">248</span><span class="refDoi"> DOI: 10.1093/jnci/92.3.242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1093%2Fjnci%2F92.3.242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10655441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtFShsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2000&pages=242-248&author=M.+G.+Marcuauthor=T.+W.+Schulteauthor=L.+Neckers&title=Novobiocin+and+related+coumarins+and+depletion+of+heat+shock+protein+90-dependent+signaling+proteins&doi=10.1093%2Fjnci%2F92.3.242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins</span></div><div class="casAuthors">Marcu, Monica G.; Schulte, Theodore W.; Neckers, Leonard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">242-248</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) interacts with and stabilizes several oncogenic protein kinases (e.g., p185erbB2, p60v-src, and Raf-1) and is required for the stability and dominant-neg. function of mutated p53 protein.  Two unrelated antibiotics, geldanamycin and radicicol, bind specifically to an atypical nucleotide-binding pocket of Hsp90, a site that shares homol. with the ATP-binding domain of bacterial DNA gyrase B.  This interaction leads to destabilization of proteins that interact with Hsp90.  Since the nucleotide-binding site of gyrase B is targeted by coumarin antibiotics (e.g., novobiocin), we investigated whether these drugs can also interact with Hsp90 and affect its activity.  We used immobilized novobiocin, geldanamycin, or radicicol to isolate either endogenous Hsp90 from cell lysates or Hsp90 deletion fragments translated in vitro.  Effects of the coumarin antibiotics novobiocin, chlorobiocin, and coumermycin A1 on several proteins interacting with Hsp90 were assessed in vitro and in vivo.  Hsp90 binding to immobilized novobiocin was competed by sol. coumarins and ATP but not by geldanamycin or radicicol.  A carboxy-terminal Hsp90 fragment bound immobilized novobiocin but not immobilized geldanamycin, while a geldanamycin-binding amino-terminal fragment did not bind novobiocin.  All three coumarins markedly reduced cellular levels of p185erbB2, p60v-src, Raf-1, and mutated p53.  Furthermore, novobiocin reduced Raf-1 levels in the spleens of mice treated with the drug.  These coumarin antibiotics, particularly novobiocin, represent a first-generation alternative to other Hsp90-targeting drugs that are not as well tolerated.  Novobiocin's unique interaction with Hsp90 identifies an addnl. site on this protein amenable to pharmacol. interference with small mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSMDAYykmhSbVg90H21EOLACvtfcHk0lgJGnN0AEPMAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtFShsbk%253D&md5=05873d976f0d6a3e721576732e580ff2</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F92.3.242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F92.3.242%26sid%3Dliteratum%253Aachs%26aulast%3DMarcu%26aufirst%3DM.%2BG.%26aulast%3DSchulte%26aufirst%3DT.%2BW.%26aulast%3DNeckers%26aufirst%3DL.%26atitle%3DNovobiocin%2520and%2520related%2520coumarins%2520and%2520depletion%2520of%2520heat%2520shock%2520protein%252090-dependent%2520signaling%2520proteins%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2000%26volume%3D92%26spage%3D242%26epage%3D248%26doi%3D10.1093%2Fjnci%2F92.3.242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Zhang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhan, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, D.</span><span> </span><span class="NLM_article-title">A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">162</span><span class="NLM_x">–</span> <span class="NLM_lpage">170</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-0484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1535-7163.MCT-07-0484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=18202019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVyhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=162-170&author=T.+Zhangauthor=A.+Hamzaauthor=X.+Caoauthor=B.+Wangauthor=S.+Yuauthor=C.+G.+Zhanauthor=D.+Sun&title=A+novel+Hsp90+inhibitor+to+disrupt+Hsp90%2FCdc37+complex+against+pancreatic+cancer+cells&doi=10.1158%2F1535-7163.MCT-07-0484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells</span></div><div class="casAuthors">Zhang, Tao; Hamza, Adel; Cao, Xianhua; Wang, Bing; Yu, Shuwen; Zhan, Chang-Guo; Sun, Duxin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">162-170</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Pancreatic cancer is an aggressive disease with multiple biochem. and genetic alterations.  Thus, a single agent to hit one mol. target may not be sufficient to treat this disease.  The purpose of this study is to identify a novel Hsp90 inhibitor to disrupt protein-protein interactions of Hsp90 and its cochaperones for down-regulating many oncogenes simultaneously against pancreatic cancer cells.  Here, we reported that celastrol disrupted Hsp90-Cdc37 interaction in the superchaperone complex to exhibit antitumor activity in vitro and in vivo.  Mol. docking and mol. dynamic simulations showed that celastrol blocked the crit. interaction of Glu33 (Hsp90) and Arg167 (Cdc37).  Immunopptn. confirmed that celastrol (10 μmol/L) disrupted the Hsp90-Cdc37 interaction in the pancreatic cancer cell line Panc-1.  In contrast to classic Hsp90 inhibitor (geldanamycin), celastrol (0.1-100 μmol/L) did not interfere with ATP binding to Hsp90.  However, celastrol (1-5 μmol/L) induced Hsp90 client protein degrdn. (Cdk4 and Akt) by 70% to 80% and increased Hsp70 expression by 12-fold.  Celastrol induced apoptosis in vitro and significantly inhibited tumor growth in Panc-1 xenografts.  Moreover, celastrol (3 mg/kg) effectively suppressed tumor metastasis by more than 80% in RIP1-Tag2 transgenic mouse model with pancreatic islet cell carcinogenesis.  The data suggest that celastrol is a novel Hsp90 inhibitor to disrupt Hsp90-Cdc37 interaction against pancreatic cancer cells. [Mol Cancer Ther 2008;7(1):162-70].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYaUNr9Bi1cbVg90H21EOLACvtfcHk0lgJGnN0AEPMAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVyhtQ%253D%253D&md5=2af27701d6ccd4397c7a7486d1335730</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0484%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DHamza%26aufirst%3DA.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DZhan%26aufirst%3DC.%2BG.%26aulast%3DSun%26aufirst%3DD.%26atitle%3DA%2520novel%2520Hsp90%2520inhibitor%2520to%2520disrupt%2520Hsp90%252FCdc37%2520complex%2520against%2520pancreatic%2520cancer%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D162%26epage%3D170%26doi%3D10.1158%2F1535-7163.MCT-07-0484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Sreeramulu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gande, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Göbel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwalbe, H.</span><span> </span><span class="NLM_article-title">Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperone-cochaperone, by triterpene celastrol</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">5853</span><span class="NLM_x">–</span> <span class="NLM_lpage">5855</span><span class="refDoi"> DOI: 10.1002/anie.200900929</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1002%2Fanie.200900929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=19585625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptFGltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=5853-5855&author=S.+Sreeramuluauthor=S.+L.+Gandeauthor=M.+G%C3%B6belauthor=H.+Schwalbe&title=Molecular+mechanism+of+inhibition+of+the+human+protein+complex+Hsp90-Cdc37%2C+a+kinome+chaperone-cochaperone%2C+by+triterpene+celastrol&doi=10.1002%2Fanie.200900929"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Mechanism of Inhibition of the Human Protein Complex Hsp90-Cdc37, a Kinome Chaperone-Cochaperone, by Triterpene Celastrol</span></div><div class="casAuthors">Sreeramulu, Sridhar; Gande, Santosh Lakshmi; Goebel, Michael; Schwalbe, Harald</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">5853-5855, S5853/1-S5853/11</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Inhibition of the ATPase activity of the kinome chaperone Hsp90 (kinome = set of all protein kinases in an organism) has long been known as mol. target for anticancer therapy.  Cdc37, a cochaperone of Hsp90 in mammalian cells, targets protein kinases and is upregulated in various cancers.  Gene-based expression studies have identified the triterpene celastrol, which represents a new class of non ATP-competitive inhibitors of Hsp90.  Herein, we describe in detail how celastrol disrupts the human Hsp90-Cdc37 complex.  We report that celastrol binds to Cdc37 but not to HSP90N as previously described.  This study is important as it will shift efforts in medicinal chem. towards the correct target within the protein-protein complex.  Our results indicates that the N-terminal kinase- binding and middle Hsp90N-binding domain of Cdc37 are the mol. target for the triterpene celastrol.  In light of the considerable potential of Cdc37 as a drug target and the binding of celastrol to it, these results can now be used to further understand the mol. basis for inhibiting this key Cdc37-Hsp90 complex in cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWgmOS-yFB6rVg90H21EOLACvtfcHk0lhPGNyromOMVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptFGltb4%253D&md5=d5264a2213c19a8b33ca56305ac2a29c</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fanie.200900929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200900929%26sid%3Dliteratum%253Aachs%26aulast%3DSreeramulu%26aufirst%3DS.%26aulast%3DGande%26aufirst%3DS.%2BL.%26aulast%3DG%25C3%25B6bel%26aufirst%3DM.%26aulast%3DSchwalbe%26aufirst%3DH.%26atitle%3DMolecular%2520mechanism%2520of%2520inhibition%2520of%2520the%2520human%2520protein%2520complex%2520Hsp90-Cdc37%252C%2520a%2520kinome%2520chaperone-cochaperone%252C%2520by%2520triterpene%2520celastrol%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2009%26volume%3D48%26spage%3D5853%26epage%3D5855%26doi%3D10.1002%2Fanie.200900929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Huang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Q. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, W.</span><span> </span><span class="NLM_article-title">FW-04–806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation</span> <span class="citation_source-journal">Mol. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">150</span><span class="refDoi"> DOI: 10.1186/1476-4598-13-150</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1186%2F1476-4598-13-150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=24927996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivFWns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=150&author=W.+Huangauthor=M.+Yeauthor=L.+R.+Zhangauthor=Q.+D.+Wuauthor=M.+Zhangauthor=J.+H.+Xuauthor=W.+Zheng&title=FW-04%E2%80%93806+inhibits+proliferation+and+induces+apoptosis+in+human+breast+cancer+cells+by+binding+to+N-terminus+of+Hsp90+and+disrupting+Hsp90-Cdc37+complex+formation&doi=10.1186%2F1476-4598-13-150"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation</span></div><div class="casAuthors">Huang, Wei; Ye, Min; Zhang, Lian-Ru; Wu, Qun-Dan; Zhang, Min; Xu, Jian-Hua; Zheng, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">150/1-150/23, 23 pp.</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Heat shock protein 90 (Hsp90) is a promising therapeutic target and inhibition of Hsp90 will presumably result in suppression of multiple signaling pathways.  FW-04-806, a bis-oxazolyl macrolide compd. extd. from China-native Streptomyces FIM-04-806, was reported to be identical in structure to the polyketide Conglobatin.  Methods: We adopted the methods of chemproteomics, computational docking, immunopptn., siRNA gene knock down, Quant. Real-time PCR and xenograft models on the research of FW-04-806 antitumor mechanism, through the HER2-overexpressing breast cancer SKBR3 and HER2-underexpressing breast cancer MCF-7 cell line.  Results: We have verified the direct binding of FW-04-806 to the N-terminal domain of Hsp90 and found that FW-04-806 inhibits Hsp90/cell division cycle protein 37 (Cdc37) chaperone/co-chaperone interactions, but does not affect ATP-binding capability of Hsp90, thereby leading to the degrdn. of multiple Hsp90 client proteins via the proteasome pathway.  In breast cancer cell lines, FW-04-806 inhibits cell proliferation, caused G2/M cell cycle arrest, induced apoptosis, and downregulated Hsp90 client proteins HER2, Akt, Raf-1 and their phosphorylated forms (p-HER2, p-Akt) in a dose and time-dependent manner.  Importantly, FW-04-806 displays a better anti-tumor effect in HER2-overexpressed SKBR3 tumor xenograft model than in HER2-underexpressed MCF-7 model.  The result is consistent with cell proliferation assay and in vitro apoptosis assay applied for SKBR-3 and MCF-7.  Furthermore, FW-04-806 has a favorable toxicity profile.  Conclusions: As a novel Hsp90 inhibitor, FW-04-806 binds to the N-terminal of Hsp90 and inhibits Hsp90/Cdc37 interaction, resulting in the disassocn. of Hsp90/Cdc37/client complexes and the degrdn. of Hsp90 client proteins.  FW-04-806 displays promising antitumor activity against breast cancer cells both in vitro and in vivo, esp. for HER2-overexpressed breast cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI4HO_8pKpELVg90H21EOLACvtfcHk0lhPGNyromOMVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivFWns7o%253D&md5=bfa6127b46be0281667d296f020fde1b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-13-150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-13-150%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DL.%2BR.%26aulast%3DWu%26aufirst%3DQ.%2BD.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DJ.%2BH.%26aulast%3DZheng%26aufirst%3DW.%26atitle%3DFW-04%25E2%2580%2593806%2520inhibits%2520proliferation%2520and%2520induces%2520apoptosis%2520in%2520human%2520breast%2520cancer%2520cells%2520by%2520binding%2520to%2520N-terminus%2520of%2520Hsp90%2520and%2520disrupting%2520Hsp90-Cdc37%2520complex%2520formation%26jtitle%3DMol.%2520Cancer%26date%3D2014%26volume%3D13%26spage%3D150%26doi%3D10.1186%2F1476-4598-13-150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Zhang, H. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasibhatla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guastella, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drewe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, S. X.</span><span> </span><span class="NLM_article-title">Discovery, characterization and SAR of gambogic acid as a potent apoptosis inducer by a HTS assay</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span><span class="refDoi"> DOI: 10.1016/j.bmc.2003.11.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.bmc.2003.11.013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=309-317&author=H.+Z.+Zhangauthor=S.+Kasibhatlaauthor=Y.+Wangauthor=J.+Herichauthor=J.+Guastellaauthor=B.+Tsengauthor=J.+Dreweauthor=S.+X.+Cai&title=Discovery%2C+characterization+and+SAR+of+gambogic+acid+as+a+potent+apoptosis+inducer+by+a+HTS+assay&doi=10.1016%2Fj.bmc.2003.11.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2003.11.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2003.11.013%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%2BZ.%26aulast%3DKasibhatla%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHerich%26aufirst%3DJ.%26aulast%3DGuastella%26aufirst%3DJ.%26aulast%3DTseng%26aufirst%3DB.%26aulast%3DDrewe%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DS.%2BX.%26atitle%3DDiscovery%252C%2520characterization%2520and%2520SAR%2520of%2520gambogic%2520acid%2520as%2520a%2520potent%2520apoptosis%2520inducer%2520by%2520a%2520HTS%2520assay%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2004%26volume%3D12%26spage%3D309%26epage%3D317%26doi%3D10.1016%2Fj.bmc.2003.11.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Vasko, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunningham, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardi, V. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agard, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAlpine, S. R.</span><span> </span><span class="NLM_article-title">Mechanistic studies of Sansalvamide A-amide: an allosteric modulator of Hsp90</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">4</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span><span class="refDoi"> DOI: 10.1021/ml900003t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml900003t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs12isg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=4-8&author=R.+C.+Vaskoauthor=R.+A.+Rodriguezauthor=C.+N.+Cunninghamauthor=V.+C.+Ardiauthor=D.+A.+Agardauthor=S.+R.+McAlpine&title=Mechanistic+studies+of+Sansalvamide+A-amide%3A+an+allosteric+modulator+of+Hsp90&doi=10.1021%2Fml900003t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic Studies of Sansalvamide A-Amide: An Allosteric Modulator of Hsp90</span></div><div class="casAuthors">Vasko, Robert C.; Rodriguez, Rodrigo A.; Cunningham, Christian N.; Ardi, Veronica C.; Agard, David A.; McAlpine, Shelli R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4-8</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein, we show that sansalvamide A-amide (San A-amide), a structurally unique mol., influences a subset of cancer-related pathways involving heat shock protein 90 (Hsp90).  We show that San A-amide specifically binds to the N-middle domain of Hsp90 and allosterically disrupts the binding of proteins thought to interact with the Hsp90 C-terminal domain, while having no effect on an N-terminal domain client protein.  This unique mechanism suggests that San A-amide is a potential tool for studying C-terminal binding proteins of Hsp90 as well as a promising lead in the development of new cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYe__7lCCo8rVg90H21EOLACvtfcHk0ljxGSJbv2-OIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs12isg%253D%253D&md5=e20bcd814c531b739ecfb91175d34232</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fml900003t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml900003t%26sid%3Dliteratum%253Aachs%26aulast%3DVasko%26aufirst%3DR.%2BC.%26aulast%3DRodriguez%26aufirst%3DR.%2BA.%26aulast%3DCunningham%26aufirst%3DC.%2BN.%26aulast%3DArdi%26aufirst%3DV.%2BC.%26aulast%3DAgard%26aufirst%3DD.%2BA.%26aulast%3DMcAlpine%26aufirst%3DS.%2BR.%26atitle%3DMechanistic%2520studies%2520of%2520Sansalvamide%2520A-amide%253A%2520an%2520allosteric%2520modulator%2520of%2520Hsp90%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D4%26epage%3D8%26doi%3D10.1021%2Fml900003t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Alexander, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardi, V. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasko, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAlpine, S. R.</span><span> </span><span class="NLM_article-title">Evaluation of di-sansalvamideA derivatives: synthesis, structure-activity relationship, and mechanism of action</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7927</span><span class="NLM_x">–</span> <span class="NLM_lpage">7930</span><span class="refDoi"> DOI: 10.1021/jm901566c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901566c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7927-7930&author=L.+D.+Alexanderauthor=R.+P.+Sellersauthor=M.+R.+Davisauthor=V.+C.+Ardiauthor=V.+A.+Johnsonauthor=R.+C.+Vaskoauthor=S.+R.+McAlpine&title=Evaluation+of+di-sansalvamideA+derivatives%3A+synthesis%2C+structure-activity+relationship%2C+and+mechanism+of+action&doi=10.1021%2Fjm901566c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm901566c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901566c%26sid%3Dliteratum%253Aachs%26aulast%3DAlexander%26aufirst%3DL.%2BD.%26aulast%3DSellers%26aufirst%3DR.%2BP.%26aulast%3DDavis%26aufirst%3DM.%2BR.%26aulast%3DArdi%26aufirst%3DV.%2BC.%26aulast%3DJohnson%26aufirst%3DV.%2BA.%26aulast%3DVasko%26aufirst%3DR.%2BC.%26aulast%3DMcAlpine%26aufirst%3DS.%2BR.%26atitle%3DEvaluation%2520of%2520di-sansalvamideA%2520derivatives%253A%2520synthesis%252C%2520structure-activity%2520relationship%252C%2520and%2520mechanism%2520of%2520action%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7927%26epage%3D7930%26doi%3D10.1021%2Fjm901566c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Jhaveri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochiana, S. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunphy, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerecitano, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corben, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peter, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janjigian, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomes-DaGama, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koren, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span> </span><span class="NLM_article-title">Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">611</span><span class="NLM_x">–</span> <span class="NLM_lpage">628</span><span class="refDoi"> DOI: 10.1517/13543784.2014.902442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1517%2F13543784.2014.902442" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=611-628&author=K.+Jhaveriauthor=S.+O.+Ochianaauthor=M.+P.+Dunphyauthor=J.+F.+Gerecitanoauthor=A.+D.+Corbenauthor=R.+I.+Peterauthor=Y.+Y.+Janjigianauthor=E.+M.+Gomes-DaGamaauthor=J.+Korenauthor=S.+Modiauthor=G.+Chiosis&title=Heat+shock+protein+90+inhibitors+in+the+treatment+of+cancer%3A+current+status+and+future+directions&doi=10.1517%2F13543784.2014.902442"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1517%2F13543784.2014.902442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2014.902442%26sid%3Dliteratum%253Aachs%26aulast%3DJhaveri%26aufirst%3DK.%26aulast%3DOchiana%26aufirst%3DS.%2BO.%26aulast%3DDunphy%26aufirst%3DM.%2BP.%26aulast%3DGerecitano%26aufirst%3DJ.%2BF.%26aulast%3DCorben%26aufirst%3DA.%2BD.%26aulast%3DPeter%26aufirst%3DR.%2BI.%26aulast%3DJanjigian%26aufirst%3DY.%2BY.%26aulast%3DGomes-DaGama%26aufirst%3DE.%2BM.%26aulast%3DKoren%26aufirst%3DJ.%26aulast%3DModi%26aufirst%3DS.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DHeat%2520shock%2520protein%252090%2520inhibitors%2520in%2520the%2520treatment%2520of%2520cancer%253A%2520current%2520status%2520and%2520future%2520directions%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2014%26volume%3D23%26spage%3D611%26epage%3D628%26doi%3D10.1517%2F13543784.2014.902442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Taipale, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krykbaeva, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeva, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kayatekin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westover, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karras, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindquist, S.</span><span> </span><span class="NLM_article-title">Quantitative analysis of Hsp90-client interactions reveals principles of substrate recognition</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">150</span><span class="NLM_x">, </span> <span class="NLM_fpage">987</span><span class="NLM_x">–</span> <span class="NLM_lpage">1001</span><span class="refDoi"> DOI: 10.1016/j.cell.2012.06.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.cell.2012.06.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22939624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlSns7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2012&pages=987-1001&author=M.+Taipaleauthor=I.+Krykbaevaauthor=M.+Koevaauthor=C.+Kayatekinauthor=K.+D.+Westoverauthor=G.+I.+Karrasauthor=S.+Lindquist&title=Quantitative+analysis+of+Hsp90-client+interactions+reveals+principles+of+substrate+recognition&doi=10.1016%2Fj.cell.2012.06.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative Analysis of Hsp90-Client Interactions Reveals Principles of Substrate Recognition</span></div><div class="casAuthors">Taipale, Mikko; Krykbaeva, Irina; Koeva, Martina; Kayatekin, Can; Westover, Kenneth D.; Karras, Georgios I.; Lindquist, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">987-1001</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">HSP90 is a mol. chaperone that assocs. with numerous substrate proteins called clients.  It plays many important roles in human biol. and medicine, but determinants of client recognition by HSP90 have remained frustratingly elusive.  We systematically and quant. surveyed most human kinases, transcription factors, and E3 ligases for interaction with HSP90 and its cochaperone CDC37.  Unexpectedly, many more kinases than transcription factors bound HSP90.  CDC37 interacted with kinases, but not with transcription factors or E3 ligases.  HSP90::kinase interactions varied continuously over a 100-fold range and provided a platform to study client protein recognition.  In wild-type clients, HSP90 did not bind particular sequence motifs, but rather assocd. with intrinsically unstable kinases.  Stabilization of the kinase in either its active or inactive conformation with diverse small mols. decreased HSP90 assocn.  Our results establish HSP90 client recognition as a combinatorial process: CDC37 provides recognition of the kinase family, whereas thermodn. parameters det. client binding within the family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHzMXLTn5hx7Vg90H21EOLACvtfcHk0lhm6YgZY-v4jA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlSns7bF&md5=2ebda06d0ce0b8f65edff9f08f10dd31</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2012.06.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2012.06.047%26sid%3Dliteratum%253Aachs%26aulast%3DTaipale%26aufirst%3DM.%26aulast%3DKrykbaeva%26aufirst%3DI.%26aulast%3DKoeva%26aufirst%3DM.%26aulast%3DKayatekin%26aufirst%3DC.%26aulast%3DWestover%26aufirst%3DK.%2BD.%26aulast%3DKarras%26aufirst%3DG.%2BI.%26aulast%3DLindquist%26aufirst%3DS.%26atitle%3DQuantitative%2520analysis%2520of%2520Hsp90-client%2520interactions%2520reveals%2520principles%2520of%2520substrate%2520recognition%26jtitle%3DCell%26date%3D2012%26volume%3D150%26spage%3D987%26epage%3D1001%26doi%3D10.1016%2Fj.cell.2012.06.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Richards, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Law, E. W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rennalls, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busacca, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Regan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fennell, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayliss, R.</span><span> </span><span class="NLM_article-title">Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">5195</span><span class="NLM_x">–</span> <span class="NLM_lpage">5200</span><span class="refDoi"> DOI: 10.1073/pnas.1322892111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1073%2Fpnas.1322892111" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=5195-5200&author=M.+W.+Richardsauthor=E.+W.+P.+Lawauthor=L.+P.+Rennallsauthor=S.+Busaccaauthor=L.+O%E2%80%99Reganauthor=A.+M.+Fryauthor=D.+A.+Fennellauthor=R.+Bayliss&title=Crystal+structure+of+EML1+reveals+the+basis+for+Hsp90+dependence+of+oncogenic+EML4-ALK+by+disruption+of+an+atypical+%CE%B2-propeller+domain&doi=10.1073%2Fpnas.1322892111"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1322892111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1322892111%26sid%3Dliteratum%253Aachs%26aulast%3DRichards%26aufirst%3DM.%2BW.%26aulast%3DLaw%26aufirst%3DE.%2BW.%2BP.%26aulast%3DRennalls%26aufirst%3DL.%2BP.%26aulast%3DBusacca%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Regan%26aufirst%3DL.%26aulast%3DFry%26aufirst%3DA.%2BM.%26aulast%3DFennell%26aufirst%3DD.%2BA.%26aulast%3DBayliss%26aufirst%3DR.%26atitle%3DCrystal%2520structure%2520of%2520EML1%2520reveals%2520the%2520basis%2520for%2520Hsp90%2520dependence%2520of%2520oncogenic%2520EML4-ALK%2520by%2520disruption%2520of%2520an%2520atypical%2520%25CE%25B2-propeller%2520domain%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D5195%26epage%3D5200%26doi%3D10.1073%2Fpnas.1322892111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Montfort, R.</span><span> </span><span class="NLM_article-title">EML4-ALK fusions: propelling cancer but creating exploitable chaperone dependence</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">642</span><span class="NLM_x">–</span> <span class="NLM_lpage">645</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F2159-8290.CD-14-0409" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=642-645&author=P.+Workmanauthor=R.+van+Montfort&title=EML4-ALK+fusions%3A+propelling+cancer+but+creating+exploitable+chaperone+dependence&doi=10.1158%2F2159-8290.CD-14-0409"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0409%26sid%3Dliteratum%253Aachs%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3Dvan%2BMontfort%26aufirst%3DR.%26atitle%3DEML4-ALK%2520fusions%253A%2520propelling%2520cancer%2520but%2520creating%2520exploitable%2520chaperone%2520dependence%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D642%26epage%3D645%26doi%3D10.1158%2F2159-8290.CD-14-0409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. F.</span><span> </span><span class="NLM_article-title">Hop as an adaptor in the heat shock protein 70 (Hsp70) and Hsp90 chaperone machinery</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">273</span><span class="NLM_x">, </span> <span class="NLM_fpage">35194</span><span class="NLM_x">–</span> <span class="NLM_lpage">35200</span><span class="refDoi"> DOI: 10.1074/jbc.273.52.35194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1074%2Fjbc.273.52.35194" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1998&pages=35194-35200&author=S.+Chenauthor=D.+F.+Smith&title=Hop+as+an+adaptor+in+the+heat+shock+protein+70+%28Hsp70%29+and+Hsp90+chaperone+machinery&doi=10.1074%2Fjbc.273.52.35194"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1074%2Fjbc.273.52.35194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.273.52.35194%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DD.%2BF.%26atitle%3DHop%2520as%2520an%2520adaptor%2520in%2520the%2520heat%2520shock%2520protein%252070%2520%2528Hsp70%2529%2520and%2520Hsp90%2520chaperone%2520machinery%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1998%26volume%3D273%26spage%3D35194%26epage%3D35200%26doi%3D10.1074%2Fjbc.273.52.35194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Roe, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaughan, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panaretou, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piper, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prodromou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearl, L. H.</span><span> </span><span class="NLM_article-title">The mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50 (cdc37)</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">–</span> <span class="NLM_lpage">98</span><span class="refDoi"> DOI: 10.1016/S0092-8674(03)01027-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2FS0092-8674%2803%2901027-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=87-98&author=S.+M.+Roeauthor=M.+M.+Aliauthor=P.+Meyerauthor=C.+K.+Vaughanauthor=B.+Panaretouauthor=P.+W.+Piperauthor=C.+Prodromouauthor=L.+H.+Pearl&title=The+mechanism+of+Hsp90+regulation+by+the+protein+kinase-specific+cochaperone+p50+%28cdc37%29&doi=10.1016%2FS0092-8674%2803%2901027-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2803%2901027-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252803%252901027-4%26sid%3Dliteratum%253Aachs%26aulast%3DRoe%26aufirst%3DS.%2BM.%26aulast%3DAli%26aufirst%3DM.%2BM.%26aulast%3DMeyer%26aufirst%3DP.%26aulast%3DVaughan%26aufirst%3DC.%2BK.%26aulast%3DPanaretou%26aufirst%3DB.%26aulast%3DPiper%26aufirst%3DP.%2BW.%26aulast%3DProdromou%26aufirst%3DC.%26aulast%3DPearl%26aufirst%3DL.%2BH.%26atitle%3DThe%2520mechanism%2520of%2520Hsp90%2520regulation%2520by%2520the%2520protein%2520kinase-specific%2520cochaperone%2520p50%2520%2528cdc37%2529%26jtitle%3DCell%26date%3D2004%26volume%3D116%26spage%3D87%26epage%3D98%26doi%3D10.1016%2FS0092-8674%2803%2901027-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Sreeramulu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonker, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancaster, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwalbe, H.</span><span> </span><span class="NLM_article-title">The human Cdc37.Hsp90 complex studied by heteronuclear NMR spectroscopy</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">284</span><span class="NLM_x">, </span> <span class="NLM_fpage">3885</span><span class="NLM_x">–</span> <span class="NLM_lpage">3896</span><span class="refDoi"> DOI: 10.1074/jbc.M806715200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1074%2Fjbc.M806715200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2009&pages=3885-3896&author=S.+Sreeramuluauthor=H.+R.+Jonkerauthor=T.+Langerauthor=C.+Richterauthor=C.+R.+Lancasterauthor=H.+Schwalbe&title=The+human+Cdc37.Hsp90+complex+studied+by+heteronuclear+NMR+spectroscopy&doi=10.1074%2Fjbc.M806715200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M806715200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M806715200%26sid%3Dliteratum%253Aachs%26aulast%3DSreeramulu%26aufirst%3DS.%26aulast%3DJonker%26aufirst%3DH.%2BR.%26aulast%3DLanger%26aufirst%3DT.%26aulast%3DRichter%26aufirst%3DC.%26aulast%3DLancaster%26aufirst%3DC.%2BR.%26aulast%3DSchwalbe%26aufirst%3DH.%26atitle%3DThe%2520human%2520Cdc37.Hsp90%2520complex%2520studied%2520by%2520heteronuclear%2520NMR%2520spectroscopy%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2009%26volume%3D284%26spage%3D3885%26epage%3D3896%26doi%3D10.1074%2Fjbc.M806715200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Ali, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roe, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaughan, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panaretou, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piper, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prodromou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearl, L. H.</span><span> </span><span class="NLM_article-title">Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">440</span><span class="NLM_x">, </span> <span class="NLM_fpage">1013</span><span class="NLM_x">–</span> <span class="NLM_lpage">1017</span><span class="refDoi"> DOI: 10.1038/nature04716</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnature04716" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=16625188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD28Xjs1agtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=440&publication_year=2006&pages=1013-1017&author=M.+M.+Aliauthor=S.+M.+Roeauthor=C.+K.+Vaughanauthor=P.+Meyerauthor=B.+Panaretouauthor=P.+W.+Piperauthor=C.+Prodromouauthor=L.+H.+Pearl&title=Crystal+structure+of+an+Hsp90-nucleotide-p23%2FSba1+closed+chaperone+complex&doi=10.1038%2Fnature04716"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex</span></div><div class="casAuthors">Ali, Maruf M. U.; Roe, S. Mark; Vaughan, Cara K.; Meyer, Phillipe; Panaretou, Barry; Piper, Peter W.; Prodromou, Chrisostomos; Pearl, Laurence H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">440</span>
        (<span class="NLM_cas:issue">7087</span>),
    <span class="NLM_cas:pages">1013-1017</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hsp90 (heat shock protein of 90 kDa) is a ubiquitous mol. chaperone responsible for the assembly and regulation of many eukaryotic signaling systems and is an emerging target for rational chemotherapy of many cancers.  Although the structures of isolated domains of Hsp90 have been detd., the arrangement and ATP-dependent dynamics of these in the full Hsp90 dimer have been elusive and contentious.  Here we present the crystal structure of full-length yeast Hsp90 in complex with an ATP analog and the co-chaperone p23/Sba1.  The structure reveals the complex architecture of the closed' state of the Hsp90 chaperone, the extensive interactions between domains and between protein chains, the detailed conformational changes in the amino-terminal domain that accompany ATP binding, and the structural basis for stabilization of the closed state by p23/Sba1.  Contrary to expectations, the closed Hsp90 would not enclose its client proteins but provides a bipartite binding surface whose formation and disruption are coupled to the chaperone ATPase cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcaj34ODndPbVg90H21EOLACvtfcHk0liR00dQKOk2vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xjs1agtLw%253D&md5=15ea0bcf7cbf297b3f4a7005c7798fb0</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fnature04716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04716%26sid%3Dliteratum%253Aachs%26aulast%3DAli%26aufirst%3DM.%2BM.%26aulast%3DRoe%26aufirst%3DS.%2BM.%26aulast%3DVaughan%26aufirst%3DC.%2BK.%26aulast%3DMeyer%26aufirst%3DP.%26aulast%3DPanaretou%26aufirst%3DB.%26aulast%3DPiper%26aufirst%3DP.%2BW.%26aulast%3DProdromou%26aufirst%3DC.%26aulast%3DPearl%26aufirst%3DL.%2BH.%26atitle%3DCrystal%2520structure%2520of%2520an%2520Hsp90-nucleotide-p23%252FSba1%2520closed%2520chaperone%2520complex%26jtitle%3DNature%26date%3D2006%26volume%3D440%26spage%3D1013%26epage%3D1017%26doi%3D10.1038%2Fnature04716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Karagöz, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duarte, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ippel, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uetrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinnige, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Rosmalen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hausmann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heck, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boelens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rüdiger, S. G.</span><span> </span><span class="NLM_article-title">N-terminal domain of human Hsp90 triggers binding to the cochaperone p23</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">580</span><span class="NLM_x">–</span> <span class="NLM_lpage">585</span><span class="refDoi"> DOI: 10.1073/pnas.1011867108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1073%2Fpnas.1011867108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=21183720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFelsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=580-585&author=G.+E.+Karag%C3%B6zauthor=A.+M.+Duarteauthor=H.+Ippelauthor=C.+Uetrechtauthor=T.+Sinnigeauthor=M.+van+Rosmalenauthor=J.+Hausmannauthor=A.+J.+Heckauthor=R.+Boelensauthor=S.+G.+R%C3%BCdiger&title=N-terminal+domain+of+human+Hsp90+triggers+binding+to+the+cochaperone+p23&doi=10.1073%2Fpnas.1011867108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">N-terminal domain of human Hsp90 triggers binding to the cochaperone p23</span></div><div class="casAuthors">Karagoz, G. Elif; Duarte, Afonso M. S.; Ippel, Hans; Uetrecht, Charlotte; Sinnige, Tessa; van Rosmalen, Martijn; Hausmann, Jens; Heck, Albert J. R.; Boelens, Rolf; Rudiger, Stefan G. D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">580-585, S580/1-S580/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The mol. chaperone Hsp90 is a protein folding machine that is conserved from bacteria to man.  Human, cytosolic Hsp90 is dedicated to folding of chiefly signal transduction components.  The chaperoning mechanism of Hsp90 is controlled by ATP and various cochaperones, but is poorly understood and controversial.  Here, we characterized the Apo and ATP states of the 170-kDa human Hsp90 full-length protein by NMR spectroscopy in soln., and we elucidated the mechanism of the inhibition of its ATPase by its cochaperone p23.  We assigned isoleucine side chains of Hsp90 via specific isotope labeling of their δ-Me groups, which allowed the NMR anal. of the full-length protein.  We found that ATP caused exclusively local changes in Hsp90's N-terminal nucleotide-binding domain.  Native mass spectrometry showed that Hsp90 and p23 form a 2:2 complex via a pos. cooperative mechanism.  Despite this stoichiometry, NMR data indicated that the complex was not fully sym.  The p23-dependent NMR shifts mapped to both the lid and the adenine end of Hsp90's ATP binding pocket, but also to large parts of the middle domain.  Shifts distant from the p23 binding site reflect p23-induced conformational changes in Hsp90.  Together, we conclude that it is Hsp90's nucleotide-binding domain that triggers the formation of the Hsp902p232 complex.  We anticipate that our NMR approach has significant impact on future studies of full-length Hsp90 with cofactors and substrates, but also for the development of Hsp90 inhibiting anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpd2efYORDc8LVg90H21EOLACvtfcHk0ljWF59Xqqc-Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFelsA%253D%253D&md5=a1d95de02cc89096d57043fd409adf20</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1011867108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1011867108%26sid%3Dliteratum%253Aachs%26aulast%3DKarag%25C3%25B6z%26aufirst%3DG.%2BE.%26aulast%3DDuarte%26aufirst%3DA.%2BM.%26aulast%3DIppel%26aufirst%3DH.%26aulast%3DUetrecht%26aufirst%3DC.%26aulast%3DSinnige%26aufirst%3DT.%26aulast%3Dvan%2BRosmalen%26aufirst%3DM.%26aulast%3DHausmann%26aufirst%3DJ.%26aulast%3DHeck%26aufirst%3DA.%2BJ.%26aulast%3DBoelens%26aufirst%3DR.%26aulast%3DR%25C3%25BCdiger%26aufirst%3DS.%2BG.%26atitle%3DN-terminal%2520domain%2520of%2520human%2520Hsp90%2520triggers%2520binding%2520to%2520the%2520cochaperone%2520p23%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D580%26epage%3D585%26doi%3D10.1073%2Fpnas.1011867108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Meyer, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prodromou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roe, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaughan, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vlasic, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panaretou, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piper, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearl, L. H.</span><span> </span><span class="NLM_article-title">Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">511</span><span class="NLM_x">–</span> <span class="NLM_lpage">519</span><span class="refDoi"> DOI: 10.1038/sj.emboj.7600060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fsj.emboj.7600060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=14739935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtV2ru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=511-519&author=P.+L.+Meyerauthor=C.+Prodromouauthor=C.+Liaoauthor=B.+Huauthor=S.+M.+Roeauthor=C.+K.+Vaughanauthor=I.+Vlasicauthor=B.+Panaretouauthor=P.+W.+Piperauthor=L.+H.+Pearl&title=Structural+basis+for+recruitment+of+the+ATPase+activator+Aha1+to+the+Hsp90+chaperone+machinery&doi=10.1038%2Fsj.emboj.7600060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery</span></div><div class="casAuthors">Meyer, Philippe; Prodromou, Chrisostomos; Liao, Chunyan; Hu, Bin; Roe, S. Mark; Vaughan, Cara K.; Vlasic, Ignacija; Panaretou, Barry; Piper, Peter W.; Pearl, Laurence H.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">511-519</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hsp90 is a mol. chaperone essential for the activation and assembly of many key eukaryotic signaling and regulatory proteins.  Hsp90 is assisted and regulated by co-chaperones that participate in an ordered series of dynamic multiprotein complexes, linked to Hsp90s conformationally coupled ATPase cycle.  The co-chaperones Aha1 and Hch1 bind to Hsp90 and stimulate its ATPase activity.  Biochem. anal. shows that this activity is dependent on the N-terminal domain of Aha1, which interacts with the central segment of Hsp90.  The structural basis for this interaction is revealed by the crystal structure of the N-terminal domain (1-153) of Aha1 (equiv. to the whole of Hch1) in complex with the middle segment of Hsp90 (273-530).  Structural anal. and mutagenesis show that binding of N-Aha1 promotes a conformational switch in the middle-segment catalytic loop (370-390) of Hsp90 that releases the catalytic Arg-380 and enables its interaction with ATP in the N-terminal nucleotide-binding domain of the chaperone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpiG2JApXabrVg90H21EOLACvtfcHk0ljWF59Xqqc-Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtV2ru7c%253D&md5=8e1699ec0804e3649a613710ba6e9001</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fsj.emboj.7600060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.emboj.7600060%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DP.%2BL.%26aulast%3DProdromou%26aufirst%3DC.%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DRoe%26aufirst%3DS.%2BM.%26aulast%3DVaughan%26aufirst%3DC.%2BK.%26aulast%3DVlasic%26aufirst%3DI.%26aulast%3DPanaretou%26aufirst%3DB.%26aulast%3DPiper%26aufirst%3DP.%2BW.%26aulast%3DPearl%26aufirst%3DL.%2BH.%26atitle%3DStructural%2520basis%2520for%2520recruitment%2520of%2520the%2520ATPase%2520activator%2520Aha1%2520to%2520the%2520Hsp90%2520chaperone%2520machinery%26jtitle%3DEMBO%2520J.%26date%3D2004%26volume%3D23%26spage%3D511%26epage%3D519%26doi%3D10.1038%2Fsj.emboj.7600060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Retzlaff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagn, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitschke, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hessling, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gugel, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchner, J.</span><span> </span><span class="NLM_article-title">Asymmetric activation of the HSP90 dimer by its cochaperone aha1</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">344</span><span class="NLM_x">–</span> <span class="NLM_lpage">354</span><span class="refDoi"> DOI: 10.1016/j.molcel.2010.01.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.molcel.2010.01.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=20159554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlt1Kktbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2010&pages=344-354&author=M.+Retzlaffauthor=F.+Hagnauthor=L.+Mitschkeauthor=M.+Hesslingauthor=F.+Gugelauthor=H.+Kesslerauthor=K.+Richterauthor=J.+Buchner&title=Asymmetric+activation+of+the+HSP90+dimer+by+its+cochaperone+aha1&doi=10.1016%2Fj.molcel.2010.01.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric activation of the Hsp90 dimer by its cochaperone Aha1</span></div><div class="casAuthors">Retzlaff, Marco; Hagn, Franz; Mitschke, Lars; Hessling, Martin; Gugel, Frederik; Kessler, Horst; Richter, Klaus; Buchner, Johannes</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">344-354</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The chaperone Hsp90 is an ATP-dependent, dimeric mol. machine regulated by several cochaperones, including inhibitors and the unique ATPase activator Aha1.  Here, we analyzed the mechanism of the Aha1-mediated acceleration of Hsp90 ATPase activity and identified the interaction surfaces of both proteins using multidimensional NMR techniques.  For max. activation of Hsp90, the two domains of Aha1 bind to sites in the middle and N-terminal domains of Hsp90 in a sequential manner.  This binding induces the kinetically unfavored N terminally dimerized state of Hsp90, which primes for the hydrolysis-competent conformation.  Surprisingly, this activation mechanism is asym.  The presence of one Aha1 mol. per Hsp90 dimer is sufficient to bridge the two subunits and to fully stimulate Hsp90 ATPase activity.  This seems to functionalize the two subunits of the Hsp90 dimer in different ways, in that one subunit can be used for conformational ATPase regulation and the other for substrate protein processing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN6haR106PYbVg90H21EOLACvtfcHk0liGbESMNGKrRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlt1Kktbo%253D&md5=a57a2df1a7d29f1388d1e426fd3b8772</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2010.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2010.01.006%26sid%3Dliteratum%253Aachs%26aulast%3DRetzlaff%26aufirst%3DM.%26aulast%3DHagn%26aufirst%3DF.%26aulast%3DMitschke%26aufirst%3DL.%26aulast%3DHessling%26aufirst%3DM.%26aulast%3DGugel%26aufirst%3DF.%26aulast%3DKessler%26aufirst%3DH.%26aulast%3DRichter%26aufirst%3DK.%26aulast%3DBuchner%26aufirst%3DJ.%26atitle%3DAsymmetric%2520activation%2520of%2520the%2520HSP90%2520dimer%2520by%2520its%2520cochaperone%2520aha1%26jtitle%3DMol.%2520Cell%26date%3D2010%26volume%3D37%26spage%3D344%26epage%3D354%26doi%3D10.1016%2Fj.molcel.2010.01.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Vaughan, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gohlke, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sobott, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, M. M. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prodromou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saibil, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearl, L. H.</span><span> </span><span class="NLM_article-title">Structure of an Hsp90-Cdc37-Cdk4 complex</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">697</span><span class="NLM_x">–</span> <span class="NLM_lpage">707</span><span class="refDoi"> DOI: 10.1016/j.molcel.2006.07.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.molcel.2006.07.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=16949366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVSkt7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2006&pages=697-707&author=C.+K.+Vaughanauthor=U.+Gohlkeauthor=F.+Sobottauthor=V.+M.+Goodauthor=M.+M.+U.+Aliauthor=C.+Prodromouauthor=C.+V.+Robinsonauthor=H.+R.+Saibilauthor=L.+H.+Pearl&title=Structure+of+an+Hsp90-Cdc37-Cdk4+complex&doi=10.1016%2Fj.molcel.2006.07.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of an Hsp90-Cdc37-Cdk4 complex</span></div><div class="casAuthors">Vaughan, Cara K.; Gohlke, Ulrich; Sobott, Frank; Good, Valerie M.; Ali, Maruf M. U.; Prodromou, Chrisostomos; Robinson, Carol V.; Saibil, Helen R.; Pearl, Laurence H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">697-707</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Activation of many protein kinases depends on their interaction with the Hsp90 mol. chaperone system.  Recruitment of protein kinase clients to the Hsp90 chaperone system is mediated by the cochaperone adaptor protein Cdc37, which acts as a scaffold, simultaneously binding protein kinases and Hsp90.  We have now expressed and purified an Hsp90-Cdc37-Cdk4 complex, defined its stoichiometry, and detd. its 3D structure by single-particle electron microscopy.  Comparison with the crystal structure of Hsp90 allows us to identify the locations of Cdc37 and Cdk4 in the complex and suggests a mechanism by which conformational changes in the kinase are coupled to the Hsp90 ATPase cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9CIsMyAPcErVg90H21EOLACvtfcHk0liGbESMNGKrRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVSkt7rI&md5=bccf0a0ac99a627ec538e01b7910120f</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2006.07.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2006.07.016%26sid%3Dliteratum%253Aachs%26aulast%3DVaughan%26aufirst%3DC.%2BK.%26aulast%3DGohlke%26aufirst%3DU.%26aulast%3DSobott%26aufirst%3DF.%26aulast%3DGood%26aufirst%3DV.%2BM.%26aulast%3DAli%26aufirst%3DM.%2BM.%2BU.%26aulast%3DProdromou%26aufirst%3DC.%26aulast%3DRobinson%26aufirst%3DC.%2BV.%26aulast%3DSaibil%26aufirst%3DH.%2BR.%26aulast%3DPearl%26aufirst%3DL.%2BH.%26atitle%3DStructure%2520of%2520an%2520Hsp90-Cdc37-Cdk4%2520complex%26jtitle%3DMol.%2520Cell%26date%3D2006%26volume%3D23%26spage%3D697%26epage%3D707%26doi%3D10.1016%2Fj.molcel.2006.07.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Karagöz, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duarte, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akoury, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ippel, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biernat, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morán Luengo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Didenko, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nordhues, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veprintsev, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickey, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandelkow, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zweckstetter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boelens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rüdiger, S. G.</span><span> </span><span class="NLM_article-title">Hsp90-Tau complex reveals molecular basis for specificity in chaperone action</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">963</span><span class="NLM_x">–</span> <span class="NLM_lpage">974</span><span class="refDoi"> DOI: 10.1016/j.cell.2014.01.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.cell.2014.01.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=24581495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A280%3ADC%252BC2cvpsFagtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2014&pages=963-974&author=G.+E.+Karag%C3%B6zauthor=A.+M.+Duarteauthor=E.+Akouryauthor=H.+Ippelauthor=J.+Biernatauthor=T.+Mor%C3%A1n+Luengoauthor=M.+Radliauthor=T.+Didenkoauthor=B.+A.+Nordhuesauthor=D.+B.+Veprintsevauthor=C.+A.+Dickeyauthor=E.+Mandelkowauthor=M.+Zweckstetterauthor=R.+Boelensauthor=T.+Madlauthor=S.+G.+R%C3%BCdiger&title=Hsp90-Tau+complex+reveals+molecular+basis+for+specificity+in+chaperone+action&doi=10.1016%2Fj.cell.2014.01.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90-Tau complex reveals molecular basis for specificity in chaperone action</span></div><div class="casAuthors">Karagoz G Elif; Duarte Afonso M S; Akoury Elias; Ippel Hans; Biernat Jacek; Moran Luengo Tania; Radli Martina; Didenko Tatiana; Nordhues Bryce A; Dickey Chad A; Veprintsev Dmitry B; Mandelkow Eckhard; Zweckstetter Markus; Boelens Rolf; Madl Tobias; Rudiger Stefan G D</div><div class="citationInfo"><span class="NLM_cas:title">Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">963-74</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Protein folding in the cell relies on the orchestrated action of conserved families of molecular chaperones, the Hsp70 and Hsp90 systems.  Hsp70 acts early and Hsp90 late in the folding path, yet the molecular basis of this timing is enigmatic, mainly because the substrate specificity of Hsp90 is poorly understood.  Here, we obtained a structural model of Hsp90 in complex with its natural disease-associated substrate, the intrinsically disordered Tau protein.  Hsp90 binds to a broad region in Tau that includes the aggregation-prone repeats.  Complementarily, a 106-ÅA-long substrate-binding interface in Hsp90 enables many low-affinity contacts.  This allows recognition of scattered hydrophobic residues in late folding intermediates that remain after early burial of the Hsp70 sites.  Our model resolves the paradox of how Hsp90 specifically selects for late folding intermediates but also for some intrinsically disordered proteins-through the eyes of Hsp90 they look the same.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQJ1lLYwX_fzXl8icjszYl0fW6udTcc2eaw5PqLj0xYN7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvpsFagtg%253D%253D&md5=ac8a4ccf143cd572c3e52517a9d4d2fc</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2014.01.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2014.01.037%26sid%3Dliteratum%253Aachs%26aulast%3DKarag%25C3%25B6z%26aufirst%3DG.%2BE.%26aulast%3DDuarte%26aufirst%3DA.%2BM.%26aulast%3DAkoury%26aufirst%3DE.%26aulast%3DIppel%26aufirst%3DH.%26aulast%3DBiernat%26aufirst%3DJ.%26aulast%3DMor%25C3%25A1n%2BLuengo%26aufirst%3DT.%26aulast%3DRadli%26aufirst%3DM.%26aulast%3DDidenko%26aufirst%3DT.%26aulast%3DNordhues%26aufirst%3DB.%2BA.%26aulast%3DVeprintsev%26aufirst%3DD.%2BB.%26aulast%3DDickey%26aufirst%3DC.%2BA.%26aulast%3DMandelkow%26aufirst%3DE.%26aulast%3DZweckstetter%26aufirst%3DM.%26aulast%3DBoelens%26aufirst%3DR.%26aulast%3DMadl%26aufirst%3DT.%26aulast%3DR%25C3%25BCdiger%26aufirst%3DS.%2BG.%26atitle%3DHsp90-Tau%2520complex%2520reveals%2520molecular%2520basis%2520for%2520specificity%2520in%2520chaperone%2520action%26jtitle%3DCell%26date%3D2014%26volume%3D156%26spage%3D963%26epage%3D974%26doi%3D10.1016%2Fj.cell.2014.01.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Pratt, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toft, D. O.</span><span> </span><span class="NLM_article-title">Steroid receptor interactions with heat shock protein and immunophilin chaperones</span> <span class="citation_source-journal">Endocr. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">306</span><span class="NLM_x">–</span> <span class="NLM_lpage">360</span><span class="refDoi"> DOI: 10.1210/edrv.18.3.0303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1210%2Fedrv.18.3.0303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=9183567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADyaK2sXktV2qsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1997&pages=306-360&author=W.+B.+Prattauthor=D.+O.+Toft&title=Steroid+receptor+interactions+with+heat+shock+protein+and+immunophilin+chaperones&doi=10.1210%2Fedrv.18.3.0303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Steroid receptor interactions with heat shock protein and immunophilin chaperones</span></div><div class="casAuthors">Pratt, William B.; Toft, David O.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine Reviews</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">306-360</span>CODEN:
                <span class="NLM_cas:coden">ERVIDP</span>;
        ISSN:<span class="NLM_cas:issn">0163-769X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review, with 698 refs., on 9S receptors, receptor transformation, molybdate stabilization of receptors, purifications of untransformed receptors leads to hsp90, role of hsp90 in receptor function, other proteins recovered in native receptor heterocomplexes and the receptor heterocomplex assembly mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIRpRIJU8Ze7Vg90H21EOLACvtfcHk0lggz17RNSqtDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktV2qsrs%253D&md5=fe81c7a7b1a1428b0dbfc6d89d628dc2</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1210%2Fedrv.18.3.0303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fedrv.18.3.0303%26sid%3Dliteratum%253Aachs%26aulast%3DPratt%26aufirst%3DW.%2BB.%26aulast%3DToft%26aufirst%3DD.%2BO.%26atitle%3DSteroid%2520receptor%2520interactions%2520with%2520heat%2520shock%2520protein%2520and%2520immunophilin%2520chaperones%26jtitle%3DEndocr.%2520Rev.%26date%3D1997%26volume%3D18%26spage%3D306%26epage%3D360%26doi%3D10.1210%2Fedrv.18.3.0303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Lorenz, O. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freiburger, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutz, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krause, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zierer, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvira, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuéllar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valpuesta, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sattler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchner, J.</span><span> </span><span class="NLM_article-title">Modulation of the Hsp90 chaperone cycle by a stringent client protein</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">941</span><span class="NLM_x">–</span> <span class="NLM_lpage">953</span><span class="refDoi"> DOI: 10.1016/j.molcel.2014.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.molcel.2014.02.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=941-953&author=O.+R.+Lorenzauthor=L.+Freiburgerauthor=D.+A.+Rutzauthor=M.+Krauseauthor=B.+K.+Ziererauthor=S.+Alviraauthor=J.+Cu%C3%A9llarauthor=J.+M.+Valpuestaauthor=T.+Madlauthor=M.+Sattlerauthor=J.+Buchner&title=Modulation+of+the+Hsp90+chaperone+cycle+by+a+stringent+client+protein&doi=10.1016%2Fj.molcel.2014.02.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2014.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2014.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DLorenz%26aufirst%3DO.%2BR.%26aulast%3DFreiburger%26aufirst%3DL.%26aulast%3DRutz%26aufirst%3DD.%2BA.%26aulast%3DKrause%26aufirst%3DM.%26aulast%3DZierer%26aufirst%3DB.%2BK.%26aulast%3DAlvira%26aufirst%3DS.%26aulast%3DCu%25C3%25A9llar%26aufirst%3DJ.%26aulast%3DValpuesta%26aufirst%3DJ.%2BM.%26aulast%3DMadl%26aufirst%3DT.%26aulast%3DSattler%26aufirst%3DM.%26aulast%3DBuchner%26aufirst%3DJ.%26atitle%3DModulation%2520of%2520the%2520Hsp90%2520chaperone%2520cycle%2520by%2520a%2520stringent%2520client%2520protein%26jtitle%3DMol.%2520Cell%26date%3D2014%26volume%3D53%26spage%3D941%26epage%3D953%26doi%3D10.1016%2Fj.molcel.2014.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Targeting cancer with small molecule kinase inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span><span class="refDoi"> DOI: 10.1038/nrc2559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnrc2559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=19104514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1yg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=28-39&author=J.+Zhangauthor=P.+L.+Yangauthor=N.+S.+Gray&title=Targeting+cancer+with+small+molecule+kinase+inhibitors&doi=10.1038%2Fnrc2559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer with small molecule kinase inhibitors</span></div><div class="casAuthors">Zhang, Jianming; Yang, Priscilla L.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-39</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiol. constraints on growth and survival.  To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small mol. inhibitors for a host of other kinases that are implicated in cancer and other diseases.  Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations.  This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriSM3BN_uEz7Vg90H21EOLACvtfcHk0li7wFyBtUGhbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1yg&md5=35bc38f414cd21eef5e61ce181b580fb</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fnrc2559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2559%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520cancer%2520with%2520small%2520molecule%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D28%26epage%3D39%26doi%3D10.1038%2Fnrc2559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Lemmon, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span> </span><span class="NLM_article-title">Cell signaling by receptor tyrosine kinases</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">141</span><span class="NLM_x">, </span> <span class="NLM_fpage">1117</span><span class="NLM_x">–</span> <span class="NLM_lpage">1134</span><span class="refDoi"> DOI: 10.1016/j.cell.2010.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.cell.2010.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=20602996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2010&pages=1117-1134&author=M.+A.+Lemmonauthor=J.+Schlessinger&title=Cell+signaling+by+receptor+tyrosine+kinases&doi=10.1016%2Fj.cell.2010.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Cell signaling by receptor tyrosine kinases</span></div><div class="casAuthors">Lemmon, Mark A.; Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1117-1134</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Recent structural studies of receptor tyrosine kinases (RTKs) have revealed unexpected diversity in the mechanisms of their activation by growth factor ligands.  Strategies for inducing dimerization by ligand binding are surprisingly diverse, as are mechanisms that couple this event to activation of the intracellular tyrosine kinase domains.  As the understanding of these details becomes increasingly sophisticated, it provides an important context for therapeutically countering the effects of pathogenic RTK mutations in cancer and other diseases.  Much remains to be learned, however, about the complex signaling networks downstream from RTKs and how alterations in these networks are translated into cellular responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd5NvoN0Q9-7Vg90H21EOLACvtfcHk0li7wFyBtUGhbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D&md5=b88b55fe7a3eebc6ff7e883425676e45</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2010.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2010.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCell%2520signaling%2520by%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCell%26date%3D2010%26volume%3D141%26spage%3D1117%26epage%3D1134%26doi%3D10.1016%2Fj.cell.2010.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Garraway, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Circumventing cancer drug resistance in the era of personalized medicine</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">214</span><span class="NLM_x">–</span> <span class="NLM_lpage">226</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F2159-8290.CD-12-0012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=214-226&author=L.+A.+Garrawayauthor=P.+A.+Janne&title=Circumventing+cancer+drug+resistance+in+the+era+of+personalized+medicine&doi=10.1158%2F2159-8290.CD-12-0012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0012%26sid%3Dliteratum%253Aachs%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DCircumventing%2520cancer%2520drug%2520resistance%2520in%2520the%2520era%2520of%2520personalized%2520medicine%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26spage%3D214%26epage%3D226%26doi%3D10.1158%2F2159-8290.CD-12-0012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span> </span><span class="NLM_article-title">Acquired resistance to TKIs in solid tumours: learning from lung cancer</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">473</span><span class="NLM_x">–</span> <span class="NLM_lpage">481</span><span class="refDoi"> DOI: 10.1038/nrclinonc.2014.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnrclinonc.2014.104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=24981256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFWisLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=473-481&author=D.+R.+Camidgeauthor=W.+Paoauthor=L.+V.+Sequist&title=Acquired+resistance+to+TKIs+in+solid+tumours%3A+learning+from+lung+cancer&doi=10.1038%2Fnrclinonc.2014.104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance to TKIs in solid tumours: learning from lung cancer</span></div><div class="casAuthors">Camidge, D. Ross; Pao, William; Sequist, Lecia V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">473-481</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The use of advanced mol. profiling to direct the use of targeted therapy, such as tyrosine kinase inhibitors (TKIs) for patients with advanced-stage non-small-cell lung cancer (NSCLC), has revolutionized the treatment of this disease.  However, acquired resistance, defined as progression after initial benefit, to targeted therapies inevitably occurs.  This Review explores breakthroughs in the understanding and treatment of acquired resistance in NSCLC, focusing on EGFR mutant and ALK rearrangement-pos. disease, which may be relevant across multiple different solid malignancies with oncogene-addicted subtypes.  Mechanisms of acquired resistance may be pharmacol. (i.e., failure of delivery of the drug to its target) or biol., resulting from evolutionary selection on molecularly diverse tumors.  A no. of clin. approaches can maintain control of the disease in the acquired resistance setting, including the use of radiation to treat isolated areas of progression and adding or switching to cytotoxic chemotherapy.  Furthermore, novel approaches that have already proven successful include the development of second-generation and third-generation inhibitors and the combination of some of these inhibitors with antibodies directed against the same target.  With our increased understanding of the spectrum of acquired resistance, major changes in how we conduct clin. research in this setting are now underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp00ixSKYoDuLVg90H21EOLACvtfcHk0lhr56tVy9LybQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFWisLrL&md5=13cc2f49f7ef320ad54f7e84f5102816</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2014.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2014.104%26sid%3Dliteratum%253Aachs%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26atitle%3DAcquired%2520resistance%2520to%2520TKIs%2520in%2520solid%2520tumours%253A%2520learning%2520from%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D11%26spage%3D473%26epage%3D481%26doi%3D10.1038%2Fnrclinonc.2014.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Factors underlying sensitivity of cancers to small-molecule kinase inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">709</span><span class="NLM_x">–</span> <span class="NLM_lpage">723</span><span class="refDoi"> DOI: 10.1038/nrd2871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnrd2871" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=709-723&author=P.+A.+Janneauthor=N.+Grayauthor=J.+Settleman&title=Factors+underlying+sensitivity+of+cancers+to+small-molecule+kinase+inhibitors&doi=10.1038%2Fnrd2871"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fnrd2871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2871%26sid%3Dliteratum%253Aachs%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DFactors%2520underlying%2520sensitivity%2520of%2520cancers%2520to%2520small-molecule%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D709%26epage%3D723%26doi%3D10.1038%2Fnrd2871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Acquired resistance to tyrosine kinase inhibitors during cancer therapy</span> <span class="citation_source-journal">Curr. Opin. Genet. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="NLM_x">–</span> <span class="NLM_lpage">79</span><span class="refDoi"> DOI: 10.1016/j.gde.2008.01.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.gde.2008.01.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=18325754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVartbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=73-79&author=J.+A.+Engelmanauthor=J.+Settleman&title=Acquired+resistance+to+tyrosine+kinase+inhibitors+during+cancer+therapy&doi=10.1016%2Fj.gde.2008.01.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance to tyrosine kinase inhibitors during cancer therapy</span></div><div class="casAuthors">Engelman, Jeffrey A.; Settleman, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Genetics & Development</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-79</span>CODEN:
                <span class="NLM_cas:coden">COGDET</span>;
        ISSN:<span class="NLM_cas:issn">0959-437X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Selective tyrosine kinase inhibitors have emerged as important therapeutic agents in the treatment of a variety of human malignancies.  Although several of these inhibitors have marked clin. activity, it is widely recognized that the overall value of these agents is substantially limited by the acquisition of drug resistance, which eventually arises in most, if not all treated patients.  Mechanisms of drug resistance are beginning to be elucidated through the mol. anal. of clin. specimens as well as through cell culture modeling.  By identifying resistance mechanisms, it should be possible to develop second-generation' inhibitors as well as rational drug combinations that can overcome or even prevent acquired resistance to kinase inhibitors, thereby enhancing clin. benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJCEQIe-JFI7Vg90H21EOLACvtfcHk0lhr56tVy9LybQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVartbc%253D&md5=db27057c8cb1a4deceb779bae6d19398</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.gde.2008.01.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gde.2008.01.004%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DAcquired%2520resistance%2520to%2520tyrosine%2520kinase%2520inhibitors%2520during%2520cancer%2520therapy%26jtitle%3DCurr.%2520Opin.%2520Genet.%2520Dev.%26date%3D2008%26volume%3D18%26spage%3D73%26epage%3D79%26doi%3D10.1016%2Fj.gde.2008.01.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Kuczynski, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sargent, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grothey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerbel, R. S.</span><span> </span><span class="NLM_article-title">Drug rechallenge and treatment beyond progression--implications for drug resistance</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">571</span><span class="NLM_x">–</span> <span class="NLM_lpage">587</span><span class="refDoi"> DOI: 10.1038/nrclinonc.2013.158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnrclinonc.2013.158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=23999218" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVWqtrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=571-587&author=E.+A.+Kuczynskiauthor=D.+J.+Sargentauthor=A.+Grotheyauthor=R.+S.+Kerbel&title=Drug+rechallenge+and+treatment+beyond+progression%2D%2Dimplications+for+drug+resistance&doi=10.1038%2Fnrclinonc.2013.158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Drug rechallenge and treatment beyond progression-implications for drug resistance</span></div><div class="casAuthors">Kuczynski, Elizabeth A.; Sargent, Daniel J.; Grothey, Axel; Kerbel, Robert S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">571-587</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The established dogma in oncol. for managing recurrent or refractory disease dictates that therapy is changed at disease progression, because the cancer is assumed to have become drug-resistant.  Drug resistance, whether pre-existing or acquired, is largely thought to be a stable and heritable process; thus, reuse of therapeutic agents that have failed is generally contraindicated.  Over the past few decades, clin. evidence has suggested a role for unstable, non-heritable mechanisms of acquired drug resistance pertaining to chemotherapy and targeted agents.  There are many examples of circumstances where patients respond to reintroduction of the same therapy (drug rechallenge) after a drug holiday following disease relapse or progression during therapy.  Addnl., albeit limited, evidence suggests that, in certain circumstances, continuing a therapy beyond disease progression can also have antitumor activity.  In this Review, we describe the anticancer agents used in these treatment strategies and discuss the potential mechanisms explaining the apparent tumor re-sensitization with reintroduced or continued therapy.  The extensive no. of malignancies and drugs that challenge the custom of permanently switching to different drugs at each line of therapy warrants a more in-depth examn. of the definitions of disease progression and drug resistance and the resulting implications for patient care.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGVmbq8ucsa7Vg90H21EOLACvtfcHk0lit5gK02D1e-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVWqtrzJ&md5=513ca799d7cabdd8208b0c4ae9507753</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2013.158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2013.158%26sid%3Dliteratum%253Aachs%26aulast%3DKuczynski%26aufirst%3DE.%2BA.%26aulast%3DSargent%26aufirst%3DD.%2BJ.%26aulast%3DGrothey%26aufirst%3DA.%26aulast%3DKerbel%26aufirst%3DR.%2BS.%26atitle%3DDrug%2520rechallenge%2520and%2520treatment%2520beyond%2520progression--implications%2520for%2520drug%2520resistance%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D10%26spage%3D571%26epage%3D587%26doi%3D10.1038%2Fnrclinonc.2013.158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Lackner, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Mechanisms of acquired resistance to targeted cancer therapies</span> <span class="citation_source-journal">Future Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">999</span><span class="NLM_x">–</span> <span class="NLM_lpage">1014</span><span class="refDoi"> DOI: 10.2217/fon.12.86</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.2217%2Ffon.12.86" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22894672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1WlsLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=999-1014&author=M.+R.+Lacknerauthor=T.+R.+Wilsonauthor=J.+Settleman&title=Mechanisms+of+acquired+resistance+to+targeted+cancer+therapies&doi=10.2217%2Ffon.12.86"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of acquired resistance to targeted cancer therapies</span></div><div class="casAuthors">Lackner, Mark R.; Wilson, Timothy R.; Settleman, Jeff</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">999-1014</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Drugs that target genomically defined vulnerabilities in human tumors have now been clin. validated as effective cancer therapies.  However, the relatively rapid acquisition of resistance to such treatments that is obsd. in virtually all cases significantly limits their utility and remains a substantial challenge to the clin. management of advanced cancers.  As mol. mechanisms of resistance have begun to be elucidated, new strategies to overcome or prevent the development of resistance have begun to emerge.  In some cases, specific mutational mechanisms contribute directly to acquired drug resistance, and in other cases it appears that nonmutational and possibly epigenetic mechanisms play a significant role.  This article discusses the various genetic and nongenetic mechanisms of acquired drug resistance that have been reported in the context of rationally targeted' drug therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooztN62IERZrVg90H21EOLACvtfcHk0lit5gK02D1e-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1WlsLzK&md5=8a0a8ccb076874d753bfed5ace2ba169</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.2217%2Ffon.12.86&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.12.86%26sid%3Dliteratum%253Aachs%26aulast%3DLackner%26aufirst%3DM.%2BR.%26aulast%3DWilson%26aufirst%3DT.%2BR.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DMechanisms%2520of%2520acquired%2520resistance%2520to%2520targeted%2520cancer%2520therapies%26jtitle%3DFuture%2520Oncol.%26date%3D2012%26volume%3D8%26spage%3D999%26epage%3D1014%26doi%3D10.2217%2Ffon.12.86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Gillies, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verduzco, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gatenby, R. A.</span><span> </span><span class="NLM_article-title">Evolutionary dynamics of carcinogenesis and why targeted therapy does not work</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">487</span><span class="NLM_x">–</span> <span class="NLM_lpage">493</span><span class="refDoi"> DOI: 10.1038/nrc3298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnrc3298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22695393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1egsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=487-493&author=R.+J.+Gilliesauthor=D.+Verduzcoauthor=R.+A.+Gatenby&title=Evolutionary+dynamics+of+carcinogenesis+and+why+targeted+therapy+does+not+work&doi=10.1038%2Fnrc3298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Evolutionary dynamics of carcinogenesis and why targeted therapy does not work</span></div><div class="casAuthors">Gillies, Robert J.; Verduzco, Daniel; Gatenby, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">487-493</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  All malignant cancers, whether inherited or sporadic, are fundamentally governed by Darwinian dynamics.  The process of carcinogenesis requires genetic instability and highly selective local microenvironments, the combination of which promotes somatic evolution.  These microenvironmental forces, specifically hypoxia, acidosis and reactive oxygen species, are not only highly selective, but are also able to induce genetic instability.  As a result, malignant cancers are dynamically evolving clades of cells living in distinct microhabitats that almost certainly ensure the emergence of therapy-resistant populations.  Cytotoxic cancer therapies also impose intense evolutionary selection pressures on the surviving cells and thus increase the evolutionary rate.  Importantly, the principles of Darwinian dynamics also embody fundamental principles that can illuminate strategies for the successful management of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorCHoXr5jY_rVg90H21EOLACvtfcHk0ljJhRSTZevqrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1egsL4%253D&md5=ae041c5a9585d882c6512e386afb26c2</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fnrc3298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3298%26sid%3Dliteratum%253Aachs%26aulast%3DGillies%26aufirst%3DR.%2BJ.%26aulast%3DVerduzco%26aufirst%3DD.%26aulast%3DGatenby%26aufirst%3DR.%2BA.%26atitle%3DEvolutionary%2520dynamics%2520of%2520carcinogenesis%2520and%2520why%2520targeted%2520therapy%2520does%2520not%2520work%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D487%26epage%3D493%26doi%3D10.1038%2Fnrc3298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Holohan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Schaeybroeck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longley, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, P. G.</span><span> </span><span class="NLM_article-title">Cancer drug resistance: an evolving paradigm</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">714</span><span class="NLM_x">–</span> <span class="NLM_lpage">726</span><span class="refDoi"> DOI: 10.1038/nrc3599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnrc3599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=24060863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyqurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=714-726&author=C.+Holohanauthor=S.+Van+Schaeybroeckauthor=D.+B.+Longleyauthor=P.+G.+Johnston&title=Cancer+drug+resistance%3A+an+evolving+paradigm&doi=10.1038%2Fnrc3599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer drug resistance: an evolving paradigm</span></div><div class="casAuthors">Holohan, Caitriona; Van Schaeybroeck, Sandra; Longley, Daniel B.; Johnston, Patrick G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">714-726</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Resistance to chemotherapy and molecularly targeted therapies is a major problem facing current cancer research.  The mechanisms of resistance to 'classical' cytotoxic chemotherapeutics and to therapies that are designed to be selective for specific mol. targets share many features, such as alterations in the drug target, activation of prosurvival pathways and ineffective induction of cell death.  With the increasing arsenal of anticancer agents, improving preclin. models and the advent of powerful high-throughput screening techniques, there are now unprecedented opportunities to understand and overcome drug resistance through the clin. assessment of rational therapeutic drug combinations and the use of predictive biomarkers to enable patient stratification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrykBEUSgvv7Vg90H21EOLACvtfcHk0ljJhRSTZevqrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyqurnE&md5=b497a823bbd968904ce1591b918d0679</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1038%2Fnrc3599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3599%26sid%3Dliteratum%253Aachs%26aulast%3DHolohan%26aufirst%3DC.%26aulast%3DVan%2BSchaeybroeck%26aufirst%3DS.%26aulast%3DLongley%26aufirst%3DD.%2BB.%26aulast%3DJohnston%26aufirst%3DP.%2BG.%26atitle%3DCancer%2520drug%2520resistance%253A%2520an%2520evolving%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D714%26epage%3D726%26doi%3D10.1038%2Fnrc3599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Tartarone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazzari, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerose, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conteduca, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Improta, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zupa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bulotta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aieta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregorc, V.</span><span> </span><span class="NLM_article-title">Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib</span> <span class="citation_source-journal">Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">328</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1016/j.lungcan.2013.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.lungcan.2013.05.020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2013&pages=328-336&author=A.+Tartaroneauthor=C.+Lazzariauthor=R.+Leroseauthor=V.+Conteducaauthor=G.+Improtaauthor=A.+Zupaauthor=A.+Bulottaauthor=M.+Aietaauthor=V.+Gregorc&title=Mechanisms+of+resistance+to+EGFR+tyrosine+kinase+inhibitors+gefitinib%2Ferlotinib+and+to+ALK+inhibitor+crizotinib&doi=10.1016%2Fj.lungcan.2013.05.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2013.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2013.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DTartarone%26aufirst%3DA.%26aulast%3DLazzari%26aufirst%3DC.%26aulast%3DLerose%26aufirst%3DR.%26aulast%3DConteduca%26aufirst%3DV.%26aulast%3DImprota%26aufirst%3DG.%26aulast%3DZupa%26aufirst%3DA.%26aulast%3DBulotta%26aufirst%3DA.%26aulast%3DAieta%26aufirst%3DM.%26aulast%3DGregorc%26aufirst%3DV.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%2520gefitinib%252Ferlotinib%2520and%2520to%2520ALK%2520inhibitor%2520crizotinib%26jtitle%3DLung%2520Cancer%26date%3D2013%26volume%3D81%26spage%3D328%26epage%3D336%26doi%3D10.1016%2Fj.lungcan.2013.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Song, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, A.</span><span> </span><span class="NLM_article-title">Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance</span> <span class="citation_source-journal">Acta Pharm. Sin. B</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">34</span><span class="NLM_x">–</span> <span class="NLM_lpage">37</span><span class="refDoi"> DOI: 10.1016/j.apsb.2014.12.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.apsb.2014.12.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=26579422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A280%3ADC%252BC28rgtlOnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=34-37&author=Z.+Songauthor=M.+Wangauthor=A.+Zhang&title=Alectinib%3A+a+novel+second+generation+anaplastic+lymphoma+kinase+%28ALK%29+inhibitor+for+overcoming+clinically-acquired+resistance&doi=10.1016%2Fj.apsb.2014.12.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance</span></div><div class="casAuthors">Song Zilan; Wang Meining; Zhang Ao</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-7</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">The development of inhibitors for the tyrosine anaplastic lymphoma kinase (ALK) has advanced rapidly, driven by biology and medicinal chemistry.  The first generation ALK inhibitor crizotinib was granted US FDA approval with only four years of preclinical and clinical testing.  Although this drug offers significant clinical benefit to the ALK-positive patients, resistance has been developed through a variety of mechanisms.  In addition to ceritinib, alectinib is another second-generation ALK inhibitor launched in 2014 in Japan.  This drug has a unique chemical structure bearing a 5H-benzo[b]carbazol-11(6H)-one structural scaffold with an IC50 value of 1.9 nmol/L, and is highly potent against ALK bearing the gatekeeper mutation L1196M with an IC50 of 1.56 nmol/L.  In the clinic, alectinib is highly efficacious in treatment of ALK-positive non-small cell lung cancer (NSCLC), and retains potency to combat crizotinib-resistant ALK mutations L1196M, F1174L, R1275Q and C1156Y.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-qtzzXrDFl0loaUqgkFHkfW6udTcc2eZ2pNfoTpzcorntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rgtlOnsQ%253D%253D&md5=897904214b032d104d09280ebe1b95ca</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2014.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2014.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DAlectinib%253A%2520a%2520novel%2520second%2520generation%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitor%2520for%2520overcoming%2520clinically-acquired%2520resistance%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2015%26volume%3D5%26spage%3D34%26epage%3D37%26doi%3D10.1016%2Fj.apsb.2014.12.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carretero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adelmant, G. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodig, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marto, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span> </span><span class="NLM_article-title">Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">9827</span><span class="NLM_x">–</span> <span class="NLM_lpage">9836</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-1671</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F0008-5472.CAN-10-1671" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=9827-9836&author=Z.+Chenauthor=T.+Sasakiauthor=X.+Tanauthor=J.+Carreteroauthor=T.+Shimamuraauthor=D.+Liauthor=C.+Xuauthor=Y.+Wangauthor=G.+O.+Adelmantauthor=M.+Capellettiauthor=H.+J.+Leeauthor=S.+J.+Rodigauthor=C.+Borgmanauthor=S.+I.+Parkauthor=H.+R.+Kimauthor=R.+Paderaauthor=J.+A.+Martoauthor=N.+S.+Grayauthor=A.+L.+Kungauthor=G.+I.+Shapiroauthor=P.+A.+J%C3%A4nneauthor=K.+K.+Wong&title=Inhibition+of+ALK%2C+PI3K%2FMEK%2C+and+HSP90+in+murine+lung+adenocarcinoma+induced+by+EML4-ALK+fusion+oncogene&doi=10.1158%2F0008-5472.CAN-10-1671"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-1671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-1671%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DX.%26aulast%3DCarretero%26aufirst%3DJ.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DAdelmant%26aufirst%3DG.%2BO.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DBorgman%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DS.%2BI.%26aulast%3DKim%26aufirst%3DH.%2BR.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DMarto%26aufirst%3DJ.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DInhibition%2520of%2520ALK%252C%2520PI3K%252FMEK%252C%2520and%2520HSP90%2520in%2520murine%2520lung%2520adenocarcinoma%2520induced%2520by%2520EML4-ALK%2520fusion%2520oncogene%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D9827%26epage%3D9836%26doi%3D10.1158%2F0008-5472.CAN-10-1671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Normant, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paez, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slocum, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tunkey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDougall, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wylie, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robison, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caliri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palombella, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritz, C. C.</span><span> </span><span class="NLM_article-title">The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2581</span><span class="NLM_x">–</span> <span class="NLM_lpage">2586</span><span class="refDoi"> DOI: 10.1038/onc.2010.625</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fonc.2010.625" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2011&pages=2581-2586&author=E.+Normantauthor=G.+Paezauthor=K.+A.+Westauthor=A.+R.+Limauthor=K.+L.+Slocumauthor=C.+Tunkeyauthor=J.+McDougallauthor=A.+A.+Wylieauthor=K.+Robisonauthor=K.+Caliriauthor=V.+J.+Palombellaauthor=C.+C.+Fritz&title=The+Hsp90+inhibitor+IPI-504+rapidly+lowers+EML4-ALK+levels+and+induces+tumor+regression+in+ALK-driven+NSCLC+models&doi=10.1038%2Fonc.2010.625"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1038%2Fonc.2010.625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2010.625%26sid%3Dliteratum%253Aachs%26aulast%3DNormant%26aufirst%3DE.%26aulast%3DPaez%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DK.%2BA.%26aulast%3DLim%26aufirst%3DA.%2BR.%26aulast%3DSlocum%26aufirst%3DK.%2BL.%26aulast%3DTunkey%26aufirst%3DC.%26aulast%3DMcDougall%26aufirst%3DJ.%26aulast%3DWylie%26aufirst%3DA.%2BA.%26aulast%3DRobison%26aufirst%3DK.%26aulast%3DCaliri%26aufirst%3DK.%26aulast%3DPalombella%26aufirst%3DV.%2BJ.%26aulast%3DFritz%26aufirst%3DC.%2BC.%26atitle%3DThe%2520Hsp90%2520inhibitor%2520IPI-504%2520rapidly%2520lowers%2520EML4-ALK%2520levels%2520and%2520induces%2520tumor%2520regression%2520in%2520ALK-driven%2520NSCLC%2520models%26jtitle%3DOncogene%26date%3D2011%26volume%3D30%26spage%3D2581%26epage%3D2586%26doi%3D10.1038%2Fonc.2010.625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Sang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acquaviva, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedland, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequeira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovly, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimenez, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doebele, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bates, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Hariry, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proia, D. A.</span><span> </span><span class="NLM_article-title">Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non–small cell lung cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">430</span><span class="NLM_x">–</span> <span class="NLM_lpage">443</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0440</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F2159-8290.CD-12-0440" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=430-443&author=J.+Sangauthor=J.+Acquavivaauthor=J.+C.+Friedlandauthor=D.+L.+Smithauthor=M.+Sequeiraauthor=C.+Zhangauthor=Q.+Jiangauthor=L.+Xueauthor=C.+M.+Lovlyauthor=J.-P.+Jimenezauthor=A.+T.+Shawauthor=R.+C.+Doebeleauthor=S.+Heauthor=R.+C.+Batesauthor=D.+R.+Camidgeauthor=S.+W.+Morrisauthor=I.+El-Hariryauthor=D.+A.+Proia&title=Targeted+inhibition+of+the+molecular+chaperone+Hsp90+overcomes+ALK+inhibitor+resistance+in+non%E2%80%93small+cell+lung+cancer&doi=10.1158%2F2159-8290.CD-12-0440"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0440%26sid%3Dliteratum%253Aachs%26aulast%3DSang%26aufirst%3DJ.%26aulast%3DAcquaviva%26aufirst%3DJ.%26aulast%3DFriedland%26aufirst%3DJ.%2BC.%26aulast%3DSmith%26aufirst%3DD.%2BL.%26aulast%3DSequeira%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DJimenez%26aufirst%3DJ.-P.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DBates%26aufirst%3DR.%2BC.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DEl-Hariry%26aufirst%3DI.%26aulast%3DProia%26aufirst%3DD.%2BA.%26atitle%3DTargeted%2520inhibition%2520of%2520the%2520molecular%2520chaperone%2520Hsp90%2520overcomes%2520ALK%2520inhibitor%2520resistance%2520in%2520non%25E2%2580%2593small%2520cell%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D430%26epage%3D443%26doi%3D10.1158%2F2159-8290.CD-12-0440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">7535</span><span class="NLM_x">–</span> <span class="NLM_lpage">7540</span><span class="refDoi"> DOI: 10.1073/pnas.1019559108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1073%2Fpnas.1019559108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=21502504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFSrsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=7535-7540&author=R.+Katayamaauthor=T.+M.+Khanauthor=C.+Benesauthor=E.+Lifshitsauthor=H.+Ebiauthor=V.+M.+Riveraauthor=W.+C.+Shakespeareauthor=A.+J.+Iafrateauthor=J.+A.+Engelmanauthor=A.+T.+Shaw&title=Therapeutic+strategies+to+overcome+crizotinib+resistance+in+non-small+cell+lung+cancers+harboring+the+fusion+oncogene+EML4-ALK&doi=10.1073%2Fpnas.1019559108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK</span></div><div class="casAuthors">Katayama, Ryohei; Khan, Tahsin M.; Benes, Cyril; Lifshits, Eugene; Ebi, Hiromichi; Rivera, Victor M.; Shakespeare, William C.; Iafrate, A. John; Engelman, Jeffrey A.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7535-7540, S7535/1-S7535/17</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The echinoderm microtubule-assocd. protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion oncogene represents a mol. target in a small subset of non-small cell lung cancers (NSCLCs).  This fusion leads to constitutive ALK activation with potent transforming activity.  In a pivotal phase 1 clin. trial, the ALK tyrosine kinase inhibitor (TKI) crizotinib (PF-02341066) demonstrated impressive antitumor activity in the majority of patients with NSCLC harboring ALK fusions.  However, despite these remarkable initial responses, cancers eventually develop resistance to crizotinib, usually within 1 y, thereby limiting the potential clin. benefit.  To det. how cancers acquire resistance to ALK inhibitors, we established a model of acquired resistance to crizotinib by exposing a highly sensitive EML4-ALK-pos. NSCLC cell line to increasing doses of crizotinib until resistance emerged.  We found that cells resistant to intermediate doses of crizotinib developed amplification of the EML4-ALK gene.  Cells resistant to higher doses (1 μM) also developed a gatekeeper mutation, L1196M, within the kinase domain, rendering EML4-ALK insensitive to crizotinib.  This gatekeeper mutation was readily detected using a unique and highly sensitive allele-specific PCR assay.  Although crizotinib was ineffectual against EML4-ALK harboring the gatekeeper mutation, we obsd. that two structurally different ALK inhibitors, NVPTAE684 and AP26113, were highly active against the resistant cancer cells in vitro and in vivo.  Furthermore, these resistant cells remained highly sensitive to the Hsp90 inhibitor 17-AAG.  Thus, we have developed a model of acquired resistance to ALK inhibitors and have shown that second-generation ALK TKIs or Hsp90 inhibitors are effective in treating crizotinib-resistant tumors harboring secondary gatekeeper mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPbiLG5xpg0LVg90H21EOLACvtfcHk0lil4zFGFxQqQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFSrsbY%253D&md5=82f47736429e6f71f9fd5852e4df64cb</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1019559108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1019559108%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DEbi%26aufirst%3DH.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTherapeutic%2520strategies%2520to%2520overcome%2520crizotinib%2520resistance%2520in%2520non-small%2520cell%2520lung%2520cancers%2520harboring%2520the%2520fusion%2520oncogene%2520EML4-ALK%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D7535%26epage%3D7540%26doi%3D10.1073%2Fpnas.1019559108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Tanimoto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nanjo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, S.</span><span> </span><span class="NLM_article-title">Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">4920</span><span class="NLM_x">–</span> <span class="NLM_lpage">4928</span><span class="refDoi"> DOI: 10.18632/oncotarget.2055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.18632%2Foncotarget.2055" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=4920-4928&author=A.+Tanimotoauthor=T.+Yamadaauthor=S.+Nanjoauthor=S.+Takeuchiauthor=H.+Ebiauthor=K.+Kitaauthor=K.+Matsumotoauthor=S.+Yano&title=Receptor+ligand-triggered+resistance+to+alectinib+and+its+circumvention+by+Hsp90+inhibition+in+EML4-ALK+lung+cancer+cells&doi=10.18632%2Foncotarget.2055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2055%26sid%3Dliteratum%253Aachs%26aulast%3DTanimoto%26aufirst%3DA.%26aulast%3DYamada%26aufirst%3DT.%26aulast%3DNanjo%26aufirst%3DS.%26aulast%3DTakeuchi%26aufirst%3DS.%26aulast%3DEbi%26aufirst%3DH.%26aulast%3DKita%26aufirst%3DK.%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DYano%26aufirst%3DS.%26atitle%3DReceptor%2520ligand-triggered%2520resistance%2520to%2520alectinib%2520and%2520its%2520circumvention%2520by%2520Hsp90%2520inhibition%2520in%2520EML4-ALK%2520lung%2520cancer%2520cells%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D4920%26epage%3D4928%26doi%3D10.18632%2Foncotarget.2055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Wong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koczywas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paschold, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lufkin, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackman, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teofilovici, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Socinski, M. A.</span><span> </span><span class="NLM_article-title">An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non–small cell lung cancer (NSCLC)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">S7500</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=S7500&author=K.+Wongauthor=M.+Koczywasauthor=J.+W.+Goldmanauthor=E.+H.+Pascholdauthor=L.+Hornauthor=J.+M.+Lufkinauthor=R.+K.+Blackmanauthor=F.+Teofiloviciauthor=G.+Shapiroauthor=M.+A.+Socinski&title=An+open-label+phase+II+study+of+the+Hsp90+inhibitor+ganetespib+%28STA-9090%29+as+monotherapy+in+patients+with+advanced+non%E2%80%93small+cell+lung+cancer+%28NSCLC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DK.%26aulast%3DKoczywas%26aufirst%3DM.%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DPaschold%26aufirst%3DE.%2BH.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DLufkin%26aufirst%3DJ.%2BM.%26aulast%3DBlackman%26aufirst%3DR.%2BK.%26aulast%3DTeofilovici%26aufirst%3DF.%26aulast%3DShapiro%26aufirst%3DG.%26aulast%3DSocinski%26aufirst%3DM.%2BA.%26atitle%3DAn%2520open-label%2520phase%2520II%2520study%2520of%2520the%2520Hsp90%2520inhibitor%2520ganetespib%2520%2528STA-9090%2529%2520as%2520monotherapy%2520in%2520patients%2520with%2520advanced%2520non%25E2%2580%2593small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3DS7500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gettinger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senzer, N. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martins, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lilenbaum, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hafeez, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grayzel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borger, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paez, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natale, R.</span><span> </span><span class="NLM_article-title">Activity of IPI-504, a novel Hsp90 inhibitor, in patients with molecularly defined non-small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">4953</span><span class="NLM_x">–</span> <span class="NLM_lpage">4960</span><span class="refDoi"> DOI: 10.1200/JCO.2010.30.8338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1200%2FJCO.2010.30.8338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=20940188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFCntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=4953-4960&author=L.+V.+Sequistauthor=S.+Gettingerauthor=N.+N.+Senzerauthor=R.+G.+Martinsauthor=P.+A.+J%C3%A4nneauthor=R.+Lilenbaumauthor=J.+E.+Grayauthor=A.+J.+Iafrateauthor=R.+Katayamaauthor=N.+Hafeezauthor=J.+Sweeneyauthor=J.+R.+Walkerauthor=C.+Fritzauthor=R.+W.+Rossauthor=D.+Grayzelauthor=J.+A.+Engelmanauthor=D.+R.+Borgerauthor=G.+Paezauthor=R.+Natale&title=Activity+of+IPI-504%2C+a+novel+Hsp90+inhibitor%2C+in+patients+with+molecularly+defined+non-small-cell+lung+cancer&doi=10.1200%2FJCO.2010.30.8338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer</span></div><div class="casAuthors">Sequist, Lecia V.; Gettinger, Scott; Senzer, Neil N.; Martins, Renato G.; Janne, Pasi A.; Lilenbaum, Rogerio; Gray, Jhanelle E.; Iafrate, A. John; Katayama, Ryohei; Hafeez, Nafeeza; Sweeney, Jennifer; Walker, John R.; Fritz, Christian; Ross, Robert W.; Grayzel, David; Engelman, Jeffrey A.; Borger, Darrell R.; Paez, Guillermo; Natale, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">4953-4960</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: IPI-504 is a novel, water-sol., potent inhibitor of heat-shock protein 90 (Hsp90).  Its potential anticancer activity has been validated in preclin. in vitro and in vivo models.  We studied the activity of IPI-504 after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced, molecularly defined non-small-cell lung cancer (NSCLC).  Patients and Methods: Patients with advanced NSCLC, prior treatment with EGFR TKIs, and tumor tissue available for mol. genotyping were enrolled in this prospective, nonrandomized, multicenter, phase II study of IPI-504 monotherapy.  The primary outcome was objective response rate (ORR).  Secondary aims included safety, progression-free survival (PFS), and anal. of activity by mol. subtypes.  Results: Seventy-six patients were enrolled between Dec. 2007 and May 2009 from 10 United States cancer centers.  An ORR of 7% (five of 76) was obsd. in the overall study population, 10% (four of 40) in patients who were EGFR wild-type, and 4% (one of 28) in those with EGFR mutations.  Although both EGFR groups were below the target ORR of 20%, among the three patients with an ALK gene rearrangement, two had partial responses and the third had prolonged stable disease (7.2 mo, 24% redn. in tumor size).  The most common adverse events included grades 1 and 2 fatigue, nausea, and diarrhea.  Grade 3 or higher liver function abnormalities were obsd. in nine patients (11.8%).  Conclusion: IPI-504 has clin. activity in patients with NSCLC, particularly among patients with ALK rearrangements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyleDQqYi1qLVg90H21EOLACvtfcHk0lg33xd0WipWxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFCntA%253D%253D&md5=accaddc9ab9e334d40d513a70fbcd9ed</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.30.8338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.30.8338%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DGettinger%26aufirst%3DS.%26aulast%3DSenzer%26aufirst%3DN.%2BN.%26aulast%3DMartins%26aufirst%3DR.%2BG.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DLilenbaum%26aufirst%3DR.%26aulast%3DGray%26aufirst%3DJ.%2BE.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DHafeez%26aufirst%3DN.%26aulast%3DSweeney%26aufirst%3DJ.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DFritz%26aufirst%3DC.%26aulast%3DRoss%26aufirst%3DR.%2BW.%26aulast%3DGrayzel%26aufirst%3DD.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DBorger%26aufirst%3DD.%2BR.%26aulast%3DPaez%26aufirst%3DG.%26aulast%3DNatale%26aufirst%3DR.%26atitle%3DActivity%2520of%2520IPI-504%252C%2520a%2520novel%2520Hsp90%2520inhibitor%252C%2520in%2520patients%2520with%2520molecularly%2520defined%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D4953%26epage%3D4960%26doi%3D10.1200%2FJCO.2010.30.8338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span>Data were obtained from the Thomson Reuters Cortellis at <a href="http://lifesciences.thomsonreuters.com/products/cortellis" class="extLink">http://lifesciences.thomsonreuters.com/products/cortellis</a> (accessed on August 1,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Data+were+obtained+from+the+Thomson+Reuters+Cortellis+at+http%3A%2F%2Flifesciences.thomsonreuters.com%2Fproducts%2Fcortellis+%28accessed+on+August+1%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Socinski, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Hariry, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koczywas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vukovic, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paschold, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonomi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brahmer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belani, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huberman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramalingam, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teofilovici, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span> </span><span class="NLM_article-title">A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3068</span><span class="NLM_x">–</span> <span class="NLM_lpage">3077</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-3381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1078-0432.CCR-12-3381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=23553849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXos12isLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=3068-3077&author=M.+A.+Socinskiauthor=J.+Goldmanauthor=I.+El-Hariryauthor=M.+Koczywasauthor=V.+Vukovicauthor=L.+Hornauthor=E.+Pascholdauthor=R.+Salgiaauthor=H.+Westauthor=L.+V.+Sequistauthor=P.+Bonomiauthor=J.+Brahmerauthor=L.+C.+Chenauthor=A.+Sandlerauthor=C.+P.+Belaniauthor=T.+Webbauthor=H.+Harperauthor=M.+Hubermanauthor=S.+Ramalingamauthor=K.+K.+Wongauthor=F.+Teofiloviciauthor=W.+Guoauthor=G.+I.+Shapiro&title=A+multicenter+phase+II+study+of+ganetespib+monotherapy+in+patients+with+genotypically+defined+advanced+non-small+cell+lung+cancer&doi=10.1158%2F1078-0432.CCR-12-3381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Socinski, Mark A.; Goldman, Jonathan; El-Hariry, Iman; Koczywas, Marianna; Vukovic, Vojo; Horn, Leora; Paschold, Eugene; Salgia, Ravi; West, Howard; Sequist, Lecia V.; Bonomi, Philip; Brahmer, Julie; Chen, Lin-Chi; Sandler, Alan; Belani, Chandra P.; Webb, Timothy; Harper, Harry; Huberman, Mark; Ramalingam, Suresh; Wong, Kwok-Kin; Teofilovici, Florentina; Guo, Wei; Shapiro, Geoffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3068-3077</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Ganetespib is a novel inhibitor of the heat shock protein 90 (Hsp90), a chaperone protein crit. to tumor growth and proliferation.  In this phase II study, we evaluated the activity and tolerability of ganetespib in previously treated patients with non-small cell lung cancer (NSCLC).  Exptl. Design: Patients were enrolled into cohort A (mutant EGFR), B (mutant KRAS), or C (no EGFR or KRAS mutations).  Patients were treated with 200 mg/m2 ganetespib by i.v. infusion once weekly for 3 wk followed by 1 wk of rest, until disease progression.  The primary endpoint was progression-free survival (PFS) at 16 wk.  Secondary endpoints included objective response (ORR), duration of treatment, tolerability, median PFS, overall survival (OS), and correlative studies.  Results: Ninety-nine patients with a median of 2 prior systemic therapies were enrolled; 98 were assigned to cohort A (n = 15), B (n = 17), or C (n = 66), with PFS rates at 16 wk of 13.3%, 5.9%, and 19.7%, resp.  Four patients (4%) achieved partial response (PR); all had disease that harbored anaplastic lymphoma kinase (ALK) gene rearrangement, retrospectively detected by FISH (n = 1) or PCR-based assays (n = 3), in crizotinib-naive patients enrolled to cohort C. Eight patients (8.1%) experienced treatment-related serious adverse events (AE); 2 of these (cardiac arrest and renal failure) resulted in death.  The most common AEs were diarrhea, fatigue, nausea, and anorexia.  Conclusions: Ganetespib monotherapy showed a manageable side effect profile as well as clin. activity in heavily pretreated patients with advanced NSCLCs, particularly in patients with tumors harboring ALK gene rearrangement.  Clin Cancer Res; 19(11); 3068-77. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFukeZlyNCmbVg90H21EOLACvtfcHk0lg0GwxETlHUhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXos12isLw%253D&md5=7fe5177633a6f003a7412431e6fb492d</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-3381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-3381%26sid%3Dliteratum%253Aachs%26aulast%3DSocinski%26aufirst%3DM.%2BA.%26aulast%3DGoldman%26aufirst%3DJ.%26aulast%3DEl-Hariry%26aufirst%3DI.%26aulast%3DKoczywas%26aufirst%3DM.%26aulast%3DVukovic%26aufirst%3DV.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DPaschold%26aufirst%3DE.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DWest%26aufirst%3DH.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DBonomi%26aufirst%3DP.%26aulast%3DBrahmer%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DL.%2BC.%26aulast%3DSandler%26aufirst%3DA.%26aulast%3DBelani%26aufirst%3DC.%2BP.%26aulast%3DWebb%26aufirst%3DT.%26aulast%3DHarper%26aufirst%3DH.%26aulast%3DHuberman%26aufirst%3DM.%26aulast%3DRamalingam%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DTeofilovici%26aufirst%3DF.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DA%2520multicenter%2520phase%2520II%2520study%2520of%2520ganetespib%2520monotherapy%2520in%2520patients%2520with%2520genotypically%2520defined%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D3068%26epage%3D3077%26doi%3D10.1158%2F1078-0432.CCR-12-3381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Garon, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlesi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groen, H. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smit, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akimov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avsar, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E. B.</span><span> </span><span class="NLM_article-title">Phase II study of the Hsp90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">7543</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=7543&issue=Suppl&author=E.+B.+Garonauthor=T.+Moranauthor=F.+Barlesiauthor=L.+Gandhiauthor=L.+V.+Sequistauthor=S.-W.+Kimauthor=H.+J.+M.+Groenauthor=B.+Besseauthor=E.+F.+Smitauthor=D.-W.+Kimauthor=M.+Akimovauthor=E.+Avsarauthor=S.+Baileyauthor=E.+B.+Felip&title=Phase+II+study+of+the+Hsp90+inhibitor+AUY922+in+patients+with+previously+treated%2C+advanced+non-small+cell+lung+cancer+%28NSCLC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGaron%26aufirst%3DE.%2BB.%26aulast%3DMoran%26aufirst%3DT.%26aulast%3DBarlesi%26aufirst%3DF.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DGroen%26aufirst%3DH.%2BJ.%2BM.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DSmit%26aufirst%3DE.%2BF.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DAkimov%26aufirst%3DM.%26aulast%3DAvsar%26aufirst%3DE.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DFelip%26aufirst%3DE.%2BB.%26atitle%3DPhase%2520II%2520study%2520of%2520the%2520Hsp90%2520inhibitor%2520AUY922%2520in%2520patients%2520with%2520previously%2520treated%252C%2520advanced%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26issue%3DSuppl%26spage%3D7543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Mahadevan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rensvold, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurtin, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleary, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lock, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G.</span><span> </span><span class="NLM_article-title">First-in-human phase I study: results of a second-generation non-ansamycin heat shock protein (Hsp90) inhibitor AT13387 in refractory solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">S3028</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=S3028&author=D.+Mahadevanauthor=D.+M.+Rensvoldauthor=S.+E.+Kurtinauthor=J.+M.+Clearyauthor=L.+Gandhiauthor=J.+F.+Lyonsauthor=V.+Lockauthor=S.+Lewisauthor=G.+Shapiro&title=First-in-human+phase+I+study%3A+results+of+a+second-generation+non-ansamycin+heat+shock+protein+%28Hsp90%29+inhibitor+AT13387+in+refractory+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMahadevan%26aufirst%3DD.%26aulast%3DRensvold%26aufirst%3DD.%2BM.%26aulast%3DKurtin%26aufirst%3DS.%2BE.%26aulast%3DCleary%26aufirst%3DJ.%2BM.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DLyons%26aufirst%3DJ.%2BF.%26aulast%3DLock%26aufirst%3DV.%26aulast%3DLewis%26aufirst%3DS.%26aulast%3DShapiro%26aufirst%3DG.%26atitle%3DFirst-in-human%2520phase%2520I%2520study%253A%2520results%2520of%2520a%2520second-generation%2520non-ansamycin%2520heat%2520shock%2520protein%2520%2528Hsp90%2529%2520inhibitor%2520AT13387%2520in%2520refractory%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3DS3028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Nguyen, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, D. B.</span><span> </span><span class="NLM_article-title">Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway</span> <span class="citation_source-journal">Clin. Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">281</span><span class="NLM_x">–</span> <span class="NLM_lpage">289</span><span class="refDoi"> DOI: 10.3816/CLC.2009.n.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.3816%2FCLC.2009.n.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=19632948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVSms7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=281-289&author=K.+S.+Nguyenauthor=S.+Kobayashiauthor=D.+B.+Costa&title=Acquired+resistance+to+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+in+non-small-cell+lung+cancers+dependent+on+the+epidermal+growth+factor+receptor+pathway&doi=10.3816%2FCLC.2009.n.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway</span></div><div class="casAuthors">Nguyen, Kim-Son H.; Kobayashi, Susumu; Costa, Daniel B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Lung Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">281-289</span>CODEN:
                <span class="NLM_cas:coden">CLCLCA</span>;
        ISSN:<span class="NLM_cas:issn">1525-7304</span>.
    
            (<span class="NLM_cas:orgname">CIG Media Group, LP</span>)
        </div><div class="casAbstract">A review.  Most advanced non-small-cell lung cancers (NSCLCs) with activating epidermal growth factor receptor (EGFR) mutations (exon 19 deletions or L858R) initially respond to the EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib.  However, over time (median of 6-12 mo), most tumors develop acquired resistance to EGFR TKIs.  Intense research in these NSCLCs has identified two major mechanisms of resistance to gefitinib/erlotinib: secondary resistance mutations and "oncogene kinase switch" systems.  The secondary T790M mutation occurs in 50% of EGFR-mutated patients with TKI resistance, and in vitro, this mutation negates the hypersensitivity of activating EGFR mutations.  Sensitive detection methods have identified a proportion of TKI-naive tumors that carry T790M, and these resistant clones may be selected after exposure to gefitinib or erlotinib.  Other secondary resistance mutations (D761Y, L747S, T854A) seem to be rare.  The amplification of the MET oncogene is present in 20% of TKI-resistant tumors; however, in half of the cases with this "oncogene kinase switch" mechanism the T790M is coexistent.  It is possible that other kinases (such as insulin-like growth factor-1 receptor [IGF-1R]) might also be selected to bypass EGFR pathways in resistant tumors.  The growing preclin. data in EGFR-mutated NSCLCs with acquired resistance to gefitinib or erlotinib has spawned the initiation or conception of clin. trials testing novel EGFR inhibitors that in vitro inhibit T790M (neratinib, XL647, BIBW 2992, and PF-00299804), MET, or IGF-1R inhibitors in combination with EGFR TKIs, and heat shock protein 90 inhibitors.  Ongoing preclin. and clin. research in EGFR-mutated NSCLC has the potential to significantly improve the outcomes of patients with these somatic mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzBC9bsn7YdrVg90H21EOLACvtfcHk0lijlFDZnIVk_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVSms7bO&md5=3522508ea4f2761e4dcedea18d914fe7</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.3816%2FCLC.2009.n.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3816%252FCLC.2009.n.039%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DK.%2BS.%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26atitle%3DAcquired%2520resistance%2520to%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520in%2520non-small-cell%2520lung%2520cancers%2520dependent%2520on%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520pathway%26jtitle%3DClin.%2520Lung%2520Cancer%26date%3D2009%26volume%3D10%26spage%3D281%26epage%3D289%26doi%3D10.3816%2FCLC.2009.n.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Pines, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Köstler, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yarden, Y.</span><span> </span><span class="NLM_article-title">Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy</span> <span class="citation_source-journal">FEBS Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">584</span><span class="NLM_x">, </span> <span class="NLM_fpage">2699</span><span class="NLM_x">–</span> <span class="NLM_lpage">2706</span><span class="refDoi"> DOI: 10.1016/j.febslet.2010.04.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.febslet.2010.04.019" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=584&publication_year=2010&pages=2699-2706&author=G.+Pinesauthor=W.+J.+K%C3%B6stlerauthor=Y.+Yarden&title=Oncogenic+mutant+forms+of+EGFR%3A+lessons+in+signal+transduction+and+targets+for+cancer+therapy&doi=10.1016%2Fj.febslet.2010.04.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.febslet.2010.04.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.febslet.2010.04.019%26sid%3Dliteratum%253Aachs%26aulast%3DPines%26aufirst%3DG.%26aulast%3DK%25C3%25B6stler%26aufirst%3DW.%2BJ.%26aulast%3DYarden%26aufirst%3DY.%26atitle%3DOncogenic%2520mutant%2520forms%2520of%2520EGFR%253A%2520lessons%2520in%2520signal%2520transduction%2520and%2520targets%2520for%2520cancer%2520therapy%26jtitle%3DFEBS%2520Lett.%26date%3D2010%26volume%3D584%26spage%3D2699%26epage%3D2706%26doi%3D10.1016%2Fj.febslet.2010.04.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Sawai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandarlapaty, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arteaga, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D. B.</span><span> </span><span class="NLM_article-title">Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">589</span><span class="NLM_x">–</span> <span class="NLM_lpage">596</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-1570</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F0008-5472.CAN-07-1570" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=589-596&author=A.+Sawaiauthor=S.+Chandarlapatyauthor=H.+Greulichauthor=M.+Gonenauthor=Q.+Yeauthor=C.+L.+Arteagaauthor=W.+Sellersauthor=N.+Rosenauthor=D.+B.+Solit&title=Inhibition+of+Hsp90+down-regulates+mutant+epidermal+growth+factor+receptor+%28EGFR%29+expression+and+sensitizes+EGFR+mutant+tumors+to+paclitaxel&doi=10.1158%2F0008-5472.CAN-07-1570"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-1570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-1570%26sid%3Dliteratum%253Aachs%26aulast%3DSawai%26aufirst%3DA.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DGonen%26aufirst%3DM.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26aulast%3DSellers%26aufirst%3DW.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26atitle%3DInhibition%2520of%2520Hsp90%2520down-regulates%2520mutant%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520expression%2520and%2520sensitizes%2520EGFR%2520mutant%2520tumors%2520to%2520paclitaxel%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D589%26epage%3D596%26doi%3D10.1158%2F0008-5472.CAN-07-1570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liniker, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgman, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perera, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaghlul, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G.</span><span> </span><span class="NLM_article-title">Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">5827</span><span class="NLM_x">–</span> <span class="NLM_lpage">5838</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-5428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F0008-5472.CAN-07-5428" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=5827-5838&author=T.+Shimamuraauthor=D.+Liauthor=H.+Jiauthor=H.+J.+Haringsmaauthor=E.+Linikerauthor=C.+L.+Borgmanauthor=A.+M.+Lowellauthor=Y.+Minamiauthor=K.+McNamaraauthor=S.+A.+Pereraauthor=S.+Zaghlulauthor=R.+K.+Thomasauthor=H.+Greulichauthor=S.+Kobayashiauthor=L.+R.+Chirieacauthor=R.+F.+Paderaauthor=S.+Kuboauthor=M.+Takahashiauthor=D.+G.+Tenenauthor=M.+Meyersonauthor=K.-K.+Wongauthor=G.+Shapiro&title=Hsp90+inhibition+suppresses+mutant+EGFR-T790M+signaling+and+overcomes+kinase+inhibitor+resistance&doi=10.1158%2F0008-5472.CAN-07-5428"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-5428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-5428%26sid%3Dliteratum%253Aachs%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DLiniker%26aufirst%3DE.%26aulast%3DBorgman%26aufirst%3DC.%2BL.%26aulast%3DLowell%26aufirst%3DA.%2BM.%26aulast%3DMinami%26aufirst%3DY.%26aulast%3DMcNamara%26aufirst%3DK.%26aulast%3DPerera%26aufirst%3DS.%2BA.%26aulast%3DZaghlul%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DPadera%26aufirst%3DR.%2BF.%26aulast%3DKubo%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DShapiro%26aufirst%3DG.%26atitle%3DHsp90%2520inhibition%2520suppresses%2520mutant%2520EGFR-T790M%2520signaling%2520and%2520overcomes%2520kinase%2520inhibitor%2520resistance%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D5827%26epage%3D5838%26doi%3D10.1158%2F0008-5472.CAN-07-5428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Ying, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proia, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackman, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatsuta, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acquaviva, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barsoum, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koya, K.</span><span> </span><span class="NLM_article-title">Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">475</span><span class="NLM_x">–</span> <span class="NLM_lpage">484</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0755</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1535-7163.MCT-11-0755" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22144665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFWksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=475-484&author=W.+Yingauthor=Z.+Duauthor=L.+Sunauthor=K.+P.+Foleyauthor=D.+A.+Proiaauthor=R.+K.+Blackmanauthor=D.+Zhouauthor=T.+Inoueauthor=N.+Tatsutaauthor=J.+Sangauthor=S.+Yeauthor=J.+Acquavivaauthor=L.+S.+Ogawaauthor=Y.+Wadaauthor=J.+Barsoumauthor=K.+Koya&title=Ganetespib%2C+a+unique+triazolone-containing+Hsp90+inhibitor%2C+exhibits+potent+antitumor+activity+and+a+superior+safety+profile+for+cancer+therapy&doi=10.1158%2F1535-7163.MCT-11-0755"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy</span></div><div class="casAuthors">Ying, Weiwen; Du, Zhenjian; Sun, Lijun; Foley, Kevin P.; Proia, David A.; Blackman, Ronald K.; Zhou, Dan; Inoue, Takayo; Tatsuta, Noriaki; Sang, Jim; Ye, Shuxia; Acquaviva, Jamie; Ogawa, Luisa Shin; Wada, Yumiko; Barsoum, James; Koya, Keizo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">475-484</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Targeted inhibition of the mol. chaperone Hsp90 results in the simultaneous blockade of multiple oncogenic signaling pathways and has, thus, emerged as an attractive strategy for the development of novel cancer therapeutics.  Ganetespib (formerly known as STA-9090) is a unique resorcinolic triazolone inhibitor of Hsp90 that is currently in clin. trials for a no. of human cancers.  In the present study, we showed that ganetespib exhibits potent in vitro cytotoxicity in a range of solid and hematol. tumor cell lines, including those that express mutated kinases that confer resistance to small-mol. tyrosine kinase inhibitors.  Ganetespib treatment rapidly induced the degrdn. of known Hsp90 client proteins, displayed superior potency to the ansamycin inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG), and exhibited sustained activity even with short exposure times.  In vivo, ganetespib showed potent antitumor efficacy in solid and hematol. xenograft models of oncogene addiction, as evidenced by significant growth inhibition and/or regressions.  Notably, evaluation of the microregional activity of ganetespib in tumor xenografts showed that ganetespib was efficiently distributed throughout tumor tissue, including hypoxic regions >150 μm from the microvasculature, to inhibit proliferation and induce apoptosis.  Importantly, ganetespib showed no evidence of cardiac or liver toxicity.  Taken together, this preclin. activity profile indicates that ganetespib may have broad application for a variety of human malignancies, and with select mechanistic and safety advantages over other first- and second-generation Hsp90 inhibitors.  Mol Cancer Ther; 11(2); 475-84.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFhzG1TPr4lbVg90H21EOLACvtfcHk0lgEuYAB0vhFyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFWksrY%253D&md5=269d41b30e5add9b9503cb43a98b0157</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0755%26sid%3Dliteratum%253Aachs%26aulast%3DYing%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DFoley%26aufirst%3DK.%2BP.%26aulast%3DProia%26aufirst%3DD.%2BA.%26aulast%3DBlackman%26aufirst%3DR.%2BK.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DTatsuta%26aufirst%3DN.%26aulast%3DSang%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DS.%26aulast%3DAcquaviva%26aufirst%3DJ.%26aulast%3DOgawa%26aufirst%3DL.%2BS.%26aulast%3DWada%26aufirst%3DY.%26aulast%3DBarsoum%26aufirst%3DJ.%26aulast%3DKoya%26aufirst%3DK.%26atitle%3DGanetespib%252C%2520a%2520unique%2520triazolone-containing%2520Hsp90%2520inhibitor%252C%2520exhibits%2520potent%2520antitumor%2520activity%2520and%2520a%2520superior%2520safety%2520profile%2520for%2520cancer%2520therapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D475%26epage%3D484%26doi%3D10.1158%2F1535-7163.MCT-11-0755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Proia, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequeira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackman, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wada, Y.</span><span> </span><span class="NLM_article-title">Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2201</span><span class="NLM_x">–</span> <span class="NLM_lpage">2209</span><span class="refDoi"> DOI: 10.1007/s10637-011-9790-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1007%2Fs10637-011-9790-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=2201-2209&author=D.+A.+Proiaauthor=J.+Sangauthor=S.+Heauthor=D.+L.+Smithauthor=M.+Sequeiraauthor=C.+Zhangauthor=Y.+Liuauthor=S.+Yeauthor=D.+Zhouauthor=R.+K.+Blackmanauthor=K.+P.+Foleyauthor=K.+Koyaauthor=Y.+Wada&title=Synergistic+activity+of+the+Hsp90+inhibitor+ganetespib+with+taxanes+in+non-small+cell+lung+cancer+models&doi=10.1007%2Fs10637-011-9790-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1007%2Fs10637-011-9790-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-011-9790-6%26sid%3Dliteratum%253Aachs%26aulast%3DProia%26aufirst%3DD.%2BA.%26aulast%3DSang%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DD.%2BL.%26aulast%3DSequeira%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DBlackman%26aufirst%3DR.%2BK.%26aulast%3DFoley%26aufirst%3DK.%2BP.%26aulast%3DKoya%26aufirst%3DK.%26aulast%3DWada%26aufirst%3DY.%26atitle%3DSynergistic%2520activity%2520of%2520the%2520Hsp90%2520inhibitor%2520ganetespib%2520with%2520taxanes%2520in%2520non-small%2520cell%2520lung%2520cancer%2520models%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2012%26volume%3D30%26spage%3D2201%26epage%3D2209%26doi%3D10.1007%2Fs10637-011-9790-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Smith, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acquaviva, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequeira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimenez, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bates, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proia, D. A.</span><span> </span><span class="NLM_article-title">The Hsp90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer</span> <span class="citation_source-journal">Target Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">245</span><span class="refDoi"> DOI: 10.1007/s11523-014-0329-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1007%2Fs11523-014-0329-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=25077897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A280%3ADC%252BC2cbntlOktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=235-245&author=D.+L.+Smithauthor=J.+Acquavivaauthor=M.+Sequeiraauthor=J.+P.+Jimenezauthor=C.+Zhangauthor=J.+Sangauthor=R.+C.+Batesauthor=D.+A.+Proia&title=The+Hsp90+inhibitor+ganetespib+potentiates+the+antitumor+activity+of+EGFR+tyrosine+kinase+inhibition+in+mutant+and+wild-type+non-small+cell+lung+cancer&doi=10.1007%2Fs11523-014-0329-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer</span></div><div class="casAuthors">Smith Donald L; Acquaviva Jaime; Sequeira Manuel; Jimenez John-Paul; Zhang Chaohua; Sang Jim; Bates Richard C; Proia David A</div><div class="citationInfo"><span class="NLM_cas:title">Targeted oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">235-45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Small molecule inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase activity, such as erlotinib and gefitinib, revolutionized therapy for non-small cell lung cancer (NSCLC) patients whose tumors harbor activating EGFR mutations.  However, mechanisms to overcome the invariable development of acquired resistance to such agents, as well as realizing their full clinical potential within the context of wild-type EGFR (WT-EGFR) disease, remain to be established.  Here, the antitumor efficacy of targeted EGFR tyrosine kinase inhibitors (TKIs) and the HSP90 inhibitor ganetespib, alone and in combination, were evaluated in NSCLC.  Ganetespib potentiated the efficacy of erlotinib in TKI-sensitive, mutant EGFR-driven NCI-HCC827 xenograft tumors, with combination treatment causing significant tumor regressions.  In erlotinib-resistant NCI-H1975 xenografts, concurrent administration of ganetespib overcame erlotinib resistance to significantly improve tumor growth inhibition.  Ganetespib co-treatment also significantly enhanced antitumor responses to afatinib in the same model.  In WT-EGFR cell lines, ganetespib potently reduced cell viability.  In NCI-H1666 cells, ganetespib-induced loss of client protein expression, perturbation of oncogenic signaling pathways, and induction of apoptosis translated to robust single-agent activity in vivo.  Dual ganetespib/erlotinib therapy induced regressions in NCI-H322 xenograft tumors, indicating that the sensitizing properties of ganetespib for erlotinib were conserved within the WT-EGFR setting.  Mechanistically, combined ganetespib/erlotinib exposure stabilized EGFR protein levels in an inactive state and completely abrogated extracellular-signal-regulated kinase (ERK) and AKT signaling activity.  Thus, selective HSP90 blockade by ganetespib represents a potentially important complementary strategy to targeted TKI inhibition alone for inducing substantial antitumor responses and overcoming resistance, in both the mutant and WT-EGFR settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR7Z4-ACfup-svLc4ARHEmzfW6udTcc2eZkWlq69fbR6bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbntlOktg%253D%253D&md5=f198433a45b62102e3a9fb3e0a063f94</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1007%2Fs11523-014-0329-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-014-0329-6%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BL.%26aulast%3DAcquaviva%26aufirst%3DJ.%26aulast%3DSequeira%26aufirst%3DM.%26aulast%3DJimenez%26aufirst%3DJ.%2BP.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DSang%26aufirst%3DJ.%26aulast%3DBates%26aufirst%3DR.%2BC.%26aulast%3DProia%26aufirst%3DD.%2BA.%26atitle%3DThe%2520Hsp90%2520inhibitor%2520ganetespib%2520potentiates%2520the%2520antitumor%2520activity%2520of%2520EGFR%2520tyrosine%2520kinase%2520inhibition%2520in%2520mutant%2520and%2520wild-type%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DTarget%2520Oncol.%26date%3D2015%26volume%3D10%26spage%3D235%26epage%3D245%26doi%3D10.1007%2Fs11523-014-0329-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Rice, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barabasz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fadden, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steed, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S.</span><span> </span><span class="NLM_article-title">Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib</span> <span class="citation_source-journal">Oncol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">229</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span><span class="refDoi"> DOI: 10.3727/096504009X12596189659240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.3727%2F096504009X12596189659240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=20225761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivFaisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=229-242&author=J.+W.+Riceauthor=J.+M.+Vealauthor=A.+Barabaszauthor=B.+Foleyauthor=P.+Faddenauthor=A.+Scottauthor=K.+Huangauthor=P.+Steedauthor=S.+Hall&title=Targeting+of+multiple+signaling+pathways+by+the+Hsp90+inhibitor+SNX-2112+in+EGFR+resistance+models+as+a+single+agent+or+in+combination+with+erlotinib&doi=10.3727%2F096504009X12596189659240"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib</span></div><div class="casAuthors">Rice, John W.; Veal, James M.; Barabasz, Amy; Foley, Briana; Fadden, Patrick; Scott, Anisa; Huang, Ken; Steed, Paul; Hall, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5/6</span>),
    <span class="NLM_cas:pages">229-242</span>CODEN:
                <span class="NLM_cas:coden">ONREE8</span>;
        ISSN:<span class="NLM_cas:issn">0965-0407</span>.
    
            (<span class="NLM_cas:orgname">Cognizant Communications Corp.</span>)
        </div><div class="casAbstract">Inhibition of Hsp90 has emerged as a therapeutic strategy to target NSCLC subtypes, which are refractory to epidermal growth factor receptor (EGFR) inhibitor-based treatment.  We report on a novel small mol. inhibitor of Hsp90, SNX-2112, and an orally bioavailable prodrug analog, SNX-5422.  In cellular models of wild-type or mutant EGFR (L858R and T790M mutations), SNX-2112 alone and in combination with erlotinib inhibited EGF activation of pAKT(473) and pSTAT3(705).  PERK1/2 and pS6 were also potently inhibited by similar treatments.  SNX-2112 reduced EGF cross-talk and activation of the c-Met receptor by causing c-Met degrdn.  In NCI-H1975 xenograft models, SNX-5422 showed activity as a single agent and in combination with erlotinib resulted in prolonged animal survival at reduced compd. concns. relative to either compd. alone.  These results support the advanced evaluation of SNX-5422 as a treatment for non-small cell lung cancer (NSCLC), esp. in cases where the cancer is driven by c-Met amplification or mutated EGFR forms that are resistant to EGFR inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFgrvd_hLObbVg90H21EOLACvtfcHk0lh_RzEoqyMl2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivFaisr8%253D&md5=30c4a56819cd7f368dd61b7f61ca9c63</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.3727%2F096504009X12596189659240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3727%252F096504009X12596189659240%26sid%3Dliteratum%253Aachs%26aulast%3DRice%26aufirst%3DJ.%2BW.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DBarabasz%26aufirst%3DA.%26aulast%3DFoley%26aufirst%3DB.%26aulast%3DFadden%26aufirst%3DP.%26aulast%3DScott%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DK.%26aulast%3DSteed%26aufirst%3DP.%26aulast%3DHall%26aufirst%3DS.%26atitle%3DTargeting%2520of%2520multiple%2520signaling%2520pathways%2520by%2520the%2520Hsp90%2520inhibitor%2520SNX-2112%2520in%2520EGFR%2520resistance%2520models%2520as%2520a%2520single%2520agent%2520or%2520in%2520combination%2520with%2520erlotinib%26jtitle%3DOncol.%2520Res.%26date%3D2009%26volume%3D18%26spage%3D229%26epage%3D242%26doi%3D10.3727%2F096504009X12596189659240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Ono, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mio, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondoh, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, Y.</span><span> </span><span class="NLM_article-title">Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">1346</span><span class="NLM_x">–</span> <span class="NLM_lpage">1352</span><span class="refDoi"> DOI: 10.1111/cas.12237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1111%2Fcas.12237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=23863134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFOgs7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2013&pages=1346-1352&author=N.+Onoauthor=T.+Yamazakiauthor=T.+Tsukaguchiauthor=T.+Fujiiauthor=K.+Sakataauthor=A.+Sudaauthor=T.+Tsukudaauthor=T.+Mioauthor=N.+Ishiiauthor=O.+Kondohauthor=Y.+Aoki&title=Enhanced+antitumor+activity+of+erlotinib+in+combination+with+the+Hsp90+inhibitor+CH5164840+against+non-small-cell+lung+cancer&doi=10.1111%2Fcas.12237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer</span></div><div class="casAuthors">Ono, Naomi; Yamazaki, Toshikazu; Tsukaguchi, Toshiyuki; Fujii, Toshihiko; Sakata, Kiyoaki; Suda, Atsushi; Tsukuda, Takuo; Mio, Toshiyuki; Ishii, Nobuya; Kondoh, Osamu; Aoki, Yuko</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1346-1352</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Inhibition of heat shock protein 90 (Hsp90) can lead to degrdn. of multiple client proteins, which are involved in tumor progression.  Epidermal growth factor receptor (EGFR) is one of the most potent oncogenic client proteins of Hsp90.  Targeted inhibition of EGFR has shown clin. efficacy in the treatment of patients with non-small-cell lung cancer (NSCLC).  However, primary and acquired resistance to the existing EGFR inhibitors is a major clin. problem.  In the present study, we investigated the effect of the novel Hsp90 inhibitor CH5164840 on the antitumor activity of erlotinib.  The NSCLC cell lines and xenograft models were treated with CH5164840 and erlotinib to examine their mechanisms of action and cell growth inhibition.  We found that CH5164840 showed remarkable antitumor activity against NSCLC cell lines and xenograft models.  The addn. of CH5164840 enhanced the antitumor activity of erlotinib against NCI-H292 EGFR-overexpressing xenograft models.  Phosphorylation of Stat3 increased with erlotinib treatment in NCI-H292 cells, which was abrogated by Hsp90 inhibition.  Furthermore, in a NCI-H1975 T790M mutation erlotinib-resistant model, CH5164840 enhanced the antitumor activity of erlotinib despite the low efficacy of erlotinib treatment alone.  In addn., ERK signaling was effectively suppressed by combination treatment with erlotinib and CH5164840 in a NCI-H1975 erlotinib-resistant model.  Taken together, these data indicate that CH5164840 has potent antitumor activity and is highly effective in combination with erlotinib against NSCLC tumors with EGFR overexpression and mutations.  Our results support the therapeutic potential of CH5164840 as a Hsp90 inhibitor for combination therapy with EGFR-targeting agents against EGFR-addicted NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3CT9qZgpeRrVg90H21EOLACvtfcHk0lh_RzEoqyMl2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFOgs7rL&md5=c967fa4d51e33b73e5eee8a668ede13f</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1111%2Fcas.12237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.12237%26sid%3Dliteratum%253Aachs%26aulast%3DOno%26aufirst%3DN.%26aulast%3DYamazaki%26aufirst%3DT.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DFujii%26aufirst%3DT.%26aulast%3DSakata%26aufirst%3DK.%26aulast%3DSuda%26aufirst%3DA.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DMio%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DKondoh%26aufirst%3DO.%26aulast%3DAoki%26aufirst%3DY.%26atitle%3DEnhanced%2520antitumor%2520activity%2520of%2520erlotinib%2520in%2520combination%2520with%2520the%2520Hsp90%2520inhibitor%2520CH5164840%2520against%2520non-small-cell%2520lung%2520cancer%26jtitle%3DCancer%2520Sci.%26date%3D2013%26volume%3D104%26spage%3D1346%26epage%3D1352%26doi%3D10.1111%2Fcas.12237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Hong, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeong, C. H.</span><span> </span><span class="NLM_article-title">Hsp90 inhibition by WK88–1 potently suppresses the growth of gefitinib-resistant H1975 cells harboring the T790M mutation in EGFR</span> <span class="citation_source-journal">Oncol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">2619</span><span class="NLM_x">–</span> <span class="NLM_lpage">2624</span><span class="refDoi"> DOI: 10.3892/or.2014.3161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.3892%2For.2014.3161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=24789511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFKksbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2014&pages=2619-2624&author=Y.+S.+Hongauthor=W.+J.+Jangauthor=K.+S.+Chunauthor=C.+H.+Jeong&title=Hsp90+inhibition+by+WK88%E2%80%931+potently+suppresses+the+growth+of+gefitinib-resistant+H1975+cells+harboring+the+T790M+mutation+in+EGFR&doi=10.3892%2For.2014.3161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 inhibition by WK88-1 potently suppresses the growth of gefitinib-resistant H1975 cells harboring the T790M mutation in EGFR</span></div><div class="casAuthors">Hong, Young-Soo; Jang, Won-Jun; Chun, Kyung-Soo; Jeong, Chul-Ho</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2619-2624</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) is a mol. chaperone for numerous client proteins, many of which are crucial for the pathogenesis of non-small cell lung cancers (NSCLCs).  To date, therapeutic approaches using epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib or erlotinib for the treatment of NSCLCs have been limited due to the emergence of acquired drug resistance mainly mediated by a secondary T790M mutation in EGFR.  Considering this, Hsp90 inhibition seems promising as it leads to overall degrdn. of the oncogenic EGFR family proteins.  In this regard, the present study provides the preclin. basis for a new Hsp90 inhibitor, WK88-1, for the treatment of NSCLCs harboring the T790M mutation in EGFR.  Our data revealed that inhibition of Hsp90 by WK88-1 induced overall degrdn. of multiple oncogenic signaling mols. including EGFR, ErbB2 and ErbB3, leading to subsequent growth arrest and apoptosis in the gefitinib-resistant H1975 cell line.  In addn., treatment with WK88-1 markedly inhibited proliferation, migration and invasion in H1975 cells.  Moreover, an in vivo xenograft assay indicated that WK88-1 markedly suppressed tumor growth in the H1975 xenografts, highlighting the potential efficacy of WK88-1 for overcoming gefitinib resistance in NSCLCs harboring the T790M mutation in EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBz7z9J02-drVg90H21EOLACvtfcHk0lj8B0zrCHhZug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFKksbbN&md5=c00bebb182c68a267bccf268fd1e81bf</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.3892%2For.2014.3161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2014.3161%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DY.%2BS.%26aulast%3DJang%26aufirst%3DW.%2BJ.%26aulast%3DChun%26aufirst%3DK.%2BS.%26aulast%3DJeong%26aufirst%3DC.%2BH.%26atitle%3DHsp90%2520inhibition%2520by%2520WK88%25E2%2580%25931%2520potently%2520suppresses%2520the%2520growth%2520of%2520gefitinib-resistant%2520H1975%2520cells%2520harboring%2520the%2520T790M%2520mutation%2520in%2520EGFR%26jtitle%3DOncol.%2520Rep.%26date%3D2014%26volume%3D31%26spage%3D2619%26epage%3D2624%26doi%3D10.3892%2For.2014.3161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group">Kobayashi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyooka, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dote, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawasaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyoshi, S.</span><span> </span><span class="NLM_article-title">The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor</span> <span class="citation_source-journal">Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">166</span><span class="refDoi"> DOI: 10.1016/j.lungcan.2011.04.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.lungcan.2011.04.022" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2012&pages=161-166&author=N.+Kobayashiauthor=S.+Toyookaauthor=J.+Sohauthor=H.+Yamamotoauthor=H.+Doteauthor=K.+Kawasakiauthor=H.+Otaniauthor=T.+Kuboauthor=M.+Jidaauthor=T.+Uenoauthor=M.+Andoauthor=A.+Oginoauthor=K.+Kiuraauthor=S.+Miyoshi&title=The+anti-proliferative+effect+of+heat+shock+protein+90+inhibitor%2C+17-DMAG%2C+on+non-small-cell+lung+cancers+being+resistant+to+EGFR+tyrosine+kinase+inhibitor&doi=10.1016%2Fj.lungcan.2011.04.022"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2011.04.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2011.04.022%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DN.%26aulast%3DToyooka%26aufirst%3DS.%26aulast%3DSoh%26aufirst%3DJ.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DDote%26aufirst%3DH.%26aulast%3DKawasaki%26aufirst%3DK.%26aulast%3DOtani%26aufirst%3DH.%26aulast%3DKubo%26aufirst%3DT.%26aulast%3DJida%26aufirst%3DM.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DM.%26aulast%3DOgino%26aufirst%3DA.%26aulast%3DKiura%26aufirst%3DK.%26aulast%3DMiyoshi%26aufirst%3DS.%26atitle%3DThe%2520anti-proliferative%2520effect%2520of%2520heat%2520shock%2520protein%252090%2520inhibitor%252C%252017-DMAG%252C%2520on%2520non-small-cell%2520lung%2520cancers%2520being%2520resistant%2520to%2520EGFR%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DLung%2520Cancer%26date%3D2012%26volume%3D75%26spage%3D161%26epage%3D166%26doi%3D10.1016%2Fj.lungcan.2011.04.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">Hashida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shien, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtsuka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furukawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyoshi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanazawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyooka, S.</span><span> </span><span class="NLM_article-title">Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors</span> <span class="citation_source-journal">Oncol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1499</span><span class="NLM_x">–</span> <span class="NLM_lpage">1504</span><span class="refDoi"> DOI: 10.3892/or.2015.3735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.3892%2For.2015.3735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=25607753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A280%3ADC%252BC2MvotVyruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=1499-1504&author=S.+Hashidaauthor=H.+Yamamotoauthor=K.+Shienauthor=T.+Ohtsukaauthor=K.+Suzawaauthor=Y.+Makiauthor=M.+Furukawaauthor=J.+Sohauthor=H.+Asanoauthor=K.+Tsukudaauthor=S.+Miyoshiauthor=S.+Kanazawaauthor=S.+Toyooka&title=Hsp90+inhibitor+NVP-AUY922+enhances+the+radiation+sensitivity+of+lung+cancer+cell+lines+with+acquired+resistance+to+EGFR-tyrosine+kinase+inhibitors&doi=10.3892%2For.2015.3735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors</span></div><div class="casAuthors">Hashida Shinsuke; Yamamoto Hiromasa; Shien Kazuhiko; Ohtsuka Tomoaki; Suzawa Ken; Maki Yuho; Furukawa Masashi; Soh Junichi; Asano Hiroaki; Tsukuda Kazunori; Miyoshi Shinichiro; Toyooka Shinichi; Kanazawa Susumu</div><div class="citationInfo"><span class="NLM_cas:title">Oncology reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1499-504</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) is a critical issue that needs to be overcome in the treatment of patients with non-small cell lung cancer (NSCLC) harboring EGFR activating mutations.  EGFR and AKT are client proteins of the 90-kDa heat shock protein (Hsp90).  Therefore, it was hypothesized that the use of Hsp90 inhibitors might allow the resistance to EGFR-TKIs to be overcome.  Furthermore, Hsp90 inhibitors are known to function as radiosensitizers in various types of cancer.  In the present study, we evaluated the radiosensitizing effect of the novel Hsp90 inhibitor, NVP-AUY922 (AUY), on NSCLC cell lines harboring EGFR activating mutations and showing acquired resistance to EGFR-TKIs via any of several mechanisms.  We used HCC827 and PC-9, which are NSCLC cell lines harboring EGFR exon 19 deletions, and gefitinib-resistant sublines derived from the same cell lines with T790M mutation, MET amplification or stem-cell like properties.  AUY was more effective against the gefitinib-resistant sublines with T790M mutation and MET amplification than against the parental cell lines, although the subline with stem cell-like properties showed more than a 10-fold higher resistance to AUY than the parental cell line.  AUY exerted a significant radiosensitizing effect on the parental cell line and the MET-amplified subline through inducing G2/M arrest and inhibition of non-homologous end joining (NHEJ).  In contrast, the radiosensitizing effect of AUY was limited on the subline with stem cell-like properties, in which it did not induce G2/M arrest or inhibition of NHEJ.  In conclusion, combined inhibition of Hsp90 plus radiation was effective, and therefore a promising treatment alternative for overcoming major EGFR-TKI resistance, such as that induced by T790M mutation or MET amplification.  However, other approaches are required to overcome minor resistance to EGFR-TKIs, such as that observed in cells with stem cell-like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQr_6qrIy_OsApJitSxOdIlfW6udTcc2ebZSmGUR4JAebntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvotVyruw%253D%253D&md5=6bc40e1827240f1c4a0384bf7e297aaf</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.3892%2For.2015.3735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2015.3735%26sid%3Dliteratum%253Aachs%26aulast%3DHashida%26aufirst%3DS.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DShien%26aufirst%3DK.%26aulast%3DOhtsuka%26aufirst%3DT.%26aulast%3DSuzawa%26aufirst%3DK.%26aulast%3DMaki%26aufirst%3DY.%26aulast%3DFurukawa%26aufirst%3DM.%26aulast%3DSoh%26aufirst%3DJ.%26aulast%3DAsano%26aufirst%3DH.%26aulast%3DTsukuda%26aufirst%3DK.%26aulast%3DMiyoshi%26aufirst%3DS.%26aulast%3DKanazawa%26aufirst%3DS.%26aulast%3DToyooka%26aufirst%3DS.%26atitle%3DHsp90%2520inhibitor%2520NVP-AUY922%2520enhances%2520the%2520radiation%2520sensitivity%2520of%2520lung%2520cancer%2520cell%2520lines%2520with%2520acquired%2520resistance%2520to%2520EGFR-tyrosine%2520kinase%2520inhibitors%26jtitle%3DOncol.%2520Rep.%26date%3D2015%26volume%3D33%26spage%3D1499%26epage%3D1504%26doi%3D10.3892%2For.2015.3735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group">Koizumi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, S.</span><span> </span><span class="NLM_article-title">Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1078</span><span class="NLM_x">–</span> <span class="NLM_lpage">1085</span><span class="refDoi"> DOI: 10.1097/JTO.0b013e3182519a2c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1097%2FJTO.0b013e3182519a2c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22592212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1aisb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1078-1085&author=H.+Koizumiauthor=T.+Yamadaauthor=S.+Takeuchiauthor=T.+Nakagawaauthor=K.+Kitaauthor=T.+Nakamuraauthor=K.+Matsumotoauthor=K.+Sudaauthor=T.+Mitsudomiauthor=S.+Yano&title=Hsp90+inhibition+overcomes+HGF-triggering+resistance+to+EGFR-TKIs+in+EGFR-mutant+lung+cancer+by+decreasing+client+protein+expression+and+angiogenesis&doi=10.1097%2FJTO.0b013e3182519a2c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis</span></div><div class="casAuthors">Koizumi, Hitomi; Yamada, Tadaaki; Takeuchi, Shinji; Nakagawa, Takayuki; Kita, Kenji; Nakamura, Takahiro; Matsumoto, Kunio; Suda, Kenichi; Mitsudomi, Tetsuya; Yano, Seiji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1078-1085</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-0864</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Introduction: The three major clin. relevant mechanisms of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR mutant lung cancer are a second mutation in the EGFR gene (T790M), Met amplification, and increased expression of hepatocyte growth factor (HGF).  Heat shock protein90 (Hsp90) is a 90 kDa mol. chaperone for proteins that include EGFR, Met, and echinoderm microtubule-assocd. proetin-like-4-the anaplastic lymphoma kinase.  Here, we detd. whether inhibition of Hsp90 could overcome HGF-triggered EGFR-TKI resistance in EGFR mutant lung cancer cells.  Methods: The effects of the Hsp90 inhibitor 17-demethoxygeldanamycin (17-DMAG) on the growth of lung cancer cells resistant to the EGFR-TKI were examd. in the presence and absence of HGF, and in cells transfected with the HGF gene in vitro and in vivo.  Results: EGFR-TKI erlotinib did not inhibit the growth of HGF-gene transfected Ma-1 (Ma-1/HGF) cells and H1975 cells, contg. the EGFR L858R and T790M mutations, resp.  Erlotinib also did not inhibit the growth of PC-9 and Ma-1 cells, with deletions in EGFR exon19, in the presence of HGF.  However, 17-DMAG induced apoptosis and markedly inhibited the growth of these cell lines, even in the presence of HGF.  This inhibition by 17-DMAG was assocd. with decreased expression of EGFR and Met in tumor cells.  An in vivo model of HGF-triggered erlotinib-resistance, which used Ma-1/HGF cells, showed that 17-DMAG markedly suppressed tumor growth by decreasing angiogenesis and increasing apoptosis.  Conclusions: Hsp90 inhibitors may overcome HGF-triggered resistance to EGFR-TKIs and may result in more successful treatment of patients with EGFR-mutant lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ_uwltpW9ErVg90H21EOLACvtfcHk0lhD5E4jCa6vAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1aisb%252FE&md5=49990a4e0826d5ae6629c8dfac7e4ea3</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1097%2FJTO.0b013e3182519a2c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0b013e3182519a2c%26sid%3Dliteratum%253Aachs%26aulast%3DKoizumi%26aufirst%3DH.%26aulast%3DYamada%26aufirst%3DT.%26aulast%3DTakeuchi%26aufirst%3DS.%26aulast%3DNakagawa%26aufirst%3DT.%26aulast%3DKita%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DSuda%26aufirst%3DK.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DYano%26aufirst%3DS.%26atitle%3DHsp90%2520inhibition%2520overcomes%2520HGF-triggering%2520resistance%2520to%2520EGFR-TKIs%2520in%2520EGFR-mutant%2520lung%2520cancer%2520by%2520decreasing%2520client%2520protein%2520expression%2520and%2520angiogenesis%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2012%26volume%3D7%26spage%3D1078%26epage%3D1085%26doi%3D10.1097%2FJTO.0b013e3182519a2c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group">Ramalingam, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaric, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceric, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poddubskaya, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciuleanu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khuri, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spicer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skrylnik, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manegold, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andric, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badovinac, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pieters, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modiano, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vukovic, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yalcin, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teofilovici, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">EI-Hariry, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahcall, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goss, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fennell, D.</span><span> </span><span class="NLM_article-title">GALAXY-1: randomized phase II study of docetaxel with or without ganetespib in advanced lung adenocarcinoma: results in biomarker sub-groups and all adenocarcinoma patients</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">S139</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=S139&author=S.+S.+Ramalingamauthor=G+Shapiroauthor=V.+Hirshauthor=B.+Zaricauthor=T.+Cericauthor=E.+Poddubskayaauthor=J.+Goldmanauthor=T.+Ciuleanuauthor=F.+R.+Khuriauthor=J.+Spicerauthor=O.+Skrylnikauthor=E.+Felipauthor=C.+Manegoldauthor=Z.+Andricauthor=R.+Rosellauthor=S.+Badovinacauthor=T.+Pietersauthor=M.+R.+Modianoauthor=V.+M.+Vukovicauthor=I.+Yalcinauthor=F.+Teofiloviciauthor=I.+EI-Hariryauthor=W.+Guoauthor=S.+R.+Bahcallauthor=G.+Gossauthor=D.+Fennell&title=GALAXY-1%3A+randomized+phase+II+study+of+docetaxel+with+or+without+ganetespib+in+advanced+lung+adenocarcinoma%3A+results+in+biomarker+sub-groups+and+all+adenocarcinoma+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DShapiro%26aufirst%3DG%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DZaric%26aufirst%3DB.%26aulast%3DCeric%26aufirst%3DT.%26aulast%3DPoddubskaya%26aufirst%3DE.%26aulast%3DGoldman%26aufirst%3DJ.%26aulast%3DCiuleanu%26aufirst%3DT.%26aulast%3DKhuri%26aufirst%3DF.%2BR.%26aulast%3DSpicer%26aufirst%3DJ.%26aulast%3DSkrylnik%26aufirst%3DO.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DManegold%26aufirst%3DC.%26aulast%3DAndric%26aufirst%3DZ.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DBadovinac%26aufirst%3DS.%26aulast%3DPieters%26aufirst%3DT.%26aulast%3DModiano%26aufirst%3DM.%2BR.%26aulast%3DVukovic%26aufirst%3DV.%2BM.%26aulast%3DYalcin%26aufirst%3DI.%26aulast%3DTeofilovici%26aufirst%3DF.%26aulast%3DEI-Hariry%26aufirst%3DI.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DBahcall%26aufirst%3DS.%2BR.%26aulast%3DGoss%26aufirst%3DG.%26aulast%3DFennell%26aufirst%3DD.%26atitle%3DGALAXY-1%253A%2520randomized%2520phase%2520II%2520study%2520of%2520docetaxel%2520with%2520or%2520without%2520ganetespib%2520in%2520advanced%2520lung%2520adenocarcinoma%253A%2520results%2520in%2520biomarker%2520sub-groups%2520and%2520all%2520adenocarcinoma%2520patients%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2013%26volume%3D8%26spage%3DS139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group">Garon, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlesi, F.</span><span> </span><span class="NLM_article-title">Phase II study of the Hsp90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">S7543</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=S7543&author=E.+B.+Garonauthor=T.+Moranauthor=F.+Barlesi&title=Phase+II+study+of+the+Hsp90+inhibitor+AUY922+in+patients+with+previously+treated%2C+advanced+non-small+cell+lung+cancer+%28NSCLC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGaron%26aufirst%3DE.%2BB.%26aulast%3DMoran%26aufirst%3DT.%26aulast%3DBarlesi%26aufirst%3DF.%26atitle%3DPhase%2520II%2520study%2520of%2520the%2520Hsp90%2520inhibitor%2520AUY922%2520in%2520patients%2520with%2520previously%2520treated%252C%2520advanced%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3DS7543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group">Johnson, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weitner, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rademaker, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span> </span><span class="NLM_article-title">Phase I/II study of Hsp90 inhibitor AUY922 and erlotinib for EGFR-mutant lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1666</span><span class="NLM_x">–</span> <span class="NLM_lpage">1673</span><span class="refDoi"> DOI: 10.1200/JCO.2014.59.7328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1200%2FJCO.2014.59.7328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=25870087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFarsLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=1666-1673&author=M.+L.+Johnsonauthor=H.+A.+Yuauthor=E.+M.+Hartauthor=B.+B.+Weitnerauthor=A.+W.+Rademakerauthor=J.+D.+Patelauthor=M.+G.+Krisauthor=G.+J.+Riely&title=Phase+I%2FII+study+of+Hsp90+inhibitor+AUY922+and+erlotinib+for+EGFR-mutant+lung+cancer+with+acquired+resistance+to+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors&doi=10.1200%2FJCO.2014.59.7328"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I/II study of HSP90 inhibitor AUY922 and erlotinib for EGFR-mutant lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors</span></div><div class="casAuthors">Johnson, Melissa L.; Yu, Helena A.; Hart, Eric M.; Weitner, Bing Bing; Rademaker, Alfred W.; Patel, Jyoti D.; Kris, Mark G.; Riely, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1666-1673</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose AUY922 is an HSP90 inhibitor that causes degrdn. of HSP chaperones and their client proteins, including epidermal growth factor receptor.  We conducted a phase I/II trial to evaluate AUY922 and erlotinib for patients with EGFR-mutant lung cancer and disease progression during erlotinib treatment.  Patients and Methods All patients had developed acquired resistance after treatment with erlotinib and underwent repeat tumor biopsies before study entry to assess for EGFR T790M.  In phase I, 18 patients were treated with AUY922 i.v. once per wk and erlotinib once per day in 28-day cycles using a 3 + 3 dose-escalation design.  In phase II, 19 addnl. patients were treated at the max.-tolerated dose.  The primary end point of the phase II trial was complete plus partial response rate.  Results In phase I (n = 18), three patients were treated in each cohort, except the highest-dose cohort (AUY922 70 mg and erlotinib 150 mg), which expanded to six patients because of a dose-limiting toxicity (ie, junctional cardiac rhythm).  Common drug-related adverse events were diarrhea, skin rash, hyperglycemia, and night blindness.  All patients treated at max.-tolerated dose (n = 25) were evaluable for response.  The partial response rate was 16% (four of 25 patients; 95% CI, 5% to 36%) and was independent of tumor T790M status.  Conclusion Partial responses were obsd., but the duration of treatment with AUY922 and erlotinib was limited by toxicities, esp. night blindness.  This phase II study of AUY922 and erlotinib did not meet its primary end point.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWsVjdo4lIfrVg90H21EOLACvtfcHk0lgSVMnAO2-kuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFarsLnM&md5=807c3e61ee5babe4c8994fd69e8888a4</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.59.7328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.59.7328%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DM.%2BL.%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DHart%26aufirst%3DE.%2BM.%26aulast%3DWeitner%26aufirst%3DB.%2BB.%26aulast%3DRademaker%26aufirst%3DA.%2BW.%26aulast%3DPatel%26aufirst%3DJ.%2BD.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26atitle%3DPhase%2520I%252FII%2520study%2520of%2520Hsp90%2520inhibitor%2520AUY922%2520and%2520erlotinib%2520for%2520EGFR-mutant%2520lung%2520cancer%2520with%2520acquired%2520resistance%2520to%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D1666%26epage%3D1673%26doi%3D10.1200%2FJCO.2014.59.7328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Johnson, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rademaker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weitner, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simm, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fountas, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worden, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span> </span><span class="NLM_article-title">A phase II study of Hsp90 inhibitor AUY922 and erlotinib (E) for patients (pts) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">S8036</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=S8036&author=M.+L.+Johnsonauthor=E.+M.+Hartauthor=A.+Rademakerauthor=B.+B.+Weitnerauthor=A.+Urmanauthor=H.+D.+Simmauthor=L.+M.+Fountasauthor=R.+Wordenauthor=J.+D.+Patelauthor=V.+A.+Millerauthor=G.+J.+Riely&title=A+phase+II+study+of+Hsp90+inhibitor+AUY922+and+erlotinib+%28E%29+for+patients+%28pts%29+with+EGFR-mutant+lung+cancer+and+acquired+resistance+%28AR%29+to+EGFR+tyrosine+kinase+inhibitors+%28EGFR+TKIs%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DM.%2BL.%26aulast%3DHart%26aufirst%3DE.%2BM.%26aulast%3DRademaker%26aufirst%3DA.%26aulast%3DWeitner%26aufirst%3DB.%2BB.%26aulast%3DUrman%26aufirst%3DA.%26aulast%3DSimm%26aufirst%3DH.%2BD.%26aulast%3DFountas%26aufirst%3DL.%2BM.%26aulast%3DWorden%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DJ.%2BD.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520Hsp90%2520inhibitor%2520AUY922%2520and%2520erlotinib%2520%2528E%2529%2520for%2520patients%2520%2528pts%2529%2520with%2520EGFR-mutant%2520lung%2520cancer%2520and%2520acquired%2520resistance%2520%2528AR%2529%2520to%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%2520%2528EGFR%2520TKIs%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3DS8036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Yu, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rademaker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weitner, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G.</span><span> </span><span class="NLM_article-title">A phase II study of Hsp90 inhibitor AUY922 and erlotinib (E) in patients with EGFR-mutant lung cancer and acquired resistance to EGFR tyrosine kinase inhibitors</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">S596</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=S596&author=H.+A.+Yuauthor=M.+L.+Johnsonauthor=A.+Urmanauthor=A.+Rademakerauthor=E.+Hartauthor=B.+B.+Weitnerauthor=J.+D.+Patelauthor=M.+Krisauthor=G.+Riely&title=A+phase+II+study+of+Hsp90+inhibitor+AUY922+and+erlotinib+%28E%29+in+patients+with+EGFR-mutant+lung+cancer+and+acquired+resistance+to+EGFR+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DJohnson%26aufirst%3DM.%2BL.%26aulast%3DUrman%26aufirst%3DA.%26aulast%3DRademaker%26aufirst%3DA.%26aulast%3DHart%26aufirst%3DE.%26aulast%3DWeitner%26aufirst%3DB.%2BB.%26aulast%3DPatel%26aufirst%3DJ.%2BD.%26aulast%3DKris%26aufirst%3DM.%26aulast%3DRiely%26aufirst%3DG.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520Hsp90%2520inhibitor%2520AUY922%2520and%2520erlotinib%2520%2528E%2529%2520in%2520patients%2520with%2520EGFR-mutant%2520lung%2520cancer%2520and%2520acquired%2520resistance%2520to%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2013%26volume%3D8%26spage%3DS596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Catalanotti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D. B.</span><span> </span><span class="NLM_article-title">Will Hsp90 inhibitors prove effective in BRAF-mutant melanomas?</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2420</span><span class="NLM_x">–</span> <span class="NLM_lpage">2422</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-0626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1078-0432.CCR-12-0626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22442059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsFejtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2420-2422&author=F.+Catalanottiauthor=D.+B.+Solit&title=Will+Hsp90+inhibitors+prove+effective+in+BRAF-mutant+melanomas%3F&doi=10.1158%2F1078-0432.CCR-12-0626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Will Hsp90 Inhibitors Prove Effective in BRAF-Mutant Melanomas?</span></div><div class="casAuthors">Catalanotti, Federica; Solit, David B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2420-2422</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The RAF inhibitor vemurafenib has unprecedented activity in BRAF-mutant melanomas, but resistance invariably develops.  As Hsp90 is required for the stability of several of the oncoproteins that mediate RAF inhibitor resistance, inhibitors of this cellular chaperone may be effective in patients with intrinsic or acquired resistance to RAF inhibitors.  Clin Cancer Res; 18(9); 2420-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwnY0Rm7HJq7Vg90H21EOLACvtfcHk0lj1aHenDnp83Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsFejtb4%253D&md5=3f771f2ea4b2e14a35243bbd7dd54f79</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0626%26sid%3Dliteratum%253Aachs%26aulast%3DCatalanotti%26aufirst%3DF.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26atitle%3DWill%2520Hsp90%2520inhibitors%2520prove%2520effective%2520in%2520BRAF-mutant%2520melanomas%253F%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D2420%26epage%3D2422%26doi%3D10.1158%2F1078-0432.CCR-12-0626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">Paraiso, K. H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haarberg, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rebecca, V. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sondak, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">John, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarnaik, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koomen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smalley, K. S. M.</span><span> </span><span class="NLM_article-title">The Hsp90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2502</span><span class="NLM_x">–</span> <span class="NLM_lpage">2514</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-2612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1078-0432.CCR-11-2612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22351686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsFeju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2502-2514&author=K.+H.+T.+Paraisoauthor=H.+E.+Haarbergauthor=E.+Woodauthor=V.+W.+Rebeccaauthor=Y.+A.+Chenauthor=Y.+Xiangauthor=A.+Ribasauthor=R.+S.+Loauthor=J.+S.+Weberauthor=V.+K.+Sondakauthor=J.+K.+Johnauthor=A.+A.+Sarnaikauthor=J.+M.+Koomenauthor=K.+S.+M.+Smalley&title=The+Hsp90+inhibitor+XL888+overcomes+BRAF+inhibitor+resistance+mediated+through+diverse+mechanisms&doi=10.1158%2F1078-0432.CCR-11-2612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms</span></div><div class="casAuthors">Paraiso, Kim H. T.; Haarberg, H. Eirik; Wood, Elizabeth; Rebecca, Vito W.; Chen, Y. Ann; Xiang, Yun; Ribas, Antoni; Lo, Roger S.; Weber, Jeffrey S.; Sondak, Vernon K.; John, Jobin K.; Sarnaik, Amod A.; Koomen, John M.; Smalley, Keiran S. M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2502-2514</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: The clin. use of BRAF inhibitors is being hampered by the acquisition of drug resistance.  This study shows the potential therapeutic use of the HSP90 inhibitor (XL888) in six different models of vemurafenib resistance.  Exptl. Design: The ability of XL888 to inhibit growth and to induce apoptosis and tumor regression of vemurafenib-resistant melanoma cell lines was shown in vitro and in vivo.  A novel mass spectrometry-based pharmacodynamic assay was developed to measure intratumoral HSP70 levels following HSP90 inhibition in melanoma cell lines, xenografts, and melanoma biopsies.  Mechanistic studies were carried out to det. the mechanism of XL888-induced apoptosis.  RESULTS: XL888 potently inhibited cell growth, induced apoptosis, and prevented the growth of vemurafenib-resistant melanoma cell lines in 3-dimensional cell culture, long-term colony formation assays, and human melanoma mouse xenografts.  The reversal of the resistance phenotype was assocd. with the degrdn. of PDGFRβ, COT, IGFR1, CRAF, ARAF, S6, cyclin D1, and AKT, which in turn led to the nuclear accumulation of FOXO3a, an increase in BIM (Bcl-2 interacting mediator of cell death) expression, and the downregulation of Mcl-1.  In most resistance models, XL888 treatment increased BIM expression, decreased Mcl-1 expression, and induced apoptosis more effectively than dual mitogen-activated protein-extracellular signal-regulated kinase/phosphoinositide 3-kinase (MEK/PI3K) inhibition.  CONCLUSIONS: HSP90 inhibition may be a highly effective strategy at managing the diverse array of resistance mechanisms being reported to BRAF inhibitors and appears to be more effective at restoring BIM expression and downregulating Mcl-1 expression than combined MEK/PI3K inhibitor therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPrQ97z5o17LVg90H21EOLACvtfcHk0lgH05LhafBdGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsFeju74%253D&md5=4aa227917f72ea77f3d44e2268dc213e</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2612%26sid%3Dliteratum%253Aachs%26aulast%3DParaiso%26aufirst%3DK.%2BH.%2BT.%26aulast%3DHaarberg%26aufirst%3DH.%2BE.%26aulast%3DWood%26aufirst%3DE.%26aulast%3DRebecca%26aufirst%3DV.%2BW.%26aulast%3DChen%26aufirst%3DY.%2BA.%26aulast%3DXiang%26aufirst%3DY.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26aulast%3DWeber%26aufirst%3DJ.%2BS.%26aulast%3DSondak%26aufirst%3DV.%2BK.%26aulast%3DJohn%26aufirst%3DJ.%2BK.%26aulast%3DSarnaik%26aufirst%3DA.%2BA.%26aulast%3DKoomen%26aufirst%3DJ.%2BM.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%2BM.%26atitle%3DThe%2520Hsp90%2520inhibitor%2520XL888%2520overcomes%2520BRAF%2520inhibitor%2520resistance%2520mediated%2520through%2520diverse%2520mechanisms%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D2502%26epage%3D2514%26doi%3D10.1158%2F1078-0432.CCR-11-2612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group">Smyth, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paraiso, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hearn, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Lopez, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munck, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haarberg, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sondak, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, N. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azab, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smalley, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallis, N. G.</span><span> </span><span class="NLM_article-title">Inhibition of Hsp90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2793</span><span class="NLM_x">–</span> <span class="NLM_lpage">2804</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0452</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1535-7163.MCT-14-0452" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=25349308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCju7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2793-2804&author=T.+Smythauthor=K.+H.+Paraisoauthor=K.+Hearnauthor=A.+M.+Rodriguez-Lopezauthor=J.+M.+Munckauthor=H.+E.+Haarbergauthor=V.+K.+Sondakauthor=N.+T.+Thompsonauthor=M.+Azabauthor=J.+F.+Lyonsauthor=K.+S.+Smalleyauthor=N.+G.+Wallis&title=Inhibition+of+Hsp90+by+AT13387+delays+the+emergence+of+resistance+to+BRAF+inhibitors+and+overcomes+resistance+to+dual+BRAF+and+MEK+inhibition+in+melanoma+models&doi=10.1158%2F1535-7163.MCT-14-0452"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models</span></div><div class="casAuthors">Smyth, Tomoko; Paraiso, Kim H. T.; Hearn, Keisha; Rodriguez-Lopez, Ana M.; Munck, Joanne M.; Haarberg, H. Eirik; Sondak, Vernon K.; Thompson, Neil T.; Azab, Mohammad; Lyons, John F.; Smalley, Keiran S. M.; Wallis, Nicola G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2793-2804</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Emergence of clin. resistance to BRAF inhibitors, alone or in combination with MEK inhibitors, limits clin. responses in melanoma.  Inhibiting HSP90 offers an approach to simultaneously interfere with multiple resistance mechanisms.  Using the HSP90 inhibitor AT13387, which is currently in clin. trials, we investigated the potential of HSP90 inhibition to overcome or delay the emergence of resistance to these kinase inhibitors in melanoma models.  In vitro, treating vemurafenib-sensitive cells (A375 or SK-MEL-28) with a combination of AT13387 and vemurafenib prevented colony growth under conditions in which vemurafenib treatment alone generated resistant colonies.  In vivo, when AT13387 was combined with vemurafenib in a SK-MEL-28, vemurafenib-sensitive model, no regrowth of tumors was obsd. over 5 mo, although 2 of 7 tumors in the vemurafenib monotherapy group relapsed in this time.  Together, these data suggest that the combination of these agents can delay the emergence of resistance.  Cell lines with acquired vemurafenib resistance, derived from these models (A375R and SK-MEL-28R) were also sensitive to HSP90 inhibitor treatment; key clients were depleted, apoptosis was induced, and growth in 3D culture was inhibited.  Similar effects were obsd. in cell lines with acquired resistance to both BRAF and MEK inhibitors (SK-MEL-28RR, WM164RR, and 1205LuRR).  These data suggest that treatment with an HSP90 inhibitor, such as AT13387, is a potential approach for combating resistance to BRAF and MEK inhibition in melanoma.  Moreover, frontline combination of these agents with an HSP90 inhibitor could delay the emergence of resistance, providing a strong rationale for clin. investigation of such combinations in BRAF-mutated melanoma.  Mol Cancer Ther; 13(12); 2793-804. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRaNHdCGIPV7Vg90H21EOLACvtfcHk0lgH05LhafBdGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCju7rF&md5=e3fc50e38f259b38a8259f8f5db959f3</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0452%26sid%3Dliteratum%253Aachs%26aulast%3DSmyth%26aufirst%3DT.%26aulast%3DParaiso%26aufirst%3DK.%2BH.%26aulast%3DHearn%26aufirst%3DK.%26aulast%3DRodriguez-Lopez%26aufirst%3DA.%2BM.%26aulast%3DMunck%26aufirst%3DJ.%2BM.%26aulast%3DHaarberg%26aufirst%3DH.%2BE.%26aulast%3DSondak%26aufirst%3DV.%2BK.%26aulast%3DThompson%26aufirst%3DN.%2BT.%26aulast%3DAzab%26aufirst%3DM.%26aulast%3DLyons%26aufirst%3DJ.%2BF.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%26aulast%3DWallis%26aufirst%3DN.%2BG.%26atitle%3DInhibition%2520of%2520Hsp90%2520by%2520AT13387%2520delays%2520the%2520emergence%2520of%2520resistance%2520to%2520BRAF%2520inhibitors%2520and%2520overcomes%2520resistance%2520to%2520dual%2520BRAF%2520and%2520MEK%2520inhibition%2520in%2520melanoma%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D2793%26epage%3D2804%26doi%3D10.1158%2F1535-7163.MCT-14-0452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group">Acquaviva, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimenez, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequeira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bates, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proia, D. A.</span><span> </span><span class="NLM_article-title">Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">353</span><span class="NLM_x">–</span> <span class="NLM_lpage">363</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1535-7163.MCT-13-0481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=24398428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWmsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=353-363&author=J.+Acquavivaauthor=D.+L.+Smithauthor=J.-P.+Jimenezauthor=C.+Zhangauthor=M.+Sequeiraauthor=S.+Heauthor=J.+Sangauthor=R.+C.+Batesauthor=D.+A.+Proia&title=Overcoming+acquired+BRAF+inhibitor+resistance+in+melanoma+via+targeted+inhibition+of+Hsp90+with+ganetespib&doi=10.1158%2F1535-7163.MCT-13-0481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib</span></div><div class="casAuthors">Acquaviva, Jaime; Smith, Donald L.; Jimenez, John-Paul; Zhang, Chaohua; Sequeira, Manuel; He, Suqin; Sang, Jim; Bates, Richard C.; Proia, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">353-363</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activating BRAF kinase mutations serve as oncogenic drivers in over half of all melanomas, a feature that has been exploited in the development of new molecularly targeted approaches to treat this disease.  Selective BRAFV600E inhibitors, such as vemurafenib, typically induce initial, profound tumor regressions within this group of patients; however, durable responses have been hampered by the emergence of drug resistance.  Here, we examd. the activity of ganetespib, a small-mol. inhibitor of Hsp90, in melanoma lines harboring the BRAFV600E mutation.  Ganetespib exposure resulted in the loss of mutant BRAF expression and depletion of mitogen-activated protein kinase and AKT signaling, resulting in greater in vitro potency and antitumor efficacy compared with targeted BRAF and MAP-ERK kinase (MEK) inhibitors.  Dual targeting of Hsp90 and BRAFV600E provided combinatorial benefit in vemurafenib-sensitive melanoma cells in vitro and in vivo.  Importantly, ganetespib overcame mechanisms of intrinsic and acquired resistance to vemurafenib, the latter of which was characterized by reactivation of extracellular signal-regulated kinase (ERK) signaling.  Continued suppression of BRAFV600E by vemurafenib potentiated sensitivity to MEK inhibitors after acquired resistance had been established.  Ganetespib treatment reduced, but not abolished, elevations in steady-state ERK activity.  Profiling studies revealed that the addn. of a MEK inhibitor could completely abrogate ERK reactivation in the resistant phenotype, with ganetespib displaying superior combinatorial activity over vemurafenib.  Moreover, ganetespib plus the MEK inhibitor TAK-733 induced tumor regressions in vemurafenib-resistant xenografts.  Overall these data highlight the potential of ganetespib as a single-agent or combination treatment in BRAFV600E-driven melanoma, particularly as a strategy to overcome acquired resistance to selective BRAF inhibitors.  Mol Cancer Ther; 13(2); 353-63. 2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4u2EBwPctjLVg90H21EOLACvtfcHk0lildTULLuf9Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWmsb0%253D&md5=de32b9abbb6d2a0ee21c0185a9966271</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0481%26sid%3Dliteratum%253Aachs%26aulast%3DAcquaviva%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DD.%2BL.%26aulast%3DJimenez%26aufirst%3DJ.-P.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DSequeira%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DSang%26aufirst%3DJ.%26aulast%3DBates%26aufirst%3DR.%2BC.%26aulast%3DProia%26aufirst%3DD.%2BA.%26atitle%3DOvercoming%2520acquired%2520BRAF%2520inhibitor%2520resistance%2520in%2520melanoma%2520via%2520targeted%2520inhibition%2520of%2520Hsp90%2520with%2520ganetespib%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D353%26epage%3D363%26doi%3D10.1158%2F1535-7163.MCT-13-0481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span>XL888; <span class="NLM_publisher-name">Exelixis</span>: <span class="NLM_publisher-loc">South San Francisco, CA</span>; <a href="http://www.exelixis.net/pipeline/xl888" class="extLink">http://www.exelixis.net/pipeline/xl888</a> (accessed on September 27,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.)</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=XL888%3B+Exelixis%3A+South+San+Francisco%2C+CA%3B+http%3A%2F%2Fwww.exelixis.net%2Fpipeline%2Fxl888+%28accessed+on+September+27%2C+2015.%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DXL888%26pub%3DExelixis%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group">Ren, R.</span><span> </span><span class="NLM_article-title">Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">172</span><span class="NLM_x">–</span> <span class="NLM_lpage">183</span><span class="refDoi"> DOI: 10.1038/nrc1567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fnrc1567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=15719031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhslSnt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=172-183&author=R.+Ren&title=Mechanisms+of+BCR-ABL+in+the+pathogenesis+of+chronic+myelogenous+leukaemia&doi=10.1038%2Fnrc1567"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukemia</span></div><div class="casAuthors">Ren, Ruibao</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">172-183</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Imatinib, a potent inhibitor of the oncogenic tyrosine kinase BCR-ABL, has shown remarkable clin. activity in patients with chronic myelogenous leukemia (CML).  However, this drug does not completely eradicate BCR-ABL-expressing cells from the body, and resistance to imatinib emerges.  Although BCR-ABL remains an attractive therapeutic target, it is important to identify other components involved in CML pathogenesis to overcome this resistance.  What have clin. trials of imatinib and studies using mouse models for BCR-ABL leukemogenesis taught us about the functions of BCR-ABL beyond its kinase activity, and how these functions contribute to CML pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZfXdfv0o4nrVg90H21EOLACvtfcHk0lildTULLuf9Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhslSnt7g%253D&md5=ab087682ff29710660e761c4dc758711</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1038%2Fnrc1567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1567%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DR.%26atitle%3DMechanisms%2520of%2520BCR-ABL%2520in%2520the%2520pathogenesis%2520of%2520chronic%2520myelogenous%2520leukaemia%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D172%26epage%3D183%26doi%3D10.1038%2Fnrc1567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group">Lamontanara, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gencer, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuzyk, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hantschel, O.</span><span> </span><span class="NLM_article-title">Mechanisms of resistance to BCR-ABL and other kinase inhibitors</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Proteins Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">1834</span><span class="NLM_x">, </span> <span class="NLM_fpage">1449</span><span class="NLM_x">–</span> <span class="NLM_lpage">1459</span><span class="refDoi"> DOI: 10.1016/j.bbapap.2012.12.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.bbapap.2012.12.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=23277196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1yjtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1834&publication_year=2013&pages=1449-1459&author=A.+J.+Lamontanaraauthor=E.+B.+Gencerauthor=O.+Kuzykauthor=O.+Hantschel&title=Mechanisms+of+resistance+to+BCR-ABL+and+other+kinase+inhibitors&doi=10.1016%2Fj.bbapap.2012.12.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of resistance to BCR-ABL and other kinase inhibitors</span></div><div class="casAuthors">Lamontanara, Allan Joaquim; Gencer, Emel Basak; Kuzyk, Orest; Hantschel, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1834</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1449-1459</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  In this article, we are reviewing the mol. mechanisms that lead to kinase inhibitor resistance.  As the oncogenic BCR-ABL kinase is the target of the first approved small-mol. kinase inhibitor imatinib, we will first focus on the structural and mechanistic basis for imatinib resistance.  We will then show ways how next generations of BCR-ABL inhibitors and alternative targeting strategies have helped to offer effective treatment options for imatinib-resistant patients.  Based on these insights, we discuss commonalities and further mechanisms that lead to resistance to other kinase inhibitors in solid tumors.  This article is part of a Special Issue entitled: Inhibitors of Protein Kinases (2012).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkaBpN0j3KxrVg90H21EOLACvtfcHk0lhJoayH-65Btw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1yjtrg%253D&md5=7706253e67a867b87ddadcec0bd5f972</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2012.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2012.12.009%26sid%3Dliteratum%253Aachs%26aulast%3DLamontanara%26aufirst%3DA.%2BJ.%26aulast%3DGencer%26aufirst%3DE.%2BB.%26aulast%3DKuzyk%26aufirst%3DO.%26aulast%3DHantschel%26aufirst%3DO.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520BCR-ABL%2520and%2520other%2520kinase%2520inhibitors%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2013%26volume%3D1834%26spage%3D1449%26epage%3D1459%26doi%3D10.1016%2Fj.bbapap.2012.12.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Gorre, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellwood-Yen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">BCR-ABL point mutants isolated from patients with imatinib mesylate–resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone Hsp90</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">3041</span><span class="NLM_x">–</span> <span class="NLM_lpage">3044</span><span class="refDoi"> DOI: 10.1182/blood-2002-05-1361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1182%2Fblood-2002-05-1361" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2002&pages=3041-3044&author=M.+E.+Gorreauthor=K.+Ellwood-Yenauthor=G.+Chiosisauthor=N.+Rosenauthor=C.+L.+Sawyers&title=BCR-ABL+point+mutants+isolated+from+patients+with+imatinib+mesylate%E2%80%93resistant+chronic+myeloid+leukemia+remain+sensitive+to+inhibitors+of+the+BCR-ABL+chaperone+Hsp90&doi=10.1182%2Fblood-2002-05-1361"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1182%2Fblood-2002-05-1361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2002-05-1361%26sid%3Dliteratum%253Aachs%26aulast%3DGorre%26aufirst%3DM.%2BE.%26aulast%3DEllwood-Yen%26aufirst%3DK.%26aulast%3DChiosis%26aufirst%3DG.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DBCR-ABL%2520point%2520mutants%2520isolated%2520from%2520patients%2520with%2520imatinib%2520mesylate%25E2%2580%2593resistant%2520chronic%2520myeloid%2520leukemia%2520remain%2520sensitive%2520to%2520inhibitors%2520of%2520the%2520BCR-ABL%2520chaperone%2520Hsp90%26jtitle%3DBlood%26date%3D2002%26volume%3D100%26spage%3D3041%26epage%3D3044%26doi%3D10.1182%2Fblood-2002-05-1361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Peng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span> </span><span class="NLM_article-title">Heat shock protein 90: a potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors</span> <span class="citation_source-journal">Cell Cycle</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2227</span><span class="NLM_x">–</span> <span class="NLM_lpage">2231</span><span class="refDoi"> DOI: 10.4161/cc.6.18.4722</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.4161%2Fcc.6.18.4722" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=2227-2231&author=C.+Pengauthor=D.+Liauthor=S.+Li&title=Heat+shock+protein+90%3A+a+potential+therapeutic+target+in+leukemic+progenitor+and+stem+cells+harboring+mutant+BCR-ABL+resistant+to+kinase+inhibitors&doi=10.4161%2Fcc.6.18.4722"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.4161%2Fcc.6.18.4722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.6.18.4722%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DS.%26atitle%3DHeat%2520shock%2520protein%252090%253A%2520a%2520potential%2520therapeutic%2520target%2520in%2520leukemic%2520progenitor%2520and%2520stem%2520cells%2520harboring%2520mutant%2520BCR-ABL%2520resistant%2520to%2520kinase%2520inhibitors%26jtitle%3DCell%2520Cycle%26date%3D2007%26volume%3D6%26spage%3D2227%26epage%3D2231%26doi%3D10.4161%2Fcc.6.18.4722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group">Peng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grayzel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pak, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span> </span><span class="NLM_article-title">Inhibition of Hsp90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">678</span><span class="NLM_x">–</span> <span class="NLM_lpage">685</span><span class="refDoi"> DOI: 10.1182/blood-2006-10-054098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1182%2Fblood-2006-10-054098" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=678-685&author=C.+Pengauthor=J.+Brainauthor=Y.+Huauthor=A.+Goodrichauthor=L.+Kongauthor=D.+Grayzelauthor=R.+Pakauthor=M.+Readauthor=S.+Li&title=Inhibition+of+Hsp90+prolongs+survival+of+mice+with+BCR-ABL-T315I-induced+leukemia+and+suppresses+leukemic+stem+cells&doi=10.1182%2Fblood-2006-10-054098"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1182%2Fblood-2006-10-054098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2006-10-054098%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DBrain%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DGoodrich%26aufirst%3DA.%26aulast%3DKong%26aufirst%3DL.%26aulast%3DGrayzel%26aufirst%3DD.%26aulast%3DPak%26aufirst%3DR.%26aulast%3DRead%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DS.%26atitle%3DInhibition%2520of%2520Hsp90%2520prolongs%2520survival%2520of%2520mice%2520with%2520BCR-ABL-T315I-induced%2520leukemia%2520and%2520suppresses%2520leukemic%2520stem%2520cells%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D678%26epage%3D685%26doi%3D10.1182%2Fblood-2006-10-054098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">Wu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span> </span><span class="NLM_article-title">Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">833</span><span class="NLM_x">–</span> <span class="NLM_lpage">843</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-3317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1078-0432.CCR-13-3317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=25501124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2MXislGgsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=833-843&author=L.+Wuauthor=J.+Yuauthor=R.+Chenauthor=Y.+Liuauthor=L.+Louauthor=Y.+Wuauthor=L.+Huangauthor=Y.+Fanauthor=P.+Gaoauthor=M.+Huangauthor=Y.+Wuauthor=Y.+Chenauthor=J.+Xu&title=Dual+inhibition+of+Bcr-Abl+and+Hsp90+by+C086+potently+inhibits+the+proliferation+of+imatinib-resistant+CML+cells&doi=10.1158%2F1078-0432.CCR-13-3317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibition of Bcr-Abl and Hsp90 by C086 Potently Inhibits the Proliferation of Imatinib-Resistant CML Cells</span></div><div class="casAuthors">Wu, Lixian; Yu, Jing; Chen, Ruijia; Liu, Yang; Lou, Liguang; Wu, Ying; Huang, Lisen; Fan, Yingjuan; Gao, Pinzhang; Huang, Meijuan; Wu, Yong; Chen, Yuanzhong; Xu, Jianhua</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">833-843</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Although tyrosine kinase inhibitors (TKI) such as imatinib provide an effective treatment against Bcr-Abl kinase activity in the mature cells of patients with chronic myelogenous leukemia (CML), TKIs probably cannot eradicate the leukemia stem cell (LSC) population.  Therefore, alternative therapies are required to target both mature CML cells with wild-type (WT) or mutant Bcr-Abl and LSCs.  To investigate the effect of C086, a deriv. of curcumin, on imatinib-resistant cells, we explored its underlying mechanisms of Bcr-Abl kinase and heat shock protein 90 (Hsp90) function inhibition.  Exptl. Design: Biochem. assays were used to test ABL kinase activity; fluorescence measurements using recombinant NHsp90, Hsp90 ATPase assay, immunopptn., and immunoblotting were applied to examine Hsp90 function.  Colony-forming unit, long-term culture-initiating cells (LTC-IC), and flow cytometry were used to test CML progenitor and stem cells.  Results: Biochem. assays with purified recombinant Abl kinase confirmed that C086 can directly inhibit the kinase activity of Abl, including WT and the Q252H, Y253F, and T315I mutations.  Furthermore, we identified C086 as a novel Hsp90 inhibitor with the capacity to disrupt the Hsp90 chaperone function in CML cells.  Consequently, it inhibited the growth of both imatinib-sensitive and -resistant CML cells.  Interestingly, C086 has the capacity to inhibit LTC-ICs and to induce apoptosis in both CD34+CD38+ and CD34+CD38- cells in vitro.  Moreover, C086 could decrease the no. of CD45+, CD45+CD34+CD38+, and CD45+CD34+CD38- cells in CML NOD-SCID mice.  Conclusions: Dual suppression of Abl kinase activity and Hsp90 chaperone function by C086 provides a new therapeutic strategy for treating Bcr-Abl-induced leukemia resistant to TKIs.  Clin Cancer Res; 21(4); 833-43. 2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQyfdHK77YL7Vg90H21EOLACvtfcHk0lgEMyknUZiRng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXislGgsL8%253D&md5=f3a1844c124c123bde13f5b4791ef731</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-3317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-3317%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLou%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DDual%2520inhibition%2520of%2520Bcr-Abl%2520and%2520Hsp90%2520by%2520C086%2520potently%2520inhibits%2520the%2520proliferation%2520of%2520imatinib-resistant%2520CML%2520cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D833%26epage%3D843%26doi%3D10.1158%2F1078-0432.CCR-13-3317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group">Samanta, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakraborty, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlette, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arlinghaus, R. B.</span><span> </span><span class="NLM_article-title">Destabilization of Bcr-Abl/Jak2 network by a Jak2/Abl kinase inhibitor ON044580 overcomes drug resistance in blast crisis chronic myelogenous leukemia (CML)</span> <span class="citation_source-journal">Genes Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">346</span><span class="NLM_x">–</span> <span class="NLM_lpage">359</span><span class="refDoi"> DOI: 10.1177/1947601910372232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1177%2F1947601910372232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=20798787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVOms7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=346-359&author=A.+K.+Samantaauthor=S.+N.+Chakrabortyauthor=Y.+Wangauthor=E.+Schletteauthor=E.+P.+Reddyauthor=R.+B.+Arlinghaus&title=Destabilization+of+Bcr-Abl%2FJak2+network+by+a+Jak2%2FAbl+kinase+inhibitor+ON044580+overcomes+drug+resistance+in+blast+crisis+chronic+myelogenous+leukemia+%28CML%29&doi=10.1177%2F1947601910372232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Destabilization of Bcr-Abl/Jak2 network by a Jak2/Abl kinase inhibitor ON044580 overcomes drug resistance in blast crisis chronic myelogenous leukemia (CML)</span></div><div class="casAuthors">Samanta, Ajoy K.; Chakraborty, Sandip N.; Wang, Yan; Schlette, Ellen; Reddy, E. Premkumar; Arlinghaus, Ralph B.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">346-359</span>CODEN:
                <span class="NLM_cas:coden">GCEAAY</span>;
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Bcr-Abl is the predominant therapeutic target in chronic myeloid leukemia (CML), and tyrosine kinase inhibitors (TKIs) that inhibit Bcr-Abl have been successful in treating CML.  With progression of CML disease esp. in blast crisis stage, cells from CML patients become resistant to imatinib mesylate (IM) and other TKIs, resulting in relapse.  Because Bcr-Abl is known to drive multiple signaling pathways, the study of the regulation of stability of Bcr-Abl in IM-resistant CML cells is a crit. issue as a possible therapeutic strategy.  Here, we report that a new dual-kinase chem. inhibitor, ON044580, induced apoptosis of Bcr-Abl+ IM-sensitive, IM-resistant cells, including the gatekeeper Bcr-Abl mutant, T315I, and also cells from blast crisis patients.  In addn., IM-resistant K562-R cells, cells from blast crisis CML patients, and all IM-resistant cell lines tested had reduced ability to form colonies in soft agar in the presence of 0.5 μM ON044580.  In in vitro kinase assays, ON044580 inhibited the recombinant Jak2 and Abl kinase activities when the resp. Jak2 and Abl peptides were used as substrates.  Incubation of the Bcr-Abl+ cells with ON044580 rapidly reduced the levels of the Bcr-Abl protein and also reduced the expression of HSP90 and its client protein levels.  Lysates of Bcr-Abl+ cell lines were found to contain a large signaling network complex composed of Bcr-Abl, Jak2, HSP90, and its client proteins as detected by a gel filtration column chromatog., which was rapidly disrupted by ON044580.  Therefore, targeting Jak2 and Bcr-Abl kinases is an effective way to destabilize Bcr-Abl and its network complex, which leads to the onset of apoptosis in IM-sensitive and IM-resistant Bcr-Abl+ cells.  This inhibitory strategy has potential to manage all types of drug-resistant CML cells, esp. at the terminal blast crisis stage of CML, where TKIs are not clin. useful.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2URs_gr_udLVg90H21EOLACvtfcHk0lgEMyknUZiRng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVOms7%252FJ&md5=059567e997e0ccf1c3711b7d5ca935f1</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1177%2F1947601910372232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1947601910372232%26sid%3Dliteratum%253Aachs%26aulast%3DSamanta%26aufirst%3DA.%2BK.%26aulast%3DChakraborty%26aufirst%3DS.%2BN.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSchlette%26aufirst%3DE.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26aulast%3DArlinghaus%26aufirst%3DR.%2BB.%26atitle%3DDestabilization%2520of%2520Bcr-Abl%252FJak2%2520network%2520by%2520a%2520Jak2%252FAbl%2520kinase%2520inhibitor%2520ON044580%2520overcomes%2520drug%2520resistance%2520in%2520blast%2520crisis%2520chronic%2520myelogenous%2520leukemia%2520%2528CML%2529%26jtitle%3DGenes%2520Cancer%26date%3D2010%26volume%3D1%26spage%3D346%26epage%3D359%26doi%3D10.1177%2F1947601910372232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group">Tao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakraborty, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arlinghaus, R. B.</span><span> </span><span class="NLM_article-title">Hsp90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and Hsp90 signaling network complex in leukemia cells</span> <span class="citation_source-journal">Genes Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">29</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=25821558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjt1Cmu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=19-29&author=W.+Taoauthor=S.+N.+Chakrabortyauthor=X.+Lengauthor=H.+Maauthor=R.+B.+Arlinghaus&title=Hsp90+inhibitor+AUY922+induces+cell+death+by+disruption+of+the+Bcr-Abl%2C+Jak2+and+Hsp90+signaling+network+complex+in+leukemia+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">HSP90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and HSP90 signaling network complex in leukemia cells</span></div><div class="casAuthors">Tao, Wenjing; Chakraborty, Sandip N.; Leng, Xiaohong; Ma, Helen; Arlinghaus, Ralph B.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">19-29, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">GCEAAY</span>;
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    
            (<span class="NLM_cas:orgname">Impact Journals LLC</span>)
        </div><div class="casAbstract">The Bcr-Abl protein is an important client protein of heat shock protein 90 (HSP90).  We evaluated the inhibitory effects of the HSP90 ATPase inhibitor AUY922 on 32D mouse hematopoietic cells expressing wild-type Bcr-Abl (b3a2, 32Dp210) and mutant Bcr-Abl imatinib (IM)-resistant cell lines.  Western blotting results of fractions from gel filtration column chromatog. of 32Dp210 cells showed that HSP90 together with Bcr-Abl, Jak2 Stat3 and several other proteins co-eluted in peak column fractions of a high mol. wt. network complex (HMWNC).  Co-IP results showed that HSP90 directly bound to Bcr-Abl, Jak2, Stat 3 and Akt.  The assocns. between HSP90 and Bcr-Abl or Bcr-Abl kinase domain mutants (T315I and E255K) were interrupted by AUY922 treatment.  Tyrosine phosphorylation of Bcr-Abl showed a dose-dependent decrease in 32Dp210T315I following AUY922 treatment for 16h.  AUY922 also markedly inhibited cell proliferation of both IM-sensitive 32Dp210 (IC50 = 6 nM) and IM-resistant 32Dp210T315I cells (IC50 ≈ 6 nM) and human KBM-5R/KBM-7R cell lines (IC50 = 50 nM).  AUY922 caused significant G1 arrest in 32Dp210 cells but not in T315I or E255K cells.  AUY922 efficiently induced apoptosis in 32Dp210 (IC50 = 10 nM) and T315I or E255K lines with IC50s around 20 to 50 nM.  Our results showed that Bcr-Abl and Jak2 form HMWNC with HSP90 in CML cells.  Inhibition of HSP90 by AUY922 disrupted the structure of HMWNC, leading to Bcr-Abl degrdn., inhibiting cell proliferation and inducing apoptosis.  Thus, inhibition of HSP90 is a powerful way to inhibit not only IM-sensitive CML cells but also IM-resistant CML cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS9Vh85mWkNbVg90H21EOLACvtfcHk0li4Pcv4iQPOQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjt1Cmu74%253D&md5=3298d8cd05ce6f3c979b05292669e004</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DW.%26aulast%3DChakraborty%26aufirst%3DS.%2BN.%26aulast%3DLeng%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DArlinghaus%26aufirst%3DR.%2BB.%26atitle%3DHsp90%2520inhibitor%2520AUY922%2520induces%2520cell%2520death%2520by%2520disruption%2520of%2520the%2520Bcr-Abl%252C%2520Jak2%2520and%2520Hsp90%2520signaling%2520network%2520complex%2520in%2520leukemia%2520cells%26jtitle%3DGenes%2520Cancer%26date%3D2015%26volume%3D6%26spage%3D19%26epage%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group">Gajria, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandarlapaty, S.</span><span> </span><span class="NLM_article-title">HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies</span> <span class="citation_source-journal">Expert Rev. Anticancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">263</span><span class="NLM_x">–</span> <span class="NLM_lpage">275</span><span class="refDoi"> DOI: 10.1586/era.10.226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1586%2Fera.10.226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=21342044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVWmsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=263-275&author=D.+Gajriaauthor=S.+Chandarlapaty&title=HER2-amplified+breast+cancer%3A+mechanisms+of+trastuzumab+resistance+and+novel+targeted+therapies&doi=10.1586%2Fera.10.226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies</span></div><div class="casAuthors">Gajria, Devika; Chandarlapaty, Sarat</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-275</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  HER2 amplification is seen in up to 20% of breast cancers and is assocd. with an aggressive phenotype.  Trastuzumab, a monoclonal antibody to HER2, accrues significant clin. benefit in the metastatic and adjuvant settings.  However, some patients suffer disease recurrence despite adjuvant trastuzumab therapy, and many patients with metastatic disease do not respond to therapy or develop refractory disease within 1 yr of treatment.  Given the increased recognition of de novo and acquired resistance to therapy, considerable research has been dedicated to understanding the mol. mechanisms of trastuzumab resistance.  Here, we highlight putative models of resistance, including activation of the downstream PI3K-signaling pathway, accumulation of a constitutively active form of HER2, and crosstalk of HER2 with other growth factor receptors.  The identification of these specific mechanisms of trastuzumab resistance has provided a rationale for the development of several novel HER2-targeted agents as the mechanisms have largely suggested a continued tumor dependence on HER2 signaling.  We explore the emerging data for the treatment of trastuzumab-refractory disease with novel agents including lapatinib, neratinib, pertuzumab, trastuzumab-DM1, HSP90 and PI3K pathway inhibitors, and the future potential for these inhibitors which, if combined with reliable biomarkers of resistance, may ultimately usher in a new era of personalized medicine for this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQzYCqTtLhBLVg90H21EOLACvtfcHk0li4Pcv4iQPOQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVWmsbk%253D&md5=28f18c9e392a7bb764f029634a915b85</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1586%2Fera.10.226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fera.10.226%26sid%3Dliteratum%253Aachs%26aulast%3DGajria%26aufirst%3DD.%26aulast%3DChandarlapaty%26aufirst%3DS.%26atitle%3DHER2-amplified%2520breast%2520cancer%253A%2520mechanisms%2520of%2520trastuzumab%2520resistance%2520and%2520novel%2520targeted%2520therapies%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2011%26volume%3D11%26spage%3D263%26epage%3D275%26doi%3D10.1586%2Fera.10.226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group">Brufsky, A. M.</span><span> </span><span class="NLM_article-title">Current approaches and emerging directions in HER2-resistant breast cancer</span> <span class="citation_source-journal">Breast Cancer: Basic Clin. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">109</span><span class="NLM_x">–</span> <span class="NLM_lpage">118</span><span class="refDoi"> DOI: 10.4137/BCBCR.S9453</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.4137%2FBCBCR.S9453" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=25125981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFSksLnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=109-118&author=A.+M.+Brufsky&title=Current+approaches+and+emerging+directions+in+HER2-resistant+breast+cancer&doi=10.4137%2FBCBCR.S9453"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Current approaches and emerging directions in HER2-resistant breast cancer</span></div><div class="casAuthors">Brufsky, Adam M.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer: Basic and Clinical Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">109-118</span>CODEN:
                <span class="NLM_cas:coden">BCRACC</span>;
        ISSN:<span class="NLM_cas:issn">1178-2234</span>.
    
            (<span class="NLM_cas:orgname">Libertas Academica Ltd.</span>)
        </div><div class="casAbstract">A review.  Human epidermal growth factor receptor-2 (HER2) is overexpressed in up to 30% of breast cancers; HER2 overexpression is indicative of poor prognosis.  Trastuzumab, an anti-HER2 monoclonal antibody, has led to improved outcomes in patients with HER2-pos. breast cancer, including improved overall survival in adjuvant and first-line settings.  However, a large proportion of patients with breast cancer have intrinsic resistance to HER2-targeted therapies, and nearly all become resistant to therapy after initial response.  Elucidation of underlying mechanisms contributing to HER2 resistance has led to development of novel therapeutic strategies, including those targeting HER2 and downstream pathways, heat shock protein 90, telomerase, and vascular endothelial growth factor inhibitors.  Numerous clin. trials are ongoing or completed, including phase 3 data for the mammalian target of rapamycin inhibitor everolimus in patients with HER2-resistant breast cancer.  This review considers the mol. mechanisms assocd. with HER2 resistance and evaluates the evidence for use of evolving strategies in patients with HER2-resistant breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq43ZVh1UUDW7Vg90H21EOLACvtfcHk0lhBky9bKNR_rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFSksLnI&md5=9202af8f5e73b21fdc80d8cac381776d</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.4137%2FBCBCR.S9453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4137%252FBCBCR.S9453%26sid%3Dliteratum%253Aachs%26aulast%3DBrufsky%26aufirst%3DA.%2BM.%26atitle%3DCurrent%2520approaches%2520and%2520emerging%2520directions%2520in%2520HER2-resistant%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%253A%2520Basic%2520Clin.%2520Res.%26date%3D2014%26volume%3D8%26spage%3D109%26epage%3D118%26doi%3D10.4137%2FBCBCR.S9453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group">Chandarlapaty, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scaltriti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angelini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudis, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arribas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span> </span><span class="NLM_article-title">Inhibitors of Hsp90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">334</span><span class="refDoi"> DOI: 10.1038/onc.2009.337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fonc.2009.337" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=325-334&author=S.+Chandarlapatyauthor=M.+Scaltritiauthor=P.+Angeliniauthor=Q.+Yeauthor=M.+Guzmanauthor=C.+A.+Hudisauthor=L.+Nortonauthor=D.+B.+Solitauthor=J.+Arribasauthor=J.+Baselgaauthor=N.+Rosen&title=Inhibitors+of+Hsp90+block+p95-HER2+signaling+in+Trastuzumab-resistant+tumors+and+suppress+their+growth&doi=10.1038%2Fonc.2009.337"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1038%2Fonc.2009.337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2009.337%26sid%3Dliteratum%253Aachs%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DAngelini%26aufirst%3DP.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DGuzman%26aufirst%3DM.%26aulast%3DHudis%26aufirst%3DC.%2BA.%26aulast%3DNorton%26aufirst%3DL.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DArribas%26aufirst%3DJ.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DInhibitors%2520of%2520Hsp90%2520block%2520p95-HER2%2520signaling%2520in%2520Trastuzumab-resistant%2520tumors%2520and%2520suppress%2520their%2520growth%26jtitle%3DOncogene%26date%3D2010%26volume%3D29%26spage%3D325%26epage%3D334%26doi%3D10.1038%2Fonc.2009.337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group">Scaltriti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serra, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Normant, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigue, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slocum, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prudkin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimenez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aura, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">817</span><span class="NLM_x">–</span> <span class="NLM_lpage">824</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-10-0966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1535-7163.MCT-10-0966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=21383049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlslKgt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=817-824&author=M.+Scaltritiauthor=V.+Serraauthor=E.+Normantauthor=M.+Guzmanauthor=O.+Rodrigueauthor=A.+R.+Limauthor=K.+L.+Slocumauthor=K.+A.+Westauthor=V.+Rodriguezauthor=L.+Prudkinauthor=J.+Jimenezauthor=C.+Auraauthor=J.+Baselga&title=Antitumor+activity+of+the+Hsp90+inhibitor+IPI-504+in+HER2-positive+trastuzumab-resistant+breast+cancer&doi=10.1158%2F1535-7163.MCT-10-0966"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer</span></div><div class="casAuthors">Scaltriti, Maurizio; Serra, Violeta; Normant, Emmanuel; Guzman, Marta; Rodriguez, Olga; Lim, Alice R.; Slocum, Kelly L.; West, Kip A.; Rodriguez, Varenka; Prudkin, Ludmila; Jimenez, Jose; Aura, Claudia; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">817-824</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Hsp90 facilitates the maturation and stability of numerous oncoproteins, including HER2.  The aim of this study was to assess the antitumor activity of the Hsp90 inhibitor IPI-504 in trastuzumab-resistant, HER2-overexpressing breast cancer cells.  Therapy with trastuzumab, IPI-504, and the combination of trastuzumab and IPI-504 was evaluated in trastuzumab-sensitive and trastuzumab-resistant cells.  Inhibition of protein targets, cell proliferation, and tumor growth was assessed in vitro and in xenograft models.  IPI-504 inhibited proliferation of both trastuzumab-sensitive and trastuzumab-resistant cells.  Administration of IPI-504 markedly reduced total levels of HER2 and Akt, as well as phosphorylated Akt and mitogen-activated protein kinase (MAPK), to an equal extent in trastuzumab-sensitive and trastuzumab-resistant cells.  IPI-504, used as single agent or in combination with trastuzumab, also inhibited in vivo the growth of both trastuzumab-sensitive and -resistant tumor xenografts.  As a mechanism for the obsd. antitumor activity, IPI-504 resulted in a marked decrease in the levels of HER2, Akt, p-Akt, and p-MAPK in trastuzumab-resistant xenografts as early as 12 h after a single dose of IPI-504.  IPI-504-mediated Hsp90 inhibition may represent a novel therapeutic approach in trastuzumab refractory HER2-pos. breast cancer.  Mol Cancer Ther; 10(5); 817-24.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhf3Bk6GOlM7Vg90H21EOLACvtfcHk0lhBky9bKNR_rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlslKgt74%253D&md5=ca88b288fc1deb6076e63f7210544338</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0966%26sid%3Dliteratum%253Aachs%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DSerra%26aufirst%3DV.%26aulast%3DNormant%26aufirst%3DE.%26aulast%3DGuzman%26aufirst%3DM.%26aulast%3DRodrigue%26aufirst%3DO.%26aulast%3DLim%26aufirst%3DA.%2BR.%26aulast%3DSlocum%26aufirst%3DK.%2BL.%26aulast%3DWest%26aufirst%3DK.%2BA.%26aulast%3DRodriguez%26aufirst%3DV.%26aulast%3DPrudkin%26aufirst%3DL.%26aulast%3DJimenez%26aufirst%3DJ.%26aulast%3DAura%26aufirst%3DC.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DAntitumor%2520activity%2520of%2520the%2520Hsp90%2520inhibitor%2520IPI-504%2520in%2520HER2-positive%2520trastuzumab-resistant%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D817%26epage%3D824%26doi%3D10.1158%2F1535-7163.MCT-10-0966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group">Wainberg, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anghel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalous, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conklin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayala, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quadt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akimov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, R. S.</span><span> </span><span class="NLM_article-title">Inhibition of Hsp90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">509</span><span class="NLM_x">–</span> <span class="NLM_lpage">519</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1535-7163.MCT-12-0507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=23395886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXls12qsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=509-519&author=Z.+A.+Wainbergauthor=A.+Anghelauthor=A.+M.+Rogersauthor=A.+J.+Desaiauthor=O.+Kalousauthor=D.+Conklinauthor=R.+Ayalaauthor=N.+A.+O%E2%80%99Brienauthor=C.+Quadtauthor=M.+Akimovauthor=D.+J.+Slamonauthor=R.+S.+Finn&title=Inhibition+of+Hsp90+with+AUY922+induces+synergy+in+HER2-amplified+trastuzumab-resistant+breast+and+gastric+cancer&doi=10.1158%2F1535-7163.MCT-12-0507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer</span></div><div class="casAuthors">Wainberg, Zev A.; Anghel, Adrian; Rogers, Amy M.; Desai, Amrita J.; Kalous, Ondrej; Conklin, Dylan; Ayala, Raul; O'Brien, Neil A.; Quadt, Cornelia; Akimov, Mikhail; Slamon, Dennis J.; Finn, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">509-519</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">HSP90 enables the activation of many client proteins of which the most clin. validated is HER2.  NVP-AUY922, a potent HSP90 inhibitor, is currently in phase II clin. trials.  To explore its potential clin. use in HER2-amplified breast and gastric cancers, we evaluated the effect of AUY922 alone and in combination with trastuzumab in both trastuzumab-sensitive and -resistant models.  A panel of 16 human gastric and 45 breast cancer cell lines, including 16 HER2-amplified (3 and 13, resp.) cells, was treated with AUY922 over various concns.  In both breast and gastric cancer, we used cell lines and xenograft models with conditioned trastuzumab-resistance to investigate the efficacy of AUY922 alongside trastuzumab.  Effects of this combination on downstream markers were analyzed via Western blot anal.  AUY922 exhibited potent antiproliferative activity in the low nanomolar range (<40 nmol/L) for 59 of 61 cell lines.  In both histologies, HER2-amplified cells expressed greater sensitivity to AUY than HER2-neg. cells.  In conditioned trastuzumab-resistant models, AUY922 showed a synergistic effect with trastuzumab.  In vitro, the combination induced greater decreases in HER2, a G2 cell-cycle arrest, and increased apoptosis.  In a trastuzumab-resistant gastric cancer xenograft model, the combination of AUY922 and trastuzumab showed greater antitumor efficacy than either drug alone.  These data suggest that AUY922 in combination with trastuzumab has unique efficacy in trastuzumab-resistant models.  The combination of HSP90 inhibition and direct HER2 blockade represents a novel approach to the treatment of HER2-amplified cancers and clin. trials based on the above data are ongoing.  Mol Cancer Ther; 12(4); 509-19. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDibuToKti3LVg90H21EOLACvtfcHk0ljqAVXHy_h-CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXls12qsLc%253D&md5=12644a86e6220c0cd2ba16c813e4728f</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0507%26sid%3Dliteratum%253Aachs%26aulast%3DWainberg%26aufirst%3DZ.%2BA.%26aulast%3DAnghel%26aufirst%3DA.%26aulast%3DRogers%26aufirst%3DA.%2BM.%26aulast%3DDesai%26aufirst%3DA.%2BJ.%26aulast%3DKalous%26aufirst%3DO.%26aulast%3DConklin%26aufirst%3DD.%26aulast%3DAyala%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DN.%2BA.%26aulast%3DQuadt%26aufirst%3DC.%26aulast%3DAkimov%26aufirst%3DM.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26atitle%3DInhibition%2520of%2520Hsp90%2520with%2520AUY922%2520induces%2520synergy%2520in%2520HER2-amplified%2520trastuzumab-resistant%2520breast%2520and%2520gastric%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D509%26epage%3D519%26doi%3D10.1158%2F1535-7163.MCT-12-0507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group">Modi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stopeck, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linden, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandarlapaty, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moynahan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugarman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannah, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudis, C.</span><span> </span><span class="NLM_article-title">Hsp90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">5132</span><span class="NLM_x">–</span> <span class="NLM_lpage">5139</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-0072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1078-0432.CCR-11-0072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=21558407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFSksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=5132-5139&author=S.+Modiauthor=A.+Stopeckauthor=H.+Lindenauthor=D.+Solitauthor=S.+Chandarlapatyauthor=N.+Rosenauthor=G.+D%E2%80%99Andreaauthor=M.+Dicklerauthor=M.+E.+Moynahanauthor=S.+Sugarmanauthor=W.+Maauthor=S.+Patilauthor=L.+Nortonauthor=A.+L.+Hannahauthor=C.+Hudis&title=Hsp90+inhibition+is+effective+in+breast+cancer%3A+a+phase+II+trial+of+tanespimycin+%2817-AAG%29+plus+trastuzumab+in+patients+with+HER2-positive+metastatic+breast+cancer+progressing+on+trastuzumab&doi=10.1158%2F1078-0432.CCR-11-0072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab</span></div><div class="casAuthors">Modi, Shanu; Stopeck, Alison; Linden, Hannah; Solit, David; Chandarlapaty, Sarat; Rosen, Neal; D'Andrea, Gabriella; Dickler, Maura; Moynahan, Mary E.; Sugarman, Steven; Ma, Weining; Patil, Sujata; Norton, Larry; Hannah, Alison L.; Hudis, Clifford</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5132-5139</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: HSP90 is a chaperone protein required for the stability of a variety of client proteins. 17-Demethoxygeldanamycin (17-AAG) is a natural product that binds to HSP90 and inhibits its activity, thereby inducing the degrdn. of these clients.  In preclin. studies, HER2 is one of the most sensitive known client proteins of 17-AAG.  On the basis of these data and activity in a phase I study, we conducted a phase II study of 17-AAG (tanespimycin) with trastuzumab in advanced trastuzumab-refractory HER2-pos. breast cancer.  Exptl. Design: We enrolled patients with metastatic HER2+ breast cancer whose disease had previously progressed on trastuzumab.  All patients received weekly treatment with tanespimycin at 450 mg/m2 i.v. and trastuzumab at a conventional dose.  Therapy was continued until disease progression.  The primary endpoint was response rate by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.  RESULTS: Thirty-one patients were enrolled with a median age of 53 years and a median Karnofsky performance status (KPS) of 90%.  The most common toxicities, largely grade 1, were diarrhea, fatigue, nausea, and headache.  The overall response rate was 22%, the clin. benefit rate [complete response + partial response + stable disease] was 59%, the median progression-free survival was 6 mo (95% CI: 4-9), and the median overall survival was 17 mo (95% CI: 16-28).  CONCLUSIONS: This is the first phase II study to definitively show RECIST-defined responses for 17-AAG in solid tumors.  Tanespimycin plus trastuzumab has significant anticancer activity in patients with HER2-pos., metastatic breast cancer previously progressing on trastuzumab.  Further research exploring this therapeutic interaction and the activity of HSP90 inhibitors is clearly warranted.  Clin Cancer Res; 17(15); 5132-9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFgVCzhN1fHLVg90H21EOLACvtfcHk0ljqAVXHy_h-CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFSksbw%253D&md5=07d9e8e06caad7cd7abe03f9e9f7375a</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-0072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-0072%26sid%3Dliteratum%253Aachs%26aulast%3DModi%26aufirst%3DS.%26aulast%3DStopeck%26aufirst%3DA.%26aulast%3DLinden%26aufirst%3DH.%26aulast%3DSolit%26aufirst%3DD.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DG.%26aulast%3DDickler%26aufirst%3DM.%26aulast%3DMoynahan%26aufirst%3DM.%2BE.%26aulast%3DSugarman%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DPatil%26aufirst%3DS.%26aulast%3DNorton%26aufirst%3DL.%26aulast%3DHannah%26aufirst%3DA.%2BL.%26aulast%3DHudis%26aufirst%3DC.%26atitle%3DHsp90%2520inhibition%2520is%2520effective%2520in%2520breast%2520cancer%253A%2520a%2520phase%2520II%2520trial%2520of%2520tanespimycin%2520%252817-AAG%2529%2520plus%2520trastuzumab%2520in%2520patients%2520with%2520HER2-positive%2520metastatic%2520breast%2520cancer%2520progressing%2520on%2520trastuzumab%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D5132%26epage%3D5139%26doi%3D10.1158%2F1078-0432.CCR-11-0072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group">Jhaveri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chap, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannah, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, S.</span><span> </span><span class="NLM_article-title">A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5090</span><span class="NLM_x">–</span> <span class="NLM_lpage">5098</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-3200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1078-0432.CCR-11-3200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22781552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2lt7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=5090-5098&author=K.+Jhaveriauthor=K.+Millerauthor=L.+Rosenauthor=B.+Schneiderauthor=L.+Chapauthor=A.+Hannahauthor=Z.+Zhongauthor=W.+Maauthor=C.+Hudisauthor=S.+Modi&title=A+phase+I+dose-escalation+trial+of+trastuzumab+and+alvespimycin+hydrochloride+%28KOS-1022%3B+17+DMAG%29+in+the+treatment+of+advanced+solid+tumors&doi=10.1158%2F1078-0432.CCR-11-3200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors</span></div><div class="casAuthors">Jhaveri, Komal; Miller, Kathy; Rosen, Lee; Schneider, Bryan; Chap, Linnea; Hannah, Alison; Zhong, Ziyang; Ma, Weining; Hudis, Clifford; Modi, Shanu</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5090-5098</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: We conducted a phase I dose-escalation study to define the max. tolerated dose (MTD), pharmacokinetics (PK), and pharmacodynamics of alvespimycin (17-DMAG), a heat shock protein 90 (Hsp90) inhibitor, given in combination with trastuzumab.  Exptl. Design: Patients were treated with trastuzumab followed by i.v. alvespimycin on a weekly schedule.  Hsp90 client proteins were measured at baseline and serially in peripheral blood lymphocytes (PBL) during cycle 1.  Patients with advanced solid tumors progressing on std. therapy were eligible.  Results: Twenty-eight patients (25, breast; 3, ovarian) were enrolled onto three dose cohorts: 60 (n = 9), 80 (n = 13), and 100 mg/m2 (n = 6).  Dose-limiting toxicities (DLT) were: grade III left ventricular systolic dysfunction presenting as congestive heart failure in 1 patient (100 mg/m2), and reversible grade III keratitis in two patients (80 mg/m2).  Drug-related grade III toxicity included one episode each of fatigue, diarrhea, myalgia, and back pain.  Common mild to moderate toxicities included diarrhea, fatigue, myalgia, arthralgia, nausea, blurry vision, headache, back pain, and dry eyes.  There was one partial response and seven cases of stable disease (range, 4-10 mo), all in HER2+ MBC.  In addn., an ovarian cancer patient had complete resoln. of ascites and pleural effusion that lasted 24.8 mo.  There was no change in PK upon weekly dosing.  Hsp70 effect continued to increase across four weeks and was most pronounced at 80 and 100 mg/m2.  Conclusion: The combination of alvespimycin and trastuzumab is safe and tolerable at MTD.  Antitumor activity was seen in patients with refractory HER2+ MBC and ovarian cancer.  The recommended dose of alvespimycin for further study in this combination is 80 mg/m2 weekly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq36__p9-L8obVg90H21EOLACvtfcHk0lgHK0EC6cHtFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2lt7vJ&md5=422b8841c2a0993fae0933d1b8ad8a52</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-3200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-3200%26sid%3Dliteratum%253Aachs%26aulast%3DJhaveri%26aufirst%3DK.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DRosen%26aufirst%3DL.%26aulast%3DSchneider%26aufirst%3DB.%26aulast%3DChap%26aufirst%3DL.%26aulast%3DHannah%26aufirst%3DA.%26aulast%3DZhong%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DHudis%26aufirst%3DC.%26aulast%3DModi%26aufirst%3DS.%26atitle%3DA%2520phase%2520I%2520dose-escalation%2520trial%2520of%2520trastuzumab%2520and%2520alvespimycin%2520hydrochloride%2520%2528KOS-1022%253B%252017%2520DMAG%2529%2520in%2520the%2520treatment%2520of%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D5090%26epage%3D5098%26doi%3D10.1158%2F1078-0432.CCR-11-3200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group">Modi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saura, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, N. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahtani, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goddard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodenas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shaughnessy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">Efficacy and safety of retaspimycin hydrochloride (IPI-504) in combination with trastuzumab in patients (pts) with pretreated, locally advanced or metastatic HER2-positive breast cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">S590</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=S590&author=S.+Modiauthor=C.+Sauraauthor=C.+A.+Hendersonauthor=N.+U.+Linauthor=R.+L.+Mahtaniauthor=J.+Goddardauthor=E.+Rodenasauthor=J.+O%E2%80%99Shaughnessyauthor=J.+Baselga&title=Efficacy+and+safety+of+retaspimycin+hydrochloride+%28IPI-504%29+in+combination+with+trastuzumab+in+patients+%28pts%29+with+pretreated%2C+locally+advanced+or+metastatic+HER2-positive+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DModi%26aufirst%3DS.%26aulast%3DSaura%26aufirst%3DC.%26aulast%3DHenderson%26aufirst%3DC.%2BA.%26aulast%3DLin%26aufirst%3DN.%2BU.%26aulast%3DMahtani%26aufirst%3DR.%2BL.%26aulast%3DGoddard%26aufirst%3DJ.%26aulast%3DRodenas%26aufirst%3DE.%26aulast%3DO%25E2%2580%2599Shaughnessy%26aufirst%3DJ.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520retaspimycin%2520hydrochloride%2520%2528IPI-504%2529%2520in%2520combination%2520with%2520trastuzumab%2520in%2520patients%2520%2528pts%2529%2520with%2520pretreated%252C%2520locally%2520advanced%2520or%2520metastatic%2520HER2-positive%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3DS590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group">Jhaveri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandarlapaty, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lake, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilewski, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldfarb, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drullinsky, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugarman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wasserheit-Leiblich, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fasano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moynahan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddington, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haque, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vukovic, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Hariry, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, S.</span><span> </span><span class="NLM_article-title">A phase II open-label study of ganetespib, a novel Hsp90 inhibitor for patients with metastatic breast cancer</span> <span class="citation_source-journal">Clin. Breast Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">154</span><span class="NLM_x">–</span> <span class="NLM_lpage">160</span><span class="refDoi"> DOI: 10.1016/j.clbc.2013.12.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.clbc.2013.12.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=24512858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFegsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=154-160&author=K.+Jhaveriauthor=S.+Chandarlapatyauthor=D.+Lakeauthor=T.+Gilewskiauthor=M.+Robsonauthor=S.+Goldfarbauthor=P.+Drullinskyauthor=S.+Sugarmanauthor=C.+Wasserheit-Leiblichauthor=J.+Fasanoauthor=M.+E.+Moynahanauthor=G.+D%E2%80%99Andreaauthor=K.+Limauthor=L.+Reddingtonauthor=S.+Haqueauthor=S.+Patilauthor=L.+Baumanauthor=V.+Vukovicauthor=I.+El-Hariryauthor=C.+Hudisauthor=S.+Modi&title=A+phase+II+open-label+study+of+ganetespib%2C+a+novel+Hsp90+inhibitor+for+patients+with+metastatic+breast+cancer&doi=10.1016%2Fj.clbc.2013.12.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer</span></div><div class="casAuthors">Jhaveri, Komal; Chandarlapaty, Sarat; Lake, Diana; Gilewski, Teresa; Robson, Mark; Goldfarb, Shari; Drullinsky, Pamela; Sugarman, Steven; Wasserheit-Leiblich, Carolyn; Fasano, Julie; Moynahan, Mary Ellen; D'Andrea, Gabriella; Lim, Kristina; Reddington, Laura; Haque, Sofia; Patil, Sujata; Bauman, Lynne; Vukovic, Vojo; El-Hariry, Iman; Hudis, Clifford; Modi, Shanu</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Breast Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">154-160</span>CODEN:
                <span class="NLM_cas:coden">CBCLB7</span>;
        ISSN:<span class="NLM_cas:issn">1526-8209</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Background:Ganetespib is a small mol., nongeldanamycin HSP90 inhibitor with potent inhibitory effects on HSP90-dependent oncoproteins of relevance to breast cancer pathogenesis.  We therefore tested ganetespib in an unselected cohort of patients with MBC.  Patients and Methods: Patients were treated with single agent ganetespib at 200 mg/m2 once weekly for 3 wk, on a 28-day cycle.  Therapy was continued until disease progression.  The primary end point was ORR using Reponse Evaluation Criteria in Solid Tumors version 1.1.  Results: Twenty-two patients were enrolled with a median age of 51(range, 38-70) years and a median Eastern Cooperative Oncol. Group performance status of 0 (range, 0-1).  Most patients had at least 2 previous lines of chemotherapy in the metastatic setting.  Most common toxicities, largely grade 1/2, were diarrhea, fatigue, nausea, and hypersensitivity reaction.  The ORR in this unselected population was 9%, with all responses coming from the subset of patients with HER2-pos. MBC (2/13; 15%).  One patient with TNBC had objective tumor regression in the lung metastases.  The clin. benefit rate (complete response + partial response + stable disease > 6 mo) was 9%, median progression-free survival was 7 wk (95% confidence interval [CI], 7-19), and median overall survival was 46 wk (95% CI, 27-not applicable).  Conclusion: The study did not meet the prespecified criteria for ORR in the first stage of the Simon 2-stage model in this heavily pretreated unselected population of MBC.  However, activity was obsd. in trastuzumab-refractory HER2-pos. and TNBC.  Ganetespib was well tolerated and responses in more targeted populations harboring specific HSP90-dependent oncoproteins justifies its further study, particularly as part of rational combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKRWFzPxBRzbVg90H21EOLACvtfcHk0ljRIg411I0Vnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFegsLc%253D&md5=15edad6cf71a9559eb42997563c57f53</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.clbc.2013.12.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clbc.2013.12.012%26sid%3Dliteratum%253Aachs%26aulast%3DJhaveri%26aufirst%3DK.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DLake%26aufirst%3DD.%26aulast%3DGilewski%26aufirst%3DT.%26aulast%3DRobson%26aufirst%3DM.%26aulast%3DGoldfarb%26aufirst%3DS.%26aulast%3DDrullinsky%26aufirst%3DP.%26aulast%3DSugarman%26aufirst%3DS.%26aulast%3DWasserheit-Leiblich%26aufirst%3DC.%26aulast%3DFasano%26aufirst%3DJ.%26aulast%3DMoynahan%26aufirst%3DM.%2BE.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DG.%26aulast%3DLim%26aufirst%3DK.%26aulast%3DReddington%26aufirst%3DL.%26aulast%3DHaque%26aufirst%3DS.%26aulast%3DPatil%26aufirst%3DS.%26aulast%3DBauman%26aufirst%3DL.%26aulast%3DVukovic%26aufirst%3DV.%26aulast%3DEl-Hariry%26aufirst%3DI.%26aulast%3DHudis%26aufirst%3DC.%26aulast%3DModi%26aufirst%3DS.%26atitle%3DA%2520phase%2520II%2520open-label%2520study%2520of%2520ganetespib%252C%2520a%2520novel%2520Hsp90%2520inhibitor%2520for%2520patients%2520with%2520metastatic%2520breast%2520cancer%26jtitle%3DClin.%2520Breast%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D154%26epage%3D160%26doi%3D10.1016%2Fj.clbc.2013.12.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group">Nogova, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardizi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheffler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papachristou, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wompner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heukamp, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schildhaus, H.-U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuhr, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberhardt, W. E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesweg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Büttner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, J.</span><span> </span><span class="NLM_article-title">A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small-cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">S914</span><span class="NLM_x">–</span> <span class="NLM_lpage">S915</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=S914-S915&author=L.+Nogovaauthor=M.+Bosauthor=M.+Gardiziauthor=M.+Schefflerauthor=I.+Papachristouauthor=C.+Wompnerauthor=L.+C.+Heukampauthor=H.-U.+Schildhausauthor=U.+Fuhrauthor=M.+L.+Sosauthor=W.+E.+E.+Eberhardtauthor=M.+Wieswegauthor=K.+W.+Schmidauthor=M.+Schulerauthor=R.+B%C3%BCttnerauthor=J.+Wolf&title=A+phase+II+study+to+evaluate+safety+and+efficacy+of+combined+trastuzumab+and+AUY922+in+advanced+non-small-cell+lung+cancer+%28NSCLC%29+with+HER2+overexpression+or+amplification+or+mutation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNogova%26aufirst%3DL.%26aulast%3DBos%26aufirst%3DM.%26aulast%3DGardizi%26aufirst%3DM.%26aulast%3DScheffler%26aufirst%3DM.%26aulast%3DPapachristou%26aufirst%3DI.%26aulast%3DWompner%26aufirst%3DC.%26aulast%3DHeukamp%26aufirst%3DL.%2BC.%26aulast%3DSchildhaus%26aufirst%3DH.-U.%26aulast%3DFuhr%26aufirst%3DU.%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DEberhardt%26aufirst%3DW.%2BE.%2BE.%26aulast%3DWiesweg%26aufirst%3DM.%26aulast%3DSchmid%26aufirst%3DK.%2BW.%26aulast%3DSchuler%26aufirst%3DM.%26aulast%3DB%25C3%25BCttner%26aufirst%3DR.%26aulast%3DWolf%26aufirst%3DJ.%26atitle%3DA%2520phase%2520II%2520study%2520to%2520evaluate%2520safety%2520and%2520efficacy%2520of%2520combined%2520trastuzumab%2520and%2520AUY922%2520in%2520advanced%2520non-small-cell%2520lung%2520cancer%2520%2528NSCLC%2529%2520with%2520HER2%2520overexpression%2520or%2520amplification%2520or%2520mutation%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2013%26volume%3D8%26spage%3DS914%26epage%3DS915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group">Vainchenker, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Constantinescu, S. N.</span><span> </span><span class="NLM_article-title">JAK/STAT signaling in hematological malignancies</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">2601</span><span class="NLM_x">–</span> <span class="NLM_lpage">2613</span><span class="refDoi"> DOI: 10.1038/onc.2012.347</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1038%2Fonc.2012.347" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22869151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCrtr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=2601-2613&author=W.+Vainchenkerauthor=S.+N.+Constantinescu&title=JAK%2FSTAT+signaling+in+hematological+malignancies&doi=10.1038%2Fonc.2012.347"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">JAK/STAT signaling in hematological malignancies</span></div><div class="casAuthors">Vainchenker, W.; Constantinescu, S. N.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2601-2613</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is crit. in blood formation and immune response.  Many of those receptors transmit anti-apoptotic, proliferative and differentiation signals, and their expression and functions are crit. for the formation of blood lineages.  Several cancers, including blood malignancies, have been assocd. with constitutive activation of members of the STAT family, which normally require JAK-mediated tyrosine phosphorylation for transcriptional activation.  More recently, human myeloproliferative neoplasms were discovered to be assocd. with a unique acquired somatic mutation in JAK2 (JAK2 V617F), rare exon 12 JAK2 mutations, or thrombopoietin receptor mutations that constitutively activate wild-type JAK2.  Prompted by these observations, many studies have explored the possibility that JAKs, cytokine receptors, or other components of the JAK/STAT pathway are mutated or upregulated in several hematol. malignancies.  This has been obsd. in certain pediatric acute lymphoblastic leukemias and adult T-cell lymphoblastic leukemias, and overexpression of JAK2 seems to be important in Hodgkin lymphoma.  Here we discuss the nature and resp. contribution of mutations dysregulating the JAK/STAT pathway in hematol. malignancies and present examples in which such mutations drive the disease, contribute to the phenotype, or provide a survival and proliferative advantage.  JAK inhibitors are making their way into the therapeutic arsenal (for example, in myelofibrosis), and we discuss the possibility that other hematol. diseases might benefit from treatment with these inhibitors in combination with other agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVwfhpAymyJbVg90H21EOLACvtfcHk0libwS44h3FNNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCrtr%252FN&md5=f491a126765e10fbfbb73f6e04fd64e6</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1038%2Fonc.2012.347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2012.347%26sid%3Dliteratum%253Aachs%26aulast%3DVainchenker%26aufirst%3DW.%26aulast%3DConstantinescu%26aufirst%3DS.%2BN.%26atitle%3DJAK%252FSTAT%2520signaling%2520in%2520hematological%2520malignancies%26jtitle%3DOncogene%26date%3D2013%26volume%3D32%26spage%3D2601%26epage%3D2613%26doi%3D10.1038%2Fonc.2012.347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group">Bareng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jilani, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorre, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannah, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albitar, M.</span><span> </span><span class="NLM_article-title">A potential role for Hsp90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry</span> <span class="citation_source-journal">Leuk. Lymphoma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">2189</span><span class="NLM_x">–</span> <span class="NLM_lpage">2195</span><span class="refDoi"> DOI: 10.1080/10428190701607576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1080%2F10428190701607576" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=17926180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1Krt7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2007&pages=2189-2195&author=J.+Barengauthor=I.+Jilaniauthor=M.+Gorreauthor=H.+Kantarjianauthor=F.+Gilesauthor=A.+Hannahauthor=M.+Albitar&title=A+potential+role+for+Hsp90+inhibitors+in+the+treatment+of+JAK2+mutant-positive+diseases+as+demonstrated+using+quantitative+flow+cytometry&doi=10.1080%2F10428190701607576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry</span></div><div class="casAuthors">Bareng, Joanne; Jilani, Iman; Gorre, Mercedes; Kantarjian, Hagop; Giles, Francis; Hannah, Alison; Albitar, Maher</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2189-2195</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1042-8194</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">The V617F mutation of the JAK2 tyrosine kinase is found in a majority of patients with myeloproliferative disorders.  Flow cytometry assays for quantitation of phosphorylated and total protein for JAK2, STAT5, and heat shock proteins (HSPs) were developed to facilitate the study of the JAK/STAT pathway.  A cell line homozygous for V617F (HEL) was treated with inhibitors of JAK2 tyrosine kinase activity and the HSP90 inhibitor 17-AAG. 17-AAG reduced HSP90 levels, but increased HSP70 levels.  Phospho-STAT5, total STAT5, and total AKT levels were also reduced by17-AAG treatment.  Further, phospho-JAK2, total JAK2, and cell viability were reduced to a greater extent by 17-AAG than by the pan-JAK kinase family inhibitor JKII or the JAK2-specific inhibitor AG490, and these inhibitors failed to synergize with 17-AAG.  Flow-cytometry-based assays for JAK/STAT signaling pathway and HSPs are likely to have broad clin. utility for monitoring patients with abnormalities in the JAK2 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaPOwsJaUsULVg90H21EOLACvtfcHk0libwS44h3FNNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1Krt7nN&md5=a85b1452d36135baebfb78ae2e287ace</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1080%2F10428190701607576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10428190701607576%26sid%3Dliteratum%253Aachs%26aulast%3DBareng%26aufirst%3DJ.%26aulast%3DJilani%26aufirst%3DI.%26aulast%3DGorre%26aufirst%3DM.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DGiles%26aufirst%3DF.%26aulast%3DHannah%26aufirst%3DA.%26aulast%3DAlbitar%26aufirst%3DM.%26atitle%3DA%2520potential%2520role%2520for%2520Hsp90%2520inhibitors%2520in%2520the%2520treatment%2520of%2520JAK2%2520mutant-positive%2520diseases%2520as%2520demonstrated%2520using%2520quantitative%2520flow%2520cytometry%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2007%26volume%3D48%26spage%3D2189%26epage%3D2195%26doi%3D10.1080%2F10428190701607576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group">Fiskus, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verstovsek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manshouri, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balusu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkannagari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, N. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ha, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hembruff, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abhyankar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGuirk, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhalla, K. N.</span><span> </span><span class="NLM_article-title">Hsp90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">7347</span><span class="NLM_x">–</span> <span class="NLM_lpage">7358</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-1541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1078-0432.CCR-11-1541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=21976548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCmtrjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=7347-7358&author=W.+Fiskusauthor=S.+Verstovsekauthor=T.+Manshouriauthor=R.+Raoauthor=R.+Balusuauthor=S.+Venkannagariauthor=N.+N.+Raoauthor=K.+Haauthor=J.+E.+Smithauthor=S.+L.+Hembruffauthor=S.+Abhyankarauthor=J.+McGuirkauthor=K.+N.+Bhalla&title=Hsp90+inhibitor+is+synergistic+with+JAK2+inhibitor+and+overcomes+resistance+to+JAK2-TKI+in+human+myeloproliferative+neoplasm+cells&doi=10.1158%2F1078-0432.CCR-11-1541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells</span></div><div class="casAuthors">Fiskus, Warren; Verstovsek, Srdan; Manshouri, Taghi; Rao, Rekha; Balusu, Ramesh; Venkannagari, Sreedhar; Rao, Nalabothula Narasimha; Ha, Kyungsoo; Smith, Jacqueline E.; Hembruff, Stacey L.; Abhyankar, Sunil; McGuirk, Joseph; Bhalla, Kapil N.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7347-7358</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: We detd. the activity of hsp90 inhibitor, and/or Janus-activated kinase 2 (JAK2) tyrosine kinase inhibitor (TKI), against JAK2-V617F-expressing cultured mouse (Ba/F3-JAK2-V617F) and human (HEL92.1.7 and UKE-1) or primary human CD34+ myeloproliferative neoplasm (MPN) cells.  Exptl. Design: Following exposure to the hsp90 inhibitor AUY922 and/or JAK2-TKI TG101209, the levels of JAK2-V617F, its downstream signaling proteins, as well as apoptosis were detd.  RESULTS: Treatment with AUY922 induced proteasomal degrdn. and depletion of JAK2-V617F as well as attenuated the signaling proteins downstream of JAK2-V617F, i.e., phospho (p)-STAT5, p-AKT, and p-ERK1/2.  AUY922 treatment also induced apoptosis of HEL92.1.7, UKE-1, and Ba/F3-hJAK2-V617F cells.  Combined treatment with AUY922 and TG101209 caused greater depletion of the signaling proteins than either agent alone and synergistically induced apoptosis of HEL92.1.7 and UKE-1 cells.  Cotreatment with AUY922 and TG101209 also induced significantly more apoptosis of human CD34+ MPN than normal hematopoietic progenitor cells.  As compared with the sensitive controls, JAK2-TKI-resistant HEL/TGR and UKE-1/TGR cells exhibited significantly higher IC50 values for JAK2-TKI (P < 0.001), which was assocd. with higher expression of p-JAK2, p-STAT5, p-AKT, and Bcl-xL, but reduced levels of BIM.  Unlike the sensitive controls, HEL/TGR and UKE/TGR cells were collaterally sensitive to the hsp90 inhibitors AUY922 and 17-AAG, accompanied by marked redn. in p-JAK2, p-STAT5, p-AKT, and Bcl-xL, with concomitant induction of BIM.  CONCLUSIONS: Findings presented here show that cotreatment with hsp90 inhibitor and JAK2-TKI exerts synergistic activity against cultured and primary MPN cells.  In addn., treatment with hsp90 inhibitor may overcome resistance to JAK2-TKI in human MPN cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7mMbjQ3mqu7Vg90H21EOLACvtfcHk0li_Aq4aUXMovA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCmtrjI&md5=c4df75f96ef342b3d54e441cb5bccc9e</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1541%26sid%3Dliteratum%253Aachs%26aulast%3DFiskus%26aufirst%3DW.%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DManshouri%26aufirst%3DT.%26aulast%3DRao%26aufirst%3DR.%26aulast%3DBalusu%26aufirst%3DR.%26aulast%3DVenkannagari%26aufirst%3DS.%26aulast%3DRao%26aufirst%3DN.%2BN.%26aulast%3DHa%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DJ.%2BE.%26aulast%3DHembruff%26aufirst%3DS.%2BL.%26aulast%3DAbhyankar%26aufirst%3DS.%26aulast%3DMcGuirk%26aufirst%3DJ.%26aulast%3DBhalla%26aufirst%3DK.%2BN.%26atitle%3DHsp90%2520inhibitor%2520is%2520synergistic%2520with%2520JAK2%2520inhibitor%2520and%2520overcomes%2520resistance%2520to%2520JAK2-TKI%2520in%2520human%2520myeloproliferative%2520neoplasm%2520cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D7347%26epage%3D7358%26doi%3D10.1158%2F1078-0432.CCR-11-1541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group">Weigert, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bird, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopp, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapuy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Bodegom, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marubayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christie, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeown, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paranal, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaul, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vangrevelinghe, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romanet, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiedt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evrot, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Pover, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Régnier, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erdmann, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sallan, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baffert, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radimerski, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstock, D. M.</span><span> </span><span class="NLM_article-title">Genetic resistance to JAK2 enzymatic inhibitors is overcome by Hsp90 inhibition</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">209</span><span class="NLM_x">, </span> <span class="NLM_fpage">259</span><span class="NLM_x">–</span> <span class="NLM_lpage">273</span><span class="refDoi"> DOI: 10.1084/jem.20111694</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1084%2Fjem.20111694" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=209&publication_year=2012&pages=259-273&author=O.+Weigertauthor=A.+A.+Laneauthor=L.+Birdauthor=N.+Koppauthor=B.+Chapuyauthor=D.+van+Bodegomauthor=A.+V.+Tomsauthor=S.+Marubayashiauthor=A.+L.+Christieauthor=M.+McKeownauthor=R.+M.+Paranalauthor=J.+E.+Bradnerauthor=A.+Yodaauthor=C.+Gaulauthor=E.+Vangrevelingheauthor=V.+Romanetauthor=M.+Murakamiauthor=R.+Tiedtauthor=N.+Ebelauthor=E.+Evrotauthor=A.+De+Poverauthor=C.+H.+R%C3%A9gnierauthor=D.+Erdmannauthor=F.+Hofmannauthor=M.+J.+Eckauthor=S.+E.+Sallanauthor=R.+L.+Levineauthor=A.+L.+Kungauthor=F.+Baffertauthor=T.+Radimerskiauthor=D.+M.+Weinstock&title=Genetic+resistance+to+JAK2+enzymatic+inhibitors+is+overcome+by+Hsp90+inhibition&doi=10.1084%2Fjem.20111694"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1084%2Fjem.20111694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20111694%26sid%3Dliteratum%253Aachs%26aulast%3DWeigert%26aufirst%3DO.%26aulast%3DLane%26aufirst%3DA.%2BA.%26aulast%3DBird%26aufirst%3DL.%26aulast%3DKopp%26aufirst%3DN.%26aulast%3DChapuy%26aufirst%3DB.%26aulast%3Dvan%2BBodegom%26aufirst%3DD.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DMarubayashi%26aufirst%3DS.%26aulast%3DChristie%26aufirst%3DA.%2BL.%26aulast%3DMcKeown%26aufirst%3DM.%26aulast%3DParanal%26aufirst%3DR.%2BM.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DYoda%26aufirst%3DA.%26aulast%3DGaul%26aufirst%3DC.%26aulast%3DVangrevelinghe%26aufirst%3DE.%26aulast%3DRomanet%26aufirst%3DV.%26aulast%3DMurakami%26aufirst%3DM.%26aulast%3DTiedt%26aufirst%3DR.%26aulast%3DEbel%26aufirst%3DN.%26aulast%3DEvrot%26aufirst%3DE.%26aulast%3DDe%2BPover%26aufirst%3DA.%26aulast%3DR%25C3%25A9gnier%26aufirst%3DC.%2BH.%26aulast%3DErdmann%26aufirst%3DD.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSallan%26aufirst%3DS.%2BE.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DBaffert%26aufirst%3DF.%26aulast%3DRadimerski%26aufirst%3DT.%26aulast%3DWeinstock%26aufirst%3DD.%2BM.%26atitle%3DGenetic%2520resistance%2520to%2520JAK2%2520enzymatic%2520inhibitors%2520is%2520overcome%2520by%2520Hsp90%2520inhibition%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2012%26volume%3D209%26spage%3D259%26epage%3D273%26doi%3D10.1084%2Fjem.20111694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group">Fridman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarlis, N. J.</span><span> </span><span class="NLM_article-title">The interplay between inhibition of JAK2 and Hsp90</span> <span class="citation_source-journal">JAKSTAT</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">–</span> <span class="NLM_lpage">79</span><span class="refDoi"> DOI: 10.4161/jkst.20293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.4161%2Fjkst.20293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=24058754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252FgsV2rug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2012&pages=77-79&author=J.+S.+Fridmanauthor=N.+J.+Sarlis&title=The+interplay+between+inhibition+of+JAK2+and+Hsp90&doi=10.4161%2Fjkst.20293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">The interplay between inhibition of JAK2 and HSP90</span></div><div class="casAuthors">Fridman Jordan S; Sarlis Nicholas J</div><div class="citationInfo"><span class="NLM_cas:title">JAK-STAT</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">77-9</span>
        ISSN:<span class="NLM_cas:issn">2162-3988</span>.
    </div><div class="casAbstract">A recent article by Weigert et al. published in The Journal of Experimental Medicine described the in vitro generation of synthetic mutations in Janus kinase 2 (JAK 2) that decreased the potency of JAK2 (or JAK1/JAK2) inhibitors in artificial systems.  The authors found that heat shock protein 90 (HSP90) inhibitors circumvented the potency shift and suggested that HSP90 inhibition may abrogate JAK inhibitor resistance in these experimental systems.  However, the clinical relevance of these laboratory-generated JAK2 mutations, which have not been identified to-date in patients treated with JAK inhibitors, and the therapeutic potential of HSP90 inhibitors in diseases involving aberrant JAK-STAT signaling remain to be determined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcScWPrS0MCP8Y2y4bB4mnvYfW6udTcc2eaQmO2Cj3J4Nbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FgsV2rug%253D%253D&md5=e8226718916d6711fe850e96eed94126</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.4161%2Fjkst.20293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fjkst.20293%26sid%3Dliteratum%253Aachs%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DSarlis%26aufirst%3DN.%2BJ.%26atitle%3DThe%2520interplay%2520between%2520inhibition%2520of%2520JAK2%2520and%2520Hsp90%26jtitle%3DJAKSTAT%26date%3D2012%26volume%3D1%26spage%3D77%26epage%3D79%26doi%3D10.4161%2Fjkst.20293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, B. P.</span><span> </span><span class="NLM_article-title">KIT mutations in GIST</span> <span class="citation_source-journal">Curr. Opin. Genet. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">7</span><span class="refDoi"> DOI: 10.1016/j.gde.2006.12.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.gde.2006.12.010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=3-7&author=J.+A.+Fletcherauthor=B.+P.+Rubin&title=KIT+mutations+in+GIST&doi=10.1016%2Fj.gde.2006.12.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.gde.2006.12.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gde.2006.12.010%26sid%3Dliteratum%253Aachs%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DRubin%26aufirst%3DB.%2BP.%26atitle%3DKIT%2520mutations%2520in%2520GIST%26jtitle%3DCurr.%2520Opin.%2520Genet.%2520Dev.%26date%3D2007%26volume%3D17%26spage%3D3%26epage%3D7%26doi%3D10.1016%2Fj.gde.2006.12.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group">Rossi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasparotto, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miceli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toffolatti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallina, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scaramel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marzotto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boscato, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messerini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearzi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzoleni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capella, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrigoni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonzogni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sidoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amore, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gronchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maestro, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dei Tos, A. P.</span><span> </span><span class="NLM_article-title">KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study</span> <span class="citation_source-journal">Am. J. Surg. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">922</span><span class="NLM_x">–</span> <span class="NLM_lpage">930</span><span class="refDoi"> DOI: 10.1097/PAS.0000000000000418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1097%2FPAS.0000000000000418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=25970686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A280%3ADC%252BC2MfjsFyguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2015&pages=922-930&author=S.+Rossiauthor=D.+Gasparottoauthor=R.+Miceliauthor=L.+Toffolattiauthor=G.+Gallinaauthor=E.+Scaramelauthor=A.+Marzottoauthor=E.+Boscatoauthor=L.+Messeriniauthor=I.+Bearziauthor=G.+Mazzoleniauthor=C.+Capellaauthor=G.+Arrigoniauthor=A.+Sonzogniauthor=A.+Sidoniauthor=L.+Marianiauthor=P.+Amoreauthor=A.+Gronchiauthor=P.+G.+Casaliauthor=R.+Maestroauthor=A.+P.+Dei+Tos&title=KIT%2C+PDGFRA%2C+and+BRAF+mutational+spectrum+impacts+on+the+natural+history+of+imatinib-naive+localized+GIST%3A+a+population-based+study&doi=10.1097%2FPAS.0000000000000418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study</span></div><div class="casAuthors">Rossi Sabrina; Gasparotto Daniela; Miceli Rosalba; Toffolatti Luisa; Gallina Giovanna; Scaramel Enrico; Marzotto Alessandra; Boscato Elena; Messerini Luca; Bearzi Italo; Mazzoleni Guido; Capella Carlo; Arrigoni Gianluigi; Sonzogni Aurelio; Sidoni Angelo; Mariani Luigi; Amore Paola; Gronchi Alessandro; Casali Paolo G; Maestro Roberta; Dei Tos Angelo P</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of surgical pathology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">922-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The mutation status of KIT or PDGFRA notoriously affects the response of advanced gastrointestinal stromal tumors (GISTs) to tyrosine kinase inhibitors.  Conversely, it is currently still unclear whether mutation status impinges on the prognosis of localized, untreated GISTs.  Hence, at present, this variable is not included in decision making for adjuvant therapy.  A series of 451 primary localized GISTs were analyzed for KIT, PDGFRA, and BRAF mutations.  Univariable and multivariable analyses and a backward selection procedure were used to assess the impact of mutation status on overall survival and to identify prognostically homogenous groups.  Mutation was a significant prognostic indicator of overall survival in naive, localized GISTs (P<0.001): KIT-mutated patients had a worse outcome than PDGFRA-mutated or triple-negative (KIT, PDGFRA, BRAF wild-type) cases.  Multivariable Cox regression models allowed us to identify 3 molecular risk groups: group I exhibited the best outcome and included PDGFRA exon 12, BRAF, and KIT exon 13-mutated cases; group II, of intermediate clinical phenotype (HR=3.06), included triple-negative, KIT exon 17, PDGFRA exon 18 D842V, and PDGFRA exon 14-mutated cases; group III displayed the worst outcome (hazard ratio=4.52), and comprised KIT exon 9 and exon 11 and PDGFRA exon 18 mutations apart from D842V.  This study highlights the prognostic impact of mutation status on the natural course of GIST and suggests that the molecular prognostic grouping may complement the conventional clinicopathologic risk stratification criteria in decision making for adjuvant therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRn1i1qso7YZ0loaUqgkFHkfW6udTcc2eaQmO2Cj3J4Nbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfjsFyguw%253D%253D&md5=85caca04b3567e99602f94a812abbae4</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1097%2FPAS.0000000000000418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FPAS.0000000000000418%26sid%3Dliteratum%253Aachs%26aulast%3DRossi%26aufirst%3DS.%26aulast%3DGasparotto%26aufirst%3DD.%26aulast%3DMiceli%26aufirst%3DR.%26aulast%3DToffolatti%26aufirst%3DL.%26aulast%3DGallina%26aufirst%3DG.%26aulast%3DScaramel%26aufirst%3DE.%26aulast%3DMarzotto%26aufirst%3DA.%26aulast%3DBoscato%26aufirst%3DE.%26aulast%3DMesserini%26aufirst%3DL.%26aulast%3DBearzi%26aufirst%3DI.%26aulast%3DMazzoleni%26aufirst%3DG.%26aulast%3DCapella%26aufirst%3DC.%26aulast%3DArrigoni%26aufirst%3DG.%26aulast%3DSonzogni%26aufirst%3DA.%26aulast%3DSidoni%26aufirst%3DA.%26aulast%3DMariani%26aufirst%3DL.%26aulast%3DAmore%26aufirst%3DP.%26aulast%3DGronchi%26aufirst%3DA.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26aulast%3DMaestro%26aufirst%3DR.%26aulast%3DDei%2BTos%26aufirst%3DA.%2BP.%26atitle%3DKIT%252C%2520PDGFRA%252C%2520and%2520BRAF%2520mutational%2520spectrum%2520impacts%2520on%2520the%2520natural%2520history%2520of%2520imatinib-naive%2520localized%2520GIST%253A%2520a%2520population-based%2520study%26jtitle%3DAm.%2520J.%2520Surg.%2520Pathol.%26date%3D2015%26volume%3D39%26spage%3D922%26epage%3D930%26doi%3D10.1097%2FPAS.0000000000000418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span> </span><span class="NLM_article-title">The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level</span> <span class="citation_source-journal">Leuk. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">575</span><span class="NLM_x">–</span> <span class="NLM_lpage">582</span><span class="refDoi"> DOI: 10.1016/j.leukres.2005.08.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.leukres.2005.08.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=16213582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD28Xit1Clsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2006&pages=575-582&author=W.+Yuauthor=Q.+Raoauthor=M.+Wangauthor=Z.+Tianauthor=D.+Linauthor=X.+Liuauthor=J.+Wang&title=The+Hsp90+inhibitor+17-allylamide-17-demethoxygeldanamycin+induces+apoptosis+and+differentiation+of+Kasumi-1+harboring+the+Asn822Lys+KIT+mutation+and+down-regulates+KIT+protein+level&doi=10.1016%2Fj.leukres.2005.08.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level</span></div><div class="casAuthors">Yu, Wenjuan; Rao, Qing; Wang, Min; Tian, Zheng; Lin, Dong; Liu, Xiangrong; Wang, Jianxiang</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">575-582</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) serves as a chaperone for a no. of cell signaling proteins, including many tyrosine and serine/threonine kinases, which are involved in proliferation and/or survival.  The benzoquinone ansamycin geldanamycin has been shown to bind to Hsp90 and to specifically inhibit this chaperone's function, resulting in client protein destabilization. 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is a chem. deriv. of geldanamycin.  KIT is the receptor for stem cell factor (SCF) and required for normal hematopoiesis.  Mutations in c-Kit result in ligand-independent tyrosine kinase activity and uncontrolled cell proliferation.  Kasumi-1 is t(8;21) acute myeloid leukemia (AML) cell line harboring mutated KIT with Asn822Lys substitution.  Our present studies demonstrate that 17-AAG inhibits Kasumi-1 cells proliferation and exerts apoptosis- and differentiation-inducing effects in a dose- and time-dependent manner.  The growth-inhibitory IC50 value for 17-AAG treatment is 0.62 μmol/L.  Characteristic apoptotic features were confirmed by morphol., internucleosomal DNA fragmentation, and annexin V staining. 17-AAG also causes the G0/G1 block of Kasumi-1 cells.  Significantly, 17-AAG-induced apoptosis of Kasumi-1 cells is assocd. with a decline in KIT protein level.  Our findings strongly suggest that 17-AAG might be an effective therapeutic agent targeting AML cells harboring mutated KIT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXmaHCIsAsBLVg90H21EOLACvtfcHk0lgB-3BoiHA_KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xit1Clsbk%253D&md5=aed39d768b6b0885712cb68856e28905</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2005.08.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2005.08.028%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26aulast%3DRao%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DTian%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DThe%2520Hsp90%2520inhibitor%252017-allylamide-17-demethoxygeldanamycin%2520induces%2520apoptosis%2520and%2520differentiation%2520of%2520Kasumi-1%2520harboring%2520the%2520Asn822Lys%2520KIT%2520mutation%2520and%2520down-regulates%2520KIT%2520protein%2520level%26jtitle%3DLeuk.%2520Res.%26date%3D2006%26volume%3D30%26spage%3D575%26epage%3D582%26doi%3D10.1016%2Fj.leukres.2005.08.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group">Tsujimura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyoi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiotsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishida, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoe, T.</span><span> </span><span class="NLM_article-title">Selective KIT inhibitor KI-328 and Hsp90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia</span> <span class="citation_source-journal">Int. J. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">624</span><span class="NLM_x">–</span> <span class="NLM_lpage">633</span><span class="refDoi"> DOI: 10.1007/s12185-010-0692-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1007%2Fs12185-010-0692-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=20890793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlyktr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2010&pages=624-633&author=A.+Tsujimuraauthor=H.+Kiyoiauthor=Y.+Shiotsuauthor=Y.+Ishikawaauthor=Y.+Moriauthor=H.+Ishidaauthor=T.+Tokiauthor=E.+Itoauthor=T.+Naoe&title=Selective+KIT+inhibitor+KI-328+and+Hsp90+inhibitor+show+different+potency+against+the+type+of+KIT+mutations+recurrently+identified+in+acute+myeloid+leukemia&doi=10.1007%2Fs12185-010-0692-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia</span></div><div class="casAuthors">Tsujimura, Akane; Kiyoi, Hitoshi; Shiotsu, Yukimasa; Ishikawa, Yu-Ichi; Mori, Yumiko; Ishida, Hiroshi; Toki, Tsutomu; Ito, Etsuro; Naoe, Tomoki</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Hematology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">624-633</span>CODEN:
                <span class="NLM_cas:coden">IJHEEY</span>;
        ISSN:<span class="NLM_cas:issn">0925-5710</span>.
    
            (<span class="NLM_cas:orgname">Springer Japan</span>)
        </div><div class="casAbstract">Activating mutations of KIT play an important role in the pathophysiol. of several human malignancies, including acute myeloid leukemia.  Activated KIT kinase is therefore a promising mol. target for the treatment of many malignancies harboring KIT activation.  Here we examd. the potency of a novel KIT inhibitor KI-328 against different types of mutant KIT kinases recurrently identified in AML.  KI-328 shows selective potency against KIT kinase for the in vitro kinase assay, and inhibits the growth of wild-type (Wt)- and mutant-KIT-expressing cells, while it has little potency against D816V-KIT.  Comparable anal. of several potent KIT inhibitors regarding growth inhibitory effects on a variety of mutant-KIT-expressing cells revealed that multi-kinase inhibitors have the same potency against D816V-KIT as other mutant KITs; however, the predominant potency against D816V-KIT was obsd. in heat shock protein 90 (HSP90) inhibitors.  Furthermore, HSP90 inhibitors suppress the growth of D816V-KIT-expressing cells at the concn. at which the growth of other mutant-KIT-expressing cells is not affected.  These results collectively indicated that potent KIT inhibitors have different potency against the type of mutant KIT kinases.  Therefore, KIT inhibitors are required to validate potency against several types of mutant KIT kinases for the clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2QECYq8hX9rVg90H21EOLACvtfcHk0lgB-3BoiHA_KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlyktr3O&md5=ae10484c99fd2fd8b4ebb5e7602ceffa</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1007%2Fs12185-010-0692-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12185-010-0692-8%26sid%3Dliteratum%253Aachs%26aulast%3DTsujimura%26aufirst%3DA.%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DShiotsu%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DMori%26aufirst%3DY.%26aulast%3DIshida%26aufirst%3DH.%26aulast%3DToki%26aufirst%3DT.%26aulast%3DIto%26aufirst%3DE.%26aulast%3DNaoe%26aufirst%3DT.%26atitle%3DSelective%2520KIT%2520inhibitor%2520KI-328%2520and%2520Hsp90%2520inhibitor%2520show%2520different%2520potency%2520against%2520the%2520type%2520of%2520KIT%2520mutations%2520recurrently%2520identified%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DInt.%2520J.%2520Hematol.%26date%3D2010%26volume%3D92%26spage%3D624%26epage%3D633%26doi%3D10.1007%2Fs12185-010-0692-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">Hsp90 inhibition in imatinib-resistant gastrointestinal stromal tumor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">9153</span><span class="NLM_x">–</span> <span class="NLM_lpage">9161</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-0165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F0008-5472.CAN-06-0165" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=9153-9161&author=S.+Bauerauthor=L.+K.+Yuauthor=G.+D.+Demetriauthor=J.+A.+Fletcher&title=Hsp90+inhibition+in+imatinib-resistant+gastrointestinal+stromal+tumor&doi=10.1158%2F0008-5472.CAN-06-0165"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-0165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-0165%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DL.%2BK.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DHsp90%2520inhibition%2520in%2520imatinib-resistant%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D9153%26epage%3D9161%26doi%3D10.1158%2F0008-5472.CAN-06-0165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group">Smyth, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Looy, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Lopez, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wozniak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayeda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schöffski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, N. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallis, N. G.</span><span> </span><span class="NLM_article-title">The Hsp90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1799</span><span class="NLM_x">–</span> <span class="NLM_lpage">1808</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-1046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1535-7163.MCT-11-1046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22714264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOisLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1799-1808&author=T.+Smythauthor=T.+V.+Van+Looyauthor=J.+E.+Curryauthor=A.+M.+Rodriguez-Lopezauthor=A.+Wozniakauthor=M.+Zhuauthor=R.+Donskyauthor=J.+G.+Morganauthor=M.+Mayedaauthor=J.+A.+Fletcherauthor=P.+Sch%C3%B6ffskiauthor=J.+Lyonsauthor=N.+T.+Thompsonauthor=N.+G.+Wallis&title=The+Hsp90+inhibitor%2C+AT13387%2C+is+effective+against+imatinib-sensitive+and+-resistant+gastrointestinal+stromal+tumor+models&doi=10.1158%2F1535-7163.MCT-11-1046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models</span></div><div class="casAuthors">Smyth, Tomoko; Van Looy, Thomas; Curry, Jayne E.; Rodriguez-Lopez, Ana M.; Wozniak, Agnieszka; Zhu, Meijun; Donsky, Rachel; Morgan, Jennifer G.; Mayeda, Mark; Fletcher, Jonathan A.; Schoeffski, Patrick; Lyons, John; Thompson, Neil T.; Wallis, Nicola G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1799-1808</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The majority of gastrointestinal stromal tumors (GIST) are characterized by activating mutations of KIT, an HSP90 client protein.  Further secondary resistance mutations within KIT limit clin. responses to tyrosine kinase inhibitors, such as imatinib.  The dependence of KIT and its mutated forms on HSP90 suggests that HSP90 inhibition might be a valuable treatment option for GIST, which would be equally effective on imatinib-sensitive and -resistant clones.  We investigated the activity of AT13387, a potent HSP90 inhibitor currently being evaluated in clin. trials, in both in vitro and in vivo GIST models.  AT13387 inhibited the proliferation of imatinib-sensitive (GIST882, GIST-T1) and -resistant (GIST430, GIST48) cell lines, including those resistant to the geldanamycin analog HSP90 inhibitor, 17-AAG.  Treatment with AT13387 resulted in depletion of HSP90 client proteins, KIT and AKT, along with their phospho-forms in imatinib-sensitive and -resistant cell lines, irresp. of KIT mutation.  KIT signaling was ablated, whereas HSP70, a marker of HSP90 inhibition, was induced.  In vivo, antitumor activity of AT13387 was showed in both the imatinib-sensitive, GIST-PSW, xenograft model and a newly characterized imatinib-resistant, GIST430, xenograft model.  Induction of HSP70, depletion of phospho-KIT and inhibition of KIT signaling were seen in tumors from both models after treatment with AT13387.  A combination of imatinib and AT13387 treatment in the imatinib-resistant GIST430 model significantly enhanced tumor growth inhibition over either of the monotherapies.  Importantly, the combination of AT13387 and imatinib was well tolerated.  These results suggest AT13387 is an excellent candidate for clin. testing in GIST in combination with imatinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot4atmFxxE_bVg90H21EOLACvtfcHk0lgXsNW7aIL8Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOisLrJ&md5=2649c9efc1250257611243731d0fa561</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-1046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-1046%26sid%3Dliteratum%253Aachs%26aulast%3DSmyth%26aufirst%3DT.%26aulast%3DVan%2BLooy%26aufirst%3DT.%2BV.%26aulast%3DCurry%26aufirst%3DJ.%2BE.%26aulast%3DRodriguez-Lopez%26aufirst%3DA.%2BM.%26aulast%3DWozniak%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DDonsky%26aufirst%3DR.%26aulast%3DMorgan%26aufirst%3DJ.%2BG.%26aulast%3DMayeda%26aufirst%3DM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DSch%25C3%25B6ffski%26aufirst%3DP.%26aulast%3DLyons%26aufirst%3DJ.%26aulast%3DThompson%26aufirst%3DN.%2BT.%26aulast%3DWallis%26aufirst%3DN.%2BG.%26atitle%3DThe%2520Hsp90%2520inhibitor%252C%2520AT13387%252C%2520is%2520effective%2520against%2520imatinib-sensitive%2520and%2520-resistant%2520gastrointestinal%2520stromal%2520tumor%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1799%26epage%3D1808%26doi%3D10.1158%2F1535-7163.MCT-11-1046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group">Dewaele, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wasag, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cools, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sciot, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prenen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandenberghe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wozniak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schöffski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marynen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debiec-Rychter, M.</span><span> </span><span class="NLM_article-title">Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, an Hsp90 inhibitor, against gastrointestinal stromal tumor associated PDGFRAD842V mutation</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">5749</span><span class="NLM_x">–</span> <span class="NLM_lpage">5758</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-0533</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1078-0432.CCR-08-0533" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=18794084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFaitrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=5749-5758&author=B.+Dewaeleauthor=B.+Wasagauthor=J.+Coolsauthor=R.+Sciotauthor=H.+Prenenauthor=P.+Vandenbergheauthor=A.+Wozniakauthor=P.+Sch%C3%B6ffskiauthor=P.+Marynenauthor=M.+Debiec-Rychter&title=Activity+of+dasatinib%2C+a+dual+SRC%2FABL+kinase+inhibitor%2C+and+IPI-504%2C+an+Hsp90+inhibitor%2C+against+gastrointestinal+stromal+tumor+associated+PDGFRAD842V+mutation&doi=10.1158%2F1078-0432.CCR-08-0533"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor-Associated PDGFRAD842V Mutation</span></div><div class="casAuthors">Dewaele, Barbara; Wasag, Bartosz; Cools, Jan; Sciot, Raf; Prenen, Hans; Vandenberghe, Peter; Wozniak, Agnieszka; Schoeffski, Patrick; Marynen, Peter; Debiec-Rychter, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5749-5758</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Activating mutations in platelet-derived growth factor receptor-α (PDGFRA) have been reported in ∼5% to 10% of patients with gastrointestinal stromal tumors (GIST).  Imatinib efficiently inhibits the juxtamembrane PDGFRA mutations, whereas many tyrosine kinase domain activation loop PDGFRA mutations confer primary resistance to imatinib.  In this study, we compared the efficacy of second-line tyrosine kinase inhibitors such as dasatinib, sorafenib, and nilotinib against two GIST-related PDGFRA mutants, PDGFRAD842V and PDGFRAΔDIM842-844.  In addn., we sought to investigate the inhibitory effect of the heat shock protein 90 inhibitor, IPI-504, on these mutants.  Exptl. Design: Primary imatinib-resistant tumor cells and cell lines expressing imatinib-resistant PDGFRAD842V or imatinib-sensitive PDGFRAΔDIM842-844 mutants were treated with different concns. of dasatinib, sorafenib, nilotinib, and IPI-504.  The effect of treatment on proliferation, survival, and signaling was detd.  Results: All inhibitors tested exhibited a high efficacy toward the PDGFRAΔDIM842-844 mutant.  In contrast, ex vivo and in vitro assays revealed that only dasatinib potently inhibited the PDGFRAD842V isoform with an IC50 value of 62 nmol/L.  Sorafenib and nilotinib were significantly less efficacious against this mutation, inhibiting the PDGFRA kinase activity at >1,000 and >5,000 nmol/L, and suppressing the proliferation of the cells expressing the PDGFRAD842V mutant with an IC50 value of 239 and 1,310 nmol/L, resp.  IPI-504 treatment potently inhibited PDGFRA kinase activity by inducing the degrdn. of PDGFRAD842V and PDGFRAΔDIM842-844 at 256 and 182 nmol/L, resp. Conclusions: Treatment with dasatinib or the heat shock protein 90 inhibitor IPI-504 may provide a therapeutic alternative for GIST patients whose tumors carry the imatinib-resistant PDGFRAD842V mutant isoform.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4gIQAF7OaK7Vg90H21EOLACvtfcHk0lh3fhKJRceoeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFaitrrF&md5=d69e8d1c2317678641ac944f59e6121b</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-0533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-0533%26sid%3Dliteratum%253Aachs%26aulast%3DDewaele%26aufirst%3DB.%26aulast%3DWasag%26aufirst%3DB.%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DSciot%26aufirst%3DR.%26aulast%3DPrenen%26aufirst%3DH.%26aulast%3DVandenberghe%26aufirst%3DP.%26aulast%3DWozniak%26aufirst%3DA.%26aulast%3DSch%25C3%25B6ffski%26aufirst%3DP.%26aulast%3DMarynen%26aufirst%3DP.%26aulast%3DDebiec-Rychter%26aufirst%3DM.%26atitle%3DActivity%2520of%2520dasatinib%252C%2520a%2520dual%2520SRC%252FABL%2520kinase%2520inhibitor%252C%2520and%2520IPI-504%252C%2520an%2520Hsp90%2520inhibitor%252C%2520against%2520gastrointestinal%2520stromal%2520tumor%2520associated%2520PDGFRAD842V%2520mutation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D5749%26epage%3D5758%26doi%3D10.1158%2F1078-0432.CCR-08-0533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group">Richardson, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chanan-Khan, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lonial, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnan, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alsina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albitar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study</span> <span class="citation_source-journal">Br. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">153</span><span class="NLM_x">, </span> <span class="NLM_fpage">729</span><span class="NLM_x">–</span> <span class="NLM_lpage">740</span><span class="refDoi"> DOI: 10.1111/j.1365-2141.2011.08664.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1111%2Fj.1365-2141.2011.08664.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=21534941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXoslajtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=2011&pages=729-740&author=P.+G.+Richardsonauthor=A.+A.+Chanan-Khanauthor=S.+Lonialauthor=A.+Y.+Krishnanauthor=M.+P.+Carrollauthor=M.+Alsinaauthor=M.+Albitarauthor=D.+Bermanauthor=M.+Messinaauthor=K.+C.+Anderson&title=Tanespimycin+and+bortezomib+combination+treatment+in+patients+with+relapsed+or+relapsed+and+refractory+multiple+myeloma%3A+results+of+a+phase+1%2F2+study&doi=10.1111%2Fj.1365-2141.2011.08664.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study</span></div><div class="casAuthors">Richardson, Paul G.; Chanan-Khan, Asher A.; Lonial, Sagar; Krishnan, Amrita Y.; Carroll, Michael P.; Alsina, Melissa; Albitar, Maher; Berman, David; Messina, Marianne; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">153</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">729-740</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">This open-label, dose escalation, multicentre phase 1/2 trial was undertaken to det. the safety and tolerability of the heat shock protein 90 (HSP90) inhibitor tanespimycin (100-340 mg/m2) + bortezomib (0.7-1.3 mg/m2) given on days 1, 4, 8 and 11 in each 21-d cycle.  Phase 2 expansion occurred at the highest tested dose of tanespimycin at 340 mg/m2 and bortezomib at 1.3 mg/m2.  Seventy-two patients (median age, 60 years) with relapsed or relapsed and refractory multiple myeloma (MM) were enrolled; 63 patients (89%) completed the study.  Tanespimycin in combination with bortezomib was well tolerated; few patients experienced significant neutropenia, constipation and anorexia (<10%), and no patients developed severe peripheral neuropathy.  Among 67 efficacy-evaluable patients, there were 2 (3%) complete responses and 8 (12%) partial responses, for an objective response rate (ORR) of 27%, including 8 (12%) minimal responses.  Response rates were highest among bortezomib-naive patients and proved durable in all patient subgroups, including those with bortezomib-refractory disease.  Pharmacodynamic analyses indicated that tanespimycin plus bortezomib effectively inhibited the proteasome, as evidenced by decreased 20S proteasome activity, and inhibited HSP90, as reflected by increased HSP70 expression.  The results of this study support addnl. studies of this combination approach in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw1MlwVkziIrVg90H21EOLACvtfcHk0lh3fhKJRceoeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXoslajtrY%253D&md5=c1d4ac3b4758b8830cf2b192979e3961</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2011.08664.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2011.08664.x%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DChanan-Khan%26aufirst%3DA.%2BA.%26aulast%3DLonial%26aufirst%3DS.%26aulast%3DKrishnan%26aufirst%3DA.%2BY.%26aulast%3DCarroll%26aufirst%3DM.%2BP.%26aulast%3DAlsina%26aufirst%3DM.%26aulast%3DAlbitar%26aufirst%3DM.%26aulast%3DBerman%26aufirst%3DD.%26aulast%3DMessina%26aufirst%3DM.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DTanespimycin%2520and%2520bortezomib%2520combination%2520treatment%2520in%2520patients%2520with%2520relapsed%2520or%2520relapsed%2520and%2520refractory%2520multiple%2520myeloma%253A%2520results%2520of%2520a%2520phase%25201%252F2%2520study%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2011%26volume%3D153%26spage%3D729%26epage%3D740%26doi%3D10.1111%2Fj.1365-2141.2011.08664.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group">Schenk, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrickson, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Northfelt, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toft, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ames, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menefee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satele, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlichman, C.</span><span> </span><span class="NLM_article-title">Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1251</span><span class="NLM_x">–</span> <span class="NLM_lpage">1256</span><span class="refDoi"> DOI: 10.1007/s10637-013-9946-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1007%2Fs10637-013-9946-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=1251-1256&author=E.+Schenkauthor=A.+E.+Hendricksonauthor=D.+Northfeltauthor=D.+O.+Toftauthor=M.+M.+Amesauthor=M.+Menefeeauthor=D.+Sateleauthor=R.+Qinauthor=C.+Erlichman&title=Phase+I+study+of+tanespimycin+in+combination+with+bortezomib+in+patients+with+advanced+solid+malignancies&doi=10.1007%2Fs10637-013-9946-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1007%2Fs10637-013-9946-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-013-9946-7%26sid%3Dliteratum%253Aachs%26aulast%3DSchenk%26aufirst%3DE.%26aulast%3DHendrickson%26aufirst%3DA.%2BE.%26aulast%3DNorthfelt%26aufirst%3DD.%26aulast%3DToft%26aufirst%3DD.%2BO.%26aulast%3DAmes%26aufirst%3DM.%2BM.%26aulast%3DMenefee%26aufirst%3DM.%26aulast%3DSatele%26aufirst%3DD.%26aulast%3DQin%26aufirst%3DR.%26aulast%3DErlichman%26aufirst%3DC.%26atitle%3DPhase%2520I%2520study%2520of%2520tanespimycin%2520in%2520combination%2520with%2520bortezomib%2520in%2520patients%2520with%2520advanced%2520solid%2520malignancies%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2013%26volume%3D31%26spage%3D1251%26epage%3D1256%26doi%3D10.1007%2Fs10637-013-9946-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group">Pedersen, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang-Gillam, A</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlichman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McWilliams, R. R.</span><span> </span><span class="NLM_article-title">Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a mayo clinic phase II consortium study</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">963</span><span class="NLM_x">–</span> <span class="NLM_lpage">968</span><span class="refDoi"> DOI: 10.1007/s10637-015-0246-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1007%2Fs10637-015-0246-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=25952464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotFaktr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=963-968&author=K.+S.+Pedersenauthor=G.+P.+Kimauthor=N.+R.+Fosterauthor=A+Wang-Gillamauthor=C.+Erlichmanauthor=R.+R.+McWilliams&title=Phase+II+trial+of+gemcitabine+and+tanespimycin+%2817AAG%29+in+metastatic+pancreatic+cancer%3A+a+mayo+clinic+phase+II+consortium+study&doi=10.1007%2Fs10637-015-0246-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study</span></div><div class="casAuthors">Pedersen, Katrina S.; Kim, George P.; Foster, Nathan R.; Wang-Gillam, Andrea; Erlichman, Charles; McWilliams, Robert R.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">963-968</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Heat Shock Protein 90 (HSP90) is a mol. chaperone that stabilizes many oncogenic proteins.  HSP90 inhibitors may sensitize tumors to cytotoxic agents by causing client protein degrdn.  Gemcitabine, which has modest activity in pancreas cancer, activates Chk1, a client protein of HSP90.  This phase II trial was designed to det. whether 17AAG could enhance the clin. activity of gemcitabine through degrdn. of Chk1 in patients with stage IV pancreatic cancer.  A multicenter, prospective study combining gemcitabine and 17AAG enrolled patients with stage IV pancreatic adenocarcinoma, adequate liver and kidney function, ECOG performance status 0-2, and no prior chemotherapy for metastatic disease.  The primary goal was to achieve a 60 % overall survival at 6 mo.  Sixty-six patients were planned for accrual, with an interim anal. after 25 patients enrolled.  After a futility anal. to achieve the endpoint, accrual was halted with 21 patients enrolled.  No complete or partial responses were seen.  Forty percent of patients were alive at 6 mo.  Median overall survival was 5.4 mo.  Tolerability was moderate, with 65 % of patients having ≥ grade 3 adverse events (AE), and 15 % having grade 4 events.  The lack of clin. activity suggests that targeting Chk1 by inhibiting HSP90 is not important in pancreatic cancer sensitivity to gemcitabine alone.  Further studies of HSP90 targeted agents with gemcitabine alone are not warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3s_FEEPV0JLVg90H21EOLACvtfcHk0lg_x1tTb-DsQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotFaktr4%253D&md5=9f29c2150dcdab2f143dc804ec504da5</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1007%2Fs10637-015-0246-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-015-0246-2%26sid%3Dliteratum%253Aachs%26aulast%3DPedersen%26aufirst%3DK.%2BS.%26aulast%3DKim%26aufirst%3DG.%2BP.%26aulast%3DFoster%26aufirst%3DN.%2BR.%26aulast%3DWang-Gillam%26aufirst%3DA%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3DMcWilliams%26aufirst%3DR.%2BR.%26atitle%3DPhase%2520II%2520trial%2520of%2520gemcitabine%2520and%2520tanespimycin%2520%252817AAG%2529%2520in%2520metastatic%2520pancreatic%2520cancer%253A%2520a%2520mayo%2520clinic%2520phase%2520II%2520consortium%2520study%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2015%26volume%3D33%26spage%3D963%26epage%3D968%26doi%3D10.1007%2Fs10637-015-0246-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group">Wahner Hendrickson, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oberg, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaser, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camoriano, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peethambaram, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colon-Otero, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlichman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karnitz, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haluska, P.</span><span> </span><span class="NLM_article-title">A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma</span> <span class="citation_source-journal">Gynecol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">210</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span><span class="refDoi"> DOI: 10.1016/j.ygyno.2011.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.ygyno.2011.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22047770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1WhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2012&pages=210-215&author=A.+E.+Wahner+Hendricksonauthor=A.+L.+Obergauthor=G.+Glaserauthor=J.+K.+Camorianoauthor=P.+P.+Peethambaramauthor=G.+Colon-Oteroauthor=C.+Erlichmanauthor=S.+P.+Ivyauthor=S.+H.+Kaufmannauthor=L.+M.+Karnitzauthor=P.+Haluska&title=A+phase+II+study+of+gemcitabine+in+combination+with+tanespimycin+in+advanced+epithelial+ovarian+and+primary+peritoneal+carcinoma&doi=10.1016%2Fj.ygyno.2011.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma</span></div><div class="casAuthors">Wahner Hendrickson, Andrea E.; Oberg, Ann L.; Glaser, Gretchen; Camoriano, John K.; Peethambaram, Prema P.; Colon-Otero, Gerardo; Erlichman, Charles; Ivy, S. Percy; Kaufmann, Scott H.; Karnitz, Larry M.; Haluska, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">210-215</span>CODEN:
                <span class="NLM_cas:coden">GYNOA3</span>;
        ISSN:<span class="NLM_cas:issn">0090-8258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Objective: To evaluate the efficacy and biol. effects of the gemcitabine/tanespimycin combination in patients with advanced ovarian and peritoneal cancer.  To assess the effect of tanespimycin on tumor cells, levels of the chaperone proteins HSP90 and HSP70 were examd. in peripheral blood mononuclear cells (PBMC) and paired tumor biopsy lysates.  Methods: Two-cohort phase II clin. trial.  Patients were grouped according to prior gemcitabine therapy.  All participants received tanespimycin 154 mg/m2 on days 1 and 9 of cycle 1 and days 2 and 9 of subsequent cycles.  Patients also received gemcitabine 750 mg/m2 on day 8 of the first treatment cycle and days 1 and 8 of subsequent cycles.  Results: The tanespimycin/gemcitabine combination induced a partial response in 1 gemcitabine naive patient and no partial responses in gemcitabine resistant patients.  Stable disease was seen in 6 patients (2 gemcitabine naive and 4 gemcitabine resistant).  The most common toxicities were hematol. (anemia and neutropenia) as well as nausea and vomiting.  Immunoblotting demonstrated limited upregulation of HSP70 but little or no change in levels of most client proteins in PBMC and paired tumor samples.  Conclusions: Although well tolerated, the tanespimycin/gemcitabine combination exhibited limited anticancer activity in patients with advanced epithelial ovarian and primary peritoneal carcinoma, perhaps because of failure to significantly downregulate the client proteins at clin. achievable exposures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-T12pU461n7Vg90H21EOLACvtfcHk0lg_x1tTb-DsQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1WhsLs%253D&md5=869250ea826ae9c99a0ea0200747e57c</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1016%2Fj.ygyno.2011.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ygyno.2011.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DWahner%2BHendrickson%26aufirst%3DA.%2BE.%26aulast%3DOberg%26aufirst%3DA.%2BL.%26aulast%3DGlaser%26aufirst%3DG.%26aulast%3DCamoriano%26aufirst%3DJ.%2BK.%26aulast%3DPeethambaram%26aufirst%3DP.%2BP.%26aulast%3DColon-Otero%26aufirst%3DG.%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3DIvy%26aufirst%3DS.%2BP.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26aulast%3DKarnitz%26aufirst%3DL.%2BM.%26aulast%3DHaluska%26aufirst%3DP.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520gemcitabine%2520in%2520combination%2520with%2520tanespimycin%2520in%2520advanced%2520epithelial%2520ovarian%2520and%2520primary%2520peritoneal%2520carcinoma%26jtitle%3DGynecol.%2520Oncol.%26date%3D2012%26volume%3D124%26spage%3D210%26epage%3D215%26doi%3D10.1016%2Fj.ygyno.2011.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group">Heath, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hillman, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaishampayan, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkar, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaskins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitot, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pili, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carducci, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlichman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, G.</span><span> </span><span class="NLM_article-title">A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">7940</span><span class="NLM_x">–</span> <span class="NLM_lpage">7946</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-0221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1078-0432.CCR-08-0221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=19047126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVegt7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=7940-7946&author=E.+I.+Heathauthor=D.+W.+Hillmanauthor=U.+Vaishampayanauthor=S.+Shengauthor=F.+Sarkarauthor=F.+Harperauthor=M.+Gaskinsauthor=H.+C.+Pitotauthor=W.+Tanauthor=S.+P.+Ivyauthor=R.+Piliauthor=M.+A.+Carducciauthor=C.+Erlichmanauthor=G.+Liu&title=A+phase+II+trial+of+17-allylamino-17-demethoxygeldanamycin+in+patients+with+hormone-refractory+metastatic+prostate+cancer&doi=10.1158%2F1078-0432.CCR-08-0221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer</span></div><div class="casAuthors">Heath, Elisabeth I.; Hillman, David W.; Vaishampayan, Ulka; Sheng, Shijie; Sarkar, Fazlul; Harper, Felicity; Gaskins, Melvin; Pitot, Henry C.; Tan, Winston; Ivy, S. Percy; Pili, Roberto; Carducci, Michael A.; Erlichman, Charles; Liu, Glenn</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7940-7946</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is a benzoquinone ansamycin antibiotic with antiproliferative activity in several mouse xenograft models, including prostate cancer models.  A two-stage phase II study was conducted to assess the activity and toxicity profile of 17-AAG administered to patients with metastatic, hormone-refractory prostate cancer.  Exptl. Design: Patients with at least one prior systemic therapy and a rising prostate-specific antigen (PSA) were eligible.  Patients received 17-AAG at a dose of 300 mg/m2 i.v. weekly for 3 of 4 wk.  The primary objective was to assess the PSA response.  Secondary objectives were to det. overall survival, to assess toxicity, and to measure interleukin-6, interleukin-8, and maspin levels and quality of life.  RESULTS: Fifteen eligible patients were enrolled.  The median age was 68 years and the median PSA was 261 ng/mL.  Patients received 17-AAG for a median no. of two cycles.  Severe adverse events included grade 3 fatigue (four patients), grade 3 lymphopenia (two patients), and grade 3 back pain (two patients).  The median PSA progression-free survival was 1.8 mo (95% confidence interval, 1.3-3.4 mo).  The 6-mo overall survival was 71% (95% confidence interval, 52-100%).  CONCLUSIONS: 17-AAG did not show any activity with regard to PSA response.  Due to insufficient PSA response, enrollment was stopped at the end of first stage per study design.  The most significant severe toxicity was grade 3 fatigue.  Further evaluation of 17-AAG at a dose of 300 mg/m2 i.v. weekly as a single agent in patients with metastatic, hormone-refractory prostate cancer who received at least one prior systemic therapy is not warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptpyi-7O-7xLVg90H21EOLACvtfcHk0lholAtvA8It3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVegt7%252FI&md5=2292fa62e7694ded8386cf693faae8c0</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-0221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-0221%26sid%3Dliteratum%253Aachs%26aulast%3DHeath%26aufirst%3DE.%2BI.%26aulast%3DHillman%26aufirst%3DD.%2BW.%26aulast%3DVaishampayan%26aufirst%3DU.%26aulast%3DSheng%26aufirst%3DS.%26aulast%3DSarkar%26aufirst%3DF.%26aulast%3DHarper%26aufirst%3DF.%26aulast%3DGaskins%26aufirst%3DM.%26aulast%3DPitot%26aufirst%3DH.%2BC.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DIvy%26aufirst%3DS.%2BP.%26aulast%3DPili%26aufirst%3DR.%26aulast%3DCarducci%26aufirst%3DM.%2BA.%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DG.%26atitle%3DA%2520phase%2520II%2520trial%2520of%252017-allylamino-17-demethoxygeldanamycin%2520in%2520patients%2520with%2520hormone-refractory%2520metastatic%2520prostate%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D7940%26epage%3D7946%26doi%3D10.1158%2F1078-0432.CCR-08-0221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group">Gartner, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorusso, P. M.</span><span> </span><span class="NLM_article-title">A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">933</span><span class="NLM_x">–</span> <span class="NLM_lpage">937</span><span class="refDoi"> DOI: 10.1007/s10549-011-1866-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1007%2Fs10549-011-1866-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22083229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFKmsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2012&pages=933-937&author=E.+M.+Gartnerauthor=P.+Silvermanauthor=M.+Simonauthor=L.+Flahertyauthor=J.+Abramsauthor=P.+Ivyauthor=P.+M.+Lorusso&title=A+phase+II+study+of+17-allylamino-17-demethoxygeldanamycin+in+metastatic+or+locally+advanced%2C+unresectable+breast+cancer&doi=10.1007%2Fs10549-011-1866-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer</span></div><div class="casAuthors">Gartner, Elaina M.; Silverman, Paula; Simon, Michael; Flaherty, Lawrence; Abrams, Judith; Ivy, Percy; LoRusso, Patricia M.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">933-937</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) is an attractive target for breast cancer treatment, as it is required for the proper folding and stabilization of several proteins known to be involved in breast cancer growth and development.  These proteins include the epidermal growth factor receptor, human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), progesterone receptor (PR), and src. 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is an i.v. Hsp90 inhibitor in development for breast cancer treatment.  We conducted a phase II study of 17-AAG 220 mg/m2 on days 1, 4, 8, and 11 every 21 days in patients with metastatic and locally advanced breast cancer.  Since we expected the mol. effects of Hsp90 inhibition to extend beyond just ER, PR, and HER2 down regulation and to impact a variety of other cellular proteins, patients were not selected based on ER, PR, or HER2 status.  Eleven patients, including 6 patients with triple neg. breast cancer, were enrolled and treated.  There were no responses and 3 patients had stable disease as their best response.  Five patients developed grade 3/4 toxicities, which were primarily hepatic and pulmonary.  Based on these results, we do not recommend further study of 17-AAG at this dosing schedule or in unselected breast cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPbrnPczyKWrVg90H21EOLACvtfcHk0lholAtvA8It3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFKmsbg%253D&md5=d2e926f25ffed4022232774aaa410203</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1007%2Fs10549-011-1866-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-011-1866-7%26sid%3Dliteratum%253Aachs%26aulast%3DGartner%26aufirst%3DE.%2BM.%26aulast%3DSilverman%26aufirst%3DP.%26aulast%3DSimon%26aufirst%3DM.%26aulast%3DFlaherty%26aufirst%3DL.%26aulast%3DAbrams%26aufirst%3DJ.%26aulast%3DIvy%26aufirst%3DP.%26aulast%3DLorusso%26aufirst%3DP.%2BM.%26atitle%3DA%2520phase%2520II%2520study%2520of%252017-allylamino-17-demethoxygeldanamycin%2520in%2520metastatic%2520or%2520locally%2520advanced%252C%2520unresectable%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2012%26volume%3D131%26spage%3D933%26epage%3D937%26doi%3D10.1007%2Fs10549-011-1866-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group">Pacey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asad, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisen, T.</span><span> </span><span class="NLM_article-title">A phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">349</span><span class="refDoi"> DOI: 10.1007/s10637-010-9493-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1007%2Fs10637-010-9493-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=341-349&author=S.+Paceyauthor=M.+Goreauthor=D.+Chaoauthor=U.+Banerjiauthor=J.+Larkinauthor=S.+Sarkerauthor=K.+Owenauthor=Y.+Asadauthor=F.+Raynaudauthor=M.+Waltonauthor=I.+Judsonauthor=P.+Workmanauthor=T.+Eisen&title=A+phase+II+trial+of+17-allylamino%2C+17-demethoxygeldanamycin+%2817-AAG%2C+tanespimycin%29+in+patients+with+metastatic+melanoma&doi=10.1007%2Fs10637-010-9493-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1007%2Fs10637-010-9493-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-010-9493-4%26sid%3Dliteratum%253Aachs%26aulast%3DPacey%26aufirst%3DS.%26aulast%3DGore%26aufirst%3DM.%26aulast%3DChao%26aufirst%3DD.%26aulast%3DBanerji%26aufirst%3DU.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DSarker%26aufirst%3DS.%26aulast%3DOwen%26aufirst%3DK.%26aulast%3DAsad%26aufirst%3DY.%26aulast%3DRaynaud%26aufirst%3DF.%26aulast%3DWalton%26aufirst%3DM.%26aulast%3DJudson%26aufirst%3DI.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DEisen%26aufirst%3DT.%26atitle%3DA%2520phase%2520II%2520trial%2520of%252017-allylamino%252C%252017-demethoxygeldanamycin%2520%252817-AAG%252C%2520tanespimycin%2529%2520in%2520patients%2520with%2520metastatic%2520melanoma%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2012%26volume%3D30%26spage%3D341%26epage%3D349%26doi%3D10.1007%2Fs10637-010-9493-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group">Hubbard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlichman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toft, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stensgard, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felten, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ten Eyck, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batzel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haluska, P.</span><span> </span><span class="NLM_article-title">Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">473</span><span class="NLM_x">–</span> <span class="NLM_lpage">480</span><span class="refDoi"> DOI: 10.1007/s10637-009-9381-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1007%2Fs10637-009-9381-y" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=473-480&author=J.+Hubbardauthor=C.+Erlichmanauthor=D.+O.+Toftauthor=R.+Qinauthor=B.+A.+Stensgardauthor=S.+Feltenauthor=C.+Ten+Eyckauthor=G.+Batzelauthor=S.+P.+Ivyauthor=P.+Haluska&title=Phase+I+study+of+17-allylamino-17+demethoxygeldanamycin%2C+gemcitabine+and%2For+cisplatin+in+patients+with+refractory+solid+tumors&doi=10.1007%2Fs10637-009-9381-y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1007%2Fs10637-009-9381-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-009-9381-y%26sid%3Dliteratum%253Aachs%26aulast%3DHubbard%26aufirst%3DJ.%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3DToft%26aufirst%3DD.%2BO.%26aulast%3DQin%26aufirst%3DR.%26aulast%3DStensgard%26aufirst%3DB.%2BA.%26aulast%3DFelten%26aufirst%3DS.%26aulast%3DTen%2BEyck%26aufirst%3DC.%26aulast%3DBatzel%26aufirst%3DG.%26aulast%3DIvy%26aufirst%3DS.%2BP.%26aulast%3DHaluska%26aufirst%3DP.%26atitle%3DPhase%2520I%2520study%2520of%252017-allylamino-17%2520demethoxygeldanamycin%252C%2520gemcitabine%2520and%252For%2520cisplatin%2520in%2520patients%2520with%2520refractory%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2011%26volume%3D29%26spage%3D473%26epage%3D480%26doi%3D10.1007%2Fs10637-009-9381-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Litzow, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesa, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steensma, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flatten, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loegering, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reid, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ames, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlichman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karnitz, L. M.</span><span> </span><span class="NLM_article-title">Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia</span> <span class="citation_source-journal">Haematologica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">1619</span><span class="NLM_x">–</span> <span class="NLM_lpage">1626</span><span class="refDoi"> DOI: 10.3324/haematol.2011.049551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.3324%2Fhaematol.2011.049551" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2011&pages=1619-1626&author=S.+H.+Kaufmannauthor=J.+E.+Karpauthor=M.+R.+Litzowauthor=R.+A.+Mesaauthor=W.+Hoganauthor=D.+P.+Steensmaauthor=K.+S.+Flattenauthor=D.+A.+Loegeringauthor=P.+A.+Schneiderauthor=K.+L.+Petersonauthor=M.+J.+Maurerauthor=B.+D.+Smithauthor=J.+Greerauthor=Y.+Chenauthor=J.+M.+Reidauthor=S.+P.+Ivyauthor=M.+M.+Amesauthor=A.+A.+Adjeiauthor=C.+Erlichmanauthor=L.+M.+Karnitz&title=Phase+I+and+pharmacological+study+of+cytarabine+and+tanespimycin+in+relapsed+and+refractory+acute+leukemia&doi=10.3324%2Fhaematol.2011.049551"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2011.049551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2011.049551%26sid%3Dliteratum%253Aachs%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26aulast%3DKarp%26aufirst%3DJ.%2BE.%26aulast%3DLitzow%26aufirst%3DM.%2BR.%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DHogan%26aufirst%3DW.%26aulast%3DSteensma%26aufirst%3DD.%2BP.%26aulast%3DFlatten%26aufirst%3DK.%2BS.%26aulast%3DLoegering%26aufirst%3DD.%2BA.%26aulast%3DSchneider%26aufirst%3DP.%2BA.%26aulast%3DPeterson%26aufirst%3DK.%2BL.%26aulast%3DMaurer%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DGreer%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DReid%26aufirst%3DJ.%2BM.%26aulast%3DIvy%26aufirst%3DS.%2BP.%26aulast%3DAmes%26aufirst%3DM.%2BM.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3DKarnitz%26aufirst%3DL.%2BM.%26atitle%3DPhase%2520I%2520and%2520pharmacological%2520study%2520of%2520cytarabine%2520and%2520tanespimycin%2520in%2520relapsed%2520and%2520refractory%2520acute%2520leukemia%26jtitle%3DHaematologica%26date%3D2011%26volume%3D96%26spage%3D1619%26epage%3D1626%26doi%3D10.3324%2Fhaematol.2011.049551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group">Iyer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rathkopf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slovin, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeLaCruz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heller, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egorin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scher, H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D. B.</span><span> </span><span class="NLM_article-title">A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">1089</span><span class="NLM_x">–</span> <span class="NLM_lpage">1097</span><span class="refDoi"> DOI: 10.1007/s00280-011-1789-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1007%2Fs00280-011-1789-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=22124669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVCrsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=1089-1097&author=G.+Iyerauthor=M.+J.+Morrisauthor=D.+Rathkopfauthor=S.+F.+Slovinauthor=M.+Steersauthor=S.+M.+Larsonauthor=L.+H.+Schwartzauthor=T.+Curleyauthor=A.+DeLaCruzauthor=Q.+Yeauthor=G.+Hellerauthor=M.+J.+Egorinauthor=S.+P.+Ivyauthor=N.+Rosenauthor=H.+I.+Scherauthor=D.+B.+Solit&title=A+phase+I+trial+of+docetaxel+and+pulse-dose+17-allylamino-17-demethoxygeldanamycin+in+adult+patients+with+solid+tumors&doi=10.1007%2Fs00280-011-1789-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors</span></div><div class="casAuthors">Iyer, Gopa; Morris, Michael J.; Rathkopf, Dana; Slovin, Susan F.; Steers, Macaulay; Larson, Steven M.; Schwartz, Lawrence H.; Curley, Tracy; DeLaCruz, Anthony; Ye, Qing; Heller, Glenn; Egorin, Merrill J.; Ivy, S. Percy; Rosen, Neal; Scher, Howard I.; Solit, David B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1089-1097</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose. To define max. tolerated dose (MTD), clin. toxicities, and pharmacokinetics of 17-allylamino-17-demethoxygeldanamycin (17-AAG) when administered in combination with docetaxel once every 21 days in patients with advanced solid tumor malignancies.  Exptl. design Docetaxel was administered over 1 h at doses of 55, 70, and 75 mg/m2. 17-AAG was administered over 1-2 h, following the completion of the docetaxel infusion, at escalating doses ranging from 80 to 650 mg/m2 in 12 patient cohorts.  Serum was collected for pharmacokinetic and pharmacodynamic studies during cycle 1.  Docetaxel, 17-AAG, and 17-AG levels were detd. by high-performance liq. chromatog.  Biol. effects of 17-AAG were monitored in peripheral blood mononuclear cells by immunoblot.  Results. Forty-nine patients received docetaxel and 17-AAG.  The most common all-cause grade 3 and 4 toxicities were leukopenia, lymphopenia, and neutropenia.  An MTD was not defined; however, three dose-limiting toxicities were obsd., including 2 incidences of neutropenic fever and 1 of junctional bradycardia.  Dose escalation was halted at docetaxel 75 mg/m2-17-AAG 650 mg/m2 due to delayed toxicities attributed to patient intolerance of the DMSO-based 17-AAG formulation.  Of 46 evaluable patients, 1 patient with lung cancer experienced a partial response.  Minor responses were obsd. in patients with lung, prostate, melanoma, and bladder cancers.  A correlation between reduced docetaxel clearance and 17-AAG dose level was obsd.  Conclusions. The combination of docetaxel and 17-AAG was well tolerated in adult patients with solid tumors, although patient intolerance to the DMSO formulation precluded further dose escalation.  The recommended phase II dose is docetaxel 70 mg/m2 and 17-AAG 500 mg/m2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvmRRqmnGc67Vg90H21EOLACvtfcHk0lgXZTphwgxDfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVCrsrc%253D&md5=2d520d32e69f8712ae6b251b606aef42</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1007%2Fs00280-011-1789-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-011-1789-3%26sid%3Dliteratum%253Aachs%26aulast%3DIyer%26aufirst%3DG.%26aulast%3DMorris%26aufirst%3DM.%2BJ.%26aulast%3DRathkopf%26aufirst%3DD.%26aulast%3DSlovin%26aufirst%3DS.%2BF.%26aulast%3DSteers%26aufirst%3DM.%26aulast%3DLarson%26aufirst%3DS.%2BM.%26aulast%3DSchwartz%26aufirst%3DL.%2BH.%26aulast%3DCurley%26aufirst%3DT.%26aulast%3DDeLaCruz%26aufirst%3DA.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DHeller%26aufirst%3DG.%26aulast%3DEgorin%26aufirst%3DM.%2BJ.%26aulast%3DIvy%26aufirst%3DS.%2BP.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DScher%26aufirst%3DH.%2BI.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26atitle%3DA%2520phase%2520I%2520trial%2520of%2520docetaxel%2520and%2520pulse-dose%252017-allylamino-17-demethoxygeldanamycin%2520in%2520adult%2520patients%2520with%2520solid%2520tumors%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2012%26volume%3D69%26spage%3D1089%26epage%3D1097%26doi%3D10.1007%2Fs00280-011-1789-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group">Pacey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eatock, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hardcastle, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zetterlund, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arkenau, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno-Farre, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roels, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peachey, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I.</span><span> </span><span class="NLM_article-title">A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1561</span><span class="NLM_x">–</span> <span class="NLM_lpage">1570</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-10-1927</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1078-0432.CCR-10-1927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=21278242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFChtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=1561-1570&author=S.+Paceyauthor=R.+H.+Wilsonauthor=M.+Waltonauthor=M.+M.+Eatockauthor=A.+Hardcastleauthor=A.+Zetterlundauthor=H.+T.+Arkenauauthor=J.+Moreno-Farreauthor=U.+Banerjiauthor=B.+Roelsauthor=H.+Peacheyauthor=W.+Aherneauthor=J.+S.+de+Bonoauthor=F.+Raynaudauthor=P.+Workmanauthor=I.+Judson&title=A+phase+I+study+of+the+heat+shock+protein+90+inhibitor+alvespimycin+%2817-DMAG%29+given+intravenously+to+patients+with+advanced+solid+tumors&doi=10.1158%2F1078-0432.CCR-10-1927"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Pacey, Simon; Wilson, Richard H.; Walton, Mike; Eatock, Martin M.; Hardcastle, Anthea; Zetterlund, Anna; Arkenau, Hendrik-Tobias; Moreno-Farre, Javier; Banerji, Udai; Roels, Belle; Peachey, Heidi; Aherne, Wynne; de Bono, Johan S.; Raynaud, Florence; Workman, Paul; Judson, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1561-1570</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A phase I study to define toxicity and recommend a phase II dose of the HSP90 inhibitor alvespimycin (17-DMAG; 17-dimethylaminoethylamino-17-demethoxygeldanamycin).  Secondary endpoints included evaluation of pharmacokinetic profile, tumor response, and definition of a biol. ED (BED).  Patients with advanced solid cancers were treated with weekly, i.v. 17-DMAG.  An accelerated titrn. dose escalation design was used.  The max. tolerated dose (MTD) was the highest dose at which ≤1/6 patients experienced dose limiting toxicity (DLT).  Dose de-escalation from the MTD was planned with mandatory, sequential tumor biopsies to det. a BED.  Pharmacokinetic and pharmacodynamic assays were validated prior to patient accrual.  25 Patients received 17-DMAG (range 2.5-106 mg/m2).  At 106 mg/m2 of 17-DMAG 2/4 patients experienced DLT, including one treatment-related death.  No DLT occurred at 80 mg/m2.  Common adverse events were gastrointestinal, liver function changes, and ocular.  Area under the curve and mean peak concn. increased proportionally with 17-DMAG doses 80 mg/m2 or less.  In peripheral blood mononuclear cells significant (P < 0.05) HSP72 induction was detected (≥20 mg/m2) and sustained for 96 h (≥40 mg/m2).  Plasma HSP72 levels were greatest in the two patients who experienced DLT.  At 80 mg/m2 client protein (CDK4, LCK) depletion was detected and tumor samples from 3 of 5 patients confirmed HSP90 inhibition.  Clin. activity included complete response (castration refractory prostate cancer, CRPC 124 wk), partial response (melanoma, 159 wk), and stable disease (chondrosarcoma, CRPC, and renal cancer for 28, 59, and 76 wk, resp.).  The recommended phase II dose of 17-DMAG is 80 mg/m2 weekly i.v.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMLxm3kvKAe7Vg90H21EOLACvtfcHk0lgXZTphwgxDfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFChtrw%253D&md5=964d12c9ee4eb41f11de41d41b98a40c</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-1927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-1927%26sid%3Dliteratum%253Aachs%26aulast%3DPacey%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DR.%2BH.%26aulast%3DWalton%26aufirst%3DM.%26aulast%3DEatock%26aufirst%3DM.%2BM.%26aulast%3DHardcastle%26aufirst%3DA.%26aulast%3DZetterlund%26aufirst%3DA.%26aulast%3DArkenau%26aufirst%3DH.%2BT.%26aulast%3DMoreno-Farre%26aufirst%3DJ.%26aulast%3DBanerji%26aufirst%3DU.%26aulast%3DRoels%26aufirst%3DB.%26aulast%3DPeachey%26aufirst%3DH.%26aulast%3DAherne%26aufirst%3DW.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DRaynaud%26aufirst%3DF.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DJudson%26aufirst%3DI.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520the%2520heat%2520shock%2520protein%252090%2520inhibitor%2520alvespimycin%2520%252817-DMAG%2529%2520given%2520intravenously%2520to%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D1561%26epage%3D1570%26doi%3D10.1158%2F1078-0432.CCR-10-1927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group">Kummar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutierrez, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figg, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zajac-Kaye, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yancey, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horneffer, Y. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juwara, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melillo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neckers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steeg, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conley, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giaccone, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doroshow, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murgo, A. J.</span><span> </span><span class="NLM_article-title">Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">340</span><span class="NLM_x">–</span> <span class="NLM_lpage">347</span><span class="refDoi"> DOI: 10.1016/j.ejca.2009.10.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.ejca.2009.10.026" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2010&pages=340-347&author=S.+Kummarauthor=M.+E.+Gutierrezauthor=E.+R.+Gardnerauthor=X.+Chenauthor=W.+D.+Figgauthor=M.+Zajac-Kayeauthor=M.+Chenauthor=S.+M.+Steinbergauthor=C.+A.+Muirauthor=M.+A.+Yanceyauthor=Y.+R.+Hornefferauthor=L.+Juwaraauthor=G.+Melilloauthor=S.+P.+Ivyauthor=M.+Merinoauthor=L.+Neckersauthor=P.+S.+Steegauthor=B.+A.+Conleyauthor=G.+Giacconeauthor=J.+H.+Doroshowauthor=A.+J.+Murgo&title=Phase+I+trial+of+17-dimethylaminoethylamino-17-demethoxygeldanamycin+%2817-DMAG%29%2C+a+heat+shock+protein+inhibitor%2C+administered+twice+weekly+in+patients+with+advanced+malignancies&doi=10.1016%2Fj.ejca.2009.10.026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2009.10.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2009.10.026%26sid%3Dliteratum%253Aachs%26aulast%3DKummar%26aufirst%3DS.%26aulast%3DGutierrez%26aufirst%3DM.%2BE.%26aulast%3DGardner%26aufirst%3DE.%2BR.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DFigg%26aufirst%3DW.%2BD.%26aulast%3DZajac-Kaye%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DSteinberg%26aufirst%3DS.%2BM.%26aulast%3DMuir%26aufirst%3DC.%2BA.%26aulast%3DYancey%26aufirst%3DM.%2BA.%26aulast%3DHorneffer%26aufirst%3DY.%2BR.%26aulast%3DJuwara%26aufirst%3DL.%26aulast%3DMelillo%26aufirst%3DG.%26aulast%3DIvy%26aufirst%3DS.%2BP.%26aulast%3DMerino%26aufirst%3DM.%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DSteeg%26aufirst%3DP.%2BS.%26aulast%3DConley%26aufirst%3DB.%2BA.%26aulast%3DGiaccone%26aufirst%3DG.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DMurgo%26aufirst%3DA.%2BJ.%26atitle%3DPhase%2520I%2520trial%2520of%252017-dimethylaminoethylamino-17-demethoxygeldanamycin%2520%252817-DMAG%2529%252C%2520a%2520heat%2520shock%2520protein%2520inhibitor%252C%2520administered%2520twice%2520weekly%2520in%2520patients%2520with%2520advanced%2520malignancies%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2010%26volume%3D46%26spage%3D340%26epage%3D347%26doi%3D10.1016%2Fj.ejca.2009.10.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group">Oh, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galsky, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stadler, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srinivas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bubley, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goddard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunbar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, R. W.</span><span> </span><span class="NLM_article-title">Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer</span> <span class="citation_source-journal">Urology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">626</span><span class="NLM_x">–</span> <span class="NLM_lpage">630</span><span class="refDoi"> DOI: 10.1016/j.urology.2011.04.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.urology.2011.04.041" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2011&pages=626-630&author=W.+K.+Ohauthor=M.+D.+Galskyauthor=W.+M.+Stadlerauthor=S.+Srinivasauthor=F.+Chuauthor=G.+Bubleyauthor=J.+Goddardauthor=J.+Dunbarauthor=R.+W.+Ross&title=Multicenter+phase+II+trial+of+the+heat+shock+protein+90+inhibitor%2C+retaspimycin+hydrochloride+%28IPI-504%29%2C+in+patients+with+castration-resistant+prostate+cancer&doi=10.1016%2Fj.urology.2011.04.041"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.urology.2011.04.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.urology.2011.04.041%26sid%3Dliteratum%253Aachs%26aulast%3DOh%26aufirst%3DW.%2BK.%26aulast%3DGalsky%26aufirst%3DM.%2BD.%26aulast%3DStadler%26aufirst%3DW.%2BM.%26aulast%3DSrinivas%26aufirst%3DS.%26aulast%3DChu%26aufirst%3DF.%26aulast%3DBubley%26aufirst%3DG.%26aulast%3DGoddard%26aufirst%3DJ.%26aulast%3DDunbar%26aufirst%3DJ.%26aulast%3DRoss%26aufirst%3DR.%2BW.%26atitle%3DMulticenter%2520phase%2520II%2520trial%2520of%2520the%2520heat%2520shock%2520protein%252090%2520inhibitor%252C%2520retaspimycin%2520hydrochloride%2520%2528IPI-504%2529%252C%2520in%2520patients%2520with%2520castration-resistant%2520prostate%2520cancer%26jtitle%3DUrology%26date%3D2011%26volume%3D78%26spage%3D626%26epage%3D630%26doi%3D10.1016%2Fj.urology.2011.04.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group">Wagner, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chugh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunbar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Normant, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grayzel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span> </span><span class="NLM_article-title">A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6020</span><span class="NLM_x">–</span> <span class="NLM_lpage">6029</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1078-0432.CCR-13-0953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=24045182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslartrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=6020-6029&author=A.+J.+Wagnerauthor=R.+Chughauthor=L.+S.+Rosenauthor=J.+A.+Morganauthor=S.+Georgeauthor=M.+Gordonauthor=J.+Dunbarauthor=E.+Normantauthor=D.+Grayzelauthor=G.+D.+Demetri&title=A+phase+I+study+of+the+HSP90+inhibitor+retaspimycin+hydrochloride+%28IPI-504%29+in+patients+with+gastrointestinal+stromal+tumors+or+soft-tissue+sarcomas&doi=10.1158%2F1078-0432.CCR-13-0953"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas</span></div><div class="casAuthors">Wagner, Andrew J.; Chugh, Rashmi; Rosen, Lee S.; Morgan, Jeffrey A.; George, Suzanne; Gordon, Michael; Dunbar, Joi; Normant, Emmanuel; Grayzel, David; Demetri, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6020-6029</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Heat shock protein 90 (HSP90) is required for the proper folding, function, and stability of various client proteins, two of which (KIT and PDGFRα) are crit. in the pathogenesis and progression of gastrointestinal stromal tumors (GIST).  This phase I study investigated the safety and max. tolerated dose (MTD) of retaspimycin hydrochloride (IPI-504), a novel potent and selective HSP90 inhibitor, in patients with metastatic and/or unresectable GIST or other soft-tissue sarcomas (STS).  Exptl. Design: IPI-504 was administered i.v. at doses ranging from 90 to 500 mg/m2 twice weekly for 2 wk on/1 wk off.  Safety, pharmacokinetic, and pharmacodynamic profiles were detd.  Response was assessed by Response Evaluation Criteria for Solid Tumors (RECIST) 1.0 and optionally via 18-fluorodeoxyglucose positron emission tomog. (18-FDG-PET) imaging.  Results: Fifty-four patients received IPI-504; 37 with GIST and 17 with other STS.  The MTD was 400 mg/m2 twice weekly for 2 wk on/1 wk off.  Common related adverse events were fatigue (59%), headache (44%), and nausea (43%).  Exposure to IPI-504, 17-AAG, and 17-AG increased with IPI-504 dose.  Stable disease (SD) was obsd. in 70% (26 of 37) of patients with GIST and 59% (10 of 17) of patients with STS.  There was one confirmed partial response (PR) in a patient with GIST and one PR in a patient with liposarcoma.  Metabolic partial responses occurred in 11 of 29 (38%) patients with GIST.  Conclusions: In this study of advanced GIST or other STS, IPI-504 was generally well-tolerated with some evidence of antitumor activity, serving as a clin. proof-of-concept that HSP90 inhibition remains a promising strategy.  Clin Cancer Res; 19(21); 6020-9. 2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVRMGwZ4YMWbVg90H21EOLACvtfcHk0li05Q7l1mS9yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslartrzM&md5=7b84094fc8bc4420ab5d3574c68eaae0</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0953%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DA.%2BJ.%26aulast%3DChugh%26aufirst%3DR.%26aulast%3DRosen%26aufirst%3DL.%2BS.%26aulast%3DMorgan%26aufirst%3DJ.%2BA.%26aulast%3DGeorge%26aufirst%3DS.%26aulast%3DGordon%26aufirst%3DM.%26aulast%3DDunbar%26aufirst%3DJ.%26aulast%3DNormant%26aufirst%3DE.%26aulast%3DGrayzel%26aufirst%3DD.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520the%2520HSP90%2520inhibitor%2520retaspimycin%2520hydrochloride%2520%2528IPI-504%2529%2520in%2520patients%2520with%2520gastrointestinal%2520stromal%2520tumors%2520or%2520soft-tissue%2520sarcomas%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D6020%26epage%3D6029%26doi%3D10.1158%2F1078-0432.CCR-13-0953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group">Siegel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagannath, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vesole, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borello, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazumder, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsiades, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goddard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunbar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Normant, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grayzel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P.</span><span> </span><span class="NLM_article-title">A phase I study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma</span> <span class="citation_source-journal">Leuk. Lymphoma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">2308</span><span class="NLM_x">–</span> <span class="NLM_lpage">2315</span><span class="refDoi"> DOI: 10.3109/10428194.2011.600481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.3109%2F10428194.2011.600481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=21851215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFeqsLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2011&pages=2308-2315&author=D.+Siegelauthor=S.+Jagannathauthor=D.+H.+Vesoleauthor=I.+Borelloauthor=A.+Mazumderauthor=C.+Mitsiadesauthor=J.+Goddardauthor=J.+Dunbarauthor=E.+Normantauthor=J.+Adamsauthor=D.+Grayzelauthor=K.+C.+Andersonauthor=P.+Richardson&title=A+phase+I+study+of+IPI-504+%28retaspimycin+hydrochloride%29+in+patients+with+relapsed+or+relapsed+and+refractory+multiple+myeloma&doi=10.3109%2F10428194.2011.600481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma</span></div><div class="casAuthors">Siegel, David; Jagannath, Sundar; Vesole, David H.; Borello, Ivan; Mazumder, Amitabha; Mitsiades, Constantine; Goddard, Jill; Dunbar, Joi; Normant, Emmanuel; Adams, Julian; Grayzel, David; Anderson, Kenneth C.; Richardson, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2308-2315</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1029-2403</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A phase 1 study of IPI-504 (retaspimycin hydrochloride) administered i.v. twice weekly for 2 wk at 22.5, 45, 90, 150, 225, 300 or 400 mg/m2 followed by 10 days off-treatment was conducted to det. the safety and max. tolerated dose (MTD) of IPI-504 in patients with relapsed or relapsed/refractory multiple myeloma (MM).  Anti-tumor activity and pharmacokinetics were also evaluated.  Eighteen patients (mean age 60.5 years; median 9 prior therapies) were enrolled.  No dose-limiting toxicities (DLTs) were reported for IPI-504 doses up to 400 mg/m2.  The most common treatment-related adverse event was grade 1 infusion site pain (four patients).  All other treatment-related events were assessed as grade 1 or 2 in severity.  The area under the curve (AUC) increased with increasing dose, and the mean half-life was approx. 2-4 h for IPI-504 and its metabolites.  Four patients had stable disease, demonstrating modest single-agent activity in relapsed or relapsed/refractory MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9MaC9a0KML7Vg90H21EOLACvtfcHk0li05Q7l1mS9yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFeqsLfI&md5=7be83ec5b9b1fdfe361a3bc7633b894f</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.3109%2F10428194.2011.600481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10428194.2011.600481%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DJagannath%26aufirst%3DS.%26aulast%3DVesole%26aufirst%3DD.%2BH.%26aulast%3DBorello%26aufirst%3DI.%26aulast%3DMazumder%26aufirst%3DA.%26aulast%3DMitsiades%26aufirst%3DC.%26aulast%3DGoddard%26aufirst%3DJ.%26aulast%3DDunbar%26aufirst%3DJ.%26aulast%3DNormant%26aufirst%3DE.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DGrayzel%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DRichardson%26aufirst%3DP.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520IPI-504%2520%2528retaspimycin%2520hydrochloride%2529%2520in%2520patients%2520with%2520relapsed%2520or%2520relapsed%2520and%2520refractory%2520multiple%2520myeloma%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2011%26volume%3D52%26spage%3D2308%26epage%3D2315%26doi%3D10.3109%2F10428194.2011.600481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group">Ramalingam, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goss, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid-Bindert, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaric, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andric, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bondarenko, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komov, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceric, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khuri, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samarzija, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciuleanu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wehler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spicer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheldon, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teofilovici, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vukovic, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fennell, D.</span><span> </span><span class="NLM_article-title">A randomized phase II study of ganetespib, an Hsp90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1741</span><span class="NLM_x">–</span> <span class="NLM_lpage">1748</span><span class="refDoi"> DOI: 10.1093/annonc/mdv220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1093%2Fannonc%2Fmdv220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=25997818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A280%3ADC%252BC2Mfmt1Wqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=1741-1748&author=S.+Ramalingamauthor=G.+Gossauthor=R.+Rosellauthor=G.+Schmid-Bindertauthor=B.+Zaricauthor=Z.+Andricauthor=I.+Bondarenkoauthor=D.+Komovauthor=T.+Cericauthor=F.+Khuriauthor=M.+Samarzijaauthor=E.+Felipauthor=T.+Ciuleanuauthor=V.+Hirshauthor=T.+Wehlerauthor=J.+Spicerauthor=R.+Salgiaauthor=G.+Shapiroauthor=E.+Sheldonauthor=F.+Teofiloviciauthor=V.+Vukovicauthor=D.+Fennell&title=A+randomized+phase+II+study+of+ganetespib%2C+an+Hsp90+inhibitor%2C+in+combination+with+docetaxel+in+second-line+therapy+of+advanced+non-small+cell+lung+cancer+%28GALAXY-1%29&doi=10.1093%2Fannonc%2Fmdv220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)</span></div><div class="casAuthors">Ramalingam S; Khuri F; Goss G; Rosell R; Schmid-Bindert G; Zaric B; Andric Z; Bondarenko I; Komov D; Ceric T; Samarzija M; Felip E; Ciuleanu T; Hirsh V; Wehler T; Spicer J; Salgia R; Shapiro G; Sheldon E; Teofilovici F; Vukovic V; Fennell D</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1741-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  This trial was designed to evaluate the activity and safety of ganetespib in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) and to identify patient populations most likely to benefit from the combination.  PATIENTS AND METHODS:  Patients with one prior systemic therapy for advanced disease were eligible.  Docetaxel (75 mg/m(2) on day 1) was administered alone or with ganetespib (150 mg/m(2) on days 1 and 15) every 3 weeks.  The primary end points were progression-free survival (PFS) in two subgroups of the adenocarcinoma population: patients with elevated lactate dehydrogenase (eLDH) and mutated KRAS (mKRAS).  RESULTS:  Of 385 patients enrolled, 381 were treated.  Early in the trial, increased hemoptysis and lack of efficacy were observed in nonadenocarcinoma patients (n = 71); therefore, only patients with adenocarcinoma histology were subsequently enrolled.  Neutropenia was the most common grade ≥3 adverse event: 41% in the combination arm versus 42% in docetaxel alone.  There was no improvement in PFS for the combination arm in the eLDH (N = 114, adjusted hazard ratio (HR) = 0.77, P = 0.1134) or mKRAS (N = 89, adjusted HR = 1.11, P = 0.3384) subgroups.  In the intent-to-treat adenocarcinoma population, there was a trend in favor of the combination, with PFS (N = 253, adjusted HR = 0.82, P = 0.0784) and overall survival (OS) (adjusted HR = 0.84, P = 0.1139).  Exploratory analyses showed significant benefit of the ganetespib combination in the prespecified subgroup of adenocarcinoma patients diagnosed with advanced disease >6 months before study entry (N = 177): PFS (adjusted HR = 0.74, P = 0.0417); OS (adjusted HR = 0.69, P = 0.0191).  CONCLUSION:  Advanced lung adenocarcinoma patients treated with ganetespib in combination with docetaxel had an acceptable safety profile.  While the study's primary end points were not met, significant prolongation of PFS and OS was observed in patients >6 months from diagnosis of advanced disease, a subgroup chosen as the target population for the phase III study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSN5VxVyhJaE0PI-fCgwosgfW6udTcc2eaPyDdXWEKJUbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mfmt1Wqsw%253D%253D&md5=cff9b71d0bb8b17bd09d5d234d3ce6ff</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdv220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdv220%26sid%3Dliteratum%253Aachs%26aulast%3DRamalingam%26aufirst%3DS.%26aulast%3DGoss%26aufirst%3DG.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DSchmid-Bindert%26aufirst%3DG.%26aulast%3DZaric%26aufirst%3DB.%26aulast%3DAndric%26aufirst%3DZ.%26aulast%3DBondarenko%26aufirst%3DI.%26aulast%3DKomov%26aufirst%3DD.%26aulast%3DCeric%26aufirst%3DT.%26aulast%3DKhuri%26aufirst%3DF.%26aulast%3DSamarzija%26aufirst%3DM.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCiuleanu%26aufirst%3DT.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DWehler%26aufirst%3DT.%26aulast%3DSpicer%26aufirst%3DJ.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DShapiro%26aufirst%3DG.%26aulast%3DSheldon%26aufirst%3DE.%26aulast%3DTeofilovici%26aufirst%3DF.%26aulast%3DVukovic%26aufirst%3DV.%26aulast%3DFennell%26aufirst%3DD.%26atitle%3DA%2520randomized%2520phase%2520II%2520study%2520of%2520ganetespib%252C%2520an%2520Hsp90%2520inhibitor%252C%2520in%2520combination%2520with%2520docetaxel%2520in%2520second-line%2520therapy%2520of%2520advanced%2520non-small%2520cell%2520lung%2520cancer%2520%2528GALAXY-1%2529%26jtitle%3DAnn.%2520Oncol.%26date%3D2015%26volume%3D26%26spage%3D1741%26epage%3D1748%26doi%3D10.1093%2Fannonc%2Fmdv220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group">Jhaveri, K.; Chandarlapaty, S.; Lake, D.; Gilewski, T.; Drullinsky, P.; Sugarman, S.; Wasserheit-Leiblich, C.; Moynahan, M. E.; D’Andrea, G.; Haque, S.; Patil, S.; Bauman, L.; Vukovic, V.; EI-Hariry, I.; Hudis, C.; Modi, S.</span><span> </span><span class="NLM_article-title">A phase II trial of ganetespib: efficacy and safety in patients (pts) with metastatic breast cancer (MBC)</span>. <span class="NLM_conf-name">Proceedings of the 34th Annual San Antonio Breast Cancer Symposium</span>, <span class="NLM_conf-loc">San Antonio, TX</span>, <span class="NLM_conf-date">December 6–10, 2011</span>,  <span class="NLM_fpage">Abstract P1-17-08</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Jhaveri%2C+K.%3B+Chandarlapaty%2C+S.%3B+Lake%2C+D.%3B+Gilewski%2C+T.%3B+Drullinsky%2C+P.%3B+Sugarman%2C+S.%3B+Wasserheit-Leiblich%2C+C.%3B+Moynahan%2C+M.+E.%3B+D%E2%80%99Andrea%2C+G.%3B+Haque%2C+S.%3B+Patil%2C+S.%3B+Bauman%2C+L.%3B+Vukovic%2C+V.%3B+EI-Hariry%2C+I.%3B+Hudis%2C+C.%3B+Modi%2C+S.+A+phase+II+trial+of+ganetespib%3A+efficacy+and+safety+in+patients+%28pts%29+with+metastatic+breast+cancer+%28MBC%29.+Proceedings+of+the+34th+Annual+San+Antonio+Breast+Cancer+Symposium%2C+San+Antonio%2C+TX%2C+December+6%E2%80%9310%2C+2011%2C+Abstract+P1-17-08."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DJhaveri%26aufirst%3DK.%26atitle%3DA%2520phase%2520II%2520trial%2520of%2520ganetespib%253A%2520efficacy%2520and%2520safety%2520in%2520patients%2520%2528pts%2529%2520with%2520metastatic%2520breast%2520cancer%2520%2528MBC%2529%26spage%3DAbstract%2520P1-17-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group">Goyal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wadlow, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaszkowsky, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolpin, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCleary, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaram, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karol, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, A. X.</span><span> </span><span class="NLM_article-title">A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">128</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span><span class="refDoi"> DOI: 10.1007/s10637-014-0164-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1007%2Fs10637-014-0164-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=128-137&author=L.+Goyalauthor=R.+C.+Wadlowauthor=L.+S.+Blaszkowskyauthor=B.+M.+Wolpinauthor=T.+A.+Abramsauthor=N.+J.+McClearyauthor=S.+Sheehanauthor=E.+Sundaramauthor=M.+D.+Karolauthor=J.+Chenauthor=A.+X.+Zhu&title=A+phase+I+and+pharmacokinetic+study+of+ganetespib+%28STA-9090%29+in+advanced+hepatocellular+carcinoma&doi=10.1007%2Fs10637-014-0164-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1007%2Fs10637-014-0164-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-014-0164-8%26sid%3Dliteratum%253Aachs%26aulast%3DGoyal%26aufirst%3DL.%26aulast%3DWadlow%26aufirst%3DR.%2BC.%26aulast%3DBlaszkowsky%26aufirst%3DL.%2BS.%26aulast%3DWolpin%26aufirst%3DB.%2BM.%26aulast%3DAbrams%26aufirst%3DT.%2BA.%26aulast%3DMcCleary%26aufirst%3DN.%2BJ.%26aulast%3DSheehan%26aufirst%3DS.%26aulast%3DSundaram%26aufirst%3DE.%26aulast%3DKarol%26aufirst%3DM.%2BD.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DA.%2BX.%26atitle%3DA%2520phase%2520I%2520and%2520pharmacokinetic%2520study%2520of%2520ganetespib%2520%2528STA-9090%2529%2520in%2520advanced%2520hepatocellular%2520carcinoma%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2015%26volume%3D33%26spage%3D128%26epage%3D137%26doi%3D10.1007%2Fs10637-014-0164-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group">Sessa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhalla, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Britten, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacks, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadimitrakopoulou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pluard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuel, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akimov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quadt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez-Ibarra, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chica, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, U.</span><span> </span><span class="NLM_article-title">First-in-human phase I dose-escalation study of the Hsp90 inhibitor AUY922 in patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3671</span><span class="NLM_x">–</span> <span class="NLM_lpage">3680</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-3404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1078-0432.CCR-12-3404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=23757357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtValt7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=3671-3680&author=C.+Sessaauthor=G.+I.+Shapiroauthor=K.+N.+Bhallaauthor=C.+Brittenauthor=K.+S.+Jacksauthor=M.+Mitaauthor=V.+Papadimitrakopoulouauthor=T.+Pluardauthor=T.+A.+Samuelauthor=M.+Akimovauthor=C.+Quadtauthor=C.+Fernandez-Ibarraauthor=H.+Luauthor=S.+Baileyauthor=S.+Chicaauthor=U.+Banerji&title=First-in-human+phase+I+dose-escalation+study+of+the+Hsp90+inhibitor+AUY922+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1078-0432.CCR-12-3404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Sessa, Cristiana; Shapiro, Geoffrey I.; Bhalla, Kapil N.; Britten, Carolyn; Jacks, Karen S.; Mita, Monica; Papadimitrakopoulou, Vali; Pluard, Tim; Samuel, Thomas A.; Akimov, Mikhail; Quadt, Cornelia; Fernandez-Ibarra, Cristina; Lu, Hong; Bailey, Stuart; Chica, Sandra; Banerji, Udai</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3671-3680</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: A phase I study was conducted with the primary objective of detg. the max. tolerated dose (MTD) of AUY922 in patients with advanced solid tumors.  Secondary objectives included characterization of the safety, pharmacokinetic, and pharmacodynamic profiles.  Patients and Methods: Patients with advanced solid tumors received 1-h i.v. infusions of AUY922 once a week in a 28-day cycle.  An adaptive Bayesian logistic regression model that employed obsd. dose-limiting toxicities (DLT) in the first treatment cycle was used to guide dose-escalation decisions, with the established MTD to be used in phase II studies.  Results: One hundred and one patients were enrolled and explored at doses in the range of 2 to 70 mg/m2.  DLTs occurred in 8 patients (22-70 mg/m2) and included diarrhea, asthenia/fatigue, anorexia, atrial flutter, and visual symptoms.  At 70 mg/m2, the AUY922 concn. achieved was consistent with active concns. in a range of xenograft models.  There was evidence of target inhibition in peripheral blood mononuclear cells (HSP70 induction) and tumor (client protein depletion and redn. of metabolic activity by 18F-FDG PET).  The recommended phase II dose (RP2D) of 70 mg/m2 was proposed on the basis of toxicity and pharmacokinetic and pharmacodynamic profiles.  Conclusions: At the RP2D of 70 mg/m2, AUY922 exhibited acceptable tolerability, and phase II single-agent and combination studies have been initiated in patients with HER2-pos. breast, gastric, and non-small cell lung cancers.  Clin Cancer Res; 19(13); 3671-80. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqWielpmNf9rVg90H21EOLACvtfcHk0lgKDjtok9EDtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtValt7fI&md5=3a428b5489b6390c84fc046945e6d575</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-3404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-3404%26sid%3Dliteratum%253Aachs%26aulast%3DSessa%26aufirst%3DC.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DBhalla%26aufirst%3DK.%2BN.%26aulast%3DBritten%26aufirst%3DC.%26aulast%3DJacks%26aufirst%3DK.%2BS.%26aulast%3DMita%26aufirst%3DM.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%26aulast%3DPluard%26aufirst%3DT.%26aulast%3DSamuel%26aufirst%3DT.%2BA.%26aulast%3DAkimov%26aufirst%3DM.%26aulast%3DQuadt%26aufirst%3DC.%26aulast%3DFernandez-Ibarra%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DChica%26aufirst%3DS.%26aulast%3DBanerji%26aufirst%3DU.%26atitle%3DFirst-in-human%2520phase%2520I%2520dose-escalation%2520study%2520of%2520the%2520Hsp90%2520inhibitor%2520AUY922%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D3671%26epage%3D3680%26doi%3D10.1158%2F1078-0432.CCR-12-3404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group">Doi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onozawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuse, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshino, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akimov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boku, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtsu, A.</span><span> </span><span class="NLM_article-title">Phase I dose-escalation study of the Hsp90 inhibitor AUY922 in Japanese patients with advanced solid tumors</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">629</span><span class="NLM_x">–</span> <span class="NLM_lpage">636</span><span class="refDoi"> DOI: 10.1007/s00280-014-2521-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1007%2Fs00280-014-2521-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=25059319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1egu7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=629-636&author=T.+Doiauthor=Y.+Onozawaauthor=N.+Fuseauthor=T.+Yoshinoauthor=K.+Yamazakiauthor=J.+Watanabeauthor=M.+Akimovauthor=M.+Robsonauthor=N.+Bokuauthor=A.+Ohtsu&title=Phase+I+dose-escalation+study+of+the+Hsp90+inhibitor+AUY922+in+Japanese+patients+with+advanced+solid+tumors&doi=10.1007%2Fs00280-014-2521-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors</span></div><div class="casAuthors">Doi, Toshihiko; Onozawa, Yusuke; Fuse, Nozomu; Yoshino, Takayuki; Yamazaki, Kentaro; Watanabe, Junichiro; Akimov, Mikhail; Robson, Matthew; Boku, Narikazu; Ohtsu, Atsushi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">629-636</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: AUY922 is a potent non-geldanamycin inhibitor of heat-shock protein 90.  This study was carried out in Japanese patients to det. the max. tolerated dose (MTD), and to characterize safety, tolerability and pharmacokinetics of single-agent AUY922.  Methods: Japanese patients with advanced solid tumors whose disease had progressed on at least one line of std. therapy, or for whom no std. therapy existed, were treated with AUY922 (i.v., once-weekly, 28-day cycle, starting dose 8 mg/m2).  Results: Thirty-one patients were treated.  Two DLTs were reported in one patient of the 54 mg/m2 cohort; fatigue and decreased appetite (both Grade 3, resolving to Grade 1 within 8 days).  No MTD was detd., and the dose recommended for Phase II studies was detd. to be 70 mg/m2 once-weekly.  Most common drug-related toxicities were diarrhea, night blindness and nausea.  Grade 1 and 2 visual toxicities at high AUY922 doses ≥22 mg/m2 were obsd.  Ten patients (32 %) achieved a best overall response of stable disease, and one patient (3 %) achieved a confirmed partial response.  Conclusion: Overall, AUY922 exhibited acceptable toxicities and demonstrated potential clin. activity in Japanese patients, with similar safety and pharmacokinetic profiles to those reported in a preceding global Phase I study in Western patients (CAUY922A2101).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHpBWf7yeQ6rVg90H21EOLACvtfcHk0lgKDjtok9EDtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1egu7bI&md5=b45329cadb86c932a68ced6951b796db</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1007%2Fs00280-014-2521-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-014-2521-x%26sid%3Dliteratum%253Aachs%26aulast%3DDoi%26aufirst%3DT.%26aulast%3DOnozawa%26aufirst%3DY.%26aulast%3DFuse%26aufirst%3DN.%26aulast%3DYoshino%26aufirst%3DT.%26aulast%3DYamazaki%26aufirst%3DK.%26aulast%3DWatanabe%26aufirst%3DJ.%26aulast%3DAkimov%26aufirst%3DM.%26aulast%3DRobson%26aufirst%3DM.%26aulast%3DBoku%26aufirst%3DN.%26aulast%3DOhtsu%26aufirst%3DA.%26atitle%3DPhase%2520I%2520dose-escalation%2520study%2520of%2520the%2520Hsp90%2520inhibitor%2520AUY922%2520in%2520Japanese%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2014%26volume%3D74%26spage%3D629%26epage%3D636%26doi%3D10.1007%2Fs00280-014-2521-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group">Seggewiss-Bernhardt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bargou, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alegre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bladé, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottmann, O. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez-Ibarra, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pain, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akimov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, S. P.</span><span> </span><span class="NLM_article-title">Phase 1/1B trial of the Hsp90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">2185</span><span class="NLM_x">–</span> <span class="NLM_lpage">2192</span><span class="refDoi"> DOI: 10.1002/cncr.29339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1002%2Fcncr.29339" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2015&pages=2185-2192&author=R.+Seggewiss-Bernhardtauthor=R.+C.+Bargouauthor=Y.+T.+Gohauthor=A.+K.+Stewartauthor=A.+Spencerauthor=A.+Alegreauthor=J.+Blad%C3%A9author=O.+G.+Ottmannauthor=C.+Fernandez-Ibarraauthor=H.+Luauthor=S.+Painauthor=M.+Akimovauthor=S.+P.+Iyer&title=Phase+1%2F1B+trial+of+the+Hsp90+inhibitor+NVP-AUY922+as+monotherapy+or+in+combination+with+bortezomib+in+patients+with+relapsed+or+refractory+multiple+myeloma&doi=10.1002%2Fcncr.29339"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1002%2Fcncr.29339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.29339%26sid%3Dliteratum%253Aachs%26aulast%3DSeggewiss-Bernhardt%26aufirst%3DR.%26aulast%3DBargou%26aufirst%3DR.%2BC.%26aulast%3DGoh%26aufirst%3DY.%2BT.%26aulast%3DStewart%26aufirst%3DA.%2BK.%26aulast%3DSpencer%26aufirst%3DA.%26aulast%3DAlegre%26aufirst%3DA.%26aulast%3DBlad%25C3%25A9%26aufirst%3DJ.%26aulast%3DOttmann%26aufirst%3DO.%2BG.%26aulast%3DFernandez-Ibarra%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DPain%26aufirst%3DS.%26aulast%3DAkimov%26aufirst%3DM.%26aulast%3DIyer%26aufirst%3DS.%2BP.%26atitle%3DPhase%25201%252F1B%2520trial%2520of%2520the%2520Hsp90%2520inhibitor%2520NVP-AUY922%2520as%2520monotherapy%2520or%2520in%2520combination%2520with%2520bortezomib%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520multiple%2520myeloma%26jtitle%3DCancer%26date%3D2015%26volume%3D121%26spage%3D2185%26epage%3D2192%26doi%3D10.1002%2Fcncr.29339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group">Do, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speranza, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polley, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bishop, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trepel, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinders, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antony, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neckers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doroshow, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kummar, S.</span><span> </span><span class="NLM_article-title">Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">921</span><span class="NLM_x">–</span> <span class="NLM_lpage">930</span><span class="refDoi"> DOI: 10.1007/s10637-015-0255-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1007%2Fs10637-015-0255-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=921-930&author=K.+Doauthor=G.+Speranzaauthor=L.+C.+Changauthor=E.+C.+Polleyauthor=R.+Bishopauthor=W.+Zhuauthor=J.+B.+Trepelauthor=S.+Leeauthor=M.+J.+Leeauthor=R.+J.+Kindersauthor=L.+Phillipsauthor=J.+Collinsauthor=J.+Lyonsauthor=W.+Jeongauthor=R.+Antonyauthor=A.+P.+Chenauthor=L.+Neckersauthor=J.+H.+Doroshowauthor=S.+Kummar&title=Phase+I+study+of+the+heat+shock+protein+90+%28Hsp90%29+inhibitor+onalespib+%28AT13387%29+administered+on+a+daily+for+2+consecutive+days+per+week+dosing+schedule+in+patients+with+advanced+solid+tumors&doi=10.1007%2Fs10637-015-0255-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1007%2Fs10637-015-0255-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-015-0255-1%26sid%3Dliteratum%253Aachs%26aulast%3DDo%26aufirst%3DK.%26aulast%3DSperanza%26aufirst%3DG.%26aulast%3DChang%26aufirst%3DL.%2BC.%26aulast%3DPolley%26aufirst%3DE.%2BC.%26aulast%3DBishop%26aufirst%3DR.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DTrepel%26aufirst%3DJ.%2BB.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DM.%2BJ.%26aulast%3DKinders%26aufirst%3DR.%2BJ.%26aulast%3DPhillips%26aufirst%3DL.%26aulast%3DCollins%26aufirst%3DJ.%26aulast%3DLyons%26aufirst%3DJ.%26aulast%3DJeong%26aufirst%3DW.%26aulast%3DAntony%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DA.%2BP.%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DKummar%26aufirst%3DS.%26atitle%3DPhase%2520I%2520study%2520of%2520the%2520heat%2520shock%2520protein%252090%2520%2528Hsp90%2529%2520inhibitor%2520onalespib%2520%2528AT13387%2529%2520administered%2520on%2520a%2520daily%2520for%25202%2520consecutive%2520days%2520per%2520week%2520dosing%2520schedule%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2015%26volume%3D33%26spage%3D921%26epage%3D930%26doi%3D10.1007%2Fs10637-015-0255-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwak, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dezube, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yule, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayrton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahadevan, D.</span><span> </span><span class="NLM_article-title">First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">–</span> <span class="NLM_lpage">97</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-0979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1158%2F1078-0432.CCR-14-0979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=25336693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC2MXis12ltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=87-97&author=G.+I.+Shapiroauthor=E.+Kwakauthor=B.+J.+Dezubeauthor=M.+Yuleauthor=J.+Ayrtonauthor=J.+Lyonsauthor=D.+Mahadevan&title=First-in-human+phase+I+dose+escalation+study+of+a+second-generation+non-ansamycin+HSP90+inhibitor%2C+AT13387%2C+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1078-0432.CCR-14-0979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Shapiro, Geoffrey I.; Kwak, Eunice; Dezube, Bruce J.; Yule, Murray; Ayrton, John; Lyons, John; Mahadevan, Daruka</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-97</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: AT13387 is a potent second-generation, fragment-derived HSP90 inhibitor.  This phase I study investigated the max. tolerated dose (MTD)/recommended phase II dose (RP2D) and safety, pharmacokinetic, and pharmacodynamic profiles of two AT13387 regimens in a refractory solid tumor population.  Exptl. Design: Std. 3+3 dose escalation was used.  MTD and RP2D detns. were based on the occurrence of dose-limiting toxicities (DLT) and overall toxicity, resp.  Pharmacokinetic parameters were measured after single and multiple doses.  AT13387-mediated induction of HSP70 was evaluated in plasma, peripheral blood mononuclear cells, and paired tumor biopsies.  Results: Sixty-two patients were treated with doses ranging from 10 to 120 mg/m2 twice weekly and 150 to 310 mg/m2 once weekly (both for 3 wk every 28 days).  One DLT of visual disturbance occurred at 120 mg/m2, which was considered the MTD and RP2D for the twice-weekly regimen.  No formal DLTs occurred in the once-weekly regimen, but multiple moderately severe toxicities, including diarrhea, nausea, vomiting, fatigue, and systemic infusion reactions, led to selection of 260 mg/m2 as the RP2D.  Exposures of AT13387 increased proportionally with dose.  Target engagement as measured by HSP70 induction occurred in plasma and tumor biopsy samples.  One patient with gastrointestinal stromal tumor (GIST) who had progressive disease on imatinib had a partial response and remained on treatment for 10 mo.  Twenty-one patients (34%) had stable disease, which lasted >120 days in 7 patients.  Conclusion: AT13387 administered once or twice weekly has an acceptable safety profile and demonstrated evidence of target engagement and preliminary antitumor activity.  Clin Cancer Res; 21(1); 87-97. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrB7A3RmZpiAbVg90H21EOLACvtfcHk0liFVTkNsBFJzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXis12ltA%253D%253D&md5=7683701e7cde5f4b599c2e6bdb8cd6ac</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-0979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-0979%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DKwak%26aufirst%3DE.%26aulast%3DDezube%26aufirst%3DB.%2BJ.%26aulast%3DYule%26aufirst%3DM.%26aulast%3DAyrton%26aufirst%3DJ.%26aulast%3DLyons%26aufirst%3DJ.%26aulast%3DMahadevan%26aufirst%3DD.%26atitle%3DFirst-in-human%2520phase%2520I%2520dose%2520escalation%2520study%2520of%2520a%2520second-generation%2520non-ansamycin%2520HSP90%2520inhibitor%252C%2520AT13387%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D87%26epage%3D97%26doi%3D10.1158%2F1078-0432.CCR-14-0979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group">Infante, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendell, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinson, J. M.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Von Hoff, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlemans, E. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramanathan, R. K.</span><span> </span><span class="NLM_article-title">Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumors</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2897</span><span class="NLM_x">–</span> <span class="NLM_lpage">2904</span><span class="refDoi"> DOI: 10.1016/j.ejca.2014.07.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.ejca.2014.07.017" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2014&pages=2897-2904&author=J.+R.+Infanteauthor=G.+J.+Weissauthor=S.+Jonesauthor=R.+Tibesauthor=T.+M.+Bauerauthor=J.+C.+Bendellauthor=J.+M.+Hinsonauthor=D.+D.+Von+Hoffauthor=H.+A.+Burrisauthor=E.+O.+Orlemansauthor=R.+K.+Ramanathan&title=Phase+I+dose-escalation+studies+of+SNX-5422%2C+an+orally+bioavailable+heat+shock+protein+90+inhibitor%2C+in+patients+with+refractory+solid+tumors&doi=10.1016%2Fj.ejca.2014.07.017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2014.07.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2014.07.017%26sid%3Dliteratum%253Aachs%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DWeiss%26aufirst%3DG.%2BJ.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DTibes%26aufirst%3DR.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DBendell%26aufirst%3DJ.%2BC.%26aulast%3DHinson%26aufirst%3DJ.%2BM.%26aulast%3DVon%2BHoff%26aufirst%3DD.%2BD.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DOrlemans%26aufirst%3DE.%2BO.%26aulast%3DRamanathan%26aufirst%3DR.%2BK.%26atitle%3DPhase%2520I%2520dose-escalation%2520studies%2520of%2520SNX-5422%252C%2520an%2520orally%2520bioavailable%2520heat%2520shock%2520protein%252090%2520inhibitor%252C%2520in%2520patients%2520with%2520refractory%2520solid%2520tumors%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2014%26volume%3D50%26spage%3D2897%26epage%3D2904%26doi%3D10.1016%2Fj.ejca.2014.07.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group">Reddy, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voorhees, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houk, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brega, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinson, J. M.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jillela, A.</span><span> </span><span class="NLM_article-title">Phase I trial of the Hsp90 inhibitor PF-04929113 (SNX5422) in adult patients with recurrent, refractory hematologic malignancies</span> <span class="citation_source-journal">Clin. Lymphoma. Myeloma. Leuk</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">391</span><span class="refDoi"> DOI: 10.1016/j.clml.2013.03.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=10.1016%2Fj.clml.2013.03.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=23763921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpt1Clt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=385-391&author=N.+Reddyauthor=P.+M.+Voorheesauthor=B.+E.+Houkauthor=N.+Bregaauthor=J.+M.+Hinsonauthor=A.+Jillela&title=Phase+I+trial+of+the+Hsp90+inhibitor+PF-04929113+%28SNX5422%29+in+adult+patients+with+recurrent%2C+refractory+hematologic+malignancies&doi=10.1016%2Fj.clml.2013.03.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Trial of the HSP90 Inhibitor PF-04929113 (SNX5422) in Adult Patients With Recurrent, Refractory Hematologic Malignancies</span></div><div class="casAuthors">Reddy, Nishitha; Voorhees, Peter M.; Houk, Brett E.; Brega, Nicoletta; Hinson, James M.; Jillela, Anand</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Lymphoma, Myeloma & Leukemia</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">385-391</span>CODEN:
                <span class="NLM_cas:coden">CLMLCQ</span>;
        ISSN:<span class="NLM_cas:issn">2152-2669</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Heat shock protein (HSP)90 regulates the function of proteins responsible for cell growth and survival, is overexpressed in many cancers and is an attractive therapeutic target.  We undertook a phase 1 trial of PF-04929113 (SNX-5422), a novel oral HSP90 inhibitor, to est. the max. tolerated dose and describe the pharmacokinetic and toxicity profiles.Patients with relapsed, refractory, hematol. malignancies and adequate organ function were eligible.  PF-04929113 was administered orally every other day for 21 days of a 28-day cycle.  Twenty-five patients were treated, with dose escalation ranging from 5.32 mg/m2 to 74 mg/m2 using a 3 plus 3 trial design.All 25 patients enrolled were evaluable for toxicity.  Most common toxicities included prolonged QTc interval, diarrhea, pruritus, thrombocytopenia, fatigue, and nausea.  Grade 3/4 treatment-related adverse events were experienced by 7/25 patients (28%); thrombocytopenia was the most common (n = 3 grade 3; n = 2 grade 4).  Partial response was experienced by a patient with transformed lymphoma, and prolonged stabilization of disease was obsd. in a patient with multiple myeloma.Alternate-day oral dosing of PF-04929113 at 74 mg/m2 for 21/28 days was generally well tolerated with reversible toxicity.  The responses obsd. in myeloma and lymphoma patients are encouraging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2rDxl5z95e7Vg90H21EOLACvtfcHk0liFVTkNsBFJzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpt1Clt7o%253D&md5=3564e52bdef2dda0ce6b8c6c869c2b8b</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1016%2Fj.clml.2013.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clml.2013.03.010%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DN.%26aulast%3DVoorhees%26aufirst%3DP.%2BM.%26aulast%3DHouk%26aufirst%3DB.%2BE.%26aulast%3DBrega%26aufirst%3DN.%26aulast%3DHinson%26aufirst%3DJ.%2BM.%26aulast%3DJillela%26aufirst%3DA.%26atitle%3DPhase%2520I%2520trial%2520of%2520the%2520Hsp90%2520inhibitor%2520PF-04929113%2520%2528SNX5422%2529%2520in%2520adult%2520patients%2520with%2520recurrent%252C%2520refractory%2520hematologic%2520malignancies%26jtitle%3DClin.%2520Lymphoma.%2520Myeloma.%2520Leuk%26date%3D2013%26volume%3D13%26spage%3D385%26epage%3D391%26doi%3D10.1016%2Fj.clml.2013.03.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group">Duerfeldt, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maynard, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eletto, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ostrovsky, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinogle, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Argon, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicchitta, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span> </span><span class="NLM_article-title">Development of a Grp94 inhibitor</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">134</span><span class="NLM_x">, </span> <span class="NLM_fpage">9796</span><span class="NLM_x">–</span> <span class="NLM_lpage">9804</span><span class="refDoi"> DOI: 10.1021/ja303477g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja303477g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;key=1%3ACAS%3A528%3ADC%252BC38XnslGqsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=9796-9804&author=A.+S.+Duerfeldtauthor=L.+B.+Petersonauthor=J.+C.+Maynardauthor=C.+L.+Ngauthor=D.+Elettoauthor=O.+Ostrovskyauthor=H.+E.+Shinogleauthor=D.+S.+Mooreauthor=Y.+Argonauthor=C.+V.+Nicchittaauthor=B.+S.+J.+Blagg&title=Development+of+a+Grp94+inhibitor&doi=10.1021%2Fja303477g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Grp94 inhibitor</span></div><div class="casAuthors">Duerfeldt, Adam S.; Peterson, Laura B.; Maynard, Jason C.; Ng, Chun Leung; Eletto, Davide; Ostrovsky, Olga; Shinogle, Heather E.; Moore, David S.; Argon, Yair; Nicchitta, Christopher V.; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9796-9804</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) represents a promising therapeutic target for the treatment of cancer and other diseases.  Unfortunately, results from clin. trials have been disappointing as off-target effects and toxicities have been obsd.  These detriments may be a consequence of pan-Hsp90 inhibition, as all clin. evaluated Hsp90 inhibitors simultaneously disrupt all four human Hsp90 isoforms.  Using a structure-based approach, we designed an inhibitor of Grp94, the ER-resident Hsp90.  The effect manifested by compd. (I) on several Grp94 and Hsp90α/β (cytosolic isoforms) clients were investigated.  Compd. I prevented intracellular trafficking of the Toll receptor, inhibited the secretion of IGF-II, affected the conformation of Grp94, and suppressed Drosophila larval growth, all Grp94-dependent processes.  In contrast, compd. I had no effect on cell viability or cytosolic Hsp90α/β client proteins at similar concns.  The design, synthesis, and evaluation of I are described herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoayCAvZU_mzrVg90H21EOLACvtfcHk0liOARd8qQn3qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnslGqsLw%253D&md5=00c0b3f15f2cfd04658225c8a6fb708d</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1021%2Fja303477g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja303477g%26sid%3Dliteratum%253Aachs%26aulast%3DDuerfeldt%26aufirst%3DA.%2BS.%26aulast%3DPeterson%26aufirst%3DL.%2BB.%26aulast%3DMaynard%26aufirst%3DJ.%2BC.%26aulast%3DNg%26aufirst%3DC.%2BL.%26aulast%3DEletto%26aufirst%3DD.%26aulast%3DOstrovsky%26aufirst%3DO.%26aulast%3DShinogle%26aufirst%3DH.%2BE.%26aulast%3DMoore%26aufirst%3DD.%2BS.%26aulast%3DArgon%26aufirst%3DY.%26aulast%3DNicchitta%26aufirst%3DC.%2BV.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DDevelopment%2520of%2520a%2520Grp94%2520inhibitor%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2012%26volume%3D134%26spage%3D9796%26epage%3D9804%26doi%3D10.1021%2Fja303477g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1US7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1US7','PDB','1US7'); return false;">PDB: 1US7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2CG9" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2CG9','PDB','2CG9'); return false;">PDB: 2CG9</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2IOQ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2IOQ','PDB','2IOQ'); return false;">PDB: 2IOQ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2W99" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2W99','PDB','2W99'); return false;">PDB: 2W99</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-12%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b01106" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b01106" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799133ab9762308","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
